data_5wpy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5wpy _Structure_validation_residue.Date_analyzed 2017-11-24 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.8 mtm . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 121.171 0.51 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.58 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 89.7 mt-30 55.64 53.21 9.87 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.402 -0.811 . . . . 0.0 109.14 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.58 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.0 m80 77.14 41.46 0.15 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.671 -0.643 . . . . 0.0 109.43 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.6 -33.41 73.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.296 -0.877 . . . . 0.0 109.444 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.16 -35.94 80.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.169 -0.957 . . . . 0.0 109.748 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -65.88 -39.8 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 0.0 109.123 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.421 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 86.1 mt -59.49 -49.58 83.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.432 -0.792 . . . . 0.0 109.298 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.415 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.7 -41.79 98.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.2 -0.938 . . . . 0.0 108.534 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.43 -37.33 86.58 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.464 -0.773 . . . . 0.0 109.172 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -59.94 -52.99 63.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.544 -0.723 . . . . 0.0 110.044 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.53 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 4.6 p -73.49 -42.39 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.213 -0.929 . . . . 0.0 109.889 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.47 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 87.6 t -64.45 -38.12 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.337 -0.852 . . . . 0.0 110.411 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -56.15 -26.51 50.6 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.691 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -64.26 -31.11 72.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 109.168 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -153.96 52.88 0.69 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 109.316 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -80.74 136.61 51.33 Favored Pre-proline 0 N--CA 1.486 1.334 0 O-C-N 120.964 -1.085 . . . . 0.0 110.023 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.4 -153.81 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.007 1.805 . . . . 0.0 110.773 178.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -82.85 16.7 2.15 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.075 -1.016 . . . . 0.0 108.839 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.2 t -112.85 138.02 43.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.56 -0.712 . . . . 0.0 110.03 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.78 137.16 96.07 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.247 -0.908 . . . . 0.0 108.651 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -48.35 -29.99 14.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.836 1.691 . . . . 0.0 112.016 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.31 -24.06 66.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.325 -0.859 . . . . 0.0 109.486 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -101.18 8.18 42.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 109.452 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -100.99 137.5 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.324 -0.86 . . . . 0.0 108.875 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.91 90.96 0.14 Allowed 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.194 -0.941 . . . . 0.0 109.367 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -61.74 6.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.345 -0.847 . . . . 0.0 109.551 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -92.05 12.44 21.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.213 -0.929 . . . . 0.0 109.135 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.2 tp -85.27 134.21 34.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.862 . . . . 0.0 109.613 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.507 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -64.3 121.54 14.54 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.369 -0.832 . . . . 0.0 109.065 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.476 ' O ' ' N ' ' A' ' 33' ' ' ASN . 67.6 mt -63.62 -8.14 9.17 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.188 -0.945 . . . . 0.0 109.602 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.468 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.33 -41.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.058 -1.027 . . . . 0.0 108.904 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -59.2 -34.92 72.73 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.644 ' O ' ' N ' ' A' ' 35' ' ' VAL . 83.1 m-20 -85.19 16.9 3.27 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.45 -14.81 0.01 OUTLIER Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.644 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.1 t -51.85 -39.56 25.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 120.909 -1.348 . . . . 0.0 108.07 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.9 tt -71.31 -25.03 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.635 -0.666 . . . . 0.0 110.319 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -60.48 -32.09 71.08 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.215 -0.928 . . . . 0.0 111.432 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.14 -65.05 1.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.892 -1.13 . . . . 0.0 111.405 -178.348 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 16.2 mt -74.01 -52.43 12.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.022 -1.048 . . . . 0.0 111.124 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.62 -35.83 91.63 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.62 -42.23 87.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.232 -1.157 . . . . 0.0 109.121 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -63.35 -44.14 95.68 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.161 -0.962 . . . . 0.0 109.011 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -68.38 -41.08 81.06 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.59 -46.94 81.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.4 -0.812 . . . . 0.0 110.177 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.23 -45.01 99.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.542 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.42 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.192 -0.942 . . . . 0.0 109.999 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.724 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.27 -49.37 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 110.085 -179.744 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.8 tp -61.8 -41.39 97.69 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.554 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.9 pt-20 -70.57 -35.66 73.19 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.17 -0.956 . . . . 0.0 109.829 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -61.59 -41.95 98.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.248 -0.907 . . . . 0.0 110.092 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.724 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 86.0 mtt180 -64.4 -38.82 92.36 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 111.133 -179.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -102.85 -4.54 24.71 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.96 -1.087 . . . . 0.0 110.244 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 61.75 35.37 91.14 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.4 mt -90.19 141.2 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -1.189 . . . . 0.0 109.849 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.0 136.26 50.24 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.025 -1.047 . . . . 0.0 108.9 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.57 -35.23 79.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.089 -1.007 . . . . 0.0 109.482 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.619 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.7 p30 -65.87 -25.93 67.4 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.35 -0.844 . . . . 0.0 110.024 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.619 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 54.3 t0 -54.27 -35.83 62.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.778 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 43.7 t -111.64 136.94 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.444 -0.785 . . . . 0.0 109.708 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -88.28 142.26 27.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 109.287 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 35.9 mt -93.05 135.28 34.37 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.223 -0.923 . . . . 0.0 109.697 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -162.27 150.35 12.06 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.269 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.42 -27.07 76.99 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.473 2.115 . . . . 0.0 112.065 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.64 -30.57 71.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.401 -0.812 . . . . 0.0 109.747 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -67.65 -27.05 66.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.743 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -102.69 10.34 38.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.234 -0.916 . . . . 0.0 109.73 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.447 HH22 ' CB ' ' A' ' 29' ' ' ASP . 32.8 tpt85 -54.15 -39.03 66.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.506 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.534 ' HG ' ' H ' ' A' ' 71' ' ' SER . 83.9 p -147.79 151.87 36.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.076 -1.015 . . . . 0.0 109.873 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.7 mt -66.1 -37.29 79.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.293 -0.879 . . . . 0.0 109.892 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -61.32 -38.44 86.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 -179.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.534 ' H ' ' HG ' ' A' ' 68' ' ' SER . 83.9 p -62.93 -40.45 97.66 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.007 -1.058 . . . . 0.0 109.581 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.3 mt -68.33 -40.97 83.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.185 -0.947 . . . . 0.0 109.74 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.421 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 54.8 t0 -59.46 -40.69 87.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.383 -0.823 . . . . 0.0 110.156 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.14 -43.05 88.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.125 -0.984 . . . . 0.0 110.001 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.33 -50.22 72.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.7 -44.84 93.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -60.08 -39.5 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.102 -0.999 . . . . 0.0 109.445 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.77 -32.95 66.52 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.51 -49.47 3.55 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.09 -1.241 . . . . 0.0 110.634 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.523 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.7 t -160.47 152.31 19.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.126 -0.983 . . . . 0.0 109.887 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.541 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.3 t . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.228 179.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.8 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.264 0.554 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -59.11 -38.04 78.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -114.57 11.32 17.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.486 -0.759 . . . . 0.0 109.296 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.477 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -56.66 -39.47 73.8 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.956 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.2 p -63.99 -36.04 82.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.008 -1.057 . . . . 0.0 109.432 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -68.79 -36.09 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.534 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 98.7 mt -59.13 -50.42 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -0.917 . . . . 0.0 109.996 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.84 -47.86 79.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.994 -1.066 . . . . 0.0 109.004 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.74 -41.22 98.06 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 121.347 0.594 . . . . 0.0 110.015 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -66.14 -51.36 58.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.32 -0.863 . . . . 0.0 111.145 -178.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.38 -43.59 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.949 . . . . 0.0 110.848 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -62.89 -36.28 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -0.962 . . . . 0.0 110.102 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -57.64 -37.59 73.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 109.508 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.69 -36.22 78.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.88 . . . . 0.0 110.303 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -91.8 -58.51 2.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 110.575 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mt -128.98 87.58 54.12 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.347 -0.845 . . . . 0.0 110.443 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -91.48 -18.96 0.88 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.154 2.569 . . . . 0.0 112.116 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -75.96 -4.99 44.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 108.734 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.99 141.62 29.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 178.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -61.19 115.96 16.94 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 120.698 -1.251 . . . . 0.0 108.628 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -63.75 -23.76 69.15 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 121.462 1.442 . . . . 0.0 111.409 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.25 -13.82 60.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.467 -0.771 . . . . 0.0 110.073 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.474 ' CG ' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -82.79 7.51 14.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.985 -1.072 . . . . 0.0 109.234 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -100.7 135.29 37.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.582 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -64.72 86.78 0.05 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.065 -1.022 . . . . 0.0 109.384 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -61.84 5.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.582 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -100.1 5.5 44.92 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.1 141.37 30.32 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.704 -0.622 . . . . 0.0 109.459 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.494 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.1 m-20 -60.37 121.4 11.96 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -68.62 8.37 0.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.289 -0.882 . . . . 0.0 109.83 -178.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.494 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.8 p -50.78 -40.01 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.121 -0.987 . . . . 0.0 108.974 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.5 t0 -57.76 -35.46 70.79 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -85.71 14.87 5.24 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.63 -14.93 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.6 t -51.73 -36.44 18.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.172 -1.193 . . . . 0.0 108.803 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.595 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.1 tt -70.45 -24.93 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 110.315 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -59.59 -34.06 72.25 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 111.08 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.5 m -105.72 -64.5 1.14 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.086 -1.009 . . . . 0.0 111.503 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.531 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 3.9 mm? -71.42 -52.2 19.86 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.045 -1.034 . . . . 0.0 111.151 -178.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.28 -37.31 92.76 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.595 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.4 tp -58.76 -40.7 84.68 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.367 -1.078 . . . . 0.0 109.091 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.48 -43.45 94.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.333 -0.855 . . . . 0.0 108.805 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -64.35 -36.74 85.1 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 58.5 t -60.25 -43.29 93.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.385 -0.822 . . . . 0.0 109.872 -179.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -60.35 -49.39 84.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.26 -42.06 96.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.905 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -71.46 -40.92 70.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.323 -0.86 . . . . 0.0 109.783 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.53 -46.39 86.88 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.324 -0.86 . . . . 0.0 109.519 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -65.41 -39.29 91.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.249 -0.907 . . . . 0.0 109.019 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -67.24 -36.79 82.39 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.391 -0.818 . . . . 0.0 110.51 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -86.22 -51.74 6.09 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.274 -0.891 . . . . 0.0 112.167 -178.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -93.67 -5.57 48.29 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.682 -1.261 . . . . 0.0 111.16 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.59 24.14 76.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.41 HG21 HD12 ' A' ' 54' ' ' ILE . 77.1 mt -92.97 144.12 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -1.096 . . . . 0.0 109.422 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.67 146.75 44.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.062 -1.024 . . . . 0.0 109.272 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.81 -33.21 68.35 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.352 -0.842 . . . . 0.0 109.569 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 59' ' ' VAL . 84.7 m-20 54.67 47.94 21.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.343 -0.848 . . . . 0.0 109.256 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.0 m-20 -42.86 90.45 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.447 -0.783 . . . . 0.0 109.875 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.591 ' N ' ' O ' ' A' ' 57' ' ' ASP . 44.1 t -125.74 139.32 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -74.42 130.77 40.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.017 -1.052 . . . . 0.0 109.671 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.28 142.68 45.55 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.652 -0.655 . . . . 0.0 109.449 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.8 149.03 66.59 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.078 -1.014 . . . . 0.0 109.462 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.79 -20.85 72.28 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.529 2.153 . . . . 0.0 112.342 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.8 -32.48 73.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 110.259 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -68.34 -26.71 65.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.985 -1.072 . . . . 0.0 109.975 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -97.41 5.98 48.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.161 -0.962 . . . . 0.0 109.725 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -55.52 -41.19 72.79 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.521 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -128.19 147.45 50.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.0 mt -61.46 -36.3 72.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.318 -0.864 . . . . 0.0 109.828 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.8 mtm180 -60.8 -37.32 81.56 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 110.19 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.7 t -59.08 -43.95 91.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.09 -1.007 . . . . 0.0 109.816 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.49 -38.88 83.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.136 -0.977 . . . . 0.0 109.628 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 21.5 t70 -57.12 -38.38 73.36 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.329 -0.857 . . . . 0.0 109.774 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.5 -44.45 90.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.719 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 74.0 t80 -63.55 -45.31 91.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.103 -0.998 . . . . 0.0 109.478 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.4 t -64.37 -43.67 97.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.341 -0.849 . . . . 0.0 110.099 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -63.16 -42.38 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.061 -1.024 . . . . 0.0 109.822 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.24 -30.54 71.12 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.39 -47.84 5.01 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.05 -1.265 . . . . 0.0 110.409 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 14.0 t -140.7 153.66 46.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.219 -0.926 . . . . 0.0 109.909 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.517 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.1 t . . . . . 0 N--CA 1.487 1.402 0 O-C-N 121.275 -0.891 . . . . 0.0 109.511 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.9 mtm . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.39 0.614 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.86 -38.39 82.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.287 -0.883 . . . . 0.0 109.59 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 59.8 m-70 -126.41 11.27 7.42 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.432 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.44 -36.52 76.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.148 -0.97 . . . . 0.0 109.849 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -62.09 -34.79 76.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 109.425 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.9 t -66.1 -36.63 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.35 -0.844 . . . . 0.0 109.264 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.463 ' O ' ' CG2' ' A' ' 11' ' ' VAL . 84.1 mt -64.98 -41.89 93.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 110.325 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.94 -50.64 67.86 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.03 -1.044 . . . . 0.0 110.514 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.413 ' HG3' ' H ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.06 -43.42 71.22 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -59.03 -43.64 91.64 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.981 -1.074 . . . . 0.0 109.26 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 7' ' ' ILE . 75.2 t -71.93 -49.73 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -0.836 . . . . 0.0 110.449 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -63.85 -36.85 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.225 -0.922 . . . . 0.0 110.045 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -61.36 -31.0 70.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.24 -0.913 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.64 -31.16 72.03 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.149 -0.97 . . . . 0.0 109.278 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -102.87 -58.8 1.81 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.24 -0.913 . . . . 0.0 110.548 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -131.12 88.59 44.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.308 -0.87 . . . . 0.0 111.317 -178.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -86.31 -13.51 5.23 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.73 2.287 . . . . 0.0 111.798 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.37 -4.28 41.43 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.164 -0.96 . . . . 0.0 109.084 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.31 142.47 25.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.23 115.67 15.63 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.75 -1.219 . . . . 0.0 108.649 -179.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -64.46 -25.41 63.22 Favored 'Trans proline' 0 N--CA 1.486 1.08 0 C-N-CA 121.527 1.485 . . . . 0.0 111.68 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.02 -14.29 61.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.354 -0.841 . . . . 0.0 109.178 179.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -82.62 2.92 30.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.838 . . . . 0.0 109.106 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -99.47 136.05 32.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.568 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.83 86.45 0.23 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.18 -0.95 . . . . 0.0 109.469 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.38 5.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.273 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.568 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -94.4 3.4 55.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 108.751 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.6 tt -97.14 138.66 34.3 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.539 -0.726 . . . . 0.0 109.496 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.8 m-20 -60.48 121.34 11.88 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.432 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 pp -65.34 5.7 0.37 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.793 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.51 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.8 p -50.57 -37.91 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.037 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.2 m-20 -57.71 -36.97 72.73 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -85.64 14.7 5.39 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -15.67 0.02 OUTLIER Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.41 -34.36 15.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.85 -1.382 . . . . 0.0 108.507 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -71.16 -24.36 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.554 -0.716 . . . . 0.0 109.883 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -57.91 -33.14 68.45 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.322 -0.861 . . . . 0.0 111.445 -178.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.2 m -105.83 -64.59 1.14 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.856 -1.153 . . . . 0.0 111.497 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.2 mp -72.42 -52.22 16.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.937 -1.102 . . . . 0.0 110.805 -178.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.45 -36.72 92.94 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.6 tp -58.52 -41.21 84.97 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.356 -1.085 . . . . 0.0 109.285 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.5 tp -65.8 -41.48 91.87 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.008 -1.057 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -70.22 -44.69 68.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 111.519 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.0 m -72.43 -42.09 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.939 -1.1 . . . . 0.0 111.624 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -58.7 -47.8 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 120.845 -1.159 . . . . 0.0 110.241 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.06 -39.61 92.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 110.241 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.753 ' HE1' HH21 ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.17 -49.35 15.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.927 -1.108 . . . . 0.0 110.403 -179.602 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.1 tp -60.15 -46.0 91.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.232 -0.917 . . . . 0.0 110.134 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.536 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -66.81 -38.06 85.73 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.013 -1.054 . . . . 0.0 109.463 -179.924 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.69 -38.91 92.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.934 . . . . 0.0 109.584 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.753 HH21 ' HE1' ' A' ' 47' ' ' TRP . 43.1 mmm-85 -59.28 -38.97 81.47 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.542 -0.724 . . . . 0.0 110.143 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -95.84 0.95 52.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.167 -0.958 . . . . 0.0 110.089 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.11 37.95 63.73 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.2 mt -104.04 148.58 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.411 -1.052 . . . . 0.0 109.79 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.25 122.77 34.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 108.396 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.36 -38.98 93.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.08 -1.012 . . . . 0.0 109.745 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -62.1 -37.12 83.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 0.0 110.093 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -57.14 -37.69 72.42 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.231 -0.918 . . . . 0.0 110.353 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.91 134.24 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.306 -0.871 . . . . 0.0 110.05 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -108.28 137.55 46.07 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.478 -0.764 . . . . 0.0 109.307 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.54 146.83 30.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.769 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.9 160.47 29.68 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.361 -0.837 . . . . 0.0 109.425 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -62.76 -32.21 78.22 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.799 2.333 . . . . 0.0 112.123 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -62.62 -29.01 70.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.399 -0.813 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.539 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 32.0 t-80 -67.84 -26.38 66.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.365 -0.834 . . . . 0.0 110.149 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -97.95 8.55 44.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.075 -1.015 . . . . 0.0 110.133 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -56.01 -41.07 74.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.193 -0.942 . . . . 0.0 109.355 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.3 m -128.8 145.73 51.11 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.5 mt -63.0 -39.64 85.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.119 -0.988 . . . . 0.0 109.855 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.6 mtm180 -61.54 -37.02 82.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.058 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -58.19 -38.88 77.58 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.121 -0.987 . . . . 0.0 109.638 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 71.0 mt -63.63 -42.3 95.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.323 -0.86 . . . . 0.0 109.612 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 52.4 t0 -59.48 -38.65 81.38 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.111 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 -46.07 80.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.087 -1.008 . . . . 0.0 110.05 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.539 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 70.5 t80 -63.38 -47.0 83.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.127 -0.983 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.528 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.4 t -64.75 -42.74 95.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.317 -0.864 . . . . 0.0 109.727 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.43 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 55.7 t -59.67 -41.47 85.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.239 -0.913 . . . . 0.0 109.845 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.65 -31.47 75.25 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 120.264 -0.97 . . . . 0.0 110.748 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -48.76 3.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.03 -1.277 . . . . 0.0 110.751 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -129.68 156.81 43.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.324 -0.86 . . . . 0.0 109.664 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.533 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 C--N 1.301 -1.51 0 O-C-N 121.13 -0.981 . . . . 0.0 109.381 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.445 ' N ' ' CB ' ' A' ' 4' ' ' ALA . 86.1 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.2 -38.27 82.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.771 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.521 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 73.4 m-70 -141.5 14.39 2.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.708 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.483 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -60.33 -33.4 72.34 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 110.097 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.529 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 85.5 p -61.26 -36.59 80.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.945 -1.097 . . . . 0.0 109.613 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.529 ' N ' ' HG ' ' A' ' 5' ' ' SER . 75.7 t -66.79 -39.68 84.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.089 -1.007 . . . . 0.0 108.819 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 11' ' ' VAL . 91.1 mt -61.73 -50.3 80.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.032 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.544 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.31 -48.78 74.31 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.397 -0.814 . . . . 0.0 109.137 179.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.02 -44.76 95.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.551 -0.718 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 66.4 t80 -69.56 -48.44 60.31 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.559 -0.713 . . . . 0.0 109.525 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 7' ' ' ILE . 94.3 t -66.8 -45.26 88.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.513 -0.742 . . . . 0.0 109.954 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 84.5 t -64.1 -37.24 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.374 -0.829 . . . . 0.0 109.523 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.57 -30.71 61.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.363 -0.836 . . . . 0.0 110.022 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.36 -29.69 70.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.104 -0.997 . . . . 0.0 109.298 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.617 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.3 p90 -149.2 50.04 0.97 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.374 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -80.16 136.86 53.23 Favored Pre-proline 0 N--CA 1.487 1.383 0 O-C-N 120.932 -1.105 . . . . 0.0 110.184 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.21 -153.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.96 1.773 . . . . 0.0 110.581 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -80.91 13.56 2.62 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.051 -1.031 . . . . 0.0 108.643 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.47 137.17 47.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.589 -0.694 . . . . 0.0 110.028 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.77 140.7 74.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.176 -0.953 . . . . 0.0 108.898 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -48.57 -30.96 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.891 1.727 . . . . 0.0 111.85 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.4 66.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.326 -0.859 . . . . 0.0 109.49 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -96.43 3.06 53.06 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.35 -0.844 . . . . 0.0 109.063 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.8 t -105.91 136.94 38.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.581 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.0 t0 -70.91 96.3 1.27 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.075 -1.016 . . . . 0.0 109.428 -179.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.3 m -61.7 6.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 109.589 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.581 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.9 m-20 -93.8 7.44 44.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 108.909 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.4 tt -92.61 135.14 34.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.593 -0.692 . . . . 0.0 109.642 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.5 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.6 m-20 -62.01 121.64 13.5 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -70.51 9.68 0.59 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.202 -0.936 . . . . 0.0 109.519 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.5 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -52.15 -38.03 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.201 -0.937 . . . . 0.0 109.462 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -56.94 -36.76 70.64 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.621 ' O ' ' N ' ' A' ' 35' ' ' VAL . 75.7 m-20 -86.25 14.76 6.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.48 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.621 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.82 -34.26 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 120.928 -1.336 . . . . 0.0 108.509 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.606 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.4 tt -71.07 -24.47 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.7 . . . . 0.0 110.134 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -58.14 -34.1 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.36 -0.837 . . . . 0.0 111.51 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.98 -65.26 1.05 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.858 -1.151 . . . . 0.0 111.148 -178.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -69.71 -47.22 63.93 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.157 -0.964 . . . . 0.0 110.722 -178.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.1 -39.97 72.63 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.921 -1.133 . . . . 0.0 110.379 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.2 tt -58.66 -39.81 81.71 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.19 -1.182 . . . . 0.0 109.078 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -62.25 -44.18 97.15 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.458 -0.897 . . . . 0.0 108.67 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -69.54 -40.15 77.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.326 -0.858 . . . . 0.0 109.857 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.6 t -64.77 -45.9 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.363 -0.836 . . . . 0.0 110.268 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.69 -46.02 97.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.238 -0.913 . . . . 0.0 109.532 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.35 97.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 109.951 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.436 ' CZ2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -75.09 -40.73 59.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.918 . . . . 0.0 109.995 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.77 -43.88 85.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.252 -0.905 . . . . 0.0 109.639 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.405 ' O ' ' N ' ' A' ' 53' ' ' GLY . 62.3 tt0 -64.18 -39.77 94.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.185 -0.947 . . . . 0.0 109.449 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -67.34 -45.28 76.85 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 110.836 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.6 ttt180 -70.02 -45.34 67.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.274 -0.891 . . . . 0.0 112.131 -178.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -103.38 -5.33 23.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.815 -1.178 . . . . 0.0 111.433 -178.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.09 27.68 73.61 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.5 mt -98.3 143.87 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -1.153 . . . . 0.0 109.451 -179.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.44 149.74 33.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.145 -0.972 . . . . 0.0 109.579 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.94 -31.93 63.36 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.431 -0.793 . . . . 0.0 109.529 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.52 43.86 29.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.365 -0.834 . . . . 0.0 109.582 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.451 ' C ' ' OD2' ' A' ' 58' ' ' ASP . 53.2 p30 -93.42 11.34 28.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.288 -0.883 . . . . 0.0 109.446 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 73.6 t -59.94 -41.05 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.305 -0.872 . . . . 0.0 109.97 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -116.33 130.22 56.66 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.433 -0.792 . . . . 0.0 109.717 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mt -121.89 141.92 50.79 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -158.27 105.55 1.69 Allowed Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.025 -1.047 . . . . 0.0 109.806 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_exo -55.32 -21.66 30.12 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.792 1.661 . . . . 0.0 111.228 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.31 -30.99 71.55 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.52 -0.738 . . . . 0.0 109.508 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.417 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 56.2 t-80 -69.19 -26.33 64.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.362 -0.836 . . . . 0.0 111.02 -179.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.68 5.67 49.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.98 -1.075 . . . . 0.0 111.368 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -60.2 -37.84 81.49 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.766 -1.208 . . . . 0.0 110.3 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.7 t -131.79 141.57 49.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.077 -1.014 . . . . 0.0 110.139 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.8 mt -62.84 -37.9 80.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.404 -0.81 . . . . 0.0 109.827 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -61.41 -37.21 82.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.265 -0.897 . . . . 0.0 110.244 -179.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -58.66 -40.37 83.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.102 -0.999 . . . . 0.0 109.496 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 72.0 mt -64.76 -38.74 83.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.299 -0.876 . . . . 0.0 109.314 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 20.8 t70 -57.45 -39.17 75.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.281 -0.887 . . . . 0.0 109.797 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.32 92.75 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.088 -1.007 . . . . 0.0 109.464 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.417 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 68.7 t80 -64.81 -46.16 83.19 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.285 -0.884 . . . . 0.0 109.318 179.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.9 t -63.89 -43.47 97.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.287 -0.883 . . . . 0.0 109.802 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.86 -40.52 85.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.165 -0.959 . . . . 0.0 109.558 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.2 -32.39 67.45 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.27 -49.0 3.69 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.027 -1.278 . . . . 0.0 110.758 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.3 p -134.92 154.94 51.5 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.198 -0.939 . . . . 0.0 110.1 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.4 t . . . . . 0 C--N 1.303 -1.42 0 O-C-N 121.198 -0.939 . . . . 0.0 109.0 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.6 mmm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.458 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.3 mt-30 -105.72 131.32 53.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.25 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.458 ' C ' ' O ' ' A' ' 2' ' ' GLN . 3.9 m80 40.93 31.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.386 -0.821 . . . . 0.0 109.486 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -39.38 85.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.752 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.459 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 86.1 p -65.05 -32.93 74.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.158 -0.964 . . . . 0.0 109.719 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.459 ' N ' ' HG ' ' A' ' 5' ' ' SER . 74.8 t -66.77 -38.55 81.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.193 -0.942 . . . . 0.0 109.399 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 91.9 mt -61.15 -49.82 83.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.176 -0.953 . . . . 0.0 109.368 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.543 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.99 -47.44 80.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 108.906 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -44.08 96.89 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.548 -0.72 . . . . 0.0 109.25 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.4 t80 -68.23 -49.13 62.75 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.656 -0.653 . . . . 0.0 109.729 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 95.3 t -67.99 -44.69 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.533 -0.73 . . . . 0.0 109.923 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 99.2 t -64.0 -35.18 72.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.444 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -56.1 -31.97 63.74 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -65.72 -32.48 74.06 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.279 -0.888 . . . . 0.0 109.785 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.597 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 31.4 p90 -140.71 46.8 1.77 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.196 -0.94 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.561 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.3 136.22 53.27 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.019 -1.05 . . . . 0.0 110.156 -179.752 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.417 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.4 Cg_endo -76.02 -151.52 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.167 1.911 . . . . 0.0 110.42 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.94 9.73 2.74 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.891 -1.131 . . . . 0.0 108.682 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 17' ' ' PRO . 28.4 t -113.51 135.75 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.576 -0.703 . . . . 0.0 109.781 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.54 140.62 81.96 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.976 . . . . 0.0 108.754 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -48.6 -33.05 22.88 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.621 1.547 . . . . 0.0 111.586 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.41 -20.22 63.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.185 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -98.27 3.86 48.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.465 -0.772 . . . . 0.0 109.316 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.6 t -104.14 136.03 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.62 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.5 95.48 0.47 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.122 -0.986 . . . . 0.0 109.366 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -60.27 6.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.328 -0.858 . . . . 0.0 109.604 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.62 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.75 5.92 49.37 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.158 -0.964 . . . . 0.0 108.606 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.1 tp -91.84 136.83 32.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.537 -0.727 . . . . 0.0 109.364 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.488 ' OD2' ' O ' ' A' ' 67' ' ' ARG . 88.5 m-20 -62.85 121.81 14.4 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.423 -0.911 . . . . 0.0 108.582 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.443 ' CD1' ' CD1' ' A' ' 69' ' ' ILE . 79.5 mt -68.46 -4.34 14.57 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.368 -0.832 . . . . 0.0 109.457 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 34' ' ' GLY . 51.2 t -51.47 -41.97 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.145 -0.972 . . . . 0.0 108.799 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.83 -35.29 66.23 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 1.7 m120 -83.24 14.83 3.24 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.26 -15.82 0.02 OUTLIER Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -179.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -51.71 -39.16 23.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 108.181 179.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.1 tt -71.24 -25.09 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.506 -0.746 . . . . 0.0 109.899 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.4 m-20 -62.97 -30.53 71.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.965 . . . . 0.0 110.839 -178.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.7 m -105.11 -65.17 1.06 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.997 -1.064 . . . . 0.0 111.056 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.62 -52.31 15.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.133 -0.979 . . . . 0.0 110.985 -178.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.55 -36.79 91.94 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.1 tp -58.71 -41.17 85.7 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.468 -1.019 . . . . 0.0 109.235 -179.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -65.53 -44.13 87.83 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 108.807 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.48 -43.7 76.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.553 -0.717 . . . . 0.0 110.104 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.514 ' O ' ' N ' ' A' ' 48' ' ' LEU . 96.1 t -64.53 -45.39 95.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.362 -0.837 . . . . 0.0 110.55 -179.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.519 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -60.53 -46.94 94.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 120.999 -1.063 . . . . 0.0 109.475 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -44.14 80.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.404 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.7 t90 -78.46 -49.05 14.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.102 -0.999 . . . . 0.0 110.338 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.514 ' N ' ' O ' ' A' ' 44' ' ' VAL . 7.6 tp -60.7 -42.35 97.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.554 -178.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.519 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -65.84 -37.82 87.21 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.984 -1.072 . . . . 0.0 109.046 -179.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -69.1 -38.96 79.21 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.421 -0.799 . . . . 0.0 109.576 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.1 ttt180 -58.95 -41.1 86.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.565 -0.709 . . . . 0.0 110.691 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -102.97 -6.5 22.33 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.965 -1.084 . . . . 0.0 109.898 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.35 30.86 78.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 pt -112.94 149.27 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.4 -1.059 . . . . 0.0 109.855 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.81 144.77 52.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.239 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -35.91 78.14 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.131 -0.981 . . . . 0.0 109.292 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 53.14 43.17 31.95 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.363 -0.836 . . . . 0.0 109.565 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -82.39 94.26 7.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.52 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 69.6 t -63.59 -43.78 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.942 . . . . 0.0 109.398 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -158.35 140.37 13.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.756 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 36.4 mt -103.16 136.79 42.29 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.329 -0.857 . . . . 0.0 109.46 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.42 147.52 13.5 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.068 -1.02 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -63.48 -21.09 70.87 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.49 2.127 . . . . 0.0 111.973 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.52 -31.35 70.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 0.0 110.056 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -68.41 -26.4 65.52 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.289 -0.882 . . . . 0.0 110.713 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -93.76 8.75 39.85 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.881 -1.137 . . . . 0.0 110.707 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.488 ' O ' ' OD2' ' A' ' 29' ' ' ASP . 17.5 mmm180 -58.34 -34.74 70.97 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.074 -1.016 . . . . 0.0 110.231 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -150.55 158.61 44.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.11 -0.994 . . . . 0.0 110.464 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.443 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 11.4 mm -62.89 -35.82 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.453 -0.78 . . . . 0.0 109.724 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 -59.99 -36.53 77.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.283 -0.885 . . . . 0.0 109.855 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.3 t -59.62 -43.07 93.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.901 -1.124 . . . . 0.0 108.91 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.15 -38.39 80.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.429 -0.794 . . . . 0.0 109.267 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -56.34 -37.64 70.25 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.387 -0.821 . . . . 0.0 109.253 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.56 -40.13 96.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.31 -0.869 . . . . 0.0 109.763 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -62.14 -51.78 66.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.959 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.8 t -65.16 -41.17 91.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.237 -0.915 . . . . 0.0 109.444 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.47 -40.62 79.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 O-C-N 121.312 -0.867 . . . . 0.0 109.538 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.21 -33.02 82.75 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.45 -48.83 4.22 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.976 -1.308 . . . . 0.0 110.581 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.503 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.8 p -129.69 154.22 47.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.4 -0.812 . . . . 0.0 108.994 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.539 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.1 t . . . . . 0 C--N 1.304 -1.407 0 O-C-N 121.15 -0.969 . . . . 0.0 109.956 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.477 0.656 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.569 ' C ' ' H ' ' A' ' 4' ' ' ALA . 92.2 mt-30 -104.76 140.72 37.67 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.421 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 53.7 t-80 49.36 11.23 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.952 -1.092 . . . . 0.0 108.497 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.569 ' H ' ' C ' ' A' ' 2' ' ' GLN . . . -62.36 -35.91 80.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.593 -0.692 . . . . 0.0 110.193 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.1 m -58.85 -42.07 88.47 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.016 . . . . 0.0 109.567 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.419 ' CG1' ' NE2' ' A' ' 3' ' ' HIS . 54.3 t -67.35 -36.36 76.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.397 -0.815 . . . . 0.0 109.221 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 98.9 mt -59.75 -49.51 83.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.831 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.539 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.51 -45.28 91.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.086 -1.008 . . . . 0.0 108.928 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.27 -43.34 91.58 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.509 -0.744 . . . . 0.0 109.051 179.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.704 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 66.3 t80 -66.07 -49.93 65.89 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.471 0.653 . . . . 0.0 109.89 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.9 t -67.17 -45.02 87.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.414 -0.804 . . . . 0.0 109.641 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 92.8 t -64.17 -35.6 74.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.438 -0.789 . . . . 0.0 109.597 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.29 -31.09 63.32 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.753 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.425 ' OE2' ' CG2' ' A' ' 44' ' ' VAL . 84.3 tt0 -65.44 -31.96 73.32 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.747 -179.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.596 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.2 p90 -141.89 45.68 1.68 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.213 -0.93 . . . . 0.0 109.627 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.556 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.51 136.03 52.69 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.941 -1.099 . . . . 0.0 110.119 -179.78 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -77.6 -150.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.222 1.948 . . . . 0.0 110.249 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.461 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 54.0 p30 -79.95 12.11 2.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.822 -1.174 . . . . 0.0 108.706 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.9 t -113.41 136.71 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.567 -0.708 . . . . 0.0 109.847 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.96 82.94 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.186 -0.946 . . . . 0.0 108.863 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -48.38 -30.32 15.2 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.746 1.631 . . . . 0.0 111.541 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.61 -20.55 62.74 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.495 -0.753 . . . . 0.0 109.513 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -103.73 8.61 37.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.32 -0.863 . . . . 0.0 109.748 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -101.13 135.93 35.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.315 -0.866 . . . . 0.0 108.99 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.593 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -67.87 89.95 0.29 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.164 -0.96 . . . . 0.0 109.082 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -60.53 6.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.379 -0.826 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.593 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.2 t0 -89.21 4.36 48.91 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.93 . . . . 0.0 108.733 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.7 tp -95.65 134.24 38.77 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.563 -0.711 . . . . 0.0 109.368 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -66.07 121.49 15.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -76.04 9.27 2.56 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 109.882 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.19 -38.28 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.112 -0.992 . . . . 0.0 108.951 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.434 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -57.08 -35.53 69.48 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.8 m-20 -83.8 15.02 3.49 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -14.76 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.8 t -51.65 -37.94 20.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.096 -1.238 . . . . 0.0 108.428 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.8 tt -70.7 -24.82 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.508 -0.745 . . . . 0.0 110.139 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.59 ' OD1' ' CD1' ' A' ' 66' ' ' PHE . 82.7 m-20 -60.24 -32.93 71.6 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -178.26 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.48 -64.97 1.09 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.926 -1.109 . . . . 0.0 111.513 -178.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.0 mp -72.39 -52.16 17.24 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.096 -1.002 . . . . 0.0 110.983 -178.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . 0.408 ' CA ' ' OE1' ' A' ' 14' ' ' GLU . . . -66.4 -36.92 92.27 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.53 -41.26 89.64 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.471 -1.017 . . . . 0.0 109.636 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -66.15 -44.37 84.34 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.486 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -67.26 -38.69 85.55 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.291 -0.881 . . . . 0.0 110.239 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.425 ' CG2' ' OE2' ' A' ' 14' ' ' GLU . 78.5 t -64.48 -44.87 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.204 -0.935 . . . . 0.0 110.576 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.07 -47.21 90.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 120.969 -1.082 . . . . 0.0 109.769 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.11 -44.37 80.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.285 -0.885 . . . . 0.0 110.537 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.704 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.0 t90 -74.8 -41.89 59.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.152 -0.967 . . . . 0.0 110.196 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -58.55 -40.13 82.17 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.254 -0.904 . . . . 0.0 109.604 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.08 -42.3 99.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -65.08 -42.94 93.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.378 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.3 ttt180 -65.98 -44.58 84.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 111.514 -178.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -105.65 -5.28 20.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.991 -1.068 . . . . 0.0 110.844 -178.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.58 32.5 71.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.56 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 76.8 mt -97.01 144.57 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 145.13 52.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.155 -0.965 . . . . 0.0 109.612 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.07 -28.69 69.79 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.841 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.572 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.0 m-20 54.7 50.82 15.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.061 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 57' ' ' ASP . 23.5 t70 -41.29 92.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.39 -0.819 . . . . 0.0 109.867 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ASP . 13.6 p -134.24 144.47 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.393 -0.817 . . . . 0.0 108.948 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -89.66 133.0 34.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 109.713 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.7 mt -110.32 140.74 44.19 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.488 -0.757 . . . . 0.0 109.534 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.7 158.18 59.95 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.482 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -60.1 -27.87 85.8 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.737 2.291 . . . . 0.0 112.042 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.83 -29.38 70.58 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -67.32 -26.39 66.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.811 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.59 ' CD1' ' OD1' ' A' ' 37' ' ' ASP . 80.1 m-85 -93.7 7.02 46.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.16 -0.962 . . . . 0.0 109.536 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -54.94 -39.08 68.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.272 -0.892 . . . . 0.0 109.553 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.0 p -138.93 151.1 46.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.09 -1.006 . . . . 0.0 109.909 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -63.27 -36.88 77.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.32 -0.863 . . . . 0.0 109.806 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 -61.2 -36.9 81.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 110.294 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.5 -44.21 89.37 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.985 -1.072 . . . . 0.0 109.368 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.3 mt -66.66 -38.55 81.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.327 -0.858 . . . . 0.0 109.408 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -58.31 -38.54 77.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.458 -0.776 . . . . 0.0 109.765 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.95 96.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.89 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -62.19 -46.1 90.43 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.815 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.0 t -63.16 -43.1 98.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.242 -0.911 . . . . 0.0 109.923 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 57.0 t -63.73 -40.6 89.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.274 -0.891 . . . . 0.0 109.832 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.03 -35.28 75.77 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.73 -48.15 5.05 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.03 -1.276 . . . . 0.0 110.215 -179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 42.1 m -131.69 134.75 46.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.345 -0.847 . . . . 0.0 109.409 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.306 -0.871 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 121.371 0.605 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.581 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -85.1 125.77 33.05 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.428 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 1.6 m-70 54.97 19.63 2.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 108.551 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.89 -39.63 92.61 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.419 -0.801 . . . . 0.0 110.183 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -63.96 -34.99 79.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.097 -1.002 . . . . 0.0 109.889 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.75 -39.67 84.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.449 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 91.2 mt -59.89 -43.02 91.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.501 -0.749 . . . . 0.0 110.195 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.548 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.09 -49.41 74.56 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.104 -0.998 . . . . 0.0 109.48 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.419 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.2 pp0? -69.55 -33.76 73.23 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.8 t80 -66.63 -51.87 51.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 110.004 -179.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.1 m -72.92 -39.89 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.257 -0.902 . . . . 0.0 110.16 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.548 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 99.5 t -64.55 -38.76 83.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.922 . . . . 0.0 109.922 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.1 -30.15 61.66 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.227 -0.921 . . . . 0.0 109.538 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.14 -29.51 70.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.304 -0.872 . . . . 0.0 108.987 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.614 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 16.9 p90 -149.52 49.63 0.95 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.298 -0.876 . . . . 0.0 109.257 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.13 136.71 53.48 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 120.89 -1.131 . . . . 0.0 110.183 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -73.36 -153.47 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 121.972 1.781 . . . . 0.0 110.603 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -80.3 13.31 2.44 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.1 -1.0 . . . . 0.0 108.776 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.7 t -113.44 136.16 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.585 -0.697 . . . . 0.0 109.996 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.32 140.19 72.46 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.283 -0.885 . . . . 0.0 108.873 179.33 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.57 -33.22 23.15 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 121.692 1.595 . . . . 0.0 111.808 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.23 -19.6 65.56 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.445 -0.784 . . . . 0.0 109.353 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -96.46 0.16 49.95 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.451 -0.781 . . . . 0.0 108.983 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -107.08 134.04 49.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.611 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.3 m-20 -70.98 99.73 1.85 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 109.376 -179.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.8 m -59.68 5.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.353 -0.842 . . . . 0.0 109.768 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.611 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -92.16 8.6 37.24 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.065 -1.022 . . . . 0.0 108.841 179.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.3 tp -94.54 136.56 34.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.593 -0.692 . . . . 0.0 109.544 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.41 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.5 m-20 -63.24 121.57 14.01 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.28 6.73 2.09 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.635 -179.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -53.4 -39.49 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 108.941 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -57.79 -36.14 71.77 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.3 m-20 -85.27 15.1 4.54 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.29 -15.06 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.83 -37.36 20.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.054 -1.262 . . . . 0.0 108.46 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.3 tt -70.69 -24.84 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.536 -0.727 . . . . 0.0 110.142 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.428 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.4 m-20 -60.04 -33.34 71.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.235 -0.916 . . . . 0.0 111.141 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -105.62 -64.79 1.11 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.91 -1.118 . . . . 0.0 111.451 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -72.21 -52.17 17.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 111.018 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.77 -36.85 91.8 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tp -58.91 -41.96 88.49 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.43 -1.041 . . . . 0.0 109.459 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.7 tp -65.68 -44.28 86.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.203 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 41.4 mttt -67.02 -36.38 81.98 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.361 -0.837 . . . . 0.0 109.913 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.428 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 79.2 t -62.41 -44.32 99.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 0.0 110.366 -179.276 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.16 -48.27 87.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.922 -1.111 . . . . 0.0 109.398 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.32 -44.33 79.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.375 -0.828 . . . . 0.0 110.658 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -75.5 -43.62 48.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.102 -0.999 . . . . 0.0 110.243 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.428 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -57.9 -40.26 79.9 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.33 -0.856 . . . . 0.0 109.548 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.583 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.7 tt0 -61.62 -42.66 99.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.141 -0.974 . . . . 0.0 109.389 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.56 -43.09 85.97 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.112 -0.992 . . . . 0.0 110.364 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.685 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 59.8 ttt-85 -64.68 -44.23 91.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.317 -0.865 . . . . 0.0 111.241 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 96.9 m-85 -104.69 -10.15 17.68 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.94 -1.1 . . . . 0.0 110.765 -178.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 24.65 73.42 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -95.01 142.41 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.122 -1.223 . . . . 0.0 109.418 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.96 149.97 34.87 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.083 -1.011 . . . . 0.0 109.228 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.17 72.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.242 -0.911 . . . . 0.0 109.586 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 50.43 48.17 22.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.108 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -63.17 123.17 17.95 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 110.037 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.0 163.09 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -65.37 132.06 48.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.975 -1.078 . . . . 0.0 109.5 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 9.7 mt -125.41 147.31 49.24 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.557 -0.715 . . . . 0.0 109.649 -179.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.61 157.75 38.41 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 109.055 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -60.12 -25.56 80.18 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.721 2.281 . . . . 0.0 112.071 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.05 -31.94 73.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.542 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 52.2 t-80 -67.9 -26.79 66.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.695 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -98.34 6.35 47.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.9 tpt180 -56.21 -39.37 72.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.213 -0.929 . . . . 0.0 109.703 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.4 p -143.59 156.23 44.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.019 -1.05 . . . . 0.0 110.063 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.7 mt -62.45 -36.51 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.345 -0.847 . . . . 0.0 109.835 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -60.61 -39.12 87.01 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 110.356 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.485 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 84.9 p -60.27 -37.63 81.05 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.067 -1.021 . . . . 0.0 109.587 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.5 mt -67.99 -38.8 80.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.289 -0.882 . . . . 0.0 109.37 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.581 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 51.5 t0 -58.29 -38.65 77.44 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.433 -0.792 . . . . 0.0 109.937 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.2 -44.34 92.26 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.092 -1.005 . . . . 0.0 109.732 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.542 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 71.4 t80 -64.89 -47.12 78.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.63 -42.08 94.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.325 -0.859 . . . . 0.0 109.917 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.4 t -64.27 -41.43 92.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.14 -0.975 . . . . 0.0 109.942 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.61 -33.85 73.9 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.66 -48.01 4.65 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.294 . . . . 0.0 110.518 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.482 ' O ' ' O ' ' A' ' 76' ' ' VAL . 43.2 m -129.49 138.07 51.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.862 . . . . 0.0 110.044 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.524 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.457 0 O-C-N 121.425 -0.797 . . . . 0.0 109.15 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.4 mtm . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.354 0.597 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.478 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 92.8 mt-30 -107.83 138.86 43.32 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.48 ' CD2' ' CG2' ' A' ' 6' ' ' VAL . 0.1 OUTLIER 44.11 27.74 0.22 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.138 -0.976 . . . . 0.0 108.912 -179.679 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.403 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -36.27 76.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.443 -0.785 . . . . 0.0 109.873 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -59.12 -40.26 84.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.167 -0.958 . . . . 0.0 109.534 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.48 ' CG2' ' CD2' ' A' ' 3' ' ' HIS . 73.3 t -66.3 -37.47 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.196 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 83.8 mt -59.88 -50.58 79.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.878 . . . . 0.0 109.436 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.544 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.18 -47.82 78.32 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.05 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.27 -40.84 98.53 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.478 -0.763 . . . . 0.0 109.662 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.469 ' CE2' ' CH2' ' A' ' 47' ' ' TRP . 67.3 t80 -66.84 -51.54 54.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.437 -0.789 . . . . 0.0 110.348 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -69.96 -41.22 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.877 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 87.4 t -64.5 -35.77 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.91 . . . . 0.0 109.575 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.68 -30.8 63.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.589 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.45 -31.49 72.6 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.273 -0.892 . . . . 0.0 109.729 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.593 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.9 p90 -142.97 46.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.563 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 136.06 53.22 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.206 -179.76 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.49 -150.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.168 1.912 . . . . 0.0 110.432 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.8 p30 -79.69 12.78 2.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.896 -1.128 . . . . 0.0 108.842 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.5 t -113.33 136.31 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.468 -0.77 . . . . 0.0 109.835 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.07 138.68 87.38 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.133 -0.98 . . . . 0.0 108.783 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.34 -26.76 8.91 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 121.869 1.713 . . . . 0.0 112.141 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.04 -16.91 61.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.106 -0.996 . . . . 0.0 109.749 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -105.36 7.01 33.12 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -0.863 . . . . 0.0 110.412 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 m -96.06 144.53 10.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 120.946 -1.096 . . . . 0.0 109.273 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.581 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -70.44 88.08 0.65 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.029 -1.044 . . . . 0.0 109.193 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.7 m -61.67 5.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.271 -0.893 . . . . 0.0 109.546 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.581 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -97.87 6.8 47.34 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 108.954 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.1 tp -96.94 135.53 38.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.484 -0.76 . . . . 0.0 109.555 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -64.26 121.75 15.02 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.86 8.42 0.52 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.762 -179.016 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.9 p -53.73 -39.83 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.131 -0.981 . . . . 0.0 109.01 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.0 t0 -58.11 -35.79 71.96 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.624 ' O ' ' N ' ' A' ' 35' ' ' VAL . 62.8 m-80 -85.2 15.07 4.48 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.27 -15.97 0.02 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.624 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.7 t -52.71 -37.14 24.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.972 -1.311 . . . . 0.0 108.311 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.613 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.1 tt -70.53 -25.16 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.479 -0.763 . . . . 0.0 109.94 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.9 m-20 -62.21 -29.66 70.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.263 -0.898 . . . . 0.0 110.66 -178.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.0 m -104.9 -64.76 1.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.02 -1.05 . . . . 0.0 110.979 -178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 19.8 mt -74.03 -52.4 12.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 110.846 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.8 93.79 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.613 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.95 -39.74 93.14 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.496 -1.002 . . . . 0.0 109.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.0 -44.04 94.8 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -67.52 -40.25 85.09 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.363 -0.836 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.16 -45.54 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 110.082 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.513 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -62.73 -41.73 93.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.063 -1.023 . . . . 0.0 109.66 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.05 -41.01 99.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.925 . . . . 0.0 109.676 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.704 ' HE1' ' NH1' ' A' ' 51' ' ' ARG . 0.8 OUTLIER -78.56 -49.1 13.91 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.954 179.884 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.31 -43.24 96.53 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.45 -0.781 . . . . 0.0 110.626 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 0.9 OUTLIER -66.53 -36.28 82.3 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.945 -1.097 . . . . 0.0 109.087 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.404 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 54.3 t0 -72.04 -44.99 62.49 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.388 -0.82 . . . . 0.0 110.223 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.704 ' NH1' ' HE1' ' A' ' 47' ' ' TRP . 22.5 ttm180 -60.95 -40.63 94.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.381 -0.825 . . . . 0.0 111.105 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -103.18 -6.14 22.47 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.824 -1.172 . . . . 0.0 110.21 -179.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.71 34.06 87.77 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -98.39 133.51 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.244 -1.15 . . . . 0.0 109.423 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.83 137.07 58.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.118 -0.989 . . . . 0.0 109.421 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.7 -29.02 67.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.362 -0.836 . . . . 0.0 110.233 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.456 ' C ' ' OD2' ' A' ' 57' ' ' ASP . 52.8 p30 -85.5 2.08 46.2 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -0.95 . . . . 0.0 110.457 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -60.34 -37.83 81.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.914 -1.116 . . . . 0.0 109.627 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.41 159.89 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.464 -0.773 . . . . 0.0 109.504 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -96.35 138.27 34.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.211 -0.931 . . . . 0.0 109.323 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.08 140.32 36.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.309 -0.87 . . . . 0.0 109.795 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.24 157.41 75.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.362 -0.836 . . . . 0.0 109.238 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.27 -31.26 82.05 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.609 2.206 . . . . 0.0 112.136 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.48 -31.91 73.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.4 -0.812 . . . . 0.0 109.765 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -68.2 -27.09 66.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.196 -0.94 . . . . 0.0 109.861 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.71 6.37 47.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -55.8 -38.64 70.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 97.0 p -135.15 152.92 52.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.318 -0.863 . . . . 0.0 109.749 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -63.54 -36.48 76.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.371 -0.831 . . . . 0.0 109.885 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -60.47 -38.31 83.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 110.271 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.6 t -57.92 -42.98 85.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.017 -1.052 . . . . 0.0 109.661 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -62.0 -39.58 84.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.213 -0.929 . . . . 0.0 109.328 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -57.83 -37.0 73.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.341 -0.849 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.5 -41.15 96.86 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.233 -0.917 . . . . 0.0 109.524 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -62.87 -46.93 85.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.84 -43.22 97.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.294 -0.879 . . . . 0.0 109.818 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.5 t -60.89 -40.79 86.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.295 -0.878 . . . . 0.0 109.833 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.14 -30.78 74.66 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 120.409 -0.9 . . . . 0.0 110.949 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.15 -48.43 3.87 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.952 -1.323 . . . . 0.0 110.593 -178.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -128.23 155.3 44.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.154 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.528 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.3 t . . . . . 0 C--N 1.303 -1.44 0 O-C-N 121.148 -0.97 . . . . 0.0 109.77 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.0 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -59.06 -38.18 78.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.828 . . . . 0.0 109.634 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.5 p-80 -122.9 23.43 9.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.491 -0.756 . . . . 0.0 109.148 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.69 -34.4 72.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.362 -0.836 . . . . 0.0 109.764 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.5 t -59.0 -41.84 88.64 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.2 t -66.23 -38.4 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.305 -0.872 . . . . 0.0 109.118 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.453 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 94.0 mt -59.34 -50.62 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.395 -0.815 . . . . 0.0 109.69 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.98 97.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 108.864 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.48 -39.64 92.16 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.537 -0.727 . . . . 0.0 109.442 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.6 t80 -61.22 -51.42 69.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.431 -0.793 . . . . 0.0 110.011 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.433 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 12.4 p -72.96 -48.95 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.313 -0.867 . . . . 0.0 110.87 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.433 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 61.9 t -60.9 -35.87 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.162 -0.961 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -59.51 -34.57 72.77 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.991 -1.068 . . . . 0.0 110.005 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.65 -36.3 82.22 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 111.028 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -100.61 -57.78 2.04 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.894 -1.128 . . . . 0.0 111.052 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.6 mp -123.97 87.3 53.2 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.238 -0.914 . . . . 0.0 110.944 -178.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -91.51 -16.67 1.23 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.199 2.599 . . . . 0.0 112.084 178.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -76.39 -4.5 42.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.157 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.5 145.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD2' ' A' ' 23' ' ' ASP . . . -60.84 115.58 14.57 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 120.755 -1.215 . . . . 0.0 108.289 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.62 -23.93 69.89 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 C-N-CA 121.329 1.353 . . . . 0.0 111.819 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.21 -15.66 62.47 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -0.89 . . . . 0.0 109.865 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD2' ' O ' ' A' ' 20' ' ' ALA . 49.6 p30 -89.09 3.24 52.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.014 -1.054 . . . . 0.0 109.767 -179.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 m -77.21 140.74 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.114 -0.991 . . . . 0.0 108.672 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -66.42 82.71 0.09 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.067 -1.021 . . . . 0.0 109.278 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.5 m -62.47 5.71 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -0.927 . . . . 0.0 109.465 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.7 m-20 -103.08 7.17 38.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -0.892 . . . . 0.0 108.936 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.9 tp -98.51 137.45 37.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.498 -0.751 . . . . 0.0 109.525 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.575 ' OD1' ' NH2' ' A' ' 67' ' ' ARG . 89.0 m-20 -61.08 122.1 14.15 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.48 7.72 1.31 Allowed 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.192 -0.942 . . . . 0.0 110.177 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 34' ' ' GLY . 66.5 t -54.74 -43.75 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 120.823 -1.173 . . . . 0.0 108.362 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.76 -35.48 66.27 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -83.89 15.34 3.39 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 178.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.44 -14.82 0.01 OUTLIER Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.6 t -51.42 -38.81 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -1.122 . . . . 0.0 108.236 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.599 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -70.38 -24.98 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-O 121.717 0.77 . . . . 0.0 109.498 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.4 t0 -58.37 -34.02 70.22 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.503 -0.748 . . . . 0.0 111.24 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.59 -64.24 1.16 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.009 -1.057 . . . . 0.0 111.25 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.558 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -72.05 -52.03 18.84 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.061 -1.024 . . . . 0.0 111.014 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.08 -37.93 94.76 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.599 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.84 -41.27 86.54 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.389 -1.065 . . . . 0.0 109.107 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 33.6 tp -61.91 -44.14 97.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 108.663 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -68.13 -39.53 82.7 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.431 -0.793 . . . . 0.0 109.715 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.55 -45.46 95.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 110.197 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.2 -47.99 91.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.213 -0.93 . . . . 0.0 109.444 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.43 -42.95 95.74 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.773 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -71.37 -39.83 70.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.346 -0.846 . . . . 0.0 109.737 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.4 tp -59.28 -47.18 86.34 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.233 -0.917 . . . . 0.0 109.468 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -65.91 -39.0 90.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.181 -0.95 . . . . 0.0 108.972 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -66.23 -36.01 81.92 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 110.614 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -84.98 -52.42 5.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.197 -0.939 . . . . 0.0 112.012 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -94.99 -5.35 44.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.721 -1.237 . . . . 0.0 111.306 -177.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.09 24.77 76.33 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.971 -1.651 . . . . 0.0 108.971 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.5 145.51 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.311 -1.111 . . . . 0.0 109.482 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.73 150.33 32.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 109.444 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.25 -30.59 62.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.422 -0.799 . . . . 0.0 109.611 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 55.11 46.47 23.97 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -0.878 . . . . 0.0 109.558 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -95.14 16.23 16.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.232 -0.917 . . . . 0.0 109.737 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 63.3 t -56.72 -43.75 80.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.105 -0.997 . . . . 0.0 109.548 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -138.36 132.0 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.163 -0.961 . . . . 0.0 109.671 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.6 mp -131.35 140.13 49.65 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.303 -0.873 . . . . 0.0 109.594 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.29 146.58 20.21 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.383 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.79 -22.98 74.34 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.57 2.18 . . . . 0.0 112.195 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.07 -31.63 72.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.382 -0.824 . . . . 0.0 109.934 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.606 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 58.3 t-80 -67.87 -26.95 66.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.175 -0.953 . . . . 0.0 109.654 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.77 11.18 34.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.33 -0.856 . . . . 0.0 109.835 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.575 ' NH2' ' OD1' ' A' ' 29' ' ' ASP . 41.6 tpt85 -54.36 -38.51 66.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.18 -0.95 . . . . 0.0 109.571 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.5 p -149.12 156.28 41.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.144 -0.972 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -62.71 -36.67 76.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.344 -0.848 . . . . 0.0 109.83 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.7 ttp180 -60.41 -40.85 92.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.897 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.9 t -60.61 -44.19 96.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.361 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.7 mt -66.54 -38.58 81.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.308 -0.87 . . . . 0.0 109.727 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.454 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 88.7 m-20 -57.77 -41.1 81.33 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.312 -0.867 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.22 -46.15 78.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.103 -0.998 . . . . 0.0 109.631 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.606 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 66.0 t80 -64.12 -46.44 84.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.353 -0.842 . . . . 0.0 109.366 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.1 t -64.86 -41.69 92.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.368 -0.832 . . . . 0.0 109.881 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.454 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 54.4 t -62.31 -41.08 90.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.084 -1.01 . . . . 0.0 109.803 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.07 -34.75 73.94 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.34 -48.12 4.48 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.09 -1.241 . . . . 0.0 110.522 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.3 m -129.53 138.09 51.15 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.349 -0.844 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.524 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.489 1.5 0 O-C-N 121.408 -0.808 . . . . 0.0 109.292 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.9 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.343 0.592 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -58.51 -40.77 83.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 109.644 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.518 ' NE2' ' OG1' ' A' ' 81' ' ' THR . 57.0 m-70 -126.62 12.0 7.37 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.38 -0.825 . . . . 0.0 109.516 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.58 -32.27 70.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 110.045 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -58.66 -37.13 75.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.076 -1.015 . . . . 0.0 109.662 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.51 -36.97 76.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.198 -0.939 . . . . 0.0 109.005 179.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 83.5 mt -60.63 -50.63 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.29 -0.882 . . . . 0.0 109.643 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.33 -47.18 80.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.042 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.7 -44.31 96.57 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.5 t80 -66.22 -45.06 82.03 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.6 -0.688 . . . . 0.0 109.652 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.8 -49.7 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.438 -0.788 . . . . 0.0 110.556 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.12 -35.13 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.359 -0.838 . . . . 0.0 110.199 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -56.56 -34.59 67.25 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.429 -0.794 . . . . 0.0 109.996 -179.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.61 -30.8 71.17 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 110.621 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -109.84 -57.86 2.13 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.116 -0.99 . . . . 0.0 111.32 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -123.66 86.9 52.67 Favored Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.111 -0.993 . . . . 0.0 111.362 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.33 -19.21 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 123.154 2.569 . . . . 0.0 111.868 177.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.28 -4.1 40.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.239 -0.913 . . . . 0.0 109.091 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.15 143.81 22.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.94 115.76 15.5 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.728 -1.232 . . . . 0.0 108.557 -179.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.26 -25.86 71.97 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 C-N-CA 121.479 1.452 . . . . 0.0 111.746 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.92 -14.92 62.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.285 -0.884 . . . . 0.0 109.227 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -88.84 8.43 29.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.378 -0.826 . . . . 0.0 109.151 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -93.33 137.35 22.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.605 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -64.44 85.63 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.146 -0.971 . . . . 0.0 109.57 -179.334 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.506 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 2.6 p -59.64 5.72 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.301 -0.874 . . . . 0.0 109.677 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.605 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -101.93 6.44 41.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.07 -1.019 . . . . 0.0 108.787 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 15.0 tp -100.14 133.47 44.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.519 -0.738 . . . . 0.0 109.586 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.484 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -66.67 121.78 16.17 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.618 ' H ' ' CD1' ' A' ' 30' ' ' LEU . 0.0 OUTLIER -70.03 11.63 0.29 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.173 -0.955 . . . . 0.0 109.946 -179.077 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 29' ' ' ASP . 34.0 m -52.38 -44.07 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 120.869 -1.144 . . . . 0.0 108.495 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.412 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 91.7 m-20 -56.67 -35.28 68.23 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.5 m-20 -83.51 15.24 3.19 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.45 -13.88 0.01 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 50.2 t -50.63 -37.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.059 -1.259 . . . . 0.0 108.523 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.626 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.9 tt -70.57 -24.45 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.446 -0.784 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -61.51 -31.65 71.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.135 -0.978 . . . . 0.0 111.079 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 m -105.67 -65.28 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.93 -1.106 . . . . 0.0 111.486 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.55 -52.51 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.11 -0.994 . . . . 0.0 110.97 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.1 -37.17 92.83 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.626 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.2 tp -58.8 -43.4 90.51 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.489 -1.007 . . . . 0.0 109.196 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.55 -43.19 93.59 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.445 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -66.99 -36.62 82.59 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.41 -0.806 . . . . 0.0 109.419 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 73.1 t -65.66 -49.58 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.323 -0.86 . . . . 0.0 110.605 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.9 mm -62.32 -41.34 91.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 120.922 -1.111 . . . . 0.0 109.65 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.26 -43.21 92.02 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.606 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -74.61 -39.85 61.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.367 -0.833 . . . . 0.0 109.786 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.6 tp -58.25 -42.08 85.6 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.293 -0.879 . . . . 0.0 109.625 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 53' ' ' GLY . 55.0 tt0 -63.01 -40.35 97.51 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -67.93 -47.14 69.51 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.13 -0.982 . . . . 0.0 110.764 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -68.08 -43.47 78.46 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.314 -0.866 . . . . 0.0 111.972 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -103.6 -6.33 21.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.846 -1.159 . . . . 0.0 111.299 -178.11 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.13 27.43 73.81 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.5 142.16 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -1.136 . . . . 0.0 109.366 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.6 144.33 51.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.02 . . . . 0.0 109.708 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.83 -34.07 74.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.437 -0.79 . . . . 0.0 109.717 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 57' ' ' ASP . 53.2 p30 -89.62 12.1 17.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.823 . . . . 0.0 109.817 -179.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -53.34 -34.89 59.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.231 -0.918 . . . . 0.0 109.913 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.5 p -129.31 144.6 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.432 -0.793 . . . . 0.0 109.769 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -71.6 144.05 49.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.8 mt -96.58 136.22 37.41 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.26 -0.9 . . . . 0.0 109.923 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.85 144.05 10.83 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.908 . . . . 0.0 109.132 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.09 -25.81 73.25 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.255 1.97 . . . . 0.0 111.929 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.41 -31.0 71.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.433 -0.792 . . . . 0.0 109.757 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -68.25 -26.56 65.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 110.562 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' LEU . 94.0 m-85 -99.14 10.27 41.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.058 -1.026 . . . . 0.0 111.089 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -58.46 -35.86 72.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.709 -1.244 . . . . 0.0 109.747 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.3 p -142.6 147.91 36.62 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.12 -0.987 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.447 HD11 HG22 ' A' ' 69' ' ' ILE . 90.7 mt -66.41 -36.6 77.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 O-C-N 121.307 -0.871 . . . . 0.0 110.113 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.3 mtm180 -61.16 -38.36 86.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.872 . . . . 0.0 110.573 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.0 p -62.59 -39.62 94.31 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.94 -1.1 . . . . 0.0 110.071 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.1 mt -68.45 -40.94 82.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.178 -0.951 . . . . 0.0 109.939 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.496 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 49.4 t0 -59.04 -39.34 81.72 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.309 -0.87 . . . . 0.0 110.17 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.18 -45.48 88.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.081 -1.012 . . . . 0.0 109.95 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -64.52 -46.87 81.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -0.941 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.6 t -64.76 -41.42 92.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.867 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.496 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 79.8 t -60.56 -41.53 88.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.147 -0.97 . . . . 0.0 109.921 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.47 -32.83 79.01 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 120.308 -0.948 . . . . 0.0 110.829 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -48.22 3.93 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.115 -1.227 . . . . 0.0 110.886 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.1 m -128.11 138.39 52.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.298 -0.876 . . . . 0.0 109.879 -179.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.518 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 1.6 t . . . . . 0 N--CA 1.487 1.404 0 O-C-N 121.327 -0.858 . . . . 0.0 109.539 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.408 0.623 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tp60 -58.02 -41.58 83.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.346 -0.846 . . . . 0.0 109.735 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 70.6 m80 -118.32 4.13 11.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.449 -0.782 . . . . 0.0 109.816 -179.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.47 -38.06 73.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.151 -0.968 . . . . 0.0 109.674 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 m -61.87 -43.65 98.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.745 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 10' ' ' PHE . 78.5 t -65.11 -39.58 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.951 . . . . 0.0 108.913 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 95.9 mt -59.36 -49.84 82.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.365 -0.834 . . . . 0.0 109.337 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.39 -48.34 78.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 108.937 179.563 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.89 -39.53 94.76 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.494 -0.754 . . . . 0.0 109.553 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.426 ' N ' ' O ' ' A' ' 6' ' ' VAL . 63.6 t80 -66.94 -51.93 49.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.531 -0.73 . . . . 0.0 110.484 -178.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 20.7 m -73.07 -40.35 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 110.434 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 91.2 t -64.75 -37.04 79.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.966 . . . . 0.0 110.047 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.25 -34.46 66.39 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.177 -0.952 . . . . 0.0 110.017 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -66.11 -31.23 71.97 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.282 -0.886 . . . . 0.0 109.824 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -137.68 43.5 2.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.168 -0.957 . . . . 0.0 109.845 -179.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.556 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.09 135.65 54.58 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 120.785 -1.197 . . . . 0.0 110.069 -179.656 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -78.09 -151.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.147 1.898 . . . . 0.0 110.256 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.82 11.74 2.48 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 108.616 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.59 136.31 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.5 -0.75 . . . . 0.0 109.966 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.66 140.83 71.75 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 108.636 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.45 -28.23 11.49 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.8 1.667 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -24.8 67.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -0.827 . . . . 0.0 109.304 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.5 5.57 46.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.441 -0.787 . . . . 0.0 108.912 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.0 t -103.75 136.98 34.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.602 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.83 95.94 0.39 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.565 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.9 m -60.7 5.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 109.516 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.602 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -94.02 8.34 41.82 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.097 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.0 tp -89.12 138.78 31.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.584 -0.697 . . . . 0.0 109.39 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.8 m-20 -63.09 121.5 13.77 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.484 ' O ' ' OD1' ' A' ' 33' ' ' ASN . 0.4 OUTLIER -70.32 3.39 2.95 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 109.405 -179.364 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.7 p -53.99 -35.88 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.261 -0.9 . . . . 0.0 109.557 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -57.17 -40.24 76.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.191 -0.943 . . . . 0.0 108.473 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.4 p30 -91.45 15.99 11.19 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' ASP . . . -42.48 -14.11 0.01 OUTLIER Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.8 t -49.86 -33.28 8.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.973 -1.31 . . . . 0.0 108.383 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.581 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.6 tt -70.1 -24.63 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.849 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 34' ' ' GLY . 85.8 m-20 -61.81 -33.61 74.44 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.413 -0.804 . . . . 0.0 111.255 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.51 -65.15 1.08 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.946 -1.096 . . . . 0.0 111.516 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.2 tt -71.93 -49.85 34.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 111.515 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -68.79 -41.8 81.66 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.629 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.581 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -63.15 -43.55 98.0 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.291 -1.123 . . . . 0.0 110.236 -179.052 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 42.6 tp -58.32 -44.42 88.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.84 -1.162 . . . . 0.0 109.437 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.8 mttt -68.9 -37.06 78.74 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.116 -0.99 . . . . 0.0 109.557 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 48' ' ' LEU . 81.5 t -66.7 -47.67 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 111.239 -178.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.15 -45.64 92.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 120.586 -1.321 . . . . 0.0 110.162 -179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.64 -45.57 74.98 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.032 -1.043 . . . . 0.0 110.51 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.504 ' CZ2' ' CZ ' ' A' ' 51' ' ' ARG . 2.0 t90 -76.91 -46.12 25.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 110.29 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 44' ' ' VAL . 12.0 tp -57.15 -41.48 79.24 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.355 -0.841 . . . . 0.0 109.603 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 25.6 tt0 -63.15 -36.6 84.16 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.637 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.11 -39.65 86.95 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.086 -1.009 . . . . 0.0 110.04 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.504 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 77.8 mtm180 -77.3 -43.17 34.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -0.967 . . . . 0.0 111.934 -179.039 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -102.34 -6.5 22.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.826 -1.171 . . . . 0.0 110.803 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.16 30.56 77.07 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.442 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 94.4 mt -85.01 147.05 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.202 -1.175 . . . . 0.0 109.958 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 148.02 42.4 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.229 -0.92 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.24 -32.02 69.6 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.329 -0.857 . . . . 0.0 109.741 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 52.47 43.04 31.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.3 p30 -93.7 16.31 14.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.386 -0.821 . . . . 0.0 109.672 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -53.76 -44.22 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 110.04 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -173.34 118.2 0.29 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.121 -0.987 . . . . 0.0 110.092 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -109.25 138.11 46.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.381 -0.824 . . . . 0.0 109.083 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 141.94 37.04 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.42 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -63.74 -21.72 69.65 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.291 1.994 . . . . 0.0 112.385 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.89 -32.89 72.33 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 110.307 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -74.06 -26.49 60.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.131 -0.98 . . . . 0.0 110.708 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -94.65 8.0 43.84 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.94 -1.1 . . . . 0.0 110.75 -178.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.1 mmt180 -58.9 -34.32 71.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.724 -1.235 . . . . 0.0 110.19 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.645 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 96.7 p -135.5 149.94 49.65 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.052 -1.03 . . . . 0.0 110.122 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -64.3 -36.86 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.391 -0.818 . . . . 0.0 110.04 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -61.16 -37.24 82.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.25 -0.906 . . . . 0.0 110.686 -178.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.645 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.8 m -58.82 -44.1 90.79 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.977 -1.077 . . . . 0.0 109.765 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.0 mt -64.95 -38.66 83.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.189 -0.944 . . . . 0.0 109.622 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -56.8 -41.1 77.15 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.387 -0.821 . . . . 0.0 110.103 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.52 -46.22 76.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.086 -1.009 . . . . 0.0 110.231 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -63.42 -46.14 87.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.04 -1.038 . . . . 0.0 109.626 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.94 -44.5 92.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.368 -0.832 . . . . 0.0 110.267 -179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.0 t -63.17 -41.37 92.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.079 -1.013 . . . . 0.0 110.098 -179.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.56 -32.48 69.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.52 -48.27 3.86 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.101 -1.235 . . . . 0.0 110.819 -179.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.2 m -130.13 138.97 50.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.161 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.539 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.442 0 O-C-N 121.334 -0.854 . . . . 0.0 109.125 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.347 0.594 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.05 -36.19 74.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.31 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -150.1 44.68 0.9 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.385 -0.822 . . . . 0.0 109.273 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.04 -32.4 72.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.893 . . . . 0.0 109.934 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -58.46 -37.65 75.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.101 -0.999 . . . . 0.0 109.929 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.6 -39.49 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.148 -0.97 . . . . 0.0 109.357 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 94.6 mt -59.84 -40.07 81.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.265 -0.897 . . . . 0.0 109.627 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.39 -48.63 77.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.965 . . . . 0.0 109.118 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.427 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.37 -32.37 71.38 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.492 -0.755 . . . . 0.0 109.371 179.697 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -58.35 -51.51 69.49 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.296 -0.877 . . . . 0.0 109.722 -179.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 33.8 m -73.73 -45.01 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.062 -1.023 . . . . 0.0 110.781 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.3 t -64.43 -35.89 75.67 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.176 -0.953 . . . . 0.0 111.131 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -58.1 -33.01 68.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.011 -1.056 . . . . 0.0 110.005 -178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.19 -31.27 72.01 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 110.825 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -110.12 -55.87 2.4 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.214 -0.929 . . . . 0.0 111.472 -178.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.2 mt -124.44 87.65 53.96 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.082 -1.011 . . . . 0.0 111.389 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.91 -13.99 1.25 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 123.205 2.603 . . . . 0.0 111.776 178.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.45 -3.99 40.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.18 -0.95 . . . . 0.0 109.39 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.2 p -114.09 146.42 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.29 115.18 13.27 Favored Pre-proline 0 C--N 1.303 -1.441 0 O-C-N 120.742 -1.224 . . . . 0.0 108.362 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -64.84 -33.04 54.54 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.458 1.439 . . . . 0.0 111.913 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.46 -14.96 61.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -92.55 6.98 45.22 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.512 -0.742 . . . . 0.0 109.036 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.8 t -95.84 137.06 24.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.631 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.7 m-20 -61.58 90.61 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.223 -0.923 . . . . 0.0 109.589 -179.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -59.22 6.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.273 -0.892 . . . . 0.0 109.692 179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.631 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.2 m-20 -97.86 11.4 37.47 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.074 -1.016 . . . . 0.0 108.971 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.6 tp -89.51 133.89 34.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.43 -0.794 . . . . 0.0 109.704 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 91.2 m-20 -65.37 122.3 16.84 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.419 -0.801 . . . . 0.0 108.97 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.433 ' O ' ' N ' ' A' ' 33' ' ' ASN . 65.8 mt -62.06 -7.2 3.64 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.179 -0.951 . . . . 0.0 108.992 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.479 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -50.05 -41.16 17.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.03 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.479 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -58.8 -36.63 74.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 82.6 m-20 -85.29 16.86 3.37 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.48 -15.15 0.01 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.4 t -54.11 -38.78 39.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.78 -1.423 . . . . 0.0 107.853 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.23 -25.06 24.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.599 -0.688 . . . . 0.0 110.046 179.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.8 m-20 -62.37 -30.98 71.58 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 111.252 -178.306 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -104.97 -64.76 1.09 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.903 -1.123 . . . . 0.0 111.216 -178.62 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.5 mt -74.13 -52.58 12.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.121 -0.987 . . . . 0.0 110.964 -178.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.58 -36.59 93.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -61.33 -40.37 93.96 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.492 -1.005 . . . . 0.0 109.306 -179.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 34.2 tp -61.24 -44.21 97.62 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.535 -0.866 . . . . 0.0 108.797 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 46.1 mttp -70.5 -39.87 73.89 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.408 -0.808 . . . . 0.0 109.907 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 79.7 t -65.72 -45.72 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.881 . . . . 0.0 110.514 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.97 -44.36 99.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.032 -1.042 . . . . 0.0 109.697 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -63.43 -43.09 98.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.323 -0.86 . . . . 0.0 109.802 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -76.21 -43.35 42.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.189 -0.945 . . . . 0.0 109.992 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.4 tp -58.09 -47.97 81.58 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 110.055 -179.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.614 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.2 tt0 -67.95 -39.55 83.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.114 -0.991 . . . . 0.0 108.827 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 93.8 m-20 -64.9 -40.52 95.21 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.586 -0.696 . . . . 0.0 110.235 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -61.7 -44.79 96.25 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 111.3 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -113.94 -1.87 13.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.095 -1.003 . . . . 0.0 111.042 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.614 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.2 37.89 81.87 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.7 mt -96.18 142.76 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -1.181 . . . . 0.0 109.263 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.92 138.94 58.41 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.915 -1.115 . . . . 0.0 109.491 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.8 -32.47 73.66 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -57.69 -37.75 74.0 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.382 -0.823 . . . . 0.0 109.9 -179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.06 -37.74 67.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.118 -0.989 . . . . 0.0 109.377 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 60' ' ' GLU . 70.9 t -63.62 -37.16 78.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.85 . . . . 0.0 109.72 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . 86.3 tt0 58.57 127.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.559 -0.713 . . . . 0.0 109.654 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 17.5 mt -103.14 134.16 47.02 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.907 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -172.23 139.56 1.03 Allowed Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -63.02 -26.62 73.8 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 121.986 1.791 . . . . 0.0 111.622 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -30.89 71.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.588 -0.695 . . . . 0.0 109.596 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.403 ' HE2' HG23 ' A' ' 72' ' ' ILE . 84.5 t60 -68.73 -26.3 65.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.58 -0.7 . . . . 0.0 110.824 -178.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -101.39 6.2 42.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.977 -1.077 . . . . 0.0 111.607 -178.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 34.2 mmt180 -60.08 -34.11 73.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.743 -1.223 . . . . 0.0 110.028 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.456 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 84.7 p -144.04 147.25 33.57 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.874 -1.141 . . . . 0.0 110.185 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 78.6 mt -66.6 -36.74 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 O-C-N 121.482 -0.761 . . . . 0.0 109.896 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.4 mtm180 -61.03 -39.92 91.61 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.322 -0.861 . . . . 0.0 110.317 -178.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.456 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.9 m -60.61 -43.95 96.85 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.974 -1.079 . . . . 0.0 109.427 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.403 HG23 ' HE2' ' A' ' 65' ' ' HIS . 79.0 mt -68.51 -38.57 79.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.356 -0.84 . . . . 0.0 109.908 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -58.35 -42.0 85.92 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.398 -0.814 . . . . 0.0 110.438 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -40.12 88.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.11 -0.994 . . . . 0.0 110.368 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -61.41 -51.42 68.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 109.851 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 76.8 t -67.64 -43.79 86.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.261 -0.899 . . . . 0.0 109.763 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -63.02 -39.87 86.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.074 -1.016 . . . . 0.0 109.621 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.85 70.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.03 -48.88 3.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.146 -1.208 . . . . 0.0 110.565 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 57.9 m -157.37 137.96 13.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.138 -0.976 . . . . 0.0 110.168 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.0 t . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 108.944 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.6 mtt . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.322 0.582 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -60.08 -38.0 81.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.349 -0.844 . . . . 0.0 109.507 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -133.99 12.87 3.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.4 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.53 -35.61 76.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.316 -0.865 . . . . 0.0 110.051 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.514 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 86.8 p -61.76 -36.49 81.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.07 -1.019 . . . . 0.0 109.593 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.514 ' N ' ' HG ' ' A' ' 5' ' ' SER . 72.4 t -66.16 -37.47 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 108.94 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.49 -41.69 88.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.407 -0.808 . . . . 0.0 110.336 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.496 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.89 -50.55 68.31 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.042 -1.036 . . . . 0.0 110.378 -179.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.418 ' HG3' ' H ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.4 -44.22 68.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.073 -1.017 . . . . 0.0 109.614 179.866 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.418 ' H ' ' HG3' ' A' ' 9' ' ' GLN . 71.1 t80 -60.18 -48.32 82.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.284 -0.885 . . . . 0.0 109.463 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.547 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 97.6 t -68.82 -47.48 75.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.486 -0.759 . . . . 0.0 109.837 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.496 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 89.6 t -64.29 -36.67 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.427 -0.796 . . . . 0.0 109.964 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.81 -28.5 61.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.339 -0.85 . . . . 0.0 109.879 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.56 -29.45 70.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -155.94 55.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.155 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -80.59 136.8 51.67 Favored Pre-proline 0 C--N 1.306 -1.283 0 O-C-N 120.995 -1.065 . . . . 0.0 110.197 -179.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.58 -153.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 121.937 1.758 . . . . 0.0 110.641 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -81.24 14.2 2.5 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.092 -1.005 . . . . 0.0 108.79 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.5 t -113.3 136.9 48.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.646 -0.658 . . . . 0.0 109.994 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.07 140.21 73.38 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 108.962 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -48.86 -29.97 16.31 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 121.849 1.699 . . . . 0.0 112.081 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.6 -16.17 63.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.3 -0.875 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -102.2 5.48 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.347 -0.846 . . . . 0.0 109.234 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -105.0 136.78 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.586 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.9 t0 -71.15 96.2 1.34 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.157 -0.965 . . . . 0.0 109.431 -179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.2 m -60.91 6.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.356 -0.84 . . . . 0.0 109.676 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.586 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.0 6.79 48.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.132 -0.98 . . . . 0.0 109.118 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 tt -95.85 135.87 37.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.705 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.0 m-20 -60.86 121.92 13.56 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.75 14.92 0.07 Allowed 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.31 -0.868 . . . . 0.0 110.281 -178.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.505 ' H ' ' C ' ' A' ' 29' ' ' ASP . 73.4 t -54.34 -41.17 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 108.508 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -55.17 -35.21 64.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -83.07 14.53 3.32 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.86 -14.44 0.01 OUTLIER Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 44.4 t -51.21 -36.86 17.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 121.143 -1.21 . . . . 0.0 108.69 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.66 -24.56 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.438 -0.789 . . . . 0.0 110.229 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.3 m-20 -58.9 -34.87 72.17 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 111.474 -178.103 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.9 m -106.26 -64.97 1.11 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.931 -1.106 . . . . 0.0 111.673 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -71.37 -52.53 18.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.042 -1.036 . . . . 0.0 111.037 -177.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.76 -36.45 91.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tp -58.15 -42.76 86.61 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.372 -1.075 . . . . 0.0 108.898 -179.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.39 -44.12 95.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -68.55 -34.68 76.26 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.458 -0.776 . . . . 0.0 109.518 179.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 75.3 t -61.47 -45.8 97.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.329 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mm -62.66 -41.14 91.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.95 -1.093 . . . . 0.0 109.577 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.73 -44.49 81.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 109.867 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.444 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -76.35 -45.14 33.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.181 -0.949 . . . . 0.0 109.702 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.444 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.04 -40.98 77.8 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.347 -0.846 . . . . 0.0 109.512 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.551 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 2.9 tm-20 -60.86 -43.13 98.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.159 -0.963 . . . . 0.0 108.751 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -68.91 -43.3 75.48 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.294 -0.879 . . . . 0.0 110.045 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.6 tpt180 -64.27 -44.72 90.86 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.436 -0.79 . . . . 0.0 111.062 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -106.23 -5.39 19.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.063 -1.023 . . . . 0.0 110.998 -178.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.02 30.28 65.73 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.551 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 71.6 mt -96.71 138.82 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.177 . . . . 0.0 109.056 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 136.07 57.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.991 -1.068 . . . . 0.0 109.801 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.32 -24.84 65.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.528 -0.732 . . . . 0.0 109.414 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.18 -31.64 61.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.468 -0.77 . . . . 0.0 110.217 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.07 120.69 11.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.054 -1.029 . . . . 0.0 109.839 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.8 m -115.29 27.46 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.567 -0.708 . . . . 0.0 109.309 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -51.08 -26.04 5.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.379 -0.825 . . . . 0.0 109.922 -179.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.0 mt -71.73 138.99 48.91 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.08 -1.012 . . . . 0.0 109.792 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.85 162.4 51.91 Favored Pre-proline 0 N--CA 1.487 1.406 0 O-C-N 121.455 -0.778 . . . . 0.0 109.294 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -56.69 -36.21 98.12 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.324 2.016 . . . . 0.0 111.395 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.04 -25.8 65.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.474 -0.766 . . . . 0.0 109.185 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.48 ' CD2' ' CD2' ' A' ' 75' ' ' PHE . 34.1 t-80 -67.74 -26.03 65.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.415 -0.803 . . . . 0.0 109.863 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.533 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 92.0 m-85 -90.4 10.06 26.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.271 -0.893 . . . . 0.0 109.802 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 16.4 tpt180 -56.91 -40.35 76.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.921 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -144.75 153.41 41.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.951 -1.093 . . . . 0.0 110.263 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.4 mt -66.3 -36.8 78.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.462 -0.774 . . . . 0.0 110.123 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 14.1 ttm180 -60.77 -43.05 98.54 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.433 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.3 m -58.4 -40.46 82.48 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.226 -0.921 . . . . 0.0 109.918 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -61.54 -40.74 87.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.178 -0.951 . . . . 0.0 109.718 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -59.32 -37.5 77.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.288 -0.882 . . . . 0.0 109.996 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.8 -46.3 85.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.48 ' CD2' ' CD2' ' A' ' 65' ' ' HIS . 52.9 m-85 -68.45 -40.72 80.96 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.152 -0.967 . . . . 0.0 109.34 179.584 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -65.13 -41.99 93.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.296 -0.877 . . . . 0.0 109.585 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 56.3 t -63.74 -41.01 91.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 O-C-N 121.187 -0.946 . . . . 0.0 109.836 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.08 -30.96 71.47 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.33 -48.58 4.14 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.039 -1.271 . . . . 0.0 110.559 -178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.8 p -132.04 154.35 49.48 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.281 -0.887 . . . . 0.0 109.647 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.526 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.0 t . . . . . 0 C--N 1.303 -1.418 0 O-C-N 121.222 -0.924 . . . . 0.0 109.315 179.579 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -59.86 -37.28 78.84 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.598 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -144.36 34.87 1.19 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.241 -0.912 . . . . 0.0 109.542 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.438 ' CB ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.57 -32.48 70.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -0.912 . . . . 0.0 109.676 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.5 m -58.46 -37.42 75.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.125 -0.984 . . . . 0.0 109.971 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.8 t -63.97 -40.85 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.131 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 76.7 mt -60.02 -47.92 89.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.443 -0.786 . . . . 0.0 109.27 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.29 -43.01 99.11 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.14 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -37.38 86.42 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' VAL . 33.5 t80 -60.67 -52.89 63.22 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.513 -0.742 . . . . 0.0 109.886 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.472 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -73.48 -42.01 56.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.106 -0.996 . . . . 0.0 109.89 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.507 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 79.2 t -65.02 -35.59 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.36 -0.837 . . . . 0.0 110.911 -179.16 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -56.17 -36.17 68.04 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.023 -1.048 . . . . 0.0 110.353 -178.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.405 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 75.6 mm-40 -66.06 -31.5 72.42 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.043 -1.036 . . . . 0.0 109.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.405 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.2 OUTLIER -135.02 43.84 2.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.126 -0.984 . . . . 0.0 109.907 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.565 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.5 135.89 52.85 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.119 . . . . 0.0 110.116 -179.733 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.4 ' C ' ' H ' ' A' ' 19' ' ' VAL . 71.6 Cg_endo -77.4 -149.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.143 1.895 . . . . 0.0 110.184 178.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.46 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -79.52 11.25 3.16 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 120.794 -1.191 . . . . 0.0 108.637 179.08 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.4 ' H ' ' C ' ' A' ' 17' ' ' PRO . 26.8 t -113.75 136.16 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.519 -0.738 . . . . 0.0 109.841 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.57 140.92 75.65 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.126 -0.983 . . . . 0.0 108.916 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -48.41 -29.33 13.29 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 121.875 1.717 . . . . 0.0 111.998 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.21 -21.16 66.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.384 -0.823 . . . . 0.0 109.283 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -103.27 3.25 35.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.44 -0.787 . . . . 0.0 108.886 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -104.93 138.94 27.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.609 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.5 t0 -68.78 102.59 1.57 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.105 -0.997 . . . . 0.0 109.354 -179.255 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.0 m -59.62 6.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.433 -0.792 . . . . 0.0 109.933 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.609 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -89.92 10.11 25.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.03 -1.044 . . . . 0.0 108.632 179.248 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.2 tp -86.88 133.67 33.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.533 -0.729 . . . . 0.0 109.499 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.442 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.3 m-20 -67.45 121.27 15.43 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -73.31 9.79 1.19 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.123 -0.986 . . . . 0.0 109.349 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.51 -39.45 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.891 . . . . 0.0 108.825 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.4 m-20 -57.71 -36.18 71.65 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.9 m-80 -84.43 14.81 4.11 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.53 -15.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.617 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.58 -37.75 20.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.852 -1.381 . . . . 0.0 108.223 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.6 tt -71.04 -24.56 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.547 -0.721 . . . . 0.0 110.104 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.427 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.57 -32.15 71.24 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.153 -0.967 . . . . 0.0 111.358 -178.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.84 -65.11 1.09 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.864 -1.148 . . . . 0.0 111.393 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.33 -52.36 16.49 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.177 -0.952 . . . . 0.0 110.916 -178.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.07 -36.69 92.28 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tp -58.88 -41.12 86.34 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.379 -1.071 . . . . 0.0 109.301 -179.625 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.9 tp -62.8 -44.33 96.45 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.213 -0.93 . . . . 0.0 108.762 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -71.87 -38.26 70.07 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.421 -0.8 . . . . 0.0 109.948 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.79 -45.12 96.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 110.249 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.9 -42.47 94.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.171 -0.956 . . . . 0.0 109.607 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.77 -43.09 97.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.181 -0.949 . . . . 0.0 109.971 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -76.38 -43.68 39.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 109.842 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 31.4 tp -60.0 -42.5 94.41 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 0.0 109.842 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.609 ' O ' ' N ' ' A' ' 53' ' ' GLY . 4.1 tt0 -66.46 -41.69 88.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.12 -0.988 . . . . 0.0 108.996 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -66.61 -37.15 84.27 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.419 -0.8 . . . . 0.0 109.828 179.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -59.04 -41.72 88.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.498 -0.751 . . . . 0.0 110.818 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -118.93 -4.02 10.67 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.101 -0.999 . . . . 0.0 110.437 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.74 43.19 29.4 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -101.08 140.7 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.138 -1.213 . . . . 0.0 109.323 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.26 136.61 58.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.884 -1.135 . . . . 0.0 109.374 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.23 -33.63 76.25 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.363 -0.836 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -94.48 8.24 42.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.265 -0.897 . . . . 0.0 109.809 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.05 -37.31 61.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.093 -1.004 . . . . 0.0 109.293 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.27 144.78 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.451 -0.781 . . . . 0.0 109.169 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -77.75 137.38 38.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.429 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.3 mt -104.04 138.82 40.02 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.344 -0.848 . . . . 0.0 109.711 -179.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -135.58 154.85 78.53 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.321 -0.862 . . . . 0.0 109.06 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.34 -30.66 81.13 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.608 2.205 . . . . 0.0 112.339 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.79 -32.1 73.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.376 -0.828 . . . . 0.0 110.013 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -68.8 -26.48 65.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.288 -0.882 . . . . 0.0 110.897 -179.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -94.38 5.59 51.32 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.846 -1.159 . . . . 0.0 110.932 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -59.65 -40.87 89.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.034 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.0 m -129.45 145.26 51.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.25 -0.906 . . . . 0.0 110.184 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.1 mt -63.7 -36.28 75.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.467 -0.771 . . . . 0.0 109.759 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -60.33 -37.66 81.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.339 -0.851 . . . . 0.0 110.402 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -57.66 -43.46 84.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.999 -1.063 . . . . 0.0 109.633 -179.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -68.04 -38.74 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.261 -0.899 . . . . 0.0 109.634 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.438 ' OD1' ' CB ' ' A' ' 4' ' ' ALA . 50.4 t0 -57.72 -40.45 79.62 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.384 -0.823 . . . . 0.0 110.302 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.04 -45.68 80.56 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.029 -1.044 . . . . 0.0 109.624 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -63.54 -45.84 88.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.373 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' A' ' 80' ' ' THR . 59.1 t -65.22 -44.74 95.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.362 -0.836 . . . . 0.0 109.976 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.6 t -63.65 -39.39 85.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 O-C-N 121.11 -0.994 . . . . 0.0 109.838 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -33.65 68.34 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.5 -48.7 3.74 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.195 -1.179 . . . . 0.0 110.601 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.496 ' O ' ' O ' ' A' ' 76' ' ' VAL . 53.3 m -163.17 139.71 7.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.12 -0.987 . . . . 0.0 109.827 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.516 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.366 -0.834 . . . . 0.0 109.307 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.44 ' CE ' ' OG ' ' A' ' 5' ' ' SER . 4.2 ptt? . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.402 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.8 mt-30 55.6 44.15 27.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.27 -0.894 . . . . 0.0 109.107 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 2' ' ' GLN . 67.0 m170 46.45 37.69 4.58 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.181 -0.95 . . . . 0.0 109.048 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.75 -36.74 79.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.331 -0.856 . . . . 0.0 109.485 -179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' CE ' ' A' ' 1' ' ' MET . 22.9 m -59.23 -39.58 83.2 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.19 -0.944 . . . . 0.0 109.285 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.41 ' O ' ' N ' ' A' ' 10' ' ' PHE . 68.8 t -66.83 -37.66 79.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.203 -0.936 . . . . 0.0 109.0 179.33 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.5 mt -60.48 -51.01 78.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.251 -0.906 . . . . 0.0 109.177 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.534 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.81 -48.14 75.48 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.828 . . . . 0.0 109.301 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.85 -44.28 96.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.523 -0.736 . . . . 0.0 109.344 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.477 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.2 t80 -65.7 -48.7 71.14 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.57 -0.706 . . . . 0.0 109.486 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.33 -44.89 86.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.383 -0.823 . . . . 0.0 109.521 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.534 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 94.3 t -64.25 -35.28 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.488 -0.757 . . . . 0.0 109.527 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.8 -30.38 61.26 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.299 -0.876 . . . . 0.0 109.969 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -65.66 -31.09 71.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.114 -0.992 . . . . 0.0 109.702 -179.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.563 ' O ' ' CD1' ' A' ' 15' ' ' PHE . 33.5 p90 -143.29 45.79 1.53 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -0.999 . . . . 0.0 109.671 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.561 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.63 135.9 52.37 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.036 -1.04 . . . . 0.0 110.177 -179.813 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . 0.41 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.8 Cg_endo -77.58 -151.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.218 1.946 . . . . 0.0 110.364 178.293 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -78.72 12.18 2.22 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.826 -1.171 . . . . 0.0 108.748 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.41 ' H ' ' C ' ' A' ' 17' ' ' PRO . 22.0 t -113.4 137.0 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.52 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.72 84.34 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.151 -0.968 . . . . 0.0 108.911 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -48.2 -30.93 15.68 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.864 1.709 . . . . 0.0 112.179 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.8 -22.92 66.0 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.419 -0.8 . . . . 0.0 109.434 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -102.51 8.64 39.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.834 . . . . 0.0 109.434 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.1 t -101.3 136.73 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.318 -0.864 . . . . 0.0 108.862 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.585 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.71 89.34 0.38 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.134 -0.979 . . . . 0.0 109.275 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -61.57 6.39 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.563 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.585 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -93.34 8.55 39.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.111 -0.993 . . . . 0.0 108.918 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -91.41 136.81 32.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.487 -0.758 . . . . 0.0 109.575 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -62.43 121.79 14.12 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.61 10.53 1.68 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.257 -0.902 . . . . 0.0 110.101 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.5 t -55.42 -42.08 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.907 -1.12 . . . . 0.0 108.932 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.4 t0 -55.81 -35.53 66.44 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.28 14.77 4.88 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -15.19 0.02 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.5 t -53.24 -36.81 26.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.151 -1.205 . . . . 0.0 108.611 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.2 tt -70.46 -24.73 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.462 -0.774 . . . . 0.0 110.087 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.425 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.8 m-20 -61.11 -32.31 71.99 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.215 -0.928 . . . . 0.0 110.969 -178.588 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 46.1 m -105.77 -64.57 1.14 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.047 -1.033 . . . . 0.0 111.475 -178.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.1 mp -72.56 -52.4 15.75 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.072 -1.018 . . . . 0.0 110.969 -178.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.91 -37.4 93.25 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.7 tp -59.39 -41.03 88.48 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.461 -1.023 . . . . 0.0 109.141 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.9 tp -62.03 -43.96 97.72 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -65.48 -35.45 80.94 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.48 -0.763 . . . . 0.0 109.281 179.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -60.11 -43.86 93.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.427 -0.796 . . . . 0.0 110.102 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.5 -44.88 97.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.688 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.9 -43.3 96.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 110.203 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.477 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -75.3 -38.84 60.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.875 . . . . 0.0 109.936 -179.694 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.7 tp -57.92 -44.16 86.67 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.285 -0.884 . . . . 0.0 110.014 -179.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.588 ' O ' ' N ' ' A' ' 53' ' ' GLY . 30.1 tt0 -66.34 -40.36 89.78 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 109.41 179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -64.7 -44.04 91.54 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.319 -0.863 . . . . 0.0 110.574 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.15 -43.23 92.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.333 -0.854 . . . . 0.0 111.596 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -106.57 -7.07 17.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.952 -1.093 . . . . 0.0 110.782 -178.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.38 33.51 82.29 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.0 pt -108.78 153.12 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.363 -1.081 . . . . 0.0 109.961 -179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.84 151.37 30.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.714 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.01 70.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.434 -0.791 . . . . 0.0 109.987 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 52.91 49.53 20.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.162 -0.961 . . . . 0.0 108.864 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -74.85 118.17 17.51 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.334 -0.854 . . . . 0.0 110.214 -179.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.8 m -129.59 163.78 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -59.4 127.69 33.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.909 -1.119 . . . . 0.0 109.467 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.6 mt -114.93 146.03 41.59 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.35 155.7 39.01 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.33 -0.856 . . . . 0.0 109.096 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.11 -25.57 77.42 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.644 2.229 . . . . 0.0 112.014 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.54 -29.74 70.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.534 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.67 -26.66 66.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.268 -0.895 . . . . 0.0 109.795 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -99.39 8.49 44.58 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.69 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.93 -38.15 69.91 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.726 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.8 p -141.36 156.63 45.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.1 -1.0 . . . . 0.0 110.16 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.3 mt -61.79 -35.74 69.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.431 -0.793 . . . . 0.0 109.847 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -59.74 -39.03 83.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.848 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.2 t -58.48 -39.89 81.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.066 -1.021 . . . . 0.0 108.924 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.2 mt -60.84 -38.72 79.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.299 -0.876 . . . . 0.0 108.874 179.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -56.21 -36.92 68.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.448 -0.783 . . . . 0.0 109.02 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.67 -40.64 92.83 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.257 -0.902 . . . . 0.0 108.768 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -60.64 -46.41 90.41 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.97 -40.62 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.411 -0.805 . . . . 0.0 108.934 179.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.97 -40.75 78.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.482 -0.761 . . . . 0.0 109.186 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.77 -34.31 86.36 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.88 -48.85 4.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.893 -1.357 . . . . 0.0 110.553 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.6 p -128.7 152.74 48.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 108.721 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.534 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.0 t . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.213 -0.929 . . . . 0.0 110.237 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.657 ' SD ' ' NH2' ' A' ' 70' ' ' ARG . 59.8 mtt . . . . . 0 N--CA 1.488 1.427 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.49 -34.4 72.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.199 -0.938 . . . . 0.0 108.84 179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -171.94 26.79 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.28 -35.04 76.22 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.295 -0.878 . . . . 0.0 109.584 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.11 -41.65 88.67 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.965 . . . . 0.0 109.489 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.5 t -65.24 -39.82 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.224 -0.922 . . . . 0.0 108.907 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 88.9 mt -59.55 -50.71 78.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.456 -0.778 . . . . 0.0 109.351 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.11 -42.3 96.94 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 108.865 179.389 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.82 -39.57 91.0 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.509 -0.745 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -61.5 -52.22 65.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.356 -0.84 . . . . 0.0 109.847 -179.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.516 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 4.3 p -72.51 -42.44 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.275 -0.891 . . . . 0.0 109.929 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 84.4 t -64.38 -38.39 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.356 -0.84 . . . . 0.0 110.294 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.55 -28.0 59.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.216 -0.927 . . . . 0.0 110.143 -179.46 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -64.77 -30.05 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.054 -1.029 . . . . 0.0 109.028 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -154.47 55.47 0.69 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.352 -0.842 . . . . 0.0 109.208 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.403 ' H ' ' CD2' ' A' ' 16' ' ' LEU . 1.8 pt? -80.82 137.05 50.64 Favored Pre-proline 0 N--CA 1.486 1.331 0 O-C-N 121.079 -1.013 . . . . 0.0 110.106 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.15 -153.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 121.925 1.75 . . . . 0.0 110.837 179.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.453 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.0 p30 -82.16 15.31 2.42 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 108.838 179.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.7 t -112.96 137.15 46.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.623 -0.673 . . . . 0.0 109.912 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.69 137.76 88.13 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.911 . . . . 0.0 109.06 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -48.94 -31.01 19.03 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.87 1.713 . . . . 0.0 112.152 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.27 -16.61 64.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.89 . . . . 0.0 109.427 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -102.2 8.81 40.46 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.172 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.86 136.47 31.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.609 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.4 90.12 0.51 Allowed 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -59.17 6.22 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.327 -0.858 . . . . 0.0 109.845 179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.609 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -90.12 5.79 45.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.068 -1.02 . . . . 0.0 108.852 179.393 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.5 tp -94.39 136.25 34.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.468 -0.77 . . . . 0.0 109.449 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.2 m-20 -62.53 121.65 13.82 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.59 13.91 0.09 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.282 -0.886 . . . . 0.0 110.03 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.518 ' H ' ' C ' ' A' ' 29' ' ' ASP . 79.6 t -55.15 -42.38 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 0.0 108.702 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.61 -35.36 65.77 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -84.29 14.39 4.41 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.91 -14.53 0.01 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.43 -34.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.19 -1.183 . . . . 0.0 108.817 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -69.84 -24.34 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.463 -0.773 . . . . 0.0 110.11 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 82.9 m-20 -57.11 -34.76 68.68 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 111.33 -178.3 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.65 -64.79 1.11 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.851 -1.156 . . . . 0.0 111.381 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.604 ' CD2' ' HZ3' ' A' ' 43' ' ' LYS . 7.3 tt -70.88 -52.36 20.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.071 -1.018 . . . . 0.0 110.93 -178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.39 -36.83 92.15 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.2 tt -58.76 -42.09 88.08 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.451 -1.029 . . . . 0.0 109.484 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -61.88 -44.09 97.53 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.175 -0.953 . . . . 0.0 108.54 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . 0.604 ' HZ3' ' CD2' ' A' ' 39' ' ' LEU . 54.3 mttp -70.09 -38.33 75.64 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.426 -0.796 . . . . 0.0 109.897 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.09 -45.14 97.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 110.372 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -60.8 -44.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.727 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.37 -41.78 96.52 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.89 . . . . 0.0 110.106 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -76.44 -43.47 39.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.929 . . . . 0.0 110.097 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.04 -44.43 87.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -0.947 . . . . 0.0 109.668 -179.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.3 tt0 -64.69 -38.17 90.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.17 -0.956 . . . . 0.0 109.088 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -71.42 -48.94 46.46 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.378 -0.826 . . . . 0.0 110.623 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -62.41 -42.47 99.46 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.362 -0.836 . . . . 0.0 111.279 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.2 -6.52 24.14 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.866 -1.146 . . . . 0.0 110.353 -178.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.98 28.25 73.73 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.0 mt -101.55 137.01 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.281 -1.129 . . . . 0.0 109.192 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.95 57.38 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.076 -1.015 . . . . 0.0 109.291 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.71 -36.82 79.78 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.27 -0.894 . . . . 0.0 109.441 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -61.39 -33.26 73.39 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -50.72 -34.59 27.51 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.836 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.8 t -101.4 135.87 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.187 -0.945 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -89.51 141.81 28.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.471 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 36.5 mt -97.31 134.26 40.83 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.74 -179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.48 153.19 8.46 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.216 -0.928 . . . . 0.0 109.226 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.07 -28.58 80.31 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.487 2.125 . . . . 0.0 111.964 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.05 -29.56 70.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.368 -0.833 . . . . 0.0 109.572 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.65 -26.97 66.48 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.347 -0.846 . . . . 0.0 109.75 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.578 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 96.1 m-85 -103.49 6.82 37.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 110.161 -179.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.7 tpt180 -58.35 -41.69 85.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.029 -1.044 . . . . 0.0 109.904 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -153.74 158.86 41.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.902 -1.124 . . . . 0.0 110.116 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.3 mp -62.74 -36.98 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.34 -0.85 . . . . 0.0 109.871 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.657 ' NH2' ' SD ' ' A' ' 1' ' ' MET . 4.6 tpm_? -60.7 -40.86 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.25 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.25 -44.07 95.58 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.102 -0.999 . . . . 0.0 109.695 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.5 mt -66.11 -39.76 85.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.225 -0.922 . . . . 0.0 109.79 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -58.02 -38.41 76.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.396 -0.815 . . . . 0.0 109.857 -179.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.5 -46.2 80.61 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.207 -0.933 . . . . 0.0 109.847 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -66.6 -41.63 88.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.091 -1.006 . . . . 0.0 109.225 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -64.9 -42.48 94.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.349 -0.845 . . . . 0.0 109.706 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.6 t -63.1 -41.46 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.253 -0.904 . . . . 0.0 109.79 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.0 -30.33 66.51 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.44 -48.08 4.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -1.22 . . . . 0.0 110.21 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.49 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.2 t -143.3 155.53 44.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.184 -0.947 . . . . 0.0 109.737 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.516 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.2 t . . . . . 0 C--N 1.303 -1.434 0 O-C-N 121.29 -0.881 . . . . 0.0 109.281 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.241 0.543 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -82.08 135.05 35.37 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.32 -0.862 . . . . 0.0 108.745 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 56.4 m80 55.62 38.37 30.09 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.182 -0.949 . . . . 0.0 108.959 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.93 -34.0 71.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -0.806 . . . . 0.0 109.548 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.02 -38.64 79.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.21 -0.931 . . . . 0.0 109.679 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 10' ' ' PHE . 53.2 t -64.4 -37.61 80.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.157 -0.964 . . . . 0.0 109.595 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.49 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.4 mt -59.3 -50.42 79.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.37 -0.831 . . . . 0.0 109.618 -179.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.501 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.91 -42.66 97.34 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.154 -0.966 . . . . 0.0 108.787 179.28 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.36 -34.77 77.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.645 -0.659 . . . . 0.0 109.613 179.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.457 ' N ' ' O ' ' A' ' 6' ' ' VAL . 58.3 t80 -59.57 -53.11 61.83 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.397 -0.814 . . . . 0.0 110.352 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.2 m -74.4 -40.88 49.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.101 -0.999 . . . . 0.0 109.948 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.501 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 60.0 t -64.91 -37.6 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.309 -0.87 . . . . 0.0 110.451 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -56.64 -30.65 63.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.072 -1.018 . . . . 0.0 109.853 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.529 ' OE2' ' CD1' ' A' ' 36' ' ' ILE . 84.4 tt0 -65.27 -31.27 72.33 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.719 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.3 p90 -143.06 46.17 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 109.774 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.559 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.58 136.07 52.4 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.061 -1.024 . . . . 0.0 110.157 -179.837 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_endo -77.62 -149.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 122.143 1.895 . . . . 0.0 110.308 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.453 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.8 p30 -79.63 12.08 2.76 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.803 -1.185 . . . . 0.0 108.782 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.5 t -113.35 136.2 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.579 -0.701 . . . . 0.0 109.805 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.43 84.15 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.971 . . . . 0.0 108.85 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -48.23 -30.71 15.36 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.775 1.65 . . . . 0.0 112.129 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -23.81 66.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 0.0 109.348 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -98.94 3.44 47.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.105 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.0 t -104.88 137.03 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.613 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -63.65 99.28 0.22 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.198 -0.939 . . . . 0.0 109.514 -179.443 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.1 m -60.91 6.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.557 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.613 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -88.77 11.29 18.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.171 -0.956 . . . . 0.0 108.905 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.5 tp -82.59 131.72 35.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.98 122.22 17.75 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.349 -0.845 . . . . 0.0 109.063 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 66.2 mt -62.97 -10.12 12.5 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.341 -0.849 . . . . 0.0 109.491 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.9 p -50.19 -39.44 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.099 -1.001 . . . . 0.0 109.245 -179.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -58.08 -37.66 74.92 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.603 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.2 m-80 -87.6 15.5 6.69 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 178.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.4 -18.37 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.003 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -52.48 -35.37 20.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 120.797 -1.414 . . . . 0.0 108.185 179.163 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.8 tt -71.19 -25.06 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.589 -0.694 . . . . 0.0 109.869 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -62.82 -30.19 71.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.302 -0.874 . . . . 0.0 110.999 -178.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.6 m -104.95 -65.14 1.06 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.006 -1.059 . . . . 0.0 111.178 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.17 -52.14 13.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.162 -0.961 . . . . 0.0 111.069 -178.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.86 -38.93 96.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.7 -42.12 98.52 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -1.084 . . . . 0.0 109.593 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.73 -44.17 90.39 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.097 -1.002 . . . . 0.0 108.541 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -66.82 -37.84 85.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.188 -0.945 . . . . 0.0 109.331 179.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.469 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 72.0 t -67.44 -47.85 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.398 -0.813 . . . . 0.0 111.102 -179.115 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -60.84 -43.49 95.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.727 -1.233 . . . . 0.0 109.922 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -45.29 76.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.063 . . . . 0.0 110.191 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.5 t90 -77.22 -46.84 21.89 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 110.09 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.469 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 11.6 tp -56.97 -41.01 77.59 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.377 -0.827 . . . . 0.0 109.818 -179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.605 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.5 tt0 -61.4 -42.52 98.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.982 -1.074 . . . . 0.0 108.955 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.9 -36.98 83.51 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.245 -0.909 . . . . 0.0 109.55 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.7 ttt85 -59.98 -46.31 89.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 111.137 -178.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -117.21 0.17 12.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.14 -0.975 . . . . 0.0 110.94 -179.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.605 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.68 40.37 65.91 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.9 mt -96.0 141.43 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.214 -1.168 . . . . 0.0 109.225 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.86 140.67 58.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.004 -1.06 . . . . 0.0 109.427 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.09 -32.22 72.75 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.338 -0.851 . . . . 0.0 109.381 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -91.03 9.82 29.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.335 -0.853 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -52.9 -34.11 53.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.626 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.06 158.9 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.463 -0.773 . . . . 0.0 109.604 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -93.16 150.59 20.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.885 . . . . 0.0 109.303 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.621 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 4.4 mp -98.12 132.24 43.81 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 109.801 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.77 143.51 3.94 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.21 -0.931 . . . . 0.0 109.058 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.81 -24.92 74.54 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.146 1.898 . . . . 0.0 112.104 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.27 -32.52 74.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.236 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -72.89 -26.67 61.52 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.322 -0.861 . . . . 0.0 111.318 -178.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -97.85 11.04 38.66 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.77 -1.206 . . . . 0.0 110.953 -178.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -58.56 -34.29 70.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.936 -1.102 . . . . 0.0 109.952 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -145.78 151.0 37.26 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.031 -1.043 . . . . 0.0 110.018 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.4 mt -66.27 -36.74 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.405 -0.809 . . . . 0.0 109.846 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.0 ttp180 -60.69 -39.09 87.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.574 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -58.28 -42.41 86.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.984 -1.073 . . . . 0.0 109.927 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.4 mt -68.03 -39.24 81.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.49 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.3 t0 -59.13 -41.21 87.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.347 -0.846 . . . . 0.0 110.474 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.09 -43.11 88.24 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.123 -0.986 . . . . 0.0 110.212 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -62.7 -48.67 78.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.179 -0.951 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.37 -46.33 90.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.235 -0.916 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 41.4 t -59.62 -39.55 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 O-C-N 121.068 -1.02 . . . . 0.0 109.534 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.82 -32.63 66.24 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.8 -49.61 3.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -1.234 . . . . 0.0 110.479 -179.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -158.52 149.92 20.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 0.0 109.547 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.499 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 N--CA 1.489 1.488 0 O-C-N 121.292 -0.88 . . . . 0.0 109.182 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.9 mmm . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -98.99 119.57 38.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.361 -0.837 . . . . 0.0 109.229 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.4 m170 46.85 30.25 1.17 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.195 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.93 -35.8 79.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.697 -179.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.9 -38.55 82.61 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.0 109.859 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -64.28 -41.06 91.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 90.6 mt -59.53 -43.52 91.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.338 -0.851 . . . . 0.0 109.739 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.51 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.38 -47.74 80.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.21 -0.931 . . . . 0.0 109.158 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.69 -33.14 72.13 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.357 -0.839 . . . . 0.0 109.591 179.611 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -59.86 -53.12 61.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.167 -0.958 . . . . 0.0 110.19 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' ' CE1' ' A' ' 15' ' ' PHE . 34.6 m -74.41 -40.67 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.147 -0.97 . . . . 0.0 110.193 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.51 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 64.2 t -64.91 -36.35 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.354 -0.841 . . . . 0.0 110.588 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.46 -33.94 66.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 109.931 -179.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -65.68 -32.18 73.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.269 -0.894 . . . . 0.0 109.871 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.588 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 7.8 p90 -138.27 45.82 2.07 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.145 -0.972 . . . . 0.0 109.931 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.562 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 135.74 53.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.951 -1.093 . . . . 0.0 109.946 -179.823 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.58 -150.38 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.105 1.87 . . . . 0.0 110.264 178.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.433 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.8 p30 -79.52 12.09 2.69 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.8 -1.187 . . . . 0.0 108.708 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.64 136.64 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.549 -0.719 . . . . 0.0 109.818 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.89 139.58 82.95 Favored Pre-proline 0 N--CA 1.488 1.444 0 O-C-N 121.152 -0.967 . . . . 0.0 108.751 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.52 -31.74 19.07 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 121.699 1.599 . . . . 0.0 111.966 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.17 -26.6 67.49 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.301 -0.874 . . . . 0.0 109.395 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -103.34 4.8 36.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -99.22 144.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.326 -0.859 . . . . 0.0 108.695 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.3 t0 -71.82 95.06 1.47 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.034 -1.041 . . . . 0.0 109.357 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -62.25 6.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.342 -0.849 . . . . 0.0 109.588 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.6 m-20 -90.77 12.08 20.34 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.184 -0.948 . . . . 0.0 109.017 179.605 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 tp -84.53 133.87 34.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.433 -0.792 . . . . 0.0 109.484 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -65.21 122.34 16.87 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.271 -0.893 . . . . 0.0 108.824 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 67.3 mt -64.92 -6.28 8.04 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.249 -0.907 . . . . 0.0 109.618 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 73.0 t -50.91 -45.06 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.021 . . . . 0.0 108.904 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.7 -35.99 69.14 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -86.02 15.24 5.19 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.94 -16.88 0.02 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.76 -38.05 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 120.867 -1.372 . . . . 0.0 108.267 179.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.618 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.09 -25.3 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.538 -0.726 . . . . 0.0 110.324 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.7 m-20 -59.68 -35.65 74.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 111.105 -178.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.31 -64.22 1.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.13 -0.981 . . . . 0.0 111.556 -178.419 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -69.99 -52.09 27.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.057 -1.027 . . . . 0.0 111.301 -178.056 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -69.3 -36.75 79.41 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.249 -179.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.618 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tp -58.43 -47.83 82.67 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.335 -1.097 . . . . 0.0 109.582 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.5 mt -61.38 -42.62 99.01 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.109 -0.995 . . . . 0.0 109.77 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -63.63 -39.66 94.92 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.402 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.478 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.2 t -70.22 -49.7 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.268 -0.895 . . . . 0.0 110.554 -179.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -62.17 -40.48 87.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 120.959 -1.088 . . . . 0.0 109.948 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.18 -45.99 75.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.081 -1.012 . . . . 0.0 110.039 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.6 OUTLIER -77.61 -47.05 20.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.145 -0.972 . . . . 0.0 109.635 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.478 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 31.4 tp -56.75 -39.2 73.57 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.433 -0.792 . . . . 0.0 109.466 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.611 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.0 tm-20 -61.53 -42.74 99.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.953 . . . . 0.0 109.466 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' OE2' ' A' ' 49' ' ' GLU . 20.9 t70 -64.33 -39.45 93.93 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.071 -1.018 . . . . 0.0 109.71 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -66.19 -45.53 80.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 111.549 -178.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -111.17 -1.49 16.15 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.98 -1.075 . . . . 0.0 111.151 -178.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.611 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.67 38.48 67.42 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.54 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 72.5 mt -88.44 145.38 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.103 -1.233 . . . . 0.0 109.37 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.96 122.9 16.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.08 -19.72 56.69 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.468 -0.77 . . . . 0.0 109.741 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.03 11.06 5.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.352 -0.842 . . . . 0.0 110.165 -179.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.94 112.37 16.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.03 -1.044 . . . . 0.0 109.527 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.1 m -116.58 18.13 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.56 -0.713 . . . . 0.0 109.313 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -55.7 -28.27 54.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.827 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.0 mt -77.21 142.09 39.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.092 -1.005 . . . . 0.0 109.905 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.92 164.78 21.46 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -51.98 -33.13 51.0 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.349 2.033 . . . . 0.0 111.54 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -66.72 -27.42 67.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.512 -0.742 . . . . 0.0 109.251 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.404 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 19.6 t-80 -67.63 -26.62 66.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.377 -0.827 . . . . 0.0 109.768 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -90.24 11.91 19.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.208 -0.933 . . . . 0.0 109.282 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 -53.82 -37.64 63.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.381 -0.825 . . . . 0.0 109.792 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.4 p -146.14 157.17 43.83 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.044 -1.035 . . . . 0.0 110.036 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.36 -36.82 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.336 -0.853 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 43.8 ttp180 -60.57 -40.55 92.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.314 -0.866 . . . . 0.0 110.381 -179.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -62.55 -38.64 90.83 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.012 -1.055 . . . . 0.0 109.71 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.6 mt -68.23 -39.35 80.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.827 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.415 ' OD2' ' CD1' ' A' ' 7' ' ' ILE . 59.4 t0 -59.43 -41.14 88.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.363 -0.836 . . . . 0.0 110.334 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -43.29 86.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.098 -1.001 . . . . 0.0 110.512 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.404 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 67.3 t80 -61.96 -49.3 76.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.081 -1.012 . . . . 0.0 109.775 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 68.4 t -66.52 -44.74 90.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.268 -0.895 . . . . 0.0 109.825 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 47.3 t -63.03 -39.53 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.011 -1.056 . . . . 0.0 109.894 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.7 -33.97 69.05 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.39 -48.79 3.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -1.222 . . . . 0.0 110.644 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 60.2 m -158.36 137.86 11.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.125 -0.985 . . . . 0.0 109.839 -179.534 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.537 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.325 -0.859 . . . . 0.0 109.1 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.391 0.615 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.492 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 93.9 mt-30 -58.9 -36.61 74.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.062 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -147.59 29.86 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.38 -32.5 71.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.427 -0.796 . . . . 0.0 110.008 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.0 p -58.97 -39.94 83.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.03 -1.044 . . . . 0.0 109.563 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.07 -39.07 80.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 108.44 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.2 mt -61.26 -50.48 80.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.502 -0.749 . . . . 0.0 109.151 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.535 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.36 -47.36 79.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.346 -0.846 . . . . 0.0 109.183 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -44.25 96.12 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.483 -0.76 . . . . 0.0 109.227 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.592 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.5 t80 -68.34 -48.85 63.73 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.626 0.727 . . . . 0.0 109.452 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -67.02 -45.41 87.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.601 -0.687 . . . . 0.0 109.901 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.535 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 98.4 t -63.7 -37.74 80.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.272 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.5 -30.59 63.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.462 -0.774 . . . . 0.0 109.789 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.93 -32.21 73.82 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.201 -0.937 . . . . 0.0 109.357 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -147.01 52.86 1.08 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 109.112 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.3 136.58 52.94 Favored Pre-proline 0 N--CA 1.486 1.374 0 O-C-N 121.207 -0.933 . . . . 0.0 110.187 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.67 -152.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 121.815 1.676 . . . . 0.0 110.388 178.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -78.26 9.75 3.58 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.908 -1.12 . . . . 0.0 108.709 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -113.85 136.16 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.498 -0.751 . . . . 0.0 109.883 -179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.92 142.48 90.76 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.19 -0.944 . . . . 0.0 108.574 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -48.67 -32.4 21.53 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 121.593 1.529 . . . . 0.0 111.638 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.81 -25.27 65.49 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.372 -0.83 . . . . 0.0 109.395 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -105.01 6.42 33.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -96.6 143.4 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.282 -0.886 . . . . 0.0 108.762 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -72.39 92.33 1.42 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.126 -0.984 . . . . 0.0 109.365 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.3 m -62.79 6.23 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.9 m-20 -95.9 9.7 39.74 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 108.723 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 11.1 tp -90.22 135.6 33.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.487 -0.758 . . . . 0.0 109.561 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.585 ' OD2' ' NH2' ' A' ' 67' ' ' ARG . 90.0 m-20 -63.98 121.89 15.19 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.81 7.89 3.52 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.286 -0.884 . . . . 0.0 110.046 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.403 HG22 HH21 ' A' ' 67' ' ' ARG . 53.0 t -53.43 -42.79 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.063 -1.023 . . . . 0.0 108.636 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -55.74 -35.5 66.24 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.4 m-80 -85.19 15.12 4.44 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.39 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.7 t -51.73 -37.33 20.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.014 -1.286 . . . . 0.0 108.547 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.5 tt -70.81 -25.24 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 0.0 110.426 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -58.1 -34.33 70.07 Favored 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 111.009 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.92 -64.29 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.984 -1.073 . . . . 0.0 111.575 -178.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 4.2 mm? -72.37 -52.5 15.8 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.976 -1.078 . . . . 0.0 111.211 -178.091 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.07 -36.02 91.37 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.3 tp -57.71 -43.95 85.59 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.365 -1.079 . . . . 0.0 109.208 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.2 mt -63.64 -41.82 98.21 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 108.98 179.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -64.26 -36.95 85.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.413 -0.804 . . . . 0.0 109.53 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.8 t -62.66 -45.57 98.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.379 -0.825 . . . . 0.0 110.22 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.8 mm -61.35 -44.24 98.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.146 -0.971 . . . . 0.0 109.829 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.0 -43.78 91.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.242 -0.911 . . . . 0.0 109.766 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.592 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -73.39 -38.92 65.46 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.796 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 28.5 tp -59.69 -43.34 94.07 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.2 -0.938 . . . . 0.0 109.917 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.577 ' O ' ' N ' ' A' ' 53' ' ' GLY . 59.3 tt0 -65.16 -36.09 83.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 109.951 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -60.59 -38.99 86.47 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.984 -1.072 . . . . 0.0 110.125 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 mtp180 -74.67 -44.65 49.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.143 -0.973 . . . . 0.0 112.079 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -108.11 -7.17 16.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.765 -1.209 . . . . 0.0 111.354 -178.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.78 32.18 73.8 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.1 mt -91.22 152.42 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.257 -1.143 . . . . 0.0 109.835 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.1 150.48 29.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.075 -1.016 . . . . 0.0 109.008 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.85 -40.27 72.61 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.251 -0.906 . . . . 0.0 109.969 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 50.79 49.76 20.36 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.11 -0.994 . . . . 0.0 109.205 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -74.62 116.03 14.85 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.939 . . . . 0.0 109.909 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.415 HG11 ' H ' ' A' ' 61' ' ' LEU . 27.3 t -124.91 141.68 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 61' ' ' LEU . 19.8 pt-20 -60.5 -31.95 70.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.085 -1.009 . . . . 0.0 110.466 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.486 ' O ' ' O ' ' A' ' 60' ' ' GLU . 60.7 mt 44.04 -170.5 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.055 -1.028 . . . . 0.0 109.642 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -134.23 162.25 58.81 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.344 -0.848 . . . . 0.0 109.409 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.83 -26.81 83.76 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.756 2.304 . . . . 0.0 112.17 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -61.04 -31.53 71.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.39 -0.818 . . . . 0.0 109.909 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.501 ' O ' ' OG ' ' A' ' 71' ' ' SER . 81.8 t60 -68.07 -26.46 65.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.184 -0.948 . . . . 0.0 110.205 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -97.41 10.17 40.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 109.763 -179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.585 ' NH2' ' OD2' ' A' ' 29' ' ' ASP . 34.2 tpt85 -55.61 -38.32 69.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.076 -1.015 . . . . 0.0 109.879 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -137.75 153.99 49.66 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.095 -1.003 . . . . 0.0 110.145 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.4 mt -62.68 -36.58 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.264 -0.898 . . . . 0.0 110.006 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -60.76 -36.78 79.8 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.235 -0.916 . . . . 0.0 110.251 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 90.5 p -61.37 -36.16 79.45 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.022 -1.049 . . . . 0.0 109.449 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.97 -38.96 83.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.238 -0.914 . . . . 0.0 109.097 179.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -57.51 -36.98 72.26 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.46 -0.775 . . . . 0.0 109.352 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.38 -43.53 98.71 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.224 -0.923 . . . . 0.0 109.222 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -65.04 -46.95 79.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.259 -0.9 . . . . 0.0 109.207 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 53.2 t -65.24 -40.58 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 121.45 -0.781 . . . . 0.0 109.712 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.0 t -58.99 -42.46 86.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.243 -0.91 . . . . 0.0 109.684 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.83 -35.02 91.4 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 120.222 -0.989 . . . . 0.0 110.645 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -86.29 -48.02 8.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.899 -1.353 . . . . 0.0 109.853 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.2 t -138.54 151.03 46.97 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.492 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 10.0 t . . . . . 0 N--CA 1.487 1.414 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.302 0.573 . . . . 0.0 109.931 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLN . . . . . 0.484 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 98.5 mm-40 -87.07 123.76 32.49 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 54.54 15.78 1.14 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.107 -0.996 . . . . 0.0 108.654 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.401 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -64.19 -39.81 94.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.459 -0.776 . . . . 0.0 110.196 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.72 -39.24 87.89 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.177 -0.952 . . . . 0.0 110.157 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.6 t -64.77 -37.69 80.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.158 -0.964 . . . . 0.0 109.307 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 90.4 mt -63.98 -36.73 77.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 110.54 -179.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.527 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.47 -51.09 67.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.959 -1.088 . . . . 0.0 110.049 -179.422 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.41 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 3.5 pp0? -70.92 -36.72 72.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.101 -0.999 . . . . 0.0 109.473 179.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.423 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 59.6 t80 -65.74 -51.32 60.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.345 -0.847 . . . . 0.0 109.97 -179.611 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.5 p -68.33 -41.87 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.925 . . . . 0.0 109.589 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 87.0 t -64.61 -39.32 85.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -0.928 . . . . 0.0 109.521 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.95 -28.16 55.75 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.392 -0.817 . . . . 0.0 109.731 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -65.09 -29.16 70.01 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.263 -0.898 . . . . 0.0 108.833 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.617 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 22.8 p90 -151.0 48.99 0.85 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.376 -0.827 . . . . 0.0 109.076 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.485 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -79.76 137.12 54.52 Favored Pre-proline 0 N--CA 1.487 1.4 0 O-C-N 120.975 -1.078 . . . . 0.0 110.343 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.83 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.974 1.782 . . . . 0.0 110.51 178.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.448 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -81.05 13.29 2.82 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.923 -1.111 . . . . 0.0 108.803 179.242 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.43 136.65 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.609 -0.682 . . . . 0.0 109.91 -179.35 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.03 140.61 73.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.039 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -48.41 -31.75 18.6 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.795 1.664 . . . . 0.0 111.575 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.37 -21.87 65.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.519 -0.738 . . . . 0.0 109.412 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -97.6 1.61 48.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.421 -0.8 . . . . 0.0 109.119 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.2 t -107.09 137.54 37.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.604 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.0 t0 -70.56 99.87 1.72 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 109.319 -179.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.07 5.84 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.379 -0.826 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.604 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -96.4 9.19 42.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 0.0 108.748 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.3 tp -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.561 -0.712 . . . . 0.0 109.52 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . 0.46 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.0 m-20 -65.14 121.51 14.92 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 179.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.07 8.51 0.93 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.195 -0.94 . . . . 0.0 109.493 -179.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.46 ' H ' ' C ' ' A' ' 29' ' ' ASP . 57.0 t -56.39 -41.81 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.164 -0.96 . . . . 0.0 108.8 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -55.51 -34.09 64.33 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 178.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . 0.697 ' N ' HD21 ' A' ' 33' ' ' ASN . 0.8 OUTLIER -84.02 14.45 4.14 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.953 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.46 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.134 -1.187 . . . . 0.0 110.134 -179.116 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.8 t -52.09 -39.29 26.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 120.921 -1.341 . . . . 0.0 108.324 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.14 -25.2 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.605 -0.685 . . . . 0.0 110.118 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.6 m-20 -62.12 -32.1 72.64 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 110.797 -178.465 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.5 m -105.44 -64.93 1.09 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.004 -1.06 . . . . 0.0 111.306 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.0 tt -71.71 -52.15 19.25 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 0.0 111.19 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -68.1 -36.69 86.12 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.5 tp -58.53 -43.36 89.19 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.348 -1.089 . . . . 0.0 109.881 -179.051 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.9 mt -67.53 -44.11 79.15 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 110.111 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -65.08 -35.03 79.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.438 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 73.7 t -63.21 -44.99 99.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.293 -0.879 . . . . 0.0 110.979 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.06 -43.85 93.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.655 -1.278 . . . . 0.0 110.062 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.29 -45.32 76.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.109 -0.994 . . . . 0.0 110.396 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.485 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -76.6 -44.63 33.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.167 -0.958 . . . . 0.0 109.957 -179.709 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.5 tp -57.02 -39.0 73.94 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.337 -0.852 . . . . 0.0 109.207 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' A' ' 53' ' ' GLY . 12.0 tt0 -60.87 -43.27 98.63 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.204 -0.935 . . . . 0.0 109.25 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.09 -40.04 90.5 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.199 -0.938 . . . . 0.0 110.025 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.423 ' NH2' ' CZ ' ' A' ' 10' ' ' PHE . 73.8 ttt180 -63.48 -45.94 88.44 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.252 -0.905 . . . . 0.0 111.177 -178.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -106.86 -5.3 18.42 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.002 -1.062 . . . . 0.0 110.63 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.602 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.63 34.04 72.44 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 71.9 mt -98.88 144.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.301 -1.117 . . . . 0.0 109.633 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.45 148.57 41.37 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.136 -0.978 . . . . 0.0 109.586 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.48 -29.8 68.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.442 -0.786 . . . . 0.0 109.693 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.3 m-20 54.62 49.03 19.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.283 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' A' ' 58' ' ' ASP . 45.1 p30 -39.25 91.8 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.498 -0.751 . . . . 0.0 110.254 -179.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ASP . 29.4 m -128.43 158.05 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 108.981 179.564 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.35 129.96 46.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 109.729 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.3 140.92 42.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.448 -0.782 . . . . 0.0 109.421 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.83 156.13 55.57 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.517 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.98 -26.59 83.44 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.666 2.244 . . . . 0.0 112.031 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.35 -30.87 71.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.328 -0.857 . . . . 0.0 109.715 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -67.74 -26.79 66.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 109.662 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -93.65 9.22 37.83 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.179 -0.951 . . . . 0.0 109.358 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 15.2 tpt180 -54.91 -39.59 68.96 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.807 -179.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -141.96 153.98 44.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.017 -1.052 . . . . 0.0 110.098 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.2 mt -59.09 -36.66 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.365 -0.834 . . . . 0.0 109.838 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.9 ttp180 -60.28 -39.13 85.77 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.268 -0.895 . . . . 0.0 110.234 -179.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 t -58.3 -44.08 88.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.016 -1.053 . . . . 0.0 109.619 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -62.96 -38.74 82.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.177 -0.952 . . . . 0.0 109.427 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 2' ' ' GLN . 53.6 t0 -56.8 -37.88 71.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.396 -0.815 . . . . 0.0 109.702 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.78 -42.57 97.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.2 -0.938 . . . . 0.0 109.672 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -64.07 -48.34 76.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.148 -0.97 . . . . 0.0 109.459 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.75 -42.4 92.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.355 -0.841 . . . . 0.0 109.982 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.9 t -63.14 -40.89 90.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.167 -0.958 . . . . 0.0 109.903 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.7 -33.78 74.13 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.16 -47.99 4.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.046 -1.267 . . . . 0.0 110.506 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.8 m -128.68 138.16 52.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.341 -0.849 . . . . 0.0 109.943 -179.62 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.536 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.438 0 O-C-N 121.308 -0.87 . . . . 0.0 109.185 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.8 mtm . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 121.171 0.51 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.58 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 89.7 mt-30 55.64 53.21 9.87 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.402 -0.811 . . . . 0.0 109.14 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.58 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.0 m80 77.14 41.46 0.15 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.671 -0.643 . . . . 0.0 109.43 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.6 -33.41 73.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.296 -0.877 . . . . 0.0 109.444 179.922 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.16 -35.94 80.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.169 -0.957 . . . . 0.0 109.748 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.414 HG11 ' H ' ' A' ' 84' ' ' VAL . 74.7 t -65.88 -39.8 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 0.0 109.123 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.421 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 86.1 mt -59.49 -49.58 83.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.432 -0.792 . . . . 0.0 109.298 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.415 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.7 -41.79 98.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.2 -0.938 . . . . 0.0 108.534 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.43 -37.33 86.58 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.464 -0.773 . . . . 0.0 109.172 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -59.94 -52.99 63.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.544 -0.723 . . . . 0.0 110.044 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.53 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 4.6 p -73.49 -42.39 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.213 -0.929 . . . . 0.0 109.889 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.47 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 87.6 t -64.45 -38.12 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.337 -0.852 . . . . 0.0 110.411 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -56.15 -26.51 50.6 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.691 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -64.26 -31.11 72.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 109.168 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -153.96 52.88 0.69 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 109.316 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -80.74 136.61 51.33 Favored Pre-proline 0 N--CA 1.486 1.334 0 O-C-N 120.964 -1.085 . . . . 0.0 110.023 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.4 -153.81 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.007 1.805 . . . . 0.0 110.773 178.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -82.85 16.7 2.15 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.075 -1.016 . . . . 0.0 108.839 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 40.2 t -112.85 138.02 43.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.56 -0.712 . . . . 0.0 110.03 -179.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.78 137.16 96.07 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.247 -0.908 . . . . 0.0 108.651 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -48.35 -29.99 14.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.836 1.691 . . . . 0.0 112.016 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.31 -24.06 66.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.325 -0.859 . . . . 0.0 109.486 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -101.18 8.18 42.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 109.452 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -100.99 137.5 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.324 -0.86 . . . . 0.0 108.875 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.91 90.96 0.14 Allowed 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.194 -0.941 . . . . 0.0 109.367 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -61.74 6.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.345 -0.847 . . . . 0.0 109.551 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -92.05 12.44 21.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.213 -0.929 . . . . 0.0 109.135 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.2 tp -85.27 134.21 34.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.862 . . . . 0.0 109.613 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.507 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -64.3 121.54 14.54 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.369 -0.832 . . . . 0.0 109.065 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.476 ' O ' ' N ' ' A' ' 33' ' ' ASN . 67.6 mt -63.62 -8.14 9.17 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.188 -0.945 . . . . 0.0 109.602 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.468 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.33 -41.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.058 -1.027 . . . . 0.0 108.904 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.468 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -59.2 -34.92 72.73 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.644 ' O ' ' N ' ' A' ' 35' ' ' VAL . 83.1 m-20 -85.19 16.9 3.27 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.45 -14.81 0.01 OUTLIER Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.644 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.1 t -51.85 -39.56 25.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 120.909 -1.348 . . . . 0.0 108.07 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.9 tt -71.31 -25.03 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.635 -0.666 . . . . 0.0 110.319 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -60.48 -32.09 71.08 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.215 -0.928 . . . . 0.0 111.432 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.565 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.14 -65.05 1.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.892 -1.13 . . . . 0.0 111.405 -178.348 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 16.2 mt -74.01 -52.43 12.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.022 -1.048 . . . . 0.0 111.124 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.62 -35.83 91.63 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -179.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.62 -42.23 87.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.232 -1.157 . . . . 0.0 109.121 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -63.35 -44.14 95.68 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.161 -0.962 . . . . 0.0 109.011 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -68.38 -41.08 81.06 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 73.7 t -67.59 -46.94 81.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.4 -0.812 . . . . 0.0 110.177 -179.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.23 -45.01 99.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.542 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.42 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.192 -0.942 . . . . 0.0 109.999 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.724 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.27 -49.37 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 110.085 -179.744 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.8 tp -61.8 -41.39 97.69 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.554 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.9 pt-20 -70.57 -35.66 73.19 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.17 -0.956 . . . . 0.0 109.829 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -61.59 -41.95 98.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.248 -0.907 . . . . 0.0 110.092 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.724 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 86.0 mtt180 -64.4 -38.82 92.36 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 111.133 -179.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -102.85 -4.54 24.71 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.96 -1.087 . . . . 0.0 110.244 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.554 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 61.75 35.37 91.14 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.4 mt -90.19 141.2 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -1.189 . . . . 0.0 109.849 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.0 136.26 50.24 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.025 -1.047 . . . . 0.0 108.9 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.57 -35.23 79.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.089 -1.007 . . . . 0.0 109.482 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.619 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.7 p30 -65.87 -25.93 67.4 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.35 -0.844 . . . . 0.0 110.024 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.619 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 54.3 t0 -54.27 -35.83 62.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.778 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 43.7 t -111.64 136.94 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.444 -0.785 . . . . 0.0 109.708 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -88.28 142.26 27.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 109.287 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 35.9 mt -93.05 135.28 34.37 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.223 -0.923 . . . . 0.0 109.697 -179.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -162.27 150.35 12.06 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.269 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.42 -27.07 76.99 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.473 2.115 . . . . 0.0 112.065 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.64 -30.57 71.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.401 -0.812 . . . . 0.0 109.747 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -67.65 -27.05 66.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.743 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.6 m-85 -102.69 10.34 38.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.234 -0.916 . . . . 0.0 109.73 -179.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.447 HH22 ' CB ' ' A' ' 29' ' ' ASP . 32.8 tpt85 -54.15 -39.03 66.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.506 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.534 ' HG ' ' H ' ' A' ' 71' ' ' SER . 83.9 p -147.79 151.87 36.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.076 -1.015 . . . . 0.0 109.873 179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.7 mt -66.1 -37.29 79.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.293 -0.879 . . . . 0.0 109.892 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -61.32 -38.44 86.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 -179.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.534 ' H ' ' HG ' ' A' ' 68' ' ' SER . 83.9 p -62.93 -40.45 97.66 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.007 -1.058 . . . . 0.0 109.581 -179.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.3 mt -68.33 -40.97 83.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.185 -0.947 . . . . 0.0 109.74 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.421 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 54.8 t0 -59.46 -40.69 87.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.383 -0.823 . . . . 0.0 110.156 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.14 -43.05 88.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.125 -0.984 . . . . 0.0 110.001 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.33 -50.22 72.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.7 -44.84 93.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -60.08 -39.5 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.102 -0.999 . . . . 0.0 109.445 179.772 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.77 -32.95 66.52 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.51 -49.47 3.55 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.09 -1.241 . . . . 0.0 110.634 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.523 ' O ' ' O ' ' A' ' 76' ' ' VAL . 10.7 t -160.47 152.31 19.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.126 -0.983 . . . . 0.0 109.887 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.541 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.3 t -131.46 90.11 38.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.228 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -91.78 114.39 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 123.194 2.596 . . . . 0.0 112.963 -179.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -78.28 133.64 12.19 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 C-N-CA 122.003 1.802 . . . . 0.0 111.822 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.414 ' H ' HG11 ' A' ' 6' ' ' VAL . 37.6 t -126.09 133.49 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.322 -0.861 . . . . 0.0 109.644 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.82 -36.14 83.37 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.44 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -150.35 151.68 33.25 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.334 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 13.5 tttm -59.54 -37.34 78.15 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.148 -0.97 . . . . 0.0 109.641 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.1 tp -56.65 -37.63 71.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -0.923 . . . . 0.0 109.454 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.459 179.983 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.565 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.8 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.264 0.554 . . . . 0.0 109.612 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -59.11 -38.04 78.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.462 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 26.2 m-70 -114.57 11.32 17.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.486 -0.759 . . . . 0.0 109.296 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.477 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -56.66 -39.47 73.8 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.956 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.589 ' CB ' ' HZ3' ' A' ' 87' ' ' LYS . 89.2 p -63.99 -36.04 82.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.008 -1.057 . . . . 0.0 109.432 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -68.79 -36.09 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.534 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 98.7 mt -59.13 -50.42 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -0.917 . . . . 0.0 109.996 -179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.84 -47.86 79.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.994 -1.066 . . . . 0.0 109.004 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.74 -41.22 98.06 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 121.347 0.594 . . . . 0.0 110.015 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -66.14 -51.36 58.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.32 -0.863 . . . . 0.0 111.145 -178.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 17.1 m -72.38 -43.59 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.949 . . . . 0.0 110.848 -178.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.1 t -62.89 -36.28 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -0.962 . . . . 0.0 110.102 -179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -57.64 -37.59 73.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 109.508 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.69 -36.22 78.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.88 . . . . 0.0 110.303 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -91.8 -58.51 2.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 110.575 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.6 mt -128.98 87.58 54.12 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.347 -0.845 . . . . 0.0 110.443 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -91.48 -18.96 0.88 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.154 2.569 . . . . 0.0 112.116 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -75.96 -4.99 44.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 108.734 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 45.9 t -113.99 141.62 29.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 178.694 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -61.19 115.96 16.94 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 120.698 -1.251 . . . . 0.0 108.628 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -63.75 -23.76 69.15 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 121.462 1.442 . . . . 0.0 111.409 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.25 -13.82 60.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.467 -0.771 . . . . 0.0 110.073 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.474 ' CG ' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -82.79 7.51 14.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.985 -1.072 . . . . 0.0 109.234 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -100.7 135.29 37.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.582 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -64.72 86.78 0.05 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.065 -1.022 . . . . 0.0 109.384 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -61.84 5.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.582 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -100.1 5.5 44.92 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.1 141.37 30.32 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.704 -0.622 . . . . 0.0 109.459 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.494 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.1 m-20 -60.37 121.4 11.96 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -68.62 8.37 0.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.289 -0.882 . . . . 0.0 109.83 -178.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.494 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.8 p -50.78 -40.01 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.121 -0.987 . . . . 0.0 108.974 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.5 t0 -57.76 -35.46 70.79 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -85.71 14.87 5.24 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.63 -14.93 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.6 t -51.73 -36.44 18.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.172 -1.193 . . . . 0.0 108.803 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.595 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.1 tt -70.45 -24.93 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 110.315 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -59.59 -34.06 72.25 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 111.08 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.5 m -105.72 -64.5 1.14 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.086 -1.009 . . . . 0.0 111.503 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.531 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.9 mm? -71.42 -52.2 19.86 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.045 -1.034 . . . . 0.0 111.151 -178.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.28 -37.31 92.76 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.595 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.4 tp -58.76 -40.7 84.68 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.367 -1.078 . . . . 0.0 109.091 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.48 -43.45 94.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.333 -0.855 . . . . 0.0 108.805 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -64.35 -36.74 85.1 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 58.5 t -60.25 -43.29 93.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.385 -0.822 . . . . 0.0 109.872 -179.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -60.35 -49.39 84.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.26 -42.06 96.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.905 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -71.46 -40.92 70.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.323 -0.86 . . . . 0.0 109.783 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.53 -46.39 86.88 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.324 -0.86 . . . . 0.0 109.519 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -65.41 -39.29 91.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.249 -0.907 . . . . 0.0 109.019 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -67.24 -36.79 82.39 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.391 -0.818 . . . . 0.0 110.51 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -86.22 -51.74 6.09 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.274 -0.891 . . . . 0.0 112.167 -178.146 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -93.67 -5.57 48.29 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.682 -1.261 . . . . 0.0 111.16 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.59 24.14 76.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.41 HG21 HD12 ' A' ' 54' ' ' ILE . 77.1 mt -92.97 144.12 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -1.096 . . . . 0.0 109.422 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.67 146.75 44.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.062 -1.024 . . . . 0.0 109.272 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.81 -33.21 68.35 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.352 -0.842 . . . . 0.0 109.569 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.591 ' O ' ' N ' ' A' ' 59' ' ' VAL . 84.7 m-20 54.67 47.94 21.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.343 -0.848 . . . . 0.0 109.256 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.0 m-20 -42.86 90.45 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.447 -0.783 . . . . 0.0 109.875 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.591 ' N ' ' O ' ' A' ' 57' ' ' ASP . 44.1 t -125.74 139.32 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -74.42 130.77 40.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.017 -1.052 . . . . 0.0 109.671 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.28 142.68 45.55 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.652 -0.655 . . . . 0.0 109.449 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.8 149.03 66.59 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.078 -1.014 . . . . 0.0 109.462 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.79 -20.85 72.28 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.529 2.153 . . . . 0.0 112.342 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.8 -32.48 73.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 110.259 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -68.34 -26.71 65.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.985 -1.072 . . . . 0.0 109.975 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -97.41 5.98 48.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.161 -0.962 . . . . 0.0 109.725 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -55.52 -41.19 72.79 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.521 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -128.19 147.45 50.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.0 mt -61.46 -36.3 72.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.318 -0.864 . . . . 0.0 109.828 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.8 mtm180 -60.8 -37.32 81.56 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 110.19 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.7 t -59.08 -43.95 91.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.09 -1.007 . . . . 0.0 109.816 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.49 -38.88 83.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.136 -0.977 . . . . 0.0 109.628 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 21.5 t70 -57.12 -38.38 73.36 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.329 -0.857 . . . . 0.0 109.774 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.5 -44.45 90.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.719 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 74.0 t80 -63.55 -45.31 91.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.103 -0.998 . . . . 0.0 109.478 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.4 t -64.37 -43.67 97.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.341 -0.849 . . . . 0.0 110.099 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -63.16 -42.38 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.061 -1.024 . . . . 0.0 109.822 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.24 -30.54 71.12 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.39 -47.84 5.01 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.05 -1.265 . . . . 0.0 110.409 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 14.0 t -140.7 153.66 46.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.219 -0.926 . . . . 0.0 109.909 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.517 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.1 t -140.29 90.72 10.19 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.275 -0.891 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 53.5 Cg_endo -79.95 169.09 18.3 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.466 2.111 . . . . 0.0 112.097 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_exo -57.78 150.23 63.85 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.842 1.694 . . . . 0.0 111.784 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.41 HG23 ' HD1' ' A' ' 3' ' ' HIS . 36.7 t -103.38 131.45 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.312 -0.867 . . . . 0.0 109.699 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -129.68 150.12 51.14 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.46 -0.775 . . . . 0.0 109.303 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.18 145.77 55.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -0.952 . . . . 0.0 109.398 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.589 ' HZ3' ' CB ' ' A' ' 5' ' ' SER . 62.6 mttp -57.6 -34.3 69.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.8 mt -58.75 -35.2 72.36 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.221 -0.924 . . . . 0.0 109.443 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.961 -1.019 . . . . 0.0 109.389 -179.978 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.497 ' O3 ' ' C6 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.9 mtm . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.39 0.614 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.86 -38.39 82.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.287 -0.883 . . . . 0.0 109.59 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 59.8 m-70 -126.41 11.27 7.42 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.432 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.44 -36.52 76.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.148 -0.97 . . . . 0.0 109.849 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -62.09 -34.79 76.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 109.425 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.9 t -66.1 -36.63 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.35 -0.844 . . . . 0.0 109.264 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.463 ' O ' ' CG2' ' A' ' 11' ' ' VAL . 84.1 mt -64.98 -41.89 93.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 110.325 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.94 -50.64 67.86 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.03 -1.044 . . . . 0.0 110.514 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.413 ' HG3' ' H ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.06 -43.42 71.22 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 -179.973 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -59.03 -43.64 91.64 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.981 -1.074 . . . . 0.0 109.26 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.463 ' CG2' ' O ' ' A' ' 7' ' ' ILE . 75.2 t -71.93 -49.73 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -0.836 . . . . 0.0 110.449 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -63.85 -36.85 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.225 -0.922 . . . . 0.0 110.045 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -61.36 -31.0 70.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.24 -0.913 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.64 -31.16 72.03 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.149 -0.97 . . . . 0.0 109.278 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -102.87 -58.8 1.81 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.24 -0.913 . . . . 0.0 110.548 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -131.12 88.59 44.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.308 -0.87 . . . . 0.0 111.317 -178.086 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -86.31 -13.51 5.23 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.73 2.287 . . . . 0.0 111.798 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.37 -4.28 41.43 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.164 -0.96 . . . . 0.0 109.084 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.0 t -113.31 142.47 25.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 179.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.23 115.67 15.63 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.75 -1.219 . . . . 0.0 108.649 -179.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -64.46 -25.41 63.22 Favored 'Trans proline' 0 N--CA 1.486 1.08 0 C-N-CA 121.527 1.485 . . . . 0.0 111.68 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.02 -14.29 61.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.354 -0.841 . . . . 0.0 109.178 179.24 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.3 m-20 -82.62 2.92 30.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.838 . . . . 0.0 109.106 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -99.47 136.05 32.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.568 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.83 86.45 0.23 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.18 -0.95 . . . . 0.0 109.469 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.38 5.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.273 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.568 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -94.4 3.4 55.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 108.751 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.6 tt -97.14 138.66 34.3 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.539 -0.726 . . . . 0.0 109.496 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.8 m-20 -60.48 121.34 11.88 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.432 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 pp -65.34 5.7 0.37 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.793 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.51 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.8 p -50.57 -37.91 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.037 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.2 m-20 -57.71 -36.97 72.73 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -85.64 14.7 5.39 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -15.67 0.02 OUTLIER Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.41 -34.36 15.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.85 -1.382 . . . . 0.0 108.507 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -71.16 -24.36 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.554 -0.716 . . . . 0.0 109.883 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -57.91 -33.14 68.45 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.322 -0.861 . . . . 0.0 111.445 -178.18 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.2 m -105.83 -64.59 1.14 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.856 -1.153 . . . . 0.0 111.497 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.2 mp -72.42 -52.22 16.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.937 -1.102 . . . . 0.0 110.805 -178.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.45 -36.72 92.94 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.6 tp -58.52 -41.21 84.97 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.356 -1.085 . . . . 0.0 109.285 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.5 tp -65.8 -41.48 91.87 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.008 -1.057 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -70.22 -44.69 68.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 111.519 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 16.0 m -72.43 -42.09 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.939 -1.1 . . . . 0.0 111.624 -178.214 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -58.7 -47.8 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 120.845 -1.159 . . . . 0.0 110.241 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.06 -39.61 92.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 110.241 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.753 ' HE1' HH21 ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.17 -49.35 15.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.927 -1.108 . . . . 0.0 110.403 -179.602 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.1 tp -60.15 -46.0 91.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.232 -0.917 . . . . 0.0 110.134 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.536 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -66.81 -38.06 85.73 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.013 -1.054 . . . . 0.0 109.463 -179.924 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.69 -38.91 92.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.934 . . . . 0.0 109.584 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.753 HH21 ' HE1' ' A' ' 47' ' ' TRP . 43.1 mmm-85 -59.28 -38.97 81.47 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.542 -0.724 . . . . 0.0 110.143 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -95.84 0.95 52.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.167 -0.958 . . . . 0.0 110.089 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.11 37.95 63.73 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.2 mt -104.04 148.58 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.411 -1.052 . . . . 0.0 109.79 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -91.25 122.77 34.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 108.396 179.219 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.36 -38.98 93.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.08 -1.012 . . . . 0.0 109.745 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -62.1 -37.12 83.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 0.0 110.093 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -57.14 -37.69 72.42 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.231 -0.918 . . . . 0.0 110.353 -179.34 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.91 134.24 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.306 -0.871 . . . . 0.0 110.05 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -108.28 137.55 46.07 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.478 -0.764 . . . . 0.0 109.307 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.54 146.83 30.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.769 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.9 160.47 29.68 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.361 -0.837 . . . . 0.0 109.425 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -62.76 -32.21 78.22 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.799 2.333 . . . . 0.0 112.123 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -62.62 -29.01 70.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.399 -0.813 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.539 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 32.0 t-80 -67.84 -26.38 66.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.365 -0.834 . . . . 0.0 110.149 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -97.95 8.55 44.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.075 -1.015 . . . . 0.0 110.133 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -56.01 -41.07 74.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.193 -0.942 . . . . 0.0 109.355 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.3 m -128.8 145.73 51.11 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.5 mt -63.0 -39.64 85.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.119 -0.988 . . . . 0.0 109.855 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.6 mtm180 -61.54 -37.02 82.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.058 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -58.19 -38.88 77.58 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.121 -0.987 . . . . 0.0 109.638 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 71.0 mt -63.63 -42.3 95.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.323 -0.86 . . . . 0.0 109.612 179.953 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 4' ' ' ALA . 52.4 t0 -59.48 -38.65 81.38 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.111 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 -46.07 80.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.087 -1.008 . . . . 0.0 110.05 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.539 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 70.5 t80 -63.38 -47.0 83.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.127 -0.983 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.528 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.4 t -64.75 -42.74 95.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.317 -0.864 . . . . 0.0 109.727 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.43 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 55.7 t -59.67 -41.47 85.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.239 -0.913 . . . . 0.0 109.845 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.65 -31.47 75.25 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 120.264 -0.97 . . . . 0.0 110.748 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -48.76 3.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.03 -1.277 . . . . 0.0 110.751 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -129.68 156.81 43.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.324 -0.86 . . . . 0.0 109.664 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.533 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.1 t -140.25 89.48 10.85 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.13 -0.981 . . . . 0.0 109.381 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 14.0 Cg_exo -64.74 159.24 46.37 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.588 2.192 . . . . 0.0 112.021 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -59.37 150.62 73.83 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.659 2.24 . . . . 0.0 111.65 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.14 129.2 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.776 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -135.46 166.72 22.52 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.464 -0.772 . . . . 0.0 108.93 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.13 139.36 35.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.074 -1.016 . . . . 0.0 109.063 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 55.6 tttm -58.92 -35.89 73.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.193 -0.942 . . . . 0.0 109.55 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.58 -35.22 72.06 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -0.948 . . . . 0.0 109.433 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.957 -1.021 . . . . 0.0 109.423 179.958 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.482 ' S12' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.445 ' N ' ' CB ' ' A' ' 4' ' ' ALA . 86.1 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.2 -38.27 82.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.771 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.592 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 73.4 m-70 -141.5 14.39 2.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.708 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.483 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -60.33 -33.4 72.34 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 110.097 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.529 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 85.5 p -61.26 -36.59 80.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.945 -1.097 . . . . 0.0 109.613 -179.595 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.529 ' N ' ' HG ' ' A' ' 5' ' ' SER . 75.7 t -66.79 -39.68 84.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.089 -1.007 . . . . 0.0 108.819 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.427 ' O ' ' CG2' ' A' ' 11' ' ' VAL . 91.1 mt -61.73 -50.3 80.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.032 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.544 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.31 -48.78 74.31 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.397 -0.814 . . . . 0.0 109.137 179.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.02 -44.76 95.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.551 -0.718 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 66.4 t80 -69.56 -48.44 60.31 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.559 -0.713 . . . . 0.0 109.525 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 7' ' ' ILE . 94.3 t -66.8 -45.26 88.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.513 -0.742 . . . . 0.0 109.954 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 84.5 t -64.1 -37.24 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.374 -0.829 . . . . 0.0 109.523 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.57 -30.71 61.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.363 -0.836 . . . . 0.0 110.022 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.36 -29.69 70.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.104 -0.997 . . . . 0.0 109.298 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.617 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.3 p90 -149.2 50.04 0.97 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.374 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.47 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -80.16 136.86 53.23 Favored Pre-proline 0 N--CA 1.487 1.383 0 O-C-N 120.932 -1.105 . . . . 0.0 110.184 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.21 -153.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.96 1.773 . . . . 0.0 110.581 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -80.91 13.56 2.62 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.051 -1.031 . . . . 0.0 108.643 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.47 137.17 47.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.589 -0.694 . . . . 0.0 110.028 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.77 140.7 74.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.176 -0.953 . . . . 0.0 108.898 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -48.57 -30.96 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.891 1.727 . . . . 0.0 111.85 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.4 66.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.326 -0.859 . . . . 0.0 109.49 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -96.43 3.06 53.06 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.35 -0.844 . . . . 0.0 109.063 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.8 t -105.91 136.94 38.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.581 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.0 t0 -70.91 96.3 1.27 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.075 -1.016 . . . . 0.0 109.428 -179.439 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.401 HG13 ' HZ1' ' A' ' 87' ' ' LYS . 14.3 m -61.7 6.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 109.589 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.581 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.9 m-20 -93.8 7.44 44.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 108.909 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.4 tt -92.61 135.14 34.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.593 -0.692 . . . . 0.0 109.642 -179.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.5 ' C ' ' H ' ' A' ' 31' ' ' VAL . 91.6 m-20 -62.01 121.64 13.5 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -70.51 9.68 0.59 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.202 -0.936 . . . . 0.0 109.519 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.5 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -52.15 -38.03 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.201 -0.937 . . . . 0.0 109.462 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -56.94 -36.76 70.64 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.621 ' O ' ' N ' ' A' ' 35' ' ' VAL . 75.7 m-20 -86.25 14.76 6.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.48 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.621 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.82 -34.26 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 120.928 -1.336 . . . . 0.0 108.509 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.606 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.4 tt -71.07 -24.47 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.7 . . . . 0.0 110.134 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -58.14 -34.1 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.36 -0.837 . . . . 0.0 111.51 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.562 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -104.98 -65.26 1.05 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.858 -1.151 . . . . 0.0 111.148 -178.54 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -69.71 -47.22 63.93 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.157 -0.964 . . . . 0.0 110.722 -178.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -70.1 -39.97 72.63 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.921 -1.133 . . . . 0.0 110.379 -179.417 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.2 tt -58.66 -39.81 81.71 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.19 -1.182 . . . . 0.0 109.078 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -62.25 -44.18 97.15 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.458 -0.897 . . . . 0.0 108.67 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -69.54 -40.15 77.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.326 -0.858 . . . . 0.0 109.857 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.6 t -64.77 -45.9 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.363 -0.836 . . . . 0.0 110.268 -179.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.69 -46.02 97.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.238 -0.913 . . . . 0.0 109.532 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.35 97.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 109.951 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.436 ' CZ2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -75.09 -40.73 59.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.918 . . . . 0.0 109.995 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.77 -43.88 85.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.252 -0.905 . . . . 0.0 109.639 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.405 ' O ' ' N ' ' A' ' 53' ' ' GLY . 62.3 tt0 -64.18 -39.77 94.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.185 -0.947 . . . . 0.0 109.449 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -67.34 -45.28 76.85 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 110.836 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.6 ttt180 -70.02 -45.34 67.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.274 -0.891 . . . . 0.0 112.131 -178.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -103.38 -5.33 23.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.815 -1.178 . . . . 0.0 111.433 -178.088 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.405 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.09 27.68 73.61 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.5 mt -98.3 143.87 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -1.153 . . . . 0.0 109.451 -179.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.44 149.74 33.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.145 -0.972 . . . . 0.0 109.579 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.94 -31.93 63.36 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.431 -0.793 . . . . 0.0 109.529 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.52 43.86 29.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.365 -0.834 . . . . 0.0 109.582 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.451 ' C ' ' OD2' ' A' ' 58' ' ' ASP . 53.2 p30 -93.42 11.34 28.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.288 -0.883 . . . . 0.0 109.446 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 73.6 t -59.94 -41.05 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.305 -0.872 . . . . 0.0 109.97 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.8 mt-10 -116.33 130.22 56.66 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.433 -0.792 . . . . 0.0 109.717 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.9 mt -121.89 141.92 50.79 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -158.27 105.55 1.69 Allowed Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.025 -1.047 . . . . 0.0 109.806 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_exo -55.32 -21.66 30.12 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.792 1.661 . . . . 0.0 111.228 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.31 -30.99 71.55 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.52 -0.738 . . . . 0.0 109.508 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.417 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 56.2 t-80 -69.19 -26.33 64.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.362 -0.836 . . . . 0.0 111.02 -179.21 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.68 5.67 49.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.98 -1.075 . . . . 0.0 111.368 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -60.2 -37.84 81.49 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.766 -1.208 . . . . 0.0 110.3 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.7 t -131.79 141.57 49.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.077 -1.014 . . . . 0.0 110.139 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 83.8 mt -62.84 -37.9 80.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.404 -0.81 . . . . 0.0 109.827 179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -61.41 -37.21 82.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.265 -0.897 . . . . 0.0 110.244 -179.389 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -58.66 -40.37 83.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.102 -0.999 . . . . 0.0 109.496 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 72.0 mt -64.76 -38.74 83.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.299 -0.876 . . . . 0.0 109.314 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.483 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 20.8 t70 -57.45 -39.17 75.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.281 -0.887 . . . . 0.0 109.797 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.32 92.75 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.088 -1.007 . . . . 0.0 109.464 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.417 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 68.7 t80 -64.81 -46.16 83.19 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.285 -0.884 . . . . 0.0 109.318 179.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.9 t -63.89 -43.47 97.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.287 -0.883 . . . . 0.0 109.802 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -60.86 -40.52 85.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.165 -0.959 . . . . 0.0 109.558 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.2 -32.39 67.45 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.27 -49.0 3.69 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.027 -1.278 . . . . 0.0 110.758 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.3 p -134.92 154.94 51.5 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.198 -0.939 . . . . 0.0 110.1 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.531 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.4 t -140.6 89.32 10.43 Favored Pre-proline 0 C--N 1.303 -1.42 0 O-C-N 121.198 -0.939 . . . . 0.0 109.0 179.208 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.592 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 79.1 Cg_endo -85.67 160.81 10.72 Favored 'Trans proline' 0 C--N 1.311 -1.443 0 C-N-CA 122.878 2.385 . . . . 0.0 112.993 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.15 150.9 82.27 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 123.024 2.482 . . . . 0.0 111.788 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.431 ' CG2' ' HD1' ' A' ' 3' ' ' HIS . 45.3 t -100.07 127.72 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 110.005 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.54 ' O ' ' CB ' ' A' ' 86' ' ' ALA . 97.2 mt-10 -67.72 -30.5 70.01 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.496 -0.753 . . . . 0.0 109.416 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.54 ' CB ' ' O ' ' A' ' 85' ' ' GLU . . . 82.03 116.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.629 -0.669 . . . . 0.0 109.283 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.401 ' HZ1' HG13 ' A' ' 26' ' ' VAL . 20.5 mttp -57.9 -32.97 68.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.188 -0.945 . . . . 0.0 109.452 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.3 mt -88.37 142.4 27.76 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.441 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.538 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.562 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.6 mmm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.458 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.3 mt-30 -105.72 131.32 53.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.25 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.458 ' C ' ' O ' ' A' ' 2' ' ' GLN . 3.9 m80 40.93 31.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.386 -0.821 . . . . 0.0 109.486 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -39.38 85.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.752 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.459 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 86.1 p -65.05 -32.93 74.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.158 -0.964 . . . . 0.0 109.719 -179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.459 ' N ' ' HG ' ' A' ' 5' ' ' SER . 74.8 t -66.77 -38.55 81.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.193 -0.942 . . . . 0.0 109.399 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 91.9 mt -61.15 -49.82 83.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.176 -0.953 . . . . 0.0 109.368 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.543 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.99 -47.44 80.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 108.906 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -44.08 96.89 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.548 -0.72 . . . . 0.0 109.25 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.4 t80 -68.23 -49.13 62.75 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.656 -0.653 . . . . 0.0 109.729 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 95.3 t -67.99 -44.69 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.533 -0.73 . . . . 0.0 109.923 -179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.543 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 99.2 t -64.0 -35.18 72.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.444 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -56.1 -31.97 63.74 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -65.72 -32.48 74.06 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.279 -0.888 . . . . 0.0 109.785 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.597 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 31.4 p90 -140.71 46.8 1.77 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.196 -0.94 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.561 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.3 136.22 53.27 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.019 -1.05 . . . . 0.0 110.156 -179.752 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.417 ' C ' ' H ' ' A' ' 19' ' ' VAL . 74.4 Cg_endo -76.02 -151.52 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.167 1.911 . . . . 0.0 110.42 178.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.94 9.73 2.74 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.891 -1.131 . . . . 0.0 108.682 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 17' ' ' PRO . 28.4 t -113.51 135.75 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.576 -0.703 . . . . 0.0 109.781 -179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.54 140.62 81.96 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.976 . . . . 0.0 108.754 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_exo -48.6 -33.05 22.88 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.621 1.547 . . . . 0.0 111.586 179.562 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.41 -20.22 63.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.185 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -98.27 3.86 48.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.465 -0.772 . . . . 0.0 109.316 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.6 t -104.14 136.03 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.62 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.5 95.48 0.47 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.122 -0.986 . . . . 0.0 109.366 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.501 ' CG2' ' OXT' ' A' ' 89' ' ' GLN . 19.5 m -60.27 6.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.328 -0.858 . . . . 0.0 109.604 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.62 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.75 5.92 49.37 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.158 -0.964 . . . . 0.0 108.606 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.1 tp -91.84 136.83 32.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.537 -0.727 . . . . 0.0 109.364 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.488 ' OD2' ' O ' ' A' ' 67' ' ' ARG . 88.5 m-20 -62.85 121.81 14.4 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.423 -0.911 . . . . 0.0 108.582 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.443 ' CD1' ' CD1' ' A' ' 69' ' ' ILE . 79.5 mt -68.46 -4.34 14.57 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.368 -0.832 . . . . 0.0 109.457 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 34' ' ' GLY . 51.2 t -51.47 -41.97 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.145 -0.972 . . . . 0.0 108.799 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.83 -35.29 66.23 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 1.7 m120 -83.24 14.83 3.24 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.835 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.43 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.26 -15.82 0.02 OUTLIER Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -179.332 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -51.71 -39.16 23.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 108.181 179.386 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.1 tt -71.24 -25.09 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.506 -0.746 . . . . 0.0 109.899 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.4 m-20 -62.97 -30.53 71.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.965 . . . . 0.0 110.839 -178.652 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.7 m -105.11 -65.17 1.06 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.997 -1.064 . . . . 0.0 111.056 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.62 -52.31 15.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.133 -0.979 . . . . 0.0 110.985 -178.406 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.55 -36.79 91.94 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.381 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.1 tp -58.71 -41.17 85.7 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.468 -1.019 . . . . 0.0 109.235 -179.436 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -65.53 -44.13 87.83 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 108.807 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.48 -43.7 76.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.553 -0.717 . . . . 0.0 110.104 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.514 ' O ' ' N ' ' A' ' 48' ' ' LEU . 96.1 t -64.53 -45.39 95.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.362 -0.837 . . . . 0.0 110.55 -179.03 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.519 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -60.53 -46.94 94.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 120.999 -1.063 . . . . 0.0 109.475 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -44.14 80.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.404 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.7 t90 -78.46 -49.05 14.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.102 -0.999 . . . . 0.0 110.338 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.514 ' N ' ' O ' ' A' ' 44' ' ' VAL . 7.6 tp -60.7 -42.35 97.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.554 -178.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.519 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -65.84 -37.82 87.21 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.984 -1.072 . . . . 0.0 109.046 -179.696 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -69.1 -38.96 79.21 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.421 -0.799 . . . . 0.0 109.576 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.1 ttt180 -58.95 -41.1 86.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.565 -0.709 . . . . 0.0 110.691 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -102.97 -6.5 22.33 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.965 -1.084 . . . . 0.0 109.898 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.35 30.86 78.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 pt -112.94 149.27 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.4 -1.059 . . . . 0.0 109.855 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.81 144.77 52.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.239 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -35.91 78.14 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.131 -0.981 . . . . 0.0 109.292 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 53.14 43.17 31.95 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.363 -0.836 . . . . 0.0 109.565 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -82.39 94.26 7.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.52 179.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 69.6 t -63.59 -43.78 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.942 . . . . 0.0 109.398 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -158.35 140.37 13.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.756 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 36.4 mt -103.16 136.79 42.29 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.329 -0.857 . . . . 0.0 109.46 179.885 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.425 ' OG ' ' O8 ' ' A' ' 101' ' ' PN7 . 0.1 OUTLIER -159.42 147.52 13.5 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.068 -1.02 . . . . 0.0 109.447 179.713 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -63.48 -21.09 70.87 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.49 2.127 . . . . 0.0 111.973 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.52 -31.35 70.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 0.0 110.056 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -68.41 -26.4 65.52 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.289 -0.882 . . . . 0.0 110.713 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -93.76 8.75 39.85 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.881 -1.137 . . . . 0.0 110.707 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.488 ' O ' ' OD2' ' A' ' 29' ' ' ASP . 17.5 mmm180 -58.34 -34.74 70.97 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.074 -1.016 . . . . 0.0 110.231 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -150.55 158.61 44.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.11 -0.994 . . . . 0.0 110.464 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.443 ' CD1' ' CD1' ' A' ' 30' ' ' LEU . 11.4 mm -62.89 -35.82 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.453 -0.78 . . . . 0.0 109.724 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 -59.99 -36.53 77.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.283 -0.885 . . . . 0.0 109.855 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.3 t -59.62 -43.07 93.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.901 -1.124 . . . . 0.0 108.91 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.15 -38.39 80.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.429 -0.794 . . . . 0.0 109.267 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 83.5 m-20 -56.34 -37.64 70.25 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.387 -0.821 . . . . 0.0 109.253 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.56 -40.13 96.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.31 -0.869 . . . . 0.0 109.763 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -62.14 -51.78 66.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.959 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.8 t -65.16 -41.17 91.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.237 -0.915 . . . . 0.0 109.444 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.1 t -58.47 -40.62 79.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 O-C-N 121.312 -0.867 . . . . 0.0 109.538 179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.21 -33.02 82.75 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.45 -48.83 4.22 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.976 -1.308 . . . . 0.0 110.581 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.503 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.8 p -129.69 154.22 47.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.4 -0.812 . . . . 0.0 108.994 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.539 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.1 t -138.08 89.08 14.86 Favored Pre-proline 0 C--N 1.304 -1.407 0 O-C-N 121.15 -0.969 . . . . 0.0 109.956 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.441 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 14.5 Cg_exo -65.88 -176.64 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.704 2.27 . . . . 0.0 111.697 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 27.1 Cg_exo -58.6 150.6 68.35 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.418 2.079 . . . . 0.0 111.485 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 25.3 t -91.95 128.35 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.027 -1.046 . . . . 0.0 109.844 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.61 153.53 47.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.37 -0.831 . . . . 0.0 109.215 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.94 141.4 57.63 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.156 -0.965 . . . . 0.0 109.452 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.421 ' NZ ' ' CG2' ' A' ' 26' ' ' VAL . 18.3 tttm -83.55 136.14 34.37 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -0.926 . . . . 0.0 109.273 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.46 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 53.8 mt -88.39 142.09 28.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.925 . . . . 0.0 109.492 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.501 ' OXT' ' CG2' ' A' ' 26' ' ' VAL . 25.9 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.425 ' O8 ' ' OG ' ' A' ' 62' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.477 0.656 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.569 ' C ' ' H ' ' A' ' 4' ' ' ALA . 92.2 mt-30 -104.76 140.72 37.67 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.421 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 53.7 t-80 49.36 11.23 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.952 -1.092 . . . . 0.0 108.497 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.569 ' H ' ' C ' ' A' ' 2' ' ' GLN . . . -62.36 -35.91 80.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.593 -0.692 . . . . 0.0 110.193 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.1 m -58.85 -42.07 88.47 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.016 . . . . 0.0 109.567 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.419 ' CG1' ' NE2' ' A' ' 3' ' ' HIS . 54.3 t -67.35 -36.36 76.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.397 -0.815 . . . . 0.0 109.221 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 98.9 mt -59.75 -49.51 83.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.831 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.539 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.51 -45.28 91.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.086 -1.008 . . . . 0.0 108.928 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.27 -43.34 91.58 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.509 -0.744 . . . . 0.0 109.051 179.431 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.704 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 66.3 t80 -66.07 -49.93 65.89 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.471 0.653 . . . . 0.0 109.89 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 97.9 t -67.17 -45.02 87.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.414 -0.804 . . . . 0.0 109.641 -179.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.539 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 92.8 t -64.17 -35.6 74.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.438 -0.789 . . . . 0.0 109.597 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.29 -31.09 63.32 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.753 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.425 ' OE2' ' CG2' ' A' ' 44' ' ' VAL . 84.3 tt0 -65.44 -31.96 73.32 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.747 -179.706 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.596 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.2 p90 -141.89 45.68 1.68 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.213 -0.93 . . . . 0.0 109.627 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.556 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.51 136.03 52.69 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.941 -1.099 . . . . 0.0 110.119 -179.78 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -77.6 -150.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.222 1.948 . . . . 0.0 110.249 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.461 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 54.0 p30 -79.95 12.11 2.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.822 -1.174 . . . . 0.0 108.706 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 23.9 t -113.41 136.71 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.567 -0.708 . . . . 0.0 109.847 -179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.96 82.94 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.186 -0.946 . . . . 0.0 108.863 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -48.38 -30.32 15.2 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.746 1.631 . . . . 0.0 111.541 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.61 -20.55 62.74 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.495 -0.753 . . . . 0.0 109.513 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -103.73 8.61 37.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.32 -0.863 . . . . 0.0 109.748 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -101.13 135.93 35.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.315 -0.866 . . . . 0.0 108.99 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.593 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -67.87 89.95 0.29 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.164 -0.96 . . . . 0.0 109.082 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -60.53 6.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.379 -0.826 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.593 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.2 t0 -89.21 4.36 48.91 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.93 . . . . 0.0 108.733 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.7 tp -95.65 134.24 38.77 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.563 -0.711 . . . . 0.0 109.368 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -66.07 121.49 15.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -76.04 9.27 2.56 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 109.882 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.19 -38.28 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.112 -0.992 . . . . 0.0 108.951 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.434 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -57.08 -35.53 69.48 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.8 m-20 -83.8 15.02 3.49 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -14.76 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.8 t -51.65 -37.94 20.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.096 -1.238 . . . . 0.0 108.428 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.8 tt -70.7 -24.82 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.508 -0.745 . . . . 0.0 110.139 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.59 ' OD1' ' CD1' ' A' ' 66' ' ' PHE . 82.7 m-20 -60.24 -32.93 71.6 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -178.26 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.48 -64.97 1.09 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.926 -1.109 . . . . 0.0 111.513 -178.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.0 mp -72.39 -52.16 17.24 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.096 -1.002 . . . . 0.0 110.983 -178.078 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . 0.408 ' CA ' ' OE1' ' A' ' 14' ' ' GLU . . . -66.4 -36.92 92.27 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.53 -41.26 89.64 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.471 -1.017 . . . . 0.0 109.636 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -66.15 -44.37 84.34 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.486 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -67.26 -38.69 85.55 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.291 -0.881 . . . . 0.0 110.239 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.425 ' CG2' ' OE2' ' A' ' 14' ' ' GLU . 78.5 t -64.48 -44.87 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.204 -0.935 . . . . 0.0 110.576 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.07 -47.21 90.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 120.969 -1.082 . . . . 0.0 109.769 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.11 -44.37 80.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.285 -0.885 . . . . 0.0 110.537 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.704 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.0 t90 -74.8 -41.89 59.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.152 -0.967 . . . . 0.0 110.196 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -58.55 -40.13 82.17 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.254 -0.904 . . . . 0.0 109.604 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.584 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.08 -42.3 99.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -65.08 -42.94 93.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.378 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.3 ttt180 -65.98 -44.58 84.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 111.514 -178.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -105.65 -5.28 20.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.991 -1.068 . . . . 0.0 110.844 -178.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.584 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.58 32.5 71.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.56 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 76.8 mt -97.01 144.57 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.559 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 145.13 52.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.155 -0.965 . . . . 0.0 109.612 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.07 -28.69 69.79 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.841 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.572 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.0 m-20 54.7 50.82 15.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.061 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 57' ' ' ASP . 23.5 t70 -41.29 92.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.39 -0.819 . . . . 0.0 109.867 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ASP . 13.6 p -134.24 144.47 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.393 -0.817 . . . . 0.0 108.948 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -89.66 133.0 34.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 109.713 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.7 mt -110.32 140.74 44.19 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.488 -0.757 . . . . 0.0 109.534 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.7 158.18 59.95 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.482 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -60.1 -27.87 85.8 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.737 2.291 . . . . 0.0 112.042 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.83 -29.38 70.58 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -67.32 -26.39 66.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.811 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.59 ' CD1' ' OD1' ' A' ' 37' ' ' ASP . 80.1 m-85 -93.7 7.02 46.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.16 -0.962 . . . . 0.0 109.536 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -54.94 -39.08 68.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.272 -0.892 . . . . 0.0 109.553 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.0 p -138.93 151.1 46.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.09 -1.006 . . . . 0.0 109.909 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -63.27 -36.88 77.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.32 -0.863 . . . . 0.0 109.806 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 -61.2 -36.9 81.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 110.294 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.5 -44.21 89.37 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.985 -1.072 . . . . 0.0 109.368 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.3 mt -66.66 -38.55 81.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.327 -0.858 . . . . 0.0 109.408 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 74.8 m-20 -58.31 -38.54 77.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.458 -0.776 . . . . 0.0 109.765 -179.581 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.95 96.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.89 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -62.19 -46.1 90.43 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.815 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.0 t -63.16 -43.1 98.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.242 -0.911 . . . . 0.0 109.923 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 57.0 t -63.73 -40.6 89.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.274 -0.891 . . . . 0.0 109.832 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.03 -35.28 75.77 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.73 -48.15 5.05 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.03 -1.276 . . . . 0.0 110.215 -179.39 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 42.1 m -131.69 134.75 46.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.345 -0.847 . . . . 0.0 109.409 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -128.6 87.96 53.53 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.306 -0.871 . . . . 0.0 109.648 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.22 -178.84 3.12 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.766 2.311 . . . . 0.0 111.846 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.51 150.74 66.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.51 2.14 . . . . 0.0 111.554 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.2 t -93.99 130.6 42.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.179 -0.951 . . . . 0.0 109.887 -179.418 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -134.65 160.78 37.06 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.512 -0.743 . . . . 0.0 109.353 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -102.78 144.62 30.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 49.4 mttp -58.08 -33.87 69.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.202 -0.936 . . . . 0.0 109.465 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 89' ' ' GLN . 35.2 tp -97.37 130.35 44.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 88' ' ' LEU . 63.5 tt0 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.517 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 121.371 0.605 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.581 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -85.1 125.77 33.05 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.587 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 1.6 m-70 54.97 19.63 2.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 108.551 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.89 -39.63 92.61 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.419 -0.801 . . . . 0.0 110.183 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -63.96 -34.99 79.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.097 -1.002 . . . . 0.0 109.889 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.75 -39.67 84.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.449 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 91.2 mt -59.89 -43.02 91.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.501 -0.749 . . . . 0.0 110.195 -179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.548 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.09 -49.41 74.56 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.104 -0.998 . . . . 0.0 109.48 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.419 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.2 pp0? -69.55 -33.76 73.23 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.8 t80 -66.63 -51.87 51.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 110.004 -179.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 14.1 m -72.92 -39.89 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.257 -0.902 . . . . 0.0 110.16 -179.694 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.548 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 99.5 t -64.55 -38.76 83.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.922 . . . . 0.0 109.922 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.1 -30.15 61.66 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.227 -0.921 . . . . 0.0 109.538 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.14 -29.51 70.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.304 -0.872 . . . . 0.0 108.987 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.614 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 16.9 p90 -149.52 49.63 0.95 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.298 -0.876 . . . . 0.0 109.257 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.13 136.71 53.48 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 120.89 -1.131 . . . . 0.0 110.183 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -73.36 -153.47 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 121.972 1.781 . . . . 0.0 110.603 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -80.3 13.31 2.44 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.1 -1.0 . . . . 0.0 108.776 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.7 t -113.44 136.16 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.585 -0.697 . . . . 0.0 109.996 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.32 140.19 72.46 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.283 -0.885 . . . . 0.0 108.873 179.33 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.589 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 53.1 Cg_exo -48.57 -33.22 23.15 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 121.692 1.595 . . . . 0.0 111.808 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.23 -19.6 65.56 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.445 -0.784 . . . . 0.0 109.353 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -96.46 0.16 49.95 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.451 -0.781 . . . . 0.0 108.983 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -107.08 134.04 49.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.611 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.3 m-20 -70.98 99.73 1.85 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 109.376 -179.503 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.8 m -59.68 5.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.353 -0.842 . . . . 0.0 109.768 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.611 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -92.16 8.6 37.24 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.065 -1.022 . . . . 0.0 108.841 179.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.3 tp -94.54 136.56 34.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.593 -0.692 . . . . 0.0 109.544 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.41 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.5 m-20 -63.24 121.57 14.01 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -72.28 6.73 2.09 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.635 -179.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -53.4 -39.49 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 108.941 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -57.79 -36.14 71.77 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.3 m-20 -85.27 15.1 4.54 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.29 -15.06 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.83 -37.36 20.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.054 -1.262 . . . . 0.0 108.46 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.3 tt -70.69 -24.84 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.536 -0.727 . . . . 0.0 110.142 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.428 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.4 m-20 -60.04 -33.34 71.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.235 -0.916 . . . . 0.0 111.141 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -105.62 -64.79 1.11 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.91 -1.118 . . . . 0.0 111.451 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -72.21 -52.17 17.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 111.018 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.77 -36.85 91.8 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tp -58.91 -41.96 88.49 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.43 -1.041 . . . . 0.0 109.459 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.7 tp -65.68 -44.28 86.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.203 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 41.4 mttt -67.02 -36.38 81.98 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.361 -0.837 . . . . 0.0 109.913 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.428 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 79.2 t -62.41 -44.32 99.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 0.0 110.366 -179.276 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -59.16 -48.27 87.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.922 -1.111 . . . . 0.0 109.398 -179.812 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.32 -44.33 79.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.375 -0.828 . . . . 0.0 110.658 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -75.5 -43.62 48.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.102 -0.999 . . . . 0.0 110.243 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.428 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -57.9 -40.26 79.9 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.33 -0.856 . . . . 0.0 109.548 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.583 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.7 tt0 -61.62 -42.66 99.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.141 -0.974 . . . . 0.0 109.389 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.56 -43.09 85.97 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.112 -0.992 . . . . 0.0 110.364 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.685 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 59.8 ttt-85 -64.68 -44.23 91.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.317 -0.865 . . . . 0.0 111.241 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 96.9 m-85 -104.69 -10.15 17.68 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.94 -1.1 . . . . 0.0 110.765 -178.777 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 24.65 73.42 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -95.01 142.41 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.122 -1.223 . . . . 0.0 109.418 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.96 149.97 34.87 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.083 -1.011 . . . . 0.0 109.228 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.17 72.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.242 -0.911 . . . . 0.0 109.586 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 50.43 48.17 22.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.108 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -63.17 123.17 17.95 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 110.037 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 30.0 m -135.0 163.09 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 91.5 mt-10 -65.37 132.06 48.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.975 -1.078 . . . . 0.0 109.5 -179.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 9.7 mt -125.41 147.31 49.24 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.557 -0.715 . . . . 0.0 109.649 -179.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.61 157.75 38.41 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 109.055 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -60.12 -25.56 80.18 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.721 2.281 . . . . 0.0 112.071 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.05 -31.94 73.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.542 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 52.2 t-80 -67.9 -26.79 66.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.695 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -98.34 6.35 47.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.9 tpt180 -56.21 -39.37 72.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.213 -0.929 . . . . 0.0 109.703 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.4 p -143.59 156.23 44.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.019 -1.05 . . . . 0.0 110.063 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.7 mt -62.45 -36.51 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.345 -0.847 . . . . 0.0 109.835 179.792 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -60.61 -39.12 87.01 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 110.356 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.485 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 84.9 p -60.27 -37.63 81.05 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.067 -1.021 . . . . 0.0 109.587 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.5 mt -67.99 -38.8 80.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.289 -0.882 . . . . 0.0 109.37 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.581 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 51.5 t0 -58.29 -38.65 77.44 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.433 -0.792 . . . . 0.0 109.937 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.2 -44.34 92.26 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.092 -1.005 . . . . 0.0 109.732 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.542 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 71.4 t80 -64.89 -47.12 78.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.767 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.63 -42.08 94.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.325 -0.859 . . . . 0.0 109.917 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.4 t -64.27 -41.43 92.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.14 -0.975 . . . . 0.0 109.942 -179.827 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.61 -33.85 73.9 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.66 -48.01 4.65 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.294 . . . . 0.0 110.518 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.482 ' O ' ' O ' ' A' ' 76' ' ' VAL . 43.2 m -129.49 138.07 51.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.862 . . . . 0.0 110.044 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.524 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t -128.96 89.56 48.4 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.425 -0.797 . . . . 0.0 109.15 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.587 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 68.0 Cg_endo -83.1 161.44 15.56 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.777 2.318 . . . . 0.0 112.599 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -59.47 151.06 71.56 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.954 2.436 . . . . 0.0 111.903 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.484 ' CG2' ' HD1' ' A' ' 3' ' ' HIS . 46.6 t -89.77 131.08 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.661 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -128.57 165.0 21.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.533 -0.729 . . . . 0.0 109.136 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -53.68 143.39 20.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.031 -1.043 . . . . 0.0 109.142 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.589 ' NZ ' ' O ' ' A' ' 21' ' ' PRO . 55.3 tttt -57.89 -36.84 72.97 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.919 . . . . 0.0 109.419 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 62.7 mt -94.65 141.82 28.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 118.002 -0.999 . . . . 0.0 109.517 -179.965 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.447 ' C4 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.4 mtm . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.354 0.597 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 92.8 mt-30 -107.83 138.86 43.32 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.48 ' CD2' ' CG2' ' A' ' 6' ' ' VAL . 0.1 OUTLIER 44.11 27.74 0.22 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.138 -0.976 . . . . 0.0 108.912 -179.679 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.403 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -36.27 76.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.443 -0.785 . . . . 0.0 109.873 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -59.12 -40.26 84.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.167 -0.958 . . . . 0.0 109.534 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.48 ' CG2' ' CD2' ' A' ' 3' ' ' HIS . 73.3 t -66.3 -37.47 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.196 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 83.8 mt -59.88 -50.58 79.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.878 . . . . 0.0 109.436 -179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.544 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.18 -47.82 78.32 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.05 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.27 -40.84 98.53 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.478 -0.763 . . . . 0.0 109.662 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.469 ' CE2' ' CH2' ' A' ' 47' ' ' TRP . 67.3 t80 -66.84 -51.54 54.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.437 -0.789 . . . . 0.0 110.348 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -69.96 -41.22 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.877 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.544 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 87.4 t -64.5 -35.77 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.91 . . . . 0.0 109.575 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.68 -30.8 63.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.589 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.45 -31.49 72.6 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.273 -0.892 . . . . 0.0 109.729 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.593 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 30.9 p90 -142.97 46.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.563 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 136.06 53.22 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.206 -179.76 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.49 -150.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.168 1.912 . . . . 0.0 110.432 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.8 p30 -79.69 12.78 2.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.896 -1.128 . . . . 0.0 108.842 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 32.5 t -113.33 136.31 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.468 -0.77 . . . . 0.0 109.835 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.07 138.68 87.38 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.133 -0.98 . . . . 0.0 108.783 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -48.34 -26.76 8.91 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 121.869 1.713 . . . . 0.0 112.141 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.04 -16.91 61.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.106 -0.996 . . . . 0.0 109.749 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -105.36 7.01 33.12 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -0.863 . . . . 0.0 110.412 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 3.5 m -96.06 144.53 10.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 120.946 -1.096 . . . . 0.0 109.273 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.581 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -70.44 88.08 0.65 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.029 -1.044 . . . . 0.0 109.193 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.7 m -61.67 5.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.271 -0.893 . . . . 0.0 109.546 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.581 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -97.87 6.8 47.34 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 108.954 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.1 tp -96.94 135.53 38.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.484 -0.76 . . . . 0.0 109.555 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -64.26 121.75 15.02 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -68.86 8.42 0.52 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.762 -179.016 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.48 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.9 p -53.73 -39.83 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.131 -0.981 . . . . 0.0 109.01 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.0 t0 -58.11 -35.79 71.96 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.624 ' O ' ' N ' ' A' ' 35' ' ' VAL . 62.8 m-80 -85.2 15.07 4.48 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.27 -15.97 0.02 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.624 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.7 t -52.71 -37.14 24.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.972 -1.311 . . . . 0.0 108.311 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.613 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.1 tt -70.53 -25.16 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.479 -0.763 . . . . 0.0 109.94 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.9 m-20 -62.21 -29.66 70.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.263 -0.898 . . . . 0.0 110.66 -178.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.0 m -104.9 -64.76 1.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.02 -1.05 . . . . 0.0 110.979 -178.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 19.8 mt -74.03 -52.4 12.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 110.846 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.8 93.79 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.613 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.95 -39.74 93.14 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.496 -1.002 . . . . 0.0 109.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.0 -44.04 94.8 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -67.52 -40.25 85.09 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.363 -0.836 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.16 -45.54 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 110.082 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.513 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -62.73 -41.73 93.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.063 -1.023 . . . . 0.0 109.66 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.05 -41.01 99.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.925 . . . . 0.0 109.676 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.704 ' HE1' ' NH1' ' A' ' 51' ' ' ARG . 0.8 OUTLIER -78.56 -49.1 13.91 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.954 179.884 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.31 -43.24 96.53 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.45 -0.781 . . . . 0.0 110.626 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 0.9 OUTLIER -66.53 -36.28 82.3 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.945 -1.097 . . . . 0.0 109.087 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.404 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 54.3 t0 -72.04 -44.99 62.49 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.388 -0.82 . . . . 0.0 110.223 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.704 ' NH1' ' HE1' ' A' ' 47' ' ' TRP . 22.5 ttm180 -60.95 -40.63 94.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.381 -0.825 . . . . 0.0 111.105 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -103.18 -6.14 22.47 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.824 -1.172 . . . . 0.0 110.21 -179.215 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.71 34.06 87.77 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -98.39 133.51 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.244 -1.15 . . . . 0.0 109.423 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.83 137.07 58.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.118 -0.989 . . . . 0.0 109.421 -179.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.7 -29.02 67.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.362 -0.836 . . . . 0.0 110.233 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.456 ' C ' ' OD2' ' A' ' 57' ' ' ASP . 52.8 p30 -85.5 2.08 46.2 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -0.95 . . . . 0.0 110.457 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 97.2 m-20 -60.34 -37.83 81.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.914 -1.116 . . . . 0.0 109.627 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.41 159.89 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.464 -0.773 . . . . 0.0 109.504 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -96.35 138.27 34.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.211 -0.931 . . . . 0.0 109.323 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.08 140.32 36.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.309 -0.87 . . . . 0.0 109.795 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.24 157.41 75.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.362 -0.836 . . . . 0.0 109.238 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.27 -31.26 82.05 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.609 2.206 . . . . 0.0 112.136 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.48 -31.91 73.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.4 -0.812 . . . . 0.0 109.765 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -68.2 -27.09 66.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.196 -0.94 . . . . 0.0 109.861 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.71 6.37 47.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -55.8 -38.64 70.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 97.0 p -135.15 152.92 52.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.318 -0.863 . . . . 0.0 109.749 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -63.54 -36.48 76.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.371 -0.831 . . . . 0.0 109.885 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -60.47 -38.31 83.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 110.271 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.6 t -57.92 -42.98 85.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.017 -1.052 . . . . 0.0 109.661 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -62.0 -39.58 84.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.213 -0.929 . . . . 0.0 109.328 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -57.83 -37.0 73.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.341 -0.849 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.5 -41.15 96.86 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.233 -0.917 . . . . 0.0 109.524 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -62.87 -46.93 85.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.84 -43.22 97.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.294 -0.879 . . . . 0.0 109.818 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.5 t -60.89 -40.79 86.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.295 -0.878 . . . . 0.0 109.833 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.14 -30.78 74.66 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 120.409 -0.9 . . . . 0.0 110.949 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.15 -48.43 3.87 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.952 -1.323 . . . . 0.0 110.593 -178.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -128.23 155.3 44.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.154 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.528 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.3 t -138.83 89.11 13.23 Favored Pre-proline 0 C--N 1.303 -1.44 0 O-C-N 121.148 -0.97 . . . . 0.0 109.77 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.446 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.3 Cg_exo -65.6 -176.26 0.54 Allowed 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 122.7 2.267 . . . . 0.0 111.701 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 28.9 Cg_exo -58.49 150.64 67.27 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.475 2.117 . . . . 0.0 111.539 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 43.7 t -90.06 128.39 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.819 -179.379 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -138.56 147.22 42.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.407 -0.808 . . . . 0.0 109.111 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.79 139.33 54.26 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.061 -1.024 . . . . 0.0 109.218 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 47.1 tttp -59.36 -36.94 76.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.417 -179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.4 mt -92.56 142.12 27.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.486 -179.965 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.565 ' C6 ' ' H1 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.0 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -59.06 -38.18 78.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.828 . . . . 0.0 109.634 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 52.5 p-80 -122.9 23.43 9.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.491 -0.756 . . . . 0.0 109.148 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.69 -34.4 72.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.362 -0.836 . . . . 0.0 109.764 -179.695 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.5 t -59.0 -41.84 88.64 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.2 t -66.23 -38.4 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.305 -0.872 . . . . 0.0 109.118 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.453 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 94.0 mt -59.34 -50.62 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.395 -0.815 . . . . 0.0 109.69 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.98 97.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 108.864 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.48 -39.64 92.16 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.537 -0.727 . . . . 0.0 109.442 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 44.6 t80 -61.22 -51.42 69.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.431 -0.793 . . . . 0.0 110.011 -179.005 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.433 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 12.4 p -72.96 -48.95 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.313 -0.867 . . . . 0.0 110.87 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.433 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 61.9 t -60.9 -35.87 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.162 -0.961 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -59.51 -34.57 72.77 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.991 -1.068 . . . . 0.0 110.005 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.65 -36.3 82.22 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 111.028 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 42.5 m-85 -100.61 -57.78 2.04 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.894 -1.128 . . . . 0.0 111.052 -178.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.6 mp -123.97 87.3 53.2 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.238 -0.914 . . . . 0.0 110.944 -178.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -91.51 -16.67 1.23 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.199 2.599 . . . . 0.0 112.084 178.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -76.39 -4.5 42.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.157 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.5 145.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD2' ' A' ' 23' ' ' ASP . . . -60.84 115.58 14.57 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 120.755 -1.215 . . . . 0.0 108.289 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.62 -23.93 69.89 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 C-N-CA 121.329 1.353 . . . . 0.0 111.819 -179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.21 -15.66 62.47 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -0.89 . . . . 0.0 109.865 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD2' ' O ' ' A' ' 20' ' ' ALA . 49.6 p30 -89.09 3.24 52.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.014 -1.054 . . . . 0.0 109.767 -179.513 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 14.5 m -77.21 140.74 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.114 -0.991 . . . . 0.0 108.672 179.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -66.42 82.71 0.09 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.067 -1.021 . . . . 0.0 109.278 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.431 ' CG1' ' HZ2' ' A' ' 87' ' ' LYS . 12.5 m -62.47 5.71 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -0.927 . . . . 0.0 109.465 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.7 m-20 -103.08 7.17 38.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -0.892 . . . . 0.0 108.936 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.9 tp -98.51 137.45 37.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.498 -0.751 . . . . 0.0 109.525 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.575 ' OD1' ' NH2' ' A' ' 67' ' ' ARG . 89.0 m-20 -61.08 122.1 14.15 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -71.48 7.72 1.31 Allowed 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.192 -0.942 . . . . 0.0 110.177 -178.892 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.407 ' O ' ' N ' ' A' ' 34' ' ' GLY . 66.5 t -54.74 -43.75 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 120.823 -1.173 . . . . 0.0 108.362 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.76 -35.48 66.27 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -83.89 15.34 3.39 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 178.806 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.44 -14.82 0.01 OUTLIER Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.6 t -51.42 -38.81 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -1.122 . . . . 0.0 108.236 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.599 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -70.38 -24.98 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-O 121.717 0.77 . . . . 0.0 109.498 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.4 t0 -58.37 -34.02 70.22 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.503 -0.748 . . . . 0.0 111.24 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.567 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.59 -64.24 1.16 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.009 -1.057 . . . . 0.0 111.25 -178.503 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.558 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -72.05 -52.03 18.84 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.061 -1.024 . . . . 0.0 111.014 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.08 -37.93 94.76 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.562 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.599 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.84 -41.27 86.54 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.389 -1.065 . . . . 0.0 109.107 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 33.6 tp -61.91 -44.14 97.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 108.663 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -68.13 -39.53 82.7 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.431 -0.793 . . . . 0.0 109.715 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 70.0 t -64.55 -45.46 95.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 110.197 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.2 -47.99 91.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.213 -0.93 . . . . 0.0 109.444 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.43 -42.95 95.74 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.773 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -71.37 -39.83 70.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.346 -0.846 . . . . 0.0 109.737 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.4 tp -59.28 -47.18 86.34 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.233 -0.917 . . . . 0.0 109.468 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -65.91 -39.0 90.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.181 -0.95 . . . . 0.0 108.972 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -66.23 -36.01 81.92 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 110.614 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -84.98 -52.42 5.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.197 -0.939 . . . . 0.0 112.012 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -94.99 -5.35 44.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.721 -1.237 . . . . 0.0 111.306 -177.942 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.09 24.77 76.33 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.971 -1.651 . . . . 0.0 108.971 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.5 145.51 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.311 -1.111 . . . . 0.0 109.482 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.73 150.33 32.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 109.444 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.25 -30.59 62.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.422 -0.799 . . . . 0.0 109.611 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 55.11 46.47 23.97 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -0.878 . . . . 0.0 109.558 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -95.14 16.23 16.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.232 -0.917 . . . . 0.0 109.737 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 63.3 t -56.72 -43.75 80.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.105 -0.997 . . . . 0.0 109.548 -179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -138.36 132.0 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.163 -0.961 . . . . 0.0 109.671 179.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.6 mp -131.35 140.13 49.65 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.303 -0.873 . . . . 0.0 109.594 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.29 146.58 20.21 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.383 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.79 -22.98 74.34 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.57 2.18 . . . . 0.0 112.195 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.07 -31.63 72.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.382 -0.824 . . . . 0.0 109.934 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.606 ' HE2' ' CB ' ' A' ' 75' ' ' PHE . 58.3 t-80 -67.87 -26.95 66.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.175 -0.953 . . . . 0.0 109.654 -179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.8 m-85 -104.77 11.18 34.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.33 -0.856 . . . . 0.0 109.835 -179.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.575 ' NH2' ' OD1' ' A' ' 29' ' ' ASP . 41.6 tpt85 -54.36 -38.51 66.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.18 -0.95 . . . . 0.0 109.571 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.5 p -149.12 156.28 41.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.144 -0.972 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -62.71 -36.67 76.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.344 -0.848 . . . . 0.0 109.83 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.7 ttp180 -60.41 -40.85 92.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.897 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.9 t -60.61 -44.19 96.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.361 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.7 mt -66.54 -38.58 81.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.308 -0.87 . . . . 0.0 109.727 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.454 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 88.7 m-20 -57.77 -41.1 81.33 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.312 -0.867 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.22 -46.15 78.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.103 -0.998 . . . . 0.0 109.631 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.606 ' CB ' ' HE2' ' A' ' 65' ' ' HIS . 66.0 t80 -64.12 -46.44 84.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.353 -0.842 . . . . 0.0 109.366 179.745 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.485 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.1 t -64.86 -41.69 92.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.368 -0.832 . . . . 0.0 109.881 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.454 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 54.4 t -62.31 -41.08 90.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.084 -1.01 . . . . 0.0 109.803 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.07 -34.75 73.94 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.34 -48.12 4.48 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.09 -1.241 . . . . 0.0 110.522 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.3 m -129.53 138.09 51.15 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.349 -0.844 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.524 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t -128.29 89.47 49.78 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.408 -0.808 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -64.45 179.73 1.15 Allowed 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 122.56 2.173 . . . . 0.0 112.223 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -59.14 150.42 73.78 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.577 2.185 . . . . 0.0 111.929 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 32.3 t -102.89 129.4 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 -179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -136.11 158.34 44.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.319 -0.863 . . . . 0.0 109.431 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.85 145.04 51.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.313 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.431 ' HZ2' ' CG1' ' A' ' 26' ' ' VAL . 13.1 tttp -129.77 133.42 46.99 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.333 -0.855 . . . . 0.0 109.371 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.43 ' O ' ' C ' ' A' ' 89' ' ' GLN . 52.4 mt -92.07 142.76 27.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.6 mt-30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.474 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.567 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.9 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.343 0.592 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.401 HE21 HG12 ' A' ' 84' ' ' VAL . 44.9 tp60 -58.51 -40.77 83.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 109.644 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.573 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 57.0 m-70 -126.62 12.0 7.37 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.38 -0.825 . . . . 0.0 109.516 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.58 -32.27 70.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 110.045 -179.463 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -58.66 -37.13 75.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.076 -1.015 . . . . 0.0 109.662 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.51 -36.97 76.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.198 -0.939 . . . . 0.0 109.005 179.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 83.5 mt -60.63 -50.63 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.29 -0.882 . . . . 0.0 109.643 -179.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.33 -47.18 80.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.042 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.7 -44.31 96.57 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.5 t80 -66.22 -45.06 82.03 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.6 -0.688 . . . . 0.0 109.652 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.7 t -66.8 -49.7 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.438 -0.788 . . . . 0.0 110.556 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 61.7 t -64.12 -35.13 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.359 -0.838 . . . . 0.0 110.199 -179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -56.56 -34.59 67.25 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.429 -0.794 . . . . 0.0 109.996 -179.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.61 -30.8 71.17 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 110.621 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 34.7 m-85 -109.84 -57.86 2.13 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.116 -0.99 . . . . 0.0 111.32 -178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.2 mm? -123.66 86.9 52.67 Favored Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.111 -0.993 . . . . 0.0 111.362 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.33 -19.21 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 123.154 2.569 . . . . 0.0 111.868 177.745 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.28 -4.1 40.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.239 -0.913 . . . . 0.0 109.091 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.15 143.81 22.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.107 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.94 115.76 15.5 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.728 -1.232 . . . . 0.0 108.557 -179.207 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.26 -25.86 71.97 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 C-N-CA 121.479 1.452 . . . . 0.0 111.746 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.92 -14.92 62.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.285 -0.884 . . . . 0.0 109.227 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -88.84 8.43 29.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.378 -0.826 . . . . 0.0 109.151 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -93.33 137.35 22.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.605 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -64.44 85.63 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.146 -0.971 . . . . 0.0 109.57 -179.334 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.506 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 2.6 p -59.64 5.72 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.301 -0.874 . . . . 0.0 109.677 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.605 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -101.93 6.44 41.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.07 -1.019 . . . . 0.0 108.787 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 15.0 tp -100.14 133.47 44.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.519 -0.738 . . . . 0.0 109.586 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.484 ' C ' ' H ' ' A' ' 31' ' ' VAL . 90.0 m-20 -66.67 121.78 16.17 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.618 ' H ' ' CD1' ' A' ' 30' ' ' LEU . 0.0 OUTLIER -70.03 11.63 0.29 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.173 -0.955 . . . . 0.0 109.946 -179.077 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.484 ' H ' ' C ' ' A' ' 29' ' ' ASP . 34.0 m -52.38 -44.07 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 120.869 -1.144 . . . . 0.0 108.495 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.412 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 91.7 m-20 -56.67 -35.28 68.23 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.5 m-20 -83.51 15.24 3.19 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.45 -13.88 0.01 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 50.2 t -50.63 -37.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.059 -1.259 . . . . 0.0 108.523 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.626 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.9 tt -70.57 -24.45 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.446 -0.784 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -61.51 -31.65 71.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.135 -0.978 . . . . 0.0 111.079 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 m -105.67 -65.28 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.93 -1.106 . . . . 0.0 111.486 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.55 -52.51 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.11 -0.994 . . . . 0.0 110.97 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.1 -37.17 92.83 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.626 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.2 tp -58.8 -43.4 90.51 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.489 -1.007 . . . . 0.0 109.196 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.55 -43.19 93.59 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.445 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -66.99 -36.62 82.59 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.41 -0.806 . . . . 0.0 109.419 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 73.1 t -65.66 -49.58 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.323 -0.86 . . . . 0.0 110.605 -179.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.9 mm -62.32 -41.34 91.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 120.922 -1.111 . . . . 0.0 109.65 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.26 -43.21 92.02 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.606 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -74.61 -39.85 61.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.367 -0.833 . . . . 0.0 109.786 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.6 tp -58.25 -42.08 85.6 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.293 -0.879 . . . . 0.0 109.625 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 53' ' ' GLY . 55.0 tt0 -63.01 -40.35 97.51 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -67.93 -47.14 69.51 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.13 -0.982 . . . . 0.0 110.764 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -68.08 -43.47 78.46 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.314 -0.866 . . . . 0.0 111.972 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -103.6 -6.33 21.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.846 -1.159 . . . . 0.0 111.299 -178.11 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.13 27.43 73.81 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.5 mt -98.5 142.16 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -1.136 . . . . 0.0 109.366 -179.571 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.6 144.33 51.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.02 . . . . 0.0 109.708 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.83 -34.07 74.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.437 -0.79 . . . . 0.0 109.717 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 57' ' ' ASP . 53.2 p30 -89.62 12.1 17.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.823 . . . . 0.0 109.817 -179.654 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -53.34 -34.89 59.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.231 -0.918 . . . . 0.0 109.913 -179.722 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.5 p -129.31 144.6 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.432 -0.793 . . . . 0.0 109.769 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -71.6 144.05 49.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.8 mt -96.58 136.22 37.41 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.26 -0.9 . . . . 0.0 109.923 -179.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.85 144.05 10.83 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.908 . . . . 0.0 109.132 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.09 -25.81 73.25 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.255 1.97 . . . . 0.0 111.929 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.41 -31.0 71.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.433 -0.792 . . . . 0.0 109.757 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -68.25 -26.56 65.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 110.562 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' LEU . 94.0 m-85 -99.14 10.27 41.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.058 -1.026 . . . . 0.0 111.089 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -58.46 -35.86 72.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.709 -1.244 . . . . 0.0 109.747 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.3 p -142.6 147.91 36.62 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.12 -0.987 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.447 HD11 HG22 ' A' ' 69' ' ' ILE . 90.7 mt -66.41 -36.6 77.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 O-C-N 121.307 -0.871 . . . . 0.0 110.113 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.3 mtm180 -61.16 -38.36 86.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.872 . . . . 0.0 110.573 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.0 p -62.59 -39.62 94.31 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.94 -1.1 . . . . 0.0 110.071 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.1 mt -68.45 -40.94 82.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.178 -0.951 . . . . 0.0 109.939 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.496 ' O ' ' CG2' ' A' ' 77' ' ' VAL . 49.4 t0 -59.04 -39.34 81.72 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.309 -0.87 . . . . 0.0 110.17 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.18 -45.48 88.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.081 -1.012 . . . . 0.0 109.95 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -64.52 -46.87 81.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -0.941 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.6 t -64.76 -41.42 92.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.867 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.496 ' CG2' ' O ' ' A' ' 73' ' ' ASP . 79.8 t -60.56 -41.53 88.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.147 -0.97 . . . . 0.0 109.921 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.47 -32.83 79.01 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 120.308 -0.948 . . . . 0.0 110.829 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -48.22 3.93 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.115 -1.227 . . . . 0.0 110.886 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 38.1 m -128.11 138.39 52.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.298 -0.876 . . . . 0.0 109.879 -179.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.518 ' OG1' ' NE2' ' A' ' 3' ' ' HIS . 1.6 t -128.79 88.08 52.93 Favored Pre-proline 0 N--CA 1.487 1.404 0 O-C-N 121.327 -0.858 . . . . 0.0 109.539 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.573 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 8.1 Cg_exo -69.4 -178.36 2.17 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.848 2.365 . . . . 0.0 112.103 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.405 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 25.9 Cg_exo -58.79 150.29 72.08 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.479 2.119 . . . . 0.0 111.783 179.49 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.401 HG12 HE21 ' A' ' 2' ' ' GLN . 41.7 t -108.49 132.35 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.357 -0.84 . . . . 0.0 109.909 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.02 149.32 49.95 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.05 134.32 41.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.585 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.409 ' O ' ' C ' ' A' ' 88' ' ' LEU . 41.2 tttp -100.29 133.32 44.88 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.224 -0.923 . . . . 0.0 109.166 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.409 ' C ' ' O ' ' A' ' 87' ' ' LYS . 30.2 tp 43.68 65.83 0.93 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.111 -0.993 . . . . 0.0 109.301 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.495 -179.938 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.41 ' O3P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.408 0.623 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tp60 -58.02 -41.58 83.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.346 -0.846 . . . . 0.0 109.735 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 70.6 m80 -118.32 4.13 11.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.449 -0.782 . . . . 0.0 109.816 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.47 -38.06 73.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.151 -0.968 . . . . 0.0 109.674 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 m -61.87 -43.65 98.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.745 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.426 ' O ' ' N ' ' A' ' 10' ' ' PHE . 78.5 t -65.11 -39.58 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.951 . . . . 0.0 108.913 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 95.9 mt -59.36 -49.84 82.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.365 -0.834 . . . . 0.0 109.337 179.777 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.39 -48.34 78.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 108.937 179.563 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.89 -39.53 94.76 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.494 -0.754 . . . . 0.0 109.553 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.426 ' N ' ' O ' ' A' ' 6' ' ' VAL . 63.6 t80 -66.94 -51.93 49.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.531 -0.73 . . . . 0.0 110.484 -178.961 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 20.7 m -73.07 -40.35 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 110.434 -179.564 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 91.2 t -64.75 -37.04 79.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.966 . . . . 0.0 110.047 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.25 -34.46 66.39 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.177 -0.952 . . . . 0.0 110.017 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -66.11 -31.23 71.97 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.282 -0.886 . . . . 0.0 109.824 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -137.68 43.5 2.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.168 -0.957 . . . . 0.0 109.845 -179.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.556 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.09 135.65 54.58 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 120.785 -1.197 . . . . 0.0 110.069 -179.656 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -78.09 -151.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.147 1.898 . . . . 0.0 110.256 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.82 11.74 2.48 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 108.616 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.59 136.31 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.5 -0.75 . . . . 0.0 109.966 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.66 140.83 71.75 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 108.636 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.45 -28.23 11.49 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.8 1.667 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -24.8 67.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -0.827 . . . . 0.0 109.304 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.5 5.57 46.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.441 -0.787 . . . . 0.0 108.912 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.0 t -103.75 136.98 34.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.602 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.83 95.94 0.39 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.565 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.9 m -60.7 5.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 109.516 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.602 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -94.02 8.34 41.82 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.097 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.0 tp -89.12 138.78 31.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.584 -0.697 . . . . 0.0 109.39 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.8 m-20 -63.09 121.5 13.77 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.354 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.484 ' O ' ' OD1' ' A' ' 33' ' ' ASN . 0.4 OUTLIER -70.32 3.39 2.95 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 109.405 -179.364 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.7 p -53.99 -35.88 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.261 -0.9 . . . . 0.0 109.557 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -57.17 -40.24 76.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.191 -0.943 . . . . 0.0 108.473 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.4 p30 -91.45 15.99 11.19 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' ASP . . . -42.48 -14.11 0.01 OUTLIER Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.8 t -49.86 -33.28 8.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.973 -1.31 . . . . 0.0 108.383 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.581 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.6 tt -70.1 -24.63 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.849 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 34' ' ' GLY . 85.8 m-20 -61.81 -33.61 74.44 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.413 -0.804 . . . . 0.0 111.255 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.51 -65.15 1.08 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.946 -1.096 . . . . 0.0 111.516 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.2 tt -71.93 -49.85 34.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 111.515 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -68.79 -41.8 81.66 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.629 -178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.581 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -63.15 -43.55 98.0 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.291 -1.123 . . . . 0.0 110.236 -179.052 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 42.6 tp -58.32 -44.42 88.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.84 -1.162 . . . . 0.0 109.437 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.8 mttt -68.9 -37.06 78.74 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.116 -0.99 . . . . 0.0 109.557 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.49 ' O ' ' N ' ' A' ' 48' ' ' LEU . 81.5 t -66.7 -47.67 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 111.239 -178.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.15 -45.64 92.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 120.586 -1.321 . . . . 0.0 110.162 -179.202 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.64 -45.57 74.98 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.032 -1.043 . . . . 0.0 110.51 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.504 ' CZ2' ' CZ ' ' A' ' 51' ' ' ARG . 2.0 t90 -76.91 -46.12 25.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 110.29 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 44' ' ' VAL . 12.0 tp -57.15 -41.48 79.24 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.355 -0.841 . . . . 0.0 109.603 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 25.6 tt0 -63.15 -36.6 84.16 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.637 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.11 -39.65 86.95 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.086 -1.009 . . . . 0.0 110.04 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.504 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 77.8 mtm180 -77.3 -43.17 34.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -0.967 . . . . 0.0 111.934 -179.039 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -102.34 -6.5 22.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.826 -1.171 . . . . 0.0 110.803 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.16 30.56 77.07 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.442 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 94.4 mt -85.01 147.05 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.202 -1.175 . . . . 0.0 109.958 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 148.02 42.4 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.229 -0.92 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.24 -32.02 69.6 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.329 -0.857 . . . . 0.0 109.741 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 52.47 43.04 31.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.3 p30 -93.7 16.31 14.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.386 -0.821 . . . . 0.0 109.672 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -53.76 -44.22 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 110.04 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -173.34 118.2 0.29 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.121 -0.987 . . . . 0.0 110.092 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.536 ' O ' ' N5 ' ' A' ' 101' ' ' PN7 . 2.3 mp -109.25 138.11 46.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.381 -0.824 . . . . 0.0 109.083 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 141.94 37.04 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.42 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -63.74 -21.72 69.65 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.291 1.994 . . . . 0.0 112.385 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.89 -32.89 72.33 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 110.307 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -74.06 -26.49 60.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.131 -0.98 . . . . 0.0 110.708 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -94.65 8.0 43.84 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.94 -1.1 . . . . 0.0 110.75 -178.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 30.1 mmt180 -58.9 -34.32 71.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.724 -1.235 . . . . 0.0 110.19 -179.927 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.645 ' HG ' ' HG ' ' A' ' 71' ' ' SER . 96.7 p -135.5 149.94 49.65 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.052 -1.03 . . . . 0.0 110.122 -179.761 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 75.8 mt -64.3 -36.86 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.391 -0.818 . . . . 0.0 110.04 179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -61.16 -37.24 82.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.25 -0.906 . . . . 0.0 110.686 -178.808 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.645 ' HG ' ' HG ' ' A' ' 68' ' ' SER . 19.8 m -58.82 -44.1 90.79 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.977 -1.077 . . . . 0.0 109.765 -179.306 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.0 mt -64.95 -38.66 83.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.189 -0.944 . . . . 0.0 109.622 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 51.2 t0 -56.8 -41.1 77.15 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.387 -0.821 . . . . 0.0 110.103 -179.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.52 -46.22 76.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.086 -1.009 . . . . 0.0 110.231 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -63.42 -46.14 87.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.04 -1.038 . . . . 0.0 109.626 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.94 -44.5 92.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.368 -0.832 . . . . 0.0 110.267 -179.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 42.0 t -63.17 -41.37 92.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.079 -1.013 . . . . 0.0 110.098 -179.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.56 -32.48 69.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.52 -48.27 3.86 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.101 -1.235 . . . . 0.0 110.819 -179.043 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.2 m -130.13 138.97 50.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.161 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.539 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t -127.04 89.02 53.05 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.334 -0.854 . . . . 0.0 109.125 179.459 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 86.6 Cg_endo -85.67 161.07 10.75 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.952 2.435 . . . . 0.0 112.652 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -60.12 150.39 79.46 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.731 2.287 . . . . 0.0 111.516 179.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -101.16 126.48 54.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.088 -1.008 . . . . 0.0 109.656 -179.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.532 ' O ' ' CB ' ' A' ' 86' ' ' ALA . 97.1 mt-10 -68.45 -32.47 72.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.358 -0.839 . . . . 0.0 109.55 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 85' ' ' GLU . . . 78.65 113.86 0.07 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.162 -179.567 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.8 mttp -58.06 -35.08 70.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.132 -0.98 . . . . 0.0 109.458 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.4 mt -94.15 141.54 28.43 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 109.432 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.483 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.536 ' N5 ' ' O ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.347 0.594 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.05 -36.19 74.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.31 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -150.1 44.68 0.9 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.385 -0.822 . . . . 0.0 109.273 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.04 -32.4 72.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.893 . . . . 0.0 109.934 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -58.46 -37.65 75.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.101 -0.999 . . . . 0.0 109.929 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.6 -39.49 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.148 -0.97 . . . . 0.0 109.357 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 94.6 mt -59.84 -40.07 81.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.265 -0.897 . . . . 0.0 109.627 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.39 -48.63 77.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.965 . . . . 0.0 109.118 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.427 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.37 -32.37 71.38 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.492 -0.755 . . . . 0.0 109.371 179.697 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -58.35 -51.51 69.49 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.296 -0.877 . . . . 0.0 109.722 -179.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 33.8 m -73.73 -45.01 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.062 -1.023 . . . . 0.0 110.781 179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 73.3 t -64.43 -35.89 75.67 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.176 -0.953 . . . . 0.0 111.131 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -58.1 -33.01 68.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.011 -1.056 . . . . 0.0 110.005 -178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.19 -31.27 72.01 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 110.825 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -110.12 -55.87 2.4 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.214 -0.929 . . . . 0.0 111.472 -178.189 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.2 mt -124.44 87.65 53.96 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.082 -1.011 . . . . 0.0 111.389 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.91 -13.99 1.25 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 123.205 2.603 . . . . 0.0 111.776 178.098 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.45 -3.99 40.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.18 -0.95 . . . . 0.0 109.39 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.2 p -114.09 146.42 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.29 115.18 13.27 Favored Pre-proline 0 C--N 1.303 -1.441 0 O-C-N 120.742 -1.224 . . . . 0.0 108.362 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -64.84 -33.04 54.54 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.458 1.439 . . . . 0.0 111.913 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.46 -14.96 61.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -92.55 6.98 45.22 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.512 -0.742 . . . . 0.0 109.036 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.8 t -95.84 137.06 24.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.631 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.7 m-20 -61.58 90.61 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.223 -0.923 . . . . 0.0 109.589 -179.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -59.22 6.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.273 -0.892 . . . . 0.0 109.692 179.763 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.631 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.2 m-20 -97.86 11.4 37.47 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.074 -1.016 . . . . 0.0 108.971 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.6 tp -89.51 133.89 34.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.43 -0.794 . . . . 0.0 109.704 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 91.2 m-20 -65.37 122.3 16.84 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.419 -0.801 . . . . 0.0 108.97 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.433 ' O ' ' N ' ' A' ' 33' ' ' ASN . 65.8 mt -62.06 -7.2 3.64 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.179 -0.951 . . . . 0.0 108.992 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.479 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.2 p -50.05 -41.16 17.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.03 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.479 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -58.8 -36.63 74.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 82.6 m-20 -85.29 16.86 3.37 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.48 -15.15 0.01 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.4 t -54.11 -38.78 39.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.78 -1.423 . . . . 0.0 107.853 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.23 -25.06 24.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.599 -0.688 . . . . 0.0 110.046 179.603 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.8 m-20 -62.37 -30.98 71.58 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 111.252 -178.306 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.561 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -104.97 -64.76 1.09 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.903 -1.123 . . . . 0.0 111.216 -178.62 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.5 mt -74.13 -52.58 12.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.121 -0.987 . . . . 0.0 110.964 -178.313 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.58 -36.59 93.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.745 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -61.33 -40.37 93.96 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.492 -1.005 . . . . 0.0 109.306 -179.599 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 34.2 tp -61.24 -44.21 97.62 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.535 -0.866 . . . . 0.0 108.797 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 46.1 mttp -70.5 -39.87 73.89 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.408 -0.808 . . . . 0.0 109.907 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 79.7 t -65.72 -45.72 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.881 . . . . 0.0 110.514 -179.165 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.97 -44.36 99.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.032 -1.042 . . . . 0.0 109.697 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -63.43 -43.09 98.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.323 -0.86 . . . . 0.0 109.802 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -76.21 -43.35 42.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.189 -0.945 . . . . 0.0 109.992 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.4 tp -58.09 -47.97 81.58 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 110.055 -179.32 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.614 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.2 tt0 -67.95 -39.55 83.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.114 -0.991 . . . . 0.0 108.827 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 93.8 m-20 -64.9 -40.52 95.21 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.586 -0.696 . . . . 0.0 110.235 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -61.7 -44.79 96.25 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 111.3 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -113.94 -1.87 13.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.095 -1.003 . . . . 0.0 111.042 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.614 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.2 37.89 81.87 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.7 mt -96.18 142.76 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -1.181 . . . . 0.0 109.263 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.92 138.94 58.41 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.915 -1.115 . . . . 0.0 109.491 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.8 -32.47 73.66 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -57.69 -37.75 74.0 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.382 -0.823 . . . . 0.0 109.9 -179.823 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.06 -37.74 67.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.118 -0.989 . . . . 0.0 109.377 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 60' ' ' GLU . 70.9 t -63.62 -37.16 78.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.85 . . . . 0.0 109.72 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . 86.3 tt0 58.57 127.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.559 -0.713 . . . . 0.0 109.654 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 17.5 mt -103.14 134.16 47.02 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.907 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -172.23 139.56 1.03 Allowed Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.482 ' CG ' ' H12' ' A' ' 101' ' ' PN7 . 18.0 Cg_endo -63.02 -26.62 73.8 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 121.986 1.791 . . . . 0.0 111.622 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -30.89 71.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.588 -0.695 . . . . 0.0 109.596 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.403 ' HE2' HG23 ' A' ' 72' ' ' ILE . 84.5 t60 -68.73 -26.3 65.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.58 -0.7 . . . . 0.0 110.824 -178.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -101.39 6.2 42.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.977 -1.077 . . . . 0.0 111.607 -178.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 34.2 mmt180 -60.08 -34.11 73.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.743 -1.223 . . . . 0.0 110.028 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.456 ' OG ' ' OG ' ' A' ' 71' ' ' SER . 84.7 p -144.04 147.25 33.57 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.874 -1.141 . . . . 0.0 110.185 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 78.6 mt -66.6 -36.74 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 O-C-N 121.482 -0.761 . . . . 0.0 109.896 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.4 mtm180 -61.03 -39.92 91.61 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.322 -0.861 . . . . 0.0 110.317 -178.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.456 ' OG ' ' OG ' ' A' ' 68' ' ' SER . 19.9 m -60.61 -43.95 96.85 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.974 -1.079 . . . . 0.0 109.427 -179.824 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.403 HG23 ' HE2' ' A' ' 65' ' ' HIS . 79.0 mt -68.51 -38.57 79.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.356 -0.84 . . . . 0.0 109.908 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 77.6 m-20 -58.35 -42.0 85.92 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.398 -0.814 . . . . 0.0 110.438 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -40.12 88.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.11 -0.994 . . . . 0.0 110.368 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -61.41 -51.42 68.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 109.851 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 76.8 t -67.64 -43.79 86.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.261 -0.899 . . . . 0.0 109.763 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -63.02 -39.87 86.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.074 -1.016 . . . . 0.0 109.621 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.85 70.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.03 -48.88 3.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.146 -1.208 . . . . 0.0 110.565 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 57.9 m -157.37 137.96 13.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.138 -0.976 . . . . 0.0 110.168 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.0 t -120.66 89.74 45.2 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 108.944 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -92.87 108.0 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.207 2.604 . . . . 0.0 113.114 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -78.65 131.75 10.53 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.005 1.803 . . . . 0.0 111.79 179.163 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 24.1 t -126.73 134.35 66.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.358 -0.839 . . . . 0.0 109.606 -179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -64.4 -34.86 79.16 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.886 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -146.79 157.27 43.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.156 -0.965 . . . . 0.0 109.708 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 41.8 tttm -70.76 132.31 45.15 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.184 -0.948 . . . . 0.0 109.243 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 44.5 mt -95.22 141.97 28.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.275 -0.89 . . . . 0.0 109.569 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.455 179.981 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.561 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.6 mtt . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.322 0.582 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -60.08 -38.0 81.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.349 -0.844 . . . . 0.0 109.507 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.593 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 45.6 m-70 -133.99 12.87 3.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.4 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.53 -35.61 76.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.316 -0.865 . . . . 0.0 110.051 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.514 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 86.8 p -61.76 -36.49 81.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.07 -1.019 . . . . 0.0 109.593 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.514 ' N ' ' HG ' ' A' ' 5' ' ' SER . 72.4 t -66.16 -37.47 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 108.94 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.2 mt -66.49 -41.69 88.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.407 -0.808 . . . . 0.0 110.336 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.496 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.89 -50.55 68.31 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.042 -1.036 . . . . 0.0 110.378 -179.022 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.418 ' HG3' ' H ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.4 -44.22 68.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.073 -1.017 . . . . 0.0 109.614 179.866 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.418 ' H ' ' HG3' ' A' ' 9' ' ' GLN . 71.1 t80 -60.18 -48.32 82.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.284 -0.885 . . . . 0.0 109.463 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.547 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 97.6 t -68.82 -47.48 75.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.486 -0.759 . . . . 0.0 109.837 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.496 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 89.6 t -64.29 -36.67 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.427 -0.796 . . . . 0.0 109.964 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.81 -28.5 61.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.339 -0.85 . . . . 0.0 109.879 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.56 -29.45 70.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -155.94 55.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.155 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 1.7 pt? -80.59 136.8 51.67 Favored Pre-proline 0 C--N 1.306 -1.283 0 O-C-N 120.995 -1.065 . . . . 0.0 110.197 -179.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.58 -153.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 121.937 1.758 . . . . 0.0 110.641 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -81.24 14.2 2.5 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.092 -1.005 . . . . 0.0 108.79 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.5 t -113.3 136.9 48.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.646 -0.658 . . . . 0.0 109.994 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.07 140.21 73.38 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 108.962 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.573 ' C ' ' HZ3' ' A' ' 87' ' ' LYS . 50.6 Cg_exo -48.86 -29.97 16.31 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 121.849 1.699 . . . . 0.0 112.081 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.6 -16.17 63.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.3 -0.875 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -102.2 5.48 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.347 -0.846 . . . . 0.0 109.234 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -105.0 136.78 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.586 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.9 t0 -71.15 96.2 1.34 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.157 -0.965 . . . . 0.0 109.431 -179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.2 m -60.91 6.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.356 -0.84 . . . . 0.0 109.676 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.586 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.0 6.79 48.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.132 -0.98 . . . . 0.0 109.118 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.5 tt -95.85 135.87 37.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.705 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.505 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.0 m-20 -60.86 121.92 13.56 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.75 14.92 0.07 Allowed 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.31 -0.868 . . . . 0.0 110.281 -178.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.505 ' H ' ' C ' ' A' ' 29' ' ' ASP . 73.4 t -54.34 -41.17 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 108.508 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -55.17 -35.21 64.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -83.07 14.53 3.32 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.842 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.86 -14.44 0.01 OUTLIER Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 44.4 t -51.21 -36.86 17.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 121.143 -1.21 . . . . 0.0 108.69 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.5 tt -70.66 -24.56 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.438 -0.789 . . . . 0.0 110.229 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.3 m-20 -58.9 -34.87 72.17 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 111.474 -178.103 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.9 m -106.26 -64.97 1.11 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.931 -1.106 . . . . 0.0 111.673 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -71.37 -52.53 18.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.042 -1.036 . . . . 0.0 111.037 -177.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.76 -36.45 91.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.65 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tp -58.15 -42.76 86.61 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.372 -1.075 . . . . 0.0 108.898 -179.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.39 -44.12 95.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -68.55 -34.68 76.26 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.458 -0.776 . . . . 0.0 109.518 179.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 75.3 t -61.47 -45.8 97.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.329 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mm -62.66 -41.14 91.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.95 -1.093 . . . . 0.0 109.577 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.73 -44.49 81.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 109.867 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.444 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -76.35 -45.14 33.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.181 -0.949 . . . . 0.0 109.702 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.444 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.04 -40.98 77.8 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.347 -0.846 . . . . 0.0 109.512 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.551 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 2.9 tm-20 -60.86 -43.13 98.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.159 -0.963 . . . . 0.0 108.751 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -68.91 -43.3 75.48 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.294 -0.879 . . . . 0.0 110.045 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.6 tpt180 -64.27 -44.72 90.86 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.436 -0.79 . . . . 0.0 111.062 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -106.23 -5.39 19.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.063 -1.023 . . . . 0.0 110.998 -178.516 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.542 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.02 30.28 65.73 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.551 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 71.6 mt -96.71 138.82 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.177 . . . . 0.0 109.056 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 136.07 57.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.991 -1.068 . . . . 0.0 109.801 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.32 -24.84 65.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.528 -0.732 . . . . 0.0 109.414 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.18 -31.64 61.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.468 -0.77 . . . . 0.0 110.217 -179.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.07 120.69 11.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.054 -1.029 . . . . 0.0 109.839 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 16.8 m -115.29 27.46 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.567 -0.708 . . . . 0.0 109.309 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -51.08 -26.04 5.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.379 -0.825 . . . . 0.0 109.922 -179.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.0 mt -71.73 138.99 48.91 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.08 -1.012 . . . . 0.0 109.792 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.85 162.4 51.91 Favored Pre-proline 0 N--CA 1.487 1.406 0 O-C-N 121.455 -0.778 . . . . 0.0 109.294 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -56.69 -36.21 98.12 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.324 2.016 . . . . 0.0 111.395 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.04 -25.8 65.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.474 -0.766 . . . . 0.0 109.185 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.48 ' CD2' ' CD2' ' A' ' 75' ' ' PHE . 34.1 t-80 -67.74 -26.03 65.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.415 -0.803 . . . . 0.0 109.863 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.533 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 92.0 m-85 -90.4 10.06 26.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.271 -0.893 . . . . 0.0 109.802 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 16.4 tpt180 -56.91 -40.35 76.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.921 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -144.75 153.41 41.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.951 -1.093 . . . . 0.0 110.263 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.4 mt -66.3 -36.8 78.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.462 -0.774 . . . . 0.0 110.123 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 14.1 ttm180 -60.77 -43.05 98.54 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.433 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.3 m -58.4 -40.46 82.48 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.226 -0.921 . . . . 0.0 109.918 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -61.54 -40.74 87.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.178 -0.951 . . . . 0.0 109.718 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 53.2 t0 -59.32 -37.5 77.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.288 -0.882 . . . . 0.0 109.996 -179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.8 -46.3 85.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.48 ' CD2' ' CD2' ' A' ' 65' ' ' HIS . 52.9 m-85 -68.45 -40.72 80.96 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.152 -0.967 . . . . 0.0 109.34 179.584 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -65.13 -41.99 93.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.296 -0.877 . . . . 0.0 109.585 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 56.3 t -63.74 -41.01 91.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 O-C-N 121.187 -0.946 . . . . 0.0 109.836 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.08 -30.96 71.47 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.33 -48.58 4.14 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.039 -1.271 . . . . 0.0 110.559 -178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.8 p -132.04 154.35 49.48 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.281 -0.887 . . . . 0.0 109.647 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.526 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.0 t -140.26 89.28 10.94 Favored Pre-proline 0 C--N 1.303 -1.418 0 O-C-N 121.222 -0.924 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 72.1 Cg_endo -85.2 161.15 11.43 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.877 2.385 . . . . 0.0 112.482 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.64 148.9 85.68 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.676 2.251 . . . . 0.0 111.778 179.637 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.405 ' HB ' ' HD1' ' A' ' 3' ' ' HIS . 14.6 p -130.44 141.26 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.382 -0.824 . . . . 0.0 109.926 -179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -112.77 160.17 18.24 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.13 135.63 43.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.976 -1.077 . . . . 0.0 109.179 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.573 ' HZ3' ' C ' ' A' ' 21' ' ' PRO . 16.1 tttm -60.13 -34.94 74.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.444 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.4 mt -84.88 142.95 29.35 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 -179.942 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.938 -1.03 . . . . 0.0 109.488 -179.914 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 91.9 mt-30 -59.86 -37.28 78.84 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.598 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -144.36 34.87 1.19 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.241 -0.912 . . . . 0.0 109.542 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.438 ' CB ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.57 -32.48 70.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -0.912 . . . . 0.0 109.676 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.5 m -58.46 -37.42 75.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.125 -0.984 . . . . 0.0 109.971 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.8 t -63.97 -40.85 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.131 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 76.7 mt -60.02 -47.92 89.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.443 -0.786 . . . . 0.0 109.27 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.29 -43.01 99.11 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.14 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -37.38 86.42 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.464 ' O ' ' CE ' ' A' ' 87' ' ' LYS . 33.5 t80 -60.67 -52.89 63.22 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.513 -0.742 . . . . 0.0 109.886 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.472 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -73.48 -42.01 56.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.106 -0.996 . . . . 0.0 109.89 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.507 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 79.2 t -65.02 -35.59 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.36 -0.837 . . . . 0.0 110.911 -179.16 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -56.17 -36.17 68.04 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.023 -1.048 . . . . 0.0 110.353 -178.435 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.405 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 75.6 mm-40 -66.06 -31.5 72.42 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.043 -1.036 . . . . 0.0 109.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.405 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.2 OUTLIER -135.02 43.84 2.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.126 -0.984 . . . . 0.0 109.907 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.565 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.5 135.89 52.85 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.119 . . . . 0.0 110.116 -179.733 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.4 ' C ' ' H ' ' A' ' 19' ' ' VAL . 71.6 Cg_endo -77.4 -149.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.143 1.895 . . . . 0.0 110.184 178.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.46 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.1 p30 -79.52 11.25 3.16 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 120.794 -1.191 . . . . 0.0 108.637 179.08 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.4 ' H ' ' C ' ' A' ' 17' ' ' PRO . 26.8 t -113.75 136.16 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.519 -0.738 . . . . 0.0 109.841 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.57 140.92 75.65 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.126 -0.983 . . . . 0.0 108.916 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -48.41 -29.33 13.29 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 121.875 1.717 . . . . 0.0 111.998 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.21 -21.16 66.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.384 -0.823 . . . . 0.0 109.283 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -103.27 3.25 35.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.44 -0.787 . . . . 0.0 108.886 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -104.93 138.94 27.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.609 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.5 t0 -68.78 102.59 1.57 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.105 -0.997 . . . . 0.0 109.354 -179.255 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.0 m -59.62 6.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.433 -0.792 . . . . 0.0 109.933 -179.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.609 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -89.92 10.11 25.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.03 -1.044 . . . . 0.0 108.632 179.248 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.2 tp -86.88 133.67 33.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.533 -0.729 . . . . 0.0 109.499 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.442 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.3 m-20 -67.45 121.27 15.43 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.081 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -73.31 9.79 1.19 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.123 -0.986 . . . . 0.0 109.349 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.51 -39.45 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.891 . . . . 0.0 108.825 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.4 m-20 -57.71 -36.18 71.65 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.9 m-80 -84.43 14.81 4.11 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.53 -15.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.617 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.58 -37.75 20.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.852 -1.381 . . . . 0.0 108.223 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.6 tt -71.04 -24.56 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.547 -0.721 . . . . 0.0 110.104 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.427 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.57 -32.15 71.24 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.153 -0.967 . . . . 0.0 111.358 -178.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.551 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -105.84 -65.11 1.09 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.864 -1.148 . . . . 0.0 111.393 -178.657 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.33 -52.36 16.49 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.177 -0.952 . . . . 0.0 110.916 -178.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.07 -36.69 92.28 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tp -58.88 -41.12 86.34 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.379 -1.071 . . . . 0.0 109.301 -179.625 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.9 tp -62.8 -44.33 96.45 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.213 -0.93 . . . . 0.0 108.762 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -71.87 -38.26 70.07 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.421 -0.8 . . . . 0.0 109.948 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 86.5 t -64.79 -45.12 96.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 110.249 -179.259 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.9 -42.47 94.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.171 -0.956 . . . . 0.0 109.607 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.77 -43.09 97.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.181 -0.949 . . . . 0.0 109.971 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -76.38 -43.68 39.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 109.842 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 31.4 tp -60.0 -42.5 94.41 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 0.0 109.842 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.609 ' O ' ' N ' ' A' ' 53' ' ' GLY . 4.1 tt0 -66.46 -41.69 88.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.12 -0.988 . . . . 0.0 108.996 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -66.61 -37.15 84.27 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.419 -0.8 . . . . 0.0 109.828 179.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -59.04 -41.72 88.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.498 -0.751 . . . . 0.0 110.818 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -118.93 -4.02 10.67 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.101 -0.999 . . . . 0.0 110.437 -179.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.74 43.19 29.4 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -101.08 140.7 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.138 -1.213 . . . . 0.0 109.323 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.26 136.61 58.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.884 -1.135 . . . . 0.0 109.374 -179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.23 -33.63 76.25 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.363 -0.836 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -94.48 8.24 42.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.265 -0.897 . . . . 0.0 109.809 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -53.05 -37.31 61.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.093 -1.004 . . . . 0.0 109.293 -179.929 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 12.6 p -133.27 144.78 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.451 -0.781 . . . . 0.0 109.169 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -77.75 137.38 38.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.429 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.3 mt -104.04 138.82 40.02 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.344 -0.848 . . . . 0.0 109.711 -179.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -135.58 154.85 78.53 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.321 -0.862 . . . . 0.0 109.06 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.34 -30.66 81.13 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.608 2.205 . . . . 0.0 112.339 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.79 -32.1 73.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.376 -0.828 . . . . 0.0 110.013 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -68.8 -26.48 65.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.288 -0.882 . . . . 0.0 110.897 -179.086 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -94.38 5.59 51.32 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.846 -1.159 . . . . 0.0 110.932 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -59.65 -40.87 89.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.034 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.0 m -129.45 145.26 51.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.25 -0.906 . . . . 0.0 110.184 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.1 mt -63.7 -36.28 75.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.467 -0.771 . . . . 0.0 109.759 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -60.33 -37.66 81.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.339 -0.851 . . . . 0.0 110.402 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -57.66 -43.46 84.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.999 -1.063 . . . . 0.0 109.633 -179.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -68.04 -38.74 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.261 -0.899 . . . . 0.0 109.634 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.438 ' OD1' ' CB ' ' A' ' 4' ' ' ALA . 50.4 t0 -57.72 -40.45 79.62 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.384 -0.823 . . . . 0.0 110.302 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.04 -45.68 80.56 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.029 -1.044 . . . . 0.0 109.624 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.7 t80 -63.54 -45.84 88.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.373 179.746 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' A' ' 80' ' ' THR . 59.1 t -65.22 -44.74 95.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.362 -0.836 . . . . 0.0 109.976 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.6 t -63.65 -39.39 85.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 O-C-N 121.11 -0.994 . . . . 0.0 109.838 179.986 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -33.65 68.34 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.5 -48.7 3.74 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.195 -1.179 . . . . 0.0 110.601 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.496 ' O ' ' O ' ' A' ' 76' ' ' VAL . 53.3 m -163.17 139.71 7.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.12 -0.987 . . . . 0.0 109.827 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.516 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.1 t -119.58 89.95 42.0 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.366 -0.834 . . . . 0.0 109.307 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -88.81 109.75 0.52 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 123.062 2.508 . . . . 0.0 112.741 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -78.51 130.27 9.8 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 122.012 1.808 . . . . 0.0 112.004 179.604 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -130.48 129.73 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.356 -0.84 . . . . 0.0 109.485 179.756 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -65.7 -39.06 90.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.454 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -161.06 159.06 28.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.317 -0.864 . . . . 0.0 109.376 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.464 ' CE ' ' O ' ' A' ' 10' ' ' PHE . 32.7 mttt -57.4 -33.31 67.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.455 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.5 mt -57.79 -35.6 71.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -0.928 . . . . 0.0 109.403 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 117.986 -1.006 . . . . 0.0 109.524 179.935 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.564 ' S12' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.708 ' N ' ' H ' ' A' ' 85' ' ' GLU . 4.2 ptt? . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.51 ' N ' ' O ' ' A' ' 83' ' ' PRO . 91.8 mt-30 55.6 44.15 27.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.27 -0.894 . . . . 0.0 109.107 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 2' ' ' GLN . 67.0 m170 46.45 37.69 4.58 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.181 -0.95 . . . . 0.0 109.048 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.75 -36.74 79.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.331 -0.856 . . . . 0.0 109.485 -179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' CE ' ' A' ' 1' ' ' MET . 22.9 m -59.23 -39.58 83.2 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.19 -0.944 . . . . 0.0 109.285 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.41 ' O ' ' N ' ' A' ' 10' ' ' PHE . 68.8 t -66.83 -37.66 79.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.203 -0.936 . . . . 0.0 109.0 179.33 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 85.5 mt -60.48 -51.01 78.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.251 -0.906 . . . . 0.0 109.177 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.534 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.81 -48.14 75.48 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.828 . . . . 0.0 109.301 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.85 -44.28 96.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.523 -0.736 . . . . 0.0 109.344 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.477 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.2 t80 -65.7 -48.7 71.14 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.57 -0.706 . . . . 0.0 109.486 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 90.9 t -67.33 -44.89 86.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.383 -0.823 . . . . 0.0 109.521 179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.534 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 94.3 t -64.25 -35.28 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.488 -0.757 . . . . 0.0 109.527 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.8 -30.38 61.26 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.299 -0.876 . . . . 0.0 109.969 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -65.66 -31.09 71.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.114 -0.992 . . . . 0.0 109.702 -179.635 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.563 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 33.5 p90 -143.29 45.79 1.53 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -0.999 . . . . 0.0 109.671 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.561 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.63 135.9 52.37 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.036 -1.04 . . . . 0.0 110.177 -179.813 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . 0.41 ' C ' ' H ' ' A' ' 19' ' ' VAL . 72.8 Cg_endo -77.58 -151.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.218 1.946 . . . . 0.0 110.364 178.293 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -78.72 12.18 2.22 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.826 -1.171 . . . . 0.0 108.748 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.41 ' H ' ' C ' ' A' ' 17' ' ' PRO . 22.0 t -113.4 137.0 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.52 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.72 84.34 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.151 -0.968 . . . . 0.0 108.911 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -48.2 -30.93 15.68 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.864 1.709 . . . . 0.0 112.179 179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.8 -22.92 66.0 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.419 -0.8 . . . . 0.0 109.434 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -102.51 8.64 39.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.834 . . . . 0.0 109.434 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.1 t -101.3 136.73 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.318 -0.864 . . . . 0.0 108.862 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.585 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.71 89.34 0.38 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.134 -0.979 . . . . 0.0 109.275 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -61.57 6.39 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.563 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.585 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -93.34 8.55 39.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.111 -0.993 . . . . 0.0 108.918 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -91.41 136.81 32.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.487 -0.758 . . . . 0.0 109.575 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -62.43 121.79 14.12 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.61 10.53 1.68 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.257 -0.902 . . . . 0.0 110.101 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.5 t -55.42 -42.08 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.907 -1.12 . . . . 0.0 108.932 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.4 t0 -55.81 -35.53 66.44 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.28 14.77 4.88 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -15.19 0.02 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.5 t -53.24 -36.81 26.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.151 -1.205 . . . . 0.0 108.611 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.2 tt -70.46 -24.73 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.462 -0.774 . . . . 0.0 110.087 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.425 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.8 m-20 -61.11 -32.31 71.99 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.215 -0.928 . . . . 0.0 110.969 -178.588 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 46.1 m -105.77 -64.57 1.14 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.047 -1.033 . . . . 0.0 111.475 -178.557 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.1 mp -72.56 -52.4 15.75 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.072 -1.018 . . . . 0.0 110.969 -178.198 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -65.91 -37.4 93.25 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.677 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.7 tp -59.39 -41.03 88.48 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.461 -1.023 . . . . 0.0 109.141 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.9 tp -62.03 -43.96 97.72 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -65.48 -35.45 80.94 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.48 -0.763 . . . . 0.0 109.281 179.197 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.2 t -60.11 -43.86 93.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.427 -0.796 . . . . 0.0 110.102 -179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.5 -44.88 97.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.688 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.9 -43.3 96.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 110.203 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.477 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -75.3 -38.84 60.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.875 . . . . 0.0 109.936 -179.694 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.7 tp -57.92 -44.16 86.67 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.285 -0.884 . . . . 0.0 110.014 -179.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.588 ' O ' ' N ' ' A' ' 53' ' ' GLY . 30.1 tt0 -66.34 -40.36 89.78 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 109.41 179.624 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -64.7 -44.04 91.54 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.319 -0.863 . . . . 0.0 110.574 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.15 -43.23 92.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.333 -0.854 . . . . 0.0 111.596 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -106.57 -7.07 17.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.952 -1.093 . . . . 0.0 110.782 -178.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.588 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.38 33.51 82.29 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.0 pt -108.78 153.12 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.363 -1.081 . . . . 0.0 109.961 -179.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.84 151.37 30.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.714 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.01 70.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.434 -0.791 . . . . 0.0 109.987 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 52.91 49.53 20.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.162 -0.961 . . . . 0.0 108.864 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -74.85 118.17 17.51 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.334 -0.854 . . . . 0.0 110.214 -179.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.8 m -129.59 163.78 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -59.4 127.69 33.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.909 -1.119 . . . . 0.0 109.467 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.6 mt -114.93 146.03 41.59 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.35 155.7 39.01 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.33 -0.856 . . . . 0.0 109.096 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.11 -25.57 77.42 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.644 2.229 . . . . 0.0 112.014 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.54 -29.74 70.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.534 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.67 -26.66 66.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.268 -0.895 . . . . 0.0 109.795 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -99.39 8.49 44.58 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.69 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.93 -38.15 69.91 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.726 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.8 p -141.36 156.63 45.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.1 -1.0 . . . . 0.0 110.16 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.3 mt -61.79 -35.74 69.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.431 -0.793 . . . . 0.0 109.847 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -59.74 -39.03 83.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.848 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.2 t -58.48 -39.89 81.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.066 -1.021 . . . . 0.0 108.924 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.2 mt -60.84 -38.72 79.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.299 -0.876 . . . . 0.0 108.874 179.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.0 t0 -56.21 -36.92 68.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.448 -0.783 . . . . 0.0 109.02 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.67 -40.64 92.83 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.257 -0.902 . . . . 0.0 108.768 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -60.64 -46.41 90.41 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.97 -40.62 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.411 -0.805 . . . . 0.0 108.934 179.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.0 t -57.97 -40.75 78.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.482 -0.761 . . . . 0.0 109.186 179.615 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.77 -34.31 86.36 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.88 -48.85 4.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.893 -1.357 . . . . 0.0 110.553 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.6 p -128.7 152.74 48.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 108.721 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.534 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.0 t -137.81 89.58 15.03 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.213 -0.929 . . . . 0.0 110.237 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.429 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.7 Cg_exo -64.28 -176.65 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.507 2.138 . . . . 0.0 111.476 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.51 ' O ' ' N ' ' A' ' 2' ' ' GLN . 25.9 Cg_exo -58.67 148.88 80.19 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.406 2.071 . . . . 0.0 111.937 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.402 ' HA ' ' H3 ' ' A' ' 1' ' ' MET . 45.7 t -112.42 136.06 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.397 -0.815 . . . . 0.0 109.889 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.708 ' H ' ' N ' ' A' ' 1' ' ' MET . 84.7 tt0 -145.4 -90.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.345 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -162.33 122.04 2.38 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.081 -1.012 . . . . 0.0 109.427 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 48.2 tttp -59.1 -36.15 74.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.7 tp -97.48 130.88 44.53 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.196 -0.94 . . . . 0.0 109.469 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.412 -179.941 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.438 ' O3 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.657 ' SD ' ' NH2' ' A' ' 70' ' ' ARG . 59.8 mtt . . . . . 0 N--CA 1.488 1.427 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.49 -34.4 72.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.199 -0.938 . . . . 0.0 108.84 179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -171.94 26.79 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.28 -35.04 76.22 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.295 -0.878 . . . . 0.0 109.584 -179.834 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.11 -41.65 88.67 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.965 . . . . 0.0 109.489 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.5 t -65.24 -39.82 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.224 -0.922 . . . . 0.0 108.907 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 88.9 mt -59.55 -50.71 78.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.456 -0.778 . . . . 0.0 109.351 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.54 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.11 -42.3 96.94 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 108.865 179.389 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.82 -39.57 91.0 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.509 -0.745 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 38.0 t80 -61.5 -52.22 65.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.356 -0.84 . . . . 0.0 109.847 -179.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.516 ' O ' ' CE2' ' A' ' 15' ' ' PHE . 4.3 p -72.51 -42.44 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.275 -0.891 . . . . 0.0 109.929 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.54 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 84.4 t -64.38 -38.39 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.356 -0.84 . . . . 0.0 110.294 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.55 -28.0 59.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.216 -0.927 . . . . 0.0 110.143 -179.46 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -64.77 -30.05 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.054 -1.029 . . . . 0.0 109.028 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -154.47 55.47 0.69 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.352 -0.842 . . . . 0.0 109.208 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.403 ' H ' ' CD2' ' A' ' 16' ' ' LEU . 1.8 pt? -80.82 137.05 50.64 Favored Pre-proline 0 N--CA 1.486 1.331 0 O-C-N 121.079 -1.013 . . . . 0.0 110.106 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.15 -153.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 121.925 1.75 . . . . 0.0 110.837 179.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.453 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 54.0 p30 -82.16 15.31 2.42 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 108.838 179.484 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.7 t -112.96 137.15 46.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.623 -0.673 . . . . 0.0 109.912 -179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.69 137.76 88.13 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.911 . . . . 0.0 109.06 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -48.94 -31.01 19.03 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.87 1.713 . . . . 0.0 112.152 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.27 -16.61 64.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.89 . . . . 0.0 109.427 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -102.2 8.81 40.46 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.172 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.86 136.47 31.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.609 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.4 90.12 0.51 Allowed 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 7.1 p -59.17 6.22 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.327 -0.858 . . . . 0.0 109.845 179.83 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.609 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -90.12 5.79 45.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.068 -1.02 . . . . 0.0 108.852 179.393 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.5 tp -94.39 136.25 34.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.468 -0.77 . . . . 0.0 109.449 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.518 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.2 m-20 -62.53 121.65 13.82 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.59 13.91 0.09 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.282 -0.886 . . . . 0.0 110.03 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.518 ' H ' ' C ' ' A' ' 29' ' ' ASP . 79.6 t -55.15 -42.38 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 0.0 108.702 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.61 -35.36 65.77 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.909 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -84.29 14.39 4.41 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.91 -14.53 0.01 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.43 -34.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.19 -1.183 . . . . 0.0 108.817 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -69.84 -24.34 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.463 -0.773 . . . . 0.0 110.11 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 82.9 m-20 -57.11 -34.76 68.68 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 111.33 -178.3 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.577 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.65 -64.79 1.11 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.851 -1.156 . . . . 0.0 111.381 -178.226 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.604 ' CD2' ' HZ3' ' A' ' 43' ' ' LYS . 7.3 tt -70.88 -52.36 20.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.071 -1.018 . . . . 0.0 110.93 -178.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.39 -36.83 92.15 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.475 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.2 tt -58.76 -42.09 88.08 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.451 -1.029 . . . . 0.0 109.484 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -61.88 -44.09 97.53 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.175 -0.953 . . . . 0.0 108.54 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . 0.604 ' HZ3' ' CD2' ' A' ' 39' ' ' LEU . 54.3 mttp -70.09 -38.33 75.64 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.426 -0.796 . . . . 0.0 109.897 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.8 t -64.09 -45.14 97.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 110.372 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -60.8 -44.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.727 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.37 -41.78 96.52 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.89 . . . . 0.0 110.106 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -76.44 -43.47 39.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.929 . . . . 0.0 110.097 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.04 -44.43 87.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -0.947 . . . . 0.0 109.668 -179.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.3 tt0 -64.69 -38.17 90.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.17 -0.956 . . . . 0.0 109.088 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -71.42 -48.94 46.46 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.378 -0.826 . . . . 0.0 110.623 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -62.41 -42.47 99.46 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.362 -0.836 . . . . 0.0 111.279 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.6 m-85 -101.2 -6.52 24.14 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.866 -1.146 . . . . 0.0 110.353 -178.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.98 28.25 73.73 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.0 mt -101.55 137.01 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.281 -1.129 . . . . 0.0 109.192 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.95 57.38 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.076 -1.015 . . . . 0.0 109.291 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.71 -36.82 79.78 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.27 -0.894 . . . . 0.0 109.441 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -61.39 -33.26 73.39 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -50.72 -34.59 27.51 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.836 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.8 t -101.4 135.87 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.187 -0.945 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -89.51 141.81 28.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.471 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 36.5 mt -97.31 134.26 40.83 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.74 -179.608 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.48 153.19 8.46 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.216 -0.928 . . . . 0.0 109.226 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.07 -28.58 80.31 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.487 2.125 . . . . 0.0 111.964 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.05 -29.56 70.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.368 -0.833 . . . . 0.0 109.572 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.65 -26.97 66.48 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.347 -0.846 . . . . 0.0 109.75 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.578 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 96.1 m-85 -103.49 6.82 37.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 110.161 -179.448 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.7 tpt180 -58.35 -41.69 85.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.029 -1.044 . . . . 0.0 109.904 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -153.74 158.86 41.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.902 -1.124 . . . . 0.0 110.116 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 3.3 mp -62.74 -36.98 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.34 -0.85 . . . . 0.0 109.871 179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.657 ' NH2' ' SD ' ' A' ' 1' ' ' MET . 4.6 tpm_? -60.7 -40.86 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.25 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.25 -44.07 95.58 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.102 -0.999 . . . . 0.0 109.695 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.5 mt -66.11 -39.76 85.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.225 -0.922 . . . . 0.0 109.79 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -58.02 -38.41 76.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.396 -0.815 . . . . 0.0 109.857 -179.568 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.5 -46.2 80.61 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.207 -0.933 . . . . 0.0 109.847 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -66.6 -41.63 88.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.091 -1.006 . . . . 0.0 109.225 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -64.9 -42.48 94.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.349 -0.845 . . . . 0.0 109.706 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.6 t -63.1 -41.46 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.253 -0.904 . . . . 0.0 109.79 -179.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.0 -30.33 66.51 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.44 -48.08 4.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -1.22 . . . . 0.0 110.21 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.49 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.2 t -143.3 155.53 44.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.184 -0.947 . . . . 0.0 109.737 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.516 ' CG2' ' O ' ' A' ' 81' ' ' THR . 9.2 t -139.33 90.2 11.77 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 121.29 -0.881 . . . . 0.0 109.281 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.8 Cg_exo -62.16 -178.11 0.32 Allowed 'Trans proline' 0 N--CA 1.493 1.497 0 C-N-CA 122.479 2.119 . . . . 0.0 112.221 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 26.4 Cg_exo -59.08 150.58 72.36 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.602 2.202 . . . . 0.0 111.913 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 26.8 t -101.6 129.37 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 109.58 -179.697 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -136.49 153.03 51.14 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.391 -0.818 . . . . 0.0 109.377 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.05 142.45 57.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.379 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 66.4 tttm -58.43 -37.5 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.451 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.3 mt -59.39 -35.07 73.27 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.212 -0.93 . . . . 0.0 109.437 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.451 -179.976 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.577 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.241 0.543 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -82.08 135.05 35.37 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.32 -0.862 . . . . 0.0 108.745 179.61 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 56.4 m80 55.62 38.37 30.09 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.182 -0.949 . . . . 0.0 108.959 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.93 -34.0 71.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -0.806 . . . . 0.0 109.548 -179.62 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.02 -38.64 79.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.21 -0.931 . . . . 0.0 109.679 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 10' ' ' PHE . 53.2 t -64.4 -37.61 80.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.157 -0.964 . . . . 0.0 109.595 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.49 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.4 mt -59.3 -50.42 79.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.37 -0.831 . . . . 0.0 109.618 -179.574 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.501 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.91 -42.66 97.34 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.154 -0.966 . . . . 0.0 108.787 179.28 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.36 -34.77 77.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.645 -0.659 . . . . 0.0 109.613 179.444 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.457 ' N ' ' O ' ' A' ' 6' ' ' VAL . 58.3 t80 -59.57 -53.11 61.83 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.397 -0.814 . . . . 0.0 110.352 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 34.2 m -74.4 -40.88 49.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.101 -0.999 . . . . 0.0 109.948 179.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.501 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 60.0 t -64.91 -37.6 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.309 -0.87 . . . . 0.0 110.451 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -56.64 -30.65 63.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.072 -1.018 . . . . 0.0 109.853 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.529 ' OE2' ' CD1' ' A' ' 36' ' ' ILE . 84.4 tt0 -65.27 -31.27 72.33 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.719 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.3 p90 -143.06 46.17 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 109.774 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.559 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.58 136.07 52.4 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.061 -1.024 . . . . 0.0 110.157 -179.837 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_endo -77.62 -149.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 122.143 1.895 . . . . 0.0 110.308 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.453 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.8 p30 -79.63 12.08 2.76 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.803 -1.185 . . . . 0.0 108.782 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.5 t -113.35 136.2 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.579 -0.701 . . . . 0.0 109.805 -179.573 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.43 84.15 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.971 . . . . 0.0 108.85 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -48.23 -30.71 15.36 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.775 1.65 . . . . 0.0 112.129 179.659 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -23.81 66.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 0.0 109.348 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -98.94 3.44 47.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.105 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.0 t -104.88 137.03 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.613 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -63.65 99.28 0.22 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.198 -0.939 . . . . 0.0 109.514 -179.443 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.1 m -60.91 6.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.557 179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.613 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -88.77 11.29 18.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.171 -0.956 . . . . 0.0 108.905 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.5 tp -82.59 131.72 35.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.98 122.22 17.75 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.349 -0.845 . . . . 0.0 109.063 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 66.2 mt -62.97 -10.12 12.5 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.341 -0.849 . . . . 0.0 109.491 -179.684 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.442 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.9 p -50.19 -39.44 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.099 -1.001 . . . . 0.0 109.245 -179.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.442 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -58.08 -37.66 74.92 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.603 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.2 m-80 -87.6 15.5 6.69 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 178.951 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.4 -18.37 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.003 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -52.48 -35.37 20.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 120.797 -1.414 . . . . 0.0 108.185 179.163 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.8 tt -71.19 -25.06 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.589 -0.694 . . . . 0.0 109.869 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -62.82 -30.19 71.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.302 -0.874 . . . . 0.0 110.999 -178.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.6 m -104.95 -65.14 1.06 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.006 -1.059 . . . . 0.0 111.178 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 5.9 mp -74.17 -52.14 13.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.162 -0.961 . . . . 0.0 111.069 -178.262 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -64.86 -38.93 96.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.442 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.7 -42.12 98.52 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -1.084 . . . . 0.0 109.593 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.73 -44.17 90.39 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.097 -1.002 . . . . 0.0 108.541 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -66.82 -37.84 85.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.188 -0.945 . . . . 0.0 109.331 179.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.469 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 72.0 t -67.44 -47.85 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.398 -0.813 . . . . 0.0 111.102 -179.115 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -60.84 -43.49 95.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.727 -1.233 . . . . 0.0 109.922 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -45.29 76.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.063 . . . . 0.0 110.191 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.5 t90 -77.22 -46.84 21.89 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 110.09 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.469 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 11.6 tp -56.97 -41.01 77.59 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.377 -0.827 . . . . 0.0 109.818 -179.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.605 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.5 tt0 -61.4 -42.52 98.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.982 -1.074 . . . . 0.0 108.955 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.9 -36.98 83.51 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.245 -0.909 . . . . 0.0 109.55 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.555 HH22 ' NE2' ' A' ' 89' ' ' GLN . 60.7 ttt85 -59.98 -46.31 89.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 111.137 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -117.21 0.17 12.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.14 -0.975 . . . . 0.0 110.94 -179.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.605 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.68 40.37 65.91 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.9 mt -96.0 141.43 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.214 -1.168 . . . . 0.0 109.225 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.86 140.67 58.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.004 -1.06 . . . . 0.0 109.427 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.09 -32.22 72.75 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.338 -0.851 . . . . 0.0 109.381 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -91.03 9.82 29.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.335 -0.853 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -52.9 -34.11 53.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.626 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.06 158.9 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.463 -0.773 . . . . 0.0 109.604 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -93.16 150.59 20.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.885 . . . . 0.0 109.303 179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.621 ' CD1' ' N ' ' A' ' 61' ' ' LEU . 4.4 mp -98.12 132.24 43.81 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 109.801 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.77 143.51 3.94 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.21 -0.931 . . . . 0.0 109.058 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.81 -24.92 74.54 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.146 1.898 . . . . 0.0 112.104 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.27 -32.52 74.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.236 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -72.89 -26.67 61.52 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.322 -0.861 . . . . 0.0 111.318 -178.768 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -97.85 11.04 38.66 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.77 -1.206 . . . . 0.0 110.953 -178.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -58.56 -34.29 70.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.936 -1.102 . . . . 0.0 109.952 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -145.78 151.0 37.26 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.031 -1.043 . . . . 0.0 110.018 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.4 mt -66.27 -36.74 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.405 -0.809 . . . . 0.0 109.846 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.0 ttp180 -60.69 -39.09 87.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.574 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -58.28 -42.41 86.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.984 -1.073 . . . . 0.0 109.927 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.4 mt -68.03 -39.24 81.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.49 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.3 t0 -59.13 -41.21 87.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.347 -0.846 . . . . 0.0 110.474 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.09 -43.11 88.24 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.123 -0.986 . . . . 0.0 110.212 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -62.7 -48.67 78.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.179 -0.951 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.537 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.37 -46.33 90.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.235 -0.916 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 41.4 t -59.62 -39.55 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 O-C-N 121.068 -1.02 . . . . 0.0 109.534 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.82 -32.63 66.24 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.8 -49.61 3.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -1.234 . . . . 0.0 110.479 -179.354 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.537 ' O ' ' O ' ' A' ' 76' ' ' VAL . 7.1 t -158.52 149.92 20.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 0.0 109.547 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.499 ' CG2' ' O ' ' A' ' 81' ' ' THR . 10.1 t -125.97 89.83 51.55 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.292 -0.88 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -92.14 109.52 0.26 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 123.232 2.621 . . . . 0.0 112.955 -179.361 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -78.43 133.71 12.03 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.994 1.796 . . . . 0.0 111.715 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 38.9 t -124.88 132.37 71.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.335 -0.853 . . . . 0.0 109.601 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -62.75 -37.13 85.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.377 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -152.33 152.69 32.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.526 179.94 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -58.67 -37.75 76.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.483 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.6 mt -94.79 142.18 27.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.254 -0.904 . . . . 0.0 109.54 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.555 ' NE2' HH22 ' A' ' 51' ' ' ARG . 94.2 mm-40 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.494 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.9 mmm . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.2 tp60 -98.99 119.57 38.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.361 -0.837 . . . . 0.0 109.229 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.4 m170 46.85 30.25 1.17 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.195 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.93 -35.8 79.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.697 -179.712 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.9 -38.55 82.61 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.0 109.859 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -64.28 -41.06 91.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 90.6 mt -59.53 -43.52 91.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.338 -0.851 . . . . 0.0 109.739 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.51 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.38 -47.74 80.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.21 -0.931 . . . . 0.0 109.158 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.69 -33.14 72.13 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.357 -0.839 . . . . 0.0 109.591 179.611 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -59.86 -53.12 61.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.167 -0.958 . . . . 0.0 110.19 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' ' CE1' ' A' ' 15' ' ' PHE . 34.6 m -74.41 -40.67 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.147 -0.97 . . . . 0.0 110.193 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.51 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 64.2 t -64.91 -36.35 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.354 -0.841 . . . . 0.0 110.588 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.46 -33.94 66.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 109.931 -179.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -65.68 -32.18 73.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.269 -0.894 . . . . 0.0 109.871 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.588 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 7.8 p90 -138.27 45.82 2.07 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.145 -0.972 . . . . 0.0 109.931 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.562 ' CD2' ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 135.74 53.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.951 -1.093 . . . . 0.0 109.946 -179.823 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.58 -150.38 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.105 1.87 . . . . 0.0 110.264 178.431 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.433 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.8 p30 -79.52 12.09 2.69 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.8 -1.187 . . . . 0.0 108.708 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.6 t -113.64 136.64 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.549 -0.719 . . . . 0.0 109.818 -179.557 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.89 139.58 82.95 Favored Pre-proline 0 N--CA 1.488 1.444 0 O-C-N 121.152 -0.967 . . . . 0.0 108.751 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.52 -31.74 19.07 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 121.699 1.599 . . . . 0.0 111.966 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.17 -26.6 67.49 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.301 -0.874 . . . . 0.0 109.395 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -103.34 4.8 36.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -99.22 144.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.326 -0.859 . . . . 0.0 108.695 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.597 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.3 t0 -71.82 95.06 1.47 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.034 -1.041 . . . . 0.0 109.357 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -62.25 6.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.342 -0.849 . . . . 0.0 109.588 179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.597 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.6 m-20 -90.77 12.08 20.34 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.184 -0.948 . . . . 0.0 109.017 179.605 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 tp -84.53 133.87 34.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.433 -0.792 . . . . 0.0 109.484 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -65.21 122.34 16.87 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.271 -0.893 . . . . 0.0 108.824 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 67.3 mt -64.92 -6.28 8.04 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.249 -0.907 . . . . 0.0 109.618 -179.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 73.0 t -50.91 -45.06 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.021 . . . . 0.0 108.904 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.7 -35.99 69.14 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -86.02 15.24 5.19 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.94 -16.88 0.02 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.76 -38.05 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 120.867 -1.372 . . . . 0.0 108.267 179.126 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.618 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.09 -25.3 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.538 -0.726 . . . . 0.0 110.324 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.7 m-20 -59.68 -35.65 74.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 111.105 -178.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.557 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -106.31 -64.22 1.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.13 -0.981 . . . . 0.0 111.556 -178.419 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -69.99 -52.09 27.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.057 -1.027 . . . . 0.0 111.301 -178.056 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -69.3 -36.75 79.41 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.249 -179.295 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.618 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tp -58.43 -47.83 82.67 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.335 -1.097 . . . . 0.0 109.582 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.5 mt -61.38 -42.62 99.01 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.109 -0.995 . . . . 0.0 109.77 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -63.63 -39.66 94.92 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.402 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.478 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.2 t -70.22 -49.7 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.268 -0.895 . . . . 0.0 110.554 -179.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -62.17 -40.48 87.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 120.959 -1.088 . . . . 0.0 109.948 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.18 -45.99 75.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.081 -1.012 . . . . 0.0 110.039 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.6 OUTLIER -77.61 -47.05 20.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.145 -0.972 . . . . 0.0 109.635 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.478 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 31.4 tp -56.75 -39.2 73.57 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.433 -0.792 . . . . 0.0 109.466 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.611 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.0 tm-20 -61.53 -42.74 99.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.953 . . . . 0.0 109.466 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' OE2' ' A' ' 49' ' ' GLU . 20.9 t70 -64.33 -39.45 93.93 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.071 -1.018 . . . . 0.0 109.71 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -66.19 -45.53 80.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 111.549 -178.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -111.17 -1.49 16.15 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.98 -1.075 . . . . 0.0 111.151 -178.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.611 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.67 38.48 67.42 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.54 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 72.5 mt -88.44 145.38 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.103 -1.233 . . . . 0.0 109.37 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.96 122.9 16.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.109 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.08 -19.72 56.69 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.468 -0.77 . . . . 0.0 109.741 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.03 11.06 5.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.352 -0.842 . . . . 0.0 110.165 -179.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.94 112.37 16.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.03 -1.044 . . . . 0.0 109.527 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.1 m -116.58 18.13 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.56 -0.713 . . . . 0.0 109.313 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -55.7 -28.27 54.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.827 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.0 mt -77.21 142.09 39.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.092 -1.005 . . . . 0.0 109.905 -179.492 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.92 164.78 21.46 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -51.98 -33.13 51.0 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.349 2.033 . . . . 0.0 111.54 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -66.72 -27.42 67.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.512 -0.742 . . . . 0.0 109.251 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.404 ' HE2' ' HB2' ' A' ' 75' ' ' PHE . 19.6 t-80 -67.63 -26.62 66.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.377 -0.827 . . . . 0.0 109.768 -179.627 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -90.24 11.91 19.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.208 -0.933 . . . . 0.0 109.282 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 -53.82 -37.64 63.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.381 -0.825 . . . . 0.0 109.792 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.4 p -146.14 157.17 43.83 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.044 -1.035 . . . . 0.0 110.036 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.8 mt -64.36 -36.82 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.336 -0.853 . . . . 0.0 110.076 179.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 43.8 ttp180 -60.57 -40.55 92.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.314 -0.866 . . . . 0.0 110.381 -179.018 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -62.55 -38.64 90.83 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.012 -1.055 . . . . 0.0 109.71 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.6 mt -68.23 -39.35 80.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.827 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.415 ' OD2' ' CD1' ' A' ' 7' ' ' ILE . 59.4 t0 -59.43 -41.14 88.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.363 -0.836 . . . . 0.0 110.334 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -43.29 86.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.098 -1.001 . . . . 0.0 110.512 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.404 ' HB2' ' HE2' ' A' ' 65' ' ' HIS . 67.3 t80 -61.96 -49.3 76.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.081 -1.012 . . . . 0.0 109.775 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.513 ' O ' ' O ' ' A' ' 80' ' ' THR . 68.4 t -66.52 -44.74 90.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.268 -0.895 . . . . 0.0 109.825 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 47.3 t -63.03 -39.53 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.011 -1.056 . . . . 0.0 109.894 179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.7 -33.97 69.05 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.39 -48.79 3.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -1.222 . . . . 0.0 110.644 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.513 ' O ' ' O ' ' A' ' 76' ' ' VAL . 60.2 m -158.36 137.86 11.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.125 -0.985 . . . . 0.0 109.839 -179.534 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.537 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t -119.26 89.39 39.75 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.325 -0.859 . . . . 0.0 109.1 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -94.85 111.71 0.16 Allowed 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 123.304 2.669 . . . . 0.0 112.634 -179.79 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -78.07 134.35 13.0 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 121.987 1.792 . . . . 0.0 111.8 179.599 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 41.9 t -124.92 133.09 70.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -61.78 -37.73 85.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.435 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -152.42 150.69 29.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.37 179.908 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 23.1 tttm -59.82 -37.07 78.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.496 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.81 142.15 27.89 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.285 -0.884 . . . . 0.0 109.424 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.488 179.892 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.557 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.391 0.615 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.492 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 93.9 mt-30 -58.9 -36.61 74.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.062 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -147.59 29.86 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.734 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.38 -32.5 71.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.427 -0.796 . . . . 0.0 110.008 -179.638 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.0 p -58.97 -39.94 83.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.03 -1.044 . . . . 0.0 109.563 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.0 t -68.07 -39.07 80.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 108.44 178.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.2 mt -61.26 -50.48 80.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.502 -0.749 . . . . 0.0 109.151 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.535 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -64.36 -47.36 79.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.346 -0.846 . . . . 0.0 109.183 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -44.25 96.12 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.483 -0.76 . . . . 0.0 109.227 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.592 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.5 t80 -68.34 -48.85 63.73 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.626 0.727 . . . . 0.0 109.452 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 93.7 t -67.02 -45.41 87.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.601 -0.687 . . . . 0.0 109.901 -179.576 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.535 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 98.4 t -63.7 -37.74 80.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.272 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.5 -30.59 63.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.462 -0.774 . . . . 0.0 109.789 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.93 -32.21 73.82 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.201 -0.937 . . . . 0.0 109.357 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 6.9 p90 -147.01 52.86 1.08 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 109.112 179.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.3 136.58 52.94 Favored Pre-proline 0 N--CA 1.486 1.374 0 O-C-N 121.207 -0.933 . . . . 0.0 110.187 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.67 -152.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 121.815 1.676 . . . . 0.0 110.388 178.741 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -78.26 9.75 3.58 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.908 -1.12 . . . . 0.0 108.709 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -113.85 136.16 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.498 -0.751 . . . . 0.0 109.883 -179.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.92 142.48 90.76 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.19 -0.944 . . . . 0.0 108.574 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -48.67 -32.4 21.53 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 121.593 1.529 . . . . 0.0 111.638 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.81 -25.27 65.49 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.372 -0.83 . . . . 0.0 109.395 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -105.01 6.42 33.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -96.6 143.4 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.282 -0.886 . . . . 0.0 108.762 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -72.39 92.33 1.42 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.126 -0.984 . . . . 0.0 109.365 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.3 m -62.79 6.23 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.9 m-20 -95.9 9.7 39.74 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 108.723 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 11.1 tp -90.22 135.6 33.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.487 -0.758 . . . . 0.0 109.561 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.585 ' OD2' ' NH2' ' A' ' 67' ' ' ARG . 90.0 m-20 -63.98 121.89 15.19 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.81 7.89 3.52 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.286 -0.884 . . . . 0.0 110.046 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.403 HG22 HH21 ' A' ' 67' ' ' ARG . 53.0 t -53.43 -42.79 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.063 -1.023 . . . . 0.0 108.636 179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -55.74 -35.5 66.24 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.4 m-80 -85.19 15.12 4.44 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.39 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.7 t -51.73 -37.33 20.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.014 -1.286 . . . . 0.0 108.547 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.601 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.5 tt -70.81 -25.24 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 0.0 110.426 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -58.1 -34.33 70.07 Favored 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 111.009 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.92 -64.29 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.984 -1.073 . . . . 0.0 111.575 -178.479 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.473 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 4.2 mm? -72.37 -52.5 15.8 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.976 -1.078 . . . . 0.0 111.211 -178.091 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -66.07 -36.02 91.37 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.3 tp -57.71 -43.95 85.59 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.365 -1.079 . . . . 0.0 109.208 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.2 mt -63.64 -41.82 98.21 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 108.98 179.259 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -64.26 -36.95 85.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.413 -0.804 . . . . 0.0 109.53 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 74.8 t -62.66 -45.57 98.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.379 -0.825 . . . . 0.0 110.22 -179.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.8 mm -61.35 -44.24 98.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.146 -0.971 . . . . 0.0 109.829 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.0 -43.78 91.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.242 -0.911 . . . . 0.0 109.766 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.592 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -73.39 -38.92 65.46 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.796 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 28.5 tp -59.69 -43.34 94.07 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.2 -0.938 . . . . 0.0 109.917 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.577 ' O ' ' N ' ' A' ' 53' ' ' GLY . 59.3 tt0 -65.16 -36.09 83.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 109.951 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -60.59 -38.99 86.47 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.984 -1.072 . . . . 0.0 110.125 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 mtp180 -74.67 -44.65 49.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.143 -0.973 . . . . 0.0 112.079 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -108.11 -7.17 16.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.765 -1.209 . . . . 0.0 111.354 -178.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.78 32.18 73.8 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.1 mt -91.22 152.42 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.257 -1.143 . . . . 0.0 109.835 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.1 150.48 29.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.075 -1.016 . . . . 0.0 109.008 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.85 -40.27 72.61 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.251 -0.906 . . . . 0.0 109.969 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 50.79 49.76 20.36 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.11 -0.994 . . . . 0.0 109.205 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -74.62 116.03 14.85 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.939 . . . . 0.0 109.909 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.415 HG11 ' H ' ' A' ' 61' ' ' LEU . 27.3 t -124.91 141.68 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 61' ' ' LEU . 19.8 pt-20 -60.5 -31.95 70.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.085 -1.009 . . . . 0.0 110.466 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.486 ' O ' ' O ' ' A' ' 60' ' ' GLU . 60.7 mt 44.04 -170.5 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.055 -1.028 . . . . 0.0 109.642 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -134.23 162.25 58.81 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.344 -0.848 . . . . 0.0 109.409 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.83 -26.81 83.76 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.756 2.304 . . . . 0.0 112.17 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -61.04 -31.53 71.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.39 -0.818 . . . . 0.0 109.909 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.501 ' O ' ' OG ' ' A' ' 71' ' ' SER . 81.8 t60 -68.07 -26.46 65.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.184 -0.948 . . . . 0.0 110.205 -179.512 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -97.41 10.17 40.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 109.763 -179.474 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.585 ' NH2' ' OD2' ' A' ' 29' ' ' ASP . 34.2 tpt85 -55.61 -38.32 69.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.076 -1.015 . . . . 0.0 109.879 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -137.75 153.99 49.66 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.095 -1.003 . . . . 0.0 110.145 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.4 mt -62.68 -36.58 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.264 -0.898 . . . . 0.0 110.006 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -60.76 -36.78 79.8 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.235 -0.916 . . . . 0.0 110.251 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.501 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 90.5 p -61.37 -36.16 79.45 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.022 -1.049 . . . . 0.0 109.449 -179.885 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.97 -38.96 83.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.238 -0.914 . . . . 0.0 109.097 179.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -57.51 -36.98 72.26 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.46 -0.775 . . . . 0.0 109.352 179.891 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.38 -43.53 98.71 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.224 -0.923 . . . . 0.0 109.222 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -65.04 -46.95 79.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.259 -0.9 . . . . 0.0 109.207 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 53.2 t -65.24 -40.58 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 121.45 -0.781 . . . . 0.0 109.712 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.0 t -58.99 -42.46 86.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.243 -0.91 . . . . 0.0 109.684 -179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.83 -35.02 91.4 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 120.222 -0.989 . . . . 0.0 110.645 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -86.29 -48.02 8.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.899 -1.353 . . . . 0.0 109.853 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.2 t -138.54 151.03 46.97 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.492 ' OG1' ' OE1' ' A' ' 2' ' ' GLN . 10.0 t -134.81 89.74 24.37 Favored Pre-proline 0 N--CA 1.487 1.414 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.452 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 17.1 Cg_exo -63.63 -175.2 0.25 Allowed 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.715 2.276 . . . . 0.0 111.6 179.222 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . 0.452 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 35.6 Cg_exo -58.4 150.59 66.77 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.423 2.082 . . . . 0.0 111.505 179.748 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 5.6 m -89.35 127.61 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 110.044 -179.139 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -139.08 142.82 38.14 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.49 -0.756 . . . . 0.0 109.151 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.75 142.07 58.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.107 -0.995 . . . . 0.0 109.432 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 49.3 tttp -81.49 138.45 35.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.265 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 71.6 mt -57.06 -36.47 70.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.602 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 95.2 mt-30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.034 -0.984 . . . . 0.0 109.535 179.89 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.455 ' O2P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.302 0.573 . . . . 0.0 109.931 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.484 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 98.5 mm-40 -87.07 123.76 32.49 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.596 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 22.3 m-70 54.54 15.78 1.14 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.107 -0.996 . . . . 0.0 108.654 -179.386 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.401 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -64.19 -39.81 94.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.459 -0.776 . . . . 0.0 110.196 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.72 -39.24 87.89 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.177 -0.952 . . . . 0.0 110.157 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.6 t -64.77 -37.69 80.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.158 -0.964 . . . . 0.0 109.307 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 90.4 mt -63.98 -36.73 77.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 110.54 -179.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.527 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.47 -51.09 67.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.959 -1.088 . . . . 0.0 110.049 -179.422 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.41 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 3.5 pp0? -70.92 -36.72 72.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.101 -0.999 . . . . 0.0 109.473 179.508 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.423 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 59.6 t80 -65.74 -51.32 60.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.345 -0.847 . . . . 0.0 109.97 -179.611 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.5 p -68.33 -41.87 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.925 . . . . 0.0 109.589 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 87.0 t -64.61 -39.32 85.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -0.928 . . . . 0.0 109.521 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.95 -28.16 55.75 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.392 -0.817 . . . . 0.0 109.731 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -65.09 -29.16 70.01 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.263 -0.898 . . . . 0.0 108.833 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.617 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 22.8 p90 -151.0 48.99 0.85 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.376 -0.827 . . . . 0.0 109.076 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.485 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -79.76 137.12 54.52 Favored Pre-proline 0 N--CA 1.487 1.4 0 O-C-N 120.975 -1.078 . . . . 0.0 110.343 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.83 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.974 1.782 . . . . 0.0 110.51 178.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.448 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -81.05 13.29 2.82 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.923 -1.111 . . . . 0.0 108.803 179.242 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 38.6 t -113.43 136.65 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.609 -0.682 . . . . 0.0 109.91 -179.35 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.03 140.61 73.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.039 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . 0.584 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 52.3 Cg_exo -48.41 -31.75 18.6 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.795 1.664 . . . . 0.0 111.575 179.307 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.37 -21.87 65.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.519 -0.738 . . . . 0.0 109.412 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -97.6 1.61 48.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.421 -0.8 . . . . 0.0 109.119 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.2 t -107.09 137.54 37.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.65 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.604 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.0 t0 -70.56 99.87 1.72 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 109.319 -179.505 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.638 ' CG1' ' HZ1' ' A' ' 87' ' ' LYS . 12.6 m -60.07 5.84 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.379 -0.826 . . . . 0.0 109.682 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.604 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -96.4 9.19 42.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 0.0 108.748 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.3 tp -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.561 -0.712 . . . . 0.0 109.52 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . 0.46 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.0 m-20 -65.14 121.51 14.92 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 179.162 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.07 8.51 0.93 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.195 -0.94 . . . . 0.0 109.493 -179.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.46 ' H ' ' C ' ' A' ' 29' ' ' ASP . 57.0 t -56.39 -41.81 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.164 -0.96 . . . . 0.0 108.8 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -55.51 -34.09 64.33 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 178.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . 0.697 ' N ' HD21 ' A' ' 33' ' ' ASN . 0.8 OUTLIER -84.02 14.45 4.14 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.953 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.46 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.134 -1.187 . . . . 0.0 110.134 -179.116 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.8 t -52.09 -39.29 26.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 120.921 -1.341 . . . . 0.0 108.324 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.14 -25.2 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.605 -0.685 . . . . 0.0 110.118 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.6 m-20 -62.12 -32.1 72.64 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 110.797 -178.465 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.5 m -105.44 -64.93 1.09 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.004 -1.06 . . . . 0.0 111.306 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.0 tt -71.71 -52.15 19.25 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 0.0 111.19 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -68.1 -36.69 86.12 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.246 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.5 tp -58.53 -43.36 89.19 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.348 -1.089 . . . . 0.0 109.881 -179.051 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.9 mt -67.53 -44.11 79.15 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 110.111 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -65.08 -35.03 79.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.438 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 73.7 t -63.21 -44.99 99.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.293 -0.879 . . . . 0.0 110.979 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.06 -43.85 93.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.655 -1.278 . . . . 0.0 110.062 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.29 -45.32 76.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.109 -0.994 . . . . 0.0 110.396 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.485 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -76.6 -44.63 33.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.167 -0.958 . . . . 0.0 109.957 -179.709 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.5 tp -57.02 -39.0 73.94 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.337 -0.852 . . . . 0.0 109.207 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' A' ' 53' ' ' GLY . 12.0 tt0 -60.87 -43.27 98.63 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.204 -0.935 . . . . 0.0 109.25 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.09 -40.04 90.5 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.199 -0.938 . . . . 0.0 110.025 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.423 ' NH2' ' CZ ' ' A' ' 10' ' ' PHE . 73.8 ttt180 -63.48 -45.94 88.44 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.252 -0.905 . . . . 0.0 111.177 -178.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -106.86 -5.3 18.42 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.002 -1.062 . . . . 0.0 110.63 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.602 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.63 34.04 72.44 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 71.9 mt -98.88 144.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.301 -1.117 . . . . 0.0 109.633 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.45 148.57 41.37 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.136 -0.978 . . . . 0.0 109.586 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.48 -29.8 68.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.442 -0.786 . . . . 0.0 109.693 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.3 m-20 54.62 49.03 19.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.283 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' A' ' 58' ' ' ASP . 45.1 p30 -39.25 91.8 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.498 -0.751 . . . . 0.0 110.254 -179.683 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.566 ' N ' ' O ' ' A' ' 57' ' ' ASP . 29.4 m -128.43 158.05 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 108.981 179.564 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . 0.482 ' OE1' ' O8 ' ' A' ' 101' ' ' PN7 . 84.3 tt0 -100.35 129.96 46.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 109.729 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.3 140.92 42.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.448 -0.782 . . . . 0.0 109.421 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.83 156.13 55.57 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.517 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.98 -26.59 83.44 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.666 2.244 . . . . 0.0 112.031 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.35 -30.87 71.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.328 -0.857 . . . . 0.0 109.715 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -67.74 -26.79 66.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 109.662 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -93.65 9.22 37.83 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.179 -0.951 . . . . 0.0 109.358 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 15.2 tpt180 -54.91 -39.59 68.96 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.807 -179.677 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -141.96 153.98 44.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.017 -1.052 . . . . 0.0 110.098 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.2 mt -59.09 -36.66 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.365 -0.834 . . . . 0.0 109.838 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.9 ttp180 -60.28 -39.13 85.77 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.268 -0.895 . . . . 0.0 110.234 -179.211 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 t -58.3 -44.08 88.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.016 -1.053 . . . . 0.0 109.619 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.0 mt -62.96 -38.74 82.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.177 -0.952 . . . . 0.0 109.427 179.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.484 ' OD1' ' O ' ' A' ' 2' ' ' GLN . 53.6 t0 -56.8 -37.88 71.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.396 -0.815 . . . . 0.0 109.702 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.78 -42.57 97.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.2 -0.938 . . . . 0.0 109.672 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.8 t80 -64.07 -48.34 76.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.148 -0.97 . . . . 0.0 109.459 179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.75 -42.4 92.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.355 -0.841 . . . . 0.0 109.982 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 62.9 t -63.14 -40.89 90.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.167 -0.958 . . . . 0.0 109.903 -179.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.7 -33.78 74.13 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.16 -47.99 4.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.046 -1.267 . . . . 0.0 110.506 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.8 m -128.68 138.16 52.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.341 -0.849 . . . . 0.0 109.943 -179.62 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.536 ' CG2' ' O ' ' A' ' 81' ' ' THR . 8.8 t -127.85 89.57 50.25 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.308 -0.87 . . . . 0.0 109.185 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . 0.596 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 63.8 Cg_endo -82.62 161.53 16.72 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.724 2.283 . . . . 0.0 112.556 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.24 150.83 71.69 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.91 2.407 . . . . 0.0 111.943 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 12.0 p -101.22 134.13 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 0.0 109.867 -179.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -124.43 163.37 21.93 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.887 -0.782 . . . . 0.0 108.887 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.12 138.45 37.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.038 -1.039 . . . . 0.0 109.192 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.638 ' HZ1' ' CG1' ' A' ' 26' ' ' VAL . 32.4 tttt -59.63 -34.57 72.97 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.187 -0.946 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 58.8 mt -57.55 -35.63 70.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 109.428 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.072 -0.966 . . . . 0.0 109.464 -179.955 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' PN7 . . . . . 0.482 ' O8 ' ' OE1' ' A' ' 60' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.8 mtm . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 121.171 0.51 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.818 ' OE1' HG13 ' A' ' 77' ' ' VAL . 89.7 mt-30 55.64 53.21 9.87 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.402 -0.811 . . . . 0.0 109.14 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.58 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.0 m80 77.14 41.46 0.15 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.671 -0.643 . . . . 0.0 109.43 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.421 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.6 -33.41 73.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.296 -0.877 . . . . 0.0 109.444 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.16 -35.94 80.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.169 -0.957 . . . . 0.0 109.748 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -65.88 -39.8 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 0.0 109.123 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.421 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.1 mt -59.49 -49.58 83.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.432 -0.792 . . . . 0.0 109.298 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -41.79 98.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.2 -0.938 . . . . 0.0 108.534 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.43 -37.33 86.58 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.464 -0.773 . . . . 0.0 109.172 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -59.94 -52.99 63.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.544 -0.723 . . . . 0.0 110.044 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.711 HG21 HD13 ' A' ' 30' ' ' LEU . 4.6 p -73.49 -42.39 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.213 -0.929 . . . . 0.0 109.889 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.6 t -64.45 -38.12 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.337 -0.852 . . . . 0.0 110.411 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -56.15 -26.51 50.6 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.691 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.454 ' OE1' HD12 ' A' ' 36' ' ' ILE . 98.0 mt-10 -64.26 -31.11 72.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 109.168 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -153.96 52.88 0.69 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 109.316 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.513 ' CB ' HG12 ' A' ' 12' ' ' VAL . 1.7 pt? -80.74 136.61 51.33 Favored Pre-proline 0 N--CA 1.486 1.334 0 O-C-N 120.964 -1.085 . . . . 0.0 110.023 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.4 -153.81 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.007 1.805 . . . . 0.0 110.773 178.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -82.85 16.7 2.15 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.075 -1.016 . . . . 0.0 108.839 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.419 HG23 ' OD2' ' A' ' 18' ' ' ASP . 40.2 t -112.85 138.02 43.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.56 -0.712 . . . . 0.0 110.03 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.78 137.16 96.07 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.247 -0.908 . . . . 0.0 108.651 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -48.35 -29.99 14.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.836 1.691 . . . . 0.0 112.016 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.31 -24.06 66.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.325 -0.859 . . . . 0.0 109.486 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -101.18 8.18 42.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 109.452 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -100.99 137.5 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.324 -0.86 . . . . 0.0 108.875 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.572 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.91 90.96 0.14 Allowed 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.194 -0.941 . . . . 0.0 109.367 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.512 ' O ' HD12 ' A' ' 69' ' ' ILE . 6.3 m -61.74 6.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.345 -0.847 . . . . 0.0 109.551 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.572 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -92.05 12.44 21.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.213 -0.929 . . . . 0.0 109.135 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.2 tp -85.27 134.21 34.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.862 . . . . 0.0 109.613 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.507 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -64.3 121.54 14.54 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.369 -0.832 . . . . 0.0 109.065 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 67.6 mt -63.62 -8.14 9.17 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.188 -0.945 . . . . 0.0 109.602 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.483 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.33 -41.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.058 -1.027 . . . . 0.0 108.904 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.483 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.2 m-20 -59.2 -34.92 72.73 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.644 ' O ' ' N ' ' A' ' 35' ' ' VAL . 83.1 m-20 -85.19 16.9 3.27 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.45 -14.81 0.01 OUTLIER Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.644 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.1 t -51.85 -39.56 25.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 120.909 -1.348 . . . . 0.0 108.07 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.9 tt -71.31 -25.03 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.635 -0.666 . . . . 0.0 110.319 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -60.48 -32.09 71.08 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.215 -0.928 . . . . 0.0 111.432 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.14 -65.05 1.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.892 -1.13 . . . . 0.0 111.405 -178.348 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 16.2 mt -74.01 -52.43 12.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.022 -1.048 . . . . 0.0 111.124 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.62 -35.83 91.63 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.62 -42.23 87.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.232 -1.157 . . . . 0.0 109.121 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -63.35 -44.14 95.68 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.161 -0.962 . . . . 0.0 109.011 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -68.38 -41.08 81.06 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -67.59 -46.94 81.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.4 -0.812 . . . . 0.0 110.177 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.23 -45.01 99.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.542 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.42 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.192 -0.942 . . . . 0.0 109.999 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.751 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.27 -49.37 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 110.085 -179.744 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.8 tp -61.8 -41.39 97.69 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.55 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.9 pt-20 -70.57 -35.66 73.19 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.17 -0.956 . . . . 0.0 109.829 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -61.59 -41.95 98.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.248 -0.907 . . . . 0.0 110.092 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.751 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 86.0 mtt180 -64.4 -38.82 92.36 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 111.133 -179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' HG21 ' A' ' 80' ' ' THR . 96.7 m-85 -102.85 -4.54 24.71 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.96 -1.087 . . . . 0.0 110.244 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 61.75 35.37 91.14 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.4 mt -90.19 141.2 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -1.189 . . . . 0.0 109.849 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.0 136.26 50.24 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.025 -1.047 . . . . 0.0 108.9 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.57 -35.23 79.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.089 -1.007 . . . . 0.0 109.482 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.619 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.7 p30 -65.87 -25.93 67.4 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.35 -0.844 . . . . 0.0 110.024 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.619 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 54.3 t0 -54.27 -35.83 62.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.778 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 43.7 t -111.64 136.94 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.444 -0.785 . . . . 0.0 109.708 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -88.28 142.26 27.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 109.287 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.479 HD13 HD22 ' A' ' 41' ' ' LEU . 35.9 mt -93.05 135.28 34.37 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.223 -0.923 . . . . 0.0 109.697 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -162.27 150.35 12.06 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.269 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.42 -27.07 76.99 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.473 2.115 . . . . 0.0 112.065 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.64 -30.57 71.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.401 -0.812 . . . . 0.0 109.747 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -67.65 -27.05 66.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.743 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.451 ' CE2' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -102.69 10.34 38.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.234 -0.916 . . . . 0.0 109.73 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.453 HH22 ' CB ' ' A' ' 29' ' ' ASP . 32.8 tpt85 -54.15 -39.03 66.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.506 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.9 p -147.79 151.87 36.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.076 -1.015 . . . . 0.0 109.873 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 83.7 mt -66.1 -37.29 79.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.293 -0.879 . . . . 0.0 109.892 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -61.32 -38.44 86.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 -179.271 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.9 p -62.93 -40.45 97.66 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.007 -1.058 . . . . 0.0 109.581 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.3 mt -68.33 -40.97 83.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.185 -0.947 . . . . 0.0 109.74 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.46 -40.69 87.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.383 -0.823 . . . . 0.0 110.156 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.14 -43.05 88.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.125 -0.984 . . . . 0.0 110.001 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.33 -50.22 72.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.619 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.7 -44.84 93.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.818 HG13 ' OE1' ' A' ' 2' ' ' GLN . 48.8 t -60.08 -39.5 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.102 -0.999 . . . . 0.0 109.445 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.77 -32.95 66.52 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.51 -49.47 3.55 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.09 -1.241 . . . . 0.0 110.634 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.619 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.7 t -160.47 152.31 19.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.126 -0.983 . . . . 0.0 109.887 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 10.3 t . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.228 179.649 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.577 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 83.8 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.264 0.554 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -59.11 -38.04 78.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -114.57 11.32 17.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.486 -0.759 . . . . 0.0 109.296 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -56.66 -39.47 73.8 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.956 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.2 p -63.99 -36.04 82.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.008 -1.057 . . . . 0.0 109.432 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -68.79 -36.09 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.534 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.66 ' O ' HG22 ' A' ' 11' ' ' VAL . 98.7 mt -59.13 -50.42 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -0.917 . . . . 0.0 109.996 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.84 -47.86 79.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.994 -1.066 . . . . 0.0 109.004 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.74 -41.22 98.06 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 121.347 0.594 . . . . 0.0 110.015 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -66.14 -51.36 58.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.32 -0.863 . . . . 0.0 111.145 -178.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.66 HG22 ' O ' ' A' ' 7' ' ' ILE . 17.1 m -72.38 -43.59 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.949 . . . . 0.0 110.848 -178.714 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.53 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.1 t -62.89 -36.28 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -0.962 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -57.64 -37.59 73.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 109.508 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.69 -36.22 78.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.88 . . . . 0.0 110.303 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -91.8 -58.51 2.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 110.575 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.686 HD22 HG23 ' A' ' 19' ' ' VAL . 1.6 mt -128.98 87.58 54.12 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.347 -0.845 . . . . 0.0 110.443 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -91.48 -18.96 0.88 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.154 2.569 . . . . 0.0 112.116 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -75.96 -4.99 44.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 108.734 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.686 HG23 HD22 ' A' ' 16' ' ' LEU . 45.9 t -113.99 141.62 29.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -61.19 115.96 16.94 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 120.698 -1.251 . . . . 0.0 108.628 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -63.75 -23.76 69.15 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 121.462 1.442 . . . . 0.0 111.409 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.25 -13.82 60.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.467 -0.771 . . . . 0.0 110.073 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.474 ' CG ' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -82.79 7.51 14.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.985 -1.072 . . . . 0.0 109.234 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -100.7 135.29 37.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -64.72 86.78 0.05 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.065 -1.022 . . . . 0.0 109.384 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -61.84 5.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -100.1 5.5 44.92 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.002 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.1 141.37 30.32 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.704 -0.622 . . . . 0.0 109.459 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.458 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.1 m-20 -60.37 121.4 11.96 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -68.62 8.37 0.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.289 -0.882 . . . . 0.0 109.83 -178.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.78 -40.01 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.121 -0.987 . . . . 0.0 108.974 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.5 t0 -57.76 -35.46 70.79 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -85.71 14.87 5.24 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.63 -14.93 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.6 t -51.73 -36.44 18.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.172 -1.193 . . . . 0.0 108.803 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.595 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.1 tt -70.45 -24.93 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 110.315 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -59.59 -34.06 72.25 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 111.08 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.5 m -105.72 -64.5 1.14 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.086 -1.009 . . . . 0.0 111.503 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.591 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -71.42 -52.2 19.86 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.045 -1.034 . . . . 0.0 111.151 -178.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.28 -37.31 92.76 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.595 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.4 tp -58.76 -40.7 84.68 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.367 -1.078 . . . . 0.0 109.091 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.48 -43.45 94.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.333 -0.855 . . . . 0.0 108.805 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -64.35 -36.74 85.1 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 40' ' ' GLY . 58.5 t -60.25 -43.29 93.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.385 -0.822 . . . . 0.0 109.872 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.425 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 1.5 mp -60.35 -49.39 84.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.26 -42.06 96.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.905 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -71.46 -40.92 70.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.323 -0.86 . . . . 0.0 109.783 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.53 -46.39 86.88 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.324 -0.86 . . . . 0.0 109.519 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -65.41 -39.29 91.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.249 -0.907 . . . . 0.0 109.019 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -67.24 -36.79 82.39 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.391 -0.818 . . . . 0.0 110.51 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -86.22 -51.74 6.09 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.274 -0.891 . . . . 0.0 112.167 -178.146 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -93.67 -5.57 48.29 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.682 -1.261 . . . . 0.0 111.16 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.59 24.14 76.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.1 mt -92.97 144.12 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -1.096 . . . . 0.0 109.422 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.67 146.75 44.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.062 -1.024 . . . . 0.0 109.272 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -57.81 -33.21 68.35 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.352 -0.842 . . . . 0.0 109.569 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.964 ' O ' HG23 ' A' ' 59' ' ' VAL . 84.7 m-20 54.67 47.94 21.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.343 -0.848 . . . . 0.0 109.256 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.0 m-20 -42.86 90.45 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.447 -0.783 . . . . 0.0 109.875 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 57' ' ' ASP . 44.1 t -125.74 139.32 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -74.42 130.77 40.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.017 -1.052 . . . . 0.0 109.671 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.28 142.68 45.55 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.652 -0.655 . . . . 0.0 109.449 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.8 149.03 66.59 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.078 -1.014 . . . . 0.0 109.462 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.79 -20.85 72.28 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.529 2.153 . . . . 0.0 112.342 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.8 -32.48 73.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 110.259 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -68.34 -26.71 65.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.985 -1.072 . . . . 0.0 109.975 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -97.41 5.98 48.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.161 -0.962 . . . . 0.0 109.725 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -55.52 -41.19 72.79 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.521 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -128.19 147.45 50.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.0 mt -61.46 -36.3 72.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.318 -0.864 . . . . 0.0 109.828 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.8 mtm180 -60.8 -37.32 81.56 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 110.19 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.7 t -59.08 -43.95 91.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.09 -1.007 . . . . 0.0 109.816 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.49 -38.88 83.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.136 -0.977 . . . . 0.0 109.628 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 21.5 t70 -57.12 -38.38 73.36 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.329 -0.857 . . . . 0.0 109.774 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.5 -44.45 90.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.719 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 74.0 t80 -63.55 -45.31 91.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.103 -0.998 . . . . 0.0 109.478 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.4 t -64.37 -43.67 97.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.341 -0.849 . . . . 0.0 110.099 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -63.16 -42.38 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.061 -1.024 . . . . 0.0 109.822 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.24 -30.54 71.12 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.39 -47.84 5.01 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.05 -1.265 . . . . 0.0 110.409 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 14.0 t -140.7 153.66 46.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.219 -0.926 . . . . 0.0 109.909 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.805 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t . . . . . 0 N--CA 1.487 1.402 0 O-C-N 121.275 -0.891 . . . . 0.0 109.511 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.9 mtm . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.39 0.614 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.86 -38.39 82.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.287 -0.883 . . . . 0.0 109.59 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 59.8 m-70 -126.41 11.27 7.42 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.432 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.44 -36.52 76.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.148 -0.97 . . . . 0.0 109.849 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -62.09 -34.79 76.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 109.425 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.9 t -66.1 -36.63 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.35 -0.844 . . . . 0.0 109.264 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.72 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.1 mt -64.98 -41.89 93.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 110.325 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.94 -50.64 67.86 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.03 -1.044 . . . . 0.0 110.514 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.06 -43.42 71.22 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -59.03 -43.64 91.64 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.981 -1.074 . . . . 0.0 109.26 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 7' ' ' ILE . 75.2 t -71.93 -49.73 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -0.836 . . . . 0.0 110.449 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -63.85 -36.85 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.225 -0.922 . . . . 0.0 110.045 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -61.36 -31.0 70.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.24 -0.913 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.64 -31.16 72.03 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.149 -0.97 . . . . 0.0 109.278 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -102.87 -58.8 1.81 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.24 -0.913 . . . . 0.0 110.548 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.849 HD12 HG23 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -131.12 88.59 44.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.308 -0.87 . . . . 0.0 111.317 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -86.31 -13.51 5.23 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.73 2.287 . . . . 0.0 111.798 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.37 -4.28 41.43 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.164 -0.96 . . . . 0.0 109.084 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.849 HG23 HD12 ' A' ' 16' ' ' LEU . 43.0 t -113.31 142.47 25.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.663 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.23 115.67 15.63 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.75 -1.219 . . . . 0.0 108.649 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -64.46 -25.41 63.22 Favored 'Trans proline' 0 N--CA 1.486 1.08 0 C-N-CA 121.527 1.485 . . . . 0.0 111.68 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.02 -14.29 61.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.354 -0.841 . . . . 0.0 109.178 179.24 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.663 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -82.62 2.92 30.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.838 . . . . 0.0 109.106 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -99.47 136.05 32.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.83 86.45 0.23 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.18 -0.95 . . . . 0.0 109.469 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.38 5.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.273 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -94.4 3.4 55.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 108.751 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.638 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.6 tt -97.14 138.66 34.3 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.539 -0.726 . . . . 0.0 109.496 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.638 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.8 m-20 -60.48 121.34 11.88 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.432 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 pp -65.34 5.7 0.37 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.793 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.8 p -50.57 -37.91 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.037 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.2 m-20 -57.71 -36.97 72.73 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -85.64 14.7 5.39 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -15.67 0.02 OUTLIER Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.41 -34.36 15.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.85 -1.382 . . . . 0.0 108.507 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -71.16 -24.36 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.554 -0.716 . . . . 0.0 109.883 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -57.91 -33.14 68.45 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.322 -0.861 . . . . 0.0 111.445 -178.18 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.2 m -105.83 -64.59 1.14 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.856 -1.153 . . . . 0.0 111.497 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.43 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -72.42 -52.22 16.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.937 -1.102 . . . . 0.0 110.805 -178.508 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.867 ' O ' HG22 ' A' ' 44' ' ' VAL . . . -65.45 -36.72 92.94 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.6 tp -58.52 -41.21 84.97 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.356 -1.085 . . . . 0.0 109.285 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.5 tp -65.8 -41.48 91.87 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.008 -1.057 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -70.22 -44.69 68.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 111.519 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.867 HG22 ' O ' ' A' ' 40' ' ' GLY . 16.0 m -72.43 -42.09 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.939 -1.1 . . . . 0.0 111.624 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -58.7 -47.8 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 120.845 -1.159 . . . . 0.0 110.241 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.06 -39.61 92.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 110.241 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.782 ' HE1' HH21 ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.17 -49.35 15.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.927 -1.108 . . . . 0.0 110.403 -179.602 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.1 tp -60.15 -46.0 91.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.232 -0.917 . . . . 0.0 110.134 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.536 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -66.81 -38.06 85.73 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.013 -1.054 . . . . 0.0 109.463 -179.924 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.69 -38.91 92.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.934 . . . . 0.0 109.584 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.782 HH21 ' HE1' ' A' ' 47' ' ' TRP . 43.1 mmm-85 -59.28 -38.97 81.47 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.542 -0.724 . . . . 0.0 110.143 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -95.84 0.95 52.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.167 -0.958 . . . . 0.0 110.089 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.11 37.95 63.73 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.2 mt -104.04 148.58 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.411 -1.052 . . . . 0.0 109.79 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.539 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -91.25 122.77 34.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 108.396 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.36 -38.98 93.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.08 -1.012 . . . . 0.0 109.745 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -62.1 -37.12 83.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 0.0 110.093 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.539 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 89.0 m-20 -57.14 -37.69 72.42 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.231 -0.918 . . . . 0.0 110.353 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.91 134.24 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.306 -0.871 . . . . 0.0 110.05 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -108.28 137.55 46.07 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.478 -0.764 . . . . 0.0 109.307 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.54 146.83 30.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.769 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.9 160.47 29.68 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.361 -0.837 . . . . 0.0 109.425 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -62.76 -32.21 78.22 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.799 2.333 . . . . 0.0 112.123 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -62.62 -29.01 70.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.399 -0.813 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.402 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 32.0 t-80 -67.84 -26.38 66.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.365 -0.834 . . . . 0.0 110.149 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -97.95 8.55 44.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.075 -1.015 . . . . 0.0 110.133 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -56.01 -41.07 74.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.193 -0.942 . . . . 0.0 109.355 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.3 m -128.8 145.73 51.11 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.5 mt -63.0 -39.64 85.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.119 -0.988 . . . . 0.0 109.855 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.6 mtm180 -61.54 -37.02 82.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.058 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -58.19 -38.88 77.58 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.121 -0.987 . . . . 0.0 109.638 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.408 ' HB ' HD13 ' A' ' 7' ' ' ILE . 71.0 mt -63.63 -42.3 95.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.323 -0.86 . . . . 0.0 109.612 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.74 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.4 t0 -59.48 -38.65 81.38 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.111 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 -46.07 80.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.087 -1.008 . . . . 0.0 110.05 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.402 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.5 t80 -63.38 -47.0 83.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.127 -0.983 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.528 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.4 t -64.75 -42.74 95.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.317 -0.864 . . . . 0.0 109.727 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.7 t -59.67 -41.47 85.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.239 -0.913 . . . . 0.0 109.845 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.65 -31.47 75.25 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 120.264 -0.97 . . . . 0.0 110.748 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -48.76 3.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.03 -1.277 . . . . 0.0 110.751 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -129.68 156.81 43.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.324 -0.86 . . . . 0.0 109.664 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.791 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 C--N 1.301 -1.51 0 O-C-N 121.13 -0.981 . . . . 0.0 109.381 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.699 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 86.1 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.2 -38.27 82.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.771 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.615 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 73.4 m-70 -141.5 14.39 2.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.708 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -60.33 -33.4 72.34 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 110.097 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -61.26 -36.59 80.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.945 -1.097 . . . . 0.0 109.613 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -66.79 -39.68 84.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.089 -1.007 . . . . 0.0 108.819 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 91.1 mt -61.73 -50.3 80.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.032 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.725 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.31 -48.78 74.31 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.397 -0.814 . . . . 0.0 109.137 179.314 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.02 -44.76 95.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.551 -0.718 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 66.4 t80 -69.56 -48.44 60.31 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.559 -0.713 . . . . 0.0 109.525 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.665 HG13 ' CD1' ' A' ' 36' ' ' ILE . 94.3 t -66.8 -45.26 88.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.513 -0.742 . . . . 0.0 109.954 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.5 t -64.1 -37.24 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.374 -0.829 . . . . 0.0 109.523 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.57 -30.71 61.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.363 -0.836 . . . . 0.0 110.022 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.36 -29.69 70.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.104 -0.997 . . . . 0.0 109.298 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.617 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.3 p90 -149.2 50.04 0.97 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.374 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.477 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.16 136.86 53.23 Favored Pre-proline 0 N--CA 1.487 1.383 0 O-C-N 120.932 -1.105 . . . . 0.0 110.184 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.21 -153.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.96 1.773 . . . . 0.0 110.581 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -80.91 13.56 2.62 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.051 -1.031 . . . . 0.0 108.643 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.47 137.17 47.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.589 -0.694 . . . . 0.0 110.028 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.77 140.7 74.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.176 -0.953 . . . . 0.0 108.898 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -48.57 -30.96 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.891 1.727 . . . . 0.0 111.85 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.4 66.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.326 -0.859 . . . . 0.0 109.49 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -96.43 3.06 53.06 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.35 -0.844 . . . . 0.0 109.063 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.8 t -105.91 136.94 38.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.0 t0 -70.91 96.3 1.27 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.075 -1.016 . . . . 0.0 109.428 -179.439 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.3 m -61.7 6.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 109.589 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.56 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.9 m-20 -93.8 7.44 44.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 108.909 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.582 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.4 tt -92.61 135.14 34.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.593 -0.692 . . . . 0.0 109.642 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.582 ' O ' HD23 ' A' ' 28' ' ' LEU . 91.6 m-20 -62.01 121.64 13.5 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -70.51 9.68 0.59 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.202 -0.936 . . . . 0.0 109.519 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -52.15 -38.03 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.201 -0.937 . . . . 0.0 109.462 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -56.94 -36.76 70.64 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.621 ' O ' ' N ' ' A' ' 35' ' ' VAL . 75.7 m-20 -86.25 14.76 6.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.48 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.621 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.82 -34.26 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 120.928 -1.336 . . . . 0.0 108.509 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.665 ' CD1' HG13 ' A' ' 11' ' ' VAL . 3.4 tt -71.07 -24.47 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.7 . . . . 0.0 110.134 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -58.14 -34.1 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.36 -0.837 . . . . 0.0 111.51 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.98 -65.26 1.05 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.858 -1.151 . . . . 0.0 111.148 -178.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -69.71 -47.22 63.93 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.157 -0.964 . . . . 0.0 110.722 -178.617 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.437 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.1 -39.97 72.63 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.921 -1.133 . . . . 0.0 110.379 -179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.2 tt -58.66 -39.81 81.71 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.19 -1.182 . . . . 0.0 109.078 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -62.25 -44.18 97.15 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.458 -0.897 . . . . 0.0 108.67 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -69.54 -40.15 77.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.326 -0.858 . . . . 0.0 109.857 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.6 t -64.77 -45.9 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.363 -0.836 . . . . 0.0 110.268 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.69 -46.02 97.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.238 -0.913 . . . . 0.0 109.532 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.35 97.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 109.951 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.436 ' CZ2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -75.09 -40.73 59.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.918 . . . . 0.0 109.995 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.77 -43.88 85.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.252 -0.905 . . . . 0.0 109.639 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -64.18 -39.77 94.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.185 -0.947 . . . . 0.0 109.449 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -67.34 -45.28 76.85 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 110.836 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.6 ttt180 -70.02 -45.34 67.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.274 -0.891 . . . . 0.0 112.131 -178.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -103.38 -5.33 23.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.815 -1.178 . . . . 0.0 111.433 -178.088 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.09 27.68 73.61 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.5 mt -98.3 143.87 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -1.153 . . . . 0.0 109.451 -179.467 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.44 149.74 33.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.145 -0.972 . . . . 0.0 109.579 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.94 -31.93 63.36 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.431 -0.793 . . . . 0.0 109.529 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.52 43.86 29.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.365 -0.834 . . . . 0.0 109.582 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.618 ' O ' HD21 ' A' ' 61' ' ' LEU . 53.2 p30 -93.42 11.34 28.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.288 -0.883 . . . . 0.0 109.446 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 73.6 t -59.94 -41.05 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.305 -0.872 . . . . 0.0 109.97 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.556 ' O ' HD23 ' A' ' 61' ' ' LEU . 87.8 mt-10 -116.33 130.22 56.66 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.433 -0.792 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.618 HD21 ' O ' ' A' ' 58' ' ' ASP . 5.9 mt -121.89 141.92 50.79 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -158.27 105.55 1.69 Allowed Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.025 -1.047 . . . . 0.0 109.806 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_exo -55.32 -21.66 30.12 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.792 1.661 . . . . 0.0 111.228 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.31 -30.99 71.55 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.52 -0.738 . . . . 0.0 109.508 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -69.19 -26.33 64.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.362 -0.836 . . . . 0.0 111.02 -179.21 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.68 5.67 49.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.98 -1.075 . . . . 0.0 111.368 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -60.2 -37.84 81.49 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.766 -1.208 . . . . 0.0 110.3 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.7 t -131.79 141.57 49.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.077 -1.014 . . . . 0.0 110.139 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.681 HD13 ' HB2' ' A' ' 8' ' ' ALA . 83.8 mt -62.84 -37.9 80.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.404 -0.81 . . . . 0.0 109.827 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -61.41 -37.21 82.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.265 -0.897 . . . . 0.0 110.244 -179.389 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -58.66 -40.37 83.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.102 -0.999 . . . . 0.0 109.496 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 72.0 mt -64.76 -38.74 83.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.299 -0.876 . . . . 0.0 109.314 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.573 ' O ' HG23 ' A' ' 77' ' ' VAL . 20.8 t70 -57.45 -39.17 75.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.281 -0.887 . . . . 0.0 109.797 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.32 92.75 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.088 -1.007 . . . . 0.0 109.464 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -64.81 -46.16 83.19 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.285 -0.884 . . . . 0.0 109.318 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.9 t -63.89 -43.47 97.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.287 -0.883 . . . . 0.0 109.802 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -60.86 -40.52 85.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.165 -0.959 . . . . 0.0 109.558 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.2 -32.39 67.45 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.27 -49.0 3.69 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.027 -1.278 . . . . 0.0 110.758 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.3 p -134.92 154.94 51.5 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.198 -0.939 . . . . 0.0 110.1 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.4 t . . . . . 0 C--N 1.303 -1.42 0 O-C-N 121.198 -0.939 . . . . 0.0 109.0 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.6 mmm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.458 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.3 mt-30 -105.72 131.32 53.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.25 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.458 ' C ' ' O ' ' A' ' 2' ' ' GLN . 1.7 m-70 40.93 31.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.386 -0.821 . . . . 0.0 109.486 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -39.38 85.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.752 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -65.05 -32.93 74.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.158 -0.964 . . . . 0.0 109.719 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.416 HG21 ' ND1' ' A' ' 3' ' ' HIS . 74.8 t -66.77 -38.55 81.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.193 -0.942 . . . . 0.0 109.399 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.674 HD12 ' OD2' ' A' ' 73' ' ' ASP . 91.9 mt -61.15 -49.82 83.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.176 -0.953 . . . . 0.0 109.368 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.99 -47.44 80.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 108.906 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -44.08 96.89 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.548 -0.72 . . . . 0.0 109.25 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.4 t80 -68.23 -49.13 62.75 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.656 -0.653 . . . . 0.0 109.729 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 7' ' ' ILE . 95.3 t -67.99 -44.69 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.533 -0.73 . . . . 0.0 109.923 -179.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.2 t -64.0 -35.18 72.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.444 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -56.1 -31.97 63.74 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -65.72 -32.48 74.06 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.279 -0.888 . . . . 0.0 109.785 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.654 ' CE2' HD12 ' A' ' 36' ' ' ILE . 31.4 p90 -140.71 46.8 1.77 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.196 -0.94 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.3 136.22 53.27 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.019 -1.05 . . . . 0.0 110.156 -179.752 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.02 -151.52 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.167 1.911 . . . . 0.0 110.42 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.94 9.73 2.74 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.891 -1.131 . . . . 0.0 108.682 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.4 t -113.51 135.75 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.576 -0.703 . . . . 0.0 109.781 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.54 140.62 81.96 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.976 . . . . 0.0 108.754 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.512 ' HD3' HD12 ' A' ' 16' ' ' LEU . 46.4 Cg_exo -48.6 -33.05 22.88 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.621 1.547 . . . . 0.0 111.586 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.41 -20.22 63.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.185 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -98.27 3.86 48.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.465 -0.772 . . . . 0.0 109.316 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.6 t -104.14 136.03 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.5 95.48 0.47 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.122 -0.986 . . . . 0.0 109.366 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -60.27 6.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.328 -0.858 . . . . 0.0 109.604 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.75 5.92 49.37 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.158 -0.964 . . . . 0.0 108.606 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.1 tp -91.84 136.83 32.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.537 -0.727 . . . . 0.0 109.364 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.488 ' OD2' ' O ' ' A' ' 67' ' ' ARG . 88.5 m-20 -62.85 121.81 14.4 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.423 -0.911 . . . . 0.0 108.582 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.67 HD11 ' CD1' ' A' ' 69' ' ' ILE . 79.5 mt -68.46 -4.34 14.57 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.368 -0.832 . . . . 0.0 109.457 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 51.2 t -51.47 -41.97 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.145 -0.972 . . . . 0.0 108.799 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.83 -35.29 66.23 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 13.2 m-20 -83.24 14.83 3.24 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.835 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.26 -15.82 0.02 OUTLIER Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -179.332 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -51.71 -39.16 23.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 108.181 179.386 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.654 HD12 ' CE2' ' A' ' 15' ' ' PHE . 5.1 tt -71.24 -25.09 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.506 -0.746 . . . . 0.0 109.899 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.4 m-20 -62.97 -30.53 71.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.965 . . . . 0.0 110.839 -178.652 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.7 m -105.11 -65.17 1.06 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.997 -1.064 . . . . 0.0 111.056 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.62 -52.31 15.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.133 -0.979 . . . . 0.0 110.985 -178.406 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.55 -36.79 91.94 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.1 tp -58.71 -41.17 85.7 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.468 -1.019 . . . . 0.0 109.235 -179.436 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -65.53 -44.13 87.83 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 108.807 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.48 -43.7 76.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.553 -0.717 . . . . 0.0 110.104 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 96.1 t -64.53 -45.39 95.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.362 -0.837 . . . . 0.0 110.55 -179.03 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.519 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -60.53 -46.94 94.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 120.999 -1.063 . . . . 0.0 109.475 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -44.14 80.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.404 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.7 t90 -78.46 -49.05 14.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.102 -0.999 . . . . 0.0 110.338 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 44' ' ' VAL . 7.6 tp -60.7 -42.35 97.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.554 -178.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.519 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -65.84 -37.82 87.21 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.984 -1.072 . . . . 0.0 109.046 -179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -69.1 -38.96 79.21 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.421 -0.799 . . . . 0.0 109.576 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.1 ttt180 -58.95 -41.1 86.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.565 -0.709 . . . . 0.0 110.691 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -102.97 -6.5 22.33 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.965 -1.084 . . . . 0.0 109.898 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.35 30.86 78.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 pt -112.94 149.27 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.4 -1.059 . . . . 0.0 109.855 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.81 144.77 52.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.239 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -35.91 78.14 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.131 -0.981 . . . . 0.0 109.292 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 53.14 43.17 31.95 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.363 -0.836 . . . . 0.0 109.565 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.408 ' HB3' HD21 ' A' ' 61' ' ' LEU . 91.2 m-20 -82.39 94.26 7.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.52 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 69.6 t -63.59 -43.78 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.942 . . . . 0.0 109.398 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -158.35 140.37 13.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.756 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.408 HD21 ' HB3' ' A' ' 58' ' ' ASP . 36.4 mt -103.16 136.79 42.29 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.329 -0.857 . . . . 0.0 109.46 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.42 147.52 13.5 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.068 -1.02 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -63.48 -21.09 70.87 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.49 2.127 . . . . 0.0 111.973 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.52 -31.35 70.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 0.0 110.056 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -68.41 -26.4 65.52 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.289 -0.882 . . . . 0.0 110.713 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -93.76 8.75 39.85 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.881 -1.137 . . . . 0.0 110.707 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.488 ' O ' ' OD2' ' A' ' 29' ' ' ASP . 17.5 mmm180 -58.34 -34.74 70.97 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.074 -1.016 . . . . 0.0 110.231 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -150.55 158.61 44.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.11 -0.994 . . . . 0.0 110.464 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 30' ' ' LEU . 11.4 mm -62.89 -35.82 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.453 -0.78 . . . . 0.0 109.724 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 -59.99 -36.53 77.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.283 -0.885 . . . . 0.0 109.855 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.3 t -59.62 -43.07 93.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.901 -1.124 . . . . 0.0 108.91 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.15 -38.39 80.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.429 -0.794 . . . . 0.0 109.267 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.681 ' O ' HG23 ' A' ' 77' ' ' VAL . 83.5 m-20 -56.34 -37.64 70.25 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.387 -0.821 . . . . 0.0 109.253 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.56 -40.13 96.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.31 -0.869 . . . . 0.0 109.763 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -62.14 -51.78 66.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.959 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.8 t -65.16 -41.17 91.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.237 -0.915 . . . . 0.0 109.444 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -58.47 -40.62 79.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 O-C-N 121.312 -0.867 . . . . 0.0 109.538 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.21 -33.02 82.75 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.45 -48.83 4.22 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.976 -1.308 . . . . 0.0 110.581 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.503 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.8 p -129.69 154.22 47.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.4 -0.812 . . . . 0.0 108.994 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.81 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t . . . . . 0 C--N 1.304 -1.407 0 O-C-N 121.15 -0.969 . . . . 0.0 109.956 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.477 0.656 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.2 mt-30 -104.76 140.72 37.67 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.553 ' NE2' HG11 ' A' ' 6' ' ' VAL . 53.7 t-80 49.36 11.23 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.952 -1.092 . . . . 0.0 108.497 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.625 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.36 -35.91 80.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.593 -0.692 . . . . 0.0 110.193 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.1 m -58.85 -42.07 88.47 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.016 . . . . 0.0 109.567 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.553 HG11 ' NE2' ' A' ' 3' ' ' HIS . 54.3 t -67.35 -36.36 76.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.397 -0.815 . . . . 0.0 109.221 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.625 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.75 -49.51 83.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.831 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.721 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.51 -45.28 91.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.086 -1.008 . . . . 0.0 108.928 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.27 -43.34 91.58 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.509 -0.744 . . . . 0.0 109.051 179.431 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.704 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 66.3 t80 -66.07 -49.93 65.89 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.471 0.653 . . . . 0.0 109.89 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 7' ' ' ILE . 97.9 t -67.17 -45.02 87.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.414 -0.804 . . . . 0.0 109.641 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 8' ' ' ALA . 92.8 t -64.17 -35.6 74.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.438 -0.789 . . . . 0.0 109.597 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.29 -31.09 63.32 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.753 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' HD11 ' A' ' 36' ' ' ILE . 84.3 tt0 -65.44 -31.96 73.32 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.747 -179.706 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.596 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.2 p90 -141.89 45.68 1.68 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.213 -0.93 . . . . 0.0 109.627 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.51 136.03 52.69 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.941 -1.099 . . . . 0.0 110.119 -179.78 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -77.6 -150.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.222 1.948 . . . . 0.0 110.249 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -79.95 12.11 2.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.822 -1.174 . . . . 0.0 108.706 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.551 HG23 ' OD2' ' A' ' 18' ' ' ASP . 23.9 t -113.41 136.71 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.567 -0.708 . . . . 0.0 109.847 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.96 82.94 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.186 -0.946 . . . . 0.0 108.863 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -48.38 -30.32 15.2 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.746 1.631 . . . . 0.0 111.541 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.61 -20.55 62.74 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.495 -0.753 . . . . 0.0 109.513 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -103.73 8.61 37.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.32 -0.863 . . . . 0.0 109.748 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -101.13 135.93 35.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.315 -0.866 . . . . 0.0 108.99 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -67.87 89.95 0.29 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.164 -0.96 . . . . 0.0 109.082 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -60.53 6.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.379 -0.826 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.2 t0 -89.21 4.36 48.91 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.93 . . . . 0.0 108.733 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.7 tp -95.65 134.24 38.77 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.563 -0.711 . . . . 0.0 109.368 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -66.07 121.49 15.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -76.04 9.27 2.56 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 109.882 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.19 -38.28 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.112 -0.992 . . . . 0.0 108.951 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.434 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -57.08 -35.53 69.48 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.8 m-20 -83.8 15.02 3.49 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -14.76 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.8 t -51.65 -37.94 20.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.096 -1.238 . . . . 0.0 108.428 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.8 tt -70.7 -24.82 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.508 -0.745 . . . . 0.0 110.139 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.59 ' OD1' ' CD1' ' A' ' 66' ' ' PHE . 82.7 m-20 -60.24 -32.93 71.6 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -178.26 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.48 -64.97 1.09 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.926 -1.109 . . . . 0.0 111.513 -178.46 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.0 mp -72.39 -52.16 17.24 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.096 -1.002 . . . . 0.0 110.983 -178.078 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.4 -36.92 92.27 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.53 -41.26 89.64 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.471 -1.017 . . . . 0.0 109.636 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -66.15 -44.37 84.34 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.486 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -67.26 -38.69 85.55 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.291 -0.881 . . . . 0.0 110.239 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.5 t -64.48 -44.87 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.204 -0.935 . . . . 0.0 110.576 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.07 -47.21 90.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 120.969 -1.082 . . . . 0.0 109.769 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.11 -44.37 80.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.285 -0.885 . . . . 0.0 110.537 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.704 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.0 t90 -74.8 -41.89 59.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.152 -0.967 . . . . 0.0 110.196 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -58.55 -40.13 82.17 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.254 -0.904 . . . . 0.0 109.604 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.08 -42.3 99.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -65.08 -42.94 93.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.378 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.3 ttt180 -65.98 -44.58 84.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 111.514 -178.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -105.65 -5.28 20.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.991 -1.068 . . . . 0.0 110.844 -178.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.58 32.5 71.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.56 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 76.8 mt -97.01 144.57 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.559 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 145.13 52.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.155 -0.965 . . . . 0.0 109.612 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.07 -28.69 69.79 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.841 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.572 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.0 m-20 54.7 50.82 15.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.061 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 57' ' ' ASP . 23.5 t70 -41.29 92.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.39 -0.819 . . . . 0.0 109.867 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ASP . 13.6 p -134.24 144.47 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.393 -0.817 . . . . 0.0 108.948 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -89.66 133.0 34.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 109.713 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.7 mt -110.32 140.74 44.19 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.488 -0.757 . . . . 0.0 109.534 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.7 158.18 59.95 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.482 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -60.1 -27.87 85.8 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.737 2.291 . . . . 0.0 112.042 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.83 -29.38 70.58 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -67.32 -26.39 66.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.811 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.59 ' CD1' ' OD1' ' A' ' 37' ' ' ASP . 80.1 m-85 -93.7 7.02 46.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.16 -0.962 . . . . 0.0 109.536 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -54.94 -39.08 68.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.272 -0.892 . . . . 0.0 109.553 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.0 p -138.93 151.1 46.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.09 -1.006 . . . . 0.0 109.909 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -63.27 -36.88 77.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.32 -0.863 . . . . 0.0 109.806 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 -61.2 -36.9 81.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 110.294 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.5 -44.21 89.37 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.985 -1.072 . . . . 0.0 109.368 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.3 mt -66.66 -38.55 81.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.327 -0.858 . . . . 0.0 109.408 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.476 ' OD1' HG21 ' A' ' 7' ' ' ILE . 74.8 m-20 -58.31 -38.54 77.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.458 -0.776 . . . . 0.0 109.765 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.95 96.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.89 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -62.19 -46.1 90.43 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.815 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.0 t -63.16 -43.1 98.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.242 -0.911 . . . . 0.0 109.923 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 57.0 t -63.73 -40.6 89.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.274 -0.891 . . . . 0.0 109.832 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.03 -35.28 75.77 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.73 -48.15 5.05 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.03 -1.276 . . . . 0.0 110.215 -179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 42.1 m -131.69 134.75 46.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.345 -0.847 . . . . 0.0 109.409 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.306 -0.871 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 121.371 0.605 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.581 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -85.1 125.77 33.05 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.428 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 1.6 m-70 54.97 19.63 2.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 108.551 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.89 -39.63 92.61 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.419 -0.801 . . . . 0.0 110.183 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -63.96 -34.99 79.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.097 -1.002 . . . . 0.0 109.889 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.75 -39.67 84.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.449 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.598 ' O ' HG22 ' A' ' 11' ' ' VAL . 91.2 mt -59.89 -43.02 91.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.501 -0.749 . . . . 0.0 110.195 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.709 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.09 -49.41 74.56 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.104 -0.998 . . . . 0.0 109.48 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.419 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.55 -33.76 73.23 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.648 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.8 t80 -66.63 -51.87 51.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 110.004 -179.519 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.598 HG22 ' O ' ' A' ' 7' ' ' ILE . 14.1 m -72.92 -39.89 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.257 -0.902 . . . . 0.0 110.16 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.5 t -64.55 -38.76 83.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.922 . . . . 0.0 109.922 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.1 -30.15 61.66 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.227 -0.921 . . . . 0.0 109.538 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.14 -29.51 70.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.304 -0.872 . . . . 0.0 108.987 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.614 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 16.9 p90 -149.52 49.63 0.95 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.298 -0.876 . . . . 0.0 109.257 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.13 136.71 53.48 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 120.89 -1.131 . . . . 0.0 110.183 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -73.36 -153.47 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 121.972 1.781 . . . . 0.0 110.603 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -80.3 13.31 2.44 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.1 -1.0 . . . . 0.0 108.776 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.7 t -113.44 136.16 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.585 -0.697 . . . . 0.0 109.996 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.32 140.19 72.46 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.283 -0.885 . . . . 0.0 108.873 179.33 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.57 -33.22 23.15 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 121.692 1.595 . . . . 0.0 111.808 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.23 -19.6 65.56 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.445 -0.784 . . . . 0.0 109.353 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -96.46 0.16 49.95 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.451 -0.781 . . . . 0.0 108.983 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -107.08 134.04 49.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.3 m-20 -70.98 99.73 1.85 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 109.376 -179.503 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.8 m -59.68 5.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.353 -0.842 . . . . 0.0 109.768 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -92.16 8.6 37.24 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.065 -1.022 . . . . 0.0 108.841 179.336 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.3 tp -94.54 136.56 34.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.593 -0.692 . . . . 0.0 109.544 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -63.24 121.57 14.01 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.465 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -72.28 6.73 2.09 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.635 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -53.4 -39.49 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 108.941 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -57.79 -36.14 71.77 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.3 m-20 -85.27 15.1 4.54 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.29 -15.06 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.571 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.83 -37.36 20.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.054 -1.262 . . . . 0.0 108.46 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.3 tt -70.69 -24.84 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.536 -0.727 . . . . 0.0 110.142 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.428 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.4 m-20 -60.04 -33.34 71.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.235 -0.916 . . . . 0.0 111.141 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -105.62 -64.79 1.11 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.91 -1.118 . . . . 0.0 111.451 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -72.21 -52.17 17.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 111.018 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.69 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.77 -36.85 91.8 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tp -58.91 -41.96 88.49 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.43 -1.041 . . . . 0.0 109.459 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.7 tp -65.68 -44.28 86.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.203 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 41.4 mttt -67.02 -36.38 81.98 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.361 -0.837 . . . . 0.0 109.913 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.2 t -62.41 -44.32 99.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 0.0 110.366 -179.276 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.428 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -59.16 -48.27 87.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.922 -1.111 . . . . 0.0 109.398 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.32 -44.33 79.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.375 -0.828 . . . . 0.0 110.658 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -75.5 -43.62 48.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.102 -0.999 . . . . 0.0 110.243 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.428 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -57.9 -40.26 79.9 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.33 -0.856 . . . . 0.0 109.548 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.583 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.7 tt0 -61.62 -42.66 99.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.141 -0.974 . . . . 0.0 109.389 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.56 -43.09 85.97 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.112 -0.992 . . . . 0.0 110.364 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.685 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 59.8 ttt-85 -64.68 -44.23 91.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.317 -0.865 . . . . 0.0 111.241 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 96.9 m-85 -104.69 -10.15 17.68 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.94 -1.1 . . . . 0.0 110.765 -178.777 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 24.65 73.42 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -95.01 142.41 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.122 -1.223 . . . . 0.0 109.418 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.96 149.97 34.87 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.083 -1.011 . . . . 0.0 109.228 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.17 72.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.242 -0.911 . . . . 0.0 109.586 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 50.43 48.17 22.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.108 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -63.17 123.17 17.95 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 110.037 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.777 HG23 HD21 ' A' ' 61' ' ' LEU . 30.0 m -135.0 163.09 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.628 ' O ' HD23 ' A' ' 61' ' ' LEU . 91.5 mt-10 -65.37 132.06 48.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.975 -1.078 . . . . 0.0 109.5 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.777 HD21 HG23 ' A' ' 59' ' ' VAL . 9.7 mt -125.41 147.31 49.24 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.557 -0.715 . . . . 0.0 109.649 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.61 157.75 38.41 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 109.055 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -60.12 -25.56 80.18 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.721 2.281 . . . . 0.0 112.071 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.05 -31.94 73.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.442 ' O ' ' OG ' ' A' ' 71' ' ' SER . 52.2 t-80 -67.9 -26.79 66.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.695 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -98.34 6.35 47.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.9 tpt180 -56.21 -39.37 72.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.213 -0.929 . . . . 0.0 109.703 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.4 p -143.59 156.23 44.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.019 -1.05 . . . . 0.0 110.063 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.593 HD13 ' HB2' ' A' ' 8' ' ' ALA . 85.7 mt -62.45 -36.51 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.345 -0.847 . . . . 0.0 109.835 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -60.61 -39.12 87.01 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 110.356 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 84.9 p -60.27 -37.63 81.05 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.067 -1.021 . . . . 0.0 109.587 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.5 mt -67.99 -38.8 80.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.289 -0.882 . . . . 0.0 109.37 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.581 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 51.5 t0 -58.29 -38.65 77.44 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.433 -0.792 . . . . 0.0 109.937 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.2 -44.34 92.26 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.092 -1.005 . . . . 0.0 109.732 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -64.89 -47.12 78.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.63 -42.08 94.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.325 -0.859 . . . . 0.0 109.917 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -64.27 -41.43 92.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.14 -0.975 . . . . 0.0 109.942 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.61 -33.85 73.9 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.66 -48.01 4.65 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.294 . . . . 0.0 110.518 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.482 ' O ' ' O ' ' A' ' 76' ' ' VAL . 43.2 m -129.49 138.07 51.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.862 . . . . 0.0 110.044 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.457 0 O-C-N 121.425 -0.797 . . . . 0.0 109.15 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.4 mtm . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.354 0.597 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.478 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 92.8 mt-30 -107.83 138.86 43.32 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.614 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER 44.11 27.74 0.22 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.138 -0.976 . . . . 0.0 108.912 -179.679 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.529 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.05 -36.27 76.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.443 -0.785 . . . . 0.0 109.873 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -59.12 -40.26 84.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.167 -0.958 . . . . 0.0 109.534 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.614 HG21 ' CE1' ' A' ' 3' ' ' HIS . 73.3 t -66.3 -37.47 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.196 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.8 mt -59.88 -50.58 79.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.878 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.18 -47.82 78.32 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.05 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.27 -40.84 98.53 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.478 -0.763 . . . . 0.0 109.662 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.469 ' CE2' ' CH2' ' A' ' 47' ' ' TRP . 67.3 t80 -66.84 -51.54 54.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.437 -0.789 . . . . 0.0 110.348 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -69.96 -41.22 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.877 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.4 t -64.5 -35.77 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.91 . . . . 0.0 109.575 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.68 -30.8 63.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.589 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.45 -31.49 72.6 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.273 -0.892 . . . . 0.0 109.729 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' CE1' HD12 ' A' ' 36' ' ' ILE . 30.9 p90 -142.97 46.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.871 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 136.06 53.22 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.206 -179.76 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.49 -150.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.168 1.912 . . . . 0.0 110.432 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.537 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.69 12.78 2.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.896 -1.128 . . . . 0.0 108.842 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.537 HG23 ' OD1' ' A' ' 18' ' ' ASP . 32.5 t -113.33 136.31 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.468 -0.77 . . . . 0.0 109.835 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.07 138.68 87.38 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.133 -0.98 . . . . 0.0 108.783 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.663 ' O ' HG22 ' A' ' 24' ' ' VAL . 52.1 Cg_exo -48.34 -26.76 8.91 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 121.869 1.713 . . . . 0.0 112.141 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.04 -16.91 61.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.106 -0.996 . . . . 0.0 109.749 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -105.36 7.01 33.12 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -0.863 . . . . 0.0 110.412 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.663 HG22 ' O ' ' A' ' 21' ' ' PRO . 3.5 m -96.06 144.53 10.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 120.946 -1.096 . . . . 0.0 109.273 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.545 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -70.44 88.08 0.65 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.029 -1.044 . . . . 0.0 109.193 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.7 m -61.67 5.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.271 -0.893 . . . . 0.0 109.546 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.545 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -97.87 6.8 47.34 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 108.954 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.1 tp -96.94 135.53 38.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.484 -0.76 . . . . 0.0 109.555 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -64.26 121.75 15.02 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.86 8.42 0.52 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.762 -179.016 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 4.9 p -53.73 -39.83 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.131 -0.981 . . . . 0.0 109.01 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.0 t0 -58.11 -35.79 71.96 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.624 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.0 m120 -85.2 15.07 4.48 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.27 -15.97 0.02 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.624 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.7 t -52.71 -37.14 24.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.972 -1.311 . . . . 0.0 108.311 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.613 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.1 tt -70.53 -25.16 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.479 -0.763 . . . . 0.0 109.94 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.9 m-20 -62.21 -29.66 70.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.263 -0.898 . . . . 0.0 110.66 -178.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.0 m -104.9 -64.76 1.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.02 -1.05 . . . . 0.0 110.979 -178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 19.8 mt -74.03 -52.4 12.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 110.846 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.8 93.79 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.613 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.95 -39.74 93.14 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.496 -1.002 . . . . 0.0 109.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.0 -44.04 94.8 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -67.52 -40.25 85.09 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.363 -0.836 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.16 -45.54 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 110.082 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.513 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -62.73 -41.73 93.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.063 -1.023 . . . . 0.0 109.66 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.05 -41.01 99.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.925 . . . . 0.0 109.676 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NH1' ' A' ' 51' ' ' ARG . 0.8 OUTLIER -78.56 -49.1 13.91 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.954 179.884 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.31 -43.24 96.53 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.45 -0.781 . . . . 0.0 110.626 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 0.9 OUTLIER -66.53 -36.28 82.3 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.945 -1.097 . . . . 0.0 109.087 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -72.04 -44.99 62.49 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.388 -0.82 . . . . 0.0 110.223 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NH1' ' HE1' ' A' ' 47' ' ' TRP . 22.5 ttm180 -60.95 -40.63 94.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.381 -0.825 . . . . 0.0 111.105 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -103.18 -6.14 22.47 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.824 -1.172 . . . . 0.0 110.21 -179.215 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.71 34.06 87.77 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -98.39 133.51 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.244 -1.15 . . . . 0.0 109.423 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.86 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -62.83 137.07 58.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.118 -0.989 . . . . 0.0 109.421 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.7 -29.02 67.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.362 -0.836 . . . . 0.0 110.233 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.456 ' C ' ' OD2' ' A' ' 57' ' ' ASP . 52.8 p30 -85.5 2.08 46.2 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -0.95 . . . . 0.0 110.457 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.86 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 97.2 m-20 -60.34 -37.83 81.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.914 -1.116 . . . . 0.0 109.627 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.41 159.89 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.464 -0.773 . . . . 0.0 109.504 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -96.35 138.27 34.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.211 -0.931 . . . . 0.0 109.323 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.08 140.32 36.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.309 -0.87 . . . . 0.0 109.795 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.24 157.41 75.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.362 -0.836 . . . . 0.0 109.238 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.27 -31.26 82.05 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.609 2.206 . . . . 0.0 112.136 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.48 -31.91 73.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.4 -0.812 . . . . 0.0 109.765 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -68.2 -27.09 66.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.196 -0.94 . . . . 0.0 109.861 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.71 6.37 47.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -55.8 -38.64 70.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 97.0 p -135.15 152.92 52.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.318 -0.863 . . . . 0.0 109.749 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -63.54 -36.48 76.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.371 -0.831 . . . . 0.0 109.885 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -60.47 -38.31 83.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 110.271 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.6 t -57.92 -42.98 85.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.017 -1.052 . . . . 0.0 109.661 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -62.0 -39.58 84.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.213 -0.929 . . . . 0.0 109.328 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -57.83 -37.0 73.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.341 -0.849 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.5 -41.15 96.86 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.233 -0.917 . . . . 0.0 109.524 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -62.87 -46.93 85.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.84 -43.22 97.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.294 -0.879 . . . . 0.0 109.818 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.5 t -60.89 -40.79 86.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.295 -0.878 . . . . 0.0 109.833 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.14 -30.78 74.66 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 120.409 -0.9 . . . . 0.0 110.949 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.15 -48.43 3.87 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.952 -1.323 . . . . 0.0 110.593 -178.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -128.23 155.3 44.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.154 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 81' ' ' THR . 9.3 t . . . . . 0 C--N 1.303 -1.44 0 O-C-N 121.148 -0.97 . . . . 0.0 109.77 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.48 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 70.0 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -59.06 -38.18 78.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.828 . . . . 0.0 109.634 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.638 ' NE2' HG11 ' A' ' 76' ' ' VAL . 52.5 p-80 -122.9 23.43 9.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.491 -0.756 . . . . 0.0 109.148 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.602 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.69 -34.4 72.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.362 -0.836 . . . . 0.0 109.764 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.5 t -59.0 -41.84 88.64 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.2 t -66.23 -38.4 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.305 -0.872 . . . . 0.0 109.118 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.602 HD12 ' HA ' ' A' ' 4' ' ' ALA . 94.0 mt -59.34 -50.62 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.395 -0.815 . . . . 0.0 109.69 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.98 97.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 108.864 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.48 -39.64 92.16 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.537 -0.727 . . . . 0.0 109.442 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.4 ' HE2' HG22 ' A' ' 44' ' ' VAL . 44.6 t80 -61.22 -51.42 69.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.431 -0.793 . . . . 0.0 110.011 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.727 ' CG2' HD12 ' A' ' 36' ' ' ILE . 12.4 p -72.96 -48.95 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.313 -0.867 . . . . 0.0 110.87 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.637 HG21 HG11 ' A' ' 24' ' ' VAL . 61.9 t -60.9 -35.87 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.162 -0.961 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -59.51 -34.57 72.77 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.991 -1.068 . . . . 0.0 110.005 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.65 -36.3 82.22 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 111.028 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.501 ' O ' HD12 ' A' ' 16' ' ' LEU . 42.5 m-85 -100.61 -57.78 2.04 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.894 -1.128 . . . . 0.0 111.052 -178.437 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 15' ' ' PHE . 2.6 mp -123.97 87.3 53.2 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.238 -0.914 . . . . 0.0 110.944 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -91.51 -16.67 1.23 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.199 2.599 . . . . 0.0 112.084 178.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -76.39 -4.5 42.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.157 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.5 145.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD2' ' A' ' 23' ' ' ASP . . . -60.84 115.58 14.57 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 120.755 -1.215 . . . . 0.0 108.289 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.701 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.3 Cg_endo -63.62 -23.93 69.89 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 C-N-CA 121.329 1.353 . . . . 0.0 111.819 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.21 -15.66 62.47 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -0.89 . . . . 0.0 109.865 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD2' ' O ' ' A' ' 20' ' ' ALA . 49.6 p30 -89.09 3.24 52.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.014 -1.054 . . . . 0.0 109.767 -179.513 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.5 m -77.21 140.74 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.114 -0.991 . . . . 0.0 108.672 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.536 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -66.42 82.71 0.09 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.067 -1.021 . . . . 0.0 109.278 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.5 m -62.47 5.71 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -0.927 . . . . 0.0 109.465 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.536 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.7 m-20 -103.08 7.17 38.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -0.892 . . . . 0.0 108.936 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.9 tp -98.51 137.45 37.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.498 -0.751 . . . . 0.0 109.525 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.575 ' OD1' ' NH2' ' A' ' 67' ' ' ARG . 89.0 m-20 -61.08 122.1 14.15 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.405 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -71.48 7.72 1.31 Allowed 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.192 -0.942 . . . . 0.0 110.177 -178.892 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 66.5 t -54.74 -43.75 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 120.823 -1.173 . . . . 0.0 108.362 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.76 -35.48 66.27 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -83.89 15.34 3.39 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 178.806 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.44 -14.82 0.01 OUTLIER Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.6 t -51.42 -38.81 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -1.122 . . . . 0.0 108.236 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.727 HD12 ' CG2' ' A' ' 11' ' ' VAL . 2.4 tt -70.38 -24.98 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-O 121.717 0.77 . . . . 0.0 109.498 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.4 t0 -58.37 -34.02 70.22 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.503 -0.748 . . . . 0.0 111.24 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.59 -64.24 1.16 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.009 -1.057 . . . . 0.0 111.25 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.558 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -72.05 -52.03 18.84 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.061 -1.024 . . . . 0.0 111.014 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.08 -37.93 94.76 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.599 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.84 -41.27 86.54 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.389 -1.065 . . . . 0.0 109.107 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 33.6 tp -61.91 -44.14 97.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 108.663 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -68.13 -39.53 82.7 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.431 -0.793 . . . . 0.0 109.715 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.0 t -64.55 -45.46 95.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 110.197 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.2 -47.99 91.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.213 -0.93 . . . . 0.0 109.444 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.43 -42.95 95.74 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.773 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -71.37 -39.83 70.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.346 -0.846 . . . . 0.0 109.737 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.4 tp -59.28 -47.18 86.34 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.233 -0.917 . . . . 0.0 109.468 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -65.91 -39.0 90.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.181 -0.95 . . . . 0.0 108.972 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -66.23 -36.01 81.92 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 110.614 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -84.98 -52.42 5.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.197 -0.939 . . . . 0.0 112.012 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -94.99 -5.35 44.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.721 -1.237 . . . . 0.0 111.306 -177.942 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.09 24.77 76.33 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.971 -1.651 . . . . 0.0 108.971 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.5 145.51 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.311 -1.111 . . . . 0.0 109.482 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.73 150.33 32.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 109.444 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.25 -30.59 62.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.422 -0.799 . . . . 0.0 109.611 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 55.11 46.47 23.97 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -0.878 . . . . 0.0 109.558 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -95.14 16.23 16.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.232 -0.917 . . . . 0.0 109.737 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 60' ' ' GLU . 63.3 t -56.72 -43.75 80.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.105 -0.997 . . . . 0.0 109.548 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.469 ' HG3' HG12 ' A' ' 59' ' ' VAL . 95.9 mt-10 -138.36 132.0 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.163 -0.961 . . . . 0.0 109.671 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.6 mp -131.35 140.13 49.65 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.303 -0.873 . . . . 0.0 109.594 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.29 146.58 20.21 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.383 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.79 -22.98 74.34 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.57 2.18 . . . . 0.0 112.195 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.07 -31.63 72.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.382 -0.824 . . . . 0.0 109.934 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -67.87 -26.95 66.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.175 -0.953 . . . . 0.0 109.654 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.461 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.8 m-85 -104.77 11.18 34.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.33 -0.856 . . . . 0.0 109.835 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.575 ' NH2' ' OD1' ' A' ' 29' ' ' ASP . 41.6 tpt85 -54.36 -38.51 66.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.18 -0.95 . . . . 0.0 109.571 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.5 p -149.12 156.28 41.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.144 -0.972 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -62.71 -36.67 76.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.344 -0.848 . . . . 0.0 109.83 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.7 ttp180 -60.41 -40.85 92.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.897 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.9 t -60.61 -44.19 96.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.361 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.7 mt -66.54 -38.58 81.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.308 -0.87 . . . . 0.0 109.727 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.755 ' O ' HG23 ' A' ' 77' ' ' VAL . 88.7 m-20 -57.77 -41.1 81.33 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.312 -0.867 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.22 -46.15 78.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.103 -0.998 . . . . 0.0 109.631 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -64.12 -46.44 84.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.353 -0.842 . . . . 0.0 109.366 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.638 HG11 ' NE2' ' A' ' 3' ' ' HIS . 60.1 t -64.86 -41.69 92.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.368 -0.832 . . . . 0.0 109.881 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.755 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -62.31 -41.08 90.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.084 -1.01 . . . . 0.0 109.803 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.07 -34.75 73.94 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.34 -48.12 4.48 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.09 -1.241 . . . . 0.0 110.522 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.3 m -129.53 138.09 51.15 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.349 -0.844 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.489 1.5 0 O-C-N 121.408 -0.808 . . . . 0.0 109.292 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.9 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.343 0.592 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -58.51 -40.77 83.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 109.644 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.458 ' CD2' HG22 ' A' ' 77' ' ' VAL . 57.0 m-70 -126.62 12.0 7.37 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.38 -0.825 . . . . 0.0 109.516 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.583 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.58 -32.27 70.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 110.045 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -58.66 -37.13 75.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.076 -1.015 . . . . 0.0 109.662 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.51 -36.97 76.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.198 -0.939 . . . . 0.0 109.005 179.305 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.583 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.5 mt -60.63 -50.63 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.29 -0.882 . . . . 0.0 109.643 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.33 -47.18 80.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.042 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.7 -44.31 96.57 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.5 t80 -66.22 -45.06 82.03 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.6 -0.688 . . . . 0.0 109.652 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.826 HG13 HD12 ' A' ' 36' ' ' ILE . 55.7 t -66.8 -49.7 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.438 -0.788 . . . . 0.0 110.556 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 16' ' ' LEU . 61.7 t -64.12 -35.13 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.359 -0.838 . . . . 0.0 110.199 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -56.56 -34.59 67.25 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.429 -0.794 . . . . 0.0 109.996 -179.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.61 -30.8 71.17 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 110.621 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' HD22 ' A' ' 16' ' ' LEU . 34.7 m-85 -109.84 -57.86 2.13 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.116 -0.99 . . . . 0.0 111.32 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.681 HD12 HG23 ' A' ' 19' ' ' VAL . 1.2 mm? -123.66 86.9 52.67 Favored Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.111 -0.993 . . . . 0.0 111.362 -178.176 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.33 -19.21 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 123.154 2.569 . . . . 0.0 111.868 177.745 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.28 -4.1 40.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.239 -0.913 . . . . 0.0 109.091 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.681 HG23 HD12 ' A' ' 16' ' ' LEU . 42.4 t -113.15 143.81 22.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.107 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.94 115.76 15.5 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.728 -1.232 . . . . 0.0 108.557 -179.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.26 -25.86 71.97 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 C-N-CA 121.479 1.452 . . . . 0.0 111.746 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.92 -14.92 62.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.285 -0.884 . . . . 0.0 109.227 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -88.84 8.43 29.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.378 -0.826 . . . . 0.0 109.151 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -93.33 137.35 22.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.561 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -64.44 85.63 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.146 -0.971 . . . . 0.0 109.57 -179.334 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -59.64 5.72 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.301 -0.874 . . . . 0.0 109.677 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.561 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -101.93 6.44 41.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.07 -1.019 . . . . 0.0 108.787 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 15.0 tp -100.14 133.47 44.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.519 -0.738 . . . . 0.0 109.586 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.487 ' HB3' HG13 ' A' ' 31' ' ' VAL . 90.0 m-20 -66.67 121.78 16.17 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.724 ' H ' HD12 ' A' ' 30' ' ' LEU . 0.0 OUTLIER -70.03 11.63 0.29 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.173 -0.955 . . . . 0.0 109.946 -179.077 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.569 HG23 ' N ' ' A' ' 32' ' ' ASP . 34.0 m -52.38 -44.07 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 120.869 -1.144 . . . . 0.0 108.495 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.569 ' N ' HG23 ' A' ' 31' ' ' VAL . 91.7 m-20 -56.67 -35.28 68.23 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.5 m-20 -83.51 15.24 3.19 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.45 -13.88 0.01 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 50.2 t -50.63 -37.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.059 -1.259 . . . . 0.0 108.523 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.826 HD12 HG13 ' A' ' 11' ' ' VAL . 5.9 tt -70.57 -24.45 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.446 -0.784 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -61.51 -31.65 71.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.135 -0.978 . . . . 0.0 111.079 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 m -105.67 -65.28 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.93 -1.106 . . . . 0.0 111.486 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.55 -52.51 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.11 -0.994 . . . . 0.0 110.97 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.571 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.1 -37.17 92.83 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 61' ' ' LEU . 6.2 tp -58.8 -43.4 90.51 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.489 -1.007 . . . . 0.0 109.196 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.55 -43.19 93.59 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.445 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -66.99 -36.62 82.59 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.41 -0.806 . . . . 0.0 109.419 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.1 t -65.66 -49.58 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.323 -0.86 . . . . 0.0 110.605 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.9 mm -62.32 -41.34 91.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 120.922 -1.111 . . . . 0.0 109.65 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.26 -43.21 92.02 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.606 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -74.61 -39.85 61.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.367 -0.833 . . . . 0.0 109.786 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.6 tp -58.25 -42.08 85.6 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.293 -0.879 . . . . 0.0 109.625 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 53' ' ' GLY . 55.0 tt0 -63.01 -40.35 97.51 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -67.93 -47.14 69.51 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.13 -0.982 . . . . 0.0 110.764 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -68.08 -43.47 78.46 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.314 -0.866 . . . . 0.0 111.972 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 80' ' ' THR . 99.2 m-85 -103.6 -6.33 21.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.846 -1.159 . . . . 0.0 111.299 -178.11 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.13 27.43 73.81 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.509 HG22 ' HB2' ' A' ' 58' ' ' ASP . 70.5 mt -98.5 142.16 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -1.136 . . . . 0.0 109.366 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.6 144.33 51.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.02 . . . . 0.0 109.708 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.83 -34.07 74.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.437 -0.79 . . . . 0.0 109.717 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 57' ' ' ASP . 53.2 p30 -89.62 12.1 17.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.823 . . . . 0.0 109.817 -179.654 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.509 ' HB2' HG22 ' A' ' 54' ' ' ILE . 21.4 t70 -53.34 -34.89 59.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.231 -0.918 . . . . 0.0 109.913 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.5 p -129.31 144.6 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.432 -0.793 . . . . 0.0 109.769 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -71.6 144.05 49.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 41' ' ' LEU . 42.8 mt -96.58 136.22 37.41 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.26 -0.9 . . . . 0.0 109.923 -179.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.85 144.05 10.83 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.908 . . . . 0.0 109.132 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.09 -25.81 73.25 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.255 1.97 . . . . 0.0 111.929 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.41 -31.0 71.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.433 -0.792 . . . . 0.0 109.757 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -68.25 -26.56 65.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 110.562 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' LEU . 94.0 m-85 -99.14 10.27 41.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.058 -1.026 . . . . 0.0 111.089 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -58.46 -35.86 72.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.709 -1.244 . . . . 0.0 109.747 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.3 p -142.6 147.91 36.62 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.12 -0.987 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.538 HG12 HD21 ' A' ' 30' ' ' LEU . 90.7 mt -66.41 -36.6 77.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 O-C-N 121.307 -0.871 . . . . 0.0 110.113 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.3 mtm180 -61.16 -38.36 86.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.872 . . . . 0.0 110.573 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.0 p -62.59 -39.62 94.31 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.94 -1.1 . . . . 0.0 110.071 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.1 mt -68.45 -40.94 82.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.178 -0.951 . . . . 0.0 109.939 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.845 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.4 t0 -59.04 -39.34 81.72 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.309 -0.87 . . . . 0.0 110.17 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.18 -45.48 88.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.081 -1.012 . . . . 0.0 109.95 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -64.52 -46.87 81.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -0.941 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.6 t -64.76 -41.42 92.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.867 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.845 HG23 ' O ' ' A' ' 73' ' ' ASP . 79.8 t -60.56 -41.53 88.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.147 -0.97 . . . . 0.0 109.921 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.47 -32.83 79.01 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 120.308 -0.948 . . . . 0.0 110.829 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -48.22 3.93 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.115 -1.227 . . . . 0.0 110.886 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.699 HG21 ' CE2' ' A' ' 52' ' ' PHE . 38.1 m -128.11 138.39 52.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.298 -0.876 . . . . 0.0 109.879 -179.437 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 81' ' ' THR . 1.6 t . . . . . 0 N--CA 1.487 1.404 0 O-C-N 121.327 -0.858 . . . . 0.0 109.539 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.408 0.623 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tp60 -58.02 -41.58 83.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.346 -0.846 . . . . 0.0 109.735 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.401 ' ND1' HG22 ' A' ' 77' ' ' VAL . 70.6 m80 -118.32 4.13 11.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.449 -0.782 . . . . 0.0 109.816 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.575 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.47 -38.06 73.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.151 -0.968 . . . . 0.0 109.674 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 m -61.87 -43.65 98.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.745 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -65.11 -39.58 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.951 . . . . 0.0 108.913 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.676 ' O ' HG22 ' A' ' 11' ' ' VAL . 95.9 mt -59.36 -49.84 82.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.365 -0.834 . . . . 0.0 109.337 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.865 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.39 -48.34 78.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 108.937 179.563 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.89 -39.53 94.76 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.494 -0.754 . . . . 0.0 109.553 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -66.94 -51.93 49.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.531 -0.73 . . . . 0.0 110.484 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.7 m -73.07 -40.35 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 110.434 -179.564 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.724 HG23 ' O ' ' A' ' 8' ' ' ALA . 91.2 t -64.75 -37.04 79.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.966 . . . . 0.0 110.047 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.25 -34.46 66.39 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.177 -0.952 . . . . 0.0 110.017 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.409 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.11 -31.23 71.97 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.282 -0.886 . . . . 0.0 109.824 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE1' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -137.68 43.5 2.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.168 -0.957 . . . . 0.0 109.845 -179.711 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.09 135.65 54.58 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 120.785 -1.197 . . . . 0.0 110.069 -179.656 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -78.09 -151.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.147 1.898 . . . . 0.0 110.256 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.82 11.74 2.48 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 108.616 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.59 136.31 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.5 -0.75 . . . . 0.0 109.966 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.66 140.83 71.75 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 108.636 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.45 -28.23 11.49 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.8 1.667 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -24.8 67.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -0.827 . . . . 0.0 109.304 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.5 5.57 46.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.441 -0.787 . . . . 0.0 108.912 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.0 t -103.75 136.98 34.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.83 95.94 0.39 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.565 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.9 m -60.7 5.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 109.516 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -94.02 8.34 41.82 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.097 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.0 tp -89.12 138.78 31.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.584 -0.697 . . . . 0.0 109.39 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.09 121.5 13.77 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.524 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -70.32 3.39 2.95 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 109.405 -179.364 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.41 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.7 p -53.99 -35.88 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.261 -0.9 . . . . 0.0 109.557 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -57.17 -40.24 76.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.191 -0.943 . . . . 0.0 108.473 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.4 p30 -91.45 15.99 11.19 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' ASP . . . -42.48 -14.11 0.01 OUTLIER Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.8 t -49.86 -33.28 8.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.973 -1.31 . . . . 0.0 108.383 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.581 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.6 tt -70.1 -24.63 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.849 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 34' ' ' GLY . 85.8 m-20 -61.81 -33.61 74.44 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.413 -0.804 . . . . 0.0 111.255 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.51 -65.15 1.08 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.946 -1.096 . . . . 0.0 111.516 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.2 tt -71.93 -49.85 34.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 111.515 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.79 -41.8 81.66 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.629 -178.901 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.581 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -63.15 -43.55 98.0 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.291 -1.123 . . . . 0.0 110.236 -179.052 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 42.6 tp -58.32 -44.42 88.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.84 -1.162 . . . . 0.0 109.437 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.8 mttt -68.9 -37.06 78.74 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.116 -0.99 . . . . 0.0 109.557 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.5 t -66.7 -47.67 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 111.239 -178.865 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.15 -45.64 92.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 120.586 -1.321 . . . . 0.0 110.162 -179.202 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.64 -45.57 74.98 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.032 -1.043 . . . . 0.0 110.51 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.504 ' CZ2' ' CZ ' ' A' ' 51' ' ' ARG . 2.0 t90 -76.91 -46.12 25.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 110.29 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.488 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 12.0 tp -57.15 -41.48 79.24 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.355 -0.841 . . . . 0.0 109.603 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 25.6 tt0 -63.15 -36.6 84.16 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.637 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.11 -39.65 86.95 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.086 -1.009 . . . . 0.0 110.04 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.504 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 77.8 mtm180 -77.3 -43.17 34.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -0.967 . . . . 0.0 111.934 -179.039 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -102.34 -6.5 22.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.826 -1.171 . . . . 0.0 110.803 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.16 30.56 77.07 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.442 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 94.4 mt -85.01 147.05 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.202 -1.175 . . . . 0.0 109.958 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 148.02 42.4 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.229 -0.92 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.24 -32.02 69.6 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.329 -0.857 . . . . 0.0 109.741 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 52.47 43.04 31.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.3 p30 -93.7 16.31 14.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.386 -0.821 . . . . 0.0 109.672 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -53.76 -44.22 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 110.04 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -173.34 118.2 0.29 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.121 -0.987 . . . . 0.0 110.092 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -109.25 138.11 46.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.381 -0.824 . . . . 0.0 109.083 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 141.94 37.04 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.42 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -63.74 -21.72 69.65 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.291 1.994 . . . . 0.0 112.385 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.89 -32.89 72.33 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 110.307 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -74.06 -26.49 60.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.131 -0.98 . . . . 0.0 110.708 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -94.65 8.0 43.84 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.94 -1.1 . . . . 0.0 110.75 -178.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.41 ' NH2' HG21 ' A' ' 31' ' ' VAL . 30.1 mmt180 -58.9 -34.32 71.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.724 -1.235 . . . . 0.0 110.19 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.7 p -135.5 149.94 49.65 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.052 -1.03 . . . . 0.0 110.122 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.865 HD13 ' HB2' ' A' ' 8' ' ' ALA . 75.8 mt -64.3 -36.86 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.391 -0.818 . . . . 0.0 110.04 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -61.16 -37.24 82.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.25 -0.906 . . . . 0.0 110.686 -178.808 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -58.82 -44.1 90.79 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.977 -1.077 . . . . 0.0 109.765 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.0 mt -64.95 -38.66 83.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.189 -0.944 . . . . 0.0 109.622 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.49 ' HA ' HD11 ' A' ' 7' ' ' ILE . 51.2 t0 -56.8 -41.1 77.15 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.387 -0.821 . . . . 0.0 110.103 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.52 -46.22 76.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.086 -1.009 . . . . 0.0 110.231 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -63.42 -46.14 87.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.04 -1.038 . . . . 0.0 109.626 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.94 -44.5 92.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.368 -0.832 . . . . 0.0 110.267 -179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.401 HG22 ' ND1' ' A' ' 3' ' ' HIS . 42.0 t -63.17 -41.37 92.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.079 -1.013 . . . . 0.0 110.098 -179.611 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.56 -32.48 69.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.52 -48.27 3.86 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.101 -1.235 . . . . 0.0 110.819 -179.043 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.2 m -130.13 138.97 50.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.161 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.442 0 O-C-N 121.334 -0.854 . . . . 0.0 109.125 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.347 0.594 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.05 -36.19 74.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.31 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -150.1 44.68 0.9 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.385 -0.822 . . . . 0.0 109.273 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.04 -32.4 72.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.893 . . . . 0.0 109.934 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -58.46 -37.65 75.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.101 -0.999 . . . . 0.0 109.929 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.6 -39.49 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.148 -0.97 . . . . 0.0 109.357 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.477 HD13 ' OD2' ' A' ' 73' ' ' ASP . 94.6 mt -59.84 -40.07 81.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.265 -0.897 . . . . 0.0 109.627 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.39 -48.63 77.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.965 . . . . 0.0 109.118 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.427 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.37 -32.37 71.38 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.492 -0.755 . . . . 0.0 109.371 179.697 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -58.35 -51.51 69.49 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.296 -0.877 . . . . 0.0 109.722 -179.115 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.535 HG23 ' N ' ' A' ' 12' ' ' VAL . 33.8 m -73.73 -45.01 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.062 -1.023 . . . . 0.0 110.781 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.535 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.3 t -64.43 -35.89 75.67 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.176 -0.953 . . . . 0.0 111.131 -178.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -58.1 -33.01 68.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.011 -1.056 . . . . 0.0 110.005 -178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.19 -31.27 72.01 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 110.825 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -110.12 -55.87 2.4 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.214 -0.929 . . . . 0.0 111.472 -178.189 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.2 mt -124.44 87.65 53.96 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.082 -1.011 . . . . 0.0 111.389 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.91 -13.99 1.25 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 123.205 2.603 . . . . 0.0 111.776 178.098 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.45 -3.99 40.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.18 -0.95 . . . . 0.0 109.39 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.2 p -114.09 146.42 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.29 115.18 13.27 Favored Pre-proline 0 C--N 1.303 -1.441 0 O-C-N 120.742 -1.224 . . . . 0.0 108.362 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -64.84 -33.04 54.54 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.458 1.439 . . . . 0.0 111.913 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.46 -14.96 61.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -92.55 6.98 45.22 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.512 -0.742 . . . . 0.0 109.036 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.8 t -95.84 137.06 24.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.6 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.7 m-20 -61.58 90.61 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.223 -0.923 . . . . 0.0 109.589 -179.362 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -59.22 6.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.273 -0.892 . . . . 0.0 109.692 179.763 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.6 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.2 m-20 -97.86 11.4 37.47 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.074 -1.016 . . . . 0.0 108.971 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.6 tp -89.51 133.89 34.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.43 -0.794 . . . . 0.0 109.704 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 91.2 m-20 -65.37 122.3 16.84 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.419 -0.801 . . . . 0.0 108.97 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.584 HD11 HG12 ' A' ' 69' ' ' ILE . 65.8 mt -62.06 -7.2 3.64 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.179 -0.951 . . . . 0.0 108.992 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.2 p -50.05 -41.16 17.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.03 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.491 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.9 m-20 -58.8 -36.63 74.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 82.6 m-20 -85.29 16.86 3.37 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.48 -15.15 0.01 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.204 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.4 t -54.11 -38.78 39.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.78 -1.423 . . . . 0.0 107.853 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.618 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.23 -25.06 24.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.599 -0.688 . . . . 0.0 110.046 179.603 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.8 m-20 -62.37 -30.98 71.58 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 111.252 -178.306 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -104.97 -64.76 1.09 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.903 -1.123 . . . . 0.0 111.216 -178.62 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.5 mt -74.13 -52.58 12.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.121 -0.987 . . . . 0.0 110.964 -178.313 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.58 -36.59 93.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.618 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -61.33 -40.37 93.96 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.492 -1.005 . . . . 0.0 109.306 -179.599 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 34.2 tp -61.24 -44.21 97.62 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.535 -0.866 . . . . 0.0 108.797 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 46.1 mttp -70.5 -39.87 73.89 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.408 -0.808 . . . . 0.0 109.907 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.7 t -65.72 -45.72 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.881 . . . . 0.0 110.514 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.97 -44.36 99.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.032 -1.042 . . . . 0.0 109.697 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -63.43 -43.09 98.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.323 -0.86 . . . . 0.0 109.802 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -76.21 -43.35 42.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.189 -0.945 . . . . 0.0 109.992 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.4 tp -58.09 -47.97 81.58 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 110.055 -179.32 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.614 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.2 tt0 -67.95 -39.55 83.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.114 -0.991 . . . . 0.0 108.827 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 93.8 m-20 -64.9 -40.52 95.21 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.586 -0.696 . . . . 0.0 110.235 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -61.7 -44.79 96.25 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 111.3 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -113.94 -1.87 13.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.095 -1.003 . . . . 0.0 111.042 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.614 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.2 37.89 81.87 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.7 mt -96.18 142.76 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -1.181 . . . . 0.0 109.263 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.92 138.94 58.41 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.915 -1.115 . . . . 0.0 109.491 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.8 -32.47 73.66 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -57.69 -37.75 74.0 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.382 -0.823 . . . . 0.0 109.9 -179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.06 -37.74 67.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.118 -0.989 . . . . 0.0 109.377 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 60' ' ' GLU . 70.9 t -63.62 -37.16 78.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.85 . . . . 0.0 109.72 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . 86.3 tt0 58.57 127.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.559 -0.713 . . . . 0.0 109.654 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.41 HD22 HD21 ' A' ' 41' ' ' LEU . 17.5 mt -103.14 134.16 47.02 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.907 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -172.23 139.56 1.03 Allowed Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -63.02 -26.62 73.8 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 121.986 1.791 . . . . 0.0 111.622 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -30.89 71.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.588 -0.695 . . . . 0.0 109.596 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -68.73 -26.3 65.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.58 -0.7 . . . . 0.0 110.824 -178.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.514 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.0 m-85 -101.39 6.2 42.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.977 -1.077 . . . . 0.0 111.607 -178.193 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 34.2 mmt180 -60.08 -34.11 73.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.743 -1.223 . . . . 0.0 110.028 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -144.04 147.25 33.57 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.874 -1.141 . . . . 0.0 110.185 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.584 HG12 HD11 ' A' ' 30' ' ' LEU . 78.6 mt -66.6 -36.74 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 O-C-N 121.482 -0.761 . . . . 0.0 109.896 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.4 mtm180 -61.03 -39.92 91.61 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.322 -0.861 . . . . 0.0 110.317 -178.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.61 -43.95 96.85 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.974 -1.079 . . . . 0.0 109.427 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.514 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -68.51 -38.57 79.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.356 -0.84 . . . . 0.0 109.908 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' HD13 ' A' ' 7' ' ' ILE . 77.6 m-20 -58.35 -42.0 85.92 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.398 -0.814 . . . . 0.0 110.438 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -40.12 88.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.11 -0.994 . . . . 0.0 110.368 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -61.41 -51.42 68.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 109.851 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 80' ' ' THR . 76.8 t -67.64 -43.79 86.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.261 -0.899 . . . . 0.0 109.763 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -63.02 -39.87 86.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.074 -1.016 . . . . 0.0 109.621 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.85 70.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.576 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.03 -48.88 3.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.146 -1.208 . . . . 0.0 110.565 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.571 ' O ' HG12 ' A' ' 76' ' ' VAL . 57.9 m -157.37 137.96 13.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.138 -0.976 . . . . 0.0 110.168 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.768 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 108.944 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.6 mtt . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.322 0.582 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -60.08 -38.0 81.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.349 -0.844 . . . . 0.0 109.507 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -133.99 12.87 3.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.4 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.53 -35.61 76.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.316 -0.865 . . . . 0.0 110.051 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.8 p -61.76 -36.49 81.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.07 -1.019 . . . . 0.0 109.593 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -66.16 -37.47 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 108.94 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.2 mt -66.49 -41.69 88.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.407 -0.808 . . . . 0.0 110.336 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.703 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.89 -50.55 68.31 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.042 -1.036 . . . . 0.0 110.378 -179.022 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.4 -44.22 68.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.073 -1.017 . . . . 0.0 109.614 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -60.18 -48.32 82.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.284 -0.885 . . . . 0.0 109.463 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.7 HG13 HD12 ' A' ' 36' ' ' ILE . 97.6 t -68.82 -47.48 75.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.486 -0.759 . . . . 0.0 109.837 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.6 t -64.29 -36.67 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.427 -0.796 . . . . 0.0 109.964 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.81 -28.5 61.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.339 -0.85 . . . . 0.0 109.879 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.56 -29.45 70.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -155.94 55.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.155 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.473 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.7 pt? -80.59 136.8 51.67 Favored Pre-proline 0 C--N 1.306 -1.283 0 O-C-N 120.995 -1.065 . . . . 0.0 110.197 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.58 -153.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 121.937 1.758 . . . . 0.0 110.641 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -81.24 14.2 2.5 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.092 -1.005 . . . . 0.0 108.79 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.5 t -113.3 136.9 48.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.646 -0.658 . . . . 0.0 109.994 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.07 140.21 73.38 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 108.962 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -48.86 -29.97 16.31 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 121.849 1.699 . . . . 0.0 112.081 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.6 -16.17 63.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.3 -0.875 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -102.2 5.48 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.347 -0.846 . . . . 0.0 109.234 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -105.0 136.78 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.569 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.9 t0 -71.15 96.2 1.34 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.157 -0.965 . . . . 0.0 109.431 -179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.2 m -60.91 6.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.356 -0.84 . . . . 0.0 109.676 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.569 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.0 6.79 48.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.132 -0.98 . . . . 0.0 109.118 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.5 tt -95.85 135.87 37.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.61 ' O ' HD23 ' A' ' 28' ' ' LEU . 88.0 m-20 -60.86 121.92 13.56 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.75 14.92 0.07 Allowed 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.31 -0.868 . . . . 0.0 110.281 -178.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 29' ' ' ASP . 73.4 t -54.34 -41.17 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 108.508 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -55.17 -35.21 64.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -83.07 14.53 3.32 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.842 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.86 -14.44 0.01 OUTLIER Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 44.4 t -51.21 -36.86 17.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 121.143 -1.21 . . . . 0.0 108.69 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.7 HD12 HG13 ' A' ' 11' ' ' VAL . 5.5 tt -70.66 -24.56 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.438 -0.789 . . . . 0.0 110.229 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.3 m-20 -58.9 -34.87 72.17 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 111.474 -178.103 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.9 m -106.26 -64.97 1.11 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.931 -1.106 . . . . 0.0 111.673 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -71.37 -52.53 18.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.042 -1.036 . . . . 0.0 111.037 -177.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.76 -36.45 91.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tp -58.15 -42.76 86.61 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.372 -1.075 . . . . 0.0 108.898 -179.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.39 -44.12 95.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -68.55 -34.68 76.26 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.458 -0.776 . . . . 0.0 109.518 179.191 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.3 t -61.47 -45.8 97.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.329 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mm -62.66 -41.14 91.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.95 -1.093 . . . . 0.0 109.577 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.73 -44.49 81.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 109.867 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.444 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -76.35 -45.14 33.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.181 -0.949 . . . . 0.0 109.702 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.444 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.04 -40.98 77.8 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.347 -0.846 . . . . 0.0 109.512 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.551 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 2.9 tm-20 -60.86 -43.13 98.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.159 -0.963 . . . . 0.0 108.751 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -68.91 -43.3 75.48 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.294 -0.879 . . . . 0.0 110.045 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.6 tpt180 -64.27 -44.72 90.86 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.436 -0.79 . . . . 0.0 111.062 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -106.23 -5.39 19.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.063 -1.023 . . . . 0.0 110.998 -178.516 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.02 30.28 65.73 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.551 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 71.6 mt -96.71 138.82 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.177 . . . . 0.0 109.056 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 136.07 57.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.991 -1.068 . . . . 0.0 109.801 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.32 -24.84 65.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.528 -0.732 . . . . 0.0 109.414 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.443 ' O ' HG13 ' A' ' 59' ' ' VAL . 92.2 m-20 -55.18 -31.64 61.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.468 -0.77 . . . . 0.0 110.217 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.07 120.69 11.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.054 -1.029 . . . . 0.0 109.839 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 57' ' ' ASP . 16.8 m -115.29 27.46 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.567 -0.708 . . . . 0.0 109.309 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -51.08 -26.04 5.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.379 -0.825 . . . . 0.0 109.922 -179.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.0 mt -71.73 138.99 48.91 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.08 -1.012 . . . . 0.0 109.792 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.85 162.4 51.91 Favored Pre-proline 0 N--CA 1.487 1.406 0 O-C-N 121.455 -0.778 . . . . 0.0 109.294 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -56.69 -36.21 98.12 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.324 2.016 . . . . 0.0 111.395 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.04 -25.8 65.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.474 -0.766 . . . . 0.0 109.185 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.48 ' CD2' ' CD2' ' A' ' 75' ' ' PHE . 34.1 t-80 -67.74 -26.03 65.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.415 -0.803 . . . . 0.0 109.863 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.533 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 92.0 m-85 -90.4 10.06 26.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.271 -0.893 . . . . 0.0 109.802 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 16.4 tpt180 -56.91 -40.35 76.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.921 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -144.75 153.41 41.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.951 -1.093 . . . . 0.0 110.263 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.4 mt -66.3 -36.8 78.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.462 -0.774 . . . . 0.0 110.123 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 14.1 ttm180 -60.77 -43.05 98.54 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.433 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.3 m -58.4 -40.46 82.48 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.226 -0.921 . . . . 0.0 109.918 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -61.54 -40.74 87.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.178 -0.951 . . . . 0.0 109.718 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.637 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.2 t0 -59.32 -37.5 77.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.288 -0.882 . . . . 0.0 109.996 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.8 -46.3 85.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.48 ' CD2' ' CD2' ' A' ' 65' ' ' HIS . 52.9 m-85 -68.45 -40.72 80.96 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.152 -0.967 . . . . 0.0 109.34 179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -65.13 -41.99 93.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.296 -0.877 . . . . 0.0 109.585 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.3 t -63.74 -41.01 91.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 O-C-N 121.187 -0.946 . . . . 0.0 109.836 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.08 -30.96 71.47 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.33 -48.58 4.14 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.039 -1.271 . . . . 0.0 110.559 -178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.8 p -132.04 154.35 49.48 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.281 -0.887 . . . . 0.0 109.647 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.806 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t . . . . . 0 C--N 1.303 -1.418 0 O-C-N 121.222 -0.924 . . . . 0.0 109.315 179.579 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.748 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.9 mt-30 -59.86 -37.28 78.84 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.598 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -144.36 34.87 1.19 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.241 -0.912 . . . . 0.0 109.542 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.847 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -59.57 -32.48 70.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -0.912 . . . . 0.0 109.676 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.5 m -58.46 -37.42 75.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.125 -0.984 . . . . 0.0 109.971 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.8 t -63.97 -40.85 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.131 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.538 HG22 HG23 ' A' ' 69' ' ' ILE . 76.7 mt -60.02 -47.92 89.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.443 -0.786 . . . . 0.0 109.27 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.01 99.11 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.14 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -37.38 86.42 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' VAL . 33.5 t80 -60.67 -52.89 63.22 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.513 -0.742 . . . . 0.0 109.886 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.496 HG23 ' CD1' ' A' ' 36' ' ' ILE . 4.0 p -73.48 -42.01 56.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.106 -0.996 . . . . 0.0 109.89 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.2 t -65.02 -35.59 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.36 -0.837 . . . . 0.0 110.911 -179.16 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -56.17 -36.17 68.04 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.023 -1.048 . . . . 0.0 110.353 -178.435 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.434 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 75.6 mm-40 -66.06 -31.5 72.42 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.043 -1.036 . . . . 0.0 109.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.434 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.2 OUTLIER -135.02 43.84 2.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.126 -0.984 . . . . 0.0 109.907 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.5 135.89 52.85 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.119 . . . . 0.0 110.116 -179.733 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.4 -149.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.143 1.895 . . . . 0.0 110.184 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.591 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.52 11.25 3.16 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 120.794 -1.191 . . . . 0.0 108.637 179.08 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.591 HG23 ' OD1' ' A' ' 18' ' ' ASP . 26.8 t -113.75 136.16 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.519 -0.738 . . . . 0.0 109.841 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.57 140.92 75.65 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.126 -0.983 . . . . 0.0 108.916 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -48.41 -29.33 13.29 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 121.875 1.717 . . . . 0.0 111.998 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.21 -21.16 66.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.384 -0.823 . . . . 0.0 109.283 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -103.27 3.25 35.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.44 -0.787 . . . . 0.0 108.886 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -104.93 138.94 27.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.579 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.5 t0 -68.78 102.59 1.57 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.105 -0.997 . . . . 0.0 109.354 -179.255 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 8' ' ' ALA . 26.0 m -59.62 6.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.433 -0.792 . . . . 0.0 109.933 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.579 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -89.92 10.11 25.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.03 -1.044 . . . . 0.0 108.632 179.248 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.2 tp -86.88 133.67 33.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.533 -0.729 . . . . 0.0 109.499 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -67.45 121.27 15.43 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.081 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -73.31 9.79 1.19 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.123 -0.986 . . . . 0.0 109.349 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.51 -39.45 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.891 . . . . 0.0 108.825 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.4 m-20 -57.71 -36.18 71.65 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' A' ' 35' ' ' VAL . 32.0 m120 -84.43 14.81 4.11 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.53 -15.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.617 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.58 -37.75 20.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.852 -1.381 . . . . 0.0 108.223 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.6 tt -71.04 -24.56 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.547 -0.721 . . . . 0.0 110.104 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.427 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.57 -32.15 71.24 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.153 -0.967 . . . . 0.0 111.358 -178.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.84 -65.11 1.09 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.864 -1.148 . . . . 0.0 111.393 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.33 -52.36 16.49 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.177 -0.952 . . . . 0.0 110.916 -178.235 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.69 92.28 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.616 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tp -58.88 -41.12 86.34 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.379 -1.071 . . . . 0.0 109.301 -179.625 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.9 tp -62.8 -44.33 96.45 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.213 -0.93 . . . . 0.0 108.762 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -71.87 -38.26 70.07 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.421 -0.8 . . . . 0.0 109.948 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 86.5 t -64.79 -45.12 96.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 110.249 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.9 -42.47 94.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.171 -0.956 . . . . 0.0 109.607 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.77 -43.09 97.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.181 -0.949 . . . . 0.0 109.971 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -76.38 -43.68 39.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 109.842 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 31.4 tp -60.0 -42.5 94.41 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 0.0 109.842 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.609 ' O ' ' N ' ' A' ' 53' ' ' GLY . 4.1 tt0 -66.46 -41.69 88.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.12 -0.988 . . . . 0.0 108.996 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -66.61 -37.15 84.27 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.419 -0.8 . . . . 0.0 109.828 179.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -59.04 -41.72 88.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.498 -0.751 . . . . 0.0 110.818 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.563 ' CE1' HG21 ' A' ' 80' ' ' THR . 1.1 m-85 -118.93 -4.02 10.67 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.101 -0.999 . . . . 0.0 110.437 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.74 43.19 29.4 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -101.08 140.7 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.138 -1.213 . . . . 0.0 109.323 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.59 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -62.26 136.61 58.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.884 -1.135 . . . . 0.0 109.374 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.23 -33.63 76.25 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.363 -0.836 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -94.48 8.24 42.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.265 -0.897 . . . . 0.0 109.809 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.59 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 21.3 t70 -53.05 -37.31 61.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.093 -1.004 . . . . 0.0 109.293 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.465 HG21 ' CZ ' ' A' ' 75' ' ' PHE . 12.6 p -133.27 144.78 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.451 -0.781 . . . . 0.0 109.169 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -77.75 137.38 38.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.429 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.3 mt -104.04 138.82 40.02 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.344 -0.848 . . . . 0.0 109.711 -179.588 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -135.58 154.85 78.53 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.321 -0.862 . . . . 0.0 109.06 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.34 -30.66 81.13 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.608 2.205 . . . . 0.0 112.339 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.79 -32.1 73.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.376 -0.828 . . . . 0.0 110.013 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -68.8 -26.48 65.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.288 -0.882 . . . . 0.0 110.897 -179.086 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -94.38 5.59 51.32 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.846 -1.159 . . . . 0.0 110.932 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -59.65 -40.87 89.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.034 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.0 m -129.45 145.26 51.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.25 -0.906 . . . . 0.0 110.184 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.636 HD13 ' HA ' ' A' ' 8' ' ' ALA . 82.1 mt -63.7 -36.28 75.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.467 -0.771 . . . . 0.0 109.759 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -60.33 -37.66 81.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.339 -0.851 . . . . 0.0 110.402 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -57.66 -43.46 84.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.999 -1.063 . . . . 0.0 109.633 -179.501 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -68.04 -38.74 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.261 -0.899 . . . . 0.0 109.634 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.847 ' OD1' ' HB2' ' A' ' 4' ' ' ALA . 50.4 t0 -57.72 -40.45 79.62 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.384 -0.823 . . . . 0.0 110.302 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.04 -45.68 80.56 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.029 -1.044 . . . . 0.0 109.624 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.465 ' CZ ' HG21 ' A' ' 59' ' ' VAL . 71.7 t80 -63.54 -45.84 88.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.373 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' A' ' 80' ' ' THR . 59.1 t -65.22 -44.74 95.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.362 -0.836 . . . . 0.0 109.976 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.6 t -63.65 -39.39 85.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 O-C-N 121.11 -0.994 . . . . 0.0 109.838 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -33.65 68.34 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.5 -48.7 3.74 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.195 -1.179 . . . . 0.0 110.601 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.563 HG21 ' CE1' ' A' ' 52' ' ' PHE . 53.3 m -163.17 139.71 7.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.12 -0.987 . . . . 0.0 109.827 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.366 -0.834 . . . . 0.0 109.307 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.44 ' CE ' ' OG ' ' A' ' 5' ' ' SER . 4.2 ptt? . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.402 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.8 mt-30 55.6 44.15 27.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.27 -0.894 . . . . 0.0 109.107 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 2' ' ' GLN . 67.0 m170 46.45 37.69 4.58 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.181 -0.95 . . . . 0.0 109.048 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.541 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.75 -36.74 79.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.331 -0.856 . . . . 0.0 109.485 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' CE ' ' A' ' 1' ' ' MET . 22.9 m -59.23 -39.58 83.2 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.19 -0.944 . . . . 0.0 109.285 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.8 t -66.83 -37.66 79.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.203 -0.936 . . . . 0.0 109.0 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.577 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.5 mt -60.48 -51.01 78.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.251 -0.906 . . . . 0.0 109.177 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.761 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.81 -48.14 75.48 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.828 . . . . 0.0 109.301 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.85 -44.28 96.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.523 -0.736 . . . . 0.0 109.344 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.477 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.2 t80 -65.7 -48.7 71.14 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.57 -0.706 . . . . 0.0 109.486 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 7' ' ' ILE . 90.9 t -67.33 -44.89 86.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.383 -0.823 . . . . 0.0 109.521 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.3 t -64.25 -35.28 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.488 -0.757 . . . . 0.0 109.527 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.8 -30.38 61.26 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.299 -0.876 . . . . 0.0 109.969 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -65.66 -31.09 71.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.114 -0.992 . . . . 0.0 109.702 -179.635 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.563 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 33.5 p90 -143.29 45.79 1.53 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -0.999 . . . . 0.0 109.671 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.851 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.63 135.9 52.37 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.036 -1.04 . . . . 0.0 110.177 -179.813 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.58 -151.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.218 1.946 . . . . 0.0 110.364 178.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -78.72 12.18 2.22 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.826 -1.171 . . . . 0.0 108.748 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.0 t -113.4 137.0 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.72 84.34 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.151 -0.968 . . . . 0.0 108.911 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.408 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.2 Cg_exo -48.2 -30.93 15.68 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.864 1.709 . . . . 0.0 112.179 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.8 -22.92 66.0 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.419 -0.8 . . . . 0.0 109.434 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -102.51 8.64 39.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.834 . . . . 0.0 109.434 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.1 t -101.3 136.73 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.318 -0.864 . . . . 0.0 108.862 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.71 89.34 0.38 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.134 -0.979 . . . . 0.0 109.275 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -61.57 6.39 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.563 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -93.34 8.55 39.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.111 -0.993 . . . . 0.0 108.918 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -91.41 136.81 32.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.487 -0.758 . . . . 0.0 109.575 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -62.43 121.79 14.12 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.61 10.53 1.68 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.257 -0.902 . . . . 0.0 110.101 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.5 t -55.42 -42.08 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.907 -1.12 . . . . 0.0 108.932 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.4 t0 -55.81 -35.53 66.44 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.28 14.77 4.88 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -15.19 0.02 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.5 t -53.24 -36.81 26.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.151 -1.205 . . . . 0.0 108.611 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.2 tt -70.46 -24.73 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.462 -0.774 . . . . 0.0 110.087 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.425 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.8 m-20 -61.11 -32.31 71.99 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.215 -0.928 . . . . 0.0 110.969 -178.588 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 46.1 m -105.77 -64.57 1.14 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.047 -1.033 . . . . 0.0 111.475 -178.557 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.1 mp -72.56 -52.4 15.75 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.072 -1.018 . . . . 0.0 110.969 -178.198 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.91 -37.4 93.25 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.7 tp -59.39 -41.03 88.48 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.461 -1.023 . . . . 0.0 109.141 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.9 tp -62.03 -43.96 97.72 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -65.48 -35.45 80.94 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.48 -0.763 . . . . 0.0 109.281 179.197 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.2 t -60.11 -43.86 93.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.427 -0.796 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.5 -44.88 97.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.688 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.9 -43.3 96.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 110.203 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.477 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -75.3 -38.84 60.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.875 . . . . 0.0 109.936 -179.694 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.7 tp -57.92 -44.16 86.67 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.285 -0.884 . . . . 0.0 110.014 -179.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.587 ' O ' ' N ' ' A' ' 53' ' ' GLY . 30.1 tt0 -66.34 -40.36 89.78 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 109.41 179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -64.7 -44.04 91.54 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.319 -0.863 . . . . 0.0 110.574 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.15 -43.23 92.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.333 -0.854 . . . . 0.0 111.596 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -106.57 -7.07 17.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.952 -1.093 . . . . 0.0 110.782 -178.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.38 33.51 82.29 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.0 pt -108.78 153.12 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.363 -1.081 . . . . 0.0 109.961 -179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.84 151.37 30.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.714 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.01 70.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.434 -0.791 . . . . 0.0 109.987 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 52.91 49.53 20.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.162 -0.961 . . . . 0.0 108.864 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -74.85 118.17 17.51 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.334 -0.854 . . . . 0.0 110.214 -179.136 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.8 m -129.59 163.78 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -59.4 127.69 33.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.909 -1.119 . . . . 0.0 109.467 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.54 HD12 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -114.93 146.03 41.59 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.35 155.7 39.01 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.33 -0.856 . . . . 0.0 109.096 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.11 -25.57 77.42 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.644 2.229 . . . . 0.0 112.014 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.54 -29.74 70.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.534 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.67 -26.66 66.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.268 -0.895 . . . . 0.0 109.795 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -99.39 8.49 44.58 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.69 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.93 -38.15 69.91 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.726 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.8 p -141.36 156.63 45.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.1 -1.0 . . . . 0.0 110.16 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.3 mt -61.79 -35.74 69.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.431 -0.793 . . . . 0.0 109.847 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -59.74 -39.03 83.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.848 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.2 t -58.48 -39.89 81.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.066 -1.021 . . . . 0.0 108.924 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.2 mt -60.84 -38.72 79.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.299 -0.876 . . . . 0.0 108.874 179.395 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.0 t0 -56.21 -36.92 68.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.448 -0.783 . . . . 0.0 109.02 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.67 -40.64 92.83 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.257 -0.902 . . . . 0.0 108.768 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -60.64 -46.41 90.41 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.97 -40.62 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.411 -0.805 . . . . 0.0 108.934 179.201 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -57.97 -40.75 78.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.482 -0.761 . . . . 0.0 109.186 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.77 -34.31 86.36 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.88 -48.85 4.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.893 -1.357 . . . . 0.0 110.553 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.6 p -128.7 152.74 48.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 108.721 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.213 -0.929 . . . . 0.0 110.237 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.657 ' SD ' ' NH2' ' A' ' 70' ' ' ARG . 59.8 mtt . . . . . 0 N--CA 1.488 1.427 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.49 -34.4 72.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.199 -0.938 . . . . 0.0 108.84 179.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.508 ' CE1' HG22 ' A' ' 77' ' ' VAL . 4.2 p-80 -171.94 26.79 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.622 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.563 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.28 -35.04 76.22 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.295 -0.878 . . . . 0.0 109.584 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.11 -41.65 88.67 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.965 . . . . 0.0 109.489 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.5 t -65.24 -39.82 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.224 -0.922 . . . . 0.0 108.907 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.633 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.9 mt -59.55 -50.71 78.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.456 -0.778 . . . . 0.0 109.351 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.11 -42.3 96.94 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 108.865 179.389 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.82 -39.57 91.0 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.509 -0.745 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.434 ' HE2' HG22 ' A' ' 44' ' ' VAL . 38.0 t80 -61.5 -52.22 65.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.356 -0.84 . . . . 0.0 109.847 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.633 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.3 p -72.51 -42.44 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.275 -0.891 . . . . 0.0 109.929 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.4 t -64.38 -38.39 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.356 -0.84 . . . . 0.0 110.294 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.55 -28.0 59.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.216 -0.927 . . . . 0.0 110.143 -179.46 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -64.77 -30.05 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.054 -1.029 . . . . 0.0 109.028 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -154.47 55.47 0.69 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.352 -0.842 . . . . 0.0 109.208 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.518 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.82 137.05 50.64 Favored Pre-proline 0 N--CA 1.486 1.331 0 O-C-N 121.079 -1.013 . . . . 0.0 110.106 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.15 -153.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 121.925 1.75 . . . . 0.0 110.837 179.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.483 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -82.16 15.31 2.42 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 108.838 179.484 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.483 HG23 ' OD1' ' A' ' 18' ' ' ASP . 44.7 t -112.96 137.15 46.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.623 -0.673 . . . . 0.0 109.912 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.69 137.76 88.13 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.911 . . . . 0.0 109.06 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -48.94 -31.01 19.03 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.87 1.713 . . . . 0.0 112.152 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.27 -16.61 64.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.89 . . . . 0.0 109.427 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -102.2 8.81 40.46 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.172 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.86 136.47 31.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.4 90.12 0.51 Allowed 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.595 HG23 ' HB2' ' A' ' 8' ' ' ALA . 7.1 p -59.17 6.22 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.327 -0.858 . . . . 0.0 109.845 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -90.12 5.79 45.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.068 -1.02 . . . . 0.0 108.852 179.393 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.5 tp -94.39 136.25 34.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.468 -0.77 . . . . 0.0 109.449 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.498 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.2 m-20 -62.53 121.65 13.82 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.59 13.91 0.09 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.282 -0.886 . . . . 0.0 110.03 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.498 ' H ' ' C ' ' A' ' 29' ' ' ASP . 79.6 t -55.15 -42.38 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 0.0 108.702 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.61 -35.36 65.77 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.909 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -84.29 14.39 4.41 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.91 -14.53 0.01 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.43 -34.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.19 -1.183 . . . . 0.0 108.817 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -69.84 -24.34 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.463 -0.773 . . . . 0.0 110.11 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 82.9 m-20 -57.11 -34.76 68.68 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 111.33 -178.3 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.65 -64.79 1.11 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.851 -1.156 . . . . 0.0 111.381 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.415 HD21 ' NZ ' ' A' ' 43' ' ' LYS . 7.3 tt -70.88 -52.36 20.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.071 -1.018 . . . . 0.0 110.93 -178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.39 -36.83 92.15 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.706 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.76 -42.09 88.08 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.451 -1.029 . . . . 0.0 109.484 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -61.88 -44.09 97.53 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.175 -0.953 . . . . 0.0 108.54 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . 0.415 ' NZ ' HD21 ' A' ' 39' ' ' LEU . 54.3 mttp -70.09 -38.33 75.64 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.426 -0.796 . . . . 0.0 109.897 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.8 t -64.09 -45.14 97.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 110.372 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -60.8 -44.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.727 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.37 -41.78 96.52 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.89 . . . . 0.0 110.106 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -76.44 -43.47 39.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.929 . . . . 0.0 110.097 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.04 -44.43 87.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -0.947 . . . . 0.0 109.668 -179.396 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.3 tt0 -64.69 -38.17 90.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.17 -0.956 . . . . 0.0 109.088 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -71.42 -48.94 46.46 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.378 -0.826 . . . . 0.0 110.623 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -62.41 -42.47 99.46 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.362 -0.836 . . . . 0.0 111.279 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.765 ' CE1' HG21 ' A' ' 80' ' ' THR . 98.6 m-85 -101.2 -6.52 24.14 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.866 -1.146 . . . . 0.0 110.353 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.98 28.25 73.73 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.0 mt -101.55 137.01 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.281 -1.129 . . . . 0.0 109.192 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.95 57.38 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.076 -1.015 . . . . 0.0 109.291 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.71 -36.82 79.78 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.27 -0.894 . . . . 0.0 109.441 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -61.39 -33.26 73.39 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -50.72 -34.59 27.51 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.836 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.8 t -101.4 135.87 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.187 -0.945 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -89.51 141.81 28.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.471 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.407 HD13 HD21 ' A' ' 41' ' ' LEU . 36.5 mt -97.31 134.26 40.83 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.74 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.48 153.19 8.46 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.216 -0.928 . . . . 0.0 109.226 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.07 -28.58 80.31 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.487 2.125 . . . . 0.0 111.964 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.05 -29.56 70.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.368 -0.833 . . . . 0.0 109.572 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.65 -26.97 66.48 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.347 -0.846 . . . . 0.0 109.75 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.578 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 96.1 m-85 -103.49 6.82 37.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 110.161 -179.448 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.7 tpt180 -58.35 -41.69 85.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.029 -1.044 . . . . 0.0 109.904 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -153.74 158.86 41.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.902 -1.124 . . . . 0.0 110.116 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.441 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -62.74 -36.98 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.34 -0.85 . . . . 0.0 109.871 179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.657 ' NH2' ' SD ' ' A' ' 1' ' ' MET . 4.6 tpm_? -60.7 -40.86 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.25 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.25 -44.07 95.58 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.102 -0.999 . . . . 0.0 109.695 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.5 mt -66.11 -39.76 85.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.225 -0.922 . . . . 0.0 109.79 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.667 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.5 t0 -58.02 -38.41 76.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.396 -0.815 . . . . 0.0 109.857 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.5 -46.2 80.61 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.207 -0.933 . . . . 0.0 109.847 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -66.6 -41.63 88.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.091 -1.006 . . . . 0.0 109.225 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -64.9 -42.48 94.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.349 -0.845 . . . . 0.0 109.706 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.667 HG23 ' O ' ' A' ' 73' ' ' ASP . 72.6 t -63.1 -41.46 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.253 -0.904 . . . . 0.0 109.79 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.0 -30.33 66.51 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.44 -48.08 4.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -1.22 . . . . 0.0 110.21 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.765 HG21 ' CE1' ' A' ' 52' ' ' PHE . 7.2 t -143.3 155.53 44.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.184 -0.947 . . . . 0.0 109.737 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.2 t . . . . . 0 C--N 1.303 -1.434 0 O-C-N 121.29 -0.881 . . . . 0.0 109.281 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.241 0.543 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.872 ' OE1' HG21 ' A' ' 81' ' ' THR . 90.6 mt-30 -82.08 135.05 35.37 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.32 -0.862 . . . . 0.0 108.745 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 56.4 m80 55.62 38.37 30.09 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.182 -0.949 . . . . 0.0 108.959 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -58.93 -34.0 71.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -0.806 . . . . 0.0 109.548 -179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.02 -38.64 79.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.21 -0.931 . . . . 0.0 109.679 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 10' ' ' PHE . 53.2 t -64.4 -37.61 80.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.157 -0.964 . . . . 0.0 109.595 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.49 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.4 mt -59.3 -50.42 79.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.37 -0.831 . . . . 0.0 109.618 -179.574 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.741 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -42.66 97.34 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.154 -0.966 . . . . 0.0 108.787 179.28 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.36 -34.77 77.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.645 -0.659 . . . . 0.0 109.613 179.444 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.457 ' N ' ' O ' ' A' ' 6' ' ' VAL . 58.3 t80 -59.57 -53.11 61.83 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.397 -0.814 . . . . 0.0 110.352 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' N ' ' A' ' 12' ' ' VAL . 34.2 m -74.4 -40.88 49.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.101 -0.999 . . . . 0.0 109.948 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.0 t -64.91 -37.6 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.309 -0.87 . . . . 0.0 110.451 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -56.64 -30.65 63.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.072 -1.018 . . . . 0.0 109.853 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.529 ' OE2' ' CD1' ' A' ' 36' ' ' ILE . 84.4 tt0 -65.27 -31.27 72.33 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.719 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.672 ' CE2' ' ND2' ' A' ' 33' ' ' ASN . 32.3 p90 -143.06 46.17 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 109.774 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.859 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.58 136.07 52.4 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.061 -1.024 . . . . 0.0 110.157 -179.837 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_endo -77.62 -149.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 122.143 1.895 . . . . 0.0 110.308 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.565 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.63 12.08 2.76 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.803 -1.185 . . . . 0.0 108.782 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.565 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.5 t -113.35 136.2 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.579 -0.701 . . . . 0.0 109.805 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.43 84.15 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.971 . . . . 0.0 108.85 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.415 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.1 Cg_exo -48.23 -30.71 15.36 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.775 1.65 . . . . 0.0 112.129 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -23.81 66.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 0.0 109.348 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -98.94 3.44 47.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.105 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.0 t -104.88 137.03 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -63.65 99.28 0.22 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.198 -0.939 . . . . 0.0 109.514 -179.443 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB1' ' A' ' 8' ' ' ALA . 15.1 m -60.91 6.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.557 179.733 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -88.77 11.29 18.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.171 -0.956 . . . . 0.0 108.905 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.5 tp -82.59 131.72 35.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.98 122.22 17.75 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.349 -0.845 . . . . 0.0 109.063 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.692 HD11 HG12 ' A' ' 69' ' ' ILE . 66.2 mt -62.97 -10.12 12.5 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.341 -0.849 . . . . 0.0 109.491 -179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.461 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.9 p -50.19 -39.44 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.099 -1.001 . . . . 0.0 109.245 -179.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.7 m-20 -58.08 -37.66 74.92 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.672 ' ND2' ' CE2' ' A' ' 15' ' ' PHE . 28.7 m120 -87.6 15.5 6.69 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 178.951 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.4 -18.37 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.003 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -52.48 -35.37 20.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 120.797 -1.414 . . . . 0.0 108.185 179.163 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.8 tt -71.19 -25.06 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.589 -0.694 . . . . 0.0 109.869 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -62.82 -30.19 71.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.302 -0.874 . . . . 0.0 110.999 -178.521 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.6 m -104.95 -65.14 1.06 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.006 -1.059 . . . . 0.0 111.178 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.452 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -74.17 -52.14 13.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.162 -0.961 . . . . 0.0 111.069 -178.262 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.528 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.86 -38.93 96.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.7 -42.12 98.52 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -1.084 . . . . 0.0 109.593 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.568 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -58.73 -44.17 90.39 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.097 -1.002 . . . . 0.0 108.541 -179.562 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -66.82 -37.84 85.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.188 -0.945 . . . . 0.0 109.331 179.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.0 t -67.44 -47.85 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.398 -0.813 . . . . 0.0 111.102 -179.115 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -60.84 -43.49 95.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.727 -1.233 . . . . 0.0 109.922 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -45.29 76.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.063 . . . . 0.0 110.191 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.5 t90 -77.22 -46.84 21.89 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 110.09 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.469 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 11.6 tp -56.97 -41.01 77.59 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.377 -0.827 . . . . 0.0 109.818 -179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.605 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.5 tt0 -61.4 -42.52 98.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.982 -1.074 . . . . 0.0 108.955 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.9 -36.98 83.51 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.245 -0.909 . . . . 0.0 109.55 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.7 ttt85 -59.98 -46.31 89.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 111.137 -178.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -117.21 0.17 12.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.14 -0.975 . . . . 0.0 110.94 -179.066 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.605 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.68 40.37 65.91 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.9 mt -96.0 141.43 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.214 -1.168 . . . . 0.0 109.225 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.86 140.67 58.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.004 -1.06 . . . . 0.0 109.427 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.09 -32.22 72.75 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.338 -0.851 . . . . 0.0 109.381 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -91.03 9.82 29.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.335 -0.853 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -52.9 -34.11 53.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.626 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.06 158.9 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.463 -0.773 . . . . 0.0 109.604 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.492 ' C ' HD12 ' A' ' 61' ' ' LEU . 95.5 mt-10 -93.16 150.59 20.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.885 . . . . 0.0 109.303 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.86 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.4 mp -98.12 132.24 43.81 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 109.801 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.77 143.51 3.94 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.21 -0.931 . . . . 0.0 109.058 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.81 -24.92 74.54 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.146 1.898 . . . . 0.0 112.104 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.27 -32.52 74.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.236 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -72.89 -26.67 61.52 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.322 -0.861 . . . . 0.0 111.318 -178.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -97.85 11.04 38.66 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.77 -1.206 . . . . 0.0 110.953 -178.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -58.56 -34.29 70.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.936 -1.102 . . . . 0.0 109.952 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -145.78 151.0 37.26 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.031 -1.043 . . . . 0.0 110.018 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.692 HG12 HD11 ' A' ' 30' ' ' LEU . 82.4 mt -66.27 -36.74 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.405 -0.809 . . . . 0.0 109.846 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.0 ttp180 -60.69 -39.09 87.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.574 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -58.28 -42.41 86.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.984 -1.073 . . . . 0.0 109.927 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.4 mt -68.03 -39.24 81.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.49 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.3 t0 -59.13 -41.21 87.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.347 -0.846 . . . . 0.0 110.474 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.09 -43.11 88.24 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.123 -0.986 . . . . 0.0 110.212 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -62.7 -48.67 78.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.179 -0.951 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.608 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.37 -46.33 90.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.235 -0.916 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.451 HG23 ' OD2' ' A' ' 73' ' ' ASP . 41.4 t -59.62 -39.55 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 O-C-N 121.068 -1.02 . . . . 0.0 109.534 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.82 -32.63 66.24 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.8 -49.61 3.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -1.234 . . . . 0.0 110.479 -179.354 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.608 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.1 t -158.52 149.92 20.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 0.0 109.547 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.872 HG21 ' OE1' ' A' ' 2' ' ' GLN . 10.1 t . . . . . 0 N--CA 1.489 1.488 0 O-C-N 121.292 -0.88 . . . . 0.0 109.182 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.407 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 86.9 mmm . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 8.9 tp-100 -98.99 119.57 38.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.361 -0.837 . . . . 0.0 109.229 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.6 m-70 46.85 30.25 1.17 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.195 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.93 -35.8 79.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.697 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.9 -38.55 82.61 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.0 109.859 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -64.28 -41.06 91.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 90.6 mt -59.53 -43.52 91.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.338 -0.851 . . . . 0.0 109.739 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.738 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.38 -47.74 80.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.21 -0.931 . . . . 0.0 109.158 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.69 -33.14 72.13 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.357 -0.839 . . . . 0.0 109.591 179.611 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -59.86 -53.12 61.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.167 -0.958 . . . . 0.0 110.19 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' ' CE1' ' A' ' 15' ' ' PHE . 34.6 m -74.41 -40.67 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.147 -0.97 . . . . 0.0 110.193 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 8' ' ' ALA . 64.2 t -64.91 -36.35 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.354 -0.841 . . . . 0.0 110.588 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.46 -33.94 66.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 109.931 -179.16 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -65.68 -32.18 73.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.269 -0.894 . . . . 0.0 109.871 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.745 ' CE2' ' ND2' ' A' ' 33' ' ' ASN . 7.8 p90 -138.27 45.82 2.07 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.145 -0.972 . . . . 0.0 109.931 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.869 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 135.74 53.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.951 -1.093 . . . . 0.0 109.946 -179.823 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.58 -150.38 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.105 1.87 . . . . 0.0 110.264 178.431 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.558 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.52 12.09 2.69 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.8 -1.187 . . . . 0.0 108.708 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.558 HG23 ' OD2' ' A' ' 18' ' ' ASP . 25.6 t -113.64 136.64 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.549 -0.719 . . . . 0.0 109.818 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.89 139.58 82.95 Favored Pre-proline 0 N--CA 1.488 1.444 0 O-C-N 121.152 -0.967 . . . . 0.0 108.751 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.52 -31.74 19.07 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 121.699 1.599 . . . . 0.0 111.966 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.17 -26.6 67.49 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.301 -0.874 . . . . 0.0 109.395 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -103.34 4.8 36.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -99.22 144.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.326 -0.859 . . . . 0.0 108.695 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.3 t0 -71.82 95.06 1.47 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.034 -1.041 . . . . 0.0 109.357 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.48 ' O ' HD12 ' A' ' 69' ' ' ILE . 18.9 m -62.25 6.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.342 -0.849 . . . . 0.0 109.588 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.6 m-20 -90.77 12.08 20.34 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.184 -0.948 . . . . 0.0 109.017 179.605 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 tp -84.53 133.87 34.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.433 -0.792 . . . . 0.0 109.484 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -65.21 122.34 16.87 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.271 -0.893 . . . . 0.0 108.824 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.74 HD11 HG12 ' A' ' 69' ' ' ILE . 67.3 mt -64.92 -6.28 8.04 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.249 -0.907 . . . . 0.0 109.618 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 73.0 t -50.91 -45.06 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.021 . . . . 0.0 108.904 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.7 -35.99 69.14 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.745 ' ND2' ' CE2' ' A' ' 15' ' ' PHE . 25.2 m-20 -86.02 15.24 5.19 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.94 -16.88 0.02 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.76 -38.05 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 120.867 -1.372 . . . . 0.0 108.267 179.126 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.616 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.09 -25.3 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.538 -0.726 . . . . 0.0 110.324 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.7 m-20 -59.68 -35.65 74.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 111.105 -178.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.31 -64.22 1.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.13 -0.981 . . . . 0.0 111.556 -178.419 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -69.99 -52.09 27.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.057 -1.027 . . . . 0.0 111.301 -178.056 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -69.3 -36.75 79.41 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.249 -179.295 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.616 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tp -58.43 -47.83 82.67 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.335 -1.097 . . . . 0.0 109.582 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.5 mt -61.38 -42.62 99.01 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.109 -0.995 . . . . 0.0 109.77 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -63.63 -39.66 94.92 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.402 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.478 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.2 t -70.22 -49.7 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.268 -0.895 . . . . 0.0 110.554 -179.593 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -62.17 -40.48 87.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 120.959 -1.088 . . . . 0.0 109.948 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.18 -45.99 75.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.081 -1.012 . . . . 0.0 110.039 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.6 OUTLIER -77.61 -47.05 20.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.145 -0.972 . . . . 0.0 109.635 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.478 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 31.4 tp -56.75 -39.2 73.57 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.433 -0.792 . . . . 0.0 109.466 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.611 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.0 tm-20 -61.53 -42.74 99.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.953 . . . . 0.0 109.466 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' OE2' ' A' ' 49' ' ' GLU . 20.9 t70 -64.33 -39.45 93.93 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.071 -1.018 . . . . 0.0 109.71 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -66.19 -45.53 80.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 111.549 -178.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -111.17 -1.49 16.15 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.98 -1.075 . . . . 0.0 111.151 -178.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.611 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.67 38.48 67.42 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.54 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 72.5 mt -88.44 145.38 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.103 -1.233 . . . . 0.0 109.37 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.96 122.9 16.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.109 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.08 -19.72 56.69 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.468 -0.77 . . . . 0.0 109.741 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.03 11.06 5.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.352 -0.842 . . . . 0.0 110.165 -179.261 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.94 112.37 16.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.03 -1.044 . . . . 0.0 109.527 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.1 m -116.58 18.13 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.56 -0.713 . . . . 0.0 109.313 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -55.7 -28.27 54.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.827 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.676 HD21 ' CZ ' ' A' ' 75' ' ' PHE . 64.0 mt -77.21 142.09 39.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.092 -1.005 . . . . 0.0 109.905 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.92 164.78 21.46 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -51.98 -33.13 51.0 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.349 2.033 . . . . 0.0 111.54 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -66.72 -27.42 67.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.512 -0.742 . . . . 0.0 109.251 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 19.6 t-80 -67.63 -26.62 66.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.377 -0.827 . . . . 0.0 109.768 -179.627 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -90.24 11.91 19.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.208 -0.933 . . . . 0.0 109.282 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 -53.82 -37.64 63.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.381 -0.825 . . . . 0.0 109.792 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.4 p -146.14 157.17 43.83 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.044 -1.035 . . . . 0.0 110.036 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.74 HG12 HD11 ' A' ' 30' ' ' LEU . 84.8 mt -64.36 -36.82 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.336 -0.853 . . . . 0.0 110.076 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 43.8 ttp180 -60.57 -40.55 92.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.314 -0.866 . . . . 0.0 110.381 -179.018 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -62.55 -38.64 90.83 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.012 -1.055 . . . . 0.0 109.71 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.6 mt -68.23 -39.35 80.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.827 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.444 ' OD2' HG23 ' A' ' 77' ' ' VAL . 59.4 t0 -59.43 -41.14 88.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.363 -0.836 . . . . 0.0 110.334 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -43.29 86.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.098 -1.001 . . . . 0.0 110.512 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CZ ' HD21 ' A' ' 61' ' ' LEU . 67.3 t80 -61.96 -49.3 76.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.081 -1.012 . . . . 0.0 109.775 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 80' ' ' THR . 68.4 t -66.52 -44.74 90.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.268 -0.895 . . . . 0.0 109.825 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.444 HG23 ' OD2' ' A' ' 73' ' ' ASP . 47.3 t -63.03 -39.53 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.011 -1.056 . . . . 0.0 109.894 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.7 -33.97 69.05 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.39 -48.79 3.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -1.222 . . . . 0.0 110.644 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' HG12 ' A' ' 76' ' ' VAL . 60.2 m -158.36 137.86 11.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.125 -0.985 . . . . 0.0 109.839 -179.534 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.795 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.325 -0.859 . . . . 0.0 109.1 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.391 0.615 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.492 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 93.9 mt-30 -58.9 -36.61 74.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.062 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' HIS . . . . . 0.564 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -147.59 29.86 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.734 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.486 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.38 -32.5 71.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.427 -0.796 . . . . 0.0 110.008 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.0 p -58.97 -39.94 83.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.03 -1.044 . . . . 0.0 109.563 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.564 HG21 ' CE1' ' A' ' 3' ' ' HIS . 70.0 t -68.07 -39.07 80.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 108.44 178.982 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 82.2 mt -61.26 -50.48 80.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.502 -0.749 . . . . 0.0 109.151 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.739 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.36 -47.36 79.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.346 -0.846 . . . . 0.0 109.183 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -44.25 96.12 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.483 -0.76 . . . . 0.0 109.227 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.592 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.5 t80 -68.34 -48.85 63.73 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.626 0.727 . . . . 0.0 109.452 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.701 HG13 ' CD1' ' A' ' 36' ' ' ILE . 93.7 t -67.02 -45.41 87.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.601 -0.687 . . . . 0.0 109.901 -179.576 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.4 t -63.7 -37.74 80.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.272 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.5 -30.59 63.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.462 -0.774 . . . . 0.0 109.789 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.93 -32.21 73.82 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.201 -0.937 . . . . 0.0 109.357 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.453 ' HE1' HD12 ' A' ' 36' ' ' ILE . 6.9 p90 -147.01 52.86 1.08 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 109.112 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.3 136.58 52.94 Favored Pre-proline 0 N--CA 1.486 1.374 0 O-C-N 121.207 -0.933 . . . . 0.0 110.187 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.67 -152.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 121.815 1.676 . . . . 0.0 110.388 178.741 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -78.26 9.75 3.58 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.908 -1.12 . . . . 0.0 108.709 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -113.85 136.16 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.498 -0.751 . . . . 0.0 109.883 -179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.92 142.48 90.76 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.19 -0.944 . . . . 0.0 108.574 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -48.67 -32.4 21.53 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 121.593 1.529 . . . . 0.0 111.638 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.81 -25.27 65.49 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.372 -0.83 . . . . 0.0 109.395 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -105.01 6.42 33.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -96.6 143.4 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.282 -0.886 . . . . 0.0 108.762 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -72.39 92.33 1.42 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.126 -0.984 . . . . 0.0 109.365 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.3 m -62.79 6.23 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.9 m-20 -95.9 9.7 39.74 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 108.723 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 11.1 tp -90.22 135.6 33.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.487 -0.758 . . . . 0.0 109.561 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.585 ' OD2' ' NH2' ' A' ' 67' ' ' ARG . 90.0 m-20 -63.98 121.89 15.19 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.81 7.89 3.52 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.286 -0.884 . . . . 0.0 110.046 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.0 t -53.43 -42.79 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.063 -1.023 . . . . 0.0 108.636 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -55.74 -35.5 66.24 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.526 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.5 m120 -85.19 15.12 4.44 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.896 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.39 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.7 t -51.73 -37.33 20.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.014 -1.286 . . . . 0.0 108.547 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.701 ' CD1' HG13 ' A' ' 11' ' ' VAL . 2.5 tt -70.81 -25.24 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 0.0 110.426 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -58.1 -34.33 70.07 Favored 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 111.009 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.92 -64.29 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.984 -1.073 . . . . 0.0 111.575 -178.479 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.531 ' N ' HD22 ' A' ' 39' ' ' LEU . 4.2 mm? -72.37 -52.5 15.8 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.976 -1.078 . . . . 0.0 111.211 -178.091 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.522 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.02 91.37 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.3 tp -57.71 -43.95 85.59 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.365 -1.079 . . . . 0.0 109.208 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 42' ' ' LEU . 94.2 mt -63.64 -41.82 98.21 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 108.98 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -64.26 -36.95 85.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.413 -0.804 . . . . 0.0 109.53 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 40' ' ' GLY . 74.8 t -62.66 -45.57 98.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.379 -0.825 . . . . 0.0 110.22 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.8 mm -61.35 -44.24 98.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.146 -0.971 . . . . 0.0 109.829 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.0 -43.78 91.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.242 -0.911 . . . . 0.0 109.766 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.592 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -73.39 -38.92 65.46 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.796 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 28.5 tp -59.69 -43.34 94.07 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.2 -0.938 . . . . 0.0 109.917 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.577 ' O ' ' N ' ' A' ' 53' ' ' GLY . 59.3 tt0 -65.16 -36.09 83.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 109.951 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -60.59 -38.99 86.47 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.984 -1.072 . . . . 0.0 110.125 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 mtp180 -74.67 -44.65 49.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.143 -0.973 . . . . 0.0 112.079 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -108.11 -7.17 16.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.765 -1.209 . . . . 0.0 111.354 -178.088 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.78 32.18 73.8 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.1 mt -91.22 152.42 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.257 -1.143 . . . . 0.0 109.835 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.1 150.48 29.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.075 -1.016 . . . . 0.0 109.008 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.85 -40.27 72.61 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.251 -0.906 . . . . 0.0 109.969 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 50.79 49.76 20.36 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.11 -0.994 . . . . 0.0 109.205 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -74.62 116.03 14.85 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.939 . . . . 0.0 109.909 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 ' H ' ' A' ' 61' ' ' LEU . 27.3 t -124.91 141.68 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 61' ' ' LEU . 19.8 pt-20 -60.5 -31.95 70.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.085 -1.009 . . . . 0.0 110.466 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.486 ' O ' ' O ' ' A' ' 60' ' ' GLU . 60.7 mt 44.04 -170.5 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.055 -1.028 . . . . 0.0 109.642 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -134.23 162.25 58.81 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.344 -0.848 . . . . 0.0 109.409 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.83 -26.81 83.76 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.756 2.304 . . . . 0.0 112.17 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -61.04 -31.53 71.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.39 -0.818 . . . . 0.0 109.909 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.8 t60 -68.07 -26.46 65.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.184 -0.948 . . . . 0.0 110.205 -179.512 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.432 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 94.1 m-85 -97.41 10.17 40.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 109.763 -179.474 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.585 ' NH2' ' OD2' ' A' ' 29' ' ' ASP . 34.2 tpt85 -55.61 -38.32 69.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.076 -1.015 . . . . 0.0 109.879 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -137.75 153.99 49.66 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.095 -1.003 . . . . 0.0 110.145 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.4 mt -62.68 -36.58 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.264 -0.898 . . . . 0.0 110.006 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -60.76 -36.78 79.8 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.235 -0.916 . . . . 0.0 110.251 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 90.5 p -61.37 -36.16 79.45 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.022 -1.049 . . . . 0.0 109.449 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.97 -38.96 83.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.238 -0.914 . . . . 0.0 109.097 179.522 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.712 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.3 t0 -57.51 -36.98 72.26 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.46 -0.775 . . . . 0.0 109.352 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.38 -43.53 98.71 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.224 -0.923 . . . . 0.0 109.222 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -65.04 -46.95 79.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.259 -0.9 . . . . 0.0 109.207 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 53.2 t -65.24 -40.58 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 121.45 -0.781 . . . . 0.0 109.712 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -58.99 -42.46 86.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.243 -0.91 . . . . 0.0 109.684 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.83 -35.02 91.4 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 120.222 -0.989 . . . . 0.0 110.645 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -86.29 -48.02 8.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.899 -1.353 . . . . 0.0 109.853 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.2 t -138.54 151.03 46.97 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.511 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.759 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t . . . . . 0 N--CA 1.487 1.414 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.302 0.573 . . . . 0.0 109.931 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLN . . . . . 0.484 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 98.5 mm-40 -87.07 123.76 32.49 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 11.8 m80 54.54 15.78 1.14 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.107 -0.996 . . . . 0.0 108.654 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.401 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -64.19 -39.81 94.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.459 -0.776 . . . . 0.0 110.196 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.72 -39.24 87.89 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.177 -0.952 . . . . 0.0 110.157 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.6 t -64.77 -37.69 80.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.158 -0.964 . . . . 0.0 109.307 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.402 ' O ' HG12 ' A' ' 11' ' ' VAL . 90.4 mt -63.98 -36.73 77.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 110.54 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.47 -51.09 67.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.959 -1.088 . . . . 0.0 110.049 -179.422 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLN . . . . . 0.41 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -70.92 -36.72 72.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.101 -0.999 . . . . 0.0 109.473 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.423 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 59.6 t80 -65.74 -51.32 60.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.345 -0.847 . . . . 0.0 109.97 -179.611 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.5 p -68.33 -41.87 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.925 . . . . 0.0 109.589 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.0 t -64.61 -39.32 85.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -0.928 . . . . 0.0 109.521 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.95 -28.16 55.75 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.392 -0.817 . . . . 0.0 109.731 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -65.09 -29.16 70.01 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.263 -0.898 . . . . 0.0 108.833 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.617 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 22.8 p90 -151.0 48.99 0.85 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.376 -0.827 . . . . 0.0 109.076 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.485 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -79.76 137.12 54.52 Favored Pre-proline 0 N--CA 1.487 1.4 0 O-C-N 120.975 -1.078 . . . . 0.0 110.343 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.83 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.974 1.782 . . . . 0.0 110.51 178.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.544 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.9 p30 -81.05 13.29 2.82 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.923 -1.111 . . . . 0.0 108.803 179.242 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.544 HG23 ' OD2' ' A' ' 18' ' ' ASP . 38.6 t -113.43 136.65 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.609 -0.682 . . . . 0.0 109.91 -179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.03 140.61 73.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.039 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -48.41 -31.75 18.6 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.795 1.664 . . . . 0.0 111.575 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.37 -21.87 65.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.519 -0.738 . . . . 0.0 109.412 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -97.6 1.61 48.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.421 -0.8 . . . . 0.0 109.119 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.2 t -107.09 137.54 37.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.65 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.0 t0 -70.56 99.87 1.72 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 109.319 -179.505 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.07 5.84 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.379 -0.826 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -96.4 9.19 42.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 0.0 108.748 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.3 tp -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.561 -0.712 . . . . 0.0 109.52 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . 0.411 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.0 m-20 -65.14 121.51 14.92 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 179.162 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.519 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -71.07 8.51 0.93 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.195 -0.94 . . . . 0.0 109.493 -179.231 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.459 ' O ' ' N ' ' A' ' 34' ' ' GLY . 57.0 t -56.39 -41.81 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.164 -0.96 . . . . 0.0 108.8 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -55.51 -34.09 64.33 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 178.696 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 3.6 m-20 -84.02 14.45 4.14 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.953 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.46 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.134 -1.187 . . . . 0.0 110.134 -179.116 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.8 t -52.09 -39.29 26.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 120.921 -1.341 . . . . 0.0 108.324 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.14 -25.2 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.605 -0.685 . . . . 0.0 110.118 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.6 m-20 -62.12 -32.1 72.64 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 110.797 -178.465 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.5 m -105.44 -64.93 1.09 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.004 -1.06 . . . . 0.0 111.306 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.0 tt -71.71 -52.15 19.25 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 0.0 111.19 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.1 -36.69 86.12 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.5 tp -58.53 -43.36 89.19 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.348 -1.089 . . . . 0.0 109.881 -179.051 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 93.9 mt -67.53 -44.11 79.15 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 110.111 -179.639 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -65.08 -35.03 79.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -63.21 -44.99 99.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.293 -0.879 . . . . 0.0 110.979 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.06 -43.85 93.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.655 -1.278 . . . . 0.0 110.062 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.29 -45.32 76.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.109 -0.994 . . . . 0.0 110.396 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.485 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -76.6 -44.63 33.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.167 -0.958 . . . . 0.0 109.957 -179.709 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.5 tp -57.02 -39.0 73.94 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.337 -0.852 . . . . 0.0 109.207 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' A' ' 53' ' ' GLY . 12.0 tt0 -60.87 -43.27 98.63 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.204 -0.935 . . . . 0.0 109.25 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.09 -40.04 90.5 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.199 -0.938 . . . . 0.0 110.025 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.423 ' NH2' ' CZ ' ' A' ' 10' ' ' PHE . 73.8 ttt180 -63.48 -45.94 88.44 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.252 -0.905 . . . . 0.0 111.177 -178.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -106.86 -5.3 18.42 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.002 -1.062 . . . . 0.0 110.63 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.602 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.63 34.04 72.44 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 71.9 mt -98.88 144.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.301 -1.117 . . . . 0.0 109.633 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.45 148.57 41.37 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.136 -0.978 . . . . 0.0 109.586 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.48 -29.8 68.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.442 -0.786 . . . . 0.0 109.693 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.96 ' O ' HG13 ' A' ' 59' ' ' VAL . 85.3 m-20 54.62 49.03 19.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.283 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' A' ' 58' ' ' ASP . 45.1 p30 -39.25 91.8 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.498 -0.751 . . . . 0.0 110.254 -179.683 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 ' O ' ' A' ' 57' ' ' ASP . 29.4 m -128.43 158.05 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 108.981 179.564 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.35 129.96 46.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 109.729 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.3 140.92 42.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.448 -0.782 . . . . 0.0 109.421 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.83 156.13 55.57 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.517 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.98 -26.59 83.44 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.666 2.244 . . . . 0.0 112.031 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.35 -30.87 71.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.328 -0.857 . . . . 0.0 109.715 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.408 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.0 t60 -67.74 -26.79 66.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 109.662 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -93.65 9.22 37.83 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.179 -0.951 . . . . 0.0 109.358 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 15.2 tpt180 -54.91 -39.59 68.96 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.807 -179.677 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -141.96 153.98 44.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.017 -1.052 . . . . 0.0 110.098 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.2 mt -59.09 -36.66 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.365 -0.834 . . . . 0.0 109.838 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.9 ttp180 -60.28 -39.13 85.77 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.268 -0.895 . . . . 0.0 110.234 -179.211 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 t -58.3 -44.08 88.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.016 -1.053 . . . . 0.0 109.619 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.494 HD11 HD11 ' A' ' 30' ' ' LEU . 80.0 mt -62.96 -38.74 82.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.177 -0.952 . . . . 0.0 109.427 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.606 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.6 t0 -56.8 -37.88 71.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.396 -0.815 . . . . 0.0 109.702 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.78 -42.57 97.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.2 -0.938 . . . . 0.0 109.672 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.408 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.8 t80 -64.07 -48.34 76.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.148 -0.97 . . . . 0.0 109.459 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.75 -42.4 92.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.355 -0.841 . . . . 0.0 109.982 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.9 t -63.14 -40.89 90.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.167 -0.958 . . . . 0.0 109.903 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.7 -33.78 74.13 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.16 -47.99 4.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.046 -1.267 . . . . 0.0 110.506 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.8 m -128.68 138.16 52.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.341 -0.849 . . . . 0.0 109.943 -179.62 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.793 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.438 0 O-C-N 121.308 -0.87 . . . . 0.0 109.185 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.8 mtm . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 121.171 0.51 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.818 ' OE1' HG13 ' A' ' 77' ' ' VAL . 89.7 mt-30 55.64 53.21 9.87 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.402 -0.811 . . . . 0.0 109.14 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.58 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.0 m80 77.14 41.46 0.15 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.671 -0.643 . . . . 0.0 109.43 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.421 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.6 -33.41 73.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.296 -0.877 . . . . 0.0 109.444 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.16 -35.94 80.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.169 -0.957 . . . . 0.0 109.748 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.65 HG11 ' H ' ' A' ' 84' ' ' VAL . 74.7 t -65.88 -39.8 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 0.0 109.123 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.421 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.1 mt -59.49 -49.58 83.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.432 -0.792 . . . . 0.0 109.298 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -41.79 98.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.2 -0.938 . . . . 0.0 108.534 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.43 -37.33 86.58 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.464 -0.773 . . . . 0.0 109.172 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.402 ' CZ ' ' HG3' ' A' ' 87' ' ' LYS . 33.6 t80 -59.94 -52.99 63.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.544 -0.723 . . . . 0.0 110.044 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.711 HG21 HD13 ' A' ' 30' ' ' LEU . 4.6 p -73.49 -42.39 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.213 -0.929 . . . . 0.0 109.889 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.6 t -64.45 -38.12 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.337 -0.852 . . . . 0.0 110.411 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -56.15 -26.51 50.6 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.691 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.454 ' OE1' HD12 ' A' ' 36' ' ' ILE . 98.0 mt-10 -64.26 -31.11 72.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 109.168 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -153.96 52.88 0.69 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 109.316 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.513 ' CB ' HG12 ' A' ' 12' ' ' VAL . 1.7 pt? -80.74 136.61 51.33 Favored Pre-proline 0 N--CA 1.486 1.334 0 O-C-N 120.964 -1.085 . . . . 0.0 110.023 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.4 -153.81 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.007 1.805 . . . . 0.0 110.773 178.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -82.85 16.7 2.15 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.075 -1.016 . . . . 0.0 108.839 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.419 HG23 ' OD2' ' A' ' 18' ' ' ASP . 40.2 t -112.85 138.02 43.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.56 -0.712 . . . . 0.0 110.03 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.78 137.16 96.07 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.247 -0.908 . . . . 0.0 108.651 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -48.35 -29.99 14.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.836 1.691 . . . . 0.0 112.016 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.31 -24.06 66.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.325 -0.859 . . . . 0.0 109.486 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -101.18 8.18 42.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 109.452 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -100.99 137.5 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.324 -0.86 . . . . 0.0 108.875 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.572 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.91 90.96 0.14 Allowed 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.194 -0.941 . . . . 0.0 109.367 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.512 ' O ' HD12 ' A' ' 69' ' ' ILE . 6.3 m -61.74 6.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.345 -0.847 . . . . 0.0 109.551 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.572 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -92.05 12.44 21.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.213 -0.929 . . . . 0.0 109.135 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.2 tp -85.27 134.21 34.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.862 . . . . 0.0 109.613 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.507 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -64.3 121.54 14.54 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.369 -0.832 . . . . 0.0 109.065 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 67.6 mt -63.62 -8.14 9.17 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.188 -0.945 . . . . 0.0 109.602 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.483 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.33 -41.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.058 -1.027 . . . . 0.0 108.904 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.483 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.2 m-20 -59.2 -34.92 72.73 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.644 ' O ' ' N ' ' A' ' 35' ' ' VAL . 83.1 m-20 -85.19 16.9 3.27 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.45 -14.81 0.01 OUTLIER Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.644 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.1 t -51.85 -39.56 25.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 120.909 -1.348 . . . . 0.0 108.07 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.9 tt -71.31 -25.03 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.635 -0.666 . . . . 0.0 110.319 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -60.48 -32.09 71.08 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.215 -0.928 . . . . 0.0 111.432 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.565 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.14 -65.05 1.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.892 -1.13 . . . . 0.0 111.405 -178.348 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 16.2 mt -74.01 -52.43 12.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.022 -1.048 . . . . 0.0 111.124 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.62 -35.83 91.63 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -179.406 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.62 -42.23 87.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.232 -1.157 . . . . 0.0 109.121 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -63.35 -44.14 95.68 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.161 -0.962 . . . . 0.0 109.011 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -68.38 -41.08 81.06 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -67.59 -46.94 81.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.4 -0.812 . . . . 0.0 110.177 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.23 -45.01 99.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.542 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.42 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.192 -0.942 . . . . 0.0 109.999 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.751 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.27 -49.37 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 110.085 -179.744 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.8 tp -61.8 -41.39 97.69 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.55 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.9 pt-20 -70.57 -35.66 73.19 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.17 -0.956 . . . . 0.0 109.829 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -61.59 -41.95 98.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.248 -0.907 . . . . 0.0 110.092 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.751 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 86.0 mtt180 -64.4 -38.82 92.36 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 111.133 -179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' HG21 ' A' ' 80' ' ' THR . 96.7 m-85 -102.85 -4.54 24.71 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.96 -1.087 . . . . 0.0 110.244 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 61.75 35.37 91.14 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.4 mt -90.19 141.2 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -1.189 . . . . 0.0 109.849 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.0 136.26 50.24 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.025 -1.047 . . . . 0.0 108.9 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.57 -35.23 79.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.089 -1.007 . . . . 0.0 109.482 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.619 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.7 p30 -65.87 -25.93 67.4 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.35 -0.844 . . . . 0.0 110.024 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.619 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 54.3 t0 -54.27 -35.83 62.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.778 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 43.7 t -111.64 136.94 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.444 -0.785 . . . . 0.0 109.708 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -88.28 142.26 27.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 109.287 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.479 HD13 HD22 ' A' ' 41' ' ' LEU . 35.9 mt -93.05 135.28 34.37 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.223 -0.923 . . . . 0.0 109.697 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -162.27 150.35 12.06 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.269 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.42 -27.07 76.99 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.473 2.115 . . . . 0.0 112.065 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.64 -30.57 71.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.401 -0.812 . . . . 0.0 109.747 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -67.65 -27.05 66.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.743 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.451 ' CE2' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -102.69 10.34 38.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.234 -0.916 . . . . 0.0 109.73 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.453 HH22 ' CB ' ' A' ' 29' ' ' ASP . 32.8 tpt85 -54.15 -39.03 66.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.506 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.9 p -147.79 151.87 36.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.076 -1.015 . . . . 0.0 109.873 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 83.7 mt -66.1 -37.29 79.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.293 -0.879 . . . . 0.0 109.892 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -61.32 -38.44 86.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 -179.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.9 p -62.93 -40.45 97.66 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.007 -1.058 . . . . 0.0 109.581 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.3 mt -68.33 -40.97 83.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.185 -0.947 . . . . 0.0 109.74 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.46 -40.69 87.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.383 -0.823 . . . . 0.0 110.156 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.14 -43.05 88.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.125 -0.984 . . . . 0.0 110.001 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.33 -50.22 72.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.619 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.7 -44.84 93.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.818 HG13 ' OE1' ' A' ' 2' ' ' GLN . 48.8 t -60.08 -39.5 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.102 -0.999 . . . . 0.0 109.445 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.77 -32.95 66.52 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.51 -49.47 3.55 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.09 -1.241 . . . . 0.0 110.634 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.619 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.7 t -160.47 152.31 19.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.126 -0.983 . . . . 0.0 109.887 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 10.3 t -131.46 90.11 38.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.228 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -91.78 114.39 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 123.194 2.596 . . . . 0.0 112.963 -179.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -78.28 133.64 12.19 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 C-N-CA 122.003 1.802 . . . . 0.0 111.822 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.65 ' H ' HG11 ' A' ' 6' ' ' VAL . 37.6 t -126.09 133.49 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.322 -0.861 . . . . 0.0 109.644 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.82 -36.14 83.37 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.44 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.419 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -150.35 151.68 33.25 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.402 ' HG3' ' CZ ' ' A' ' 10' ' ' PHE . 13.5 tttm -59.54 -37.34 78.15 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.148 -0.97 . . . . 0.0 109.641 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.1 tp -56.65 -37.63 71.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -0.923 . . . . 0.0 109.454 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.459 179.983 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.565 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.577 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 83.8 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.264 0.554 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -59.11 -38.04 78.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.543 ' HD1' HG22 ' A' ' 84' ' ' VAL . 26.2 m-70 -114.57 11.32 17.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.486 -0.759 . . . . 0.0 109.296 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -56.66 -39.47 73.8 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.956 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.528 ' HB2' ' HZ2' ' A' ' 87' ' ' LYS . 89.2 p -63.99 -36.04 82.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.008 -1.057 . . . . 0.0 109.432 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -68.79 -36.09 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.534 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.66 ' O ' HG22 ' A' ' 11' ' ' VAL . 98.7 mt -59.13 -50.42 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -0.917 . . . . 0.0 109.996 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.84 -47.86 79.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.994 -1.066 . . . . 0.0 109.004 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.74 -41.22 98.06 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 121.347 0.594 . . . . 0.0 110.015 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -66.14 -51.36 58.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.32 -0.863 . . . . 0.0 111.145 -178.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.66 HG22 ' O ' ' A' ' 7' ' ' ILE . 17.1 m -72.38 -43.59 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.949 . . . . 0.0 110.848 -178.714 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.53 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.1 t -62.89 -36.28 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -0.962 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -57.64 -37.59 73.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 109.508 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.69 -36.22 78.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.88 . . . . 0.0 110.303 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -91.8 -58.51 2.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 110.575 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.686 HD22 HG23 ' A' ' 19' ' ' VAL . 1.6 mt -128.98 87.58 54.12 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.347 -0.845 . . . . 0.0 110.443 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -91.48 -18.96 0.88 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.154 2.569 . . . . 0.0 112.116 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -75.96 -4.99 44.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 108.734 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.686 HG23 HD22 ' A' ' 16' ' ' LEU . 45.9 t -113.99 141.62 29.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -61.19 115.96 16.94 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 120.698 -1.251 . . . . 0.0 108.628 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -63.75 -23.76 69.15 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 121.462 1.442 . . . . 0.0 111.409 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.25 -13.82 60.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.467 -0.771 . . . . 0.0 110.073 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.474 ' CG ' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -82.79 7.51 14.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.985 -1.072 . . . . 0.0 109.234 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -100.7 135.29 37.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -64.72 86.78 0.05 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.065 -1.022 . . . . 0.0 109.384 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.497 HG11 ' HE2' ' A' ' 87' ' ' LYS . 16.3 m -61.84 5.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -100.1 5.5 44.92 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.002 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.1 141.37 30.32 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.704 -0.622 . . . . 0.0 109.459 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.458 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.1 m-20 -60.37 121.4 11.96 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -68.62 8.37 0.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.289 -0.882 . . . . 0.0 109.83 -178.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.78 -40.01 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.121 -0.987 . . . . 0.0 108.974 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.5 t0 -57.76 -35.46 70.79 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -85.71 14.87 5.24 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.63 -14.93 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.6 t -51.73 -36.44 18.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.172 -1.193 . . . . 0.0 108.803 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.595 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.1 tt -70.45 -24.93 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 110.315 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -59.59 -34.06 72.25 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 111.08 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.5 m -105.72 -64.5 1.14 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.086 -1.009 . . . . 0.0 111.503 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.591 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -71.42 -52.2 19.86 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.045 -1.034 . . . . 0.0 111.151 -178.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.28 -37.31 92.76 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.595 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.4 tp -58.76 -40.7 84.68 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.367 -1.078 . . . . 0.0 109.091 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.48 -43.45 94.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.333 -0.855 . . . . 0.0 108.805 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -64.35 -36.74 85.1 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 40' ' ' GLY . 58.5 t -60.25 -43.29 93.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.385 -0.822 . . . . 0.0 109.872 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.425 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 1.5 mp -60.35 -49.39 84.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.26 -42.06 96.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.905 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -71.46 -40.92 70.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.323 -0.86 . . . . 0.0 109.783 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.53 -46.39 86.88 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.324 -0.86 . . . . 0.0 109.519 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -65.41 -39.29 91.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.249 -0.907 . . . . 0.0 109.019 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -67.24 -36.79 82.39 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.391 -0.818 . . . . 0.0 110.51 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -86.22 -51.74 6.09 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.274 -0.891 . . . . 0.0 112.167 -178.146 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -93.67 -5.57 48.29 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.682 -1.261 . . . . 0.0 111.16 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.59 24.14 76.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.1 mt -92.97 144.12 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -1.096 . . . . 0.0 109.422 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.67 146.75 44.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.062 -1.024 . . . . 0.0 109.272 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -57.81 -33.21 68.35 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.352 -0.842 . . . . 0.0 109.569 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.964 ' O ' HG23 ' A' ' 59' ' ' VAL . 84.7 m-20 54.67 47.94 21.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.343 -0.848 . . . . 0.0 109.256 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.0 m-20 -42.86 90.45 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.447 -0.783 . . . . 0.0 109.875 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 57' ' ' ASP . 44.1 t -125.74 139.32 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -74.42 130.77 40.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.017 -1.052 . . . . 0.0 109.671 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.28 142.68 45.55 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.652 -0.655 . . . . 0.0 109.449 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.8 149.03 66.59 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.078 -1.014 . . . . 0.0 109.462 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.79 -20.85 72.28 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.529 2.153 . . . . 0.0 112.342 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.8 -32.48 73.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 110.259 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -68.34 -26.71 65.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.985 -1.072 . . . . 0.0 109.975 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -97.41 5.98 48.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.161 -0.962 . . . . 0.0 109.725 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -55.52 -41.19 72.79 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.521 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -128.19 147.45 50.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.0 mt -61.46 -36.3 72.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.318 -0.864 . . . . 0.0 109.828 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.8 mtm180 -60.8 -37.32 81.56 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 110.19 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.7 t -59.08 -43.95 91.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.09 -1.007 . . . . 0.0 109.816 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.49 -38.88 83.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.136 -0.977 . . . . 0.0 109.628 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 21.5 t70 -57.12 -38.38 73.36 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.329 -0.857 . . . . 0.0 109.774 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.5 -44.45 90.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.719 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 74.0 t80 -63.55 -45.31 91.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.103 -0.998 . . . . 0.0 109.478 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.4 t -64.37 -43.67 97.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.341 -0.849 . . . . 0.0 110.099 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -63.16 -42.38 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.061 -1.024 . . . . 0.0 109.822 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.24 -30.54 71.12 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.39 -47.84 5.01 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.05 -1.265 . . . . 0.0 110.409 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 14.0 t -140.7 153.66 46.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.219 -0.926 . . . . 0.0 109.909 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.805 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t -140.29 90.72 10.19 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.275 -0.891 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 53.5 Cg_endo -79.95 169.09 18.3 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.466 2.111 . . . . 0.0 112.097 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_exo -57.78 150.23 63.85 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.842 1.694 . . . . 0.0 111.784 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.543 HG22 ' HD1' ' A' ' 3' ' ' HIS . 36.7 t -103.38 131.45 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.312 -0.867 . . . . 0.0 109.699 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -129.68 150.12 51.14 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.46 -0.775 . . . . 0.0 109.303 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.18 145.77 55.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -0.952 . . . . 0.0 109.398 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.528 ' HZ2' ' HB2' ' A' ' 5' ' ' SER . 62.6 mttp -57.6 -34.3 69.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.8 mt -58.75 -35.2 72.36 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.221 -0.924 . . . . 0.0 109.443 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.961 -1.019 . . . . 0.0 109.389 -179.978 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.497 ' O3 ' ' C6 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.9 mtm . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.39 0.614 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.86 -38.39 82.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.287 -0.883 . . . . 0.0 109.59 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 59.8 m-70 -126.41 11.27 7.42 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.432 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.44 -36.52 76.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.148 -0.97 . . . . 0.0 109.849 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -62.09 -34.79 76.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 109.425 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.9 t -66.1 -36.63 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.35 -0.844 . . . . 0.0 109.264 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.72 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.1 mt -64.98 -41.89 93.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 110.325 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.564 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . . . -63.94 -50.64 67.86 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.03 -1.044 . . . . 0.0 110.514 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.06 -43.42 71.22 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -59.03 -43.64 91.64 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.981 -1.074 . . . . 0.0 109.26 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 7' ' ' ILE . 75.2 t -71.93 -49.73 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -0.836 . . . . 0.0 110.449 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -63.85 -36.85 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.225 -0.922 . . . . 0.0 110.045 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -61.36 -31.0 70.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.24 -0.913 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.64 -31.16 72.03 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.149 -0.97 . . . . 0.0 109.278 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -102.87 -58.8 1.81 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.24 -0.913 . . . . 0.0 110.548 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.849 HD12 HG23 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -131.12 88.59 44.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.308 -0.87 . . . . 0.0 111.317 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -86.31 -13.51 5.23 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.73 2.287 . . . . 0.0 111.798 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.37 -4.28 41.43 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.164 -0.96 . . . . 0.0 109.084 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.849 HG23 HD12 ' A' ' 16' ' ' LEU . 43.0 t -113.31 142.47 25.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.663 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.23 115.67 15.63 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.75 -1.219 . . . . 0.0 108.649 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -64.46 -25.41 63.22 Favored 'Trans proline' 0 N--CA 1.486 1.08 0 C-N-CA 121.527 1.485 . . . . 0.0 111.68 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.02 -14.29 61.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.354 -0.841 . . . . 0.0 109.178 179.24 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.663 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -82.62 2.92 30.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.838 . . . . 0.0 109.106 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -99.47 136.05 32.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.83 86.45 0.23 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.18 -0.95 . . . . 0.0 109.469 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.38 5.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.273 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -94.4 3.4 55.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 108.751 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.638 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.6 tt -97.14 138.66 34.3 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.539 -0.726 . . . . 0.0 109.496 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.638 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.8 m-20 -60.48 121.34 11.88 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.432 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 pp -65.34 5.7 0.37 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.793 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.8 p -50.57 -37.91 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.037 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.2 m-20 -57.71 -36.97 72.73 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -85.64 14.7 5.39 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -15.67 0.02 OUTLIER Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.41 -34.36 15.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.85 -1.382 . . . . 0.0 108.507 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -71.16 -24.36 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.554 -0.716 . . . . 0.0 109.883 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -57.91 -33.14 68.45 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.322 -0.861 . . . . 0.0 111.445 -178.18 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.2 m -105.83 -64.59 1.14 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.856 -1.153 . . . . 0.0 111.497 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.43 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -72.42 -52.22 16.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.937 -1.102 . . . . 0.0 110.805 -178.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.867 ' O ' HG22 ' A' ' 44' ' ' VAL . . . -65.45 -36.72 92.94 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.6 tp -58.52 -41.21 84.97 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.356 -1.085 . . . . 0.0 109.285 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.5 tp -65.8 -41.48 91.87 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.008 -1.057 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -70.22 -44.69 68.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 111.519 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.867 HG22 ' O ' ' A' ' 40' ' ' GLY . 16.0 m -72.43 -42.09 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.939 -1.1 . . . . 0.0 111.624 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -58.7 -47.8 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 120.845 -1.159 . . . . 0.0 110.241 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.06 -39.61 92.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 110.241 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.782 ' HE1' HH21 ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.17 -49.35 15.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.927 -1.108 . . . . 0.0 110.403 -179.602 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.1 tp -60.15 -46.0 91.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.232 -0.917 . . . . 0.0 110.134 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.536 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -66.81 -38.06 85.73 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.013 -1.054 . . . . 0.0 109.463 -179.924 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.69 -38.91 92.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.934 . . . . 0.0 109.584 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.782 HH21 ' HE1' ' A' ' 47' ' ' TRP . 43.1 mmm-85 -59.28 -38.97 81.47 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.542 -0.724 . . . . 0.0 110.143 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -95.84 0.95 52.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.167 -0.958 . . . . 0.0 110.089 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.11 37.95 63.73 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.2 mt -104.04 148.58 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.411 -1.052 . . . . 0.0 109.79 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.539 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -91.25 122.77 34.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 108.396 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.36 -38.98 93.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.08 -1.012 . . . . 0.0 109.745 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -62.1 -37.12 83.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 0.0 110.093 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.539 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 89.0 m-20 -57.14 -37.69 72.42 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.231 -0.918 . . . . 0.0 110.353 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.91 134.24 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.306 -0.871 . . . . 0.0 110.05 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -108.28 137.55 46.07 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.478 -0.764 . . . . 0.0 109.307 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.54 146.83 30.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.769 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.9 160.47 29.68 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.361 -0.837 . . . . 0.0 109.425 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -62.76 -32.21 78.22 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.799 2.333 . . . . 0.0 112.123 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -62.62 -29.01 70.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.399 -0.813 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.402 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 32.0 t-80 -67.84 -26.38 66.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.365 -0.834 . . . . 0.0 110.149 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -97.95 8.55 44.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.075 -1.015 . . . . 0.0 110.133 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -56.01 -41.07 74.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.193 -0.942 . . . . 0.0 109.355 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.3 m -128.8 145.73 51.11 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.5 mt -63.0 -39.64 85.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.119 -0.988 . . . . 0.0 109.855 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.6 mtm180 -61.54 -37.02 82.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.058 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -58.19 -38.88 77.58 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.121 -0.987 . . . . 0.0 109.638 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.408 ' HB ' HD13 ' A' ' 7' ' ' ILE . 71.0 mt -63.63 -42.3 95.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.323 -0.86 . . . . 0.0 109.612 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.74 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.4 t0 -59.48 -38.65 81.38 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.111 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 -46.07 80.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.087 -1.008 . . . . 0.0 110.05 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.402 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.5 t80 -63.38 -47.0 83.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.127 -0.983 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.528 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.4 t -64.75 -42.74 95.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.317 -0.864 . . . . 0.0 109.727 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.7 t -59.67 -41.47 85.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.239 -0.913 . . . . 0.0 109.845 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.65 -31.47 75.25 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 120.264 -0.97 . . . . 0.0 110.748 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -48.76 3.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.03 -1.277 . . . . 0.0 110.751 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -129.68 156.81 43.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.324 -0.86 . . . . 0.0 109.664 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.791 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t -140.25 89.48 10.85 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.13 -0.981 . . . . 0.0 109.381 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 14.0 Cg_exo -64.74 159.24 46.37 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.588 2.192 . . . . 0.0 112.021 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -59.37 150.62 73.83 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.659 2.24 . . . . 0.0 111.65 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.14 129.2 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.776 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -135.46 166.72 22.52 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.464 -0.772 . . . . 0.0 108.93 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.13 139.36 35.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.074 -1.016 . . . . 0.0 109.063 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.564 ' HE2' ' HB3' ' A' ' 8' ' ' ALA . 55.6 tttm -58.92 -35.89 73.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.193 -0.942 . . . . 0.0 109.55 -179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.58 -35.22 72.06 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -0.948 . . . . 0.0 109.433 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.957 -1.021 . . . . 0.0 109.423 179.958 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.482 ' S12' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.699 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 86.1 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.2 -38.27 82.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.771 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.615 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 73.4 m-70 -141.5 14.39 2.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.708 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -60.33 -33.4 72.34 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 110.097 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -61.26 -36.59 80.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.945 -1.097 . . . . 0.0 109.613 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.779 HG23 HG13 ' A' ' 84' ' ' VAL . 75.7 t -66.79 -39.68 84.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.089 -1.007 . . . . 0.0 108.819 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 91.1 mt -61.73 -50.3 80.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.032 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.725 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.31 -48.78 74.31 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.397 -0.814 . . . . 0.0 109.137 179.314 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.02 -44.76 95.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.551 -0.718 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 66.4 t80 -69.56 -48.44 60.31 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.559 -0.713 . . . . 0.0 109.525 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.665 HG13 ' CD1' ' A' ' 36' ' ' ILE . 94.3 t -66.8 -45.26 88.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.513 -0.742 . . . . 0.0 109.954 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.5 t -64.1 -37.24 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.374 -0.829 . . . . 0.0 109.523 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.57 -30.71 61.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.363 -0.836 . . . . 0.0 110.022 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.36 -29.69 70.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.104 -0.997 . . . . 0.0 109.298 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.617 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.3 p90 -149.2 50.04 0.97 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.374 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.477 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.16 136.86 53.23 Favored Pre-proline 0 N--CA 1.487 1.383 0 O-C-N 120.932 -1.105 . . . . 0.0 110.184 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.21 -153.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.96 1.773 . . . . 0.0 110.581 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -80.91 13.56 2.62 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.051 -1.031 . . . . 0.0 108.643 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.47 137.17 47.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.589 -0.694 . . . . 0.0 110.028 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.77 140.7 74.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.176 -0.953 . . . . 0.0 108.898 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -48.57 -30.96 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.891 1.727 . . . . 0.0 111.85 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.676 ' HB2' ' HB3' ' A' ' 87' ' ' LYS . . . -66.58 -23.4 66.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.326 -0.859 . . . . 0.0 109.49 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -96.43 3.06 53.06 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.35 -0.844 . . . . 0.0 109.063 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.8 t -105.91 136.94 38.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.0 t0 -70.91 96.3 1.27 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.075 -1.016 . . . . 0.0 109.428 -179.439 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.918 HG11 ' NZ ' ' A' ' 87' ' ' LYS . 14.3 m -61.7 6.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 109.589 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.56 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.9 m-20 -93.8 7.44 44.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 108.909 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.582 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.4 tt -92.61 135.14 34.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.593 -0.692 . . . . 0.0 109.642 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.582 ' O ' HD23 ' A' ' 28' ' ' LEU . 91.6 m-20 -62.01 121.64 13.5 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -70.51 9.68 0.59 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.202 -0.936 . . . . 0.0 109.519 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -52.15 -38.03 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.201 -0.937 . . . . 0.0 109.462 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -56.94 -36.76 70.64 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.621 ' O ' ' N ' ' A' ' 35' ' ' VAL . 75.7 m-20 -86.25 14.76 6.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.48 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.621 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.82 -34.26 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 120.928 -1.336 . . . . 0.0 108.509 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.665 ' CD1' HG13 ' A' ' 11' ' ' VAL . 3.4 tt -71.07 -24.47 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.7 . . . . 0.0 110.134 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -58.14 -34.1 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.36 -0.837 . . . . 0.0 111.51 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.562 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -104.98 -65.26 1.05 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.858 -1.151 . . . . 0.0 111.148 -178.54 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -69.71 -47.22 63.93 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.157 -0.964 . . . . 0.0 110.722 -178.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.437 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.1 -39.97 72.63 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.921 -1.133 . . . . 0.0 110.379 -179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.2 tt -58.66 -39.81 81.71 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.19 -1.182 . . . . 0.0 109.078 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -62.25 -44.18 97.15 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.458 -0.897 . . . . 0.0 108.67 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -69.54 -40.15 77.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.326 -0.858 . . . . 0.0 109.857 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.6 t -64.77 -45.9 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.363 -0.836 . . . . 0.0 110.268 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.69 -46.02 97.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.238 -0.913 . . . . 0.0 109.532 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.35 97.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 109.951 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.436 ' CZ2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -75.09 -40.73 59.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.918 . . . . 0.0 109.995 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.77 -43.88 85.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.252 -0.905 . . . . 0.0 109.639 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -64.18 -39.77 94.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.185 -0.947 . . . . 0.0 109.449 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -67.34 -45.28 76.85 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 110.836 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.6 ttt180 -70.02 -45.34 67.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.274 -0.891 . . . . 0.0 112.131 -178.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -103.38 -5.33 23.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.815 -1.178 . . . . 0.0 111.433 -178.088 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.09 27.68 73.61 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.5 mt -98.3 143.87 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -1.153 . . . . 0.0 109.451 -179.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.44 149.74 33.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.145 -0.972 . . . . 0.0 109.579 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.94 -31.93 63.36 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.431 -0.793 . . . . 0.0 109.529 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.52 43.86 29.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.365 -0.834 . . . . 0.0 109.582 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.618 ' O ' HD21 ' A' ' 61' ' ' LEU . 53.2 p30 -93.42 11.34 28.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.288 -0.883 . . . . 0.0 109.446 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 73.6 t -59.94 -41.05 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.305 -0.872 . . . . 0.0 109.97 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.556 ' O ' HD23 ' A' ' 61' ' ' LEU . 87.8 mt-10 -116.33 130.22 56.66 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.433 -0.792 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.618 HD21 ' O ' ' A' ' 58' ' ' ASP . 5.9 mt -121.89 141.92 50.79 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -158.27 105.55 1.69 Allowed Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.025 -1.047 . . . . 0.0 109.806 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HD3' ' N5 ' ' A' ' 101' ' ' PN7 . 30.7 Cg_exo -55.32 -21.66 30.12 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.792 1.661 . . . . 0.0 111.228 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.31 -30.99 71.55 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.52 -0.738 . . . . 0.0 109.508 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -69.19 -26.33 64.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.362 -0.836 . . . . 0.0 111.02 -179.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.68 5.67 49.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.98 -1.075 . . . . 0.0 111.368 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -60.2 -37.84 81.49 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.766 -1.208 . . . . 0.0 110.3 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.7 t -131.79 141.57 49.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.077 -1.014 . . . . 0.0 110.139 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.681 HD13 ' HB2' ' A' ' 8' ' ' ALA . 83.8 mt -62.84 -37.9 80.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.404 -0.81 . . . . 0.0 109.827 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -61.41 -37.21 82.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.265 -0.897 . . . . 0.0 110.244 -179.389 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -58.66 -40.37 83.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.102 -0.999 . . . . 0.0 109.496 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 72.0 mt -64.76 -38.74 83.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.299 -0.876 . . . . 0.0 109.314 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.573 ' O ' HG23 ' A' ' 77' ' ' VAL . 20.8 t70 -57.45 -39.17 75.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.281 -0.887 . . . . 0.0 109.797 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.32 92.75 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.088 -1.007 . . . . 0.0 109.464 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -64.81 -46.16 83.19 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.285 -0.884 . . . . 0.0 109.318 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.9 t -63.89 -43.47 97.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.287 -0.883 . . . . 0.0 109.802 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -60.86 -40.52 85.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.165 -0.959 . . . . 0.0 109.558 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.2 -32.39 67.45 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.27 -49.0 3.69 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.027 -1.278 . . . . 0.0 110.758 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.3 p -134.92 154.94 51.5 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.198 -0.939 . . . . 0.0 110.1 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.4 t -140.6 89.32 10.43 Favored Pre-proline 0 C--N 1.303 -1.42 0 O-C-N 121.198 -0.939 . . . . 0.0 109.0 179.208 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.592 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 79.1 Cg_endo -85.67 160.81 10.72 Favored 'Trans proline' 0 C--N 1.311 -1.443 0 C-N-CA 122.878 2.385 . . . . 0.0 112.993 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.15 150.9 82.27 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 123.024 2.482 . . . . 0.0 111.788 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.779 HG13 HG23 ' A' ' 6' ' ' VAL . 45.3 t -100.07 127.72 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 110.005 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.708 ' O ' ' HB3' ' A' ' 86' ' ' ALA . 97.2 mt-10 -67.72 -30.5 70.01 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.496 -0.753 . . . . 0.0 109.416 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.708 ' HB3' ' O ' ' A' ' 85' ' ' GLU . . . 82.03 116.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.629 -0.669 . . . . 0.0 109.283 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.918 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 20.5 mttp -57.9 -32.97 68.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.188 -0.945 . . . . 0.0 109.452 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.3 mt -88.37 142.4 27.76 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.441 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.538 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.562 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.6 mmm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.725 ' HG2' HG22 ' A' ' 84' ' ' VAL . 91.3 mt-30 -105.72 131.32 53.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.25 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.616 ' CD2' HG21 ' A' ' 6' ' ' VAL . 3.9 m80 40.93 31.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.386 -0.821 . . . . 0.0 109.486 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -39.38 85.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.752 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -65.05 -32.93 74.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.158 -0.964 . . . . 0.0 109.719 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.616 HG21 ' CD2' ' A' ' 3' ' ' HIS . 74.8 t -66.77 -38.55 81.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.193 -0.942 . . . . 0.0 109.399 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.674 HD12 ' OD2' ' A' ' 73' ' ' ASP . 91.9 mt -61.15 -49.82 83.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.176 -0.953 . . . . 0.0 109.368 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.99 -47.44 80.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 108.906 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -44.08 96.89 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.548 -0.72 . . . . 0.0 109.25 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.4 t80 -68.23 -49.13 62.75 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.656 -0.653 . . . . 0.0 109.729 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 7' ' ' ILE . 95.3 t -67.99 -44.69 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.533 -0.73 . . . . 0.0 109.923 -179.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.2 t -64.0 -35.18 72.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.444 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -56.1 -31.97 63.74 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -65.72 -32.48 74.06 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.279 -0.888 . . . . 0.0 109.785 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.654 ' CE2' HD12 ' A' ' 36' ' ' ILE . 31.4 p90 -140.71 46.8 1.77 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.196 -0.94 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.3 136.22 53.27 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.019 -1.05 . . . . 0.0 110.156 -179.752 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.02 -151.52 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.167 1.911 . . . . 0.0 110.42 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.94 9.73 2.74 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.891 -1.131 . . . . 0.0 108.682 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.4 t -113.51 135.75 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.576 -0.703 . . . . 0.0 109.781 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.54 140.62 81.96 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.976 . . . . 0.0 108.754 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.512 ' HD3' HD12 ' A' ' 16' ' ' LEU . 46.4 Cg_exo -48.6 -33.05 22.88 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.621 1.547 . . . . 0.0 111.586 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.41 -20.22 63.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.185 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -98.27 3.86 48.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.465 -0.772 . . . . 0.0 109.316 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.6 t -104.14 136.03 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.5 95.48 0.47 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.122 -0.986 . . . . 0.0 109.366 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.869 HG21 ' NZ ' ' A' ' 87' ' ' LYS . 19.5 m -60.27 6.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.328 -0.858 . . . . 0.0 109.604 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.75 5.92 49.37 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.158 -0.964 . . . . 0.0 108.606 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.1 tp -91.84 136.83 32.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.537 -0.727 . . . . 0.0 109.364 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.488 ' OD2' ' O ' ' A' ' 67' ' ' ARG . 88.5 m-20 -62.85 121.81 14.4 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.423 -0.911 . . . . 0.0 108.582 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.67 HD11 ' CD1' ' A' ' 69' ' ' ILE . 79.5 mt -68.46 -4.34 14.57 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.368 -0.832 . . . . 0.0 109.457 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 51.2 t -51.47 -41.97 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.145 -0.972 . . . . 0.0 108.799 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.83 -35.29 66.23 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 13.2 m-20 -83.24 14.83 3.24 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.835 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.26 -15.82 0.02 OUTLIER Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -179.332 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -51.71 -39.16 23.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 108.181 179.386 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.654 HD12 ' CE2' ' A' ' 15' ' ' PHE . 5.1 tt -71.24 -25.09 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.506 -0.746 . . . . 0.0 109.899 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.4 m-20 -62.97 -30.53 71.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.965 . . . . 0.0 110.839 -178.652 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.7 m -105.11 -65.17 1.06 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.997 -1.064 . . . . 0.0 111.056 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.62 -52.31 15.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.133 -0.979 . . . . 0.0 110.985 -178.406 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.55 -36.79 91.94 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.381 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.1 tp -58.71 -41.17 85.7 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.468 -1.019 . . . . 0.0 109.235 -179.436 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -65.53 -44.13 87.83 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 108.807 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.48 -43.7 76.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.553 -0.717 . . . . 0.0 110.104 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 96.1 t -64.53 -45.39 95.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.362 -0.837 . . . . 0.0 110.55 -179.03 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.519 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -60.53 -46.94 94.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 120.999 -1.063 . . . . 0.0 109.475 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -44.14 80.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.404 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.7 t90 -78.46 -49.05 14.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.102 -0.999 . . . . 0.0 110.338 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 44' ' ' VAL . 7.6 tp -60.7 -42.35 97.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.554 -178.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.519 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -65.84 -37.82 87.21 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.984 -1.072 . . . . 0.0 109.046 -179.696 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -69.1 -38.96 79.21 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.421 -0.799 . . . . 0.0 109.576 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.1 ttt180 -58.95 -41.1 86.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.565 -0.709 . . . . 0.0 110.691 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -102.97 -6.5 22.33 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.965 -1.084 . . . . 0.0 109.898 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.35 30.86 78.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 pt -112.94 149.27 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.4 -1.059 . . . . 0.0 109.855 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.81 144.77 52.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.239 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -35.91 78.14 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.131 -0.981 . . . . 0.0 109.292 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 53.14 43.17 31.95 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.363 -0.836 . . . . 0.0 109.565 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.408 ' HB3' HD21 ' A' ' 61' ' ' LEU . 91.2 m-20 -82.39 94.26 7.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.52 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 69.6 t -63.59 -43.78 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.942 . . . . 0.0 109.398 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -158.35 140.37 13.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.756 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.408 HD21 ' HB3' ' A' ' 58' ' ' ASP . 36.4 mt -103.16 136.79 42.29 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.329 -0.857 . . . . 0.0 109.46 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.42 147.52 13.5 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.068 -1.02 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -63.48 -21.09 70.87 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.49 2.127 . . . . 0.0 111.973 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.52 -31.35 70.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 0.0 110.056 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -68.41 -26.4 65.52 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.289 -0.882 . . . . 0.0 110.713 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -93.76 8.75 39.85 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.881 -1.137 . . . . 0.0 110.707 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.488 ' O ' ' OD2' ' A' ' 29' ' ' ASP . 17.5 mmm180 -58.34 -34.74 70.97 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.074 -1.016 . . . . 0.0 110.231 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -150.55 158.61 44.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.11 -0.994 . . . . 0.0 110.464 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 30' ' ' LEU . 11.4 mm -62.89 -35.82 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.453 -0.78 . . . . 0.0 109.724 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 -59.99 -36.53 77.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.283 -0.885 . . . . 0.0 109.855 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.3 t -59.62 -43.07 93.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.901 -1.124 . . . . 0.0 108.91 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.15 -38.39 80.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.429 -0.794 . . . . 0.0 109.267 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.681 ' O ' HG23 ' A' ' 77' ' ' VAL . 83.5 m-20 -56.34 -37.64 70.25 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.387 -0.821 . . . . 0.0 109.253 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.56 -40.13 96.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.31 -0.869 . . . . 0.0 109.763 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -62.14 -51.78 66.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.959 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.8 t -65.16 -41.17 91.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.237 -0.915 . . . . 0.0 109.444 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -58.47 -40.62 79.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 O-C-N 121.312 -0.867 . . . . 0.0 109.538 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.21 -33.02 82.75 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.45 -48.83 4.22 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.976 -1.308 . . . . 0.0 110.581 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.503 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.8 p -129.69 154.22 47.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.4 -0.812 . . . . 0.0 108.994 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.81 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t -138.08 89.08 14.86 Favored Pre-proline 0 C--N 1.304 -1.407 0 O-C-N 121.15 -0.969 . . . . 0.0 109.956 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.441 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 14.5 Cg_exo -65.88 -176.64 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.704 2.27 . . . . 0.0 111.697 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 27.1 Cg_exo -58.6 150.6 68.35 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.418 2.079 . . . . 0.0 111.485 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.725 HG22 ' HG2' ' A' ' 2' ' ' GLN . 25.3 t -91.95 128.35 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.027 -1.046 . . . . 0.0 109.844 -179.357 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.61 153.53 47.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.37 -0.831 . . . . 0.0 109.215 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.94 141.4 57.63 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.156 -0.965 . . . . 0.0 109.452 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.869 ' NZ ' HG21 ' A' ' 26' ' ' VAL . 18.3 tttm -83.55 136.14 34.37 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -0.926 . . . . 0.0 109.273 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.46 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 53.8 mt -88.39 142.09 28.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.925 . . . . 0.0 109.492 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.501 ' OXT' ' CG2' ' A' ' 26' ' ' VAL . 82.4 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.406 ' O3 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.477 0.656 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.2 mt-30 -104.76 140.72 37.67 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.553 ' NE2' HG11 ' A' ' 6' ' ' VAL . 53.7 t-80 49.36 11.23 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.952 -1.092 . . . . 0.0 108.497 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.625 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.36 -35.91 80.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.593 -0.692 . . . . 0.0 110.193 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.1 m -58.85 -42.07 88.47 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.016 . . . . 0.0 109.567 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.553 HG11 ' NE2' ' A' ' 3' ' ' HIS . 54.3 t -67.35 -36.36 76.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.397 -0.815 . . . . 0.0 109.221 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.625 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.75 -49.51 83.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.831 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.721 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.51 -45.28 91.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.086 -1.008 . . . . 0.0 108.928 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.27 -43.34 91.58 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.509 -0.744 . . . . 0.0 109.051 179.431 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.704 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 66.3 t80 -66.07 -49.93 65.89 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.471 0.653 . . . . 0.0 109.89 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 7' ' ' ILE . 97.9 t -67.17 -45.02 87.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.414 -0.804 . . . . 0.0 109.641 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 8' ' ' ALA . 92.8 t -64.17 -35.6 74.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.438 -0.789 . . . . 0.0 109.597 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.29 -31.09 63.32 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.753 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' HD11 ' A' ' 36' ' ' ILE . 84.3 tt0 -65.44 -31.96 73.32 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.747 -179.706 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.596 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.2 p90 -141.89 45.68 1.68 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.213 -0.93 . . . . 0.0 109.627 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.51 136.03 52.69 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.941 -1.099 . . . . 0.0 110.119 -179.78 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -77.6 -150.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.222 1.948 . . . . 0.0 110.249 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -79.95 12.11 2.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.822 -1.174 . . . . 0.0 108.706 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.551 HG23 ' OD2' ' A' ' 18' ' ' ASP . 23.9 t -113.41 136.71 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.567 -0.708 . . . . 0.0 109.847 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.96 82.94 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.186 -0.946 . . . . 0.0 108.863 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -48.38 -30.32 15.2 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.746 1.631 . . . . 0.0 111.541 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.61 -20.55 62.74 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.495 -0.753 . . . . 0.0 109.513 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -103.73 8.61 37.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.32 -0.863 . . . . 0.0 109.748 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -101.13 135.93 35.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.315 -0.866 . . . . 0.0 108.99 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -67.87 89.95 0.29 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.164 -0.96 . . . . 0.0 109.082 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.576 HG11 ' HE2' ' A' ' 87' ' ' LYS . 17.0 m -60.53 6.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.379 -0.826 . . . . 0.0 109.769 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.2 t0 -89.21 4.36 48.91 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.93 . . . . 0.0 108.733 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.7 tp -95.65 134.24 38.77 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.563 -0.711 . . . . 0.0 109.368 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -66.07 121.49 15.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -76.04 9.27 2.56 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 109.882 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.19 -38.28 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.112 -0.992 . . . . 0.0 108.951 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.434 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -57.08 -35.53 69.48 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.8 m-20 -83.8 15.02 3.49 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -14.76 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.8 t -51.65 -37.94 20.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.096 -1.238 . . . . 0.0 108.428 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.8 tt -70.7 -24.82 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.508 -0.745 . . . . 0.0 110.139 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.59 ' OD1' ' CD1' ' A' ' 66' ' ' PHE . 82.7 m-20 -60.24 -32.93 71.6 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -178.26 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.48 -64.97 1.09 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.926 -1.109 . . . . 0.0 111.513 -178.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.0 mp -72.39 -52.16 17.24 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.096 -1.002 . . . . 0.0 110.983 -178.078 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.4 -36.92 92.27 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.53 -41.26 89.64 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.471 -1.017 . . . . 0.0 109.636 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -66.15 -44.37 84.34 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.486 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -67.26 -38.69 85.55 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.291 -0.881 . . . . 0.0 110.239 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.5 t -64.48 -44.87 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.204 -0.935 . . . . 0.0 110.576 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.07 -47.21 90.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 120.969 -1.082 . . . . 0.0 109.769 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.11 -44.37 80.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.285 -0.885 . . . . 0.0 110.537 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.704 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.0 t90 -74.8 -41.89 59.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.152 -0.967 . . . . 0.0 110.196 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -58.55 -40.13 82.17 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.254 -0.904 . . . . 0.0 109.604 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.08 -42.3 99.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -65.08 -42.94 93.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.378 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.3 ttt180 -65.98 -44.58 84.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 111.514 -178.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -105.65 -5.28 20.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.991 -1.068 . . . . 0.0 110.844 -178.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.58 32.5 71.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.56 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 76.8 mt -97.01 144.57 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.559 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 145.13 52.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.155 -0.965 . . . . 0.0 109.612 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.07 -28.69 69.79 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.841 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.572 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.0 m-20 54.7 50.82 15.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.061 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 57' ' ' ASP . 23.5 t70 -41.29 92.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.39 -0.819 . . . . 0.0 109.867 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ASP . 13.6 p -134.24 144.47 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.393 -0.817 . . . . 0.0 108.948 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -89.66 133.0 34.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 109.713 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.7 mt -110.32 140.74 44.19 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.488 -0.757 . . . . 0.0 109.534 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.7 158.18 59.95 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.482 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -60.1 -27.87 85.8 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.737 2.291 . . . . 0.0 112.042 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.83 -29.38 70.58 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -67.32 -26.39 66.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.811 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.59 ' CD1' ' OD1' ' A' ' 37' ' ' ASP . 80.1 m-85 -93.7 7.02 46.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.16 -0.962 . . . . 0.0 109.536 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -54.94 -39.08 68.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.272 -0.892 . . . . 0.0 109.553 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.0 p -138.93 151.1 46.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.09 -1.006 . . . . 0.0 109.909 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -63.27 -36.88 77.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.32 -0.863 . . . . 0.0 109.806 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 -61.2 -36.9 81.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 110.294 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.5 -44.21 89.37 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.985 -1.072 . . . . 0.0 109.368 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.3 mt -66.66 -38.55 81.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.327 -0.858 . . . . 0.0 109.408 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.476 ' OD1' HG21 ' A' ' 7' ' ' ILE . 74.8 m-20 -58.31 -38.54 77.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.458 -0.776 . . . . 0.0 109.765 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.95 96.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.89 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -62.19 -46.1 90.43 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.815 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.0 t -63.16 -43.1 98.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.242 -0.911 . . . . 0.0 109.923 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 57.0 t -63.73 -40.6 89.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.274 -0.891 . . . . 0.0 109.832 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.03 -35.28 75.77 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.73 -48.15 5.05 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.03 -1.276 . . . . 0.0 110.215 -179.39 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 42.1 m -131.69 134.75 46.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.345 -0.847 . . . . 0.0 109.409 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -128.6 87.96 53.53 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.306 -0.871 . . . . 0.0 109.648 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.22 -178.84 3.12 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.766 2.311 . . . . 0.0 111.846 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.51 150.74 66.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.51 2.14 . . . . 0.0 111.554 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.417 ' HA ' ' H ' ' A' ' 3' ' ' HIS . 41.2 t -93.99 130.6 42.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.179 -0.951 . . . . 0.0 109.887 -179.418 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -134.65 160.78 37.06 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.512 -0.743 . . . . 0.0 109.353 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -102.78 144.62 30.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.576 ' HE2' HG11 ' A' ' 26' ' ' VAL . 49.4 mttp -58.08 -33.87 69.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.202 -0.936 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 89' ' ' GLN . 35.2 tp -97.37 130.35 44.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 88' ' ' LEU . 63.5 tt0 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.517 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 121.371 0.605 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.581 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -85.1 125.77 33.05 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.717 ' ND1' HG22 ' A' ' 84' ' ' VAL . 1.6 m-70 54.97 19.63 2.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 108.551 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.89 -39.63 92.61 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.419 -0.801 . . . . 0.0 110.183 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -63.96 -34.99 79.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.097 -1.002 . . . . 0.0 109.889 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.75 -39.67 84.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.449 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.598 ' O ' HG22 ' A' ' 11' ' ' VAL . 91.2 mt -59.89 -43.02 91.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.501 -0.749 . . . . 0.0 110.195 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.709 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.09 -49.41 74.56 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.104 -0.998 . . . . 0.0 109.48 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.419 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -69.55 -33.76 73.23 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.648 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.8 t80 -66.63 -51.87 51.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 110.004 -179.519 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.598 HG22 ' O ' ' A' ' 7' ' ' ILE . 14.1 m -72.92 -39.89 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.257 -0.902 . . . . 0.0 110.16 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.5 t -64.55 -38.76 83.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.922 . . . . 0.0 109.922 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.1 -30.15 61.66 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.227 -0.921 . . . . 0.0 109.538 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.14 -29.51 70.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.304 -0.872 . . . . 0.0 108.987 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.614 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 16.9 p90 -149.52 49.63 0.95 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.298 -0.876 . . . . 0.0 109.257 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.13 136.71 53.48 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 120.89 -1.131 . . . . 0.0 110.183 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -73.36 -153.47 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 121.972 1.781 . . . . 0.0 110.603 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -80.3 13.31 2.44 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.1 -1.0 . . . . 0.0 108.776 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.7 t -113.44 136.16 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.585 -0.697 . . . . 0.0 109.996 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.32 140.19 72.46 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.283 -0.885 . . . . 0.0 108.873 179.33 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.589 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 53.1 Cg_exo -48.57 -33.22 23.15 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 121.692 1.595 . . . . 0.0 111.808 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.617 ' HB2' HD21 ' A' ' 88' ' ' LEU . . . -67.23 -19.6 65.56 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.445 -0.784 . . . . 0.0 109.353 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -96.46 0.16 49.95 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.451 -0.781 . . . . 0.0 108.983 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -107.08 134.04 49.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.3 m-20 -70.98 99.73 1.85 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 109.376 -179.503 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.8 m -59.68 5.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.353 -0.842 . . . . 0.0 109.768 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -92.16 8.6 37.24 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.065 -1.022 . . . . 0.0 108.841 179.336 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.3 tp -94.54 136.56 34.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.593 -0.692 . . . . 0.0 109.544 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -63.24 121.57 14.01 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.465 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -72.28 6.73 2.09 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.635 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -53.4 -39.49 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 108.941 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -57.79 -36.14 71.77 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.3 m-20 -85.27 15.1 4.54 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.29 -15.06 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.571 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.83 -37.36 20.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.054 -1.262 . . . . 0.0 108.46 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.3 tt -70.69 -24.84 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.536 -0.727 . . . . 0.0 110.142 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.428 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.4 m-20 -60.04 -33.34 71.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.235 -0.916 . . . . 0.0 111.141 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -105.62 -64.79 1.11 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.91 -1.118 . . . . 0.0 111.451 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -72.21 -52.17 17.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 111.018 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.69 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.77 -36.85 91.8 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tp -58.91 -41.96 88.49 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.43 -1.041 . . . . 0.0 109.459 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.7 tp -65.68 -44.28 86.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.203 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 41.4 mttt -67.02 -36.38 81.98 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.361 -0.837 . . . . 0.0 109.913 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.2 t -62.41 -44.32 99.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 0.0 110.366 -179.276 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.428 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -59.16 -48.27 87.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.922 -1.111 . . . . 0.0 109.398 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.32 -44.33 79.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.375 -0.828 . . . . 0.0 110.658 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -75.5 -43.62 48.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.102 -0.999 . . . . 0.0 110.243 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.428 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -57.9 -40.26 79.9 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.33 -0.856 . . . . 0.0 109.548 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.583 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.7 tt0 -61.62 -42.66 99.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.141 -0.974 . . . . 0.0 109.389 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.56 -43.09 85.97 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.112 -0.992 . . . . 0.0 110.364 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.685 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 59.8 ttt-85 -64.68 -44.23 91.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.317 -0.865 . . . . 0.0 111.241 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 96.9 m-85 -104.69 -10.15 17.68 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.94 -1.1 . . . . 0.0 110.765 -178.777 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 24.65 73.42 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -95.01 142.41 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.122 -1.223 . . . . 0.0 109.418 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.96 149.97 34.87 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.083 -1.011 . . . . 0.0 109.228 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.17 72.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.242 -0.911 . . . . 0.0 109.586 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 50.43 48.17 22.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.108 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -63.17 123.17 17.95 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 110.037 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.777 HG23 HD21 ' A' ' 61' ' ' LEU . 30.0 m -135.0 163.09 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.628 ' O ' HD23 ' A' ' 61' ' ' LEU . 91.5 mt-10 -65.37 132.06 48.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.975 -1.078 . . . . 0.0 109.5 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.777 HD21 HG23 ' A' ' 59' ' ' VAL . 9.7 mt -125.41 147.31 49.24 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.557 -0.715 . . . . 0.0 109.649 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.61 157.75 38.41 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 109.055 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -60.12 -25.56 80.18 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.721 2.281 . . . . 0.0 112.071 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.05 -31.94 73.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.442 ' O ' ' OG ' ' A' ' 71' ' ' SER . 52.2 t-80 -67.9 -26.79 66.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.695 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -98.34 6.35 47.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.9 tpt180 -56.21 -39.37 72.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.213 -0.929 . . . . 0.0 109.703 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.4 p -143.59 156.23 44.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.019 -1.05 . . . . 0.0 110.063 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.593 HD13 ' HB2' ' A' ' 8' ' ' ALA . 85.7 mt -62.45 -36.51 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.345 -0.847 . . . . 0.0 109.835 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -60.61 -39.12 87.01 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 110.356 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 84.9 p -60.27 -37.63 81.05 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.067 -1.021 . . . . 0.0 109.587 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.5 mt -67.99 -38.8 80.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.289 -0.882 . . . . 0.0 109.37 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.581 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 51.5 t0 -58.29 -38.65 77.44 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.433 -0.792 . . . . 0.0 109.937 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.2 -44.34 92.26 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.092 -1.005 . . . . 0.0 109.732 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -64.89 -47.12 78.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.63 -42.08 94.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.325 -0.859 . . . . 0.0 109.917 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -64.27 -41.43 92.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.14 -0.975 . . . . 0.0 109.942 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.61 -33.85 73.9 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.66 -48.01 4.65 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.294 . . . . 0.0 110.518 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.482 ' O ' ' O ' ' A' ' 76' ' ' VAL . 43.2 m -129.49 138.07 51.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.862 . . . . 0.0 110.044 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -128.96 89.56 48.4 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.425 -0.797 . . . . 0.0 109.15 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.587 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 68.0 Cg_endo -83.1 161.44 15.56 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.777 2.318 . . . . 0.0 112.599 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -59.47 151.06 71.56 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.954 2.436 . . . . 0.0 111.903 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.717 HG22 ' ND1' ' A' ' 3' ' ' HIS . 46.6 t -89.77 131.08 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.661 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -128.57 165.0 21.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.533 -0.729 . . . . 0.0 109.136 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -53.68 143.39 20.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.031 -1.043 . . . . 0.0 109.142 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.589 ' NZ ' ' O ' ' A' ' 21' ' ' PRO . 55.3 tttt -57.89 -36.84 72.97 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.919 . . . . 0.0 109.419 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.617 HD21 ' HB2' ' A' ' 22' ' ' ALA . 62.7 mt -94.65 141.82 28.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 118.002 -0.999 . . . . 0.0 109.517 -179.965 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.447 ' C4 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.4 mtm . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.354 0.597 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' HG2' HG22 ' A' ' 84' ' ' VAL . 92.8 mt-30 -107.83 138.86 43.32 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.757 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER 44.11 27.74 0.22 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.138 -0.976 . . . . 0.0 108.912 -179.679 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.529 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.05 -36.27 76.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.443 -0.785 . . . . 0.0 109.873 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -59.12 -40.26 84.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.167 -0.958 . . . . 0.0 109.534 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.757 HG21 ' CD2' ' A' ' 3' ' ' HIS . 73.3 t -66.3 -37.47 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.196 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.8 mt -59.88 -50.58 79.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.878 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.18 -47.82 78.32 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.05 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.27 -40.84 98.53 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.478 -0.763 . . . . 0.0 109.662 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.469 ' CE2' ' CH2' ' A' ' 47' ' ' TRP . 67.3 t80 -66.84 -51.54 54.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.437 -0.789 . . . . 0.0 110.348 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -69.96 -41.22 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.877 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.4 t -64.5 -35.77 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.91 . . . . 0.0 109.575 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.68 -30.8 63.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.589 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.45 -31.49 72.6 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.273 -0.892 . . . . 0.0 109.729 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' CE1' HD12 ' A' ' 36' ' ' ILE . 30.9 p90 -142.97 46.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.871 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 136.06 53.22 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.206 -179.76 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.49 -150.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.168 1.912 . . . . 0.0 110.432 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.537 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.69 12.78 2.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.896 -1.128 . . . . 0.0 108.842 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.537 HG23 ' OD1' ' A' ' 18' ' ' ASP . 32.5 t -113.33 136.31 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.468 -0.77 . . . . 0.0 109.835 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.07 138.68 87.38 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.133 -0.98 . . . . 0.0 108.783 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.663 ' O ' HG22 ' A' ' 24' ' ' VAL . 52.1 Cg_exo -48.34 -26.76 8.91 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 121.869 1.713 . . . . 0.0 112.141 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.04 -16.91 61.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.106 -0.996 . . . . 0.0 109.749 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -105.36 7.01 33.12 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -0.863 . . . . 0.0 110.412 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.663 HG22 ' O ' ' A' ' 21' ' ' PRO . 3.5 m -96.06 144.53 10.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 120.946 -1.096 . . . . 0.0 109.273 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.545 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -70.44 88.08 0.65 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.029 -1.044 . . . . 0.0 109.193 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.465 HG21 ' HE3' ' A' ' 87' ' ' LYS . 26.7 m -61.67 5.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.271 -0.893 . . . . 0.0 109.546 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.545 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -97.87 6.8 47.34 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 108.954 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.1 tp -96.94 135.53 38.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.484 -0.76 . . . . 0.0 109.555 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -64.26 121.75 15.02 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.86 8.42 0.52 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.762 -179.016 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 4.9 p -53.73 -39.83 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.131 -0.981 . . . . 0.0 109.01 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.0 t0 -58.11 -35.79 71.96 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.624 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.0 m120 -85.2 15.07 4.48 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.27 -15.97 0.02 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.624 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.7 t -52.71 -37.14 24.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.972 -1.311 . . . . 0.0 108.311 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.613 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.1 tt -70.53 -25.16 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.479 -0.763 . . . . 0.0 109.94 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.9 m-20 -62.21 -29.66 70.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.263 -0.898 . . . . 0.0 110.66 -178.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.0 m -104.9 -64.76 1.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.02 -1.05 . . . . 0.0 110.979 -178.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 19.8 mt -74.03 -52.4 12.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 110.846 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.8 93.79 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.613 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.95 -39.74 93.14 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.496 -1.002 . . . . 0.0 109.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.0 -44.04 94.8 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -67.52 -40.25 85.09 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.363 -0.836 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.16 -45.54 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 110.082 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.513 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -62.73 -41.73 93.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.063 -1.023 . . . . 0.0 109.66 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.05 -41.01 99.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.925 . . . . 0.0 109.676 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NH1' ' A' ' 51' ' ' ARG . 0.8 OUTLIER -78.56 -49.1 13.91 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.954 179.884 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.31 -43.24 96.53 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.45 -0.781 . . . . 0.0 110.626 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 0.9 OUTLIER -66.53 -36.28 82.3 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.945 -1.097 . . . . 0.0 109.087 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -72.04 -44.99 62.49 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.388 -0.82 . . . . 0.0 110.223 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NH1' ' HE1' ' A' ' 47' ' ' TRP . 22.5 ttm180 -60.95 -40.63 94.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.381 -0.825 . . . . 0.0 111.105 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -103.18 -6.14 22.47 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.824 -1.172 . . . . 0.0 110.21 -179.215 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.71 34.06 87.77 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -98.39 133.51 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.244 -1.15 . . . . 0.0 109.423 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.86 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -62.83 137.07 58.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.118 -0.989 . . . . 0.0 109.421 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.7 -29.02 67.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.362 -0.836 . . . . 0.0 110.233 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.456 ' C ' ' OD2' ' A' ' 57' ' ' ASP . 52.8 p30 -85.5 2.08 46.2 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -0.95 . . . . 0.0 110.457 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.86 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 97.2 m-20 -60.34 -37.83 81.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.914 -1.116 . . . . 0.0 109.627 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.41 159.89 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.464 -0.773 . . . . 0.0 109.504 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -96.35 138.27 34.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.211 -0.931 . . . . 0.0 109.323 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.08 140.32 36.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.309 -0.87 . . . . 0.0 109.795 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.24 157.41 75.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.362 -0.836 . . . . 0.0 109.238 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.27 -31.26 82.05 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.609 2.206 . . . . 0.0 112.136 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.48 -31.91 73.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.4 -0.812 . . . . 0.0 109.765 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -68.2 -27.09 66.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.196 -0.94 . . . . 0.0 109.861 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.71 6.37 47.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -55.8 -38.64 70.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 97.0 p -135.15 152.92 52.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.318 -0.863 . . . . 0.0 109.749 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -63.54 -36.48 76.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.371 -0.831 . . . . 0.0 109.885 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -60.47 -38.31 83.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 110.271 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.6 t -57.92 -42.98 85.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.017 -1.052 . . . . 0.0 109.661 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -62.0 -39.58 84.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.213 -0.929 . . . . 0.0 109.328 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -57.83 -37.0 73.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.341 -0.849 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.5 -41.15 96.86 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.233 -0.917 . . . . 0.0 109.524 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -62.87 -46.93 85.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.84 -43.22 97.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.294 -0.879 . . . . 0.0 109.818 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.5 t -60.89 -40.79 86.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.295 -0.878 . . . . 0.0 109.833 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.14 -30.78 74.66 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 120.409 -0.9 . . . . 0.0 110.949 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.15 -48.43 3.87 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.952 -1.323 . . . . 0.0 110.593 -178.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -128.23 155.3 44.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.154 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 81' ' ' THR . 9.3 t -138.83 89.11 13.23 Favored Pre-proline 0 C--N 1.303 -1.44 0 O-C-N 121.148 -0.97 . . . . 0.0 109.77 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.446 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.3 Cg_exo -65.6 -176.26 0.54 Allowed 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 122.7 2.267 . . . . 0.0 111.701 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 28.9 Cg_exo -58.49 150.64 67.27 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.475 2.117 . . . . 0.0 111.539 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.579 HG22 ' HG2' ' A' ' 2' ' ' GLN . 43.7 t -90.06 128.39 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.819 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.433 ' H ' ' H ' ' A' ' 3' ' ' HIS . 84.5 tt0 -138.56 147.22 42.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.407 -0.808 . . . . 0.0 109.111 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.79 139.33 54.26 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.061 -1.024 . . . . 0.0 109.218 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.465 ' HE3' HG21 ' A' ' 26' ' ' VAL . 47.1 tttp -59.36 -36.94 76.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.417 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.4 mt -92.56 142.12 27.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.486 -179.965 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.48 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 70.0 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.68 ' HB3' HG22 ' A' ' 84' ' ' VAL . 94.8 mt-30 -59.06 -38.18 78.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.828 . . . . 0.0 109.634 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.638 ' NE2' HG11 ' A' ' 76' ' ' VAL . 52.5 p-80 -122.9 23.43 9.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.491 -0.756 . . . . 0.0 109.148 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.602 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.69 -34.4 72.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.362 -0.836 . . . . 0.0 109.764 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.5 t -59.0 -41.84 88.64 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.2 t -66.23 -38.4 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.305 -0.872 . . . . 0.0 109.118 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.602 HD12 ' HA ' ' A' ' 4' ' ' ALA . 94.0 mt -59.34 -50.62 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.395 -0.815 . . . . 0.0 109.69 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.98 97.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 108.864 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.48 -39.64 92.16 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.537 -0.727 . . . . 0.0 109.442 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.4 ' HE2' HG22 ' A' ' 44' ' ' VAL . 44.6 t80 -61.22 -51.42 69.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.431 -0.793 . . . . 0.0 110.011 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.727 ' CG2' HD12 ' A' ' 36' ' ' ILE . 12.4 p -72.96 -48.95 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.313 -0.867 . . . . 0.0 110.87 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.637 HG21 HG11 ' A' ' 24' ' ' VAL . 61.9 t -60.9 -35.87 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.162 -0.961 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -59.51 -34.57 72.77 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.991 -1.068 . . . . 0.0 110.005 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.65 -36.3 82.22 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 111.028 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.501 ' O ' HD12 ' A' ' 16' ' ' LEU . 42.5 m-85 -100.61 -57.78 2.04 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.894 -1.128 . . . . 0.0 111.052 -178.437 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 15' ' ' PHE . 2.6 mp -123.97 87.3 53.2 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.238 -0.914 . . . . 0.0 110.944 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -91.51 -16.67 1.23 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.199 2.599 . . . . 0.0 112.084 178.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -76.39 -4.5 42.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.157 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.5 145.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD2' ' A' ' 23' ' ' ASP . . . -60.84 115.58 14.57 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 120.755 -1.215 . . . . 0.0 108.289 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.701 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.3 Cg_endo -63.62 -23.93 69.89 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 C-N-CA 121.329 1.353 . . . . 0.0 111.819 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.21 -15.66 62.47 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -0.89 . . . . 0.0 109.865 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD2' ' O ' ' A' ' 20' ' ' ALA . 49.6 p30 -89.09 3.24 52.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.014 -1.054 . . . . 0.0 109.767 -179.513 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.5 m -77.21 140.74 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.114 -0.991 . . . . 0.0 108.672 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.536 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -66.42 82.71 0.09 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.067 -1.021 . . . . 0.0 109.278 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.799 HG11 ' NZ ' ' A' ' 87' ' ' LYS . 12.5 m -62.47 5.71 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -0.927 . . . . 0.0 109.465 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.536 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.7 m-20 -103.08 7.17 38.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -0.892 . . . . 0.0 108.936 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.9 tp -98.51 137.45 37.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.498 -0.751 . . . . 0.0 109.525 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.575 ' OD1' ' NH2' ' A' ' 67' ' ' ARG . 89.0 m-20 -61.08 122.1 14.15 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.405 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -71.48 7.72 1.31 Allowed 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.192 -0.942 . . . . 0.0 110.177 -178.892 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 66.5 t -54.74 -43.75 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 120.823 -1.173 . . . . 0.0 108.362 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.76 -35.48 66.27 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -83.89 15.34 3.39 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 178.806 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.44 -14.82 0.01 OUTLIER Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.6 t -51.42 -38.81 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -1.122 . . . . 0.0 108.236 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.727 HD12 ' CG2' ' A' ' 11' ' ' VAL . 2.4 tt -70.38 -24.98 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-O 121.717 0.77 . . . . 0.0 109.498 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.4 t0 -58.37 -34.02 70.22 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.503 -0.748 . . . . 0.0 111.24 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.567 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.59 -64.24 1.16 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.009 -1.057 . . . . 0.0 111.25 -178.503 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.558 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -72.05 -52.03 18.84 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.061 -1.024 . . . . 0.0 111.014 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.08 -37.93 94.76 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.599 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.84 -41.27 86.54 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.389 -1.065 . . . . 0.0 109.107 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 33.6 tp -61.91 -44.14 97.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 108.663 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -68.13 -39.53 82.7 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.431 -0.793 . . . . 0.0 109.715 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.0 t -64.55 -45.46 95.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 110.197 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.2 -47.99 91.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.213 -0.93 . . . . 0.0 109.444 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.43 -42.95 95.74 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.773 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -71.37 -39.83 70.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.346 -0.846 . . . . 0.0 109.737 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.4 tp -59.28 -47.18 86.34 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.233 -0.917 . . . . 0.0 109.468 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -65.91 -39.0 90.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.181 -0.95 . . . . 0.0 108.972 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -66.23 -36.01 81.92 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 110.614 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -84.98 -52.42 5.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.197 -0.939 . . . . 0.0 112.012 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -94.99 -5.35 44.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.721 -1.237 . . . . 0.0 111.306 -177.942 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.09 24.77 76.33 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.971 -1.651 . . . . 0.0 108.971 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.5 145.51 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.311 -1.111 . . . . 0.0 109.482 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.73 150.33 32.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 109.444 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.25 -30.59 62.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.422 -0.799 . . . . 0.0 109.611 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 55.11 46.47 23.97 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -0.878 . . . . 0.0 109.558 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -95.14 16.23 16.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.232 -0.917 . . . . 0.0 109.737 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 60' ' ' GLU . 63.3 t -56.72 -43.75 80.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.105 -0.997 . . . . 0.0 109.548 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.469 ' HG3' HG12 ' A' ' 59' ' ' VAL . 95.9 mt-10 -138.36 132.0 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.163 -0.961 . . . . 0.0 109.671 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.6 mp -131.35 140.13 49.65 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.303 -0.873 . . . . 0.0 109.594 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.29 146.58 20.21 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.383 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.79 -22.98 74.34 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.57 2.18 . . . . 0.0 112.195 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.07 -31.63 72.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.382 -0.824 . . . . 0.0 109.934 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -67.87 -26.95 66.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.175 -0.953 . . . . 0.0 109.654 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.461 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.8 m-85 -104.77 11.18 34.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.33 -0.856 . . . . 0.0 109.835 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.575 ' NH2' ' OD1' ' A' ' 29' ' ' ASP . 41.6 tpt85 -54.36 -38.51 66.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.18 -0.95 . . . . 0.0 109.571 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.5 p -149.12 156.28 41.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.144 -0.972 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -62.71 -36.67 76.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.344 -0.848 . . . . 0.0 109.83 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.7 ttp180 -60.41 -40.85 92.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.897 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.9 t -60.61 -44.19 96.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.361 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.7 mt -66.54 -38.58 81.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.308 -0.87 . . . . 0.0 109.727 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.755 ' O ' HG23 ' A' ' 77' ' ' VAL . 88.7 m-20 -57.77 -41.1 81.33 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.312 -0.867 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.22 -46.15 78.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.103 -0.998 . . . . 0.0 109.631 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -64.12 -46.44 84.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.353 -0.842 . . . . 0.0 109.366 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.638 HG11 ' NE2' ' A' ' 3' ' ' HIS . 60.1 t -64.86 -41.69 92.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.368 -0.832 . . . . 0.0 109.881 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.755 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -62.31 -41.08 90.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.084 -1.01 . . . . 0.0 109.803 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.07 -34.75 73.94 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.34 -48.12 4.48 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.09 -1.241 . . . . 0.0 110.522 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.3 m -129.53 138.09 51.15 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.349 -0.844 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -128.29 89.47 49.78 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.408 -0.808 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -64.45 179.73 1.15 Allowed 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 122.56 2.173 . . . . 0.0 112.223 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -59.14 150.42 73.78 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.577 2.185 . . . . 0.0 111.929 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.68 HG22 ' HB3' ' A' ' 2' ' ' GLN . 32.3 t -102.89 129.4 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -136.11 158.34 44.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.319 -0.863 . . . . 0.0 109.431 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.85 145.04 51.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.313 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.799 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 13.1 tttp -129.77 133.42 46.99 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.333 -0.855 . . . . 0.0 109.371 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.43 ' O ' ' C ' ' A' ' 89' ' ' GLN . 52.4 mt -92.07 142.76 27.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.6 mt-30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.474 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.567 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.9 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.343 0.592 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.507 ' O ' HG13 ' A' ' 84' ' ' VAL . 6.6 tp-100 -58.51 -40.77 83.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 109.644 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.573 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 57.0 m-70 -126.62 12.0 7.37 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.38 -0.825 . . . . 0.0 109.516 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.583 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.58 -32.27 70.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 110.045 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -58.66 -37.13 75.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.076 -1.015 . . . . 0.0 109.662 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.51 -36.97 76.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.198 -0.939 . . . . 0.0 109.005 179.305 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.583 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.5 mt -60.63 -50.63 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.29 -0.882 . . . . 0.0 109.643 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.33 -47.18 80.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.042 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.7 -44.31 96.57 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.5 t80 -66.22 -45.06 82.03 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.6 -0.688 . . . . 0.0 109.652 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.826 HG13 HD12 ' A' ' 36' ' ' ILE . 55.7 t -66.8 -49.7 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.438 -0.788 . . . . 0.0 110.556 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 16' ' ' LEU . 61.7 t -64.12 -35.13 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.359 -0.838 . . . . 0.0 110.199 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -56.56 -34.59 67.25 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.429 -0.794 . . . . 0.0 109.996 -179.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.61 -30.8 71.17 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 110.621 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' HD22 ' A' ' 16' ' ' LEU . 34.7 m-85 -109.84 -57.86 2.13 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.116 -0.99 . . . . 0.0 111.32 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.681 HD12 HG23 ' A' ' 19' ' ' VAL . 1.2 mm? -123.66 86.9 52.67 Favored Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.111 -0.993 . . . . 0.0 111.362 -178.176 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.33 -19.21 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 123.154 2.569 . . . . 0.0 111.868 177.745 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.28 -4.1 40.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.239 -0.913 . . . . 0.0 109.091 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.681 HG23 HD12 ' A' ' 16' ' ' LEU . 42.4 t -113.15 143.81 22.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.107 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.94 115.76 15.5 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.728 -1.232 . . . . 0.0 108.557 -179.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.26 -25.86 71.97 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 C-N-CA 121.479 1.452 . . . . 0.0 111.746 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.571 ' HB1' ' H ' ' A' ' 88' ' ' LEU . . . -70.92 -14.92 62.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.285 -0.884 . . . . 0.0 109.227 179.466 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -88.84 8.43 29.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.378 -0.826 . . . . 0.0 109.151 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -93.33 137.35 22.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.561 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -64.44 85.63 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.146 -0.971 . . . . 0.0 109.57 -179.334 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -59.64 5.72 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.301 -0.874 . . . . 0.0 109.677 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.561 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -101.93 6.44 41.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.07 -1.019 . . . . 0.0 108.787 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 15.0 tp -100.14 133.47 44.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.519 -0.738 . . . . 0.0 109.586 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.487 ' HB3' HG13 ' A' ' 31' ' ' VAL . 90.0 m-20 -66.67 121.78 16.17 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.724 ' H ' HD12 ' A' ' 30' ' ' LEU . 0.0 OUTLIER -70.03 11.63 0.29 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.173 -0.955 . . . . 0.0 109.946 -179.077 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.569 HG23 ' N ' ' A' ' 32' ' ' ASP . 34.0 m -52.38 -44.07 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 120.869 -1.144 . . . . 0.0 108.495 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.569 ' N ' HG23 ' A' ' 31' ' ' VAL . 91.7 m-20 -56.67 -35.28 68.23 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.5 m-20 -83.51 15.24 3.19 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.45 -13.88 0.01 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 50.2 t -50.63 -37.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.059 -1.259 . . . . 0.0 108.523 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.826 HD12 HG13 ' A' ' 11' ' ' VAL . 5.9 tt -70.57 -24.45 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.446 -0.784 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -61.51 -31.65 71.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.135 -0.978 . . . . 0.0 111.079 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 m -105.67 -65.28 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.93 -1.106 . . . . 0.0 111.486 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.55 -52.51 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.11 -0.994 . . . . 0.0 110.97 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.571 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.1 -37.17 92.83 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 61' ' ' LEU . 6.2 tp -58.8 -43.4 90.51 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.489 -1.007 . . . . 0.0 109.196 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.55 -43.19 93.59 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.445 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -66.99 -36.62 82.59 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.41 -0.806 . . . . 0.0 109.419 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.1 t -65.66 -49.58 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.323 -0.86 . . . . 0.0 110.605 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.9 mm -62.32 -41.34 91.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 120.922 -1.111 . . . . 0.0 109.65 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.26 -43.21 92.02 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.606 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -74.61 -39.85 61.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.367 -0.833 . . . . 0.0 109.786 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.6 tp -58.25 -42.08 85.6 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.293 -0.879 . . . . 0.0 109.625 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 53' ' ' GLY . 55.0 tt0 -63.01 -40.35 97.51 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -67.93 -47.14 69.51 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.13 -0.982 . . . . 0.0 110.764 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -68.08 -43.47 78.46 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.314 -0.866 . . . . 0.0 111.972 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 80' ' ' THR . 99.2 m-85 -103.6 -6.33 21.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.846 -1.159 . . . . 0.0 111.299 -178.11 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.13 27.43 73.81 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.509 HG22 ' HB2' ' A' ' 58' ' ' ASP . 70.5 mt -98.5 142.16 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -1.136 . . . . 0.0 109.366 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.6 144.33 51.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.02 . . . . 0.0 109.708 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.83 -34.07 74.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.437 -0.79 . . . . 0.0 109.717 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 57' ' ' ASP . 53.2 p30 -89.62 12.1 17.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.823 . . . . 0.0 109.817 -179.654 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.509 ' HB2' HG22 ' A' ' 54' ' ' ILE . 21.4 t70 -53.34 -34.89 59.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.231 -0.918 . . . . 0.0 109.913 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.5 p -129.31 144.6 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.432 -0.793 . . . . 0.0 109.769 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -71.6 144.05 49.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 41' ' ' LEU . 42.8 mt -96.58 136.22 37.41 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.26 -0.9 . . . . 0.0 109.923 -179.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.85 144.05 10.83 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.908 . . . . 0.0 109.132 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.09 -25.81 73.25 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.255 1.97 . . . . 0.0 111.929 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.41 -31.0 71.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.433 -0.792 . . . . 0.0 109.757 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -68.25 -26.56 65.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 110.562 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' LEU . 94.0 m-85 -99.14 10.27 41.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.058 -1.026 . . . . 0.0 111.089 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -58.46 -35.86 72.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.709 -1.244 . . . . 0.0 109.747 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.3 p -142.6 147.91 36.62 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.12 -0.987 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.538 HG12 HD21 ' A' ' 30' ' ' LEU . 90.7 mt -66.41 -36.6 77.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 O-C-N 121.307 -0.871 . . . . 0.0 110.113 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.3 mtm180 -61.16 -38.36 86.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.872 . . . . 0.0 110.573 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.0 p -62.59 -39.62 94.31 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.94 -1.1 . . . . 0.0 110.071 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.1 mt -68.45 -40.94 82.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.178 -0.951 . . . . 0.0 109.939 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.845 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.4 t0 -59.04 -39.34 81.72 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.309 -0.87 . . . . 0.0 110.17 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.18 -45.48 88.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.081 -1.012 . . . . 0.0 109.95 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -64.52 -46.87 81.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -0.941 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.6 t -64.76 -41.42 92.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.867 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.845 HG23 ' O ' ' A' ' 73' ' ' ASP . 79.8 t -60.56 -41.53 88.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.147 -0.97 . . . . 0.0 109.921 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.47 -32.83 79.01 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 120.308 -0.948 . . . . 0.0 110.829 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -48.22 3.93 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.115 -1.227 . . . . 0.0 110.886 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.699 HG21 ' CE2' ' A' ' 52' ' ' PHE . 38.1 m -128.11 138.39 52.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.298 -0.876 . . . . 0.0 109.879 -179.437 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 81' ' ' THR . 1.6 t -128.79 88.08 52.93 Favored Pre-proline 0 N--CA 1.487 1.404 0 O-C-N 121.327 -0.858 . . . . 0.0 109.539 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.573 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 8.1 Cg_exo -69.4 -178.36 2.17 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.848 2.365 . . . . 0.0 112.103 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.405 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 25.9 Cg_exo -58.79 150.29 72.08 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.479 2.119 . . . . 0.0 111.783 179.49 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.507 HG13 ' O ' ' A' ' 2' ' ' GLN . 41.7 t -108.49 132.35 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.357 -0.84 . . . . 0.0 109.909 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.02 149.32 49.95 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.05 134.32 41.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.585 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.49 ' HZ2' ' HA ' ' A' ' 22' ' ' ALA . 41.2 tttp -100.29 133.32 44.88 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.224 -0.923 . . . . 0.0 109.166 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.571 ' H ' ' HB1' ' A' ' 22' ' ' ALA . 30.2 tp 43.68 65.83 0.93 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.111 -0.993 . . . . 0.0 109.301 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.495 -179.938 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.41 ' O3P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.408 0.623 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.5 ' O ' HG21 ' A' ' 84' ' ' VAL . 60.6 tp60 -58.02 -41.58 83.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.346 -0.846 . . . . 0.0 109.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 70.6 m80 -118.32 4.13 11.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.449 -0.782 . . . . 0.0 109.816 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.575 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.47 -38.06 73.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.151 -0.968 . . . . 0.0 109.674 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 m -61.87 -43.65 98.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.745 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.761 HG23 HG13 ' A' ' 84' ' ' VAL . 78.5 t -65.11 -39.58 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.951 . . . . 0.0 108.913 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.676 ' O ' HG22 ' A' ' 11' ' ' VAL . 95.9 mt -59.36 -49.84 82.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.365 -0.834 . . . . 0.0 109.337 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.865 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.39 -48.34 78.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 108.937 179.563 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.2 tt0 -62.89 -39.53 94.76 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.494 -0.754 . . . . 0.0 109.553 179.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -66.94 -51.93 49.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.531 -0.73 . . . . 0.0 110.484 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.7 m -73.07 -40.35 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 110.434 -179.564 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.724 HG23 ' O ' ' A' ' 8' ' ' ALA . 91.2 t -64.75 -37.04 79.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.966 . . . . 0.0 110.047 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.25 -34.46 66.39 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.177 -0.952 . . . . 0.0 110.017 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.409 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.11 -31.23 71.97 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.282 -0.886 . . . . 0.0 109.824 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE1' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -137.68 43.5 2.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.168 -0.957 . . . . 0.0 109.845 -179.711 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.09 135.65 54.58 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 120.785 -1.197 . . . . 0.0 110.069 -179.656 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -78.09 -151.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.147 1.898 . . . . 0.0 110.256 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.82 11.74 2.48 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 108.616 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.59 136.31 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.5 -0.75 . . . . 0.0 109.966 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.66 140.83 71.75 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 108.636 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.45 -28.23 11.49 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.8 1.667 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.526 ' HB2' ' HB3' ' A' ' 87' ' ' LYS . . . -65.03 -24.8 67.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -0.827 . . . . 0.0 109.304 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.5 5.57 46.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.441 -0.787 . . . . 0.0 108.912 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.0 t -103.75 136.98 34.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.83 95.94 0.39 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.565 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.62 HG11 ' NZ ' ' A' ' 87' ' ' LYS . 15.9 m -60.7 5.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 109.516 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -94.02 8.34 41.82 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.097 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.0 tp -89.12 138.78 31.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.584 -0.697 . . . . 0.0 109.39 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.09 121.5 13.77 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.524 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -70.32 3.39 2.95 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 109.405 -179.364 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.41 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.7 p -53.99 -35.88 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.261 -0.9 . . . . 0.0 109.557 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -57.17 -40.24 76.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.191 -0.943 . . . . 0.0 108.473 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.4 p30 -91.45 15.99 11.19 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' ASP . . . -42.48 -14.11 0.01 OUTLIER Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.8 t -49.86 -33.28 8.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.973 -1.31 . . . . 0.0 108.383 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.581 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.6 tt -70.1 -24.63 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.849 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 34' ' ' GLY . 85.8 m-20 -61.81 -33.61 74.44 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.413 -0.804 . . . . 0.0 111.255 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.51 -65.15 1.08 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.946 -1.096 . . . . 0.0 111.516 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.2 tt -71.93 -49.85 34.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 111.515 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.79 -41.8 81.66 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.629 -178.901 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.581 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -63.15 -43.55 98.0 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.291 -1.123 . . . . 0.0 110.236 -179.052 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 42.6 tp -58.32 -44.42 88.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.84 -1.162 . . . . 0.0 109.437 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.8 mttt -68.9 -37.06 78.74 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.116 -0.99 . . . . 0.0 109.557 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.5 t -66.7 -47.67 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 111.239 -178.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.15 -45.64 92.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 120.586 -1.321 . . . . 0.0 110.162 -179.202 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.64 -45.57 74.98 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.032 -1.043 . . . . 0.0 110.51 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.504 ' CZ2' ' CZ ' ' A' ' 51' ' ' ARG . 2.0 t90 -76.91 -46.12 25.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 110.29 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.488 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 12.0 tp -57.15 -41.48 79.24 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.355 -0.841 . . . . 0.0 109.603 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 25.6 tt0 -63.15 -36.6 84.16 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.637 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.11 -39.65 86.95 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.086 -1.009 . . . . 0.0 110.04 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.504 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 77.8 mtm180 -77.3 -43.17 34.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -0.967 . . . . 0.0 111.934 -179.039 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -102.34 -6.5 22.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.826 -1.171 . . . . 0.0 110.803 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.16 30.56 77.07 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.442 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 94.4 mt -85.01 147.05 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.202 -1.175 . . . . 0.0 109.958 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 148.02 42.4 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.229 -0.92 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.24 -32.02 69.6 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.329 -0.857 . . . . 0.0 109.741 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 52.47 43.04 31.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.3 p30 -93.7 16.31 14.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.386 -0.821 . . . . 0.0 109.672 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -53.76 -44.22 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 110.04 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -173.34 118.2 0.29 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.121 -0.987 . . . . 0.0 110.092 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.536 ' O ' ' N5 ' ' A' ' 101' ' ' PN7 . 2.3 mp -109.25 138.11 46.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.381 -0.824 . . . . 0.0 109.083 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 141.94 37.04 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.42 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -63.74 -21.72 69.65 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.291 1.994 . . . . 0.0 112.385 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.89 -32.89 72.33 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 110.307 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -74.06 -26.49 60.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.131 -0.98 . . . . 0.0 110.708 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -94.65 8.0 43.84 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.94 -1.1 . . . . 0.0 110.75 -178.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.41 ' NH2' HG21 ' A' ' 31' ' ' VAL . 30.1 mmt180 -58.9 -34.32 71.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.724 -1.235 . . . . 0.0 110.19 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.7 p -135.5 149.94 49.65 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.052 -1.03 . . . . 0.0 110.122 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.865 HD13 ' HB2' ' A' ' 8' ' ' ALA . 75.8 mt -64.3 -36.86 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.391 -0.818 . . . . 0.0 110.04 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -61.16 -37.24 82.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.25 -0.906 . . . . 0.0 110.686 -178.808 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -58.82 -44.1 90.79 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.977 -1.077 . . . . 0.0 109.765 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.0 mt -64.95 -38.66 83.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.189 -0.944 . . . . 0.0 109.622 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.49 ' HA ' HD11 ' A' ' 7' ' ' ILE . 51.2 t0 -56.8 -41.1 77.15 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.387 -0.821 . . . . 0.0 110.103 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.52 -46.22 76.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.086 -1.009 . . . . 0.0 110.231 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -63.42 -46.14 87.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.04 -1.038 . . . . 0.0 109.626 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.94 -44.5 92.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.368 -0.832 . . . . 0.0 110.267 -179.672 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.401 HG22 ' ND1' ' A' ' 3' ' ' HIS . 42.0 t -63.17 -41.37 92.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.079 -1.013 . . . . 0.0 110.098 -179.611 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.56 -32.48 69.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.52 -48.27 3.86 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.101 -1.235 . . . . 0.0 110.819 -179.043 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.2 m -130.13 138.97 50.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.161 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -127.04 89.02 53.05 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.334 -0.854 . . . . 0.0 109.125 179.459 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 86.6 Cg_endo -85.67 161.07 10.75 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.952 2.435 . . . . 0.0 112.652 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -60.12 150.39 79.46 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.731 2.287 . . . . 0.0 111.516 179.43 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.761 HG13 HG23 ' A' ' 6' ' ' VAL . 44.1 t -101.16 126.48 54.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.088 -1.008 . . . . 0.0 109.656 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.704 ' O ' ' HB3' ' A' ' 86' ' ' ALA . 97.1 mt-10 -68.45 -32.47 72.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.358 -0.839 . . . . 0.0 109.55 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.704 ' HB3' ' O ' ' A' ' 85' ' ' GLU . . . 78.65 113.86 0.07 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.162 -179.567 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.62 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 19.8 mttp -58.06 -35.08 70.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.132 -0.98 . . . . 0.0 109.458 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.4 mt -94.15 141.54 28.43 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 109.432 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.483 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.536 ' N5 ' ' O ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.347 0.594 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.05 -36.19 74.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.31 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -150.1 44.68 0.9 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.385 -0.822 . . . . 0.0 109.273 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.04 -32.4 72.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.893 . . . . 0.0 109.934 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -58.46 -37.65 75.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.101 -0.999 . . . . 0.0 109.929 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.549 HG11 ' H ' ' A' ' 84' ' ' VAL . 63.9 t -64.6 -39.49 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.148 -0.97 . . . . 0.0 109.357 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.477 HD13 ' OD2' ' A' ' 73' ' ' ASP . 94.6 mt -59.84 -40.07 81.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.265 -0.897 . . . . 0.0 109.627 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.39 -48.63 77.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.965 . . . . 0.0 109.118 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.427 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.37 -32.37 71.38 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.492 -0.755 . . . . 0.0 109.371 179.697 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -58.35 -51.51 69.49 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.296 -0.877 . . . . 0.0 109.722 -179.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.535 HG23 ' N ' ' A' ' 12' ' ' VAL . 33.8 m -73.73 -45.01 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.062 -1.023 . . . . 0.0 110.781 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.535 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.3 t -64.43 -35.89 75.67 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.176 -0.953 . . . . 0.0 111.131 -178.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -58.1 -33.01 68.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.011 -1.056 . . . . 0.0 110.005 -178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.19 -31.27 72.01 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 110.825 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -110.12 -55.87 2.4 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.214 -0.929 . . . . 0.0 111.472 -178.189 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.2 mt -124.44 87.65 53.96 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.082 -1.011 . . . . 0.0 111.389 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.91 -13.99 1.25 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 123.205 2.603 . . . . 0.0 111.776 178.098 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.45 -3.99 40.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.18 -0.95 . . . . 0.0 109.39 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.2 p -114.09 146.42 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.29 115.18 13.27 Favored Pre-proline 0 C--N 1.303 -1.441 0 O-C-N 120.742 -1.224 . . . . 0.0 108.362 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -64.84 -33.04 54.54 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.458 1.439 . . . . 0.0 111.913 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.46 -14.96 61.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -92.55 6.98 45.22 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.512 -0.742 . . . . 0.0 109.036 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.8 t -95.84 137.06 24.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.6 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.7 m-20 -61.58 90.61 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.223 -0.923 . . . . 0.0 109.589 -179.362 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -59.22 6.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.273 -0.892 . . . . 0.0 109.692 179.763 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.6 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.2 m-20 -97.86 11.4 37.47 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.074 -1.016 . . . . 0.0 108.971 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.6 tp -89.51 133.89 34.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.43 -0.794 . . . . 0.0 109.704 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 91.2 m-20 -65.37 122.3 16.84 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.419 -0.801 . . . . 0.0 108.97 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.584 HD11 HG12 ' A' ' 69' ' ' ILE . 65.8 mt -62.06 -7.2 3.64 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.179 -0.951 . . . . 0.0 108.992 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.2 p -50.05 -41.16 17.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.03 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.491 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.9 m-20 -58.8 -36.63 74.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 82.6 m-20 -85.29 16.86 3.37 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.48 -15.15 0.01 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.204 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.4 t -54.11 -38.78 39.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.78 -1.423 . . . . 0.0 107.853 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.618 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.23 -25.06 24.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.599 -0.688 . . . . 0.0 110.046 179.603 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.8 m-20 -62.37 -30.98 71.58 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 111.252 -178.306 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.561 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -104.97 -64.76 1.09 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.903 -1.123 . . . . 0.0 111.216 -178.62 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.5 mt -74.13 -52.58 12.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.121 -0.987 . . . . 0.0 110.964 -178.313 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.58 -36.59 93.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.745 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.618 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -61.33 -40.37 93.96 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.492 -1.005 . . . . 0.0 109.306 -179.599 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 34.2 tp -61.24 -44.21 97.62 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.535 -0.866 . . . . 0.0 108.797 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 46.1 mttp -70.5 -39.87 73.89 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.408 -0.808 . . . . 0.0 109.907 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.7 t -65.72 -45.72 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.881 . . . . 0.0 110.514 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.97 -44.36 99.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.032 -1.042 . . . . 0.0 109.697 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -63.43 -43.09 98.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.323 -0.86 . . . . 0.0 109.802 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -76.21 -43.35 42.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.189 -0.945 . . . . 0.0 109.992 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.4 tp -58.09 -47.97 81.58 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 110.055 -179.32 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.614 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.2 tt0 -67.95 -39.55 83.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.114 -0.991 . . . . 0.0 108.827 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 93.8 m-20 -64.9 -40.52 95.21 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.586 -0.696 . . . . 0.0 110.235 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -61.7 -44.79 96.25 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 111.3 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -113.94 -1.87 13.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.095 -1.003 . . . . 0.0 111.042 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.614 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.2 37.89 81.87 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.7 mt -96.18 142.76 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -1.181 . . . . 0.0 109.263 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.92 138.94 58.41 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.915 -1.115 . . . . 0.0 109.491 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.8 -32.47 73.66 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -57.69 -37.75 74.0 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.382 -0.823 . . . . 0.0 109.9 -179.823 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.06 -37.74 67.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.118 -0.989 . . . . 0.0 109.377 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 60' ' ' GLU . 70.9 t -63.62 -37.16 78.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.85 . . . . 0.0 109.72 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . 86.3 tt0 58.57 127.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.559 -0.713 . . . . 0.0 109.654 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.41 HD22 HD21 ' A' ' 41' ' ' LEU . 17.5 mt -103.14 134.16 47.02 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.907 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -172.23 139.56 1.03 Allowed Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -63.02 -26.62 73.8 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 121.986 1.791 . . . . 0.0 111.622 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -30.89 71.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.588 -0.695 . . . . 0.0 109.596 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -68.73 -26.3 65.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.58 -0.7 . . . . 0.0 110.824 -178.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.514 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.0 m-85 -101.39 6.2 42.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.977 -1.077 . . . . 0.0 111.607 -178.193 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 34.2 mmt180 -60.08 -34.11 73.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.743 -1.223 . . . . 0.0 110.028 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -144.04 147.25 33.57 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.874 -1.141 . . . . 0.0 110.185 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.584 HG12 HD11 ' A' ' 30' ' ' LEU . 78.6 mt -66.6 -36.74 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 O-C-N 121.482 -0.761 . . . . 0.0 109.896 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.4 mtm180 -61.03 -39.92 91.61 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.322 -0.861 . . . . 0.0 110.317 -178.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.61 -43.95 96.85 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.974 -1.079 . . . . 0.0 109.427 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.514 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -68.51 -38.57 79.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.356 -0.84 . . . . 0.0 109.908 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' HD13 ' A' ' 7' ' ' ILE . 77.6 m-20 -58.35 -42.0 85.92 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.398 -0.814 . . . . 0.0 110.438 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -40.12 88.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.11 -0.994 . . . . 0.0 110.368 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -61.41 -51.42 68.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 109.851 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 80' ' ' THR . 76.8 t -67.64 -43.79 86.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.261 -0.899 . . . . 0.0 109.763 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -63.02 -39.87 86.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.074 -1.016 . . . . 0.0 109.621 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.85 70.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.576 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.03 -48.88 3.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.146 -1.208 . . . . 0.0 110.565 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.571 ' O ' HG12 ' A' ' 76' ' ' VAL . 57.9 m -157.37 137.96 13.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.138 -0.976 . . . . 0.0 110.168 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.768 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t -120.66 89.74 45.2 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 108.944 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -92.87 108.0 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.207 2.604 . . . . 0.0 113.114 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -78.65 131.75 10.53 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.005 1.803 . . . . 0.0 111.79 179.163 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.549 ' H ' HG11 ' A' ' 6' ' ' VAL . 24.1 t -126.73 134.35 66.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.358 -0.839 . . . . 0.0 109.606 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -64.4 -34.86 79.16 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.886 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.441 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -146.79 157.27 43.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.156 -0.965 . . . . 0.0 109.708 -179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 41.8 tttm -70.76 132.31 45.15 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.184 -0.948 . . . . 0.0 109.243 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 44.5 mt -95.22 141.97 28.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.275 -0.89 . . . . 0.0 109.569 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.455 179.981 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.561 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.6 mtt . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.322 0.582 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 82.1 mt-30 -60.08 -38.0 81.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.349 -0.844 . . . . 0.0 109.507 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.593 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 45.6 m-70 -133.99 12.87 3.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.4 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.53 -35.61 76.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.316 -0.865 . . . . 0.0 110.051 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.8 p -61.76 -36.49 81.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.07 -1.019 . . . . 0.0 109.593 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.568 HG23 HG23 ' A' ' 84' ' ' VAL . 72.4 t -66.16 -37.47 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 108.94 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.2 mt -66.49 -41.69 88.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.407 -0.808 . . . . 0.0 110.336 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.703 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.89 -50.55 68.31 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.042 -1.036 . . . . 0.0 110.378 -179.022 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.4 -44.22 68.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.073 -1.017 . . . . 0.0 109.614 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -60.18 -48.32 82.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.284 -0.885 . . . . 0.0 109.463 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.7 HG13 HD12 ' A' ' 36' ' ' ILE . 97.6 t -68.82 -47.48 75.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.486 -0.759 . . . . 0.0 109.837 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.6 t -64.29 -36.67 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.427 -0.796 . . . . 0.0 109.964 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.81 -28.5 61.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.339 -0.85 . . . . 0.0 109.879 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.56 -29.45 70.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -155.94 55.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.155 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.473 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.7 pt? -80.59 136.8 51.67 Favored Pre-proline 0 C--N 1.306 -1.283 0 O-C-N 120.995 -1.065 . . . . 0.0 110.197 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.58 -153.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 121.937 1.758 . . . . 0.0 110.641 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -81.24 14.2 2.5 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.092 -1.005 . . . . 0.0 108.79 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.5 t -113.3 136.9 48.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.646 -0.658 . . . . 0.0 109.994 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.07 140.21 73.38 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 108.962 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.626 ' C ' ' HZ1' ' A' ' 87' ' ' LYS . 50.6 Cg_exo -48.86 -29.97 16.31 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 121.849 1.699 . . . . 0.0 112.081 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.566 ' HB1' ' CD2' ' A' ' 88' ' ' LEU . . . -68.6 -16.17 63.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.3 -0.875 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -102.2 5.48 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.347 -0.846 . . . . 0.0 109.234 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -105.0 136.78 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.569 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.9 t0 -71.15 96.2 1.34 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.157 -0.965 . . . . 0.0 109.431 -179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.2 m -60.91 6.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.356 -0.84 . . . . 0.0 109.676 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.569 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.0 6.79 48.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.132 -0.98 . . . . 0.0 109.118 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.5 tt -95.85 135.87 37.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.61 ' O ' HD23 ' A' ' 28' ' ' LEU . 88.0 m-20 -60.86 121.92 13.56 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.75 14.92 0.07 Allowed 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.31 -0.868 . . . . 0.0 110.281 -178.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 29' ' ' ASP . 73.4 t -54.34 -41.17 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 108.508 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -55.17 -35.21 64.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -83.07 14.53 3.32 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.842 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.86 -14.44 0.01 OUTLIER Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 44.4 t -51.21 -36.86 17.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 121.143 -1.21 . . . . 0.0 108.69 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.7 HD12 HG13 ' A' ' 11' ' ' VAL . 5.5 tt -70.66 -24.56 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.438 -0.789 . . . . 0.0 110.229 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.3 m-20 -58.9 -34.87 72.17 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 111.474 -178.103 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.9 m -106.26 -64.97 1.11 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.931 -1.106 . . . . 0.0 111.673 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -71.37 -52.53 18.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.042 -1.036 . . . . 0.0 111.037 -177.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.76 -36.45 91.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tp -58.15 -42.76 86.61 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.372 -1.075 . . . . 0.0 108.898 -179.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.39 -44.12 95.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -68.55 -34.68 76.26 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.458 -0.776 . . . . 0.0 109.518 179.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.3 t -61.47 -45.8 97.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.329 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mm -62.66 -41.14 91.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.95 -1.093 . . . . 0.0 109.577 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.73 -44.49 81.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 109.867 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.444 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -76.35 -45.14 33.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.181 -0.949 . . . . 0.0 109.702 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.444 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.04 -40.98 77.8 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.347 -0.846 . . . . 0.0 109.512 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.551 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 2.9 tm-20 -60.86 -43.13 98.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.159 -0.963 . . . . 0.0 108.751 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -68.91 -43.3 75.48 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.294 -0.879 . . . . 0.0 110.045 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.6 tpt180 -64.27 -44.72 90.86 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.436 -0.79 . . . . 0.0 111.062 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -106.23 -5.39 19.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.063 -1.023 . . . . 0.0 110.998 -178.516 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.02 30.28 65.73 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.551 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 71.6 mt -96.71 138.82 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.177 . . . . 0.0 109.056 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 136.07 57.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.991 -1.068 . . . . 0.0 109.801 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.32 -24.84 65.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.528 -0.732 . . . . 0.0 109.414 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.443 ' O ' HG13 ' A' ' 59' ' ' VAL . 92.2 m-20 -55.18 -31.64 61.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.468 -0.77 . . . . 0.0 110.217 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.07 120.69 11.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.054 -1.029 . . . . 0.0 109.839 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 57' ' ' ASP . 16.8 m -115.29 27.46 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.567 -0.708 . . . . 0.0 109.309 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -51.08 -26.04 5.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.379 -0.825 . . . . 0.0 109.922 -179.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.0 mt -71.73 138.99 48.91 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.08 -1.012 . . . . 0.0 109.792 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.85 162.4 51.91 Favored Pre-proline 0 N--CA 1.487 1.406 0 O-C-N 121.455 -0.778 . . . . 0.0 109.294 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -56.69 -36.21 98.12 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.324 2.016 . . . . 0.0 111.395 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.04 -25.8 65.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.474 -0.766 . . . . 0.0 109.185 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.48 ' CD2' ' CD2' ' A' ' 75' ' ' PHE . 34.1 t-80 -67.74 -26.03 65.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.415 -0.803 . . . . 0.0 109.863 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.533 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 92.0 m-85 -90.4 10.06 26.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.271 -0.893 . . . . 0.0 109.802 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 16.4 tpt180 -56.91 -40.35 76.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.921 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -144.75 153.41 41.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.951 -1.093 . . . . 0.0 110.263 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.4 mt -66.3 -36.8 78.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.462 -0.774 . . . . 0.0 110.123 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 14.1 ttm180 -60.77 -43.05 98.54 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.433 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.3 m -58.4 -40.46 82.48 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.226 -0.921 . . . . 0.0 109.918 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -61.54 -40.74 87.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.178 -0.951 . . . . 0.0 109.718 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.637 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.2 t0 -59.32 -37.5 77.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.288 -0.882 . . . . 0.0 109.996 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.8 -46.3 85.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.48 ' CD2' ' CD2' ' A' ' 65' ' ' HIS . 52.9 m-85 -68.45 -40.72 80.96 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.152 -0.967 . . . . 0.0 109.34 179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -65.13 -41.99 93.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.296 -0.877 . . . . 0.0 109.585 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.3 t -63.74 -41.01 91.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 O-C-N 121.187 -0.946 . . . . 0.0 109.836 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.08 -30.96 71.47 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.33 -48.58 4.14 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.039 -1.271 . . . . 0.0 110.559 -178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.8 p -132.04 154.35 49.48 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.281 -0.887 . . . . 0.0 109.647 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.806 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t -140.26 89.28 10.94 Favored Pre-proline 0 C--N 1.303 -1.418 0 O-C-N 121.222 -0.924 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 72.1 Cg_endo -85.2 161.15 11.43 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.877 2.385 . . . . 0.0 112.482 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.64 148.9 85.68 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.676 2.251 . . . . 0.0 111.778 179.637 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.568 HG23 HG23 ' A' ' 6' ' ' VAL . 14.6 p -130.44 141.26 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.382 -0.824 . . . . 0.0 109.926 -179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -112.77 160.17 18.24 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.13 135.63 43.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.976 -1.077 . . . . 0.0 109.179 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.626 ' HZ1' ' C ' ' A' ' 21' ' ' PRO . 16.1 tttm -60.13 -34.94 74.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.444 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.566 ' CD2' ' HB1' ' A' ' 22' ' ' ALA . 53.4 mt -84.88 142.95 29.35 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 82.6 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.938 -1.03 . . . . 0.0 109.488 -179.914 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.748 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.9 mt-30 -59.86 -37.28 78.84 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.598 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -144.36 34.87 1.19 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.241 -0.912 . . . . 0.0 109.542 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.847 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -59.57 -32.48 70.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -0.912 . . . . 0.0 109.676 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.5 m -58.46 -37.42 75.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.125 -0.984 . . . . 0.0 109.971 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.8 t -63.97 -40.85 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.131 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.538 HG22 HG23 ' A' ' 69' ' ' ILE . 76.7 mt -60.02 -47.92 89.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.443 -0.786 . . . . 0.0 109.27 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.01 99.11 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.14 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 2.9 tt0 -65.62 -37.38 86.42 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.464 ' O ' ' CE ' ' A' ' 87' ' ' LYS . 33.5 t80 -60.67 -52.89 63.22 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.513 -0.742 . . . . 0.0 109.886 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.496 HG23 ' CD1' ' A' ' 36' ' ' ILE . 4.0 p -73.48 -42.01 56.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.106 -0.996 . . . . 0.0 109.89 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.2 t -65.02 -35.59 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.36 -0.837 . . . . 0.0 110.911 -179.16 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -56.17 -36.17 68.04 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.023 -1.048 . . . . 0.0 110.353 -178.435 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.434 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 75.6 mm-40 -66.06 -31.5 72.42 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.043 -1.036 . . . . 0.0 109.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.434 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.2 OUTLIER -135.02 43.84 2.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.126 -0.984 . . . . 0.0 109.907 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.5 135.89 52.85 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.119 . . . . 0.0 110.116 -179.733 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.4 -149.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.143 1.895 . . . . 0.0 110.184 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.591 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.52 11.25 3.16 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 120.794 -1.191 . . . . 0.0 108.637 179.08 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.591 HG23 ' OD1' ' A' ' 18' ' ' ASP . 26.8 t -113.75 136.16 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.519 -0.738 . . . . 0.0 109.841 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.57 140.92 75.65 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.126 -0.983 . . . . 0.0 108.916 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -48.41 -29.33 13.29 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 121.875 1.717 . . . . 0.0 111.998 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.21 -21.16 66.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.384 -0.823 . . . . 0.0 109.283 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -103.27 3.25 35.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.44 -0.787 . . . . 0.0 108.886 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -104.93 138.94 27.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.579 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.5 t0 -68.78 102.59 1.57 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.105 -0.997 . . . . 0.0 109.354 -179.255 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 8' ' ' ALA . 26.0 m -59.62 6.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.433 -0.792 . . . . 0.0 109.933 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.579 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -89.92 10.11 25.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.03 -1.044 . . . . 0.0 108.632 179.248 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.2 tp -86.88 133.67 33.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.533 -0.729 . . . . 0.0 109.499 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -67.45 121.27 15.43 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.081 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -73.31 9.79 1.19 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.123 -0.986 . . . . 0.0 109.349 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.51 -39.45 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.891 . . . . 0.0 108.825 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.4 m-20 -57.71 -36.18 71.65 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' A' ' 35' ' ' VAL . 32.0 m120 -84.43 14.81 4.11 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.53 -15.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.617 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.58 -37.75 20.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.852 -1.381 . . . . 0.0 108.223 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.6 tt -71.04 -24.56 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.547 -0.721 . . . . 0.0 110.104 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.427 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.57 -32.15 71.24 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.153 -0.967 . . . . 0.0 111.358 -178.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.551 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -105.84 -65.11 1.09 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.864 -1.148 . . . . 0.0 111.393 -178.657 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.33 -52.36 16.49 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.177 -0.952 . . . . 0.0 110.916 -178.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.69 92.28 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.616 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tp -58.88 -41.12 86.34 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.379 -1.071 . . . . 0.0 109.301 -179.625 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.9 tp -62.8 -44.33 96.45 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.213 -0.93 . . . . 0.0 108.762 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -71.87 -38.26 70.07 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.421 -0.8 . . . . 0.0 109.948 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 86.5 t -64.79 -45.12 96.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 110.249 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.9 -42.47 94.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.171 -0.956 . . . . 0.0 109.607 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.77 -43.09 97.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.181 -0.949 . . . . 0.0 109.971 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -76.38 -43.68 39.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 109.842 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 31.4 tp -60.0 -42.5 94.41 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 0.0 109.842 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.609 ' O ' ' N ' ' A' ' 53' ' ' GLY . 4.1 tt0 -66.46 -41.69 88.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.12 -0.988 . . . . 0.0 108.996 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -66.61 -37.15 84.27 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.419 -0.8 . . . . 0.0 109.828 179.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -59.04 -41.72 88.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.498 -0.751 . . . . 0.0 110.818 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.563 ' CE1' HG21 ' A' ' 80' ' ' THR . 1.1 m-85 -118.93 -4.02 10.67 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.101 -0.999 . . . . 0.0 110.437 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.74 43.19 29.4 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -101.08 140.7 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.138 -1.213 . . . . 0.0 109.323 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.59 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -62.26 136.61 58.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.884 -1.135 . . . . 0.0 109.374 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.23 -33.63 76.25 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.363 -0.836 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -94.48 8.24 42.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.265 -0.897 . . . . 0.0 109.809 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.59 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 21.3 t70 -53.05 -37.31 61.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.093 -1.004 . . . . 0.0 109.293 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.465 HG21 ' CZ ' ' A' ' 75' ' ' PHE . 12.6 p -133.27 144.78 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.451 -0.781 . . . . 0.0 109.169 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -77.75 137.38 38.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.429 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.3 mt -104.04 138.82 40.02 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.344 -0.848 . . . . 0.0 109.711 -179.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -135.58 154.85 78.53 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.321 -0.862 . . . . 0.0 109.06 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.34 -30.66 81.13 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.608 2.205 . . . . 0.0 112.339 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.79 -32.1 73.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.376 -0.828 . . . . 0.0 110.013 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -68.8 -26.48 65.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.288 -0.882 . . . . 0.0 110.897 -179.086 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -94.38 5.59 51.32 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.846 -1.159 . . . . 0.0 110.932 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -59.65 -40.87 89.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.034 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.0 m -129.45 145.26 51.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.25 -0.906 . . . . 0.0 110.184 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.636 HD13 ' HA ' ' A' ' 8' ' ' ALA . 82.1 mt -63.7 -36.28 75.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.467 -0.771 . . . . 0.0 109.759 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -60.33 -37.66 81.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.339 -0.851 . . . . 0.0 110.402 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -57.66 -43.46 84.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.999 -1.063 . . . . 0.0 109.633 -179.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -68.04 -38.74 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.261 -0.899 . . . . 0.0 109.634 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.847 ' OD1' ' HB2' ' A' ' 4' ' ' ALA . 50.4 t0 -57.72 -40.45 79.62 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.384 -0.823 . . . . 0.0 110.302 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.04 -45.68 80.56 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.029 -1.044 . . . . 0.0 109.624 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.465 ' CZ ' HG21 ' A' ' 59' ' ' VAL . 71.7 t80 -63.54 -45.84 88.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.373 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' A' ' 80' ' ' THR . 59.1 t -65.22 -44.74 95.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.362 -0.836 . . . . 0.0 109.976 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.6 t -63.65 -39.39 85.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 O-C-N 121.11 -0.994 . . . . 0.0 109.838 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -33.65 68.34 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.5 -48.7 3.74 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.195 -1.179 . . . . 0.0 110.601 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.563 HG21 ' CE1' ' A' ' 52' ' ' PHE . 53.3 m -163.17 139.71 7.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.12 -0.987 . . . . 0.0 109.827 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t -119.58 89.95 42.0 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.366 -0.834 . . . . 0.0 109.307 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -88.81 109.75 0.52 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 123.062 2.508 . . . . 0.0 112.741 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -78.51 130.27 9.8 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 122.012 1.808 . . . . 0.0 112.004 179.604 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -130.48 129.73 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.356 -0.84 . . . . 0.0 109.485 179.756 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -65.7 -39.06 90.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.454 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -161.06 159.06 28.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.317 -0.864 . . . . 0.0 109.376 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.464 ' CE ' ' O ' ' A' ' 10' ' ' PHE . 32.7 mttt -57.4 -33.31 67.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.455 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.5 mt -57.79 -35.6 71.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -0.928 . . . . 0.0 109.403 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 117.986 -1.006 . . . . 0.0 109.524 179.935 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.564 ' S12' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.75 ' N ' ' H ' ' A' ' 85' ' ' GLU . 4.2 ptt? . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.51 ' N ' ' O ' ' A' ' 83' ' ' PRO . 91.8 mt-30 55.6 44.15 27.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.27 -0.894 . . . . 0.0 109.107 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 2' ' ' GLN . 67.0 m170 46.45 37.69 4.58 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.181 -0.95 . . . . 0.0 109.048 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.541 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.75 -36.74 79.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.331 -0.856 . . . . 0.0 109.485 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' CE ' ' A' ' 1' ' ' MET . 22.9 m -59.23 -39.58 83.2 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.19 -0.944 . . . . 0.0 109.285 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.8 t -66.83 -37.66 79.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.203 -0.936 . . . . 0.0 109.0 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.577 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.5 mt -60.48 -51.01 78.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.251 -0.906 . . . . 0.0 109.177 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.761 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.81 -48.14 75.48 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.828 . . . . 0.0 109.301 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.85 -44.28 96.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.523 -0.736 . . . . 0.0 109.344 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.477 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.2 t80 -65.7 -48.7 71.14 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.57 -0.706 . . . . 0.0 109.486 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 7' ' ' ILE . 90.9 t -67.33 -44.89 86.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.383 -0.823 . . . . 0.0 109.521 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.3 t -64.25 -35.28 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.488 -0.757 . . . . 0.0 109.527 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.8 -30.38 61.26 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.299 -0.876 . . . . 0.0 109.969 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -65.66 -31.09 71.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.114 -0.992 . . . . 0.0 109.702 -179.635 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.563 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 33.5 p90 -143.29 45.79 1.53 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -0.999 . . . . 0.0 109.671 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.851 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.63 135.9 52.37 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.036 -1.04 . . . . 0.0 110.177 -179.813 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.58 -151.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.218 1.946 . . . . 0.0 110.364 178.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -78.72 12.18 2.22 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.826 -1.171 . . . . 0.0 108.748 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.0 t -113.4 137.0 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.72 84.34 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.151 -0.968 . . . . 0.0 108.911 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.408 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.2 Cg_exo -48.2 -30.93 15.68 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.864 1.709 . . . . 0.0 112.179 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.8 -22.92 66.0 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.419 -0.8 . . . . 0.0 109.434 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -102.51 8.64 39.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.834 . . . . 0.0 109.434 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.1 t -101.3 136.73 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.318 -0.864 . . . . 0.0 108.862 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.71 89.34 0.38 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.134 -0.979 . . . . 0.0 109.275 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -61.57 6.39 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.563 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -93.34 8.55 39.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.111 -0.993 . . . . 0.0 108.918 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -91.41 136.81 32.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.487 -0.758 . . . . 0.0 109.575 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -62.43 121.79 14.12 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.61 10.53 1.68 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.257 -0.902 . . . . 0.0 110.101 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.5 t -55.42 -42.08 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.907 -1.12 . . . . 0.0 108.932 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.4 t0 -55.81 -35.53 66.44 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.28 14.77 4.88 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -15.19 0.02 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.5 t -53.24 -36.81 26.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.151 -1.205 . . . . 0.0 108.611 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.2 tt -70.46 -24.73 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.462 -0.774 . . . . 0.0 110.087 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.425 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.8 m-20 -61.11 -32.31 71.99 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.215 -0.928 . . . . 0.0 110.969 -178.588 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 46.1 m -105.77 -64.57 1.14 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.047 -1.033 . . . . 0.0 111.475 -178.557 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.1 mp -72.56 -52.4 15.75 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.072 -1.018 . . . . 0.0 110.969 -178.198 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.91 -37.4 93.25 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.7 tp -59.39 -41.03 88.48 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.461 -1.023 . . . . 0.0 109.141 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.9 tp -62.03 -43.96 97.72 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -65.48 -35.45 80.94 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.48 -0.763 . . . . 0.0 109.281 179.197 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.2 t -60.11 -43.86 93.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.427 -0.796 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.5 -44.88 97.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.688 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.9 -43.3 96.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 110.203 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.477 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -75.3 -38.84 60.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.875 . . . . 0.0 109.936 -179.694 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.7 tp -57.92 -44.16 86.67 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.285 -0.884 . . . . 0.0 110.014 -179.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.587 ' O ' ' N ' ' A' ' 53' ' ' GLY . 30.1 tt0 -66.34 -40.36 89.78 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 109.41 179.624 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -64.7 -44.04 91.54 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.319 -0.863 . . . . 0.0 110.574 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.15 -43.23 92.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.333 -0.854 . . . . 0.0 111.596 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -106.57 -7.07 17.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.952 -1.093 . . . . 0.0 110.782 -178.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.38 33.51 82.29 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.0 pt -108.78 153.12 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.363 -1.081 . . . . 0.0 109.961 -179.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.84 151.37 30.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.714 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.01 70.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.434 -0.791 . . . . 0.0 109.987 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 52.91 49.53 20.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.162 -0.961 . . . . 0.0 108.864 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -74.85 118.17 17.51 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.334 -0.854 . . . . 0.0 110.214 -179.136 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.8 m -129.59 163.78 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -59.4 127.69 33.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.909 -1.119 . . . . 0.0 109.467 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.54 HD12 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -114.93 146.03 41.59 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.35 155.7 39.01 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.33 -0.856 . . . . 0.0 109.096 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.11 -25.57 77.42 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.644 2.229 . . . . 0.0 112.014 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.54 -29.74 70.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.534 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.67 -26.66 66.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.268 -0.895 . . . . 0.0 109.795 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -99.39 8.49 44.58 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.69 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.93 -38.15 69.91 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.726 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.8 p -141.36 156.63 45.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.1 -1.0 . . . . 0.0 110.16 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.3 mt -61.79 -35.74 69.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.431 -0.793 . . . . 0.0 109.847 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -59.74 -39.03 83.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.848 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.2 t -58.48 -39.89 81.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.066 -1.021 . . . . 0.0 108.924 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.2 mt -60.84 -38.72 79.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.299 -0.876 . . . . 0.0 108.874 179.395 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.0 t0 -56.21 -36.92 68.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.448 -0.783 . . . . 0.0 109.02 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.67 -40.64 92.83 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.257 -0.902 . . . . 0.0 108.768 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -60.64 -46.41 90.41 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.97 -40.62 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.411 -0.805 . . . . 0.0 108.934 179.201 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -57.97 -40.75 78.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.482 -0.761 . . . . 0.0 109.186 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.77 -34.31 86.36 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.88 -48.85 4.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.893 -1.357 . . . . 0.0 110.553 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.6 p -128.7 152.74 48.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 108.721 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t -137.81 89.58 15.03 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.213 -0.929 . . . . 0.0 110.237 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.429 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.7 Cg_exo -64.28 -176.65 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.507 2.138 . . . . 0.0 111.476 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.51 ' O ' ' N ' ' A' ' 2' ' ' GLN . 25.9 Cg_exo -58.67 148.88 80.19 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.406 2.071 . . . . 0.0 111.937 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.416 ' HA ' ' H2 ' ' A' ' 1' ' ' MET . 45.7 t -112.42 136.06 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.397 -0.815 . . . . 0.0 109.889 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.75 ' H ' ' N ' ' A' ' 1' ' ' MET . 84.7 tt0 -145.4 -90.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.345 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -162.33 122.04 2.38 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.081 -1.012 . . . . 0.0 109.427 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 48.2 tttp -59.1 -36.15 74.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.7 tp -97.48 130.88 44.53 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.196 -0.94 . . . . 0.0 109.469 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.412 -179.941 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.438 ' O3 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.657 ' SD ' ' NH2' ' A' ' 70' ' ' ARG . 59.8 mtt . . . . . 0 N--CA 1.488 1.427 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.477 ' HA ' HG22 ' A' ' 84' ' ' VAL . 99.8 mm-40 -59.49 -34.4 72.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.199 -0.938 . . . . 0.0 108.84 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.508 ' CE1' HG22 ' A' ' 77' ' ' VAL . 4.2 p-80 -171.94 26.79 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.622 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.563 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.28 -35.04 76.22 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.295 -0.878 . . . . 0.0 109.584 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.11 -41.65 88.67 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.965 . . . . 0.0 109.489 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.5 t -65.24 -39.82 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.224 -0.922 . . . . 0.0 108.907 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.633 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.9 mt -59.55 -50.71 78.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.456 -0.778 . . . . 0.0 109.351 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.11 -42.3 96.94 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 108.865 179.389 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.82 -39.57 91.0 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.509 -0.745 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.434 ' HE2' HG22 ' A' ' 44' ' ' VAL . 38.0 t80 -61.5 -52.22 65.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.356 -0.84 . . . . 0.0 109.847 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.633 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.3 p -72.51 -42.44 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.275 -0.891 . . . . 0.0 109.929 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.4 t -64.38 -38.39 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.356 -0.84 . . . . 0.0 110.294 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.55 -28.0 59.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.216 -0.927 . . . . 0.0 110.143 -179.46 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -64.77 -30.05 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.054 -1.029 . . . . 0.0 109.028 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -154.47 55.47 0.69 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.352 -0.842 . . . . 0.0 109.208 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.518 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.82 137.05 50.64 Favored Pre-proline 0 N--CA 1.486 1.331 0 O-C-N 121.079 -1.013 . . . . 0.0 110.106 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.15 -153.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 121.925 1.75 . . . . 0.0 110.837 179.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.483 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -82.16 15.31 2.42 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 108.838 179.484 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.483 HG23 ' OD1' ' A' ' 18' ' ' ASP . 44.7 t -112.96 137.15 46.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.623 -0.673 . . . . 0.0 109.912 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.69 137.76 88.13 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.911 . . . . 0.0 109.06 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -48.94 -31.01 19.03 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.87 1.713 . . . . 0.0 112.152 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.27 -16.61 64.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.89 . . . . 0.0 109.427 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -102.2 8.81 40.46 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.172 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.86 136.47 31.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.4 90.12 0.51 Allowed 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.595 HG23 ' HB2' ' A' ' 8' ' ' ALA . 7.1 p -59.17 6.22 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.327 -0.858 . . . . 0.0 109.845 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -90.12 5.79 45.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.068 -1.02 . . . . 0.0 108.852 179.393 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.5 tp -94.39 136.25 34.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.468 -0.77 . . . . 0.0 109.449 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.498 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.2 m-20 -62.53 121.65 13.82 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.59 13.91 0.09 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.282 -0.886 . . . . 0.0 110.03 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.498 ' H ' ' C ' ' A' ' 29' ' ' ASP . 79.6 t -55.15 -42.38 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 0.0 108.702 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.61 -35.36 65.77 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.909 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -84.29 14.39 4.41 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.91 -14.53 0.01 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.43 -34.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.19 -1.183 . . . . 0.0 108.817 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -69.84 -24.34 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.463 -0.773 . . . . 0.0 110.11 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 82.9 m-20 -57.11 -34.76 68.68 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 111.33 -178.3 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.577 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.65 -64.79 1.11 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.851 -1.156 . . . . 0.0 111.381 -178.226 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.415 HD21 ' NZ ' ' A' ' 43' ' ' LYS . 7.3 tt -70.88 -52.36 20.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.071 -1.018 . . . . 0.0 110.93 -178.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.39 -36.83 92.15 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.706 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.76 -42.09 88.08 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.451 -1.029 . . . . 0.0 109.484 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -61.88 -44.09 97.53 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.175 -0.953 . . . . 0.0 108.54 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . 0.415 ' NZ ' HD21 ' A' ' 39' ' ' LEU . 54.3 mttp -70.09 -38.33 75.64 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.426 -0.796 . . . . 0.0 109.897 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.8 t -64.09 -45.14 97.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 110.372 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -60.8 -44.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.727 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.37 -41.78 96.52 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.89 . . . . 0.0 110.106 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -76.44 -43.47 39.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.929 . . . . 0.0 110.097 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.04 -44.43 87.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -0.947 . . . . 0.0 109.668 -179.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.3 tt0 -64.69 -38.17 90.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.17 -0.956 . . . . 0.0 109.088 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -71.42 -48.94 46.46 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.378 -0.826 . . . . 0.0 110.623 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -62.41 -42.47 99.46 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.362 -0.836 . . . . 0.0 111.279 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.765 ' CE1' HG21 ' A' ' 80' ' ' THR . 98.6 m-85 -101.2 -6.52 24.14 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.866 -1.146 . . . . 0.0 110.353 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.98 28.25 73.73 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.0 mt -101.55 137.01 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.281 -1.129 . . . . 0.0 109.192 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.95 57.38 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.076 -1.015 . . . . 0.0 109.291 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.71 -36.82 79.78 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.27 -0.894 . . . . 0.0 109.441 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -61.39 -33.26 73.39 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -50.72 -34.59 27.51 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.836 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.8 t -101.4 135.87 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.187 -0.945 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -89.51 141.81 28.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.471 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.407 HD13 HD21 ' A' ' 41' ' ' LEU . 36.5 mt -97.31 134.26 40.83 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.74 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.48 153.19 8.46 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.216 -0.928 . . . . 0.0 109.226 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.07 -28.58 80.31 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.487 2.125 . . . . 0.0 111.964 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.05 -29.56 70.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.368 -0.833 . . . . 0.0 109.572 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.65 -26.97 66.48 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.347 -0.846 . . . . 0.0 109.75 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.578 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 96.1 m-85 -103.49 6.82 37.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 110.161 -179.448 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.7 tpt180 -58.35 -41.69 85.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.029 -1.044 . . . . 0.0 109.904 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -153.74 158.86 41.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.902 -1.124 . . . . 0.0 110.116 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.441 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -62.74 -36.98 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.34 -0.85 . . . . 0.0 109.871 179.641 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.657 ' NH2' ' SD ' ' A' ' 1' ' ' MET . 4.6 tpm_? -60.7 -40.86 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.25 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.25 -44.07 95.58 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.102 -0.999 . . . . 0.0 109.695 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.5 mt -66.11 -39.76 85.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.225 -0.922 . . . . 0.0 109.79 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.667 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.5 t0 -58.02 -38.41 76.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.396 -0.815 . . . . 0.0 109.857 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.5 -46.2 80.61 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.207 -0.933 . . . . 0.0 109.847 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -66.6 -41.63 88.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.091 -1.006 . . . . 0.0 109.225 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -64.9 -42.48 94.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.349 -0.845 . . . . 0.0 109.706 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.667 HG23 ' O ' ' A' ' 73' ' ' ASP . 72.6 t -63.1 -41.46 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.253 -0.904 . . . . 0.0 109.79 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.0 -30.33 66.51 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.44 -48.08 4.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -1.22 . . . . 0.0 110.21 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.765 HG21 ' CE1' ' A' ' 52' ' ' PHE . 7.2 t -143.3 155.53 44.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.184 -0.947 . . . . 0.0 109.737 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.2 t -139.33 90.2 11.77 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 121.29 -0.881 . . . . 0.0 109.281 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.8 Cg_exo -62.16 -178.11 0.32 Allowed 'Trans proline' 0 N--CA 1.493 1.497 0 C-N-CA 122.479 2.119 . . . . 0.0 112.221 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 26.4 Cg_exo -59.08 150.58 72.36 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.602 2.202 . . . . 0.0 111.913 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 1' ' ' MET . 26.8 t -101.6 129.37 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 109.58 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -136.49 153.03 51.14 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.391 -0.818 . . . . 0.0 109.377 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.05 142.45 57.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.379 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 66.4 tttm -58.43 -37.5 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.451 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.3 mt -59.39 -35.07 73.27 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.212 -0.93 . . . . 0.0 109.437 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.451 -179.976 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.577 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.241 0.543 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.872 ' OE1' HG21 ' A' ' 81' ' ' THR . 90.6 mt-30 -82.08 135.05 35.37 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.32 -0.862 . . . . 0.0 108.745 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 56.4 m80 55.62 38.37 30.09 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.182 -0.949 . . . . 0.0 108.959 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -58.93 -34.0 71.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -0.806 . . . . 0.0 109.548 -179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.02 -38.64 79.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.21 -0.931 . . . . 0.0 109.679 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.571 HG11 ' H ' ' A' ' 84' ' ' VAL . 53.2 t -64.4 -37.61 80.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.157 -0.964 . . . . 0.0 109.595 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.49 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.4 mt -59.3 -50.42 79.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.37 -0.831 . . . . 0.0 109.618 -179.574 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.741 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -42.66 97.34 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.154 -0.966 . . . . 0.0 108.787 179.28 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.36 -34.77 77.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.645 -0.659 . . . . 0.0 109.613 179.444 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.457 ' N ' ' O ' ' A' ' 6' ' ' VAL . 58.3 t80 -59.57 -53.11 61.83 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.397 -0.814 . . . . 0.0 110.352 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' N ' ' A' ' 12' ' ' VAL . 34.2 m -74.4 -40.88 49.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.101 -0.999 . . . . 0.0 109.948 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.0 t -64.91 -37.6 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.309 -0.87 . . . . 0.0 110.451 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -56.64 -30.65 63.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.072 -1.018 . . . . 0.0 109.853 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.529 ' OE2' ' CD1' ' A' ' 36' ' ' ILE . 84.4 tt0 -65.27 -31.27 72.33 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.719 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.672 ' CE2' ' ND2' ' A' ' 33' ' ' ASN . 32.3 p90 -143.06 46.17 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 109.774 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.859 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.58 136.07 52.4 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.061 -1.024 . . . . 0.0 110.157 -179.837 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_endo -77.62 -149.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 122.143 1.895 . . . . 0.0 110.308 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.565 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.63 12.08 2.76 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.803 -1.185 . . . . 0.0 108.782 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.565 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.5 t -113.35 136.2 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.579 -0.701 . . . . 0.0 109.805 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.43 84.15 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.971 . . . . 0.0 108.85 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.415 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.1 Cg_exo -48.23 -30.71 15.36 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.775 1.65 . . . . 0.0 112.129 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -23.81 66.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 0.0 109.348 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -98.94 3.44 47.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.105 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.0 t -104.88 137.03 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -63.65 99.28 0.22 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.198 -0.939 . . . . 0.0 109.514 -179.443 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB1' ' A' ' 8' ' ' ALA . 15.1 m -60.91 6.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.557 179.733 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -88.77 11.29 18.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.171 -0.956 . . . . 0.0 108.905 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.5 tp -82.59 131.72 35.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.98 122.22 17.75 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.349 -0.845 . . . . 0.0 109.063 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.692 HD11 HG12 ' A' ' 69' ' ' ILE . 66.2 mt -62.97 -10.12 12.5 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.341 -0.849 . . . . 0.0 109.491 -179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.461 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.9 p -50.19 -39.44 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.099 -1.001 . . . . 0.0 109.245 -179.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.7 m-20 -58.08 -37.66 74.92 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.672 ' ND2' ' CE2' ' A' ' 15' ' ' PHE . 28.7 m120 -87.6 15.5 6.69 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 178.951 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.4 -18.37 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.003 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -52.48 -35.37 20.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 120.797 -1.414 . . . . 0.0 108.185 179.163 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.8 tt -71.19 -25.06 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.589 -0.694 . . . . 0.0 109.869 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -62.82 -30.19 71.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.302 -0.874 . . . . 0.0 110.999 -178.521 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.6 m -104.95 -65.14 1.06 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.006 -1.059 . . . . 0.0 111.178 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.452 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -74.17 -52.14 13.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.162 -0.961 . . . . 0.0 111.069 -178.262 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.528 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.86 -38.93 96.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.7 -42.12 98.52 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -1.084 . . . . 0.0 109.593 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.568 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -58.73 -44.17 90.39 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.097 -1.002 . . . . 0.0 108.541 -179.562 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -66.82 -37.84 85.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.188 -0.945 . . . . 0.0 109.331 179.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.0 t -67.44 -47.85 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.398 -0.813 . . . . 0.0 111.102 -179.115 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -60.84 -43.49 95.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.727 -1.233 . . . . 0.0 109.922 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -45.29 76.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.063 . . . . 0.0 110.191 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.5 t90 -77.22 -46.84 21.89 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 110.09 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.469 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 11.6 tp -56.97 -41.01 77.59 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.377 -0.827 . . . . 0.0 109.818 -179.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.605 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.5 tt0 -61.4 -42.52 98.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.982 -1.074 . . . . 0.0 108.955 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.9 -36.98 83.51 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.245 -0.909 . . . . 0.0 109.55 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.565 HH22 ' CD ' ' A' ' 89' ' ' GLN . 60.7 ttt85 -59.98 -46.31 89.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 111.137 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.413 ' CZ ' ' HB3' ' A' ' 82' ' ' PRO . 47.3 m-85 -117.21 0.17 12.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.14 -0.975 . . . . 0.0 110.94 -179.066 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.605 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.68 40.37 65.91 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.9 mt -96.0 141.43 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.214 -1.168 . . . . 0.0 109.225 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.86 140.67 58.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.004 -1.06 . . . . 0.0 109.427 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.09 -32.22 72.75 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.338 -0.851 . . . . 0.0 109.381 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -91.03 9.82 29.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.335 -0.853 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -52.9 -34.11 53.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.626 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.06 158.9 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.463 -0.773 . . . . 0.0 109.604 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.492 ' C ' HD12 ' A' ' 61' ' ' LEU . 95.5 mt-10 -93.16 150.59 20.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.885 . . . . 0.0 109.303 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.86 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.4 mp -98.12 132.24 43.81 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 109.801 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.77 143.51 3.94 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.21 -0.931 . . . . 0.0 109.058 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.81 -24.92 74.54 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.146 1.898 . . . . 0.0 112.104 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.27 -32.52 74.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.236 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -72.89 -26.67 61.52 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.322 -0.861 . . . . 0.0 111.318 -178.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -97.85 11.04 38.66 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.77 -1.206 . . . . 0.0 110.953 -178.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -58.56 -34.29 70.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.936 -1.102 . . . . 0.0 109.952 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -145.78 151.0 37.26 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.031 -1.043 . . . . 0.0 110.018 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.692 HG12 HD11 ' A' ' 30' ' ' LEU . 82.4 mt -66.27 -36.74 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.405 -0.809 . . . . 0.0 109.846 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.0 ttp180 -60.69 -39.09 87.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.574 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -58.28 -42.41 86.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.984 -1.073 . . . . 0.0 109.927 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.4 mt -68.03 -39.24 81.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.49 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.3 t0 -59.13 -41.21 87.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.347 -0.846 . . . . 0.0 110.474 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.09 -43.11 88.24 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.123 -0.986 . . . . 0.0 110.212 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -62.7 -48.67 78.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.179 -0.951 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.608 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.37 -46.33 90.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.235 -0.916 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.451 HG23 ' OD2' ' A' ' 73' ' ' ASP . 41.4 t -59.62 -39.55 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 O-C-N 121.068 -1.02 . . . . 0.0 109.534 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.82 -32.63 66.24 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.8 -49.61 3.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -1.234 . . . . 0.0 110.479 -179.354 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.608 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.1 t -158.52 149.92 20.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 0.0 109.547 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.872 HG21 ' OE1' ' A' ' 2' ' ' GLN . 10.1 t -125.97 89.83 51.55 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.292 -0.88 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 52' ' ' PHE . 88.8 Cg_endo -92.14 109.52 0.26 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 123.232 2.621 . . . . 0.0 112.955 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -78.43 133.71 12.03 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.994 1.796 . . . . 0.0 111.715 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.571 ' H ' HG11 ' A' ' 6' ' ' VAL . 38.9 t -124.88 132.37 71.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.335 -0.853 . . . . 0.0 109.601 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -62.75 -37.13 85.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.377 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.417 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -152.33 152.69 32.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.526 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -58.67 -37.75 76.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.483 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.6 mt -94.79 142.18 27.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.254 -0.904 . . . . 0.0 109.54 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.565 ' CD ' HH22 ' A' ' 51' ' ' ARG . 28.0 mm100 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.494 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.407 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 86.9 mmm . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 8.9 tp-100 -98.99 119.57 38.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.361 -0.837 . . . . 0.0 109.229 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 37.4 m170 46.85 30.25 1.17 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.195 -179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.93 -35.8 79.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.697 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.9 -38.55 82.61 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.0 109.859 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.576 HG11 ' H ' ' A' ' 84' ' ' VAL . 72.7 t -64.28 -41.06 91.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.169 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 90.6 mt -59.53 -43.52 91.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.338 -0.851 . . . . 0.0 109.739 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.738 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.38 -47.74 80.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.21 -0.931 . . . . 0.0 109.158 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.69 -33.14 72.13 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.357 -0.839 . . . . 0.0 109.591 179.611 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -59.86 -53.12 61.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.167 -0.958 . . . . 0.0 110.19 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' ' CE1' ' A' ' 15' ' ' PHE . 34.6 m -74.41 -40.67 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.147 -0.97 . . . . 0.0 110.193 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 8' ' ' ALA . 64.2 t -64.91 -36.35 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.354 -0.841 . . . . 0.0 110.588 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.46 -33.94 66.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 109.931 -179.16 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -65.68 -32.18 73.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.269 -0.894 . . . . 0.0 109.871 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.745 ' CE2' ' ND2' ' A' ' 33' ' ' ASN . 7.8 p90 -138.27 45.82 2.07 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.145 -0.972 . . . . 0.0 109.931 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.869 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 135.74 53.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.951 -1.093 . . . . 0.0 109.946 -179.823 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.58 -150.38 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.105 1.87 . . . . 0.0 110.264 178.431 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.558 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.52 12.09 2.69 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.8 -1.187 . . . . 0.0 108.708 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.558 HG23 ' OD2' ' A' ' 18' ' ' ASP . 25.6 t -113.64 136.64 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.549 -0.719 . . . . 0.0 109.818 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.89 139.58 82.95 Favored Pre-proline 0 N--CA 1.488 1.444 0 O-C-N 121.152 -0.967 . . . . 0.0 108.751 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.52 -31.74 19.07 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 121.699 1.599 . . . . 0.0 111.966 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.17 -26.6 67.49 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.301 -0.874 . . . . 0.0 109.395 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -103.34 4.8 36.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -99.22 144.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.326 -0.859 . . . . 0.0 108.695 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.3 t0 -71.82 95.06 1.47 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.034 -1.041 . . . . 0.0 109.357 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.48 ' O ' HD12 ' A' ' 69' ' ' ILE . 18.9 m -62.25 6.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.342 -0.849 . . . . 0.0 109.588 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.6 m-20 -90.77 12.08 20.34 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.184 -0.948 . . . . 0.0 109.017 179.605 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 tp -84.53 133.87 34.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.433 -0.792 . . . . 0.0 109.484 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -65.21 122.34 16.87 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.271 -0.893 . . . . 0.0 108.824 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.74 HD11 HG12 ' A' ' 69' ' ' ILE . 67.3 mt -64.92 -6.28 8.04 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.249 -0.907 . . . . 0.0 109.618 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 73.0 t -50.91 -45.06 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.021 . . . . 0.0 108.904 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.7 -35.99 69.14 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.745 ' ND2' ' CE2' ' A' ' 15' ' ' PHE . 25.2 m-20 -86.02 15.24 5.19 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.94 -16.88 0.02 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.76 -38.05 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 120.867 -1.372 . . . . 0.0 108.267 179.126 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.616 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.09 -25.3 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.538 -0.726 . . . . 0.0 110.324 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.7 m-20 -59.68 -35.65 74.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 111.105 -178.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.557 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -106.31 -64.22 1.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.13 -0.981 . . . . 0.0 111.556 -178.419 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -69.99 -52.09 27.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.057 -1.027 . . . . 0.0 111.301 -178.056 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -69.3 -36.75 79.41 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.249 -179.295 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.616 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tp -58.43 -47.83 82.67 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.335 -1.097 . . . . 0.0 109.582 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.5 mt -61.38 -42.62 99.01 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.109 -0.995 . . . . 0.0 109.77 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -63.63 -39.66 94.92 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.402 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.478 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.2 t -70.22 -49.7 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.268 -0.895 . . . . 0.0 110.554 -179.593 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -62.17 -40.48 87.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 120.959 -1.088 . . . . 0.0 109.948 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.18 -45.99 75.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.081 -1.012 . . . . 0.0 110.039 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.6 OUTLIER -77.61 -47.05 20.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.145 -0.972 . . . . 0.0 109.635 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.478 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 31.4 tp -56.75 -39.2 73.57 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.433 -0.792 . . . . 0.0 109.466 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.611 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.0 tm-20 -61.53 -42.74 99.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.953 . . . . 0.0 109.466 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' OE2' ' A' ' 49' ' ' GLU . 20.9 t70 -64.33 -39.45 93.93 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.071 -1.018 . . . . 0.0 109.71 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -66.19 -45.53 80.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 111.549 -178.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 82' ' ' PRO . 53.5 m-85 -111.17 -1.49 16.15 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.98 -1.075 . . . . 0.0 111.151 -178.76 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.611 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.67 38.48 67.42 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.54 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 72.5 mt -88.44 145.38 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.103 -1.233 . . . . 0.0 109.37 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.96 122.9 16.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.109 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.08 -19.72 56.69 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.468 -0.77 . . . . 0.0 109.741 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.03 11.06 5.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.352 -0.842 . . . . 0.0 110.165 -179.261 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.94 112.37 16.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.03 -1.044 . . . . 0.0 109.527 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.1 m -116.58 18.13 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.56 -0.713 . . . . 0.0 109.313 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -55.7 -28.27 54.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.827 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.676 HD21 ' CZ ' ' A' ' 75' ' ' PHE . 64.0 mt -77.21 142.09 39.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.092 -1.005 . . . . 0.0 109.905 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.92 164.78 21.46 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -51.98 -33.13 51.0 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.349 2.033 . . . . 0.0 111.54 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -66.72 -27.42 67.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.512 -0.742 . . . . 0.0 109.251 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 19.6 t-80 -67.63 -26.62 66.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.377 -0.827 . . . . 0.0 109.768 -179.627 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -90.24 11.91 19.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.208 -0.933 . . . . 0.0 109.282 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 -53.82 -37.64 63.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.381 -0.825 . . . . 0.0 109.792 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.4 p -146.14 157.17 43.83 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.044 -1.035 . . . . 0.0 110.036 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.74 HG12 HD11 ' A' ' 30' ' ' LEU . 84.8 mt -64.36 -36.82 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.336 -0.853 . . . . 0.0 110.076 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 43.8 ttp180 -60.57 -40.55 92.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.314 -0.866 . . . . 0.0 110.381 -179.018 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -62.55 -38.64 90.83 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.012 -1.055 . . . . 0.0 109.71 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.6 mt -68.23 -39.35 80.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.827 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.444 ' OD2' HG23 ' A' ' 77' ' ' VAL . 59.4 t0 -59.43 -41.14 88.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.363 -0.836 . . . . 0.0 110.334 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -43.29 86.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.098 -1.001 . . . . 0.0 110.512 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CZ ' HD21 ' A' ' 61' ' ' LEU . 67.3 t80 -61.96 -49.3 76.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.081 -1.012 . . . . 0.0 109.775 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 80' ' ' THR . 68.4 t -66.52 -44.74 90.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.268 -0.895 . . . . 0.0 109.825 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.444 HG23 ' OD2' ' A' ' 73' ' ' ASP . 47.3 t -63.03 -39.53 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.011 -1.056 . . . . 0.0 109.894 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.7 -33.97 69.05 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.39 -48.79 3.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -1.222 . . . . 0.0 110.644 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' HG12 ' A' ' 76' ' ' VAL . 60.2 m -158.36 137.86 11.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.125 -0.985 . . . . 0.0 109.839 -179.534 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.795 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -119.26 89.39 39.75 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.325 -0.859 . . . . 0.0 109.1 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' HB3' ' CZ ' ' A' ' 52' ' ' PHE . 64.2 Cg_endo -94.85 111.71 0.16 Allowed 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 123.304 2.669 . . . . 0.0 112.634 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -78.07 134.35 13.0 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 121.987 1.792 . . . . 0.0 111.8 179.599 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.576 ' H ' HG11 ' A' ' 6' ' ' VAL . 41.9 t -124.92 133.09 70.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -61.78 -37.73 85.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.435 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.423 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -152.42 150.69 29.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.37 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 23.1 tttm -59.82 -37.07 78.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.496 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.81 142.15 27.89 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.285 -0.884 . . . . 0.0 109.424 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.488 179.892 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.557 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.391 0.615 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.492 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 93.9 mt-30 -58.9 -36.61 74.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.062 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.564 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -147.59 29.86 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.734 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.486 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.38 -32.5 71.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.427 -0.796 . . . . 0.0 110.008 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.0 p -58.97 -39.94 83.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.03 -1.044 . . . . 0.0 109.563 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.564 HG21 ' CE1' ' A' ' 3' ' ' HIS . 70.0 t -68.07 -39.07 80.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 108.44 178.982 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 82.2 mt -61.26 -50.48 80.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.502 -0.749 . . . . 0.0 109.151 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.739 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.36 -47.36 79.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.346 -0.846 . . . . 0.0 109.183 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -44.25 96.12 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.483 -0.76 . . . . 0.0 109.227 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.592 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.5 t80 -68.34 -48.85 63.73 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.626 0.727 . . . . 0.0 109.452 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.701 HG13 ' CD1' ' A' ' 36' ' ' ILE . 93.7 t -67.02 -45.41 87.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.601 -0.687 . . . . 0.0 109.901 -179.576 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.4 t -63.7 -37.74 80.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.272 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.5 -30.59 63.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.462 -0.774 . . . . 0.0 109.789 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.93 -32.21 73.82 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.201 -0.937 . . . . 0.0 109.357 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.453 ' HE1' HD12 ' A' ' 36' ' ' ILE . 6.9 p90 -147.01 52.86 1.08 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 109.112 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.3 136.58 52.94 Favored Pre-proline 0 N--CA 1.486 1.374 0 O-C-N 121.207 -0.933 . . . . 0.0 110.187 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.67 -152.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 121.815 1.676 . . . . 0.0 110.388 178.741 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -78.26 9.75 3.58 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.908 -1.12 . . . . 0.0 108.709 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -113.85 136.16 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.498 -0.751 . . . . 0.0 109.883 -179.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.92 142.48 90.76 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.19 -0.944 . . . . 0.0 108.574 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -48.67 -32.4 21.53 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 121.593 1.529 . . . . 0.0 111.638 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.81 -25.27 65.49 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.372 -0.83 . . . . 0.0 109.395 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -105.01 6.42 33.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -96.6 143.4 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.282 -0.886 . . . . 0.0 108.762 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -72.39 92.33 1.42 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.126 -0.984 . . . . 0.0 109.365 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.688 HG21 ' HE3' ' A' ' 87' ' ' LYS . 18.3 m -62.79 6.23 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.9 m-20 -95.9 9.7 39.74 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 108.723 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 11.1 tp -90.22 135.6 33.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.487 -0.758 . . . . 0.0 109.561 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.585 ' OD2' ' NH2' ' A' ' 67' ' ' ARG . 90.0 m-20 -63.98 121.89 15.19 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -75.81 7.89 3.52 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.286 -0.884 . . . . 0.0 110.046 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.0 t -53.43 -42.79 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.063 -1.023 . . . . 0.0 108.636 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -55.74 -35.5 66.24 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.526 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 33.5 m120 -85.19 15.12 4.44 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.39 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.7 t -51.73 -37.33 20.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.014 -1.286 . . . . 0.0 108.547 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.701 ' CD1' HG13 ' A' ' 11' ' ' VAL . 2.5 tt -70.81 -25.24 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 0.0 110.426 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -58.1 -34.33 70.07 Favored 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 111.009 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.92 -64.29 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.984 -1.073 . . . . 0.0 111.575 -178.479 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.531 ' N ' HD22 ' A' ' 39' ' ' LEU . 4.2 mm? -72.37 -52.5 15.8 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.976 -1.078 . . . . 0.0 111.211 -178.091 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.522 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.02 91.37 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.3 tp -57.71 -43.95 85.59 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.365 -1.079 . . . . 0.0 109.208 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 42' ' ' LEU . 94.2 mt -63.64 -41.82 98.21 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 108.98 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -64.26 -36.95 85.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.413 -0.804 . . . . 0.0 109.53 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 40' ' ' GLY . 74.8 t -62.66 -45.57 98.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.379 -0.825 . . . . 0.0 110.22 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.8 mm -61.35 -44.24 98.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.146 -0.971 . . . . 0.0 109.829 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.0 -43.78 91.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.242 -0.911 . . . . 0.0 109.766 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.592 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -73.39 -38.92 65.46 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.796 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 28.5 tp -59.69 -43.34 94.07 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.2 -0.938 . . . . 0.0 109.917 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.577 ' O ' ' N ' ' A' ' 53' ' ' GLY . 59.3 tt0 -65.16 -36.09 83.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 109.951 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -60.59 -38.99 86.47 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.984 -1.072 . . . . 0.0 110.125 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 mtp180 -74.67 -44.65 49.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.143 -0.973 . . . . 0.0 112.079 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -108.11 -7.17 16.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.765 -1.209 . . . . 0.0 111.354 -178.088 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.78 32.18 73.8 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.1 mt -91.22 152.42 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.257 -1.143 . . . . 0.0 109.835 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.1 150.48 29.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.075 -1.016 . . . . 0.0 109.008 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.85 -40.27 72.61 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.251 -0.906 . . . . 0.0 109.969 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 50.79 49.76 20.36 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.11 -0.994 . . . . 0.0 109.205 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -74.62 116.03 14.85 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.939 . . . . 0.0 109.909 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 ' H ' ' A' ' 61' ' ' LEU . 27.3 t -124.91 141.68 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 61' ' ' LEU . 19.8 pt-20 -60.5 -31.95 70.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.085 -1.009 . . . . 0.0 110.466 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.486 ' O ' ' O ' ' A' ' 60' ' ' GLU . 60.7 mt 44.04 -170.5 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.055 -1.028 . . . . 0.0 109.642 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -134.23 162.25 58.81 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.344 -0.848 . . . . 0.0 109.409 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.83 -26.81 83.76 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.756 2.304 . . . . 0.0 112.17 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -61.04 -31.53 71.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.39 -0.818 . . . . 0.0 109.909 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.8 t60 -68.07 -26.46 65.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.184 -0.948 . . . . 0.0 110.205 -179.512 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.432 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 94.1 m-85 -97.41 10.17 40.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 109.763 -179.474 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.585 ' NH2' ' OD2' ' A' ' 29' ' ' ASP . 34.2 tpt85 -55.61 -38.32 69.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.076 -1.015 . . . . 0.0 109.879 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -137.75 153.99 49.66 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.095 -1.003 . . . . 0.0 110.145 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.4 mt -62.68 -36.58 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.264 -0.898 . . . . 0.0 110.006 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -60.76 -36.78 79.8 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.235 -0.916 . . . . 0.0 110.251 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 90.5 p -61.37 -36.16 79.45 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.022 -1.049 . . . . 0.0 109.449 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.97 -38.96 83.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.238 -0.914 . . . . 0.0 109.097 179.522 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.712 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.3 t0 -57.51 -36.98 72.26 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.46 -0.775 . . . . 0.0 109.352 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.38 -43.53 98.71 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.224 -0.923 . . . . 0.0 109.222 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -65.04 -46.95 79.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.259 -0.9 . . . . 0.0 109.207 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 53.2 t -65.24 -40.58 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 121.45 -0.781 . . . . 0.0 109.712 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -58.99 -42.46 86.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.243 -0.91 . . . . 0.0 109.684 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.83 -35.02 91.4 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 120.222 -0.989 . . . . 0.0 110.645 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -86.29 -48.02 8.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.899 -1.353 . . . . 0.0 109.853 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.2 t -138.54 151.03 46.97 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.759 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t -134.81 89.74 24.37 Favored Pre-proline 0 N--CA 1.487 1.414 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.452 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 17.1 Cg_exo -63.63 -175.2 0.25 Allowed 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.715 2.276 . . . . 0.0 111.6 179.222 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.452 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 35.6 Cg_exo -58.4 150.59 66.77 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.423 2.082 . . . . 0.0 111.505 179.748 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 84' ' ' VAL . 5.6 m -89.35 127.61 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 110.044 -179.139 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -139.08 142.82 38.14 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.49 -0.756 . . . . 0.0 109.151 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.75 142.07 58.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.107 -0.995 . . . . 0.0 109.432 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.688 ' HE3' HG21 ' A' ' 26' ' ' VAL . 49.3 tttp -81.49 138.45 35.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.265 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 71.6 mt -57.06 -36.47 70.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.602 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 95.2 mt-30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.034 -0.984 . . . . 0.0 109.535 179.89 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.455 ' O2P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.302 0.573 . . . . 0.0 109.931 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.484 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 98.5 mm-40 -87.07 123.76 32.49 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.596 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 22.3 m-70 54.54 15.78 1.14 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.107 -0.996 . . . . 0.0 108.654 -179.386 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.401 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -64.19 -39.81 94.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.459 -0.776 . . . . 0.0 110.196 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.72 -39.24 87.89 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.177 -0.952 . . . . 0.0 110.157 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.6 t -64.77 -37.69 80.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.158 -0.964 . . . . 0.0 109.307 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.402 ' O ' HG12 ' A' ' 11' ' ' VAL . 90.4 mt -63.98 -36.73 77.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 110.54 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.47 -51.09 67.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.959 -1.088 . . . . 0.0 110.049 -179.422 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . 0.41 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.0 OUTLIER -70.92 -36.72 72.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.101 -0.999 . . . . 0.0 109.473 179.508 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.423 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 59.6 t80 -65.74 -51.32 60.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.345 -0.847 . . . . 0.0 109.97 -179.611 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.5 p -68.33 -41.87 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.925 . . . . 0.0 109.589 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.0 t -64.61 -39.32 85.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -0.928 . . . . 0.0 109.521 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.95 -28.16 55.75 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.392 -0.817 . . . . 0.0 109.731 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -65.09 -29.16 70.01 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.263 -0.898 . . . . 0.0 108.833 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.617 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 22.8 p90 -151.0 48.99 0.85 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.376 -0.827 . . . . 0.0 109.076 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.485 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -79.76 137.12 54.52 Favored Pre-proline 0 N--CA 1.487 1.4 0 O-C-N 120.975 -1.078 . . . . 0.0 110.343 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.83 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.974 1.782 . . . . 0.0 110.51 178.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.544 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.9 p30 -81.05 13.29 2.82 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.923 -1.111 . . . . 0.0 108.803 179.242 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.544 HG23 ' OD2' ' A' ' 18' ' ' ASP . 38.6 t -113.43 136.65 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.609 -0.682 . . . . 0.0 109.91 -179.35 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.03 140.61 73.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.039 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.584 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 52.3 Cg_exo -48.41 -31.75 18.6 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.795 1.664 . . . . 0.0 111.575 179.307 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.37 -21.87 65.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.519 -0.738 . . . . 0.0 109.412 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -97.6 1.61 48.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.421 -0.8 . . . . 0.0 109.119 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.2 t -107.09 137.54 37.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.65 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.0 t0 -70.56 99.87 1.72 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 109.319 -179.505 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.69 ' CG1' ' HZ2' ' A' ' 87' ' ' LYS . 12.6 m -60.07 5.84 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.379 -0.826 . . . . 0.0 109.682 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -96.4 9.19 42.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 0.0 108.748 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.3 tp -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.561 -0.712 . . . . 0.0 109.52 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . 0.411 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.0 m-20 -65.14 121.51 14.92 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 179.162 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.519 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -71.07 8.51 0.93 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.195 -0.94 . . . . 0.0 109.493 -179.231 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.459 ' O ' ' N ' ' A' ' 34' ' ' GLY . 57.0 t -56.39 -41.81 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.164 -0.96 . . . . 0.0 108.8 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -55.51 -34.09 64.33 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 178.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.598 ' O ' ' N ' ' A' ' 35' ' ' VAL . 3.6 m-20 -84.02 14.45 4.14 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.953 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.46 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.134 -1.187 . . . . 0.0 110.134 -179.116 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.8 t -52.09 -39.29 26.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 120.921 -1.341 . . . . 0.0 108.324 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.14 -25.2 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.605 -0.685 . . . . 0.0 110.118 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.6 m-20 -62.12 -32.1 72.64 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 110.797 -178.465 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.5 m -105.44 -64.93 1.09 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.004 -1.06 . . . . 0.0 111.306 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.0 tt -71.71 -52.15 19.25 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 0.0 111.19 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.1 -36.69 86.12 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.5 tp -58.53 -43.36 89.19 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.348 -1.089 . . . . 0.0 109.881 -179.051 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 93.9 mt -67.53 -44.11 79.15 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 110.111 -179.639 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -65.08 -35.03 79.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -63.21 -44.99 99.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.293 -0.879 . . . . 0.0 110.979 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.06 -43.85 93.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.655 -1.278 . . . . 0.0 110.062 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.29 -45.32 76.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.109 -0.994 . . . . 0.0 110.396 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.485 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -76.6 -44.63 33.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.167 -0.958 . . . . 0.0 109.957 -179.709 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.5 tp -57.02 -39.0 73.94 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.337 -0.852 . . . . 0.0 109.207 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' A' ' 53' ' ' GLY . 12.0 tt0 -60.87 -43.27 98.63 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.204 -0.935 . . . . 0.0 109.25 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.09 -40.04 90.5 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.199 -0.938 . . . . 0.0 110.025 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.423 ' NH2' ' CZ ' ' A' ' 10' ' ' PHE . 73.8 ttt180 -63.48 -45.94 88.44 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.252 -0.905 . . . . 0.0 111.177 -178.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -106.86 -5.3 18.42 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.002 -1.062 . . . . 0.0 110.63 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.602 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.63 34.04 72.44 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 71.9 mt -98.88 144.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.301 -1.117 . . . . 0.0 109.633 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.45 148.57 41.37 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.136 -0.978 . . . . 0.0 109.586 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.48 -29.8 68.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.442 -0.786 . . . . 0.0 109.693 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.96 ' O ' HG13 ' A' ' 59' ' ' VAL . 85.3 m-20 54.62 49.03 19.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.283 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' A' ' 58' ' ' ASP . 45.1 p30 -39.25 91.8 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.498 -0.751 . . . . 0.0 110.254 -179.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 ' O ' ' A' ' 57' ' ' ASP . 29.4 m -128.43 158.05 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 108.981 179.564 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.482 ' OE1' ' O8 ' ' A' ' 101' ' ' PN7 . 84.3 tt0 -100.35 129.96 46.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 109.729 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.3 140.92 42.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.448 -0.782 . . . . 0.0 109.421 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.83 156.13 55.57 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.517 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.98 -26.59 83.44 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.666 2.244 . . . . 0.0 112.031 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.35 -30.87 71.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.328 -0.857 . . . . 0.0 109.715 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.408 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.0 t60 -67.74 -26.79 66.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 109.662 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -93.65 9.22 37.83 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.179 -0.951 . . . . 0.0 109.358 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 15.2 tpt180 -54.91 -39.59 68.96 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.807 -179.677 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -141.96 153.98 44.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.017 -1.052 . . . . 0.0 110.098 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.2 mt -59.09 -36.66 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.365 -0.834 . . . . 0.0 109.838 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.9 ttp180 -60.28 -39.13 85.77 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.268 -0.895 . . . . 0.0 110.234 -179.211 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 t -58.3 -44.08 88.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.016 -1.053 . . . . 0.0 109.619 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.494 HD11 HD11 ' A' ' 30' ' ' LEU . 80.0 mt -62.96 -38.74 82.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.177 -0.952 . . . . 0.0 109.427 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.606 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.6 t0 -56.8 -37.88 71.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.396 -0.815 . . . . 0.0 109.702 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.78 -42.57 97.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.2 -0.938 . . . . 0.0 109.672 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.408 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.8 t80 -64.07 -48.34 76.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.148 -0.97 . . . . 0.0 109.459 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.75 -42.4 92.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.355 -0.841 . . . . 0.0 109.982 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.9 t -63.14 -40.89 90.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.167 -0.958 . . . . 0.0 109.903 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.7 -33.78 74.13 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.16 -47.99 4.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.046 -1.267 . . . . 0.0 110.506 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.8 m -128.68 138.16 52.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.341 -0.849 . . . . 0.0 109.943 -179.62 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.793 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -127.85 89.57 50.25 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.308 -0.87 . . . . 0.0 109.185 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . 0.596 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 63.8 Cg_endo -82.62 161.53 16.72 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.724 2.283 . . . . 0.0 112.556 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.24 150.83 71.69 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.91 2.407 . . . . 0.0 111.943 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 84' ' ' VAL . 12.0 p -101.22 134.13 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 0.0 109.867 -179.602 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -124.43 163.37 21.93 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.887 -0.782 . . . . 0.0 108.887 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.12 138.45 37.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.038 -1.039 . . . . 0.0 109.192 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.69 ' HZ2' ' CG1' ' A' ' 26' ' ' VAL . 32.4 tttt -59.63 -34.57 72.97 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.187 -0.946 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 58.8 mt -57.55 -35.63 70.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 109.428 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.072 -0.966 . . . . 0.0 109.464 -179.955 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 101' ' ' PN7 . . . . . 0.482 ' O8 ' ' OE1' ' A' ' 60' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.8 mtm . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 121.171 0.51 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.818 ' OE1' HG13 ' A' ' 77' ' ' VAL . 89.7 mt-30 55.64 53.21 9.87 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.402 -0.811 . . . . 0.0 109.14 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.58 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.0 m80 77.14 41.46 0.15 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.671 -0.643 . . . . 0.0 109.43 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.421 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.6 -33.41 73.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.296 -0.877 . . . . 0.0 109.444 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.16 -35.94 80.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.169 -0.957 . . . . 0.0 109.748 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 74.7 t -65.88 -39.8 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 0.0 109.123 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.421 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.1 mt -59.49 -49.58 83.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.432 -0.792 . . . . 0.0 109.298 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -41.79 98.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.2 -0.938 . . . . 0.0 108.534 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.43 -37.33 86.58 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.464 -0.773 . . . . 0.0 109.172 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -59.94 -52.99 63.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.544 -0.723 . . . . 0.0 110.044 -178.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.711 HG21 HD13 ' A' ' 30' ' ' LEU . 4.6 p -73.49 -42.39 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.213 -0.929 . . . . 0.0 109.889 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.6 t -64.45 -38.12 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.337 -0.852 . . . . 0.0 110.411 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -56.15 -26.51 50.6 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.691 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.454 ' OE1' HD12 ' A' ' 36' ' ' ILE . 98.0 mt-10 -64.26 -31.11 72.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 109.168 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -153.96 52.88 0.69 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 109.316 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.513 ' CB ' HG12 ' A' ' 12' ' ' VAL . 1.7 pt? -80.74 136.61 51.33 Favored Pre-proline 0 N--CA 1.486 1.334 0 O-C-N 120.964 -1.085 . . . . 0.0 110.023 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.4 -153.81 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.007 1.805 . . . . 0.0 110.773 178.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -82.85 16.7 2.15 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.075 -1.016 . . . . 0.0 108.839 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.419 HG23 ' OD2' ' A' ' 18' ' ' ASP . 40.2 t -112.85 138.02 43.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.56 -0.712 . . . . 0.0 110.03 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.78 137.16 96.07 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.247 -0.908 . . . . 0.0 108.651 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -48.35 -29.99 14.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.836 1.691 . . . . 0.0 112.016 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.31 -24.06 66.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.325 -0.859 . . . . 0.0 109.486 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -101.18 8.18 42.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 109.452 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -100.99 137.5 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.324 -0.86 . . . . 0.0 108.875 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.572 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.91 90.96 0.14 Allowed 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.194 -0.941 . . . . 0.0 109.367 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.512 ' O ' HD12 ' A' ' 69' ' ' ILE . 6.3 m -61.74 6.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.345 -0.847 . . . . 0.0 109.551 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.572 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -92.05 12.44 21.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.213 -0.929 . . . . 0.0 109.135 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.2 tp -85.27 134.21 34.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.862 . . . . 0.0 109.613 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.507 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -64.3 121.54 14.54 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.369 -0.832 . . . . 0.0 109.065 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 67.6 mt -63.62 -8.14 9.17 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.188 -0.945 . . . . 0.0 109.602 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.483 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.33 -41.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.058 -1.027 . . . . 0.0 108.904 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.483 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.2 m-20 -59.2 -34.92 72.73 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.644 ' O ' ' N ' ' A' ' 35' ' ' VAL . 83.1 m-20 -85.19 16.9 3.27 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.45 -14.81 0.01 OUTLIER Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.644 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.1 t -51.85 -39.56 25.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 120.909 -1.348 . . . . 0.0 108.07 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.9 tt -71.31 -25.03 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.635 -0.666 . . . . 0.0 110.319 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -60.48 -32.09 71.08 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.215 -0.928 . . . . 0.0 111.432 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.14 -65.05 1.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.892 -1.13 . . . . 0.0 111.405 -178.348 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 16.2 mt -74.01 -52.43 12.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.022 -1.048 . . . . 0.0 111.124 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.62 -35.83 91.63 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.62 -42.23 87.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.232 -1.157 . . . . 0.0 109.121 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -63.35 -44.14 95.68 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.161 -0.962 . . . . 0.0 109.011 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -68.38 -41.08 81.06 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -67.59 -46.94 81.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.4 -0.812 . . . . 0.0 110.177 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.23 -45.01 99.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.542 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.42 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.192 -0.942 . . . . 0.0 109.999 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.751 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.27 -49.37 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 110.085 -179.744 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.8 tp -61.8 -41.39 97.69 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.55 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.9 pt-20 -70.57 -35.66 73.19 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.17 -0.956 . . . . 0.0 109.829 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -61.59 -41.95 98.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.248 -0.907 . . . . 0.0 110.092 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.751 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 86.0 mtt180 -64.4 -38.82 92.36 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 111.133 -179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' HG21 ' A' ' 80' ' ' THR . 96.7 m-85 -102.85 -4.54 24.71 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.96 -1.087 . . . . 0.0 110.244 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 61.75 35.37 91.14 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.4 mt -90.19 141.2 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -1.189 . . . . 0.0 109.849 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.0 136.26 50.24 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.025 -1.047 . . . . 0.0 108.9 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.57 -35.23 79.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.089 -1.007 . . . . 0.0 109.482 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.619 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.7 p30 -65.87 -25.93 67.4 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.35 -0.844 . . . . 0.0 110.024 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.619 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 54.3 t0 -54.27 -35.83 62.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.778 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 43.7 t -111.64 136.94 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.444 -0.785 . . . . 0.0 109.708 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -88.28 142.26 27.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 109.287 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.479 HD13 HD22 ' A' ' 41' ' ' LEU . 35.9 mt -93.05 135.28 34.37 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.223 -0.923 . . . . 0.0 109.697 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -162.27 150.35 12.06 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.269 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.42 -27.07 76.99 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.473 2.115 . . . . 0.0 112.065 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.64 -30.57 71.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.401 -0.812 . . . . 0.0 109.747 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -67.65 -27.05 66.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.743 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.451 ' CE2' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -102.69 10.34 38.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.234 -0.916 . . . . 0.0 109.73 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.453 HH22 ' CB ' ' A' ' 29' ' ' ASP . 32.8 tpt85 -54.15 -39.03 66.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.506 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.9 p -147.79 151.87 36.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.076 -1.015 . . . . 0.0 109.873 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 83.7 mt -66.1 -37.29 79.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.293 -0.879 . . . . 0.0 109.892 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -61.32 -38.44 86.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 -179.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.9 p -62.93 -40.45 97.66 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.007 -1.058 . . . . 0.0 109.581 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.3 mt -68.33 -40.97 83.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.185 -0.947 . . . . 0.0 109.74 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.46 -40.69 87.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.383 -0.823 . . . . 0.0 110.156 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.14 -43.05 88.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.125 -0.984 . . . . 0.0 110.001 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.33 -50.22 72.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.619 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.7 -44.84 93.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.818 HG13 ' OE1' ' A' ' 2' ' ' GLN . 48.8 t -60.08 -39.5 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.102 -0.999 . . . . 0.0 109.445 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.77 -32.95 66.52 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.51 -49.47 3.55 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.09 -1.241 . . . . 0.0 110.634 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.619 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.7 t -160.47 152.31 19.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.126 -0.983 . . . . 0.0 109.887 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 10.3 t . . . . . 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.228 179.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.577 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 83.8 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.264 0.554 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -59.11 -38.04 78.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 26.2 m-70 -114.57 11.32 17.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.486 -0.759 . . . . 0.0 109.296 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -56.66 -39.47 73.8 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.956 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 89.2 p -63.99 -36.04 82.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.008 -1.057 . . . . 0.0 109.432 -179.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -68.79 -36.09 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.534 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.66 ' O ' HG22 ' A' ' 11' ' ' VAL . 98.7 mt -59.13 -50.42 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -0.917 . . . . 0.0 109.996 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.84 -47.86 79.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.994 -1.066 . . . . 0.0 109.004 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.74 -41.22 98.06 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 121.347 0.594 . . . . 0.0 110.015 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -66.14 -51.36 58.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.32 -0.863 . . . . 0.0 111.145 -178.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.66 HG22 ' O ' ' A' ' 7' ' ' ILE . 17.1 m -72.38 -43.59 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.949 . . . . 0.0 110.848 -178.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.53 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.1 t -62.89 -36.28 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -0.962 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -57.64 -37.59 73.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 109.508 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.69 -36.22 78.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.88 . . . . 0.0 110.303 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -91.8 -58.51 2.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 110.575 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.686 HD22 HG23 ' A' ' 19' ' ' VAL . 1.6 mt -128.98 87.58 54.12 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.347 -0.845 . . . . 0.0 110.443 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -91.48 -18.96 0.88 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.154 2.569 . . . . 0.0 112.116 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -75.96 -4.99 44.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 108.734 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.686 HG23 HD22 ' A' ' 16' ' ' LEU . 45.9 t -113.99 141.62 29.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -61.19 115.96 16.94 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 120.698 -1.251 . . . . 0.0 108.628 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -63.75 -23.76 69.15 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 121.462 1.442 . . . . 0.0 111.409 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.25 -13.82 60.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.467 -0.771 . . . . 0.0 110.073 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.474 ' CG ' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -82.79 7.51 14.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.985 -1.072 . . . . 0.0 109.234 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -100.7 135.29 37.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -64.72 86.78 0.05 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.065 -1.022 . . . . 0.0 109.384 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.3 m -61.84 5.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -100.1 5.5 44.92 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.1 141.37 30.32 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.704 -0.622 . . . . 0.0 109.459 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.458 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.1 m-20 -60.37 121.4 11.96 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -68.62 8.37 0.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.289 -0.882 . . . . 0.0 109.83 -178.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.78 -40.01 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.121 -0.987 . . . . 0.0 108.974 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.5 t0 -57.76 -35.46 70.79 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -85.71 14.87 5.24 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.63 -14.93 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.6 t -51.73 -36.44 18.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.172 -1.193 . . . . 0.0 108.803 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.595 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.1 tt -70.45 -24.93 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 110.315 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -59.59 -34.06 72.25 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 111.08 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.5 m -105.72 -64.5 1.14 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.086 -1.009 . . . . 0.0 111.503 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.591 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -71.42 -52.2 19.86 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.045 -1.034 . . . . 0.0 111.151 -178.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.28 -37.31 92.76 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.595 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.4 tp -58.76 -40.7 84.68 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.367 -1.078 . . . . 0.0 109.091 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.48 -43.45 94.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.333 -0.855 . . . . 0.0 108.805 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -64.35 -36.74 85.1 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 40' ' ' GLY . 58.5 t -60.25 -43.29 93.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.385 -0.822 . . . . 0.0 109.872 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.425 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 1.5 mp -60.35 -49.39 84.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.26 -42.06 96.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.905 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -71.46 -40.92 70.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.323 -0.86 . . . . 0.0 109.783 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.53 -46.39 86.88 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.324 -0.86 . . . . 0.0 109.519 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -65.41 -39.29 91.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.249 -0.907 . . . . 0.0 109.019 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -67.24 -36.79 82.39 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.391 -0.818 . . . . 0.0 110.51 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -86.22 -51.74 6.09 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.274 -0.891 . . . . 0.0 112.167 -178.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -93.67 -5.57 48.29 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.682 -1.261 . . . . 0.0 111.16 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.59 24.14 76.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.1 mt -92.97 144.12 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -1.096 . . . . 0.0 109.422 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.67 146.75 44.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.062 -1.024 . . . . 0.0 109.272 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -57.81 -33.21 68.35 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.352 -0.842 . . . . 0.0 109.569 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.964 ' O ' HG23 ' A' ' 59' ' ' VAL . 84.7 m-20 54.67 47.94 21.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.343 -0.848 . . . . 0.0 109.256 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.0 m-20 -42.86 90.45 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.447 -0.783 . . . . 0.0 109.875 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 57' ' ' ASP . 44.1 t -125.74 139.32 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -74.42 130.77 40.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.017 -1.052 . . . . 0.0 109.671 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.28 142.68 45.55 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.652 -0.655 . . . . 0.0 109.449 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.8 149.03 66.59 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.078 -1.014 . . . . 0.0 109.462 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.79 -20.85 72.28 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.529 2.153 . . . . 0.0 112.342 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.8 -32.48 73.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 110.259 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -68.34 -26.71 65.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.985 -1.072 . . . . 0.0 109.975 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -97.41 5.98 48.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.161 -0.962 . . . . 0.0 109.725 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -55.52 -41.19 72.79 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.521 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -128.19 147.45 50.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.0 mt -61.46 -36.3 72.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.318 -0.864 . . . . 0.0 109.828 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.8 mtm180 -60.8 -37.32 81.56 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 110.19 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.7 t -59.08 -43.95 91.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.09 -1.007 . . . . 0.0 109.816 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.49 -38.88 83.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.136 -0.977 . . . . 0.0 109.628 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 21.5 t70 -57.12 -38.38 73.36 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.329 -0.857 . . . . 0.0 109.774 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.5 -44.45 90.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.719 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 74.0 t80 -63.55 -45.31 91.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.103 -0.998 . . . . 0.0 109.478 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.4 t -64.37 -43.67 97.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.341 -0.849 . . . . 0.0 110.099 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -63.16 -42.38 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.061 -1.024 . . . . 0.0 109.822 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.24 -30.54 71.12 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.39 -47.84 5.01 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.05 -1.265 . . . . 0.0 110.409 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 14.0 t -140.7 153.66 46.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.219 -0.926 . . . . 0.0 109.909 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.805 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t . . . . . 0 N--CA 1.487 1.402 0 O-C-N 121.275 -0.891 . . . . 0.0 109.511 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.9 mtm . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.39 0.614 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.86 -38.39 82.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.287 -0.883 . . . . 0.0 109.59 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 59.8 m-70 -126.41 11.27 7.42 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 -179.847 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.432 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.44 -36.52 76.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.148 -0.97 . . . . 0.0 109.849 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -62.09 -34.79 76.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 109.425 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.9 t -66.1 -36.63 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.35 -0.844 . . . . 0.0 109.264 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.72 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.1 mt -64.98 -41.89 93.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 110.325 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.94 -50.64 67.86 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.03 -1.044 . . . . 0.0 110.514 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.06 -43.42 71.22 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -59.03 -43.64 91.64 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.981 -1.074 . . . . 0.0 109.26 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 7' ' ' ILE . 75.2 t -71.93 -49.73 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -0.836 . . . . 0.0 110.449 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -63.85 -36.85 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.225 -0.922 . . . . 0.0 110.045 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -61.36 -31.0 70.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.24 -0.913 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.64 -31.16 72.03 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.149 -0.97 . . . . 0.0 109.278 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -102.87 -58.8 1.81 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.24 -0.913 . . . . 0.0 110.548 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.849 HD12 HG23 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -131.12 88.59 44.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.308 -0.87 . . . . 0.0 111.317 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -86.31 -13.51 5.23 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.73 2.287 . . . . 0.0 111.798 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.37 -4.28 41.43 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.164 -0.96 . . . . 0.0 109.084 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.849 HG23 HD12 ' A' ' 16' ' ' LEU . 43.0 t -113.31 142.47 25.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.663 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.23 115.67 15.63 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.75 -1.219 . . . . 0.0 108.649 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -64.46 -25.41 63.22 Favored 'Trans proline' 0 N--CA 1.486 1.08 0 C-N-CA 121.527 1.485 . . . . 0.0 111.68 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.02 -14.29 61.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.354 -0.841 . . . . 0.0 109.178 179.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.663 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -82.62 2.92 30.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.838 . . . . 0.0 109.106 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -99.47 136.05 32.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.83 86.45 0.23 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.18 -0.95 . . . . 0.0 109.469 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.38 5.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.273 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -94.4 3.4 55.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 108.751 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.638 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.6 tt -97.14 138.66 34.3 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.539 -0.726 . . . . 0.0 109.496 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.638 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.8 m-20 -60.48 121.34 11.88 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.432 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 pp -65.34 5.7 0.37 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.793 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.8 p -50.57 -37.91 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.037 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.2 m-20 -57.71 -36.97 72.73 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -85.64 14.7 5.39 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -15.67 0.02 OUTLIER Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.41 -34.36 15.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.85 -1.382 . . . . 0.0 108.507 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -71.16 -24.36 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.554 -0.716 . . . . 0.0 109.883 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -57.91 -33.14 68.45 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.322 -0.861 . . . . 0.0 111.445 -178.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.2 m -105.83 -64.59 1.14 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.856 -1.153 . . . . 0.0 111.497 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.43 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -72.42 -52.22 16.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.937 -1.102 . . . . 0.0 110.805 -178.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.867 ' O ' HG22 ' A' ' 44' ' ' VAL . . . -65.45 -36.72 92.94 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.6 tp -58.52 -41.21 84.97 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.356 -1.085 . . . . 0.0 109.285 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.5 tp -65.8 -41.48 91.87 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.008 -1.057 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -70.22 -44.69 68.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 111.519 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.867 HG22 ' O ' ' A' ' 40' ' ' GLY . 16.0 m -72.43 -42.09 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.939 -1.1 . . . . 0.0 111.624 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -58.7 -47.8 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 120.845 -1.159 . . . . 0.0 110.241 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.06 -39.61 92.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 110.241 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.782 ' HE1' HH21 ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.17 -49.35 15.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.927 -1.108 . . . . 0.0 110.403 -179.602 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.1 tp -60.15 -46.0 91.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.232 -0.917 . . . . 0.0 110.134 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.536 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -66.81 -38.06 85.73 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.013 -1.054 . . . . 0.0 109.463 -179.924 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.69 -38.91 92.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.934 . . . . 0.0 109.584 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.782 HH21 ' HE1' ' A' ' 47' ' ' TRP . 43.1 mmm-85 -59.28 -38.97 81.47 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.542 -0.724 . . . . 0.0 110.143 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -95.84 0.95 52.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.167 -0.958 . . . . 0.0 110.089 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.11 37.95 63.73 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.2 mt -104.04 148.58 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.411 -1.052 . . . . 0.0 109.79 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.539 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -91.25 122.77 34.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 108.396 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.36 -38.98 93.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.08 -1.012 . . . . 0.0 109.745 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -62.1 -37.12 83.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 0.0 110.093 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.539 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 89.0 m-20 -57.14 -37.69 72.42 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.231 -0.918 . . . . 0.0 110.353 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.91 134.24 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.306 -0.871 . . . . 0.0 110.05 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -108.28 137.55 46.07 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.478 -0.764 . . . . 0.0 109.307 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.54 146.83 30.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.769 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.9 160.47 29.68 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.361 -0.837 . . . . 0.0 109.425 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -62.76 -32.21 78.22 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.799 2.333 . . . . 0.0 112.123 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -62.62 -29.01 70.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.399 -0.813 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.402 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 32.0 t-80 -67.84 -26.38 66.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.365 -0.834 . . . . 0.0 110.149 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -97.95 8.55 44.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.075 -1.015 . . . . 0.0 110.133 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -56.01 -41.07 74.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.193 -0.942 . . . . 0.0 109.355 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.3 m -128.8 145.73 51.11 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.5 mt -63.0 -39.64 85.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.119 -0.988 . . . . 0.0 109.855 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.6 mtm180 -61.54 -37.02 82.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.058 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -58.19 -38.88 77.58 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.121 -0.987 . . . . 0.0 109.638 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.408 ' HB ' HD13 ' A' ' 7' ' ' ILE . 71.0 mt -63.63 -42.3 95.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.323 -0.86 . . . . 0.0 109.612 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.74 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.4 t0 -59.48 -38.65 81.38 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.111 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 -46.07 80.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.087 -1.008 . . . . 0.0 110.05 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.402 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.5 t80 -63.38 -47.0 83.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.127 -0.983 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.528 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.4 t -64.75 -42.74 95.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.317 -0.864 . . . . 0.0 109.727 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.7 t -59.67 -41.47 85.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.239 -0.913 . . . . 0.0 109.845 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.65 -31.47 75.25 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 120.264 -0.97 . . . . 0.0 110.748 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -48.76 3.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.03 -1.277 . . . . 0.0 110.751 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -129.68 156.81 43.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.324 -0.86 . . . . 0.0 109.664 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.791 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 C--N 1.301 -1.51 0 O-C-N 121.13 -0.981 . . . . 0.0 109.381 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.699 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 86.1 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.2 -38.27 82.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.771 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.615 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 73.4 m-70 -141.5 14.39 2.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.708 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -60.33 -33.4 72.34 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 110.097 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -61.26 -36.59 80.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.945 -1.097 . . . . 0.0 109.613 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.7 t -66.79 -39.68 84.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.089 -1.007 . . . . 0.0 108.819 179.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 91.1 mt -61.73 -50.3 80.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.032 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.725 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.31 -48.78 74.31 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.397 -0.814 . . . . 0.0 109.137 179.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.02 -44.76 95.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.551 -0.718 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.436 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 66.4 t80 -69.56 -48.44 60.31 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.559 -0.713 . . . . 0.0 109.525 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.665 HG13 ' CD1' ' A' ' 36' ' ' ILE . 94.3 t -66.8 -45.26 88.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.513 -0.742 . . . . 0.0 109.954 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.5 t -64.1 -37.24 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.374 -0.829 . . . . 0.0 109.523 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.57 -30.71 61.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.363 -0.836 . . . . 0.0 110.022 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.36 -29.69 70.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.104 -0.997 . . . . 0.0 109.298 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.617 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.3 p90 -149.2 50.04 0.97 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.374 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.477 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.16 136.86 53.23 Favored Pre-proline 0 N--CA 1.487 1.383 0 O-C-N 120.932 -1.105 . . . . 0.0 110.184 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.21 -153.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.96 1.773 . . . . 0.0 110.581 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -80.91 13.56 2.62 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.051 -1.031 . . . . 0.0 108.643 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.47 137.17 47.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.589 -0.694 . . . . 0.0 110.028 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.77 140.7 74.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.176 -0.953 . . . . 0.0 108.898 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -48.57 -30.96 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.891 1.727 . . . . 0.0 111.85 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.58 -23.4 66.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.326 -0.859 . . . . 0.0 109.49 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -96.43 3.06 53.06 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.35 -0.844 . . . . 0.0 109.063 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.8 t -105.91 136.94 38.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.56 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.0 t0 -70.91 96.3 1.27 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.075 -1.016 . . . . 0.0 109.428 -179.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 14.3 m -61.7 6.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 109.589 179.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.56 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.9 m-20 -93.8 7.44 44.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 108.909 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.582 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.4 tt -92.61 135.14 34.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.593 -0.692 . . . . 0.0 109.642 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.582 ' O ' HD23 ' A' ' 28' ' ' LEU . 91.6 m-20 -62.01 121.64 13.5 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -70.51 9.68 0.59 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.202 -0.936 . . . . 0.0 109.519 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -52.15 -38.03 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.201 -0.937 . . . . 0.0 109.462 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -56.94 -36.76 70.64 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.621 ' O ' ' N ' ' A' ' 35' ' ' VAL . 75.7 m-20 -86.25 14.76 6.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.48 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.621 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.82 -34.26 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 120.928 -1.336 . . . . 0.0 108.509 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.665 ' CD1' HG13 ' A' ' 11' ' ' VAL . 3.4 tt -71.07 -24.47 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.7 . . . . 0.0 110.134 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -58.14 -34.1 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.36 -0.837 . . . . 0.0 111.51 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -104.98 -65.26 1.05 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.858 -1.151 . . . . 0.0 111.148 -178.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -69.71 -47.22 63.93 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.157 -0.964 . . . . 0.0 110.722 -178.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.437 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.1 -39.97 72.63 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.921 -1.133 . . . . 0.0 110.379 -179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.2 tt -58.66 -39.81 81.71 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.19 -1.182 . . . . 0.0 109.078 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -62.25 -44.18 97.15 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.458 -0.897 . . . . 0.0 108.67 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -69.54 -40.15 77.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.326 -0.858 . . . . 0.0 109.857 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.6 t -64.77 -45.9 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.363 -0.836 . . . . 0.0 110.268 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.69 -46.02 97.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.238 -0.913 . . . . 0.0 109.532 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.35 97.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 109.951 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.436 ' CZ2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -75.09 -40.73 59.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.918 . . . . 0.0 109.995 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.77 -43.88 85.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.252 -0.905 . . . . 0.0 109.639 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -64.18 -39.77 94.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.185 -0.947 . . . . 0.0 109.449 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -67.34 -45.28 76.85 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 110.836 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.6 ttt180 -70.02 -45.34 67.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.274 -0.891 . . . . 0.0 112.131 -178.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -103.38 -5.33 23.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.815 -1.178 . . . . 0.0 111.433 -178.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.09 27.68 73.61 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.5 mt -98.3 143.87 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -1.153 . . . . 0.0 109.451 -179.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.44 149.74 33.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.145 -0.972 . . . . 0.0 109.579 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.94 -31.93 63.36 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.431 -0.793 . . . . 0.0 109.529 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.52 43.86 29.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.365 -0.834 . . . . 0.0 109.582 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.618 ' O ' HD21 ' A' ' 61' ' ' LEU . 53.2 p30 -93.42 11.34 28.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.288 -0.883 . . . . 0.0 109.446 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 73.6 t -59.94 -41.05 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.305 -0.872 . . . . 0.0 109.97 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.556 ' O ' HD23 ' A' ' 61' ' ' LEU . 87.8 mt-10 -116.33 130.22 56.66 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.433 -0.792 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.618 HD21 ' O ' ' A' ' 58' ' ' ASP . 5.9 mt -121.89 141.92 50.79 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -158.27 105.55 1.69 Allowed Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.025 -1.047 . . . . 0.0 109.806 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_exo -55.32 -21.66 30.12 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.792 1.661 . . . . 0.0 111.228 179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.31 -30.99 71.55 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.52 -0.738 . . . . 0.0 109.508 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -69.19 -26.33 64.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.362 -0.836 . . . . 0.0 111.02 -179.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.68 5.67 49.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.98 -1.075 . . . . 0.0 111.368 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -60.2 -37.84 81.49 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.766 -1.208 . . . . 0.0 110.3 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.7 t -131.79 141.57 49.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.077 -1.014 . . . . 0.0 110.139 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.681 HD13 ' HB2' ' A' ' 8' ' ' ALA . 83.8 mt -62.84 -37.9 80.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.404 -0.81 . . . . 0.0 109.827 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -61.41 -37.21 82.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.265 -0.897 . . . . 0.0 110.244 -179.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -58.66 -40.37 83.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.102 -0.999 . . . . 0.0 109.496 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 72.0 mt -64.76 -38.74 83.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.299 -0.876 . . . . 0.0 109.314 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.573 ' O ' HG23 ' A' ' 77' ' ' VAL . 20.8 t70 -57.45 -39.17 75.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.281 -0.887 . . . . 0.0 109.797 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.32 92.75 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.088 -1.007 . . . . 0.0 109.464 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -64.81 -46.16 83.19 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.285 -0.884 . . . . 0.0 109.318 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.9 t -63.89 -43.47 97.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.287 -0.883 . . . . 0.0 109.802 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -60.86 -40.52 85.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.165 -0.959 . . . . 0.0 109.558 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.2 -32.39 67.45 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.27 -49.0 3.69 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.027 -1.278 . . . . 0.0 110.758 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.3 p -134.92 154.94 51.5 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.198 -0.939 . . . . 0.0 110.1 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.4 t . . . . . 0 C--N 1.303 -1.42 0 O-C-N 121.198 -0.939 . . . . 0.0 109.0 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.6 mmm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.458 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.3 mt-30 -105.72 131.32 53.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.25 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.616 ' CD2' HG21 ' A' ' 6' ' ' VAL . 3.9 m80 40.93 31.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.386 -0.821 . . . . 0.0 109.486 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -39.38 85.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.752 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -65.05 -32.93 74.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.158 -0.964 . . . . 0.0 109.719 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.616 HG21 ' CD2' ' A' ' 3' ' ' HIS . 74.8 t -66.77 -38.55 81.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.193 -0.942 . . . . 0.0 109.399 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.674 HD12 ' OD2' ' A' ' 73' ' ' ASP . 91.9 mt -61.15 -49.82 83.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.176 -0.953 . . . . 0.0 109.368 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.99 -47.44 80.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 108.906 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -44.08 96.89 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.548 -0.72 . . . . 0.0 109.25 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.4 t80 -68.23 -49.13 62.75 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.656 -0.653 . . . . 0.0 109.729 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 7' ' ' ILE . 95.3 t -67.99 -44.69 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.533 -0.73 . . . . 0.0 109.923 -179.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.2 t -64.0 -35.18 72.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.444 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -56.1 -31.97 63.74 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -65.72 -32.48 74.06 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.279 -0.888 . . . . 0.0 109.785 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.654 ' CE2' HD12 ' A' ' 36' ' ' ILE . 31.4 p90 -140.71 46.8 1.77 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.196 -0.94 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.3 136.22 53.27 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.019 -1.05 . . . . 0.0 110.156 -179.752 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.02 -151.52 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.167 1.911 . . . . 0.0 110.42 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.94 9.73 2.74 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.891 -1.131 . . . . 0.0 108.682 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.4 t -113.51 135.75 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.576 -0.703 . . . . 0.0 109.781 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.54 140.62 81.96 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.976 . . . . 0.0 108.754 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.512 ' HD3' HD12 ' A' ' 16' ' ' LEU . 46.4 Cg_exo -48.6 -33.05 22.88 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.621 1.547 . . . . 0.0 111.586 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.41 -20.22 63.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.185 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -98.27 3.86 48.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.465 -0.772 . . . . 0.0 109.316 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.6 t -104.14 136.03 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.5 95.48 0.47 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.122 -0.986 . . . . 0.0 109.366 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -60.27 6.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.328 -0.858 . . . . 0.0 109.604 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.75 5.92 49.37 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.158 -0.964 . . . . 0.0 108.606 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.1 tp -91.84 136.83 32.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.537 -0.727 . . . . 0.0 109.364 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.488 ' OD2' ' O ' ' A' ' 67' ' ' ARG . 88.5 m-20 -62.85 121.81 14.4 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.423 -0.911 . . . . 0.0 108.582 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.67 HD11 ' CD1' ' A' ' 69' ' ' ILE . 79.5 mt -68.46 -4.34 14.57 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.368 -0.832 . . . . 0.0 109.457 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 51.2 t -51.47 -41.97 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.145 -0.972 . . . . 0.0 108.799 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.83 -35.29 66.23 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 1.7 m120 -83.24 14.83 3.24 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.26 -15.82 0.02 OUTLIER Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -179.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -51.71 -39.16 23.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 108.181 179.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.654 HD12 ' CE2' ' A' ' 15' ' ' PHE . 5.1 tt -71.24 -25.09 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.506 -0.746 . . . . 0.0 109.899 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.4 m-20 -62.97 -30.53 71.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.965 . . . . 0.0 110.839 -178.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.7 m -105.11 -65.17 1.06 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.997 -1.064 . . . . 0.0 111.056 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.62 -52.31 15.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.133 -0.979 . . . . 0.0 110.985 -178.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.55 -36.79 91.94 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.1 tp -58.71 -41.17 85.7 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.468 -1.019 . . . . 0.0 109.235 -179.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -65.53 -44.13 87.83 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 108.807 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.48 -43.7 76.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.553 -0.717 . . . . 0.0 110.104 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 96.1 t -64.53 -45.39 95.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.362 -0.837 . . . . 0.0 110.55 -179.03 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.519 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -60.53 -46.94 94.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 120.999 -1.063 . . . . 0.0 109.475 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -44.14 80.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.404 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.7 t90 -78.46 -49.05 14.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.102 -0.999 . . . . 0.0 110.338 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 44' ' ' VAL . 7.6 tp -60.7 -42.35 97.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.554 -178.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.519 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -65.84 -37.82 87.21 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.984 -1.072 . . . . 0.0 109.046 -179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -69.1 -38.96 79.21 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.421 -0.799 . . . . 0.0 109.576 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.1 ttt180 -58.95 -41.1 86.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.565 -0.709 . . . . 0.0 110.691 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -102.97 -6.5 22.33 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.965 -1.084 . . . . 0.0 109.898 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.35 30.86 78.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 pt -112.94 149.27 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.4 -1.059 . . . . 0.0 109.855 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.81 144.77 52.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.239 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -35.91 78.14 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.131 -0.981 . . . . 0.0 109.292 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 53.14 43.17 31.95 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.363 -0.836 . . . . 0.0 109.565 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.408 ' HB3' HD21 ' A' ' 61' ' ' LEU . 91.2 m-20 -82.39 94.26 7.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.52 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 69.6 t -63.59 -43.78 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.942 . . . . 0.0 109.398 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -158.35 140.37 13.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.756 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.408 HD21 ' HB3' ' A' ' 58' ' ' ASP . 36.4 mt -103.16 136.79 42.29 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.329 -0.857 . . . . 0.0 109.46 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.42 147.52 13.5 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.068 -1.02 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -63.48 -21.09 70.87 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.49 2.127 . . . . 0.0 111.973 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.52 -31.35 70.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 0.0 110.056 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -68.41 -26.4 65.52 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.289 -0.882 . . . . 0.0 110.713 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -93.76 8.75 39.85 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.881 -1.137 . . . . 0.0 110.707 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.488 ' O ' ' OD2' ' A' ' 29' ' ' ASP . 17.5 mmm180 -58.34 -34.74 70.97 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.074 -1.016 . . . . 0.0 110.231 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -150.55 158.61 44.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.11 -0.994 . . . . 0.0 110.464 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 30' ' ' LEU . 11.4 mm -62.89 -35.82 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.453 -0.78 . . . . 0.0 109.724 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 -59.99 -36.53 77.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.283 -0.885 . . . . 0.0 109.855 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.3 t -59.62 -43.07 93.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.901 -1.124 . . . . 0.0 108.91 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.15 -38.39 80.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.429 -0.794 . . . . 0.0 109.267 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.681 ' O ' HG23 ' A' ' 77' ' ' VAL . 83.5 m-20 -56.34 -37.64 70.25 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.387 -0.821 . . . . 0.0 109.253 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.56 -40.13 96.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.31 -0.869 . . . . 0.0 109.763 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -62.14 -51.78 66.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.959 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.8 t -65.16 -41.17 91.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.237 -0.915 . . . . 0.0 109.444 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -58.47 -40.62 79.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 O-C-N 121.312 -0.867 . . . . 0.0 109.538 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.21 -33.02 82.75 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.45 -48.83 4.22 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.976 -1.308 . . . . 0.0 110.581 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.503 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.8 p -129.69 154.22 47.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.4 -0.812 . . . . 0.0 108.994 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.81 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t . . . . . 0 C--N 1.304 -1.407 0 O-C-N 121.15 -0.969 . . . . 0.0 109.956 -179.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.477 0.656 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.2 mt-30 -104.76 140.72 37.67 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.553 ' NE2' HG11 ' A' ' 6' ' ' VAL . 53.7 t-80 49.36 11.23 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.952 -1.092 . . . . 0.0 108.497 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.625 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.36 -35.91 80.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.593 -0.692 . . . . 0.0 110.193 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.1 m -58.85 -42.07 88.47 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.016 . . . . 0.0 109.567 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.553 HG11 ' NE2' ' A' ' 3' ' ' HIS . 54.3 t -67.35 -36.36 76.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.397 -0.815 . . . . 0.0 109.221 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.625 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.75 -49.51 83.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.831 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.721 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.51 -45.28 91.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.086 -1.008 . . . . 0.0 108.928 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.27 -43.34 91.58 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.509 -0.744 . . . . 0.0 109.051 179.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.704 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 66.3 t80 -66.07 -49.93 65.89 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.471 0.653 . . . . 0.0 109.89 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 7' ' ' ILE . 97.9 t -67.17 -45.02 87.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.414 -0.804 . . . . 0.0 109.641 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 8' ' ' ALA . 92.8 t -64.17 -35.6 74.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.438 -0.789 . . . . 0.0 109.597 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.29 -31.09 63.32 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.753 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' HD11 ' A' ' 36' ' ' ILE . 84.3 tt0 -65.44 -31.96 73.32 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.747 -179.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.596 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.2 p90 -141.89 45.68 1.68 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.213 -0.93 . . . . 0.0 109.627 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.51 136.03 52.69 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.941 -1.099 . . . . 0.0 110.119 -179.78 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -77.6 -150.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.222 1.948 . . . . 0.0 110.249 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -79.95 12.11 2.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.822 -1.174 . . . . 0.0 108.706 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.551 HG23 ' OD2' ' A' ' 18' ' ' ASP . 23.9 t -113.41 136.71 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.567 -0.708 . . . . 0.0 109.847 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.96 82.94 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.186 -0.946 . . . . 0.0 108.863 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -48.38 -30.32 15.2 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.746 1.631 . . . . 0.0 111.541 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.61 -20.55 62.74 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.495 -0.753 . . . . 0.0 109.513 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -103.73 8.61 37.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.32 -0.863 . . . . 0.0 109.748 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -101.13 135.93 35.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.315 -0.866 . . . . 0.0 108.99 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -67.87 89.95 0.29 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.164 -0.96 . . . . 0.0 109.082 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -60.53 6.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.379 -0.826 . . . . 0.0 109.769 -179.855 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.2 t0 -89.21 4.36 48.91 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.93 . . . . 0.0 108.733 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.7 tp -95.65 134.24 38.77 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.563 -0.711 . . . . 0.0 109.368 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -66.07 121.49 15.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -76.04 9.27 2.56 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 109.882 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.19 -38.28 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.112 -0.992 . . . . 0.0 108.951 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.434 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -57.08 -35.53 69.48 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.8 m-20 -83.8 15.02 3.49 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -14.76 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.8 t -51.65 -37.94 20.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.096 -1.238 . . . . 0.0 108.428 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.8 tt -70.7 -24.82 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.508 -0.745 . . . . 0.0 110.139 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.59 ' OD1' ' CD1' ' A' ' 66' ' ' PHE . 82.7 m-20 -60.24 -32.93 71.6 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -178.26 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.48 -64.97 1.09 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.926 -1.109 . . . . 0.0 111.513 -178.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.0 mp -72.39 -52.16 17.24 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.096 -1.002 . . . . 0.0 110.983 -178.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.4 -36.92 92.27 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.53 -41.26 89.64 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.471 -1.017 . . . . 0.0 109.636 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -66.15 -44.37 84.34 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.486 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -67.26 -38.69 85.55 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.291 -0.881 . . . . 0.0 110.239 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.5 t -64.48 -44.87 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.204 -0.935 . . . . 0.0 110.576 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.07 -47.21 90.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 120.969 -1.082 . . . . 0.0 109.769 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.11 -44.37 80.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.285 -0.885 . . . . 0.0 110.537 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.704 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.0 t90 -74.8 -41.89 59.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.152 -0.967 . . . . 0.0 110.196 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -58.55 -40.13 82.17 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.254 -0.904 . . . . 0.0 109.604 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.08 -42.3 99.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -65.08 -42.94 93.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.378 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.3 ttt180 -65.98 -44.58 84.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 111.514 -178.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -105.65 -5.28 20.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.991 -1.068 . . . . 0.0 110.844 -178.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.58 32.5 71.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.56 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 76.8 mt -97.01 144.57 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 145.13 52.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.155 -0.965 . . . . 0.0 109.612 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.07 -28.69 69.79 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.841 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.572 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.0 m-20 54.7 50.82 15.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.061 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 57' ' ' ASP . 23.5 t70 -41.29 92.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.39 -0.819 . . . . 0.0 109.867 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ASP . 13.6 p -134.24 144.47 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.393 -0.817 . . . . 0.0 108.948 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -89.66 133.0 34.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 109.713 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.7 mt -110.32 140.74 44.19 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.488 -0.757 . . . . 0.0 109.534 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.7 158.18 59.95 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.482 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -60.1 -27.87 85.8 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.737 2.291 . . . . 0.0 112.042 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.83 -29.38 70.58 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -67.32 -26.39 66.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.811 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.59 ' CD1' ' OD1' ' A' ' 37' ' ' ASP . 80.1 m-85 -93.7 7.02 46.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.16 -0.962 . . . . 0.0 109.536 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -54.94 -39.08 68.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.272 -0.892 . . . . 0.0 109.553 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.0 p -138.93 151.1 46.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.09 -1.006 . . . . 0.0 109.909 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -63.27 -36.88 77.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.32 -0.863 . . . . 0.0 109.806 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 -61.2 -36.9 81.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 110.294 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.5 -44.21 89.37 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.985 -1.072 . . . . 0.0 109.368 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.3 mt -66.66 -38.55 81.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.327 -0.858 . . . . 0.0 109.408 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.476 ' OD1' HG21 ' A' ' 7' ' ' ILE . 74.8 m-20 -58.31 -38.54 77.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.458 -0.776 . . . . 0.0 109.765 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.95 96.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.89 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -62.19 -46.1 90.43 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.815 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.0 t -63.16 -43.1 98.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.242 -0.911 . . . . 0.0 109.923 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 57.0 t -63.73 -40.6 89.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.274 -0.891 . . . . 0.0 109.832 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.03 -35.28 75.77 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.73 -48.15 5.05 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.03 -1.276 . . . . 0.0 110.215 -179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 42.1 m -131.69 134.75 46.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.345 -0.847 . . . . 0.0 109.409 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.306 -0.871 . . . . 0.0 109.648 179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 121.371 0.605 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.581 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -85.1 125.77 33.05 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.428 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 1.6 m-70 54.97 19.63 2.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 108.551 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.89 -39.63 92.61 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.419 -0.801 . . . . 0.0 110.183 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -63.96 -34.99 79.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.097 -1.002 . . . . 0.0 109.889 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.75 -39.67 84.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.449 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.598 ' O ' HG22 ' A' ' 11' ' ' VAL . 91.2 mt -59.89 -43.02 91.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.501 -0.749 . . . . 0.0 110.195 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.709 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.09 -49.41 74.56 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.104 -0.998 . . . . 0.0 109.48 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.419 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.2 pp0? -69.55 -33.76 73.23 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.8 t80 -66.63 -51.87 51.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 110.004 -179.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.598 HG22 ' O ' ' A' ' 7' ' ' ILE . 14.1 m -72.92 -39.89 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.257 -0.902 . . . . 0.0 110.16 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.5 t -64.55 -38.76 83.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.922 . . . . 0.0 109.922 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.1 -30.15 61.66 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.227 -0.921 . . . . 0.0 109.538 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.14 -29.51 70.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.304 -0.872 . . . . 0.0 108.987 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.614 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 16.9 p90 -149.52 49.63 0.95 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.298 -0.876 . . . . 0.0 109.257 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.13 136.71 53.48 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 120.89 -1.131 . . . . 0.0 110.183 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -73.36 -153.47 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 121.972 1.781 . . . . 0.0 110.603 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -80.3 13.31 2.44 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.1 -1.0 . . . . 0.0 108.776 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.7 t -113.44 136.16 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.585 -0.697 . . . . 0.0 109.996 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.32 140.19 72.46 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.283 -0.885 . . . . 0.0 108.873 179.33 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -48.57 -33.22 23.15 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 121.692 1.595 . . . . 0.0 111.808 179.528 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.23 -19.6 65.56 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.445 -0.784 . . . . 0.0 109.353 179.639 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -96.46 0.16 49.95 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.451 -0.781 . . . . 0.0 108.983 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -107.08 134.04 49.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.3 m-20 -70.98 99.73 1.85 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 109.376 -179.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.8 m -59.68 5.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.353 -0.842 . . . . 0.0 109.768 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -92.16 8.6 37.24 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.065 -1.022 . . . . 0.0 108.841 179.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.3 tp -94.54 136.56 34.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.593 -0.692 . . . . 0.0 109.544 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -63.24 121.57 14.01 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.465 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -72.28 6.73 2.09 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.635 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -53.4 -39.49 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 108.941 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -57.79 -36.14 71.77 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.3 m-20 -85.27 15.1 4.54 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.29 -15.06 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.83 -37.36 20.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.054 -1.262 . . . . 0.0 108.46 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.3 tt -70.69 -24.84 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.536 -0.727 . . . . 0.0 110.142 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.428 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.4 m-20 -60.04 -33.34 71.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.235 -0.916 . . . . 0.0 111.141 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -105.62 -64.79 1.11 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.91 -1.118 . . . . 0.0 111.451 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -72.21 -52.17 17.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 111.018 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.69 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.77 -36.85 91.8 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tp -58.91 -41.96 88.49 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.43 -1.041 . . . . 0.0 109.459 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.7 tp -65.68 -44.28 86.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.203 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 41.4 mttt -67.02 -36.38 81.98 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.361 -0.837 . . . . 0.0 109.913 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.2 t -62.41 -44.32 99.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 0.0 110.366 -179.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.428 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -59.16 -48.27 87.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.922 -1.111 . . . . 0.0 109.398 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.32 -44.33 79.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.375 -0.828 . . . . 0.0 110.658 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -75.5 -43.62 48.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.102 -0.999 . . . . 0.0 110.243 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.428 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -57.9 -40.26 79.9 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.33 -0.856 . . . . 0.0 109.548 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.583 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.7 tt0 -61.62 -42.66 99.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.141 -0.974 . . . . 0.0 109.389 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.56 -43.09 85.97 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.112 -0.992 . . . . 0.0 110.364 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.685 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 59.8 ttt-85 -64.68 -44.23 91.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.317 -0.865 . . . . 0.0 111.241 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 96.9 m-85 -104.69 -10.15 17.68 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.94 -1.1 . . . . 0.0 110.765 -178.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 24.65 73.42 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -95.01 142.41 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.122 -1.223 . . . . 0.0 109.418 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.96 149.97 34.87 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.083 -1.011 . . . . 0.0 109.228 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.17 72.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.242 -0.911 . . . . 0.0 109.586 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 50.43 48.17 22.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.108 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -63.17 123.17 17.95 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 110.037 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.777 HG23 HD21 ' A' ' 61' ' ' LEU . 30.0 m -135.0 163.09 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.628 ' O ' HD23 ' A' ' 61' ' ' LEU . 91.5 mt-10 -65.37 132.06 48.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.975 -1.078 . . . . 0.0 109.5 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.777 HD21 HG23 ' A' ' 59' ' ' VAL . 9.7 mt -125.41 147.31 49.24 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.557 -0.715 . . . . 0.0 109.649 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.61 157.75 38.41 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 109.055 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -60.12 -25.56 80.18 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.721 2.281 . . . . 0.0 112.071 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.05 -31.94 73.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.442 ' O ' ' OG ' ' A' ' 71' ' ' SER . 52.2 t-80 -67.9 -26.79 66.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.695 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -98.34 6.35 47.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.9 tpt180 -56.21 -39.37 72.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.213 -0.929 . . . . 0.0 109.703 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.4 p -143.59 156.23 44.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.019 -1.05 . . . . 0.0 110.063 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.593 HD13 ' HB2' ' A' ' 8' ' ' ALA . 85.7 mt -62.45 -36.51 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.345 -0.847 . . . . 0.0 109.835 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -60.61 -39.12 87.01 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 110.356 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 84.9 p -60.27 -37.63 81.05 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.067 -1.021 . . . . 0.0 109.587 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.5 mt -67.99 -38.8 80.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.289 -0.882 . . . . 0.0 109.37 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.581 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 51.5 t0 -58.29 -38.65 77.44 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.433 -0.792 . . . . 0.0 109.937 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.2 -44.34 92.26 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.092 -1.005 . . . . 0.0 109.732 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -64.89 -47.12 78.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.63 -42.08 94.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.325 -0.859 . . . . 0.0 109.917 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -64.27 -41.43 92.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.14 -0.975 . . . . 0.0 109.942 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.61 -33.85 73.9 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.66 -48.01 4.65 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.294 . . . . 0.0 110.518 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.482 ' O ' ' O ' ' A' ' 76' ' ' VAL . 43.2 m -129.49 138.07 51.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.862 . . . . 0.0 110.044 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.457 0 O-C-N 121.425 -0.797 . . . . 0.0 109.15 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.4 mtm . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.354 0.597 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.478 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 92.8 mt-30 -107.83 138.86 43.32 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.757 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER 44.11 27.74 0.22 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.138 -0.976 . . . . 0.0 108.912 -179.679 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.529 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.05 -36.27 76.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.443 -0.785 . . . . 0.0 109.873 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -59.12 -40.26 84.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.167 -0.958 . . . . 0.0 109.534 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.757 HG21 ' CD2' ' A' ' 3' ' ' HIS . 73.3 t -66.3 -37.47 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.196 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.8 mt -59.88 -50.58 79.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.878 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.18 -47.82 78.32 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.05 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.27 -40.84 98.53 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.478 -0.763 . . . . 0.0 109.662 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.469 ' CE2' ' CH2' ' A' ' 47' ' ' TRP . 67.3 t80 -66.84 -51.54 54.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.437 -0.789 . . . . 0.0 110.348 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -69.96 -41.22 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.877 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.4 t -64.5 -35.77 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.91 . . . . 0.0 109.575 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.68 -30.8 63.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.589 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.45 -31.49 72.6 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.273 -0.892 . . . . 0.0 109.729 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' CE1' HD12 ' A' ' 36' ' ' ILE . 30.9 p90 -142.97 46.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.871 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 136.06 53.22 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.206 -179.76 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.49 -150.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.168 1.912 . . . . 0.0 110.432 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.537 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.69 12.78 2.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.896 -1.128 . . . . 0.0 108.842 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.537 HG23 ' OD1' ' A' ' 18' ' ' ASP . 32.5 t -113.33 136.31 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.468 -0.77 . . . . 0.0 109.835 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.07 138.68 87.38 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.133 -0.98 . . . . 0.0 108.783 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.663 ' O ' HG22 ' A' ' 24' ' ' VAL . 52.1 Cg_exo -48.34 -26.76 8.91 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 121.869 1.713 . . . . 0.0 112.141 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.04 -16.91 61.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.106 -0.996 . . . . 0.0 109.749 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -105.36 7.01 33.12 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -0.863 . . . . 0.0 110.412 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.663 HG22 ' O ' ' A' ' 21' ' ' PRO . 3.5 m -96.06 144.53 10.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 120.946 -1.096 . . . . 0.0 109.273 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.545 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -70.44 88.08 0.65 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.029 -1.044 . . . . 0.0 109.193 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 26.7 m -61.67 5.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.271 -0.893 . . . . 0.0 109.546 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.545 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -97.87 6.8 47.34 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 108.954 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.1 tp -96.94 135.53 38.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.484 -0.76 . . . . 0.0 109.555 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -64.26 121.75 15.02 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.86 8.42 0.52 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.762 -179.016 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 4.9 p -53.73 -39.83 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.131 -0.981 . . . . 0.0 109.01 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.0 t0 -58.11 -35.79 71.96 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.624 ' O ' ' N ' ' A' ' 35' ' ' VAL . 62.8 m-80 -85.2 15.07 4.48 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.27 -15.97 0.02 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.624 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.7 t -52.71 -37.14 24.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.972 -1.311 . . . . 0.0 108.311 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.613 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.1 tt -70.53 -25.16 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.479 -0.763 . . . . 0.0 109.94 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.9 m-20 -62.21 -29.66 70.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.263 -0.898 . . . . 0.0 110.66 -178.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.0 m -104.9 -64.76 1.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.02 -1.05 . . . . 0.0 110.979 -178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 19.8 mt -74.03 -52.4 12.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 110.846 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.8 93.79 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.613 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.95 -39.74 93.14 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.496 -1.002 . . . . 0.0 109.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.0 -44.04 94.8 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -67.52 -40.25 85.09 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.363 -0.836 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.16 -45.54 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 110.082 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.513 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -62.73 -41.73 93.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.063 -1.023 . . . . 0.0 109.66 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.05 -41.01 99.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.925 . . . . 0.0 109.676 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NH1' ' A' ' 51' ' ' ARG . 0.8 OUTLIER -78.56 -49.1 13.91 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.954 179.884 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.31 -43.24 96.53 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.45 -0.781 . . . . 0.0 110.626 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 0.9 OUTLIER -66.53 -36.28 82.3 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.945 -1.097 . . . . 0.0 109.087 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -72.04 -44.99 62.49 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.388 -0.82 . . . . 0.0 110.223 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NH1' ' HE1' ' A' ' 47' ' ' TRP . 22.5 ttm180 -60.95 -40.63 94.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.381 -0.825 . . . . 0.0 111.105 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -103.18 -6.14 22.47 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.824 -1.172 . . . . 0.0 110.21 -179.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.71 34.06 87.77 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -98.39 133.51 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.244 -1.15 . . . . 0.0 109.423 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.86 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -62.83 137.07 58.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.118 -0.989 . . . . 0.0 109.421 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.7 -29.02 67.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.362 -0.836 . . . . 0.0 110.233 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.456 ' C ' ' OD2' ' A' ' 57' ' ' ASP . 52.8 p30 -85.5 2.08 46.2 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -0.95 . . . . 0.0 110.457 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.86 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 97.2 m-20 -60.34 -37.83 81.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.914 -1.116 . . . . 0.0 109.627 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.41 159.89 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.464 -0.773 . . . . 0.0 109.504 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -96.35 138.27 34.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.211 -0.931 . . . . 0.0 109.323 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.08 140.32 36.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.309 -0.87 . . . . 0.0 109.795 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.24 157.41 75.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.362 -0.836 . . . . 0.0 109.238 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.27 -31.26 82.05 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.609 2.206 . . . . 0.0 112.136 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.48 -31.91 73.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.4 -0.812 . . . . 0.0 109.765 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -68.2 -27.09 66.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.196 -0.94 . . . . 0.0 109.861 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.71 6.37 47.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -55.8 -38.64 70.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 97.0 p -135.15 152.92 52.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.318 -0.863 . . . . 0.0 109.749 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -63.54 -36.48 76.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.371 -0.831 . . . . 0.0 109.885 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -60.47 -38.31 83.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 110.271 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.6 t -57.92 -42.98 85.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.017 -1.052 . . . . 0.0 109.661 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -62.0 -39.58 84.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.213 -0.929 . . . . 0.0 109.328 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -57.83 -37.0 73.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.341 -0.849 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.5 -41.15 96.86 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.233 -0.917 . . . . 0.0 109.524 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -62.87 -46.93 85.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.84 -43.22 97.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.294 -0.879 . . . . 0.0 109.818 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.5 t -60.89 -40.79 86.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.295 -0.878 . . . . 0.0 109.833 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.14 -30.78 74.66 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 120.409 -0.9 . . . . 0.0 110.949 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.15 -48.43 3.87 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.952 -1.323 . . . . 0.0 110.593 -178.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -128.23 155.3 44.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.154 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 81' ' ' THR . 9.3 t . . . . . 0 C--N 1.303 -1.44 0 O-C-N 121.148 -0.97 . . . . 0.0 109.77 179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.48 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 70.0 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -59.06 -38.18 78.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.828 . . . . 0.0 109.634 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.638 ' NE2' HG11 ' A' ' 76' ' ' VAL . 52.5 p-80 -122.9 23.43 9.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.491 -0.756 . . . . 0.0 109.148 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.602 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.69 -34.4 72.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.362 -0.836 . . . . 0.0 109.764 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.5 t -59.0 -41.84 88.64 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.2 t -66.23 -38.4 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.305 -0.872 . . . . 0.0 109.118 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.602 HD12 ' HA ' ' A' ' 4' ' ' ALA . 94.0 mt -59.34 -50.62 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.395 -0.815 . . . . 0.0 109.69 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.98 97.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 108.864 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.48 -39.64 92.16 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.537 -0.727 . . . . 0.0 109.442 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.4 ' HE2' HG22 ' A' ' 44' ' ' VAL . 44.6 t80 -61.22 -51.42 69.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.431 -0.793 . . . . 0.0 110.011 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.727 ' CG2' HD12 ' A' ' 36' ' ' ILE . 12.4 p -72.96 -48.95 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.313 -0.867 . . . . 0.0 110.87 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.637 HG21 HG11 ' A' ' 24' ' ' VAL . 61.9 t -60.9 -35.87 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.162 -0.961 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -59.51 -34.57 72.77 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.991 -1.068 . . . . 0.0 110.005 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.65 -36.3 82.22 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 111.028 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.501 ' O ' HD12 ' A' ' 16' ' ' LEU . 42.5 m-85 -100.61 -57.78 2.04 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.894 -1.128 . . . . 0.0 111.052 -178.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 15' ' ' PHE . 2.6 mp -123.97 87.3 53.2 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.238 -0.914 . . . . 0.0 110.944 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -91.51 -16.67 1.23 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.199 2.599 . . . . 0.0 112.084 178.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -76.39 -4.5 42.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.157 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.5 145.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD2' ' A' ' 23' ' ' ASP . . . -60.84 115.58 14.57 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 120.755 -1.215 . . . . 0.0 108.289 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.701 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.3 Cg_endo -63.62 -23.93 69.89 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 C-N-CA 121.329 1.353 . . . . 0.0 111.819 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.21 -15.66 62.47 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -0.89 . . . . 0.0 109.865 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD2' ' O ' ' A' ' 20' ' ' ALA . 49.6 p30 -89.09 3.24 52.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.014 -1.054 . . . . 0.0 109.767 -179.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.5 m -77.21 140.74 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.114 -0.991 . . . . 0.0 108.672 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.536 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -66.42 82.71 0.09 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.067 -1.021 . . . . 0.0 109.278 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.5 m -62.47 5.71 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -0.927 . . . . 0.0 109.465 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.536 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.7 m-20 -103.08 7.17 38.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -0.892 . . . . 0.0 108.936 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.9 tp -98.51 137.45 37.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.498 -0.751 . . . . 0.0 109.525 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.575 ' OD1' ' NH2' ' A' ' 67' ' ' ARG . 89.0 m-20 -61.08 122.1 14.15 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.405 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -71.48 7.72 1.31 Allowed 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.192 -0.942 . . . . 0.0 110.177 -178.892 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 66.5 t -54.74 -43.75 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 120.823 -1.173 . . . . 0.0 108.362 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.76 -35.48 66.27 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -83.89 15.34 3.39 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 178.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.44 -14.82 0.01 OUTLIER Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.6 t -51.42 -38.81 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -1.122 . . . . 0.0 108.236 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.727 HD12 ' CG2' ' A' ' 11' ' ' VAL . 2.4 tt -70.38 -24.98 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-O 121.717 0.77 . . . . 0.0 109.498 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.4 t0 -58.37 -34.02 70.22 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.503 -0.748 . . . . 0.0 111.24 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.59 -64.24 1.16 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.009 -1.057 . . . . 0.0 111.25 -178.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.558 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -72.05 -52.03 18.84 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.061 -1.024 . . . . 0.0 111.014 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.08 -37.93 94.76 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.599 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.84 -41.27 86.54 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.389 -1.065 . . . . 0.0 109.107 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 33.6 tp -61.91 -44.14 97.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 108.663 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -68.13 -39.53 82.7 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.431 -0.793 . . . . 0.0 109.715 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.0 t -64.55 -45.46 95.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 110.197 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.2 -47.99 91.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.213 -0.93 . . . . 0.0 109.444 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.43 -42.95 95.74 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.773 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -71.37 -39.83 70.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.346 -0.846 . . . . 0.0 109.737 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.4 tp -59.28 -47.18 86.34 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.233 -0.917 . . . . 0.0 109.468 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -65.91 -39.0 90.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.181 -0.95 . . . . 0.0 108.972 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -66.23 -36.01 81.92 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 110.614 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -84.98 -52.42 5.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.197 -0.939 . . . . 0.0 112.012 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -94.99 -5.35 44.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.721 -1.237 . . . . 0.0 111.306 -177.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.09 24.77 76.33 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.971 -1.651 . . . . 0.0 108.971 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.5 145.51 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.311 -1.111 . . . . 0.0 109.482 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.73 150.33 32.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 109.444 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.25 -30.59 62.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.422 -0.799 . . . . 0.0 109.611 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 55.11 46.47 23.97 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -0.878 . . . . 0.0 109.558 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -95.14 16.23 16.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.232 -0.917 . . . . 0.0 109.737 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 60' ' ' GLU . 63.3 t -56.72 -43.75 80.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.105 -0.997 . . . . 0.0 109.548 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.469 ' HG3' HG12 ' A' ' 59' ' ' VAL . 95.9 mt-10 -138.36 132.0 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.163 -0.961 . . . . 0.0 109.671 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.6 mp -131.35 140.13 49.65 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.303 -0.873 . . . . 0.0 109.594 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.29 146.58 20.21 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.383 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.79 -22.98 74.34 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.57 2.18 . . . . 0.0 112.195 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.07 -31.63 72.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.382 -0.824 . . . . 0.0 109.934 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -67.87 -26.95 66.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.175 -0.953 . . . . 0.0 109.654 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.461 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.8 m-85 -104.77 11.18 34.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.33 -0.856 . . . . 0.0 109.835 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.575 ' NH2' ' OD1' ' A' ' 29' ' ' ASP . 41.6 tpt85 -54.36 -38.51 66.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.18 -0.95 . . . . 0.0 109.571 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.5 p -149.12 156.28 41.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.144 -0.972 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -62.71 -36.67 76.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.344 -0.848 . . . . 0.0 109.83 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.7 ttp180 -60.41 -40.85 92.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.897 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.9 t -60.61 -44.19 96.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.361 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.7 mt -66.54 -38.58 81.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.308 -0.87 . . . . 0.0 109.727 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.755 ' O ' HG23 ' A' ' 77' ' ' VAL . 88.7 m-20 -57.77 -41.1 81.33 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.312 -0.867 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.22 -46.15 78.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.103 -0.998 . . . . 0.0 109.631 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -64.12 -46.44 84.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.353 -0.842 . . . . 0.0 109.366 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.638 HG11 ' NE2' ' A' ' 3' ' ' HIS . 60.1 t -64.86 -41.69 92.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.368 -0.832 . . . . 0.0 109.881 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.755 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -62.31 -41.08 90.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.084 -1.01 . . . . 0.0 109.803 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.07 -34.75 73.94 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.34 -48.12 4.48 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.09 -1.241 . . . . 0.0 110.522 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.3 m -129.53 138.09 51.15 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.349 -0.844 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.489 1.5 0 O-C-N 121.408 -0.808 . . . . 0.0 109.292 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.9 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.343 0.592 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 44.9 tp60 -58.51 -40.77 83.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 109.644 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.458 ' CD2' HG22 ' A' ' 77' ' ' VAL . 57.0 m-70 -126.62 12.0 7.37 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.38 -0.825 . . . . 0.0 109.516 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.583 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.58 -32.27 70.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 110.045 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -58.66 -37.13 75.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.076 -1.015 . . . . 0.0 109.662 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.51 -36.97 76.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.198 -0.939 . . . . 0.0 109.005 179.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.583 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.5 mt -60.63 -50.63 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.29 -0.882 . . . . 0.0 109.643 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.33 -47.18 80.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.042 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.7 -44.31 96.57 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.5 t80 -66.22 -45.06 82.03 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.6 -0.688 . . . . 0.0 109.652 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.826 HG13 HD12 ' A' ' 36' ' ' ILE . 55.7 t -66.8 -49.7 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.438 -0.788 . . . . 0.0 110.556 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 16' ' ' LEU . 61.7 t -64.12 -35.13 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.359 -0.838 . . . . 0.0 110.199 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -56.56 -34.59 67.25 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.429 -0.794 . . . . 0.0 109.996 -179.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.61 -30.8 71.17 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 110.621 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' HD22 ' A' ' 16' ' ' LEU . 34.7 m-85 -109.84 -57.86 2.13 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.116 -0.99 . . . . 0.0 111.32 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.681 HD12 HG23 ' A' ' 19' ' ' VAL . 1.2 mm? -123.66 86.9 52.67 Favored Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.111 -0.993 . . . . 0.0 111.362 -178.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.33 -19.21 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 123.154 2.569 . . . . 0.0 111.868 177.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.28 -4.1 40.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.239 -0.913 . . . . 0.0 109.091 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.681 HG23 HD12 ' A' ' 16' ' ' LEU . 42.4 t -113.15 143.81 22.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.94 115.76 15.5 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.728 -1.232 . . . . 0.0 108.557 -179.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.26 -25.86 71.97 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 C-N-CA 121.479 1.452 . . . . 0.0 111.746 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.92 -14.92 62.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.285 -0.884 . . . . 0.0 109.227 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -88.84 8.43 29.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.378 -0.826 . . . . 0.0 109.151 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -93.33 137.35 22.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.561 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -64.44 85.63 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.146 -0.971 . . . . 0.0 109.57 -179.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -59.64 5.72 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.301 -0.874 . . . . 0.0 109.677 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.561 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -101.93 6.44 41.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.07 -1.019 . . . . 0.0 108.787 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 15.0 tp -100.14 133.47 44.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.519 -0.738 . . . . 0.0 109.586 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.487 ' HB3' HG13 ' A' ' 31' ' ' VAL . 90.0 m-20 -66.67 121.78 16.17 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.724 ' H ' HD12 ' A' ' 30' ' ' LEU . 0.0 OUTLIER -70.03 11.63 0.29 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.173 -0.955 . . . . 0.0 109.946 -179.077 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.569 HG23 ' N ' ' A' ' 32' ' ' ASP . 34.0 m -52.38 -44.07 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 120.869 -1.144 . . . . 0.0 108.495 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.569 ' N ' HG23 ' A' ' 31' ' ' VAL . 91.7 m-20 -56.67 -35.28 68.23 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.5 m-20 -83.51 15.24 3.19 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.45 -13.88 0.01 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 50.2 t -50.63 -37.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.059 -1.259 . . . . 0.0 108.523 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.826 HD12 HG13 ' A' ' 11' ' ' VAL . 5.9 tt -70.57 -24.45 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.446 -0.784 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -61.51 -31.65 71.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.135 -0.978 . . . . 0.0 111.079 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 m -105.67 -65.28 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.93 -1.106 . . . . 0.0 111.486 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.55 -52.51 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.11 -0.994 . . . . 0.0 110.97 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.571 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.1 -37.17 92.83 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 61' ' ' LEU . 6.2 tp -58.8 -43.4 90.51 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.489 -1.007 . . . . 0.0 109.196 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.55 -43.19 93.59 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.445 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -66.99 -36.62 82.59 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.41 -0.806 . . . . 0.0 109.419 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.1 t -65.66 -49.58 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.323 -0.86 . . . . 0.0 110.605 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.9 mm -62.32 -41.34 91.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 120.922 -1.111 . . . . 0.0 109.65 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.26 -43.21 92.02 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.606 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -74.61 -39.85 61.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.367 -0.833 . . . . 0.0 109.786 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.6 tp -58.25 -42.08 85.6 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.293 -0.879 . . . . 0.0 109.625 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 53' ' ' GLY . 55.0 tt0 -63.01 -40.35 97.51 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -67.93 -47.14 69.51 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.13 -0.982 . . . . 0.0 110.764 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -68.08 -43.47 78.46 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.314 -0.866 . . . . 0.0 111.972 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 80' ' ' THR . 99.2 m-85 -103.6 -6.33 21.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.846 -1.159 . . . . 0.0 111.299 -178.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.13 27.43 73.81 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.509 HG22 ' HB2' ' A' ' 58' ' ' ASP . 70.5 mt -98.5 142.16 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -1.136 . . . . 0.0 109.366 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.6 144.33 51.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.02 . . . . 0.0 109.708 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.83 -34.07 74.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.437 -0.79 . . . . 0.0 109.717 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 57' ' ' ASP . 53.2 p30 -89.62 12.1 17.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.823 . . . . 0.0 109.817 -179.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.509 ' HB2' HG22 ' A' ' 54' ' ' ILE . 21.4 t70 -53.34 -34.89 59.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.231 -0.918 . . . . 0.0 109.913 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.5 p -129.31 144.6 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.432 -0.793 . . . . 0.0 109.769 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -71.6 144.05 49.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 41' ' ' LEU . 42.8 mt -96.58 136.22 37.41 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.26 -0.9 . . . . 0.0 109.923 -179.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.85 144.05 10.83 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.908 . . . . 0.0 109.132 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.09 -25.81 73.25 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.255 1.97 . . . . 0.0 111.929 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.41 -31.0 71.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.433 -0.792 . . . . 0.0 109.757 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -68.25 -26.56 65.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 110.562 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' LEU . 94.0 m-85 -99.14 10.27 41.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.058 -1.026 . . . . 0.0 111.089 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -58.46 -35.86 72.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.709 -1.244 . . . . 0.0 109.747 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.3 p -142.6 147.91 36.62 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.12 -0.987 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.538 HG12 HD21 ' A' ' 30' ' ' LEU . 90.7 mt -66.41 -36.6 77.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 O-C-N 121.307 -0.871 . . . . 0.0 110.113 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.3 mtm180 -61.16 -38.36 86.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.872 . . . . 0.0 110.573 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.0 p -62.59 -39.62 94.31 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.94 -1.1 . . . . 0.0 110.071 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.1 mt -68.45 -40.94 82.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.178 -0.951 . . . . 0.0 109.939 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.845 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.4 t0 -59.04 -39.34 81.72 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.309 -0.87 . . . . 0.0 110.17 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.18 -45.48 88.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.081 -1.012 . . . . 0.0 109.95 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -64.52 -46.87 81.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -0.941 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.6 t -64.76 -41.42 92.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.867 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.845 HG23 ' O ' ' A' ' 73' ' ' ASP . 79.8 t -60.56 -41.53 88.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.147 -0.97 . . . . 0.0 109.921 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.47 -32.83 79.01 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 120.308 -0.948 . . . . 0.0 110.829 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -48.22 3.93 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.115 -1.227 . . . . 0.0 110.886 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.699 HG21 ' CE2' ' A' ' 52' ' ' PHE . 38.1 m -128.11 138.39 52.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.298 -0.876 . . . . 0.0 109.879 -179.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 81' ' ' THR . 1.6 t . . . . . 0 N--CA 1.487 1.404 0 O-C-N 121.327 -0.858 . . . . 0.0 109.539 179.738 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.408 0.623 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 60.6 tp60 -58.02 -41.58 83.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.346 -0.846 . . . . 0.0 109.735 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.401 ' ND1' HG22 ' A' ' 77' ' ' VAL . 70.6 m80 -118.32 4.13 11.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.449 -0.782 . . . . 0.0 109.816 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.575 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.47 -38.06 73.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.151 -0.968 . . . . 0.0 109.674 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 m -61.87 -43.65 98.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.745 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.5 t -65.11 -39.58 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.951 . . . . 0.0 108.913 179.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.676 ' O ' HG22 ' A' ' 11' ' ' VAL . 95.9 mt -59.36 -49.84 82.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.365 -0.834 . . . . 0.0 109.337 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.865 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.39 -48.34 78.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 108.937 179.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.89 -39.53 94.76 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.494 -0.754 . . . . 0.0 109.553 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -66.94 -51.93 49.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.531 -0.73 . . . . 0.0 110.484 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.7 m -73.07 -40.35 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 110.434 -179.564 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.724 HG23 ' O ' ' A' ' 8' ' ' ALA . 91.2 t -64.75 -37.04 79.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.966 . . . . 0.0 110.047 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.25 -34.46 66.39 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.177 -0.952 . . . . 0.0 110.017 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.409 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.11 -31.23 71.97 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.282 -0.886 . . . . 0.0 109.824 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE1' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -137.68 43.5 2.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.168 -0.957 . . . . 0.0 109.845 -179.711 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.09 135.65 54.58 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 120.785 -1.197 . . . . 0.0 110.069 -179.656 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -78.09 -151.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.147 1.898 . . . . 0.0 110.256 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.82 11.74 2.48 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 108.616 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.59 136.31 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.5 -0.75 . . . . 0.0 109.966 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.66 140.83 71.75 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 108.636 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.45 -28.23 11.49 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.8 1.667 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -24.8 67.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -0.827 . . . . 0.0 109.304 179.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.5 5.57 46.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.441 -0.787 . . . . 0.0 108.912 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.0 t -103.75 136.98 34.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.83 95.94 0.39 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.565 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 15.9 m -60.7 5.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 109.516 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -94.02 8.34 41.82 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.097 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.0 tp -89.12 138.78 31.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.584 -0.697 . . . . 0.0 109.39 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.09 121.5 13.77 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.524 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -70.32 3.39 2.95 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 109.405 -179.364 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.41 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.7 p -53.99 -35.88 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.261 -0.9 . . . . 0.0 109.557 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -57.17 -40.24 76.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.191 -0.943 . . . . 0.0 108.473 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.4 p30 -91.45 15.99 11.19 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' ASP . . . -42.48 -14.11 0.01 OUTLIER Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.8 t -49.86 -33.28 8.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.973 -1.31 . . . . 0.0 108.383 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.581 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.6 tt -70.1 -24.63 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.849 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 34' ' ' GLY . 85.8 m-20 -61.81 -33.61 74.44 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.413 -0.804 . . . . 0.0 111.255 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.51 -65.15 1.08 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.946 -1.096 . . . . 0.0 111.516 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.2 tt -71.93 -49.85 34.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 111.515 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.79 -41.8 81.66 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.629 -178.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.581 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -63.15 -43.55 98.0 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.291 -1.123 . . . . 0.0 110.236 -179.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 42.6 tp -58.32 -44.42 88.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.84 -1.162 . . . . 0.0 109.437 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.8 mttt -68.9 -37.06 78.74 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.116 -0.99 . . . . 0.0 109.557 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.5 t -66.7 -47.67 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 111.239 -178.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.15 -45.64 92.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 120.586 -1.321 . . . . 0.0 110.162 -179.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.64 -45.57 74.98 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.032 -1.043 . . . . 0.0 110.51 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.504 ' CZ2' ' CZ ' ' A' ' 51' ' ' ARG . 2.0 t90 -76.91 -46.12 25.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 110.29 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.488 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 12.0 tp -57.15 -41.48 79.24 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.355 -0.841 . . . . 0.0 109.603 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 25.6 tt0 -63.15 -36.6 84.16 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.637 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.11 -39.65 86.95 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.086 -1.009 . . . . 0.0 110.04 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.504 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 77.8 mtm180 -77.3 -43.17 34.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -0.967 . . . . 0.0 111.934 -179.039 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -102.34 -6.5 22.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.826 -1.171 . . . . 0.0 110.803 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.16 30.56 77.07 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.442 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 94.4 mt -85.01 147.05 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.202 -1.175 . . . . 0.0 109.958 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 148.02 42.4 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.229 -0.92 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.24 -32.02 69.6 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.329 -0.857 . . . . 0.0 109.741 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 52.47 43.04 31.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.3 p30 -93.7 16.31 14.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.386 -0.821 . . . . 0.0 109.672 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -53.76 -44.22 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 110.04 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -173.34 118.2 0.29 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.121 -0.987 . . . . 0.0 110.092 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 2.3 mp -109.25 138.11 46.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.381 -0.824 . . . . 0.0 109.083 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 141.94 37.04 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.42 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -63.74 -21.72 69.65 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.291 1.994 . . . . 0.0 112.385 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.89 -32.89 72.33 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 110.307 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -74.06 -26.49 60.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.131 -0.98 . . . . 0.0 110.708 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -94.65 8.0 43.84 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.94 -1.1 . . . . 0.0 110.75 -178.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.41 ' NH2' HG21 ' A' ' 31' ' ' VAL . 30.1 mmt180 -58.9 -34.32 71.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.724 -1.235 . . . . 0.0 110.19 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.7 p -135.5 149.94 49.65 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.052 -1.03 . . . . 0.0 110.122 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.865 HD13 ' HB2' ' A' ' 8' ' ' ALA . 75.8 mt -64.3 -36.86 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.391 -0.818 . . . . 0.0 110.04 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -61.16 -37.24 82.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.25 -0.906 . . . . 0.0 110.686 -178.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -58.82 -44.1 90.79 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.977 -1.077 . . . . 0.0 109.765 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.0 mt -64.95 -38.66 83.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.189 -0.944 . . . . 0.0 109.622 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.49 ' HA ' HD11 ' A' ' 7' ' ' ILE . 51.2 t0 -56.8 -41.1 77.15 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.387 -0.821 . . . . 0.0 110.103 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.52 -46.22 76.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.086 -1.009 . . . . 0.0 110.231 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -63.42 -46.14 87.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.04 -1.038 . . . . 0.0 109.626 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.94 -44.5 92.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.368 -0.832 . . . . 0.0 110.267 -179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.401 HG22 ' ND1' ' A' ' 3' ' ' HIS . 42.0 t -63.17 -41.37 92.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.079 -1.013 . . . . 0.0 110.098 -179.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.56 -32.48 69.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.52 -48.27 3.86 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.101 -1.235 . . . . 0.0 110.819 -179.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.2 m -130.13 138.97 50.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.161 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.442 0 O-C-N 121.334 -0.854 . . . . 0.0 109.125 179.459 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.347 0.594 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.05 -36.19 74.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.31 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -150.1 44.68 0.9 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.385 -0.822 . . . . 0.0 109.273 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.04 -32.4 72.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.893 . . . . 0.0 109.934 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -58.46 -37.65 75.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.101 -0.999 . . . . 0.0 109.929 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 63.9 t -64.6 -39.49 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.148 -0.97 . . . . 0.0 109.357 179.908 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.477 HD13 ' OD2' ' A' ' 73' ' ' ASP . 94.6 mt -59.84 -40.07 81.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.265 -0.897 . . . . 0.0 109.627 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.39 -48.63 77.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.965 . . . . 0.0 109.118 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.427 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.37 -32.37 71.38 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.492 -0.755 . . . . 0.0 109.371 179.697 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -58.35 -51.51 69.49 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.296 -0.877 . . . . 0.0 109.722 -179.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.535 HG23 ' N ' ' A' ' 12' ' ' VAL . 33.8 m -73.73 -45.01 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.062 -1.023 . . . . 0.0 110.781 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.535 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.3 t -64.43 -35.89 75.67 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.176 -0.953 . . . . 0.0 111.131 -178.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -58.1 -33.01 68.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.011 -1.056 . . . . 0.0 110.005 -178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.19 -31.27 72.01 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 110.825 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -110.12 -55.87 2.4 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.214 -0.929 . . . . 0.0 111.472 -178.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.2 mt -124.44 87.65 53.96 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.082 -1.011 . . . . 0.0 111.389 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.91 -13.99 1.25 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 123.205 2.603 . . . . 0.0 111.776 178.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.45 -3.99 40.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.18 -0.95 . . . . 0.0 109.39 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.2 p -114.09 146.42 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.29 115.18 13.27 Favored Pre-proline 0 C--N 1.303 -1.441 0 O-C-N 120.742 -1.224 . . . . 0.0 108.362 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -64.84 -33.04 54.54 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.458 1.439 . . . . 0.0 111.913 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.46 -14.96 61.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -92.55 6.98 45.22 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.512 -0.742 . . . . 0.0 109.036 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.8 t -95.84 137.06 24.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.6 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.7 m-20 -61.58 90.61 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.223 -0.923 . . . . 0.0 109.589 -179.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -59.22 6.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.273 -0.892 . . . . 0.0 109.692 179.763 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.6 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.2 m-20 -97.86 11.4 37.47 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.074 -1.016 . . . . 0.0 108.971 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.6 tp -89.51 133.89 34.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.43 -0.794 . . . . 0.0 109.704 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 91.2 m-20 -65.37 122.3 16.84 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.419 -0.801 . . . . 0.0 108.97 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.584 HD11 HG12 ' A' ' 69' ' ' ILE . 65.8 mt -62.06 -7.2 3.64 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.179 -0.951 . . . . 0.0 108.992 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.2 p -50.05 -41.16 17.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.03 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.491 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.9 m-20 -58.8 -36.63 74.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 82.6 m-20 -85.29 16.86 3.37 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.48 -15.15 0.01 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.4 t -54.11 -38.78 39.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.78 -1.423 . . . . 0.0 107.853 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.618 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.23 -25.06 24.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.599 -0.688 . . . . 0.0 110.046 179.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.8 m-20 -62.37 -30.98 71.58 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 111.252 -178.306 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -104.97 -64.76 1.09 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.903 -1.123 . . . . 0.0 111.216 -178.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.5 mt -74.13 -52.58 12.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.121 -0.987 . . . . 0.0 110.964 -178.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.58 -36.59 93.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.618 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -61.33 -40.37 93.96 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.492 -1.005 . . . . 0.0 109.306 -179.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 34.2 tp -61.24 -44.21 97.62 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.535 -0.866 . . . . 0.0 108.797 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 46.1 mttp -70.5 -39.87 73.89 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.408 -0.808 . . . . 0.0 109.907 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.7 t -65.72 -45.72 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.881 . . . . 0.0 110.514 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.97 -44.36 99.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.032 -1.042 . . . . 0.0 109.697 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -63.43 -43.09 98.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.323 -0.86 . . . . 0.0 109.802 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -76.21 -43.35 42.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.189 -0.945 . . . . 0.0 109.992 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.4 tp -58.09 -47.97 81.58 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 110.055 -179.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.614 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.2 tt0 -67.95 -39.55 83.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.114 -0.991 . . . . 0.0 108.827 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 93.8 m-20 -64.9 -40.52 95.21 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.586 -0.696 . . . . 0.0 110.235 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -61.7 -44.79 96.25 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 111.3 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -113.94 -1.87 13.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.095 -1.003 . . . . 0.0 111.042 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.614 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.2 37.89 81.87 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.7 mt -96.18 142.76 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -1.181 . . . . 0.0 109.263 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.92 138.94 58.41 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.915 -1.115 . . . . 0.0 109.491 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.8 -32.47 73.66 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -57.69 -37.75 74.0 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.382 -0.823 . . . . 0.0 109.9 -179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.06 -37.74 67.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.118 -0.989 . . . . 0.0 109.377 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 60' ' ' GLU . 70.9 t -63.62 -37.16 78.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.85 . . . . 0.0 109.72 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . 86.3 tt0 58.57 127.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.559 -0.713 . . . . 0.0 109.654 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.41 HD22 HD21 ' A' ' 41' ' ' LEU . 17.5 mt -103.14 134.16 47.02 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.907 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -172.23 139.56 1.03 Allowed Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -63.02 -26.62 73.8 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 121.986 1.791 . . . . 0.0 111.622 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -30.89 71.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.588 -0.695 . . . . 0.0 109.596 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -68.73 -26.3 65.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.58 -0.7 . . . . 0.0 110.824 -178.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.514 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.0 m-85 -101.39 6.2 42.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.977 -1.077 . . . . 0.0 111.607 -178.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 34.2 mmt180 -60.08 -34.11 73.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.743 -1.223 . . . . 0.0 110.028 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -144.04 147.25 33.57 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.874 -1.141 . . . . 0.0 110.185 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.584 HG12 HD11 ' A' ' 30' ' ' LEU . 78.6 mt -66.6 -36.74 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 O-C-N 121.482 -0.761 . . . . 0.0 109.896 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.4 mtm180 -61.03 -39.92 91.61 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.322 -0.861 . . . . 0.0 110.317 -178.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.61 -43.95 96.85 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.974 -1.079 . . . . 0.0 109.427 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.514 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -68.51 -38.57 79.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.356 -0.84 . . . . 0.0 109.908 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' HD13 ' A' ' 7' ' ' ILE . 77.6 m-20 -58.35 -42.0 85.92 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.398 -0.814 . . . . 0.0 110.438 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -40.12 88.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.11 -0.994 . . . . 0.0 110.368 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -61.41 -51.42 68.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 109.851 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 80' ' ' THR . 76.8 t -67.64 -43.79 86.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.261 -0.899 . . . . 0.0 109.763 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -63.02 -39.87 86.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.074 -1.016 . . . . 0.0 109.621 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.85 70.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.03 -48.88 3.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.146 -1.208 . . . . 0.0 110.565 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.571 ' O ' HG12 ' A' ' 76' ' ' VAL . 57.9 m -157.37 137.96 13.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.138 -0.976 . . . . 0.0 110.168 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.768 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t . . . . . 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 108.944 179.414 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.6 mtt . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.322 0.582 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -60.08 -38.0 81.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.349 -0.844 . . . . 0.0 109.507 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 45.6 m-70 -133.99 12.87 3.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.4 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.53 -35.61 76.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.316 -0.865 . . . . 0.0 110.051 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.8 p -61.76 -36.49 81.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.07 -1.019 . . . . 0.0 109.593 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.4 t -66.16 -37.47 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 108.94 179.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.2 mt -66.49 -41.69 88.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.407 -0.808 . . . . 0.0 110.336 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.703 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.89 -50.55 68.31 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.042 -1.036 . . . . 0.0 110.378 -179.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.4 -44.22 68.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.073 -1.017 . . . . 0.0 109.614 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -60.18 -48.32 82.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.284 -0.885 . . . . 0.0 109.463 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.7 HG13 HD12 ' A' ' 36' ' ' ILE . 97.6 t -68.82 -47.48 75.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.486 -0.759 . . . . 0.0 109.837 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.6 t -64.29 -36.67 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.427 -0.796 . . . . 0.0 109.964 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.81 -28.5 61.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.339 -0.85 . . . . 0.0 109.879 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.56 -29.45 70.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -155.94 55.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.155 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.473 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.7 pt? -80.59 136.8 51.67 Favored Pre-proline 0 C--N 1.306 -1.283 0 O-C-N 120.995 -1.065 . . . . 0.0 110.197 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.58 -153.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 121.937 1.758 . . . . 0.0 110.641 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -81.24 14.2 2.5 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.092 -1.005 . . . . 0.0 108.79 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.5 t -113.3 136.9 48.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.646 -0.658 . . . . 0.0 109.994 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.07 140.21 73.38 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 108.962 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -48.86 -29.97 16.31 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 121.849 1.699 . . . . 0.0 112.081 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.6 -16.17 63.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.3 -0.875 . . . . 0.0 109.524 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -102.2 5.48 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.347 -0.846 . . . . 0.0 109.234 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -105.0 136.78 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.569 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.9 t0 -71.15 96.2 1.34 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.157 -0.965 . . . . 0.0 109.431 -179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.2 m -60.91 6.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.356 -0.84 . . . . 0.0 109.676 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.569 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.0 6.79 48.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.132 -0.98 . . . . 0.0 109.118 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.5 tt -95.85 135.87 37.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.61 ' O ' HD23 ' A' ' 28' ' ' LEU . 88.0 m-20 -60.86 121.92 13.56 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.75 14.92 0.07 Allowed 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.31 -0.868 . . . . 0.0 110.281 -178.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 29' ' ' ASP . 73.4 t -54.34 -41.17 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 108.508 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -55.17 -35.21 64.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -83.07 14.53 3.32 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.86 -14.44 0.01 OUTLIER Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 44.4 t -51.21 -36.86 17.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 121.143 -1.21 . . . . 0.0 108.69 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.7 HD12 HG13 ' A' ' 11' ' ' VAL . 5.5 tt -70.66 -24.56 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.438 -0.789 . . . . 0.0 110.229 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.3 m-20 -58.9 -34.87 72.17 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 111.474 -178.103 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.9 m -106.26 -64.97 1.11 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.931 -1.106 . . . . 0.0 111.673 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -71.37 -52.53 18.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.042 -1.036 . . . . 0.0 111.037 -177.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.76 -36.45 91.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tp -58.15 -42.76 86.61 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.372 -1.075 . . . . 0.0 108.898 -179.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.39 -44.12 95.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -68.55 -34.68 76.26 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.458 -0.776 . . . . 0.0 109.518 179.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.3 t -61.47 -45.8 97.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.329 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mm -62.66 -41.14 91.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.95 -1.093 . . . . 0.0 109.577 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.73 -44.49 81.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 109.867 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.444 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -76.35 -45.14 33.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.181 -0.949 . . . . 0.0 109.702 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.444 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.04 -40.98 77.8 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.347 -0.846 . . . . 0.0 109.512 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.551 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 2.9 tm-20 -60.86 -43.13 98.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.159 -0.963 . . . . 0.0 108.751 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -68.91 -43.3 75.48 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.294 -0.879 . . . . 0.0 110.045 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.6 tpt180 -64.27 -44.72 90.86 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.436 -0.79 . . . . 0.0 111.062 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -106.23 -5.39 19.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.063 -1.023 . . . . 0.0 110.998 -178.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.02 30.28 65.73 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.551 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 71.6 mt -96.71 138.82 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.177 . . . . 0.0 109.056 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 136.07 57.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.991 -1.068 . . . . 0.0 109.801 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.32 -24.84 65.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.528 -0.732 . . . . 0.0 109.414 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.443 ' O ' HG13 ' A' ' 59' ' ' VAL . 92.2 m-20 -55.18 -31.64 61.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.468 -0.77 . . . . 0.0 110.217 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.07 120.69 11.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.054 -1.029 . . . . 0.0 109.839 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 57' ' ' ASP . 16.8 m -115.29 27.46 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.567 -0.708 . . . . 0.0 109.309 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -51.08 -26.04 5.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.379 -0.825 . . . . 0.0 109.922 -179.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.0 mt -71.73 138.99 48.91 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.08 -1.012 . . . . 0.0 109.792 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.85 162.4 51.91 Favored Pre-proline 0 N--CA 1.487 1.406 0 O-C-N 121.455 -0.778 . . . . 0.0 109.294 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -56.69 -36.21 98.12 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.324 2.016 . . . . 0.0 111.395 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.04 -25.8 65.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.474 -0.766 . . . . 0.0 109.185 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.48 ' CD2' ' CD2' ' A' ' 75' ' ' PHE . 34.1 t-80 -67.74 -26.03 65.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.415 -0.803 . . . . 0.0 109.863 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.533 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 92.0 m-85 -90.4 10.06 26.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.271 -0.893 . . . . 0.0 109.802 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 16.4 tpt180 -56.91 -40.35 76.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.921 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -144.75 153.41 41.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.951 -1.093 . . . . 0.0 110.263 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.4 mt -66.3 -36.8 78.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.462 -0.774 . . . . 0.0 110.123 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 14.1 ttm180 -60.77 -43.05 98.54 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.433 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.3 m -58.4 -40.46 82.48 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.226 -0.921 . . . . 0.0 109.918 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -61.54 -40.74 87.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.178 -0.951 . . . . 0.0 109.718 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.637 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.2 t0 -59.32 -37.5 77.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.288 -0.882 . . . . 0.0 109.996 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.8 -46.3 85.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.48 ' CD2' ' CD2' ' A' ' 65' ' ' HIS . 52.9 m-85 -68.45 -40.72 80.96 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.152 -0.967 . . . . 0.0 109.34 179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -65.13 -41.99 93.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.296 -0.877 . . . . 0.0 109.585 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.3 t -63.74 -41.01 91.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 O-C-N 121.187 -0.946 . . . . 0.0 109.836 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.08 -30.96 71.47 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.33 -48.58 4.14 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.039 -1.271 . . . . 0.0 110.559 -178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.8 p -132.04 154.35 49.48 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.281 -0.887 . . . . 0.0 109.647 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.806 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t . . . . . 0 C--N 1.303 -1.418 0 O-C-N 121.222 -0.924 . . . . 0.0 109.315 179.579 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.748 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.9 mt-30 -59.86 -37.28 78.84 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.598 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -144.36 34.87 1.19 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.241 -0.912 . . . . 0.0 109.542 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.847 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -59.57 -32.48 70.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -0.912 . . . . 0.0 109.676 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.5 m -58.46 -37.42 75.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.125 -0.984 . . . . 0.0 109.971 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.8 t -63.97 -40.85 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.131 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.538 HG22 HG23 ' A' ' 69' ' ' ILE . 76.7 mt -60.02 -47.92 89.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.443 -0.786 . . . . 0.0 109.27 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.01 99.11 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.14 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -37.38 86.42 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.433 ' N ' ' O ' ' A' ' 6' ' ' VAL . 33.5 t80 -60.67 -52.89 63.22 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.513 -0.742 . . . . 0.0 109.886 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.496 HG23 ' CD1' ' A' ' 36' ' ' ILE . 4.0 p -73.48 -42.01 56.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.106 -0.996 . . . . 0.0 109.89 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.2 t -65.02 -35.59 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.36 -0.837 . . . . 0.0 110.911 -179.16 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -56.17 -36.17 68.04 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.023 -1.048 . . . . 0.0 110.353 -178.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.434 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 75.6 mm-40 -66.06 -31.5 72.42 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.043 -1.036 . . . . 0.0 109.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.434 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.2 OUTLIER -135.02 43.84 2.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.126 -0.984 . . . . 0.0 109.907 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.5 135.89 52.85 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.119 . . . . 0.0 110.116 -179.733 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.4 -149.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.143 1.895 . . . . 0.0 110.184 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.591 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.52 11.25 3.16 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 120.794 -1.191 . . . . 0.0 108.637 179.08 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.591 HG23 ' OD1' ' A' ' 18' ' ' ASP . 26.8 t -113.75 136.16 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.519 -0.738 . . . . 0.0 109.841 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.57 140.92 75.65 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.126 -0.983 . . . . 0.0 108.916 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -48.41 -29.33 13.29 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 121.875 1.717 . . . . 0.0 111.998 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.21 -21.16 66.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.384 -0.823 . . . . 0.0 109.283 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -103.27 3.25 35.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.44 -0.787 . . . . 0.0 108.886 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -104.93 138.94 27.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.579 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.5 t0 -68.78 102.59 1.57 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.105 -0.997 . . . . 0.0 109.354 -179.255 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 8' ' ' ALA . 26.0 m -59.62 6.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.433 -0.792 . . . . 0.0 109.933 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.579 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -89.92 10.11 25.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.03 -1.044 . . . . 0.0 108.632 179.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.2 tp -86.88 133.67 33.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.533 -0.729 . . . . 0.0 109.499 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -67.45 121.27 15.43 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -73.31 9.79 1.19 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.123 -0.986 . . . . 0.0 109.349 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.51 -39.45 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.891 . . . . 0.0 108.825 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.4 m-20 -57.71 -36.18 71.65 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.9 m-80 -84.43 14.81 4.11 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.53 -15.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.617 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.58 -37.75 20.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.852 -1.381 . . . . 0.0 108.223 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.6 tt -71.04 -24.56 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.547 -0.721 . . . . 0.0 110.104 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.427 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.57 -32.15 71.24 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.153 -0.967 . . . . 0.0 111.358 -178.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.84 -65.11 1.09 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.864 -1.148 . . . . 0.0 111.393 -178.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.33 -52.36 16.49 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.177 -0.952 . . . . 0.0 110.916 -178.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.69 92.28 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tp -58.88 -41.12 86.34 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.379 -1.071 . . . . 0.0 109.301 -179.625 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.9 tp -62.8 -44.33 96.45 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.213 -0.93 . . . . 0.0 108.762 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -71.87 -38.26 70.07 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.421 -0.8 . . . . 0.0 109.948 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 86.5 t -64.79 -45.12 96.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 110.249 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.9 -42.47 94.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.171 -0.956 . . . . 0.0 109.607 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.77 -43.09 97.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.181 -0.949 . . . . 0.0 109.971 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -76.38 -43.68 39.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 109.842 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 31.4 tp -60.0 -42.5 94.41 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 0.0 109.842 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.609 ' O ' ' N ' ' A' ' 53' ' ' GLY . 4.1 tt0 -66.46 -41.69 88.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.12 -0.988 . . . . 0.0 108.996 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -66.61 -37.15 84.27 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.419 -0.8 . . . . 0.0 109.828 179.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -59.04 -41.72 88.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.498 -0.751 . . . . 0.0 110.818 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.563 ' CE1' HG21 ' A' ' 80' ' ' THR . 1.1 m-85 -118.93 -4.02 10.67 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.101 -0.999 . . . . 0.0 110.437 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.74 43.19 29.4 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -101.08 140.7 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.138 -1.213 . . . . 0.0 109.323 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.59 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -62.26 136.61 58.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.884 -1.135 . . . . 0.0 109.374 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.23 -33.63 76.25 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.363 -0.836 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -94.48 8.24 42.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.265 -0.897 . . . . 0.0 109.809 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.59 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 21.3 t70 -53.05 -37.31 61.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.093 -1.004 . . . . 0.0 109.293 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.465 HG21 ' CZ ' ' A' ' 75' ' ' PHE . 12.6 p -133.27 144.78 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.451 -0.781 . . . . 0.0 109.169 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -77.75 137.38 38.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.429 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.3 mt -104.04 138.82 40.02 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.344 -0.848 . . . . 0.0 109.711 -179.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -135.58 154.85 78.53 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.321 -0.862 . . . . 0.0 109.06 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.34 -30.66 81.13 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.608 2.205 . . . . 0.0 112.339 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.79 -32.1 73.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.376 -0.828 . . . . 0.0 110.013 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -68.8 -26.48 65.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.288 -0.882 . . . . 0.0 110.897 -179.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -94.38 5.59 51.32 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.846 -1.159 . . . . 0.0 110.932 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -59.65 -40.87 89.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.034 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.0 m -129.45 145.26 51.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.25 -0.906 . . . . 0.0 110.184 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.636 HD13 ' HA ' ' A' ' 8' ' ' ALA . 82.1 mt -63.7 -36.28 75.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.467 -0.771 . . . . 0.0 109.759 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -60.33 -37.66 81.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.339 -0.851 . . . . 0.0 110.402 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -57.66 -43.46 84.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.999 -1.063 . . . . 0.0 109.633 -179.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -68.04 -38.74 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.261 -0.899 . . . . 0.0 109.634 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.847 ' OD1' ' HB2' ' A' ' 4' ' ' ALA . 50.4 t0 -57.72 -40.45 79.62 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.384 -0.823 . . . . 0.0 110.302 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.04 -45.68 80.56 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.029 -1.044 . . . . 0.0 109.624 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.465 ' CZ ' HG21 ' A' ' 59' ' ' VAL . 71.7 t80 -63.54 -45.84 88.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.373 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' A' ' 80' ' ' THR . 59.1 t -65.22 -44.74 95.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.362 -0.836 . . . . 0.0 109.976 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.6 t -63.65 -39.39 85.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 O-C-N 121.11 -0.994 . . . . 0.0 109.838 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -33.65 68.34 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.5 -48.7 3.74 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.195 -1.179 . . . . 0.0 110.601 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.563 HG21 ' CE1' ' A' ' 52' ' ' PHE . 53.3 m -163.17 139.71 7.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.12 -0.987 . . . . 0.0 109.827 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t . . . . . 0 N--CA 1.489 1.489 0 O-C-N 121.366 -0.834 . . . . 0.0 109.307 179.805 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.44 ' CE ' ' OG ' ' A' ' 5' ' ' SER . 4.2 ptt? . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.402 ' O ' ' C ' ' A' ' 3' ' ' HIS . 91.8 mt-30 55.6 44.15 27.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.27 -0.894 . . . . 0.0 109.107 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 2' ' ' GLN . 67.0 m170 46.45 37.69 4.58 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.181 -0.95 . . . . 0.0 109.048 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.541 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.75 -36.74 79.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.331 -0.856 . . . . 0.0 109.485 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' CE ' ' A' ' 1' ' ' MET . 22.9 m -59.23 -39.58 83.2 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.19 -0.944 . . . . 0.0 109.285 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.8 t -66.83 -37.66 79.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.203 -0.936 . . . . 0.0 109.0 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.577 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.5 mt -60.48 -51.01 78.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.251 -0.906 . . . . 0.0 109.177 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.761 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.81 -48.14 75.48 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.828 . . . . 0.0 109.301 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.85 -44.28 96.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.523 -0.736 . . . . 0.0 109.344 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.477 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.2 t80 -65.7 -48.7 71.14 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.57 -0.706 . . . . 0.0 109.486 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 7' ' ' ILE . 90.9 t -67.33 -44.89 86.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.383 -0.823 . . . . 0.0 109.521 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.3 t -64.25 -35.28 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.488 -0.757 . . . . 0.0 109.527 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.8 -30.38 61.26 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.299 -0.876 . . . . 0.0 109.969 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -65.66 -31.09 71.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.114 -0.992 . . . . 0.0 109.702 -179.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.563 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 33.5 p90 -143.29 45.79 1.53 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -0.999 . . . . 0.0 109.671 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.851 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.63 135.9 52.37 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.036 -1.04 . . . . 0.0 110.177 -179.813 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.58 -151.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.218 1.946 . . . . 0.0 110.364 178.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -78.72 12.18 2.22 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.826 -1.171 . . . . 0.0 108.748 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.0 t -113.4 137.0 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.72 84.34 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.151 -0.968 . . . . 0.0 108.911 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.408 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.2 Cg_exo -48.2 -30.93 15.68 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.864 1.709 . . . . 0.0 112.179 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.8 -22.92 66.0 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.419 -0.8 . . . . 0.0 109.434 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -102.51 8.64 39.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.834 . . . . 0.0 109.434 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.1 t -101.3 136.73 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.318 -0.864 . . . . 0.0 108.862 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.71 89.34 0.38 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.134 -0.979 . . . . 0.0 109.275 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -61.57 6.39 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.563 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -93.34 8.55 39.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.111 -0.993 . . . . 0.0 108.918 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -91.41 136.81 32.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.487 -0.758 . . . . 0.0 109.575 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -62.43 121.79 14.12 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.61 10.53 1.68 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.257 -0.902 . . . . 0.0 110.101 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.5 t -55.42 -42.08 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.907 -1.12 . . . . 0.0 108.932 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.4 t0 -55.81 -35.53 66.44 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.28 14.77 4.88 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -15.19 0.02 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.5 t -53.24 -36.81 26.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.151 -1.205 . . . . 0.0 108.611 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.2 tt -70.46 -24.73 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.462 -0.774 . . . . 0.0 110.087 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.425 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.8 m-20 -61.11 -32.31 71.99 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.215 -0.928 . . . . 0.0 110.969 -178.588 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 46.1 m -105.77 -64.57 1.14 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.047 -1.033 . . . . 0.0 111.475 -178.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.1 mp -72.56 -52.4 15.75 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.072 -1.018 . . . . 0.0 110.969 -178.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.91 -37.4 93.25 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.7 tp -59.39 -41.03 88.48 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.461 -1.023 . . . . 0.0 109.141 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.9 tp -62.03 -43.96 97.72 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -65.48 -35.45 80.94 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.48 -0.763 . . . . 0.0 109.281 179.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.2 t -60.11 -43.86 93.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.427 -0.796 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.5 -44.88 97.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.688 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.9 -43.3 96.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 110.203 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.477 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -75.3 -38.84 60.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.875 . . . . 0.0 109.936 -179.694 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.7 tp -57.92 -44.16 86.67 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.285 -0.884 . . . . 0.0 110.014 -179.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.587 ' O ' ' N ' ' A' ' 53' ' ' GLY . 30.1 tt0 -66.34 -40.36 89.78 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 109.41 179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -64.7 -44.04 91.54 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.319 -0.863 . . . . 0.0 110.574 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.15 -43.23 92.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.333 -0.854 . . . . 0.0 111.596 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -106.57 -7.07 17.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.952 -1.093 . . . . 0.0 110.782 -178.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.38 33.51 82.29 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.0 pt -108.78 153.12 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.363 -1.081 . . . . 0.0 109.961 -179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.84 151.37 30.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.714 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.01 70.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.434 -0.791 . . . . 0.0 109.987 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 52.91 49.53 20.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.162 -0.961 . . . . 0.0 108.864 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -74.85 118.17 17.51 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.334 -0.854 . . . . 0.0 110.214 -179.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.8 m -129.59 163.78 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -59.4 127.69 33.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.909 -1.119 . . . . 0.0 109.467 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.54 HD12 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -114.93 146.03 41.59 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.35 155.7 39.01 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.33 -0.856 . . . . 0.0 109.096 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.11 -25.57 77.42 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.644 2.229 . . . . 0.0 112.014 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.54 -29.74 70.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.534 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.67 -26.66 66.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.268 -0.895 . . . . 0.0 109.795 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -99.39 8.49 44.58 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.69 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.93 -38.15 69.91 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.726 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.8 p -141.36 156.63 45.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.1 -1.0 . . . . 0.0 110.16 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.3 mt -61.79 -35.74 69.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.431 -0.793 . . . . 0.0 109.847 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -59.74 -39.03 83.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.848 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.2 t -58.48 -39.89 81.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.066 -1.021 . . . . 0.0 108.924 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.2 mt -60.84 -38.72 79.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.299 -0.876 . . . . 0.0 108.874 179.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.0 t0 -56.21 -36.92 68.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.448 -0.783 . . . . 0.0 109.02 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.67 -40.64 92.83 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.257 -0.902 . . . . 0.0 108.768 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -60.64 -46.41 90.41 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.97 -40.62 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.411 -0.805 . . . . 0.0 108.934 179.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -57.97 -40.75 78.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.482 -0.761 . . . . 0.0 109.186 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.77 -34.31 86.36 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.88 -48.85 4.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.893 -1.357 . . . . 0.0 110.553 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.6 p -128.7 152.74 48.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 108.721 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t . . . . . 0 N--CA 1.489 1.491 0 O-C-N 121.213 -0.929 . . . . 0.0 110.237 -179.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.657 ' SD ' ' NH2' ' A' ' 70' ' ' ARG . 59.8 mtt . . . . . 0 N--CA 1.488 1.427 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.49 -34.4 72.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.199 -0.938 . . . . 0.0 108.84 179.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.508 ' CE1' HG22 ' A' ' 77' ' ' VAL . 4.2 p-80 -171.94 26.79 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.563 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.28 -35.04 76.22 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.295 -0.878 . . . . 0.0 109.584 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.11 -41.65 88.67 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.965 . . . . 0.0 109.489 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.5 t -65.24 -39.82 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.224 -0.922 . . . . 0.0 108.907 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.633 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.9 mt -59.55 -50.71 78.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.456 -0.778 . . . . 0.0 109.351 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.11 -42.3 96.94 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 108.865 179.389 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.82 -39.57 91.0 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.509 -0.745 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.434 ' HE2' HG22 ' A' ' 44' ' ' VAL . 38.0 t80 -61.5 -52.22 65.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.356 -0.84 . . . . 0.0 109.847 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.633 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.3 p -72.51 -42.44 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.275 -0.891 . . . . 0.0 109.929 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.4 t -64.38 -38.39 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.356 -0.84 . . . . 0.0 110.294 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.55 -28.0 59.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.216 -0.927 . . . . 0.0 110.143 -179.46 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -64.77 -30.05 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.054 -1.029 . . . . 0.0 109.028 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -154.47 55.47 0.69 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.352 -0.842 . . . . 0.0 109.208 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.518 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.82 137.05 50.64 Favored Pre-proline 0 N--CA 1.486 1.331 0 O-C-N 121.079 -1.013 . . . . 0.0 110.106 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.15 -153.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 121.925 1.75 . . . . 0.0 110.837 179.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.483 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -82.16 15.31 2.42 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 108.838 179.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.483 HG23 ' OD1' ' A' ' 18' ' ' ASP . 44.7 t -112.96 137.15 46.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.623 -0.673 . . . . 0.0 109.912 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.69 137.76 88.13 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.911 . . . . 0.0 109.06 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -48.94 -31.01 19.03 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.87 1.713 . . . . 0.0 112.152 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.27 -16.61 64.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.89 . . . . 0.0 109.427 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -102.2 8.81 40.46 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.172 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.86 136.47 31.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.4 90.12 0.51 Allowed 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.595 HG23 ' HB2' ' A' ' 8' ' ' ALA . 7.1 p -59.17 6.22 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.327 -0.858 . . . . 0.0 109.845 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -90.12 5.79 45.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.068 -1.02 . . . . 0.0 108.852 179.393 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.5 tp -94.39 136.25 34.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.468 -0.77 . . . . 0.0 109.449 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.498 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.2 m-20 -62.53 121.65 13.82 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.59 13.91 0.09 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.282 -0.886 . . . . 0.0 110.03 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.498 ' H ' ' C ' ' A' ' 29' ' ' ASP . 79.6 t -55.15 -42.38 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 0.0 108.702 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.61 -35.36 65.77 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -84.29 14.39 4.41 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.91 -14.53 0.01 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.43 -34.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.19 -1.183 . . . . 0.0 108.817 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -69.84 -24.34 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.463 -0.773 . . . . 0.0 110.11 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.578 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 82.9 m-20 -57.11 -34.76 68.68 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 111.33 -178.3 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -105.65 -64.79 1.11 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.851 -1.156 . . . . 0.0 111.381 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.415 HD21 ' NZ ' ' A' ' 43' ' ' LYS . 7.3 tt -70.88 -52.36 20.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.071 -1.018 . . . . 0.0 110.93 -178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.39 -36.83 92.15 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.706 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.76 -42.09 88.08 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.451 -1.029 . . . . 0.0 109.484 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -61.88 -44.09 97.53 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.175 -0.953 . . . . 0.0 108.54 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . 0.415 ' NZ ' HD21 ' A' ' 39' ' ' LEU . 54.3 mttp -70.09 -38.33 75.64 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.426 -0.796 . . . . 0.0 109.897 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.8 t -64.09 -45.14 97.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 110.372 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -60.8 -44.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.727 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.37 -41.78 96.52 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.89 . . . . 0.0 110.106 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -76.44 -43.47 39.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.929 . . . . 0.0 110.097 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.04 -44.43 87.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -0.947 . . . . 0.0 109.668 -179.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.3 tt0 -64.69 -38.17 90.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.17 -0.956 . . . . 0.0 109.088 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -71.42 -48.94 46.46 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.378 -0.826 . . . . 0.0 110.623 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -62.41 -42.47 99.46 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.362 -0.836 . . . . 0.0 111.279 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.765 ' CE1' HG21 ' A' ' 80' ' ' THR . 98.6 m-85 -101.2 -6.52 24.14 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.866 -1.146 . . . . 0.0 110.353 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.98 28.25 73.73 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.0 mt -101.55 137.01 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.281 -1.129 . . . . 0.0 109.192 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.95 57.38 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.076 -1.015 . . . . 0.0 109.291 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.71 -36.82 79.78 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.27 -0.894 . . . . 0.0 109.441 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -61.39 -33.26 73.39 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -50.72 -34.59 27.51 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.836 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.8 t -101.4 135.87 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.187 -0.945 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -89.51 141.81 28.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.471 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.407 HD13 HD21 ' A' ' 41' ' ' LEU . 36.5 mt -97.31 134.26 40.83 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.74 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.48 153.19 8.46 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.216 -0.928 . . . . 0.0 109.226 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.07 -28.58 80.31 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.487 2.125 . . . . 0.0 111.964 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.05 -29.56 70.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.368 -0.833 . . . . 0.0 109.572 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.65 -26.97 66.48 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.347 -0.846 . . . . 0.0 109.75 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.578 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 96.1 m-85 -103.49 6.82 37.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 110.161 -179.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.7 tpt180 -58.35 -41.69 85.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.029 -1.044 . . . . 0.0 109.904 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -153.74 158.86 41.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.902 -1.124 . . . . 0.0 110.116 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.441 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -62.74 -36.98 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.34 -0.85 . . . . 0.0 109.871 179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.657 ' NH2' ' SD ' ' A' ' 1' ' ' MET . 4.6 tpm_? -60.7 -40.86 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.25 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.25 -44.07 95.58 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.102 -0.999 . . . . 0.0 109.695 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.5 mt -66.11 -39.76 85.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.225 -0.922 . . . . 0.0 109.79 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.667 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.5 t0 -58.02 -38.41 76.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.396 -0.815 . . . . 0.0 109.857 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.5 -46.2 80.61 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.207 -0.933 . . . . 0.0 109.847 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -66.6 -41.63 88.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.091 -1.006 . . . . 0.0 109.225 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -64.9 -42.48 94.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.349 -0.845 . . . . 0.0 109.706 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.667 HG23 ' O ' ' A' ' 73' ' ' ASP . 72.6 t -63.1 -41.46 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.253 -0.904 . . . . 0.0 109.79 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.0 -30.33 66.51 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.44 -48.08 4.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -1.22 . . . . 0.0 110.21 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.765 HG21 ' CE1' ' A' ' 52' ' ' PHE . 7.2 t -143.3 155.53 44.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.184 -0.947 . . . . 0.0 109.737 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.2 t . . . . . 0 C--N 1.303 -1.434 0 O-C-N 121.29 -0.881 . . . . 0.0 109.281 179.916 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.241 0.543 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.872 ' OE1' HG21 ' A' ' 81' ' ' THR . 90.6 mt-30 -82.08 135.05 35.37 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.32 -0.862 . . . . 0.0 108.745 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 56.4 m80 55.62 38.37 30.09 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.182 -0.949 . . . . 0.0 108.959 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -58.93 -34.0 71.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -0.806 . . . . 0.0 109.548 -179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.02 -38.64 79.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.21 -0.931 . . . . 0.0 109.679 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 10' ' ' PHE . 53.2 t -64.4 -37.61 80.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.157 -0.964 . . . . 0.0 109.595 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.49 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.4 mt -59.3 -50.42 79.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.37 -0.831 . . . . 0.0 109.618 -179.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.741 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -42.66 97.34 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.154 -0.966 . . . . 0.0 108.787 179.28 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.36 -34.77 77.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.645 -0.659 . . . . 0.0 109.613 179.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.457 ' N ' ' O ' ' A' ' 6' ' ' VAL . 58.3 t80 -59.57 -53.11 61.83 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.397 -0.814 . . . . 0.0 110.352 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' N ' ' A' ' 12' ' ' VAL . 34.2 m -74.4 -40.88 49.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.101 -0.999 . . . . 0.0 109.948 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.0 t -64.91 -37.6 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.309 -0.87 . . . . 0.0 110.451 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -56.64 -30.65 63.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.072 -1.018 . . . . 0.0 109.853 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.529 ' OE2' ' CD1' ' A' ' 36' ' ' ILE . 84.4 tt0 -65.27 -31.27 72.33 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.719 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.3 p90 -143.06 46.17 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 109.774 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.859 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.58 136.07 52.4 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.061 -1.024 . . . . 0.0 110.157 -179.837 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_endo -77.62 -149.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 122.143 1.895 . . . . 0.0 110.308 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.565 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.63 12.08 2.76 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.803 -1.185 . . . . 0.0 108.782 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.565 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.5 t -113.35 136.2 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.579 -0.701 . . . . 0.0 109.805 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.43 84.15 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.971 . . . . 0.0 108.85 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.415 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.1 Cg_exo -48.23 -30.71 15.36 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.775 1.65 . . . . 0.0 112.129 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -23.81 66.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 0.0 109.348 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -98.94 3.44 47.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.105 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.0 t -104.88 137.03 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -63.65 99.28 0.22 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.198 -0.939 . . . . 0.0 109.514 -179.443 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB1' ' A' ' 8' ' ' ALA . 15.1 m -60.91 6.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.557 179.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -88.77 11.29 18.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.171 -0.956 . . . . 0.0 108.905 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.5 tp -82.59 131.72 35.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.98 122.22 17.75 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.349 -0.845 . . . . 0.0 109.063 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.692 HD11 HG12 ' A' ' 69' ' ' ILE . 66.2 mt -62.97 -10.12 12.5 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.341 -0.849 . . . . 0.0 109.491 -179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.461 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.9 p -50.19 -39.44 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.099 -1.001 . . . . 0.0 109.245 -179.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.7 m-20 -58.08 -37.66 74.92 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.603 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.2 m-80 -87.6 15.5 6.69 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 178.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.4 -18.37 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.003 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -52.48 -35.37 20.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 120.797 -1.414 . . . . 0.0 108.185 179.163 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.8 tt -71.19 -25.06 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.589 -0.694 . . . . 0.0 109.869 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -62.82 -30.19 71.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.302 -0.874 . . . . 0.0 110.999 -178.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.6 m -104.95 -65.14 1.06 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.006 -1.059 . . . . 0.0 111.178 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.452 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -74.17 -52.14 13.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.162 -0.961 . . . . 0.0 111.069 -178.262 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.528 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.86 -38.93 96.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.7 -42.12 98.52 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -1.084 . . . . 0.0 109.593 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.568 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -58.73 -44.17 90.39 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.097 -1.002 . . . . 0.0 108.541 -179.562 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -66.82 -37.84 85.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.188 -0.945 . . . . 0.0 109.331 179.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.0 t -67.44 -47.85 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.398 -0.813 . . . . 0.0 111.102 -179.115 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -60.84 -43.49 95.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.727 -1.233 . . . . 0.0 109.922 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -45.29 76.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.063 . . . . 0.0 110.191 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.5 t90 -77.22 -46.84 21.89 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 110.09 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.469 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 11.6 tp -56.97 -41.01 77.59 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.377 -0.827 . . . . 0.0 109.818 -179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.605 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.5 tt0 -61.4 -42.52 98.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.982 -1.074 . . . . 0.0 108.955 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.9 -36.98 83.51 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.245 -0.909 . . . . 0.0 109.55 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 60.7 ttt85 -59.98 -46.31 89.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 111.137 -178.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 47.3 m-85 -117.21 0.17 12.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.14 -0.975 . . . . 0.0 110.94 -179.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.605 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.68 40.37 65.91 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.9 mt -96.0 141.43 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.214 -1.168 . . . . 0.0 109.225 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.86 140.67 58.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.004 -1.06 . . . . 0.0 109.427 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.09 -32.22 72.75 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.338 -0.851 . . . . 0.0 109.381 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -91.03 9.82 29.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.335 -0.853 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -52.9 -34.11 53.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.626 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.06 158.9 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.463 -0.773 . . . . 0.0 109.604 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.492 ' C ' HD12 ' A' ' 61' ' ' LEU . 95.5 mt-10 -93.16 150.59 20.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.885 . . . . 0.0 109.303 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.86 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.4 mp -98.12 132.24 43.81 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 109.801 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.77 143.51 3.94 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.21 -0.931 . . . . 0.0 109.058 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.81 -24.92 74.54 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.146 1.898 . . . . 0.0 112.104 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.27 -32.52 74.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.236 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -72.89 -26.67 61.52 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.322 -0.861 . . . . 0.0 111.318 -178.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -97.85 11.04 38.66 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.77 -1.206 . . . . 0.0 110.953 -178.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -58.56 -34.29 70.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.936 -1.102 . . . . 0.0 109.952 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -145.78 151.0 37.26 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.031 -1.043 . . . . 0.0 110.018 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.692 HG12 HD11 ' A' ' 30' ' ' LEU . 82.4 mt -66.27 -36.74 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.405 -0.809 . . . . 0.0 109.846 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.0 ttp180 -60.69 -39.09 87.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.574 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -58.28 -42.41 86.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.984 -1.073 . . . . 0.0 109.927 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.4 mt -68.03 -39.24 81.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.49 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.3 t0 -59.13 -41.21 87.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.347 -0.846 . . . . 0.0 110.474 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.09 -43.11 88.24 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.123 -0.986 . . . . 0.0 110.212 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -62.7 -48.67 78.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.179 -0.951 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.608 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.37 -46.33 90.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.235 -0.916 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.451 HG23 ' OD2' ' A' ' 73' ' ' ASP . 41.4 t -59.62 -39.55 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 O-C-N 121.068 -1.02 . . . . 0.0 109.534 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.82 -32.63 66.24 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.8 -49.61 3.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -1.234 . . . . 0.0 110.479 -179.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.608 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.1 t -158.52 149.92 20.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 0.0 109.547 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.872 HG21 ' OE1' ' A' ' 2' ' ' GLN . 10.1 t . . . . . 0 N--CA 1.489 1.488 0 O-C-N 121.292 -0.88 . . . . 0.0 109.182 179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.407 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 86.9 mmm . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.424 HE21 ' CD2' ' A' ' 3' ' ' HIS . 60.2 tp60 -98.99 119.57 38.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.361 -0.837 . . . . 0.0 109.229 179.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.424 ' CD2' HE21 ' A' ' 2' ' ' GLN . 37.4 m170 46.85 30.25 1.17 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.195 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.93 -35.8 79.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.697 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.9 -38.55 82.61 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.0 109.859 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 72.7 t -64.28 -41.06 91.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.169 179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 90.6 mt -59.53 -43.52 91.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.338 -0.851 . . . . 0.0 109.739 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.738 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.38 -47.74 80.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.21 -0.931 . . . . 0.0 109.158 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.69 -33.14 72.13 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.357 -0.839 . . . . 0.0 109.591 179.611 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -59.86 -53.12 61.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.167 -0.958 . . . . 0.0 110.19 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' ' CE1' ' A' ' 15' ' ' PHE . 34.6 m -74.41 -40.67 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.147 -0.97 . . . . 0.0 110.193 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 8' ' ' ALA . 64.2 t -64.91 -36.35 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.354 -0.841 . . . . 0.0 110.588 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.46 -33.94 66.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 109.931 -179.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -65.68 -32.18 73.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.269 -0.894 . . . . 0.0 109.871 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.588 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 7.8 p90 -138.27 45.82 2.07 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.145 -0.972 . . . . 0.0 109.931 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.869 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 135.74 53.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.951 -1.093 . . . . 0.0 109.946 -179.823 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.58 -150.38 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.105 1.87 . . . . 0.0 110.264 178.431 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.558 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.52 12.09 2.69 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.8 -1.187 . . . . 0.0 108.708 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.558 HG23 ' OD2' ' A' ' 18' ' ' ASP . 25.6 t -113.64 136.64 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.549 -0.719 . . . . 0.0 109.818 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.89 139.58 82.95 Favored Pre-proline 0 N--CA 1.488 1.444 0 O-C-N 121.152 -0.967 . . . . 0.0 108.751 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.52 -31.74 19.07 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 121.699 1.599 . . . . 0.0 111.966 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.17 -26.6 67.49 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.301 -0.874 . . . . 0.0 109.395 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -103.34 4.8 36.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -99.22 144.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.326 -0.859 . . . . 0.0 108.695 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.3 t0 -71.82 95.06 1.47 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.034 -1.041 . . . . 0.0 109.357 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.48 ' O ' HD12 ' A' ' 69' ' ' ILE . 18.9 m -62.25 6.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.342 -0.849 . . . . 0.0 109.588 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.6 m-20 -90.77 12.08 20.34 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.184 -0.948 . . . . 0.0 109.017 179.605 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 tp -84.53 133.87 34.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.433 -0.792 . . . . 0.0 109.484 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -65.21 122.34 16.87 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.271 -0.893 . . . . 0.0 108.824 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.74 HD11 HG12 ' A' ' 69' ' ' ILE . 67.3 mt -64.92 -6.28 8.04 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.249 -0.907 . . . . 0.0 109.618 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 73.0 t -50.91 -45.06 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.021 . . . . 0.0 108.904 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.7 -35.99 69.14 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -86.02 15.24 5.19 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.94 -16.88 0.02 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.76 -38.05 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 120.867 -1.372 . . . . 0.0 108.267 179.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.616 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.09 -25.3 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.538 -0.726 . . . . 0.0 110.324 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.7 m-20 -59.68 -35.65 74.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 111.105 -178.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.31 -64.22 1.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.13 -0.981 . . . . 0.0 111.556 -178.419 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -69.99 -52.09 27.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.057 -1.027 . . . . 0.0 111.301 -178.056 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -69.3 -36.75 79.41 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.249 -179.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.616 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tp -58.43 -47.83 82.67 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.335 -1.097 . . . . 0.0 109.582 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.5 mt -61.38 -42.62 99.01 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.109 -0.995 . . . . 0.0 109.77 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -63.63 -39.66 94.92 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.402 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.478 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.2 t -70.22 -49.7 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.268 -0.895 . . . . 0.0 110.554 -179.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -62.17 -40.48 87.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 120.959 -1.088 . . . . 0.0 109.948 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.18 -45.99 75.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.081 -1.012 . . . . 0.0 110.039 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.6 OUTLIER -77.61 -47.05 20.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.145 -0.972 . . . . 0.0 109.635 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.478 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 31.4 tp -56.75 -39.2 73.57 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.433 -0.792 . . . . 0.0 109.466 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.611 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.0 tm-20 -61.53 -42.74 99.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.953 . . . . 0.0 109.466 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' OE2' ' A' ' 49' ' ' GLU . 20.9 t70 -64.33 -39.45 93.93 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.071 -1.018 . . . . 0.0 109.71 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -66.19 -45.53 80.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 111.549 -178.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 53.5 m-85 -111.17 -1.49 16.15 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.98 -1.075 . . . . 0.0 111.151 -178.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.611 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.67 38.48 67.42 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.54 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 72.5 mt -88.44 145.38 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.103 -1.233 . . . . 0.0 109.37 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.96 122.9 16.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.08 -19.72 56.69 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.468 -0.77 . . . . 0.0 109.741 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.03 11.06 5.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.352 -0.842 . . . . 0.0 110.165 -179.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.94 112.37 16.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.03 -1.044 . . . . 0.0 109.527 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.1 m -116.58 18.13 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.56 -0.713 . . . . 0.0 109.313 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -55.7 -28.27 54.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.827 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.676 HD21 ' CZ ' ' A' ' 75' ' ' PHE . 64.0 mt -77.21 142.09 39.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.092 -1.005 . . . . 0.0 109.905 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.92 164.78 21.46 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -51.98 -33.13 51.0 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.349 2.033 . . . . 0.0 111.54 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -66.72 -27.42 67.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.512 -0.742 . . . . 0.0 109.251 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 19.6 t-80 -67.63 -26.62 66.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.377 -0.827 . . . . 0.0 109.768 -179.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -90.24 11.91 19.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.208 -0.933 . . . . 0.0 109.282 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 -53.82 -37.64 63.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.381 -0.825 . . . . 0.0 109.792 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.4 p -146.14 157.17 43.83 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.044 -1.035 . . . . 0.0 110.036 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.74 HG12 HD11 ' A' ' 30' ' ' LEU . 84.8 mt -64.36 -36.82 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.336 -0.853 . . . . 0.0 110.076 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 43.8 ttp180 -60.57 -40.55 92.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.314 -0.866 . . . . 0.0 110.381 -179.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -62.55 -38.64 90.83 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.012 -1.055 . . . . 0.0 109.71 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.6 mt -68.23 -39.35 80.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.827 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.444 ' OD2' HG23 ' A' ' 77' ' ' VAL . 59.4 t0 -59.43 -41.14 88.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.363 -0.836 . . . . 0.0 110.334 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -43.29 86.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.098 -1.001 . . . . 0.0 110.512 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CZ ' HD21 ' A' ' 61' ' ' LEU . 67.3 t80 -61.96 -49.3 76.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.081 -1.012 . . . . 0.0 109.775 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 80' ' ' THR . 68.4 t -66.52 -44.74 90.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.268 -0.895 . . . . 0.0 109.825 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.444 HG23 ' OD2' ' A' ' 73' ' ' ASP . 47.3 t -63.03 -39.53 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.011 -1.056 . . . . 0.0 109.894 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.7 -33.97 69.05 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.39 -48.79 3.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -1.222 . . . . 0.0 110.644 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' HG12 ' A' ' 76' ' ' VAL . 60.2 m -158.36 137.86 11.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.125 -0.985 . . . . 0.0 109.839 -179.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.795 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.49 1.57 0 O-C-N 121.325 -0.859 . . . . 0.0 109.1 179.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.391 0.615 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.492 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 93.9 mt-30 -58.9 -36.61 74.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.062 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . 0.564 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -147.59 29.86 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.734 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.486 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.38 -32.5 71.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.427 -0.796 . . . . 0.0 110.008 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.0 p -58.97 -39.94 83.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.03 -1.044 . . . . 0.0 109.563 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.564 HG21 ' CE1' ' A' ' 3' ' ' HIS . 70.0 t -68.07 -39.07 80.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 108.44 178.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 82.2 mt -61.26 -50.48 80.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.502 -0.749 . . . . 0.0 109.151 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.739 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.36 -47.36 79.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.346 -0.846 . . . . 0.0 109.183 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -44.25 96.12 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.483 -0.76 . . . . 0.0 109.227 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.592 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.5 t80 -68.34 -48.85 63.73 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.626 0.727 . . . . 0.0 109.452 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.701 HG13 ' CD1' ' A' ' 36' ' ' ILE . 93.7 t -67.02 -45.41 87.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.601 -0.687 . . . . 0.0 109.901 -179.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.4 t -63.7 -37.74 80.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.272 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.5 -30.59 63.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.462 -0.774 . . . . 0.0 109.789 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.93 -32.21 73.82 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.201 -0.937 . . . . 0.0 109.357 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.453 ' HE1' HD12 ' A' ' 36' ' ' ILE . 6.9 p90 -147.01 52.86 1.08 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 109.112 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.3 136.58 52.94 Favored Pre-proline 0 N--CA 1.486 1.374 0 O-C-N 121.207 -0.933 . . . . 0.0 110.187 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.67 -152.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 121.815 1.676 . . . . 0.0 110.388 178.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -78.26 9.75 3.58 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.908 -1.12 . . . . 0.0 108.709 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -113.85 136.16 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.498 -0.751 . . . . 0.0 109.883 -179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.92 142.48 90.76 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.19 -0.944 . . . . 0.0 108.574 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -48.67 -32.4 21.53 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 121.593 1.529 . . . . 0.0 111.638 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.81 -25.27 65.49 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.372 -0.83 . . . . 0.0 109.395 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -105.01 6.42 33.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -96.6 143.4 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.282 -0.886 . . . . 0.0 108.762 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -72.39 92.33 1.42 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.126 -0.984 . . . . 0.0 109.365 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.3 m -62.79 6.23 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.893 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.9 m-20 -95.9 9.7 39.74 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 108.723 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 11.1 tp -90.22 135.6 33.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.487 -0.758 . . . . 0.0 109.561 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.585 ' OD2' ' NH2' ' A' ' 67' ' ' ARG . 90.0 m-20 -63.98 121.89 15.19 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.41 ' HA ' HD22 ' A' ' 33' ' ' ASN . 0.6 OUTLIER -75.81 7.89 3.52 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.286 -0.884 . . . . 0.0 110.046 -178.954 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.0 t -53.43 -42.79 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.063 -1.023 . . . . 0.0 108.636 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -55.74 -35.5 66.24 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.4 m-80 -85.19 15.12 4.44 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.39 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.7 t -51.73 -37.33 20.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.014 -1.286 . . . . 0.0 108.547 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.701 ' CD1' HG13 ' A' ' 11' ' ' VAL . 2.5 tt -70.81 -25.24 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 0.0 110.426 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -58.1 -34.33 70.07 Favored 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 111.009 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.92 -64.29 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.984 -1.073 . . . . 0.0 111.575 -178.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.531 ' N ' HD22 ' A' ' 39' ' ' LEU . 4.2 mm? -72.37 -52.5 15.8 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.976 -1.078 . . . . 0.0 111.211 -178.091 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.522 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.02 91.37 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.3 tp -57.71 -43.95 85.59 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.365 -1.079 . . . . 0.0 109.208 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 42' ' ' LEU . 94.2 mt -63.64 -41.82 98.21 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 108.98 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -64.26 -36.95 85.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.413 -0.804 . . . . 0.0 109.53 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 40' ' ' GLY . 74.8 t -62.66 -45.57 98.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.379 -0.825 . . . . 0.0 110.22 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.8 mm -61.35 -44.24 98.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.146 -0.971 . . . . 0.0 109.829 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.0 -43.78 91.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.242 -0.911 . . . . 0.0 109.766 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.592 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -73.39 -38.92 65.46 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.796 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 28.5 tp -59.69 -43.34 94.07 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.2 -0.938 . . . . 0.0 109.917 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.577 ' O ' ' N ' ' A' ' 53' ' ' GLY . 59.3 tt0 -65.16 -36.09 83.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 109.951 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -60.59 -38.99 86.47 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.984 -1.072 . . . . 0.0 110.125 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 mtp180 -74.67 -44.65 49.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.143 -0.973 . . . . 0.0 112.079 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -108.11 -7.17 16.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.765 -1.209 . . . . 0.0 111.354 -178.088 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.78 32.18 73.8 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.1 mt -91.22 152.42 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.257 -1.143 . . . . 0.0 109.835 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.1 150.48 29.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.075 -1.016 . . . . 0.0 109.008 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.85 -40.27 72.61 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.251 -0.906 . . . . 0.0 109.969 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 50.79 49.76 20.36 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.11 -0.994 . . . . 0.0 109.205 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -74.62 116.03 14.85 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.939 . . . . 0.0 109.909 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 ' H ' ' A' ' 61' ' ' LEU . 27.3 t -124.91 141.68 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 61' ' ' LEU . 19.8 pt-20 -60.5 -31.95 70.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.085 -1.009 . . . . 0.0 110.466 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.486 ' O ' ' O ' ' A' ' 60' ' ' GLU . 60.7 mt 44.04 -170.5 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.055 -1.028 . . . . 0.0 109.642 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -134.23 162.25 58.81 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.344 -0.848 . . . . 0.0 109.409 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.83 -26.81 83.76 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.756 2.304 . . . . 0.0 112.17 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -61.04 -31.53 71.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.39 -0.818 . . . . 0.0 109.909 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.8 t60 -68.07 -26.46 65.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.184 -0.948 . . . . 0.0 110.205 -179.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.432 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 94.1 m-85 -97.41 10.17 40.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 109.763 -179.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.585 ' NH2' ' OD2' ' A' ' 29' ' ' ASP . 34.2 tpt85 -55.61 -38.32 69.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.076 -1.015 . . . . 0.0 109.879 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -137.75 153.99 49.66 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.095 -1.003 . . . . 0.0 110.145 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.4 mt -62.68 -36.58 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.264 -0.898 . . . . 0.0 110.006 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -60.76 -36.78 79.8 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.235 -0.916 . . . . 0.0 110.251 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 90.5 p -61.37 -36.16 79.45 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.022 -1.049 . . . . 0.0 109.449 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.97 -38.96 83.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.238 -0.914 . . . . 0.0 109.097 179.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.712 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.3 t0 -57.51 -36.98 72.26 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.46 -0.775 . . . . 0.0 109.352 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.38 -43.53 98.71 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.224 -0.923 . . . . 0.0 109.222 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -65.04 -46.95 79.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.259 -0.9 . . . . 0.0 109.207 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 53.2 t -65.24 -40.58 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 121.45 -0.781 . . . . 0.0 109.712 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -58.99 -42.46 86.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.243 -0.91 . . . . 0.0 109.684 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.83 -35.02 91.4 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 120.222 -0.989 . . . . 0.0 110.645 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -86.29 -48.02 8.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.899 -1.353 . . . . 0.0 109.853 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.2 t -138.54 151.03 46.97 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.759 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t . . . . . 0 N--CA 1.487 1.414 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 -179.314 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.302 0.573 . . . . 0.0 109.931 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLN . . . . . 0.484 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 98.5 mm-40 -87.07 123.76 32.49 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 22.3 m-70 54.54 15.78 1.14 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.107 -0.996 . . . . 0.0 108.654 -179.386 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.401 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -64.19 -39.81 94.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.459 -0.776 . . . . 0.0 110.196 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.72 -39.24 87.89 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.177 -0.952 . . . . 0.0 110.157 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.6 t -64.77 -37.69 80.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.158 -0.964 . . . . 0.0 109.307 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.402 ' O ' HG12 ' A' ' 11' ' ' VAL . 90.4 mt -63.98 -36.73 77.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 110.54 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.47 -51.09 67.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.959 -1.088 . . . . 0.0 110.049 -179.422 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.41 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 3.5 pp0? -70.92 -36.72 72.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.101 -0.999 . . . . 0.0 109.473 179.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.423 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 59.6 t80 -65.74 -51.32 60.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.345 -0.847 . . . . 0.0 109.97 -179.611 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.5 p -68.33 -41.87 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.925 . . . . 0.0 109.589 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.0 t -64.61 -39.32 85.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -0.928 . . . . 0.0 109.521 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.95 -28.16 55.75 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.392 -0.817 . . . . 0.0 109.731 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -65.09 -29.16 70.01 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.263 -0.898 . . . . 0.0 108.833 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.617 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 22.8 p90 -151.0 48.99 0.85 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.376 -0.827 . . . . 0.0 109.076 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.485 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -79.76 137.12 54.52 Favored Pre-proline 0 N--CA 1.487 1.4 0 O-C-N 120.975 -1.078 . . . . 0.0 110.343 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.83 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.974 1.782 . . . . 0.0 110.51 178.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.544 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.9 p30 -81.05 13.29 2.82 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.923 -1.111 . . . . 0.0 108.803 179.242 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.544 HG23 ' OD2' ' A' ' 18' ' ' ASP . 38.6 t -113.43 136.65 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.609 -0.682 . . . . 0.0 109.91 -179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.03 140.61 73.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.039 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -48.41 -31.75 18.6 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.795 1.664 . . . . 0.0 111.575 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.37 -21.87 65.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.519 -0.738 . . . . 0.0 109.412 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -97.6 1.61 48.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.421 -0.8 . . . . 0.0 109.119 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.2 t -107.09 137.54 37.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.0 t0 -70.56 99.87 1.72 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 109.319 -179.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 12.6 m -60.07 5.84 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.379 -0.826 . . . . 0.0 109.682 -179.925 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -96.4 9.19 42.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 0.0 108.748 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.3 tp -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.561 -0.712 . . . . 0.0 109.52 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . 0.411 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.0 m-20 -65.14 121.51 14.92 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 179.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.519 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -71.07 8.51 0.93 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.195 -0.94 . . . . 0.0 109.493 -179.231 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.459 ' O ' ' N ' ' A' ' 34' ' ' GLY . 57.0 t -56.39 -41.81 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.164 -0.96 . . . . 0.0 108.8 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -55.51 -34.09 64.33 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 178.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.724 ' N ' HD22 ' A' ' 33' ' ' ASN . 0.8 OUTLIER -84.02 14.45 4.14 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.46 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.134 -1.187 . . . . 0.0 110.134 -179.116 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.8 t -52.09 -39.29 26.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 120.921 -1.341 . . . . 0.0 108.324 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.14 -25.2 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.605 -0.685 . . . . 0.0 110.118 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.6 m-20 -62.12 -32.1 72.64 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 110.797 -178.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.5 m -105.44 -64.93 1.09 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.004 -1.06 . . . . 0.0 111.306 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.0 tt -71.71 -52.15 19.25 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 0.0 111.19 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.1 -36.69 86.12 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.5 tp -58.53 -43.36 89.19 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.348 -1.089 . . . . 0.0 109.881 -179.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 93.9 mt -67.53 -44.11 79.15 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 110.111 -179.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -65.08 -35.03 79.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -63.21 -44.99 99.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.293 -0.879 . . . . 0.0 110.979 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.06 -43.85 93.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.655 -1.278 . . . . 0.0 110.062 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.29 -45.32 76.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.109 -0.994 . . . . 0.0 110.396 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.485 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -76.6 -44.63 33.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.167 -0.958 . . . . 0.0 109.957 -179.709 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.5 tp -57.02 -39.0 73.94 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.337 -0.852 . . . . 0.0 109.207 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' A' ' 53' ' ' GLY . 12.0 tt0 -60.87 -43.27 98.63 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.204 -0.935 . . . . 0.0 109.25 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.09 -40.04 90.5 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.199 -0.938 . . . . 0.0 110.025 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.423 ' NH2' ' CZ ' ' A' ' 10' ' ' PHE . 73.8 ttt180 -63.48 -45.94 88.44 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.252 -0.905 . . . . 0.0 111.177 -178.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -106.86 -5.3 18.42 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.002 -1.062 . . . . 0.0 110.63 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.602 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.63 34.04 72.44 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 71.9 mt -98.88 144.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.301 -1.117 . . . . 0.0 109.633 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.45 148.57 41.37 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.136 -0.978 . . . . 0.0 109.586 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.48 -29.8 68.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.442 -0.786 . . . . 0.0 109.693 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.96 ' O ' HG13 ' A' ' 59' ' ' VAL . 85.3 m-20 54.62 49.03 19.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.283 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' A' ' 58' ' ' ASP . 45.1 p30 -39.25 91.8 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.498 -0.751 . . . . 0.0 110.254 -179.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 ' O ' ' A' ' 57' ' ' ASP . 29.4 m -128.43 158.05 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 108.981 179.564 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -100.35 129.96 46.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 109.729 -179.79 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.3 140.92 42.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.448 -0.782 . . . . 0.0 109.421 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.83 156.13 55.57 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.517 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.98 -26.59 83.44 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.666 2.244 . . . . 0.0 112.031 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.35 -30.87 71.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.328 -0.857 . . . . 0.0 109.715 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.408 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.0 t60 -67.74 -26.79 66.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 109.662 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -93.65 9.22 37.83 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.179 -0.951 . . . . 0.0 109.358 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 15.2 tpt180 -54.91 -39.59 68.96 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.807 -179.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -141.96 153.98 44.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.017 -1.052 . . . . 0.0 110.098 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.2 mt -59.09 -36.66 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.365 -0.834 . . . . 0.0 109.838 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.9 ttp180 -60.28 -39.13 85.77 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.268 -0.895 . . . . 0.0 110.234 -179.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 t -58.3 -44.08 88.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.016 -1.053 . . . . 0.0 109.619 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.494 HD11 HD11 ' A' ' 30' ' ' LEU . 80.0 mt -62.96 -38.74 82.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.177 -0.952 . . . . 0.0 109.427 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.606 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.6 t0 -56.8 -37.88 71.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.396 -0.815 . . . . 0.0 109.702 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.78 -42.57 97.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.2 -0.938 . . . . 0.0 109.672 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.408 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.8 t80 -64.07 -48.34 76.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.148 -0.97 . . . . 0.0 109.459 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.75 -42.4 92.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.355 -0.841 . . . . 0.0 109.982 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.9 t -63.14 -40.89 90.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.167 -0.958 . . . . 0.0 109.903 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.7 -33.78 74.13 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.16 -47.99 4.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.046 -1.267 . . . . 0.0 110.506 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.8 m -128.68 138.16 52.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.341 -0.849 . . . . 0.0 109.943 -179.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.793 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t . . . . . 0 N--CA 1.488 1.438 0 O-C-N 121.308 -0.87 . . . . 0.0 109.185 179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.8 mtm . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 121.171 0.51 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.818 ' OE1' HG13 ' A' ' 77' ' ' VAL . 89.7 mt-30 55.64 53.21 9.87 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.402 -0.811 . . . . 0.0 109.14 -179.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.58 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.0 m80 77.14 41.46 0.15 Allowed 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.671 -0.643 . . . . 0.0 109.43 -179.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.421 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.6 -33.41 73.85 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.296 -0.877 . . . . 0.0 109.444 179.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -62.16 -35.94 80.32 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.169 -0.957 . . . . 0.0 109.748 -179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.65 HG11 ' H ' ' A' ' 84' ' ' VAL . 74.7 t -65.88 -39.8 85.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.13 -0.981 . . . . 0.0 109.123 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.421 HD12 ' HA ' ' A' ' 4' ' ' ALA . 86.1 mt -59.49 -49.58 83.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.432 -0.792 . . . . 0.0 109.298 -179.899 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.613 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.7 -41.79 98.08 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.2 -0.938 . . . . 0.0 108.534 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -65.43 -37.33 86.58 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.464 -0.773 . . . . 0.0 109.172 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.402 ' CZ ' ' HG3' ' A' ' 87' ' ' LYS . 33.6 t80 -59.94 -52.99 63.06 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.544 -0.723 . . . . 0.0 110.044 -178.888 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.711 HG21 HD13 ' A' ' 30' ' ' LEU . 4.6 p -73.49 -42.39 56.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.213 -0.929 . . . . 0.0 109.889 179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.6 t -64.45 -38.12 81.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.337 -0.852 . . . . 0.0 110.411 -179.322 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -56.15 -26.51 50.6 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.001 . . . . 0.0 109.691 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.454 ' OE1' HD12 ' A' ' 36' ' ' ILE . 98.0 mt-10 -64.26 -31.11 72.18 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.158 -0.964 . . . . 0.0 109.168 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.54 ' CD2' ' N ' ' A' ' 15' ' ' PHE . 0.1 OUTLIER -153.96 52.88 0.69 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.337 -0.852 . . . . 0.0 109.316 -179.741 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.513 ' CB ' HG12 ' A' ' 12' ' ' VAL . 1.7 pt? -80.74 136.61 51.33 Favored Pre-proline 0 N--CA 1.486 1.334 0 O-C-N 120.964 -1.085 . . . . 0.0 110.023 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -73.4 -153.81 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.482 0 C-N-CA 122.007 1.805 . . . . 0.0 110.773 178.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.457 ' C ' ' OD2' ' A' ' 18' ' ' ASP . 53.9 p30 -82.85 16.7 2.15 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.075 -1.016 . . . . 0.0 108.839 179.372 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.419 HG23 ' OD2' ' A' ' 18' ' ' ASP . 40.2 t -112.85 138.02 43.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.56 -0.712 . . . . 0.0 110.03 -179.26 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -65.78 137.16 96.07 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.247 -0.908 . . . . 0.0 108.651 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -48.35 -29.99 14.4 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 121.836 1.691 . . . . 0.0 112.016 179.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.31 -24.06 66.48 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.325 -0.859 . . . . 0.0 109.486 179.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -101.18 8.18 42.77 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.352 -0.842 . . . . 0.0 109.452 -179.782 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -100.99 137.5 28.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.463 0 O-C-N 121.324 -0.86 . . . . 0.0 108.875 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.572 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -65.91 90.96 0.14 Allowed 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.194 -0.941 . . . . 0.0 109.367 -179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.512 ' O ' HD12 ' A' ' 69' ' ' ILE . 6.3 m -61.74 6.63 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.345 -0.847 . . . . 0.0 109.551 179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.572 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -92.05 12.44 21.95 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.213 -0.929 . . . . 0.0 109.135 179.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.2 tp -85.27 134.21 34.13 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.32 -0.862 . . . . 0.0 109.613 -179.688 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.507 ' O ' ' OD1' ' A' ' 29' ' ' ASP . 37.3 p30 -64.3 121.54 14.54 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.369 -0.832 . . . . 0.0 109.065 179.847 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.733 HD11 HG12 ' A' ' 69' ' ' ILE . 67.6 mt -63.62 -8.14 9.17 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.188 -0.945 . . . . 0.0 109.602 -179.39 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.483 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.1 p -50.33 -41.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.058 -1.027 . . . . 0.0 108.904 -179.713 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.483 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.2 m-20 -59.2 -34.92 72.73 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.183 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.644 ' O ' ' N ' ' A' ' 35' ' ' VAL . 83.1 m-20 -85.19 16.9 3.27 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 178.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.43 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.45 -14.81 0.01 OUTLIER Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.224 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.644 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.1 t -51.85 -39.56 25.26 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 O-C-N 120.909 -1.348 . . . . 0.0 108.07 178.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.629 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.9 tt -71.31 -25.03 24.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.635 -0.666 . . . . 0.0 110.319 179.869 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -60.48 -32.09 71.08 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.215 -0.928 . . . . 0.0 111.432 -178.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.565 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.14 -65.05 1.07 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.892 -1.13 . . . . 0.0 111.405 -178.348 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 16.2 mt -74.01 -52.43 12.79 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.022 -1.048 . . . . 0.0 111.124 -178.107 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.452 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.62 -35.83 91.63 Favored Glycine 0 N--CA 1.488 2.139 0 N-CA-C 110.137 -1.185 . . . . 0.0 110.137 -179.406 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.629 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.62 -42.23 87.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.232 -1.157 . . . . 0.0 109.121 -179.11 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.1 mt -63.35 -44.14 95.68 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.161 -0.962 . . . . 0.0 109.011 179.357 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 19.2 mttp -68.38 -41.08 81.06 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.327 -0.858 . . . . 0.0 109.707 179.628 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -67.59 -46.94 81.97 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.4 -0.812 . . . . 0.0 110.177 -179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.23 -45.01 99.45 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.231 -0.918 . . . . 0.0 109.542 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -61.24 -41.42 96.85 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.192 -0.942 . . . . 0.0 109.999 -179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.751 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.27 -49.37 15.2 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.197 -0.939 . . . . 0.0 110.085 -179.744 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.8 tp -61.8 -41.39 97.69 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.339 -0.851 . . . . 0.0 110.279 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.55 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.9 pt-20 -70.57 -35.66 73.19 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.17 -0.956 . . . . 0.0 109.829 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -61.59 -41.95 98.16 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.248 -0.907 . . . . 0.0 110.092 -179.753 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.751 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 86.0 mtt180 -64.4 -38.82 92.36 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.273 -0.892 . . . . 0.0 111.133 -179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.615 ' CZ ' HG21 ' A' ' 80' ' ' THR . 96.7 m-85 -102.85 -4.54 24.71 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 120.96 -1.087 . . . . 0.0 110.244 -179.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 61.75 35.37 91.14 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.4 mt -90.19 141.2 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.178 -1.189 . . . . 0.0 109.849 -179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -70.0 136.26 50.24 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.025 -1.047 . . . . 0.0 108.9 179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.57 -35.23 79.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.089 -1.007 . . . . 0.0 109.482 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.619 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.7 p30 -65.87 -25.93 67.4 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.35 -0.844 . . . . 0.0 110.024 179.963 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.619 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 54.3 t0 -54.27 -35.83 62.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.778 -179.756 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 43.7 t -111.64 136.94 46.21 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.444 -0.785 . . . . 0.0 109.708 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -88.28 142.26 27.89 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.26 -0.9 . . . . 0.0 109.287 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.479 HD13 HD22 ' A' ' 41' ' ' LEU . 35.9 mt -93.05 135.28 34.37 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.223 -0.923 . . . . 0.0 109.697 -179.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -162.27 150.35 12.06 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.239 -0.913 . . . . 0.0 109.269 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.42 -27.07 76.99 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 122.473 2.115 . . . . 0.0 112.065 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -63.64 -30.57 71.66 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.401 -0.812 . . . . 0.0 109.747 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.4 t60 -67.65 -27.05 66.54 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.743 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.451 ' CE2' HD12 ' A' ' 41' ' ' LEU . 97.6 m-85 -102.69 10.34 38.67 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.234 -0.916 . . . . 0.0 109.73 -179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.453 HH22 ' CB ' ' A' ' 29' ' ' ASP . 32.8 tpt85 -54.15 -39.03 66.14 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.237 -0.915 . . . . 0.0 109.506 -179.743 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.9 p -147.79 151.87 36.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.076 -1.015 . . . . 0.0 109.873 179.909 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.733 HG12 HD11 ' A' ' 30' ' ' LEU . 83.7 mt -66.1 -37.29 79.45 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.293 -0.879 . . . . 0.0 109.892 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 72.4 mtm180 -61.32 -38.44 86.88 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.295 -0.878 . . . . 0.0 110.164 -179.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 83.9 p -62.93 -40.45 97.66 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.007 -1.058 . . . . 0.0 109.581 -179.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.3 mt -68.33 -40.97 83.28 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.185 -0.947 . . . . 0.0 109.74 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.574 ' O ' HG23 ' A' ' 77' ' ' VAL . 54.8 t0 -59.46 -40.69 87.68 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.383 -0.823 . . . . 0.0 110.156 -179.434 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.14 -43.05 88.19 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.125 -0.984 . . . . 0.0 110.001 -179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.3 t80 -62.33 -50.22 72.5 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.189 -0.944 . . . . 0.0 109.367 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.619 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.7 -44.84 93.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.229 -0.919 . . . . 0.0 109.483 179.833 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.818 HG13 ' OE1' ' A' ' 2' ' ' GLN . 48.8 t -60.08 -39.5 80.57 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.3 0 O-C-N 121.102 -0.999 . . . . 0.0 109.445 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.77 -32.95 66.52 Favored Glycine 0 N--CA 1.487 2.057 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.51 -49.47 3.55 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.09 -1.241 . . . . 0.0 110.634 -179.355 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.619 ' O ' HG12 ' A' ' 76' ' ' VAL . 10.7 t -160.47 152.31 19.96 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.126 -0.983 . . . . 0.0 109.887 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 10.3 t -131.46 90.11 38.55 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.231 -0.918 . . . . 0.0 109.228 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_endo -91.78 114.39 0.36 Allowed 'Trans proline' 0 C--N 1.311 -1.436 0 C-N-CA 123.194 2.596 . . . . 0.0 112.963 -179.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -78.28 133.64 12.19 Favored 'Trans proline' 0 C--N 1.315 -1.224 0 C-N-CA 122.003 1.802 . . . . 0.0 111.822 179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.65 ' H ' HG11 ' A' ' 6' ' ' VAL . 37.6 t -126.09 133.49 68.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.322 -0.861 . . . . 0.0 109.644 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -64.82 -36.14 83.37 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.246 -0.909 . . . . 0.0 109.44 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.419 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -150.35 151.68 33.25 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.322 -0.861 . . . . 0.0 109.334 179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.402 ' HG3' ' CZ ' ' A' ' 10' ' ' PHE . 13.5 tttm -59.54 -37.34 78.15 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.148 -0.97 . . . . 0.0 109.641 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 38.1 tp -56.65 -37.63 71.03 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.224 -0.923 . . . . 0.0 109.454 -179.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.459 179.983 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.565 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.577 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 83.8 mtp . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.264 0.554 . . . . 0.0 109.612 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.3 mt-30 -59.11 -38.04 78.61 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.228 -0.92 . . . . 0.0 109.349 -179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.543 ' HD1' HG22 ' A' ' 84' ' ' VAL . 26.2 m-70 -114.57 11.32 17.01 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.486 -0.759 . . . . 0.0 109.296 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.577 ' HB2' ' HA ' ' A' ' 1' ' ' MET . . . -56.66 -39.47 73.8 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.231 -0.918 . . . . 0.0 109.956 -179.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.528 ' HB2' ' HZ2' ' A' ' 87' ' ' LYS . 89.2 p -63.99 -36.04 82.68 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.008 -1.057 . . . . 0.0 109.432 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.2 t -68.79 -36.09 72.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.325 -0.86 . . . . 0.0 109.534 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.66 ' O ' HG22 ' A' ' 11' ' ' VAL . 98.7 mt -59.13 -50.42 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.233 -0.917 . . . . 0.0 109.996 -179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.84 -47.86 79.08 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.994 -1.066 . . . . 0.0 109.004 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.74 -41.22 98.06 Favored 'General case' 0 C--N 1.299 -1.614 0 CA-C-O 121.347 0.594 . . . . 0.0 110.015 179.981 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.0 t80 -66.14 -51.36 58.64 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.32 -0.863 . . . . 0.0 111.145 -178.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.66 HG22 ' O ' ' A' ' 7' ' ' ILE . 17.1 m -72.38 -43.59 64.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.181 -0.949 . . . . 0.0 110.848 -178.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.53 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.1 t -62.89 -36.28 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.161 -0.962 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -57.64 -37.59 73.6 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.206 -0.934 . . . . 0.0 109.508 -179.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -68.69 -36.22 78.22 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.293 -0.88 . . . . 0.0 110.303 -179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 52.1 m-85 -91.8 -58.51 2.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.052 -1.03 . . . . 0.0 110.575 -178.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.686 HD22 HG23 ' A' ' 19' ' ' VAL . 1.6 mt -128.98 87.58 54.12 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.347 -0.845 . . . . 0.0 110.443 -178.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -91.48 -18.96 0.88 Allowed 'Trans proline' 0 C--N 1.306 -1.674 0 C-N-CA 123.154 2.569 . . . . 0.0 112.116 178.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -75.96 -4.99 44.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.17 -0.956 . . . . 0.0 108.734 179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.686 HG23 HD22 ' A' ' 16' ' ' LEU . 45.9 t -113.99 141.62 29.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 N-CA-C 107.686 -1.228 . . . . 0.0 107.686 178.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.474 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -61.19 115.96 16.94 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 120.698 -1.251 . . . . 0.0 108.628 -179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_endo -63.75 -23.76 69.15 Favored 'Trans proline' 0 C--N 1.315 -1.217 0 C-N-CA 121.462 1.442 . . . . 0.0 111.409 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -74.25 -13.82 60.83 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.467 -0.771 . . . . 0.0 110.073 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.474 ' CG ' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -82.79 7.51 14.92 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 120.985 -1.072 . . . . 0.0 109.234 -179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.1 t -100.7 135.29 37.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 179.42 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.558 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -64.72 86.78 0.05 Allowed 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.065 -1.022 . . . . 0.0 109.384 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.497 HG11 ' HE2' ' A' ' 87' ' ' LYS . 16.3 m -61.84 5.36 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.33 -0.856 . . . . 0.0 109.359 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.558 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.8 m-20 -100.1 5.5 44.92 Favored 'General case' 0 N--CA 1.489 1.498 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -97.1 141.37 30.32 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.704 -0.622 . . . . 0.0 109.459 -179.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.458 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.1 m-20 -60.37 121.4 11.96 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 179.289 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' O ' ' N ' ' A' ' 33' ' ' ASN . 1.2 pp -68.62 8.37 0.5 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.289 -0.882 . . . . 0.0 109.83 -178.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.466 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -50.78 -40.01 19.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.121 -0.987 . . . . 0.0 108.974 179.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.466 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 55.5 t0 -57.76 -35.46 70.79 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 107.685 -1.228 . . . . 0.0 107.685 178.656 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.632 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -85.71 14.87 5.24 Favored 'General case' 0 C--N 1.304 -1.407 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 179.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.63 -14.93 0.02 OUTLIER Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.632 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.6 t -51.73 -36.44 18.88 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.172 -1.193 . . . . 0.0 108.803 179.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.595 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.1 tt -70.45 -24.93 26.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 110.315 -179.702 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 -59.59 -34.06 72.25 Favored 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.29 -0.881 . . . . 0.0 111.08 -178.448 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.5 m -105.72 -64.5 1.14 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.086 -1.009 . . . . 0.0 111.503 -178.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.591 ' N ' HD22 ' A' ' 39' ' ' LEU . 3.9 mm? -71.42 -52.2 19.86 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.045 -1.034 . . . . 0.0 111.151 -178.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.521 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.28 -37.31 92.76 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.76 -1.336 . . . . 0.0 109.76 -179.488 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.595 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.4 tp -58.76 -40.7 84.68 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.367 -1.078 . . . . 0.0 109.091 -179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.7 tp -64.48 -43.45 94.11 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.333 -0.855 . . . . 0.0 108.805 179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -64.35 -36.74 85.1 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.335 -0.853 . . . . 0.0 109.508 179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 40' ' ' GLY . 58.5 t -60.25 -43.29 93.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.385 -0.822 . . . . 0.0 109.872 -179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.425 ' CG2' ' HB1' ' A' ' 56' ' ' ALA . 1.5 mp -60.35 -49.39 84.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 O-C-N 121.201 -0.937 . . . . 0.0 109.482 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.26 -42.06 96.64 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.369 -0.832 . . . . 0.0 109.905 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -71.46 -40.92 70.0 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.323 -0.86 . . . . 0.0 109.783 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.9 tp -58.53 -46.39 86.88 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.324 -0.86 . . . . 0.0 109.519 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -65.41 -39.29 91.98 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.249 -0.907 . . . . 0.0 109.019 179.145 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -67.24 -36.79 82.39 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.391 -0.818 . . . . 0.0 110.51 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 54.5 ttt180 -86.22 -51.74 6.09 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.274 -0.891 . . . . 0.0 112.167 -178.146 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.2 m-85 -93.67 -5.57 48.29 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.682 -1.261 . . . . 0.0 111.16 -177.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.59 24.14 76.34 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.042 -1.623 . . . . 0.0 109.042 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 77.1 mt -92.97 144.12 10.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.337 -1.096 . . . . 0.0 109.422 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.67 146.75 44.46 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.062 -1.024 . . . . 0.0 109.272 -179.397 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.425 ' HB1' ' CG2' ' A' ' 45' ' ' ILE . . . -57.81 -33.21 68.35 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.352 -0.842 . . . . 0.0 109.569 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.964 ' O ' HG23 ' A' ' 59' ' ' VAL . 84.7 m-20 54.67 47.94 21.4 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.343 -0.848 . . . . 0.0 109.256 -179.987 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.421 ' C ' ' O ' ' A' ' 57' ' ' ASP . 92.0 m-20 -42.86 90.45 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.447 -0.783 . . . . 0.0 109.875 -179.701 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.964 HG23 ' O ' ' A' ' 57' ' ' ASP . 44.1 t -125.74 139.32 51.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 179.711 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.6 tt0 -74.42 130.77 40.26 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.017 -1.052 . . . . 0.0 109.671 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 28.8 mt -113.28 142.68 45.55 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.652 -0.655 . . . . 0.0 109.449 -179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -80.8 149.03 66.59 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.078 -1.014 . . . . 0.0 109.462 -179.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.1 Cg_endo -62.79 -20.85 72.28 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 122.529 2.153 . . . . 0.0 112.342 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -62.8 -32.48 73.67 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.265 -0.897 . . . . 0.0 110.259 -179.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.0 t60 -68.34 -26.71 65.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.985 -1.072 . . . . 0.0 109.975 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -97.41 5.98 48.93 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.161 -0.962 . . . . 0.0 109.725 -179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 22.6 tpt180 -55.52 -41.19 72.79 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.222 -0.924 . . . . 0.0 109.521 -179.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.9 m -128.19 147.45 50.57 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.238 -0.914 . . . . 0.0 109.818 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 79.0 mt -61.46 -36.3 72.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 O-C-N 121.318 -0.864 . . . . 0.0 109.828 179.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 77.8 mtm180 -60.8 -37.32 81.56 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.306 -0.871 . . . . 0.0 110.19 -179.249 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.7 t -59.08 -43.95 91.84 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.09 -1.007 . . . . 0.0 109.816 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.49 -38.88 83.38 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.136 -0.977 . . . . 0.0 109.628 179.935 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 21.5 t70 -57.12 -38.38 73.36 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.329 -0.857 . . . . 0.0 109.774 -179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.5 -44.45 90.89 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 109.719 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 74.0 t80 -63.55 -45.31 91.13 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.103 -0.998 . . . . 0.0 109.478 179.799 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 80' ' ' THR . 60.4 t -64.37 -43.67 97.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.341 -0.849 . . . . 0.0 110.099 -179.724 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 48.8 t -63.16 -42.38 96.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.061 -1.024 . . . . 0.0 109.822 -179.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.24 -30.54 71.12 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.39 -47.84 5.01 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.05 -1.265 . . . . 0.0 110.409 -179.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.502 ' O ' ' O ' ' A' ' 76' ' ' VAL . 14.0 t -140.7 153.66 46.04 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.219 -0.926 . . . . 0.0 109.909 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.805 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t -140.29 90.72 10.19 Favored Pre-proline 0 N--CA 1.487 1.402 0 O-C-N 121.275 -0.891 . . . . 0.0 109.511 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.462 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 53.5 Cg_endo -79.95 169.09 18.3 Favored 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.466 2.111 . . . . 0.0 112.097 -179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_exo -57.78 150.23 63.85 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.842 1.694 . . . . 0.0 111.784 179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.543 HG22 ' HD1' ' A' ' 3' ' ' HIS . 36.7 t -103.38 131.45 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.312 -0.867 . . . . 0.0 109.699 -179.523 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -129.68 150.12 51.14 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.46 -0.775 . . . . 0.0 109.303 179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.18 145.77 55.41 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.176 -0.952 . . . . 0.0 109.398 179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.528 ' HZ2' ' HB2' ' A' ' 5' ' ' SER . 62.6 mttp -57.6 -34.3 69.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.126 -0.984 . . . . 0.0 109.363 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.8 mt -58.75 -35.2 72.36 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.221 -0.924 . . . . 0.0 109.443 -179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 117.961 -1.019 . . . . 0.0 109.389 -179.978 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.497 ' O3 ' ' C6 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 69.9 mtm . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.39 0.614 . . . . 0.0 109.51 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -59.86 -38.39 82.02 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.287 -0.883 . . . . 0.0 109.59 -179.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 59.8 m-70 -126.41 11.27 7.42 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.477 -0.764 . . . . 0.0 109.455 -179.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.432 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -59.44 -36.52 76.08 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.148 -0.97 . . . . 0.0 109.849 -179.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -62.09 -34.79 76.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.098 -1.001 . . . . 0.0 109.425 -179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 76.9 t -66.1 -36.63 77.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.35 -0.844 . . . . 0.0 109.264 179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.72 ' O ' HG23 ' A' ' 11' ' ' VAL . 84.1 mt -64.98 -41.89 93.32 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.268 -0.895 . . . . 0.0 110.325 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.564 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . . . -63.94 -50.64 67.86 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.03 -1.044 . . . . 0.0 110.514 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.06 -43.42 71.22 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 -179.973 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.466 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 67.4 t80 -59.03 -43.64 91.64 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 120.981 -1.074 . . . . 0.0 109.26 179.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.72 HG23 ' O ' ' A' ' 7' ' ' ILE . 75.2 t -71.93 -49.73 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.362 -0.836 . . . . 0.0 110.449 -179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 59.3 t -63.85 -36.85 78.07 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 121.225 -0.922 . . . . 0.0 110.045 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.5 mt-10 -61.36 -31.0 70.87 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.24 -0.913 . . . . 0.0 109.719 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.64 -31.16 72.03 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.149 -0.97 . . . . 0.0 109.278 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -102.87 -58.8 1.81 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.24 -0.913 . . . . 0.0 110.548 -179.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.849 HD12 HG23 ' A' ' 19' ' ' VAL . 0.1 OUTLIER -131.12 88.59 44.61 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 121.308 -0.87 . . . . 0.0 111.317 -178.086 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -86.31 -13.51 5.23 Favored 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.73 2.287 . . . . 0.0 111.798 178.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -76.37 -4.28 41.43 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.164 -0.96 . . . . 0.0 109.084 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.849 HG23 HD12 ' A' ' 16' ' ' LEU . 43.0 t -113.31 142.47 25.67 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 N-CA-C 107.904 -1.147 . . . . 0.0 107.904 179.074 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.663 ' HB3' ' OD2' ' A' ' 23' ' ' ASP . . . -61.23 115.67 15.63 Favored Pre-proline 0 C--N 1.303 -1.413 0 O-C-N 120.75 -1.219 . . . . 0.0 108.649 -179.211 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -64.46 -25.41 63.22 Favored 'Trans proline' 0 N--CA 1.486 1.08 0 C-N-CA 121.527 1.485 . . . . 0.0 111.68 179.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.02 -14.29 61.39 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.354 -0.841 . . . . 0.0 109.178 179.24 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.663 ' OD2' ' HB3' ' A' ' 20' ' ' ALA . 89.3 m-20 -82.62 2.92 30.97 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.358 -0.838 . . . . 0.0 109.106 -179.738 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.5 t -99.47 136.05 32.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 179.643 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.524 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.83 86.45 0.23 Allowed 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.18 -0.95 . . . . 0.0 109.469 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -63.38 5.98 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.359 -0.838 . . . . 0.0 109.273 179.823 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.524 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.5 m-20 -94.4 3.4 55.22 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.248 -0.908 . . . . 0.0 108.751 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.638 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.6 tt -97.14 138.66 34.3 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.539 -0.726 . . . . 0.0 109.496 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.638 ' O ' HD23 ' A' ' 28' ' ' LEU . 89.8 m-20 -60.48 121.34 11.88 Favored 'General case' 0 C--N 1.304 -1.383 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.432 179.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 pp -65.34 5.7 0.37 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.24 -0.912 . . . . 0.0 109.793 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.481 ' H ' ' C ' ' A' ' 29' ' ' ASP . 4.8 p -50.57 -37.91 15.88 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.105 -0.997 . . . . 0.0 109.037 -179.823 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.443 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 92.2 m-20 -57.71 -36.97 72.73 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 178.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 61.5 m-80 -85.64 14.7 5.39 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.099 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.403 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -15.67 0.02 OUTLIER Glycine 0 N--CA 1.488 2.163 0 N-CA-C 109.908 -1.277 . . . . 0.0 109.908 -179.381 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.0 p -51.41 -34.36 15.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.85 -1.382 . . . . 0.0 108.507 179.553 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 2.4 tt -71.16 -24.36 24.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.554 -0.716 . . . . 0.0 109.883 179.639 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -57.91 -33.14 68.45 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.322 -0.861 . . . . 0.0 111.445 -178.18 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 75.2 m -105.83 -64.59 1.14 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.856 -1.153 . . . . 0.0 111.497 -178.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.43 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.2 mp -72.42 -52.22 16.9 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.937 -1.102 . . . . 0.0 110.805 -178.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.867 ' O ' HG22 ' A' ' 44' ' ' VAL . . . -65.45 -36.72 92.94 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.842 -1.303 . . . . 0.0 109.842 -179.554 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.6 tp -58.52 -41.21 84.97 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.356 -1.085 . . . . 0.0 109.285 -179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 37.5 tp -65.8 -41.48 91.87 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.008 -1.057 . . . . 0.0 109.525 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.2 mttt -70.22 -44.69 68.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.301 -0.874 . . . . 0.0 111.519 -179.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.867 HG22 ' O ' ' A' ' 40' ' ' GLY . 16.0 m -72.43 -42.09 64.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 120.939 -1.1 . . . . 0.0 111.624 -178.214 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -58.7 -47.8 87.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 120.845 -1.159 . . . . 0.0 110.241 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -62.06 -39.61 92.98 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.14 -0.975 . . . . 0.0 110.241 -179.142 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.782 ' HE1' HH21 ' A' ' 51' ' ' ARG . 0.9 OUTLIER -77.17 -49.35 15.37 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.927 -1.108 . . . . 0.0 110.403 -179.602 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.1 tp -60.15 -46.0 91.17 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.232 -0.917 . . . . 0.0 110.134 -179.024 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.536 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -66.81 -38.06 85.73 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.013 -1.054 . . . . 0.0 109.463 -179.924 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -62.69 -38.91 92.23 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.206 -0.934 . . . . 0.0 109.584 179.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.782 HH21 ' HE1' ' A' ' 47' ' ' TRP . 43.1 mmm-85 -59.28 -38.97 81.47 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.542 -0.724 . . . . 0.0 110.143 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -95.84 0.95 52.8 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.167 -0.958 . . . . 0.0 110.089 -179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.11 37.95 63.73 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.069 -1.613 . . . . 0.0 109.069 -179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 58.2 mt -104.04 148.58 8.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.411 -1.052 . . . . 0.0 109.79 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.539 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -91.25 122.77 34.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.01 -1.056 . . . . 0.0 108.396 179.219 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.36 -38.98 93.28 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.08 -1.012 . . . . 0.0 109.745 -179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -62.1 -37.12 83.87 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.276 -0.89 . . . . 0.0 110.093 -179.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.539 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 89.0 m-20 -57.14 -37.69 72.42 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.231 -0.918 . . . . 0.0 110.353 -179.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 41.8 t -118.91 134.24 63.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.306 -0.871 . . . . 0.0 110.05 -179.508 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.8 tt0 -108.28 137.55 46.07 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.478 -0.764 . . . . 0.0 109.307 179.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 22.4 mt -106.54 146.83 30.15 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.769 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -111.9 160.47 29.68 Favored Pre-proline 0 N--CA 1.491 1.603 0 O-C-N 121.361 -0.837 . . . . 0.0 109.425 179.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.4 Cg_endo -62.76 -32.21 78.22 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 122.799 2.333 . . . . 0.0 112.123 -179.788 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -62.62 -29.01 70.3 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.399 -0.813 . . . . 0.0 109.557 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.402 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 32.0 t-80 -67.84 -26.38 66.02 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.365 -0.834 . . . . 0.0 110.149 -179.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.596 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 97.6 m-85 -97.95 8.55 44.56 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.075 -1.015 . . . . 0.0 110.133 -179.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 12.9 tpt180 -56.01 -41.07 74.31 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.193 -0.942 . . . . 0.0 109.355 179.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 50.3 m -128.8 145.73 51.11 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.318 -0.864 . . . . 0.0 109.669 179.921 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 73.5 mt -63.0 -39.64 85.98 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.27 0 O-C-N 121.119 -0.988 . . . . 0.0 109.855 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.6 mtm180 -61.54 -37.02 82.22 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.058 -179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.1 m -58.19 -38.88 77.58 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.121 -0.987 . . . . 0.0 109.638 -179.66 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.408 ' HB ' HD13 ' A' ' 7' ' ' ILE . 71.0 mt -63.63 -42.3 95.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.323 -0.86 . . . . 0.0 109.612 179.953 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.74 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.4 t0 -59.48 -38.65 81.38 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.289 -0.882 . . . . 0.0 110.111 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.55 -46.07 80.92 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.087 -1.008 . . . . 0.0 110.05 -179.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.402 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.5 t80 -63.38 -47.0 83.87 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.127 -0.983 . . . . 0.0 109.418 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.528 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.4 t -64.75 -42.74 95.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.317 -0.864 . . . . 0.0 109.727 -179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.74 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.7 t -59.67 -41.47 85.31 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.239 -0.913 . . . . 0.0 109.845 -179.757 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.65 -31.47 75.25 Favored Glycine 0 N--CA 1.489 2.226 0 C-N-CA 120.264 -0.97 . . . . 0.0 110.748 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.48 -48.76 3.73 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.03 -1.277 . . . . 0.0 110.751 -178.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -129.68 156.81 43.65 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.324 -0.86 . . . . 0.0 109.664 -179.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.791 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t -140.25 89.48 10.85 Favored Pre-proline 0 C--N 1.301 -1.51 0 O-C-N 121.13 -0.981 . . . . 0.0 109.381 179.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 14.0 Cg_exo -64.74 159.24 46.37 Favored 'Trans proline' 0 N--CA 1.493 1.443 0 C-N-CA 122.588 2.192 . . . . 0.0 112.021 179.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_endo -59.37 150.62 73.83 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 C-N-CA 122.659 2.24 . . . . 0.0 111.65 179.67 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 46.4 t -96.14 129.2 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.103 -0.998 . . . . 0.0 109.776 -179.502 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -135.46 166.72 22.52 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.464 -0.772 . . . . 0.0 108.93 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.13 139.36 35.53 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.074 -1.016 . . . . 0.0 109.063 179.974 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.564 ' HE2' ' HB3' ' A' ' 8' ' ' ALA . 55.6 tttm -58.92 -35.89 73.83 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.193 -0.942 . . . . 0.0 109.55 -179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.5 mt -58.58 -35.22 72.06 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.183 -0.948 . . . . 0.0 109.433 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.4 mt-30 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 117.957 -1.021 . . . . 0.0 109.423 179.958 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.482 ' S12' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.699 ' N ' ' HB3' ' A' ' 4' ' ' ALA . 86.1 mtp . . . . . 0 N--CA 1.489 1.503 0 N-CA-C 109.318 -0.623 . . . . 0.0 109.318 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.2 mt-30 -60.2 -38.27 82.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.214 -0.929 . . . . 0.0 109.771 -179.721 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.615 ' HE2' ' HG1' ' A' ' 81' ' ' THR . 73.4 m-70 -141.5 14.39 2.17 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.254 -0.904 . . . . 0.0 109.708 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 1' ' ' MET . . . -60.33 -33.4 72.34 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.155 -0.966 . . . . 0.0 110.097 -179.464 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -61.26 -36.59 80.44 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 120.945 -1.097 . . . . 0.0 109.613 -179.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.779 HG23 HG13 ' A' ' 84' ' ' VAL . 75.7 t -66.79 -39.68 84.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.089 -1.007 . . . . 0.0 108.819 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 91.1 mt -61.73 -50.3 80.78 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.032 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.725 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.31 -48.78 74.31 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.397 -0.814 . . . . 0.0 109.137 179.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.02 -44.76 95.06 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.551 -0.718 . . . . 0.0 109.501 179.933 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.436 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 66.4 t80 -69.56 -48.44 60.31 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.559 -0.713 . . . . 0.0 109.525 -179.815 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.665 HG13 ' CD1' ' A' ' 36' ' ' ILE . 94.3 t -66.8 -45.26 88.22 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.513 -0.742 . . . . 0.0 109.954 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.725 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.5 t -64.1 -37.24 79.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.374 -0.829 . . . . 0.0 109.523 -179.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.57 -30.71 61.3 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.363 -0.836 . . . . 0.0 110.022 -179.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -65.36 -29.69 70.44 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.104 -0.997 . . . . 0.0 109.298 179.937 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.617 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 31.3 p90 -149.2 50.04 0.97 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.289 -0.882 . . . . 0.0 109.374 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.477 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.16 136.86 53.23 Favored Pre-proline 0 N--CA 1.487 1.383 0 O-C-N 120.932 -1.105 . . . . 0.0 110.184 -179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -73.21 -153.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.539 0 C-N-CA 121.96 1.773 . . . . 0.0 110.581 178.852 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -80.91 13.56 2.62 Favored 'General case' 0 C--N 1.299 -1.624 0 O-C-N 121.051 -1.031 . . . . 0.0 108.643 179.303 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.1 t -113.47 137.17 47.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.589 -0.694 . . . . 0.0 110.028 -179.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.77 140.7 74.82 Favored Pre-proline 0 N--CA 1.49 1.542 0 O-C-N 121.176 -0.953 . . . . 0.0 108.898 179.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -48.57 -30.96 17.31 Favored 'Trans proline' 0 N--CA 1.492 1.438 0 C-N-CA 121.891 1.727 . . . . 0.0 111.85 179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.676 ' HB2' ' HB3' ' A' ' 87' ' ' LYS . . . -66.58 -23.4 66.19 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.326 -0.859 . . . . 0.0 109.49 179.781 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -96.43 3.06 53.06 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.35 -0.844 . . . . 0.0 109.063 -179.92 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.8 t -105.91 136.94 38.27 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.56 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.0 t0 -70.91 96.3 1.27 Allowed 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.075 -1.016 . . . . 0.0 109.428 -179.439 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.918 HG11 ' NZ ' ' A' ' 87' ' ' LYS . 14.3 m -61.7 6.13 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 109.589 179.895 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.56 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.9 m-20 -93.8 7.44 44.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.207 -0.933 . . . . 0.0 108.909 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.582 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.4 tt -92.61 135.14 34.34 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.593 -0.692 . . . . 0.0 109.642 -179.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.582 ' O ' HD23 ' A' ' 28' ' ' LEU . 91.6 m-20 -62.01 121.64 13.5 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.3 pp -70.51 9.68 0.59 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.202 -0.936 . . . . 0.0 109.519 -179.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.459 ' H ' ' C ' ' A' ' 29' ' ' ASP . 5.4 p -52.15 -38.03 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.201 -0.937 . . . . 0.0 109.462 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.428 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.9 m-20 -56.94 -36.76 70.64 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.06 -1.089 . . . . 0.0 108.06 179.139 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.621 ' O ' ' N ' ' A' ' 35' ' ' VAL . 75.7 m-20 -86.25 14.76 6.0 Favored 'General case' 0 C--N 1.303 -1.422 0 N-CA-C 108.652 -0.869 . . . . 0.0 108.652 179.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.48 -15.61 0.02 OUTLIER Glycine 0 N--CA 1.488 2.125 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 -179.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.621 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.2 p -52.82 -34.26 19.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 120.928 -1.336 . . . . 0.0 108.509 179.36 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.665 ' CD1' HG13 ' A' ' 11' ' ' VAL . 3.4 tt -71.07 -24.47 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.581 -0.7 . . . . 0.0 110.134 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -58.14 -34.1 69.89 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.36 -0.837 . . . . 0.0 111.51 -178.138 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.562 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -104.98 -65.26 1.05 Allowed 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.858 -1.151 . . . . 0.0 111.148 -178.54 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -69.71 -47.22 63.93 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.157 -0.964 . . . . 0.0 110.722 -178.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.437 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -70.1 -39.97 72.63 Favored Glycine 0 N--CA 1.49 2.265 0 C-N-CA 119.921 -1.133 . . . . 0.0 110.379 -179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.606 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.2 tt -58.66 -39.81 81.71 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.19 -1.182 . . . . 0.0 109.078 -179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.5 tp -62.25 -44.18 97.15 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 119.458 -0.897 . . . . 0.0 108.67 179.7 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -69.54 -40.15 77.05 Favored 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.326 -0.858 . . . . 0.0 109.857 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.6 t -64.77 -45.9 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.363 -0.836 . . . . 0.0 110.268 -179.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.69 -46.02 97.42 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.238 -0.913 . . . . 0.0 109.532 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.35 97.05 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.271 -0.893 . . . . 0.0 109.951 -179.772 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.436 ' CZ2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -75.09 -40.73 59.85 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.232 -0.918 . . . . 0.0 109.995 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.8 tp -57.77 -43.88 85.83 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.252 -0.905 . . . . 0.0 109.639 -179.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 62.3 tt0 -64.18 -39.77 94.7 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.185 -0.947 . . . . 0.0 109.449 179.476 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -67.34 -45.28 76.85 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.191 -0.943 . . . . 0.0 110.836 -179.679 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.6 ttt180 -70.02 -45.34 67.4 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.274 -0.891 . . . . 0.0 112.131 -178.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.0 m-85 -103.38 -5.33 23.05 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.815 -1.178 . . . . 0.0 111.433 -178.088 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.09 27.68 73.61 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 72.5 mt -98.3 143.87 12.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.24 -1.153 . . . . 0.0 109.451 -179.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.44 149.74 33.21 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.145 -0.972 . . . . 0.0 109.579 -179.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.94 -31.93 63.36 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.431 -0.793 . . . . 0.0 109.529 -179.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.3 m-20 54.52 43.86 29.65 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.365 -0.834 . . . . 0.0 109.582 179.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.618 ' O ' HD21 ' A' ' 61' ' ' LEU . 53.2 p30 -93.42 11.34 28.74 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.288 -0.883 . . . . 0.0 109.446 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 73.6 t -59.94 -41.05 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.305 -0.872 . . . . 0.0 109.97 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.556 ' O ' HD23 ' A' ' 61' ' ' LEU . 87.8 mt-10 -116.33 130.22 56.66 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.433 -0.792 . . . . 0.0 109.717 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.618 HD21 ' O ' ' A' ' 58' ' ' ASP . 5.9 mt -121.89 141.92 50.79 Favored 'General case' 0 N--CA 1.487 1.393 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 -179.483 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -158.27 105.55 1.69 Allowed Pre-proline 0 N--CA 1.488 1.447 0 O-C-N 121.025 -1.047 . . . . 0.0 109.806 -179.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . 0.401 ' HD3' ' N5 ' ' A' ' 101' ' ' PN7 . 30.7 Cg_exo -55.32 -21.66 30.12 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 121.792 1.661 . . . . 0.0 111.228 179.595 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.31 -30.99 71.55 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.52 -0.738 . . . . 0.0 109.508 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 56.2 t-80 -69.19 -26.33 64.78 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.362 -0.836 . . . . 0.0 111.02 -179.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -97.68 5.67 49.0 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 120.98 -1.075 . . . . 0.0 111.368 -178.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 25.4 mmt180 -60.2 -37.84 81.49 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.766 -1.208 . . . . 0.0 110.3 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 32.7 t -131.79 141.57 49.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.077 -1.014 . . . . 0.0 110.139 -179.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.681 HD13 ' HB2' ' A' ' 8' ' ' ALA . 83.8 mt -62.84 -37.9 80.41 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 O-C-N 121.404 -0.81 . . . . 0.0 109.827 179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 80.6 mtm180 -61.41 -37.21 82.65 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.265 -0.897 . . . . 0.0 110.244 -179.389 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.0 m -58.66 -40.37 83.3 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.102 -0.999 . . . . 0.0 109.496 -179.653 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 72.0 mt -64.76 -38.74 83.49 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.379 0 O-C-N 121.299 -0.876 . . . . 0.0 109.314 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.573 ' O ' HG23 ' A' ' 77' ' ' VAL . 20.8 t70 -57.45 -39.17 75.73 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.281 -0.887 . . . . 0.0 109.797 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.07 -44.32 92.75 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.088 -1.007 . . . . 0.0 109.464 -179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.7 t80 -64.81 -46.16 83.19 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.285 -0.884 . . . . 0.0 109.318 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.9 t -63.89 -43.47 97.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.287 -0.883 . . . . 0.0 109.802 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.573 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -60.86 -40.52 85.5 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.305 0 O-C-N 121.165 -0.959 . . . . 0.0 109.558 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.2 -32.39 67.45 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 110.364 -1.095 . . . . 0.0 110.364 -179.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.27 -49.0 3.69 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.027 -1.278 . . . . 0.0 110.758 -179.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.3 p -134.92 154.94 51.5 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.198 -0.939 . . . . 0.0 110.1 -179.673 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.4 t -140.6 89.32 10.43 Favored Pre-proline 0 C--N 1.303 -1.42 0 O-C-N 121.198 -0.939 . . . . 0.0 109.0 179.208 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.592 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 79.1 Cg_endo -85.67 160.81 10.72 Favored 'Trans proline' 0 C--N 1.311 -1.443 0 C-N-CA 122.878 2.385 . . . . 0.0 112.993 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -61.15 150.9 82.27 Favored 'Trans proline' 0 C--N 1.308 -1.568 0 C-N-CA 123.024 2.482 . . . . 0.0 111.788 179.352 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.779 HG13 HG23 ' A' ' 6' ' ' VAL . 45.3 t -100.07 127.72 52.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.135 -0.978 . . . . 0.0 110.005 -179.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.708 ' O ' ' HB3' ' A' ' 86' ' ' ALA . 97.2 mt-10 -67.72 -30.5 70.01 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.496 -0.753 . . . . 0.0 109.416 179.552 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.708 ' HB3' ' O ' ' A' ' 85' ' ' GLU . . . 82.03 116.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.629 -0.669 . . . . 0.0 109.283 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.918 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 20.5 mttp -57.9 -32.97 68.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.188 -0.945 . . . . 0.0 109.452 -179.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.3 mt -88.37 142.4 27.76 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.236 -0.915 . . . . 0.0 109.441 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.9 mt-30 . . . . . 0 N--CA 1.49 1.535 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.538 179.982 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.562 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 86.6 mmm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.725 ' HG2' HG22 ' A' ' 84' ' ' VAL . 91.3 mt-30 -105.72 131.32 53.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.277 -0.889 . . . . 0.0 109.25 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.616 ' CD2' HG21 ' A' ' 6' ' ' VAL . 3.9 m80 40.93 31.2 0.12 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.386 -0.821 . . . . 0.0 109.486 179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.405 ' N ' ' O ' ' A' ' 2' ' ' GLN . . . -60.05 -39.38 85.76 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.211 -0.931 . . . . 0.0 109.752 -179.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -65.05 -32.93 74.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.158 -0.964 . . . . 0.0 109.719 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.616 HG21 ' CD2' ' A' ' 3' ' ' HIS . 74.8 t -66.77 -38.55 81.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.193 -0.942 . . . . 0.0 109.399 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.674 HD12 ' OD2' ' A' ' 73' ' ' ASP . 91.9 mt -61.15 -49.82 83.07 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.176 -0.953 . . . . 0.0 109.368 179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.99 -47.44 80.32 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.233 -0.917 . . . . 0.0 108.906 179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.03 -44.08 96.89 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.548 -0.72 . . . . 0.0 109.25 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.404 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.4 t80 -68.23 -49.13 62.75 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.656 -0.653 . . . . 0.0 109.729 -179.779 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 7' ' ' ILE . 95.3 t -67.99 -44.69 84.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.533 -0.73 . . . . 0.0 109.923 -179.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.2 t -64.0 -35.18 72.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.326 -0.859 . . . . 0.0 109.444 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -56.1 -31.97 63.74 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -65.72 -32.48 74.06 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.279 -0.888 . . . . 0.0 109.785 -179.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.654 ' CE2' HD12 ' A' ' 36' ' ' ILE . 31.4 p90 -140.71 46.8 1.77 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.196 -0.94 . . . . 0.0 109.663 -179.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.3 136.22 53.27 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.019 -1.05 . . . . 0.0 110.156 -179.752 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.02 -151.52 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.355 0 C-N-CA 122.167 1.911 . . . . 0.0 110.42 178.569 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.94 9.73 2.74 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 120.891 -1.131 . . . . 0.0 108.682 179.153 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 28.4 t -113.51 135.75 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.576 -0.703 . . . . 0.0 109.781 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.54 140.62 81.96 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.138 -0.976 . . . . 0.0 108.754 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.512 ' HD3' HD12 ' A' ' 16' ' ' LEU . 46.4 Cg_exo -48.6 -33.05 22.88 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.621 1.547 . . . . 0.0 111.586 179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.41 -20.22 63.8 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.53 -0.731 . . . . 0.0 109.185 179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -98.27 3.86 48.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.465 -0.772 . . . . 0.0 109.316 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.6 t -104.14 136.03 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.6 m-20 -67.5 95.48 0.47 Allowed 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.122 -0.986 . . . . 0.0 109.366 -179.553 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.869 HG21 ' NZ ' ' A' ' 87' ' ' LYS . 19.5 m -60.27 6.08 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.328 -0.858 . . . . 0.0 109.604 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.9 m-20 -92.75 5.92 49.37 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.158 -0.964 . . . . 0.0 108.606 179.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 32.1 tp -91.84 136.83 32.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.537 -0.727 . . . . 0.0 109.364 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.488 ' OD2' ' O ' ' A' ' 67' ' ' ARG . 88.5 m-20 -62.85 121.81 14.4 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 119.423 -0.911 . . . . 0.0 108.582 179.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.67 HD11 ' CD1' ' A' ' 69' ' ' ILE . 79.5 mt -68.46 -4.34 14.57 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.368 -0.832 . . . . 0.0 109.457 -179.455 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 51.2 t -51.47 -41.97 27.82 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.145 -0.972 . . . . 0.0 108.799 179.879 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.83 -35.29 66.23 Favored 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.61 ' O ' ' N ' ' A' ' 35' ' ' VAL . 1.7 m120 -83.24 14.83 3.24 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 178.835 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.26 -15.82 0.02 OUTLIER Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.945 -1.262 . . . . 0.0 109.945 -179.332 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.61 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.5 t -51.71 -39.16 23.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 108.181 179.386 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.654 HD12 ' CE2' ' A' ' 15' ' ' PHE . 5.1 tt -71.24 -25.09 24.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.506 -0.746 . . . . 0.0 109.899 179.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.422 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 87.4 m-20 -62.97 -30.53 71.65 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.155 -0.965 . . . . 0.0 110.839 -178.652 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 39.7 m -105.11 -65.17 1.06 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.997 -1.064 . . . . 0.0 111.056 -178.826 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.62 -52.31 15.94 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.133 -0.979 . . . . 0.0 110.985 -178.406 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.55 -36.79 91.94 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 110.014 -1.234 . . . . 0.0 110.014 -179.381 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 4.1 tp -58.71 -41.17 85.7 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.468 -1.019 . . . . 0.0 109.235 -179.436 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -65.53 -44.13 87.83 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.184 -0.947 . . . . 0.0 108.807 179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.48 -43.7 76.36 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.553 -0.717 . . . . 0.0 110.104 179.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 96.1 t -64.53 -45.39 95.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.362 -0.837 . . . . 0.0 110.55 -179.03 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.519 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -60.53 -46.94 94.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.593 0 O-C-N 120.999 -1.063 . . . . 0.0 109.475 -179.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -44.14 80.59 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.343 -0.848 . . . . 0.0 110.296 -179.642 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.404 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.7 t90 -78.46 -49.05 14.14 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.102 -0.999 . . . . 0.0 110.338 -179.656 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.49 ' N ' ' O ' ' A' ' 44' ' ' VAL . 7.6 tp -60.7 -42.35 97.03 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.328 -0.858 . . . . 0.0 110.554 -178.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.519 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -65.84 -37.82 87.21 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 120.984 -1.072 . . . . 0.0 109.046 -179.696 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -69.1 -38.96 79.21 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.421 -0.799 . . . . 0.0 109.576 179.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 52.1 ttt180 -58.95 -41.1 86.66 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.565 -0.709 . . . . 0.0 110.691 -179.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 94.8 m-85 -102.97 -6.5 22.33 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 120.965 -1.084 . . . . 0.0 109.898 -179.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.35 30.86 78.67 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 17.6 pt -112.94 149.27 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.4 -1.059 . . . . 0.0 109.855 -179.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -69.81 144.77 52.53 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.302 -0.874 . . . . 0.0 109.239 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -61.03 -35.91 78.14 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.131 -0.981 . . . . 0.0 109.292 179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 53.14 43.17 31.95 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.363 -0.836 . . . . 0.0 109.565 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.408 ' HB3' HD21 ' A' ' 61' ' ' LEU . 91.2 m-20 -82.39 94.26 7.36 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.245 -0.909 . . . . 0.0 109.52 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 69.6 t -63.59 -43.78 98.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.192 -0.942 . . . . 0.0 109.398 179.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -158.35 140.37 13.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.311 -0.868 . . . . 0.0 109.756 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.408 HD21 ' HB3' ' A' ' 58' ' ' ASP . 36.4 mt -103.16 136.79 42.29 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.329 -0.857 . . . . 0.0 109.46 179.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.42 147.52 13.5 Favored Pre-proline 0 N--CA 1.489 1.51 0 O-C-N 121.068 -1.02 . . . . 0.0 109.447 179.713 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -63.48 -21.09 70.87 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 C-N-CA 122.49 2.127 . . . . 0.0 111.973 179.823 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.52 -31.35 70.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.448 -0.782 . . . . 0.0 110.056 -179.586 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -68.41 -26.4 65.52 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.289 -0.882 . . . . 0.0 110.713 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -93.76 8.75 39.85 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.881 -1.137 . . . . 0.0 110.707 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.488 ' O ' ' OD2' ' A' ' 29' ' ' ASP . 17.5 mmm180 -58.34 -34.74 70.97 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.074 -1.016 . . . . 0.0 110.231 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 82.5 p -150.55 158.61 44.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.11 -0.994 . . . . 0.0 110.464 -179.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.67 ' CD1' HD11 ' A' ' 30' ' ' LEU . 11.4 mm -62.89 -35.82 72.87 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.362 0 O-C-N 121.453 -0.78 . . . . 0.0 109.724 179.722 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 63.0 mtm180 -59.99 -36.53 77.4 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.283 -0.885 . . . . 0.0 109.855 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.3 t -59.62 -43.07 93.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 120.901 -1.124 . . . . 0.0 108.91 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 82.4 mt -62.15 -38.39 80.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.429 -0.794 . . . . 0.0 109.267 179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.681 ' O ' HG23 ' A' ' 77' ' ' VAL . 83.5 m-20 -56.34 -37.64 70.25 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.387 -0.821 . . . . 0.0 109.253 -179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.56 -40.13 96.19 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.31 -0.869 . . . . 0.0 109.763 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.3 t80 -62.14 -51.78 66.49 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.165 -0.959 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.8 t -65.16 -41.17 91.04 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.237 -0.915 . . . . 0.0 109.444 179.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.681 HG23 ' O ' ' A' ' 73' ' ' ASP . 55.1 t -58.47 -40.62 79.19 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.323 0 O-C-N 121.312 -0.867 . . . . 0.0 109.538 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.21 -33.02 82.75 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 -179.578 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.45 -48.83 4.22 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.976 -1.308 . . . . 0.0 110.581 -179.038 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.503 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.8 p -129.69 154.22 47.37 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.4 -0.812 . . . . 0.0 108.994 179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.81 HG23 ' O ' ' A' ' 81' ' ' THR . 9.1 t -138.08 89.08 14.86 Favored Pre-proline 0 C--N 1.304 -1.407 0 O-C-N 121.15 -0.969 . . . . 0.0 109.956 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.441 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 14.5 Cg_exo -65.88 -176.64 0.62 Allowed 'Trans proline' 0 C--N 1.31 -1.461 0 C-N-CA 122.704 2.27 . . . . 0.0 111.697 179.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.441 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 27.1 Cg_exo -58.6 150.6 68.35 Favored 'Trans proline' 0 C--N 1.307 -1.625 0 C-N-CA 122.418 2.079 . . . . 0.0 111.485 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.725 HG22 ' HG2' ' A' ' 2' ' ' GLN . 25.3 t -91.95 128.35 43.67 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.027 -1.046 . . . . 0.0 109.844 -179.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -139.61 153.53 47.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.37 -0.831 . . . . 0.0 109.215 179.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.94 141.4 57.63 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.156 -0.965 . . . . 0.0 109.452 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.869 ' NZ ' HG21 ' A' ' 26' ' ' VAL . 18.3 tttm -83.55 136.14 34.37 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.219 -0.926 . . . . 0.0 109.273 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.46 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 53.8 mt -88.39 142.09 28.01 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.219 -0.925 . . . . 0.0 109.492 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.501 ' OXT' ' CG2' ' A' ' 26' ' ' VAL . 25.9 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.965 -1.017 . . . . 0.0 109.525 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.406 ' O3 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.9 mtm . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.477 0.656 . . . . 0.0 110.032 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.558 ' O ' ' N ' ' A' ' 4' ' ' ALA . 92.2 mt-30 -104.76 140.72 37.67 Favored 'General case' 0 N--CA 1.488 1.448 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 179.27 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.553 ' NE2' HG11 ' A' ' 6' ' ' VAL . 53.7 t-80 49.36 11.23 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.493 0 O-C-N 120.952 -1.092 . . . . 0.0 108.497 -179.533 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.625 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -62.36 -35.91 80.61 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.593 -0.692 . . . . 0.0 110.193 -179.605 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 35.1 m -58.85 -42.07 88.47 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.075 -1.016 . . . . 0.0 109.567 -179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.553 HG11 ' NE2' ' A' ' 3' ' ' HIS . 54.3 t -67.35 -36.36 76.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.397 -0.815 . . . . 0.0 109.221 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.625 HD12 ' HA ' ' A' ' 4' ' ' ALA . 98.9 mt -59.75 -49.51 83.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.831 -179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.721 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.51 -45.28 91.4 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.086 -1.008 . . . . 0.0 108.928 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.27 -43.34 91.58 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.509 -0.744 . . . . 0.0 109.051 179.431 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.704 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 66.3 t80 -66.07 -49.93 65.89 Favored 'General case' 0 C--N 1.3 -1.569 0 CA-C-O 121.471 0.653 . . . . 0.0 109.89 -179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.475 HG23 ' O ' ' A' ' 7' ' ' ILE . 97.9 t -67.17 -45.02 87.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.414 -0.804 . . . . 0.0 109.641 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.721 HG23 ' O ' ' A' ' 8' ' ' ALA . 92.8 t -64.17 -35.6 74.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.438 -0.789 . . . . 0.0 109.597 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.29 -31.09 63.32 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.896 . . . . 0.0 109.753 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' HD11 ' A' ' 36' ' ' ILE . 84.3 tt0 -65.44 -31.96 73.32 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.276 -0.89 . . . . 0.0 109.747 -179.706 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.596 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.2 p90 -141.89 45.68 1.68 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.213 -0.93 . . . . 0.0 109.627 -179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.864 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.51 136.03 52.69 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 120.941 -1.099 . . . . 0.0 110.119 -179.78 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.8 Cg_endo -77.6 -150.14 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.33 0 C-N-CA 122.222 1.948 . . . . 0.0 110.249 178.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.551 ' OD2' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -79.95 12.11 2.94 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 120.822 -1.174 . . . . 0.0 108.706 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.551 HG23 ' OD2' ' A' ' 18' ' ' ASP . 23.9 t -113.41 136.71 48.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.567 -0.708 . . . . 0.0 109.847 -179.592 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 140.96 82.94 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.186 -0.946 . . . . 0.0 108.863 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -48.38 -30.32 15.2 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 121.746 1.631 . . . . 0.0 111.541 179.51 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.61 -20.55 62.74 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.495 -0.753 . . . . 0.0 109.513 179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -103.73 8.61 37.29 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.32 -0.863 . . . . 0.0 109.748 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.5 t -101.13 135.93 35.2 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 O-C-N 121.315 -0.866 . . . . 0.0 108.99 179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.5 m-20 -67.87 89.95 0.29 Allowed 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.164 -0.96 . . . . 0.0 109.082 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.576 HG11 ' HE2' ' A' ' 87' ' ' LYS . 17.0 m -60.53 6.01 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.379 -0.826 . . . . 0.0 109.769 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 59.2 t0 -89.21 4.36 48.91 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.213 -0.93 . . . . 0.0 108.733 179.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.7 tp -95.65 134.24 38.77 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.563 -0.711 . . . . 0.0 109.368 -179.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -66.07 121.49 15.25 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 179.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.2 pp -76.04 9.27 2.56 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.122 -0.986 . . . . 0.0 109.882 -179.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.434 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.8 p -54.19 -38.28 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.112 -0.992 . . . . 0.0 108.951 179.767 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.434 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.2 m-20 -57.08 -35.53 69.48 Favored 'General case' 0 C--N 1.303 -1.442 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 178.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.8 m-20 -83.8 15.02 3.49 Favored 'General case' 0 C--N 1.303 -1.413 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 178.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.404 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.52 -14.76 0.01 OUTLIER Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.444 -1.462 . . . . 0.0 109.444 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 47.8 t -51.65 -37.94 20.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.578 0 O-C-N 121.096 -1.238 . . . . 0.0 108.428 179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.61 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.8 tt -70.7 -24.82 25.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.508 -0.745 . . . . 0.0 110.139 179.986 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.59 ' OD1' ' CD1' ' A' ' 66' ' ' PHE . 82.7 m-20 -60.24 -32.93 71.6 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.237 -0.914 . . . . 0.0 111.211 -178.26 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.48 -64.97 1.09 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.926 -1.109 . . . . 0.0 111.513 -178.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.0 mp -72.39 -52.16 17.24 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.096 -1.002 . . . . 0.0 110.983 -178.078 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.4 -36.92 92.27 Favored Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.815 -1.314 . . . . 0.0 109.815 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.61 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.0 tp -59.53 -41.26 89.64 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.471 -1.017 . . . . 0.0 109.636 -179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.3 tp -66.15 -44.37 84.34 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.232 -0.918 . . . . 0.0 109.486 -179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 52.0 mttt -67.26 -38.69 85.55 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.291 -0.881 . . . . 0.0 110.239 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.5 t -64.48 -44.87 96.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.204 -0.935 . . . . 0.0 110.576 -179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -59.07 -47.21 90.8 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 120.969 -1.082 . . . . 0.0 109.769 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.11 -44.37 80.1 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.285 -0.885 . . . . 0.0 110.537 -179.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.704 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.0 t90 -74.8 -41.89 59.13 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.152 -0.967 . . . . 0.0 110.196 -179.341 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.2 tp -58.55 -40.13 82.17 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.254 -0.904 . . . . 0.0 109.604 -179.732 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.576 ' O ' ' N ' ' A' ' 53' ' ' GLY . 3.4 tm-20 -62.08 -42.3 99.07 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.097 -1.002 . . . . 0.0 109.447 179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -65.08 -42.94 93.67 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.249 -0.907 . . . . 0.0 110.378 -179.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.3 ttt180 -65.98 -44.58 84.46 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.182 -0.949 . . . . 0.0 111.514 -178.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -105.65 -5.28 20.17 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.991 -1.068 . . . . 0.0 110.844 -178.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.576 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.58 32.5 71.19 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 -179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.56 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 76.8 mt -97.01 144.57 10.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.221 -1.164 . . . . 0.0 109.539 -179.559 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.27 145.13 52.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.155 -0.965 . . . . 0.0 109.612 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.07 -28.69 69.79 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.41 -0.806 . . . . 0.0 109.841 -179.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.572 ' O ' ' N ' ' A' ' 59' ' ' VAL . 85.0 m-20 54.7 50.82 15.01 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.261 -0.9 . . . . 0.0 109.061 -179.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.443 ' C ' ' O ' ' A' ' 57' ' ' ASP . 23.5 t70 -41.29 92.42 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.39 -0.819 . . . . 0.0 109.867 -179.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' A' ' 57' ' ' ASP . 13.6 p -134.24 144.47 35.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.393 -0.817 . . . . 0.0 108.948 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 87.0 tt0 -89.66 133.0 34.87 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 109.713 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.7 mt -110.32 140.74 44.19 Favored 'General case' 0 N--CA 1.487 1.387 0 O-C-N 121.488 -0.757 . . . . 0.0 109.534 -179.819 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -84.7 158.18 59.95 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.482 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_endo -60.1 -27.87 85.8 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 C-N-CA 122.737 2.291 . . . . 0.0 112.042 179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.83 -29.38 70.58 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.381 -0.824 . . . . 0.0 109.687 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 74.4 t60 -67.32 -26.39 66.49 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.294 -0.879 . . . . 0.0 109.811 -179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.59 ' CD1' ' OD1' ' A' ' 37' ' ' ASP . 80.1 m-85 -93.7 7.02 46.38 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.16 -0.962 . . . . 0.0 109.536 -179.719 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 13.5 tpt180 -54.94 -39.08 68.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.272 -0.892 . . . . 0.0 109.553 -179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 92.0 p -138.93 151.1 46.63 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.09 -1.006 . . . . 0.0 109.909 179.964 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.4 mt -63.27 -36.88 77.82 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.322 0 O-C-N 121.32 -0.863 . . . . 0.0 109.806 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.5 mtm180 -61.2 -36.9 81.15 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.244 -0.91 . . . . 0.0 110.294 -179.164 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.7 m -58.5 -44.21 89.37 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.985 -1.072 . . . . 0.0 109.368 -179.707 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.3 mt -66.66 -38.55 81.82 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.327 -0.858 . . . . 0.0 109.408 179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.476 ' OD1' HG21 ' A' ' 7' ' ' ILE . 74.8 m-20 -58.31 -38.54 77.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.458 -0.776 . . . . 0.0 109.765 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.23 -41.95 96.77 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.153 -0.967 . . . . 0.0 109.89 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.0 t80 -62.19 -46.1 90.43 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.198 -0.939 . . . . 0.0 109.815 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.489 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.0 t -63.16 -43.1 98.67 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.345 0 O-C-N 121.242 -0.911 . . . . 0.0 109.923 -179.856 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 57.0 t -63.73 -40.6 89.63 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.274 -0.891 . . . . 0.0 109.832 -179.863 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.03 -35.28 75.77 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 -179.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -98.73 -48.15 5.05 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.03 -1.276 . . . . 0.0 110.215 -179.39 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 76' ' ' VAL . 42.1 m -131.69 134.75 46.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.345 -0.847 . . . . 0.0 109.409 -179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -128.6 87.96 53.53 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.306 -0.871 . . . . 0.0 109.648 179.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -71.22 -178.84 3.12 Favored 'Trans proline' 0 C--N 1.309 -1.502 0 C-N-CA 122.766 2.311 . . . . 0.0 111.846 178.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -58.51 150.74 66.8 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 C-N-CA 122.51 2.14 . . . . 0.0 111.554 179.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.417 ' HA ' ' H ' ' A' ' 3' ' ' HIS . 41.2 t -93.99 130.6 42.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.179 -0.951 . . . . 0.0 109.887 -179.418 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -134.65 160.78 37.06 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.512 -0.743 . . . . 0.0 109.353 179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -102.78 144.62 30.89 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.26 -0.9 . . . . 0.0 109.416 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.576 ' HE2' HG11 ' A' ' 26' ' ' VAL . 49.4 mttp -58.08 -33.87 69.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.202 -0.936 . . . . 0.0 109.465 179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.426 ' O ' ' C ' ' A' ' 89' ' ' GLN . 35.2 tp -97.37 130.35 44.52 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.254 -0.904 . . . . 0.0 109.469 179.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.426 ' C ' ' O ' ' A' ' 88' ' ' LEU . 63.5 tt0 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.517 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.7 mtp . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 121.371 0.605 . . . . 0.0 109.909 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.581 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 93.9 mt-30 -85.1 125.77 33.05 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.717 ' ND1' HG22 ' A' ' 84' ' ' VAL . 1.6 m-70 54.97 19.63 2.78 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.14 -0.975 . . . . 0.0 108.551 -179.217 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.89 -39.63 92.61 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.419 -0.801 . . . . 0.0 110.183 -179.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.5 p -63.96 -34.99 79.23 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.097 -1.002 . . . . 0.0 109.889 -179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.3 t -66.75 -39.67 84.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.205 -0.934 . . . . 0.0 109.449 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.598 ' O ' HG22 ' A' ' 11' ' ' VAL . 91.2 mt -59.89 -43.02 91.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.501 -0.749 . . . . 0.0 110.195 -179.626 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.709 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.09 -49.41 74.56 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.104 -0.998 . . . . 0.0 109.48 -179.707 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.419 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.2 pp0? -69.55 -33.76 73.23 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.319 -0.863 . . . . 0.0 109.466 179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.691 ' CZ ' ' CH2' ' A' ' 47' ' ' TRP . 63.8 t80 -66.63 -51.87 51.41 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.253 -0.905 . . . . 0.0 110.004 -179.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.598 HG22 ' O ' ' A' ' 7' ' ' ILE . 14.1 m -72.92 -39.89 59.0 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.257 -0.902 . . . . 0.0 110.16 -179.694 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.709 HG23 ' O ' ' A' ' 8' ' ' ALA . 99.5 t -64.55 -38.76 83.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.224 -0.922 . . . . 0.0 109.922 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.1 -30.15 61.66 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.227 -0.921 . . . . 0.0 109.538 -179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -65.14 -29.51 70.36 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.304 -0.872 . . . . 0.0 108.987 179.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.614 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 16.9 p90 -149.52 49.63 0.95 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.298 -0.876 . . . . 0.0 109.257 179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.13 136.71 53.48 Favored Pre-proline 0 N--CA 1.487 1.418 0 O-C-N 120.89 -1.131 . . . . 0.0 110.183 -179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -73.36 -153.47 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 121.972 1.781 . . . . 0.0 110.603 178.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -80.3 13.31 2.44 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.1 -1.0 . . . . 0.0 108.776 179.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.7 t -113.44 136.16 50.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.585 -0.697 . . . . 0.0 109.996 -179.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.32 140.19 72.46 Favored Pre-proline 0 N--CA 1.489 1.512 0 O-C-N 121.283 -0.885 . . . . 0.0 108.873 179.33 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.589 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 53.1 Cg_exo -48.57 -33.22 23.15 Favored 'Trans proline' 0 N--CA 1.492 1.415 0 C-N-CA 121.692 1.595 . . . . 0.0 111.808 179.528 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.617 ' HB2' HD21 ' A' ' 88' ' ' LEU . . . -67.23 -19.6 65.56 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.445 -0.784 . . . . 0.0 109.353 179.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -96.46 0.16 49.95 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.451 -0.781 . . . . 0.0 108.983 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 39.0 t -107.08 134.04 49.93 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 108.531 -0.914 . . . . 0.0 108.531 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.578 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.3 m-20 -70.98 99.73 1.85 Allowed 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.092 -1.005 . . . . 0.0 109.376 -179.503 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 16.8 m -59.68 5.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.353 -0.842 . . . . 0.0 109.768 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.578 ' H ' ' C ' ' A' ' 25' ' ' ASP . 50.6 p30 -92.16 8.6 37.24 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.065 -1.022 . . . . 0.0 108.841 179.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 8.3 tp -94.54 136.56 34.7 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.593 -0.692 . . . . 0.0 109.544 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -63.24 121.57 14.01 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.465 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -72.28 6.73 2.09 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.182 -0.949 . . . . 0.0 109.635 -179.117 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.45 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 6.1 p -53.4 -39.49 36.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.101 -0.999 . . . . 0.0 108.941 179.951 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.45 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.7 m-20 -57.79 -36.14 71.77 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 178.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.636 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.3 m-20 -85.27 15.1 4.54 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.01 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.416 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.29 -15.06 0.01 OUTLIER Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 -179.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.636 ' N ' ' O ' ' A' ' 33' ' ' ASN . 52.3 t -51.83 -37.36 20.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.054 -1.262 . . . . 0.0 108.46 179.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.615 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.3 tt -70.69 -24.84 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.536 -0.727 . . . . 0.0 110.142 -179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.428 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.4 m-20 -60.04 -33.34 71.9 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.235 -0.916 . . . . 0.0 111.141 -178.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 1.5 m -105.62 -64.79 1.11 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.91 -1.118 . . . . 0.0 111.451 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 3.9 mp -72.21 -52.17 17.71 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.108 -0.995 . . . . 0.0 111.018 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.69 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.77 -36.85 91.8 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.591 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.0 tp -58.91 -41.96 88.49 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.43 -1.041 . . . . 0.0 109.459 -179.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 11.7 tp -65.68 -44.28 86.74 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.308 -0.87 . . . . 0.0 109.203 -179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 41.4 mttt -67.02 -36.38 81.98 Favored 'General case' 0 N--CA 1.487 1.411 0 O-C-N 121.361 -0.837 . . . . 0.0 109.913 179.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.2 t -62.41 -44.32 99.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.305 -0.872 . . . . 0.0 110.366 -179.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.428 HD13 ' O ' ' A' ' 41' ' ' LEU . 1.5 mp -59.16 -48.27 87.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 120.922 -1.111 . . . . 0.0 109.398 -179.812 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.32 -44.33 79.42 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.375 -0.828 . . . . 0.0 110.658 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.691 ' CH2' ' CZ ' ' A' ' 10' ' ' PHE . 2.4 t90 -75.5 -43.62 48.2 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.102 -0.999 . . . . 0.0 110.243 -179.187 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.428 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 8.7 tp -57.9 -40.26 79.9 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.33 -0.856 . . . . 0.0 109.548 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.583 ' O ' ' N ' ' A' ' 53' ' ' GLY . 20.7 tt0 -61.62 -42.66 99.2 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.141 -0.974 . . . . 0.0 109.389 179.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -66.56 -43.09 85.97 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.112 -0.992 . . . . 0.0 110.364 -179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.685 ' NH2' ' CZ ' ' A' ' 52' ' ' PHE . 59.8 ttt-85 -64.68 -44.23 91.01 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.317 -0.865 . . . . 0.0 111.241 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.685 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 96.9 m-85 -104.69 -10.15 17.68 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.94 -1.1 . . . . 0.0 110.765 -178.777 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.583 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 73.98 24.65 73.42 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.401 -1.479 . . . . 0.0 109.401 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 74.8 mt -95.01 142.41 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 O-C-N 121.122 -1.223 . . . . 0.0 109.418 -179.78 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.96 149.97 34.87 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.083 -1.011 . . . . 0.0 109.228 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.96 -40.17 72.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.242 -0.911 . . . . 0.0 109.586 -179.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 86.7 m-20 50.43 48.17 22.85 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.222 -0.924 . . . . 0.0 109.108 179.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 94.1 m-20 -63.17 123.17 17.95 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.197 -0.939 . . . . 0.0 110.037 -179.368 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.777 HG23 HD21 ' A' ' 61' ' ' LEU . 30.0 m -135.0 163.09 37.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.628 ' O ' HD23 ' A' ' 61' ' ' LEU . 91.5 mt-10 -65.37 132.06 48.05 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.975 -1.078 . . . . 0.0 109.5 -179.685 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.777 HD21 HG23 ' A' ' 59' ' ' VAL . 9.7 mt -125.41 147.31 49.24 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.557 -0.715 . . . . 0.0 109.649 -179.164 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -111.61 157.75 38.41 Favored Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.455 -0.778 . . . . 0.0 109.055 179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -60.12 -25.56 80.18 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 C-N-CA 122.721 2.281 . . . . 0.0 112.071 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.05 -31.94 73.19 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 109.657 -179.98 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.442 ' O ' ' OG ' ' A' ' 71' ' ' SER . 52.2 t-80 -67.9 -26.79 66.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.258 -0.901 . . . . 0.0 109.695 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -98.34 6.35 47.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.242 -0.911 . . . . 0.0 109.47 -179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.9 tpt180 -56.21 -39.37 72.36 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.213 -0.929 . . . . 0.0 109.703 -179.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.4 p -143.59 156.23 44.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.019 -1.05 . . . . 0.0 110.063 -179.817 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.593 HD13 ' HB2' ' A' ' 8' ' ' ALA . 85.7 mt -62.45 -36.51 75.19 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.345 -0.847 . . . . 0.0 109.835 179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.9 ttp180 -60.61 -39.12 87.01 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.351 -0.843 . . . . 0.0 110.356 -179.319 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.442 ' OG ' ' O ' ' A' ' 65' ' ' HIS . 84.9 p -60.27 -37.63 81.05 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.067 -1.021 . . . . 0.0 109.587 -179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.5 mt -67.99 -38.8 80.51 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.375 0 O-C-N 121.289 -0.882 . . . . 0.0 109.37 179.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.581 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 51.5 t0 -58.29 -38.65 77.44 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.433 -0.792 . . . . 0.0 109.937 -179.658 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.2 -44.34 92.26 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.092 -1.005 . . . . 0.0 109.732 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -64.89 -47.12 78.97 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.244 -0.91 . . . . 0.0 109.442 179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.2 t -64.63 -42.08 94.08 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.325 -0.859 . . . . 0.0 109.917 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -64.27 -41.43 92.36 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.14 -0.975 . . . . 0.0 109.942 -179.827 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.61 -33.85 73.9 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.66 -48.01 4.65 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.294 . . . . 0.0 110.518 -179.19 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.482 ' O ' ' O ' ' A' ' 76' ' ' VAL . 43.2 m -129.49 138.07 51.18 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.32 -0.862 . . . . 0.0 110.044 -179.605 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.789 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -128.96 89.56 48.4 Favored Pre-proline 0 N--CA 1.488 1.457 0 O-C-N 121.425 -0.797 . . . . 0.0 109.15 179.584 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.587 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 68.0 Cg_endo -83.1 161.44 15.56 Favored 'Trans proline' 0 C--N 1.311 -1.405 0 C-N-CA 122.777 2.318 . . . . 0.0 112.599 -179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.4 Cg_endo -59.47 151.06 71.56 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 C-N-CA 122.954 2.436 . . . . 0.0 111.903 179.682 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.717 HG22 ' ND1' ' A' ' 3' ' ' HIS . 46.6 t -89.77 131.08 37.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.108 -0.995 . . . . 0.0 109.661 -179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -128.57 165.0 21.61 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.533 -0.729 . . . . 0.0 109.136 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -53.68 143.39 20.5 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.031 -1.043 . . . . 0.0 109.142 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.589 ' NZ ' ' O ' ' A' ' 21' ' ' PRO . 55.3 tttt -57.89 -36.84 72.97 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.229 -0.919 . . . . 0.0 109.419 -179.664 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.617 HD21 ' HB2' ' A' ' 22' ' ' ALA . 62.7 mt -94.65 141.82 28.16 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.243 -0.911 . . . . 0.0 109.527 179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 118.002 -0.999 . . . . 0.0 109.517 -179.965 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.447 ' C4 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 67.4 mtm . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.354 0.597 . . . . 0.0 109.937 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' HG2' HG22 ' A' ' 84' ' ' VAL . 92.8 mt-30 -107.83 138.86 43.32 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 179.422 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.757 ' CD2' HG21 ' A' ' 6' ' ' VAL . 0.1 OUTLIER 44.11 27.74 0.22 Allowed 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.138 -0.976 . . . . 0.0 108.912 -179.679 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.529 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.05 -36.27 76.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.443 -0.785 . . . . 0.0 109.873 -179.623 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -59.12 -40.26 84.86 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.167 -0.958 . . . . 0.0 109.534 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.757 HG21 ' CD2' ' A' ' 3' ' ' HIS . 73.3 t -66.3 -37.47 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.295 -0.878 . . . . 0.0 109.196 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.529 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.8 mt -59.88 -50.58 79.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.296 -0.878 . . . . 0.0 109.436 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.723 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.18 -47.82 78.32 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.263 -0.898 . . . . 0.0 109.05 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -63.27 -40.84 98.53 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.478 -0.763 . . . . 0.0 109.662 179.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.469 ' CE2' ' CH2' ' A' ' 47' ' ' TRP . 67.3 t80 -66.84 -51.54 54.34 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.437 -0.789 . . . . 0.0 110.348 -179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.475 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.1 p -69.96 -41.22 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.22 -0.925 . . . . 0.0 109.877 -179.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.723 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.4 t -64.5 -35.77 75.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.245 -0.91 . . . . 0.0 109.575 -179.979 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.68 -30.8 63.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.272 -0.893 . . . . 0.0 109.589 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -65.45 -31.49 72.6 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.273 -0.892 . . . . 0.0 109.729 -179.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' CE1' HD12 ' A' ' 36' ' ' ILE . 30.9 p90 -142.97 46.44 1.55 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.141 -0.974 . . . . 0.0 109.693 -179.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.871 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 136.06 53.22 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.206 -179.76 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.49 -150.46 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.293 0 C-N-CA 122.168 1.912 . . . . 0.0 110.432 178.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.537 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.69 12.78 2.4 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 120.896 -1.128 . . . . 0.0 108.842 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.537 HG23 ' OD1' ' A' ' 18' ' ' ASP . 32.5 t -113.33 136.31 50.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.468 -0.77 . . . . 0.0 109.835 -179.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -70.07 138.68 87.38 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.133 -0.98 . . . . 0.0 108.783 179.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.663 ' O ' HG22 ' A' ' 24' ' ' VAL . 52.1 Cg_exo -48.34 -26.76 8.91 Favored 'Trans proline' 0 N--CA 1.492 1.437 0 C-N-CA 121.869 1.713 . . . . 0.0 112.141 179.815 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -73.04 -16.91 61.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.106 -0.996 . . . . 0.0 109.749 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -105.36 7.01 33.12 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.318 -0.863 . . . . 0.0 110.412 -179.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.663 HG22 ' O ' ' A' ' 21' ' ' PRO . 3.5 m -96.06 144.53 10.08 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 O-C-N 120.946 -1.096 . . . . 0.0 109.273 -179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.545 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -70.44 88.08 0.65 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.029 -1.044 . . . . 0.0 109.193 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.465 HG21 ' HE3' ' A' ' 87' ' ' LYS . 26.7 m -61.67 5.96 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.271 -0.893 . . . . 0.0 109.546 -179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.545 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.1 m-20 -97.87 6.8 47.34 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.212 -0.93 . . . . 0.0 108.954 179.271 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 7.1 tp -96.94 135.53 38.79 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.484 -0.76 . . . . 0.0 109.555 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 31' ' ' VAL . 89.1 m-20 -64.26 121.75 15.02 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 108.091 -1.077 . . . . 0.0 108.091 179.176 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.484 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.5 OUTLIER -68.86 8.42 0.52 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.235 -0.916 . . . . 0.0 109.762 -179.016 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.461 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 4.9 p -53.73 -39.83 40.58 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.131 -0.981 . . . . 0.0 109.01 179.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 56.0 t0 -58.11 -35.79 71.96 Favored 'General case' 0 N--CA 1.488 1.45 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 178.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.624 ' O ' ' N ' ' A' ' 35' ' ' VAL . 62.8 m-80 -85.2 15.07 4.48 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 108.498 -0.927 . . . . 0.0 108.498 179.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.41 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.27 -15.97 0.02 OUTLIER Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.348 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.624 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.7 t -52.71 -37.14 24.23 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 120.972 -1.311 . . . . 0.0 108.311 179.151 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.613 ' O ' ' N ' ' A' ' 41' ' ' LEU . 3.1 tt -70.53 -25.16 26.25 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.479 -0.763 . . . . 0.0 109.94 179.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.9 m-20 -62.21 -29.66 70.54 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.263 -0.898 . . . . 0.0 110.66 -178.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 25.0 m -104.9 -64.76 1.09 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.02 -1.05 . . . . 0.0 110.979 -178.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 19.8 mt -74.03 -52.4 12.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.17 -0.956 . . . . 0.0 110.846 -178.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -63.79 -36.8 93.79 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.357 -1.497 . . . . 0.0 109.357 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.613 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.95 -39.74 93.14 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.496 -1.002 . . . . 0.0 109.148 -179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.6 tp -60.0 -44.04 94.8 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 65.3 mttp -67.52 -40.25 85.09 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.363 -0.836 . . . . 0.0 109.55 179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 67.6 t -65.16 -45.54 93.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.377 -0.827 . . . . 0.0 110.082 -179.697 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.513 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.2 mp -62.73 -41.73 93.49 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.063 -1.023 . . . . 0.0 109.66 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.05 -41.01 99.39 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.925 . . . . 0.0 109.676 -179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.732 ' HE1' ' NH1' ' A' ' 51' ' ' ARG . 0.8 OUTLIER -78.56 -49.1 13.91 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.203 -0.935 . . . . 0.0 109.954 179.884 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.31 -43.24 96.53 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.45 -0.781 . . . . 0.0 110.626 -178.881 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.513 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 0.9 OUTLIER -66.53 -36.28 82.3 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 120.945 -1.097 . . . . 0.0 109.087 -179.878 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -72.04 -44.99 62.49 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.388 -0.82 . . . . 0.0 110.223 179.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.732 ' NH1' ' HE1' ' A' ' 47' ' ' TRP . 22.5 ttm180 -60.95 -40.63 94.04 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.381 -0.825 . . . . 0.0 111.105 -178.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -103.18 -6.14 22.47 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 120.824 -1.172 . . . . 0.0 110.21 -179.215 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 65.71 34.06 87.77 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 66.1 mt -98.39 133.51 40.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.244 -1.15 . . . . 0.0 109.423 -179.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.86 ' HB3' ' OD1' ' A' ' 58' ' ' ASP . . . -62.83 137.07 58.17 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.118 -0.989 . . . . 0.0 109.421 -179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.7 -29.02 67.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.362 -0.836 . . . . 0.0 110.233 -179.689 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.456 ' C ' ' OD2' ' A' ' 57' ' ' ASP . 52.8 p30 -85.5 2.08 46.2 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.18 -0.95 . . . . 0.0 110.457 -179.046 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.86 ' OD1' ' HB3' ' A' ' 55' ' ' ALA . 97.2 m-20 -60.34 -37.83 81.86 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.914 -1.116 . . . . 0.0 109.627 179.85 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.6 m -131.41 159.89 42.72 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.464 -0.773 . . . . 0.0 109.504 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -96.35 138.27 34.2 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.211 -0.931 . . . . 0.0 109.323 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 26.0 mt -102.08 140.32 36.52 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.309 -0.87 . . . . 0.0 109.795 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -136.24 157.41 75.61 Favored Pre-proline 0 N--CA 1.489 1.518 0 O-C-N 121.362 -0.836 . . . . 0.0 109.238 179.665 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.5 Cg_endo -62.27 -31.26 82.05 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 C-N-CA 122.609 2.206 . . . . 0.0 112.136 -179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -64.48 -31.91 73.32 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.4 -0.812 . . . . 0.0 109.765 -179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 83.2 t60 -68.2 -27.09 66.08 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.196 -0.94 . . . . 0.0 109.861 -179.597 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -98.71 6.37 47.01 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.217 -0.927 . . . . 0.0 109.631 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.2 tpt180 -55.8 -38.64 70.22 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.329 -0.857 . . . . 0.0 109.373 179.991 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 97.0 p -135.15 152.92 52.06 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.318 -0.863 . . . . 0.0 109.749 -179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 84.9 mt -63.54 -36.48 76.51 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.35 0 O-C-N 121.371 -0.831 . . . . 0.0 109.885 179.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 56.3 ttp180 -60.47 -38.31 83.81 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.227 -0.92 . . . . 0.0 110.271 -179.317 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.6 t -57.92 -42.98 85.95 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.017 -1.052 . . . . 0.0 109.661 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.7 mt -62.0 -39.58 84.22 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.213 -0.929 . . . . 0.0 109.328 179.721 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -57.83 -37.0 73.06 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.341 -0.849 . . . . 0.0 109.396 179.935 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.5 -41.15 96.86 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.233 -0.917 . . . . 0.0 109.524 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -62.87 -46.93 85.56 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.229 -0.919 . . . . 0.0 109.598 179.775 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.5 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.84 -43.22 97.78 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.294 -0.879 . . . . 0.0 109.818 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.5 t -60.89 -40.79 86.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.295 -0.878 . . . . 0.0 109.833 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.14 -30.78 74.66 Favored Glycine 0 N--CA 1.49 2.258 0 C-N-CA 120.409 -0.9 . . . . 0.0 110.949 -179.418 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.15 -48.43 3.87 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 120.952 -1.323 . . . . 0.0 110.593 -178.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.5 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.2 p -128.23 155.3 44.75 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.417 -0.802 . . . . 0.0 109.154 -179.969 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.779 HG23 ' O ' ' A' ' 81' ' ' THR . 9.3 t -138.83 89.11 13.23 Favored Pre-proline 0 C--N 1.303 -1.44 0 O-C-N 121.148 -0.97 . . . . 0.0 109.77 179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.446 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.3 Cg_exo -65.6 -176.26 0.54 Allowed 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 122.7 2.267 . . . . 0.0 111.701 179.279 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 28.9 Cg_exo -58.49 150.64 67.27 Favored 'Trans proline' 0 C--N 1.308 -1.574 0 C-N-CA 122.475 2.117 . . . . 0.0 111.539 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.579 HG22 ' HG2' ' A' ' 2' ' ' GLN . 43.7 t -90.06 128.39 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.082 -1.011 . . . . 0.0 109.819 -179.379 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.433 ' H ' ' H ' ' A' ' 3' ' ' HIS . 84.5 tt0 -138.56 147.22 42.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.407 -0.808 . . . . 0.0 109.111 179.794 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -57.79 139.33 54.26 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.061 -1.024 . . . . 0.0 109.218 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.465 ' HE3' HG21 ' A' ' 26' ' ' VAL . 47.1 tttp -59.36 -36.94 76.67 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.223 -0.923 . . . . 0.0 109.417 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.4 mt -92.56 142.12 27.74 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.335 -0.853 . . . . 0.0 109.467 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 118.005 -0.998 . . . . 0.0 109.486 -179.965 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.48 ' HA ' ' HB2' ' A' ' 4' ' ' ALA . 70.0 mtm . . . . . 0 N--CA 1.491 1.577 0 N-CA-C 109.342 -0.614 . . . . 0.0 109.342 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.68 ' HB3' HG22 ' A' ' 84' ' ' VAL . 94.8 mt-30 -59.06 -38.18 78.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.374 -0.828 . . . . 0.0 109.634 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.638 ' NE2' HG11 ' A' ' 76' ' ' VAL . 52.5 p-80 -122.9 23.43 9.37 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.491 -0.756 . . . . 0.0 109.148 179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.602 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.69 -34.4 72.82 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.362 -0.836 . . . . 0.0 109.764 -179.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.5 t -59.0 -41.84 88.64 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.075 -1.016 . . . . 0.0 109.358 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 69.2 t -66.23 -38.4 81.81 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.305 -0.872 . . . . 0.0 109.118 179.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.602 HD12 ' HA ' ' A' ' 4' ' ' ALA . 94.0 mt -59.34 -50.62 79.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.395 -0.815 . . . . 0.0 109.69 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.9 -42.98 97.28 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.23 -0.919 . . . . 0.0 108.864 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.48 -39.64 92.16 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.537 -0.727 . . . . 0.0 109.442 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.4 ' HE2' HG22 ' A' ' 44' ' ' VAL . 44.6 t80 -61.22 -51.42 69.07 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.431 -0.793 . . . . 0.0 110.011 -179.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.727 ' CG2' HD12 ' A' ' 36' ' ' ILE . 12.4 p -72.96 -48.95 42.46 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.313 -0.867 . . . . 0.0 110.87 -179.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.637 HG21 HG11 ' A' ' 24' ' ' VAL . 61.9 t -60.9 -35.87 67.87 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.893 0 O-C-N 121.162 -0.961 . . . . 0.0 111.264 -178.704 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -59.51 -34.57 72.77 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.991 -1.068 . . . . 0.0 110.005 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -66.65 -36.3 82.22 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.279 -0.888 . . . . 0.0 111.028 -179.154 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.501 ' O ' HD12 ' A' ' 16' ' ' LEU . 42.5 m-85 -100.61 -57.78 2.04 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 120.894 -1.128 . . . . 0.0 111.052 -178.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.501 HD12 ' O ' ' A' ' 15' ' ' PHE . 2.6 mp -123.97 87.3 53.2 Favored Pre-proline 0 N--CA 1.495 1.784 0 O-C-N 121.238 -0.914 . . . . 0.0 110.944 -178.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -91.51 -16.67 1.23 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 C-N-CA 123.199 2.599 . . . . 0.0 112.084 178.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -76.39 -4.5 42.65 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.21 -0.931 . . . . 0.0 109.157 -179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.4 t -113.5 145.41 19.44 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 179.027 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD2' ' A' ' 23' ' ' ASP . . . -60.84 115.58 14.57 Favored Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 120.755 -1.215 . . . . 0.0 108.289 -179.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.701 ' O ' HG22 ' A' ' 24' ' ' VAL . 1.3 Cg_endo -63.62 -23.93 69.89 Favored 'Trans proline' 0 C--N 1.317 -1.129 0 C-N-CA 121.329 1.353 . . . . 0.0 111.819 -179.896 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.21 -15.66 62.47 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.277 -0.89 . . . . 0.0 109.865 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD2' ' O ' ' A' ' 20' ' ' ALA . 49.6 p30 -89.09 3.24 52.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.014 -1.054 . . . . 0.0 109.767 -179.513 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.701 HG22 ' O ' ' A' ' 21' ' ' PRO . 14.5 m -77.21 140.74 16.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.114 -0.991 . . . . 0.0 108.672 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.536 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -66.42 82.71 0.09 Allowed 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.067 -1.021 . . . . 0.0 109.278 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.799 HG11 ' NZ ' ' A' ' 87' ' ' LYS . 12.5 m -62.47 5.71 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.217 -0.927 . . . . 0.0 109.465 179.998 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.536 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.7 m-20 -103.08 7.17 38.91 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.273 -0.892 . . . . 0.0 108.936 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 12.9 tp -98.51 137.45 37.15 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.498 -0.751 . . . . 0.0 109.525 -179.704 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.575 ' OD1' ' NH2' ' A' ' 67' ' ' ARG . 89.0 m-20 -61.08 122.1 14.15 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.405 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.2 OUTLIER -71.48 7.72 1.31 Allowed 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.192 -0.942 . . . . 0.0 110.177 -178.892 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 66.5 t -54.74 -43.75 67.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 120.823 -1.173 . . . . 0.0 108.362 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -55.76 -35.48 66.27 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 178.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.634 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.9 m-20 -83.89 15.34 3.39 Favored 'General case' 0 C--N 1.305 -1.36 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 178.806 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.421 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.44 -14.82 0.01 OUTLIER Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.634 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.6 t -51.42 -38.81 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.292 -1.122 . . . . 0.0 108.236 179.213 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.727 HD12 ' CG2' ' A' ' 11' ' ' VAL . 2.4 tt -70.38 -24.98 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.438 0 CA-C-O 121.717 0.77 . . . . 0.0 109.498 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.4 t0 -58.37 -34.02 70.22 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.503 -0.748 . . . . 0.0 111.24 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.567 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.59 -64.24 1.16 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.009 -1.057 . . . . 0.0 111.25 -178.503 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.558 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -72.05 -52.03 18.84 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.061 -1.024 . . . . 0.0 111.014 -178.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.538 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.08 -37.93 94.76 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.599 ' N ' ' O ' ' A' ' 36' ' ' ILE . 8.7 tt -58.84 -41.27 86.54 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.389 -1.065 . . . . 0.0 109.107 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 33.6 tp -61.91 -44.14 97.41 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.197 -0.939 . . . . 0.0 108.663 179.577 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 23.3 mttm -68.13 -39.53 82.7 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.431 -0.793 . . . . 0.0 109.715 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.538 HG23 ' O ' ' A' ' 40' ' ' GLY . 70.0 t -64.55 -45.46 95.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.342 -0.849 . . . . 0.0 110.197 -179.476 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.2 -47.99 91.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.213 -0.93 . . . . 0.0 109.444 -179.905 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.43 -42.95 95.74 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.281 -0.887 . . . . 0.0 109.773 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -71.37 -39.83 70.98 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.346 -0.846 . . . . 0.0 109.737 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 12.4 tp -59.28 -47.18 86.34 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.233 -0.917 . . . . 0.0 109.468 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -65.91 -39.0 90.17 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.181 -0.95 . . . . 0.0 108.972 179.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.8 t0 -66.23 -36.01 81.92 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.328 -0.858 . . . . 0.0 110.614 -179.991 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.4 ttt85 -84.98 -52.42 5.99 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.197 -0.939 . . . . 0.0 112.012 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -94.99 -5.35 44.82 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 120.721 -1.237 . . . . 0.0 111.306 -177.942 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.09 24.77 76.33 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 108.971 -1.651 . . . . 0.0 108.971 -179.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 78.8 mt -93.5 145.51 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.311 -1.111 . . . . 0.0 109.482 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.73 150.33 32.67 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.21 -0.931 . . . . 0.0 109.444 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -56.25 -30.59 62.61 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.422 -0.799 . . . . 0.0 109.611 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.0 m-20 55.11 46.47 23.97 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.296 -0.878 . . . . 0.0 109.558 -179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -95.14 16.23 16.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.232 -0.917 . . . . 0.0 109.737 -179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.469 HG12 ' HG3' ' A' ' 60' ' ' GLU . 63.3 t -56.72 -43.75 80.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.105 -0.997 . . . . 0.0 109.548 -179.59 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.469 ' HG3' HG12 ' A' ' 59' ' ' VAL . 95.9 mt-10 -138.36 132.0 30.83 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.163 -0.961 . . . . 0.0 109.671 179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.6 mp -131.35 140.13 49.65 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.303 -0.873 . . . . 0.0 109.594 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -150.29 146.58 20.21 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.182 -0.949 . . . . 0.0 109.383 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.79 -22.98 74.34 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.57 2.18 . . . . 0.0 112.195 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -62.07 -31.63 72.08 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.382 -0.824 . . . . 0.0 109.934 -179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 58.3 t-80 -67.87 -26.95 66.28 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.175 -0.953 . . . . 0.0 109.654 -179.714 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.461 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 97.8 m-85 -104.77 11.18 34.17 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.33 -0.856 . . . . 0.0 109.835 -179.745 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.575 ' NH2' ' OD1' ' A' ' 29' ' ' ASP . 41.6 tpt85 -54.36 -38.51 66.16 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.18 -0.95 . . . . 0.0 109.571 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 83.5 p -149.12 156.28 41.95 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.144 -0.972 . . . . 0.0 109.861 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 86.9 mt -62.71 -36.67 76.36 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.344 -0.848 . . . . 0.0 109.83 179.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 48.7 ttp180 -60.41 -40.85 92.47 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.232 -0.918 . . . . 0.0 109.897 -179.332 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 21.9 t -60.61 -44.19 96.6 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.064 -1.023 . . . . 0.0 109.361 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.7 mt -66.54 -38.58 81.97 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 O-C-N 121.308 -0.87 . . . . 0.0 109.727 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.755 ' O ' HG23 ' A' ' 77' ' ' VAL . 88.7 m-20 -57.77 -41.1 81.33 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.312 -0.867 . . . . 0.0 110.136 -179.333 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.22 -46.15 78.21 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.103 -0.998 . . . . 0.0 109.631 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 66.0 t80 -64.12 -46.44 84.17 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.353 -0.842 . . . . 0.0 109.366 179.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.638 HG11 ' NE2' ' A' ' 3' ' ' HIS . 60.1 t -64.86 -41.69 92.83 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.357 0 O-C-N 121.368 -0.832 . . . . 0.0 109.881 -179.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.755 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.4 t -62.31 -41.08 90.23 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.084 -1.01 . . . . 0.0 109.803 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.07 -34.75 73.94 Favored Glycine 0 N--CA 1.488 2.159 0 N-CA-C 110.37 -1.092 . . . . 0.0 110.37 -179.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -101.34 -48.12 4.48 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.09 -1.241 . . . . 0.0 110.522 -179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.485 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.3 m -129.53 138.09 51.15 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.349 -0.844 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.804 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -128.29 89.47 49.78 Favored Pre-proline 0 N--CA 1.489 1.5 0 O-C-N 121.408 -0.808 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.5 Cg_exo -64.45 179.73 1.15 Allowed 'Trans proline' 0 N--CA 1.492 1.404 0 C-N-CA 122.56 2.173 . . . . 0.0 112.223 179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -59.14 150.42 73.78 Favored 'Trans proline' 0 N--CA 1.493 1.465 0 C-N-CA 122.577 2.185 . . . . 0.0 111.929 179.786 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.68 HG22 ' HB3' ' A' ' 2' ' ' GLN . 32.3 t -102.89 129.4 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.219 -0.925 . . . . 0.0 109.416 -179.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -136.11 158.34 44.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.319 -0.863 . . . . 0.0 109.431 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.85 145.04 51.48 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.183 -0.948 . . . . 0.0 109.313 179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.799 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 13.1 tttp -129.77 133.42 46.99 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.333 -0.855 . . . . 0.0 109.371 -179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.43 ' O ' ' C ' ' A' ' 89' ' ' GLN . 52.4 mt -92.07 142.76 27.16 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.297 -0.877 . . . . 0.0 109.51 179.98 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.43 ' C ' ' O ' ' A' ' 88' ' ' LEU . 93.6 mt-30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.474 -179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.567 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.9 mtm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 121.343 0.592 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.507 ' O ' HG13 ' A' ' 84' ' ' VAL . 44.9 tp60 -58.51 -40.77 83.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.324 -0.86 . . . . 0.0 109.644 -179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.573 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 57.0 m-70 -126.62 12.0 7.37 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.38 -0.825 . . . . 0.0 109.516 179.961 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.583 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -59.58 -32.27 70.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.248 -0.908 . . . . 0.0 110.045 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.2 p -58.66 -37.13 75.33 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.076 -1.015 . . . . 0.0 109.662 -179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.51 -36.97 76.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.198 -0.939 . . . . 0.0 109.005 179.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.583 HD12 ' HA ' ' A' ' 4' ' ' ALA . 83.5 mt -60.63 -50.63 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.29 -0.882 . . . . 0.0 109.643 -179.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -64.33 -47.18 80.38 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.244 -0.91 . . . . 0.0 109.042 179.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -62.7 -44.31 96.57 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.5 t80 -66.22 -45.06 82.03 Favored 'General case' 0 C--N 1.298 -1.652 0 O-C-N 121.6 -0.688 . . . . 0.0 109.652 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.826 HG13 HD12 ' A' ' 36' ' ' ILE . 55.7 t -66.8 -49.7 71.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.438 -0.788 . . . . 0.0 110.556 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 16' ' ' LEU . 61.7 t -64.12 -35.13 72.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.359 -0.838 . . . . 0.0 110.199 -179.609 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -56.56 -34.59 67.25 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.429 -0.794 . . . . 0.0 109.996 -179.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.61 -30.8 71.17 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.284 -0.885 . . . . 0.0 110.621 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.567 ' O ' HD22 ' A' ' 16' ' ' LEU . 34.7 m-85 -109.84 -57.86 2.13 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.116 -0.99 . . . . 0.0 111.32 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.681 HD12 HG23 ' A' ' 19' ' ' VAL . 1.2 mm? -123.66 86.9 52.67 Favored Pre-proline 0 N--CA 1.496 1.856 0 O-C-N 121.111 -0.993 . . . . 0.0 111.362 -178.176 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -90.33 -19.21 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 C-N-CA 123.154 2.569 . . . . 0.0 111.868 177.745 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -76.28 -4.1 40.16 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.239 -0.913 . . . . 0.0 109.091 -179.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.681 HG23 HD12 ' A' ' 16' ' ' LEU . 42.4 t -113.15 143.81 22.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 179.107 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -60.94 115.76 15.5 Favored Pre-proline 0 C--N 1.303 -1.451 0 O-C-N 120.728 -1.232 . . . . 0.0 108.557 -179.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -63.26 -25.86 71.97 Favored 'Trans proline' 0 C--N 1.317 -1.12 0 C-N-CA 121.479 1.452 . . . . 0.0 111.746 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.571 ' HB1' ' H ' ' A' ' 88' ' ' LEU . . . -70.92 -14.92 62.55 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.285 -0.884 . . . . 0.0 109.227 179.466 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -88.84 8.43 29.17 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.378 -0.826 . . . . 0.0 109.151 -179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.6 t -93.33 137.35 22.75 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.561 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.8 m-20 -64.44 85.63 0.04 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.146 -0.971 . . . . 0.0 109.57 -179.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 26' ' ' VAL . 2.6 p -59.64 5.72 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.301 -0.874 . . . . 0.0 109.677 179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.561 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.2 m-20 -101.93 6.44 41.33 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.07 -1.019 . . . . 0.0 108.787 179.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 15.0 tp -100.14 133.47 44.5 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.519 -0.738 . . . . 0.0 109.586 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.487 ' HB3' HG13 ' A' ' 31' ' ' VAL . 90.0 m-20 -66.67 121.78 16.17 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 179.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.724 ' H ' HD12 ' A' ' 30' ' ' LEU . 0.0 OUTLIER -70.03 11.63 0.29 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.173 -0.955 . . . . 0.0 109.946 -179.077 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.569 HG23 ' N ' ' A' ' 32' ' ' ASP . 34.0 m -52.38 -44.07 42.33 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.334 0 O-C-N 120.869 -1.144 . . . . 0.0 108.495 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.569 ' N ' HG23 ' A' ' 31' ' ' VAL . 91.7 m-20 -56.67 -35.28 68.23 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 107.451 -1.314 . . . . 0.0 107.451 178.374 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.639 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.5 m-20 -83.51 15.24 3.19 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 178.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.406 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.45 -13.88 0.01 OUTLIER Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.639 ' N ' ' O ' ' A' ' 33' ' ' ASN . 50.2 t -50.63 -37.2 15.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.059 -1.259 . . . . 0.0 108.523 179.69 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.826 HD12 HG13 ' A' ' 11' ' ' VAL . 5.9 tt -70.57 -24.45 25.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.446 -0.784 . . . . 0.0 109.812 179.695 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.432 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 81.9 m-20 -61.51 -31.65 71.66 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.135 -0.978 . . . . 0.0 111.079 -178.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 49.5 m -105.67 -65.28 1.07 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.93 -1.106 . . . . 0.0 111.486 -178.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.55 -52.51 15.29 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.11 -0.994 . . . . 0.0 110.97 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.571 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.1 -37.17 92.83 Favored Glycine 0 N--CA 1.489 2.192 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.607 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.7 HD21 HD13 ' A' ' 61' ' ' LEU . 6.2 tp -58.8 -43.4 90.51 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.489 -1.007 . . . . 0.0 109.196 -179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.55 -43.19 93.59 Favored 'General case' 0 C--N 1.299 -1.595 0 C-N-CA 119.305 -0.958 . . . . 0.0 108.445 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -66.99 -36.62 82.59 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.41 -0.806 . . . . 0.0 109.419 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.571 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.1 t -65.66 -49.58 76.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.323 -0.86 . . . . 0.0 110.605 -179.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.9 mm -62.32 -41.34 91.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 120.922 -1.111 . . . . 0.0 109.65 -179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.26 -43.21 92.02 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.137 -0.977 . . . . 0.0 109.606 -179.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.1 t90 -74.61 -39.85 61.91 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.367 -0.833 . . . . 0.0 109.786 179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 10.6 tp -58.25 -42.08 85.6 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.293 -0.879 . . . . 0.0 109.625 -179.536 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.427 ' O ' ' N ' ' A' ' 53' ' ' GLY . 55.0 tt0 -63.01 -40.35 97.51 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.233 -0.917 . . . . 0.0 109.507 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -67.93 -47.14 69.51 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.13 -0.982 . . . . 0.0 110.764 -179.758 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 50.4 ttt180 -68.08 -43.47 78.46 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.314 -0.866 . . . . 0.0 111.972 -178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.699 ' CE2' HG21 ' A' ' 80' ' ' THR . 99.2 m-85 -103.6 -6.33 21.79 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.846 -1.159 . . . . 0.0 111.299 -178.11 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.13 27.43 73.81 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.1 -1.6 . . . . 0.0 109.1 -179.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.509 HG22 ' HB2' ' A' ' 58' ' ' ASP . 70.5 mt -98.5 142.16 15.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.269 -1.136 . . . . 0.0 109.366 -179.571 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.6 144.33 51.97 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.069 -1.02 . . . . 0.0 109.708 -179.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.83 -34.07 74.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.437 -0.79 . . . . 0.0 109.717 -179.569 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.451 ' C ' ' OD1' ' A' ' 57' ' ' ASP . 53.2 p30 -89.62 12.1 17.78 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.382 -0.823 . . . . 0.0 109.817 -179.654 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.509 ' HB2' HG22 ' A' ' 54' ' ' ILE . 21.4 t70 -53.34 -34.89 59.31 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.231 -0.918 . . . . 0.0 109.913 -179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 14.5 p -129.31 144.6 37.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.432 -0.793 . . . . 0.0 109.769 -179.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -71.6 144.05 49.61 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.248 -0.908 . . . . 0.0 109.457 -179.985 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.7 HD13 HD21 ' A' ' 41' ' ' LEU . 42.8 mt -96.58 136.22 37.41 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.26 -0.9 . . . . 0.0 109.923 -179.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -159.85 144.05 10.83 Favored Pre-proline 0 N--CA 1.488 1.472 0 O-C-N 121.248 -0.908 . . . . 0.0 109.132 179.469 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.09 -25.81 73.25 Favored 'Trans proline' 0 N--CA 1.493 1.493 0 C-N-CA 122.255 1.97 . . . . 0.0 111.929 -179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.41 -31.0 71.87 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.433 -0.792 . . . . 0.0 109.757 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.4 t60 -68.25 -26.56 65.75 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.333 -0.854 . . . . 0.0 110.562 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.545 ' O ' ' CD1' ' A' ' 30' ' ' LEU . 94.0 m-85 -99.14 10.27 41.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.058 -1.026 . . . . 0.0 111.089 -178.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -58.46 -35.86 72.82 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.709 -1.244 . . . . 0.0 109.747 179.564 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 85.3 p -142.6 147.91 36.62 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.12 -0.987 . . . . 0.0 109.83 179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.538 HG12 HD21 ' A' ' 30' ' ' LEU . 90.7 mt -66.41 -36.6 77.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.301 0 O-C-N 121.307 -0.871 . . . . 0.0 110.113 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 79.3 mtm180 -61.16 -38.36 86.2 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.304 -0.872 . . . . 0.0 110.573 -178.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.0 p -62.59 -39.62 94.31 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.94 -1.1 . . . . 0.0 110.071 -179.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.1 mt -68.45 -40.94 82.93 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 O-C-N 121.178 -0.951 . . . . 0.0 109.939 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.845 ' O ' HG23 ' A' ' 77' ' ' VAL . 49.4 t0 -59.04 -39.34 81.72 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.309 -0.87 . . . . 0.0 110.17 -179.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -64.18 -45.48 88.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.081 -1.012 . . . . 0.0 109.95 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 t80 -64.52 -46.87 81.07 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.194 -0.941 . . . . 0.0 109.344 179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 54.6 t -64.76 -41.42 92.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.304 -0.873 . . . . 0.0 109.867 -179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.845 HG23 ' O ' ' A' ' 73' ' ' ASP . 79.8 t -60.56 -41.53 88.2 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.147 -0.97 . . . . 0.0 109.921 -179.774 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.47 -32.83 79.01 Favored Glycine 0 N--CA 1.49 2.264 0 C-N-CA 120.308 -0.948 . . . . 0.0 110.829 -179.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.18 -48.22 3.93 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.115 -1.227 . . . . 0.0 110.886 -178.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.699 HG21 ' CE2' ' A' ' 52' ' ' PHE . 38.1 m -128.11 138.39 52.51 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.298 -0.876 . . . . 0.0 109.879 -179.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.468 HG23 ' O ' ' A' ' 81' ' ' THR . 1.6 t -128.79 88.08 52.93 Favored Pre-proline 0 N--CA 1.487 1.404 0 O-C-N 121.327 -0.858 . . . . 0.0 109.539 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.573 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 8.1 Cg_exo -69.4 -178.36 2.17 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 122.848 2.365 . . . . 0.0 112.103 179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.405 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 25.9 Cg_exo -58.79 150.29 72.08 Favored 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 122.479 2.119 . . . . 0.0 111.783 179.49 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.507 HG13 ' O ' ' A' ' 2' ' ' GLN . 41.7 t -108.49 132.35 56.6 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.357 -0.84 . . . . 0.0 109.909 -179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -127.02 149.32 49.95 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.519 -0.738 . . . . 0.0 109.117 179.457 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -75.05 134.32 41.41 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.18 -0.95 . . . . 0.0 109.585 -180.0 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.49 ' HZ2' ' HA ' ' A' ' 22' ' ' ALA . 41.2 tttp -100.29 133.32 44.88 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.224 -0.923 . . . . 0.0 109.166 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.571 ' H ' ' HB1' ' A' ' 22' ' ' ALA . 30.2 tp 43.68 65.83 0.93 Allowed 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.111 -0.993 . . . . 0.0 109.301 -179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 51.4 tt0 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.495 -179.938 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.41 ' O3P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.8 mtp . . . . . 0 N--CA 1.491 1.579 0 CA-C-O 121.408 0.623 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.5 ' O ' HG21 ' A' ' 84' ' ' VAL . 60.6 tp60 -58.02 -41.58 83.46 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.346 -0.846 . . . . 0.0 109.735 179.984 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.589 ' NE2' ' O ' ' A' ' 82' ' ' PRO . 70.6 m80 -118.32 4.13 11.89 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.449 -0.782 . . . . 0.0 109.816 -179.764 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.575 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -57.47 -38.06 73.9 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.151 -0.968 . . . . 0.0 109.674 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.6 m -61.87 -43.65 98.41 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.745 -179.815 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.761 HG23 HG13 ' A' ' 84' ' ' VAL . 78.5 t -65.11 -39.58 86.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.179 -0.951 . . . . 0.0 108.913 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.676 ' O ' HG22 ' A' ' 11' ' ' VAL . 95.9 mt -59.36 -49.84 82.05 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.365 -0.834 . . . . 0.0 109.337 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.865 ' HB2' HD13 ' A' ' 69' ' ' ILE . . . -63.39 -48.34 78.28 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.287 -0.883 . . . . 0.0 108.937 179.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.89 -39.53 94.76 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.494 -0.754 . . . . 0.0 109.553 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -66.94 -51.93 49.29 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.531 -0.73 . . . . 0.0 110.484 -178.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.676 HG22 ' O ' ' A' ' 7' ' ' ILE . 20.7 m -73.07 -40.35 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.154 -0.966 . . . . 0.0 110.434 -179.564 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.724 HG23 ' O ' ' A' ' 8' ' ' ALA . 91.2 t -64.75 -37.04 79.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.966 . . . . 0.0 110.047 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -56.25 -34.46 66.39 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.177 -0.952 . . . . 0.0 110.017 -179.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.409 ' HB2' ' CE1' ' A' ' 15' ' ' PHE . 97.6 mt-10 -66.11 -31.23 71.97 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.282 -0.886 . . . . 0.0 109.824 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.409 ' CE1' ' HB2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -137.68 43.5 2.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.168 -0.957 . . . . 0.0 109.845 -179.711 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.09 135.65 54.58 Favored Pre-proline 0 N--CA 1.49 1.548 0 O-C-N 120.785 -1.197 . . . . 0.0 110.069 -179.656 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -78.09 -151.02 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.334 0 C-N-CA 122.147 1.898 . . . . 0.0 110.256 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -78.82 11.74 2.48 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.905 -1.122 . . . . 0.0 108.616 179.092 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 24.2 t -113.59 136.31 50.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.5 -0.75 . . . . 0.0 109.966 -179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.66 140.83 71.75 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 108.636 179.139 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -48.45 -28.23 11.49 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.8 1.667 . . . . 0.0 111.97 179.667 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.526 ' HB2' ' HB3' ' A' ' 87' ' ' LYS . . . -65.03 -24.8 67.59 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.378 -0.827 . . . . 0.0 109.304 179.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -99.5 5.57 46.11 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.441 -0.787 . . . . 0.0 108.912 179.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.0 t -103.75 136.98 34.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.642 -0.873 . . . . 0.0 108.642 179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.573 ' C ' ' H ' ' A' ' 27' ' ' ASP . 89.7 m-20 -66.83 95.94 0.39 Allowed 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.174 -0.954 . . . . 0.0 109.565 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.62 HG11 ' NZ ' ' A' ' 87' ' ' LYS . 15.9 m -60.7 5.87 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 O-C-N 121.308 -0.87 . . . . 0.0 109.516 179.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.573 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -94.02 8.34 41.82 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 179.097 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.0 tp -89.12 138.78 31.11 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.584 -0.697 . . . . 0.0 109.39 -179.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -63.09 121.5 13.77 Favored 'General case' 0 C--N 1.301 -1.509 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 179.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.524 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -70.32 3.39 2.95 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.287 -0.883 . . . . 0.0 109.405 -179.364 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.41 HG21 ' NH2' ' A' ' 67' ' ' ARG . 5.7 p -53.99 -35.88 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.261 -0.9 . . . . 0.0 109.557 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -57.17 -40.24 76.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.191 -0.943 . . . . 0.0 108.473 179.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.613 ' O ' ' N ' ' A' ' 35' ' ' VAL . 25.4 p30 -91.45 15.99 11.19 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 178.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' O ' ' N ' ' A' ' 37' ' ' ASP . . . -42.48 -14.11 0.01 OUTLIER Glycine 0 N--CA 1.493 2.452 0 N-CA-C 110.147 -1.181 . . . . 0.0 110.147 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.613 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.8 t -49.86 -33.28 8.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 120.973 -1.31 . . . . 0.0 108.383 179.738 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.581 ' O ' ' N ' ' A' ' 41' ' ' LEU . 7.6 tt -70.1 -24.63 26.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.511 -0.743 . . . . 0.0 109.849 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.412 ' N ' ' O ' ' A' ' 34' ' ' GLY . 85.8 m-20 -61.81 -33.61 74.44 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.413 -0.804 . . . . 0.0 111.255 -178.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -105.51 -65.15 1.08 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.946 -1.096 . . . . 0.0 111.516 -178.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.2 tt -71.93 -49.85 34.1 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.173 -0.954 . . . . 0.0 111.515 -177.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.711 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.79 -41.8 81.66 Favored Glycine 0 N--CA 1.489 2.173 0 C-N-CA 120.006 -1.092 . . . . 0.0 110.629 -178.901 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.581 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -63.15 -43.55 98.0 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.291 -1.123 . . . . 0.0 110.236 -179.052 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 42.6 tp -58.32 -44.42 88.62 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.84 -1.162 . . . . 0.0 109.437 -179.03 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.8 mttt -68.9 -37.06 78.74 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.116 -0.99 . . . . 0.0 109.557 179.299 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.711 HG23 ' O ' ' A' ' 40' ' ' GLY . 81.5 t -66.7 -47.67 82.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.309 -0.87 . . . . 0.0 111.239 -178.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.6 mm -59.15 -45.64 92.56 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 120.586 -1.321 . . . . 0.0 110.162 -179.202 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.64 -45.57 74.98 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.032 -1.043 . . . . 0.0 110.51 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.504 ' CZ2' ' CZ ' ' A' ' 51' ' ' ARG . 2.0 t90 -76.91 -46.12 25.47 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.252 -0.905 . . . . 0.0 110.29 -179.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.488 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 12.0 tp -57.15 -41.48 79.24 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.355 -0.841 . . . . 0.0 109.603 -179.644 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.6 ' O ' ' N ' ' A' ' 53' ' ' GLY . 25.6 tt0 -63.15 -36.6 84.16 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.136 -0.978 . . . . 0.0 109.637 179.711 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -60.11 -39.65 86.95 Favored 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.086 -1.009 . . . . 0.0 110.04 -179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.504 ' CZ ' ' CZ2' ' A' ' 47' ' ' TRP . 77.8 mtm180 -77.3 -43.17 34.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.153 -0.967 . . . . 0.0 111.934 -179.039 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -102.34 -6.5 22.99 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 120.826 -1.171 . . . . 0.0 110.803 -178.387 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.6 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.16 30.56 77.07 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.442 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 94.4 mt -85.01 147.05 5.82 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 O-C-N 121.202 -1.175 . . . . 0.0 109.958 -179.772 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.23 148.02 42.4 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.229 -0.92 . . . . 0.0 109.314 -179.74 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.24 -32.02 69.6 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.329 -0.857 . . . . 0.0 109.741 -179.359 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 52.47 43.04 31.42 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.171 -0.955 . . . . 0.0 109.434 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.423 ' C ' ' OD1' ' A' ' 58' ' ' ASP . 53.3 p30 -93.7 16.31 14.26 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.386 -0.821 . . . . 0.0 109.672 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 56.0 t -53.76 -44.22 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.214 -0.929 . . . . 0.0 110.04 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -173.34 118.2 0.29 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.121 -0.987 . . . . 0.0 110.092 179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.536 ' O ' ' N5 ' ' A' ' 101' ' ' PN7 . 2.3 mp -109.25 138.11 46.1 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.381 -0.824 . . . . 0.0 109.083 179.364 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -123.08 141.94 37.04 Favored Pre-proline 0 N--CA 1.491 1.581 0 O-C-N 121.29 -0.881 . . . . 0.0 109.42 179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -63.74 -21.72 69.65 Favored 'Trans proline' 0 N--CA 1.493 1.481 0 C-N-CA 122.291 1.994 . . . . 0.0 112.385 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -60.89 -32.89 72.33 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.268 -0.895 . . . . 0.0 110.307 -179.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 80.3 t60 -74.06 -26.49 60.42 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.131 -0.98 . . . . 0.0 110.708 -179.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -94.65 8.0 43.84 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.94 -1.1 . . . . 0.0 110.75 -178.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.41 ' NH2' HG21 ' A' ' 31' ' ' VAL . 30.1 mmt180 -58.9 -34.32 71.55 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.724 -1.235 . . . . 0.0 110.19 -179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.7 p -135.5 149.94 49.65 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.052 -1.03 . . . . 0.0 110.122 -179.761 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.865 HD13 ' HB2' ' A' ' 8' ' ' ALA . 75.8 mt -64.3 -36.86 78.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.356 0 O-C-N 121.391 -0.818 . . . . 0.0 110.04 179.915 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 82.0 mtm180 -61.16 -37.24 82.18 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.25 -0.906 . . . . 0.0 110.686 -178.808 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.8 m -58.82 -44.1 90.79 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.977 -1.077 . . . . 0.0 109.765 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 77.0 mt -64.95 -38.66 83.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 O-C-N 121.189 -0.944 . . . . 0.0 109.622 179.834 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.49 ' HA ' HD11 ' A' ' 7' ' ' ILE . 51.2 t0 -56.8 -41.1 77.15 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.387 -0.821 . . . . 0.0 110.103 -179.37 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.52 -46.22 76.9 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.086 -1.009 . . . . 0.0 110.231 -179.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.4 t80 -63.42 -46.14 87.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.04 -1.038 . . . . 0.0 109.626 -179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.509 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.94 -44.5 92.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.415 0 O-C-N 121.368 -0.832 . . . . 0.0 110.267 -179.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.401 HG22 ' ND1' ' A' ' 3' ' ' HIS . 42.0 t -63.17 -41.37 92.56 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.079 -1.013 . . . . 0.0 110.098 -179.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.56 -32.48 69.07 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.412 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.52 -48.27 3.86 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.101 -1.235 . . . . 0.0 110.819 -179.043 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.509 ' O ' ' O ' ' A' ' 76' ' ' VAL . 47.2 m -130.13 138.97 50.93 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.237 -0.914 . . . . 0.0 110.161 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.784 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -127.04 89.02 53.05 Favored Pre-proline 0 N--CA 1.488 1.442 0 O-C-N 121.334 -0.854 . . . . 0.0 109.125 179.459 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.589 ' O ' ' NE2' ' A' ' 3' ' ' HIS . 86.6 Cg_endo -85.67 161.07 10.75 Favored 'Trans proline' 0 C--N 1.312 -1.392 0 C-N-CA 122.952 2.435 . . . . 0.0 112.652 -179.906 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.3 Cg_endo -60.12 150.39 79.46 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.731 2.287 . . . . 0.0 111.516 179.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.761 HG13 HG23 ' A' ' 6' ' ' VAL . 44.1 t -101.16 126.48 54.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.088 -1.008 . . . . 0.0 109.656 -179.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.704 ' O ' ' HB3' ' A' ' 86' ' ' ALA . 97.1 mt-10 -68.45 -32.47 72.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.358 -0.839 . . . . 0.0 109.55 179.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.704 ' HB3' ' O ' ' A' ' 85' ' ' GLU . . . 78.65 113.86 0.07 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.404 -0.81 . . . . 0.0 109.162 -179.567 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.62 ' NZ ' HG11 ' A' ' 26' ' ' VAL . 19.8 mttp -58.06 -35.08 70.84 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.132 -0.98 . . . . 0.0 109.458 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.4 mt -94.15 141.54 28.43 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.218 -0.926 . . . . 0.0 109.432 -179.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.483 -179.993 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.536 ' N5 ' ' O ' ' A' ' 61' ' ' LEU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.347 0.594 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 99.8 mm-40 -59.05 -36.19 74.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.35 -0.844 . . . . 0.0 109.31 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -150.1 44.68 0.9 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.385 -0.822 . . . . 0.0 109.273 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.04 -32.4 72.02 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.272 -0.893 . . . . 0.0 109.934 -179.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -58.46 -37.65 75.92 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.101 -0.999 . . . . 0.0 109.929 -179.469 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.549 HG11 ' H ' ' A' ' 84' ' ' VAL . 63.9 t -64.6 -39.49 85.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.148 -0.97 . . . . 0.0 109.357 179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.477 HD13 ' OD2' ' A' ' 73' ' ' ASP . 94.6 mt -59.84 -40.07 81.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.265 -0.897 . . . . 0.0 109.627 -179.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.39 -48.63 77.07 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.155 -0.965 . . . . 0.0 109.118 179.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.427 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 1.0 OUTLIER -69.37 -32.37 71.38 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.492 -0.755 . . . . 0.0 109.371 179.697 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 53.2 t80 -58.35 -51.51 69.49 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.296 -0.877 . . . . 0.0 109.722 -179.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.535 HG23 ' N ' ' A' ' 12' ' ' VAL . 33.8 m -73.73 -45.01 51.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.062 -1.023 . . . . 0.0 110.781 179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.535 ' N ' HG23 ' A' ' 11' ' ' VAL . 73.3 t -64.43 -35.89 75.67 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.176 -0.953 . . . . 0.0 111.131 -178.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -58.1 -33.01 68.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.011 -1.056 . . . . 0.0 110.005 -178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -66.19 -31.27 72.01 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 110.825 -179.237 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 33.1 m-85 -110.12 -55.87 2.4 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.214 -0.929 . . . . 0.0 111.472 -178.189 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 2.2 mt -124.44 87.65 53.96 Favored Pre-proline 0 N--CA 1.495 1.787 0 O-C-N 121.082 -1.011 . . . . 0.0 111.389 -178.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -92.91 -13.99 1.25 Allowed 'Trans proline' 0 C--N 1.307 -1.639 0 C-N-CA 123.205 2.603 . . . . 0.0 111.776 178.098 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -76.45 -3.99 40.12 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.18 -0.95 . . . . 0.0 109.39 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 8.2 p -114.09 146.42 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 N-CA-C 107.697 -1.223 . . . . 0.0 107.697 179.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -61.29 115.18 13.27 Favored Pre-proline 0 C--N 1.303 -1.441 0 O-C-N 120.742 -1.224 . . . . 0.0 108.362 -179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_endo -64.84 -33.04 54.54 Favored 'Trans proline' 0 C--N 1.317 -1.1 0 C-N-CA 121.458 1.439 . . . . 0.0 111.913 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -72.46 -14.96 61.8 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.203 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.3 m-20 -92.55 6.98 45.22 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.512 -0.742 . . . . 0.0 109.036 -179.992 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 45.8 t -95.84 137.06 24.87 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.752 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.6 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.7 m-20 -61.58 90.61 0.03 OUTLIER 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.223 -0.923 . . . . 0.0 109.589 -179.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.409 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.8 OUTLIER -59.22 6.06 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.273 -0.892 . . . . 0.0 109.692 179.763 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.6 ' H ' ' C ' ' A' ' 25' ' ' ASP . 90.2 m-20 -97.86 11.4 37.47 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.074 -1.016 . . . . 0.0 108.971 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.6 tp -89.51 133.89 34.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.43 -0.794 . . . . 0.0 109.704 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.433 ' CB ' ' O ' ' A' ' 67' ' ' ARG . 91.2 m-20 -65.37 122.3 16.84 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.419 -0.801 . . . . 0.0 108.97 179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.584 HD11 HG12 ' A' ' 69' ' ' ILE . 65.8 mt -62.06 -7.2 3.64 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.179 -0.951 . . . . 0.0 108.992 -179.823 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.491 HG13 ' N ' ' A' ' 32' ' ' ASP . 6.2 p -50.05 -41.16 17.78 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.436 0 O-C-N 121.223 -0.923 . . . . 0.0 109.03 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.491 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.9 m-20 -58.8 -36.63 74.77 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.454 -1.313 . . . . 0.0 107.454 178.449 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.643 ' O ' ' N ' ' A' ' 35' ' ' VAL . 82.6 m-20 -85.29 16.86 3.37 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 178.795 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.48 -15.15 0.01 OUTLIER Glycine 0 N--CA 1.488 2.133 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 -179.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.643 ' N ' ' O ' ' A' ' 33' ' ' ASN . 54.4 t -54.11 -38.78 39.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 120.78 -1.423 . . . . 0.0 107.853 178.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.618 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.23 -25.06 24.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.599 -0.688 . . . . 0.0 110.046 179.603 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.417 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.8 m-20 -62.37 -30.98 71.58 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.299 -0.875 . . . . 0.0 111.252 -178.306 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.561 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -104.97 -64.76 1.09 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.903 -1.123 . . . . 0.0 111.216 -178.62 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 18.5 mt -74.13 -52.58 12.1 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.121 -0.987 . . . . 0.0 110.964 -178.313 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.58 -36.59 93.34 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.654 -1.379 . . . . 0.0 109.654 -179.745 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.618 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.8 tt -61.33 -40.37 93.96 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.492 -1.005 . . . . 0.0 109.306 -179.599 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 34.2 tp -61.24 -44.21 97.62 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.535 -0.866 . . . . 0.0 108.797 179.767 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 46.1 mttp -70.5 -39.87 73.89 Favored 'General case' 0 C--N 1.305 -1.365 0 O-C-N 121.408 -0.808 . . . . 0.0 109.907 179.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 79.7 t -65.72 -45.72 91.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.291 -0.881 . . . . 0.0 110.514 -179.165 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.3 mp -62.97 -44.36 99.6 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.032 -1.042 . . . . 0.0 109.697 -179.71 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.447 ' O ' ' CG ' ' A' ' 50' ' ' ASP . . . -63.43 -43.09 98.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.323 -0.86 . . . . 0.0 109.802 -179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 2.2 t90 -76.21 -43.35 42.68 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.189 -0.945 . . . . 0.0 109.992 -179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.4 tp -58.09 -47.97 81.58 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.276 -0.89 . . . . 0.0 110.055 -179.32 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.614 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.2 tt0 -67.95 -39.55 83.41 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.114 -0.991 . . . . 0.0 108.827 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.447 ' CG ' ' O ' ' A' ' 46' ' ' ALA . 93.8 m-20 -64.9 -40.52 95.21 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.586 -0.696 . . . . 0.0 110.235 179.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.4 ttt180 -61.7 -44.79 96.25 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.408 -0.807 . . . . 0.0 111.3 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 41.5 m-85 -113.94 -1.87 13.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.095 -1.003 . . . . 0.0 111.042 -178.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.614 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.2 37.89 81.87 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 70.7 mt -96.18 142.76 13.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.192 -1.181 . . . . 0.0 109.263 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.92 138.94 58.41 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 120.915 -1.115 . . . . 0.0 109.491 -179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.8 -32.47 73.66 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.313 -0.867 . . . . 0.0 109.458 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 93.6 m-20 -57.69 -37.75 74.0 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.382 -0.823 . . . . 0.0 109.9 -179.823 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.06 -37.74 67.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.118 -0.989 . . . . 0.0 109.377 -179.888 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 60' ' ' GLU . 70.9 t -63.62 -37.16 78.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.85 . . . . 0.0 109.72 179.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . 86.3 tt0 58.57 127.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.559 -0.713 . . . . 0.0 109.654 -179.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.41 HD22 HD21 ' A' ' 41' ' ' LEU . 17.5 mt -103.14 134.16 47.02 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.263 -0.898 . . . . 0.0 109.907 -179.488 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -172.23 139.56 1.03 Allowed Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_endo -63.02 -26.62 73.8 Favored 'Trans proline' 0 C--N 1.312 -1.345 0 C-N-CA 121.986 1.791 . . . . 0.0 111.622 -179.791 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -66.96 -30.89 71.15 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.588 -0.695 . . . . 0.0 109.596 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 84.5 t60 -68.73 -26.3 65.19 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.58 -0.7 . . . . 0.0 110.824 -178.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.514 ' HA ' HD11 ' A' ' 72' ' ' ILE . 97.0 m-85 -101.39 6.2 42.48 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.977 -1.077 . . . . 0.0 111.607 -178.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.433 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 34.2 mmt180 -60.08 -34.11 73.0 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.743 -1.223 . . . . 0.0 110.028 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.7 p -144.04 147.25 33.57 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.874 -1.141 . . . . 0.0 110.185 -179.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.584 HG12 HD11 ' A' ' 30' ' ' LEU . 78.6 mt -66.6 -36.74 78.0 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.311 0 O-C-N 121.482 -0.761 . . . . 0.0 109.896 179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 84.4 mtm180 -61.03 -39.92 91.61 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.322 -0.861 . . . . 0.0 110.317 -178.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.61 -43.95 96.85 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.974 -1.079 . . . . 0.0 109.427 -179.824 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.514 HD11 ' HA ' ' A' ' 66' ' ' PHE . 79.0 mt -68.51 -38.57 79.38 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.356 -0.84 . . . . 0.0 109.908 179.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.477 ' OD2' HD13 ' A' ' 7' ' ' ILE . 77.6 m-20 -58.35 -42.0 85.92 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.398 -0.814 . . . . 0.0 110.438 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -40.12 88.88 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.11 -0.994 . . . . 0.0 110.368 -179.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -61.41 -51.42 68.82 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.191 -0.943 . . . . 0.0 109.851 -179.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.571 HG12 ' O ' ' A' ' 80' ' ' THR . 76.8 t -67.64 -43.79 86.59 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.261 -0.899 . . . . 0.0 109.763 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.7 t -63.02 -39.87 86.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 O-C-N 121.074 -1.016 . . . . 0.0 109.621 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.95 -33.85 70.14 Favored Glycine 0 N--CA 1.488 2.135 0 N-CA-C 110.2 -1.16 . . . . 0.0 110.2 -179.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.03 -48.88 3.76 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.146 -1.208 . . . . 0.0 110.565 -179.272 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.571 ' O ' HG12 ' A' ' 76' ' ' VAL . 57.9 m -157.37 137.96 13.06 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.138 -0.976 . . . . 0.0 110.168 -179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.768 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t -120.66 89.74 45.2 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.329 -0.857 . . . . 0.0 108.944 179.414 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -92.87 108.0 0.2 Allowed 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 123.207 2.604 . . . . 0.0 113.114 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -78.65 131.75 10.53 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.005 1.803 . . . . 0.0 111.79 179.163 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.549 ' H ' HG11 ' A' ' 6' ' ' VAL . 24.1 t -126.73 134.35 66.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.358 -0.839 . . . . 0.0 109.606 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -64.4 -34.86 79.16 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.296 -0.877 . . . . 0.0 109.886 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.441 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -146.79 157.27 43.63 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.156 -0.965 . . . . 0.0 109.708 -179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 41.8 tttm -70.76 132.31 45.15 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.184 -0.948 . . . . 0.0 109.243 -179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 44.5 mt -95.22 141.97 28.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.275 -0.89 . . . . 0.0 109.569 -179.76 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 117.984 -1.008 . . . . 0.0 109.455 179.981 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.561 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.6 mtt . . . . . 0 N--CA 1.491 1.589 0 CA-C-O 121.322 0.582 . . . . 0.0 109.497 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 -60.08 -38.0 81.59 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.349 -0.844 . . . . 0.0 109.507 -179.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.593 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 45.6 m-70 -133.99 12.87 3.96 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.4 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.53 -35.61 76.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.316 -0.865 . . . . 0.0 110.051 -179.489 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.8 p -61.76 -36.49 81.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.07 -1.019 . . . . 0.0 109.593 -179.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.568 HG23 HG23 ' A' ' 84' ' ' VAL . 72.4 t -66.16 -37.47 79.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 108.94 179.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.2 mt -66.49 -41.69 88.98 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.407 -0.808 . . . . 0.0 110.336 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.703 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.89 -50.55 68.31 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.042 -1.036 . . . . 0.0 110.378 -179.022 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -70.4 -44.22 68.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.073 -1.017 . . . . 0.0 109.614 179.866 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.1 t80 -60.18 -48.32 82.24 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.284 -0.885 . . . . 0.0 109.463 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.7 HG13 HD12 ' A' ' 36' ' ' ILE . 97.6 t -68.82 -47.48 75.94 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.486 -0.759 . . . . 0.0 109.837 -179.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.703 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.6 t -64.29 -36.67 77.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.427 -0.796 . . . . 0.0 109.964 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -56.81 -28.5 61.57 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.339 -0.85 . . . . 0.0 109.879 -179.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.56 -29.45 70.47 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.295 -0.878 . . . . 0.0 109.286 -179.754 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.547 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -155.94 55.8 0.59 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.294 -0.879 . . . . 0.0 109.155 179.97 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.473 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.7 pt? -80.59 136.8 51.67 Favored Pre-proline 0 C--N 1.306 -1.283 0 O-C-N 120.995 -1.065 . . . . 0.0 110.197 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -72.58 -153.79 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.523 0 C-N-CA 121.937 1.758 . . . . 0.0 110.641 179.012 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -81.24 14.2 2.5 Favored 'General case' 0 C--N 1.298 -1.636 0 O-C-N 121.092 -1.005 . . . . 0.0 108.79 179.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 37.5 t -113.3 136.9 48.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.646 -0.658 . . . . 0.0 109.994 -179.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.07 140.21 73.38 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.215 -0.928 . . . . 0.0 108.962 179.367 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.626 ' C ' ' HZ1' ' A' ' 87' ' ' LYS . 50.6 Cg_exo -48.86 -29.97 16.31 Favored 'Trans proline' 0 N--CA 1.493 1.448 0 C-N-CA 121.849 1.699 . . . . 0.0 112.081 179.599 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.566 ' HB1' ' CD2' ' A' ' 88' ' ' LEU . . . -68.6 -16.17 63.76 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.3 -0.875 . . . . 0.0 109.524 179.961 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -102.2 5.48 40.21 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.347 -0.846 . . . . 0.0 109.234 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 44.7 t -105.0 136.78 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.39 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.711 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.569 ' C ' ' H ' ' A' ' 27' ' ' ASP . 56.9 t0 -71.15 96.2 1.34 Allowed 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.157 -0.965 . . . . 0.0 109.431 -179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.2 m -60.91 6.0 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.356 -0.84 . . . . 0.0 109.676 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.569 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.5 m-20 -96.0 6.79 48.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.132 -0.98 . . . . 0.0 109.118 179.609 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.61 HD23 ' O ' ' A' ' 29' ' ' ASP . 7.5 tt -95.85 135.87 37.02 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.433 -0.792 . . . . 0.0 109.705 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.61 ' O ' HD23 ' A' ' 28' ' ' LEU . 88.0 m-20 -60.86 121.92 13.56 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 179.603 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -68.75 14.92 0.07 Allowed 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.31 -0.868 . . . . 0.0 110.281 -178.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.497 ' H ' ' C ' ' A' ' 29' ' ' ASP . 73.4 t -54.34 -41.17 51.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 121.02 -1.05 . . . . 0.0 108.508 179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -55.17 -35.21 64.56 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 107.786 -1.19 . . . . 0.0 107.786 178.985 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.629 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.4 m-20 -83.07 14.53 3.32 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.465 -0.939 . . . . 0.0 108.465 178.842 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.86 -14.44 0.01 OUTLIER Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.375 -1.49 . . . . 0.0 109.375 -179.924 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.629 ' N ' ' O ' ' A' ' 33' ' ' ASN . 44.4 t -51.21 -36.86 17.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.571 0 O-C-N 121.143 -1.21 . . . . 0.0 108.69 179.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.7 HD12 HG13 ' A' ' 11' ' ' VAL . 5.5 tt -70.66 -24.56 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.438 -0.789 . . . . 0.0 110.229 -179.883 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.404 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.3 m-20 -58.9 -34.87 72.17 Favored 'General case' 0 C--N 1.298 -1.666 0 O-C-N 121.271 -0.893 . . . . 0.0 111.474 -178.103 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.9 m -106.26 -64.97 1.11 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.931 -1.106 . . . . 0.0 111.673 -178.316 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.4 tt -71.37 -52.53 18.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.042 -1.036 . . . . 0.0 111.037 -177.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.712 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.76 -36.45 91.22 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -179.65 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.615 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tp -58.15 -42.76 86.61 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.372 -1.075 . . . . 0.0 108.898 -179.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 12.0 tp -60.39 -44.12 95.98 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 179.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 60.0 mttm -68.55 -34.68 76.26 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.458 -0.776 . . . . 0.0 109.518 179.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 40' ' ' GLY . 75.3 t -61.47 -45.8 97.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.447 -0.783 . . . . 0.0 110.329 -179.27 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 37.8 mm -62.66 -41.14 91.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 120.95 -1.093 . . . . 0.0 109.577 -179.881 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.73 -44.49 81.42 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.275 -0.89 . . . . 0.0 109.867 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.444 ' CE3' ' N ' ' A' ' 48' ' ' LEU . 0.8 OUTLIER -76.35 -45.14 33.38 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.181 -0.949 . . . . 0.0 109.702 -179.962 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.444 ' N ' ' CE3' ' A' ' 47' ' ' TRP . 6.8 tp -57.04 -40.98 77.8 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.347 -0.846 . . . . 0.0 109.512 -179.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.551 ' CG ' ' O ' ' A' ' 54' ' ' ILE . 2.9 tm-20 -60.86 -43.13 98.79 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.159 -0.963 . . . . 0.0 108.751 179.517 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -68.91 -43.3 75.48 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.294 -0.879 . . . . 0.0 110.045 179.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.6 tpt180 -64.27 -44.72 90.86 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.436 -0.79 . . . . 0.0 111.062 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -106.23 -5.39 19.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.063 -1.023 . . . . 0.0 110.998 -178.516 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 72.02 30.28 65.73 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.414 -1.475 . . . . 0.0 109.414 -179.928 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.551 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 71.6 mt -96.71 138.82 20.81 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.2 -1.177 . . . . 0.0 109.056 -179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.75 136.07 57.85 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.991 -1.068 . . . . 0.0 109.801 -179.196 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.32 -24.84 65.78 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.528 -0.732 . . . . 0.0 109.414 179.848 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.443 ' O ' HG13 ' A' ' 59' ' ' VAL . 92.2 m-20 -55.18 -31.64 61.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.468 -0.77 . . . . 0.0 110.217 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.07 120.69 11.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.054 -1.029 . . . . 0.0 109.839 -179.32 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.443 HG13 ' O ' ' A' ' 57' ' ' ASP . 16.8 m -115.29 27.46 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.567 -0.708 . . . . 0.0 109.309 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -51.08 -26.04 5.85 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.379 -0.825 . . . . 0.0 109.922 -179.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 52.0 mt -71.73 138.99 48.91 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.08 -1.012 . . . . 0.0 109.792 -179.468 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -128.85 162.4 51.91 Favored Pre-proline 0 N--CA 1.487 1.406 0 O-C-N 121.455 -0.778 . . . . 0.0 109.294 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -56.69 -36.21 98.12 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 C-N-CA 122.324 2.016 . . . . 0.0 111.395 179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -68.04 -25.8 65.55 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.474 -0.766 . . . . 0.0 109.185 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.48 ' CD2' ' CD2' ' A' ' 75' ' ' PHE . 34.1 t-80 -67.74 -26.03 65.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.415 -0.803 . . . . 0.0 109.863 -179.51 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.533 ' CZ ' ' CD1' ' A' ' 41' ' ' LEU . 92.0 m-85 -90.4 10.06 26.59 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.271 -0.893 . . . . 0.0 109.802 -179.593 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 16.4 tpt180 -56.91 -40.35 76.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.271 -0.893 . . . . 0.0 109.921 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -144.75 153.41 41.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.951 -1.093 . . . . 0.0 110.263 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.4 mt -66.3 -36.8 78.26 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.399 0 O-C-N 121.462 -0.774 . . . . 0.0 110.123 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 14.1 ttm180 -60.77 -43.05 98.54 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.302 -0.874 . . . . 0.0 110.433 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 20.3 m -58.4 -40.46 82.48 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.226 -0.921 . . . . 0.0 109.918 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.1 mt -61.54 -40.74 87.57 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.39 0 O-C-N 121.178 -0.951 . . . . 0.0 109.718 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.637 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.2 t0 -59.32 -37.5 77.93 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.288 -0.882 . . . . 0.0 109.996 -179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.8 -46.3 85.79 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.127 -0.983 . . . . 0.0 109.947 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.48 ' CD2' ' CD2' ' A' ' 65' ' ' HIS . 52.9 m-85 -68.45 -40.72 80.96 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.152 -0.967 . . . . 0.0 109.34 179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.1 t -65.13 -41.99 93.2 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.296 -0.877 . . . . 0.0 109.585 179.676 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.637 HG23 ' O ' ' A' ' 73' ' ' ASP . 56.3 t -63.74 -41.01 91.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.303 0 O-C-N 121.187 -0.946 . . . . 0.0 109.836 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.08 -30.96 71.47 Favored Glycine 0 N--CA 1.489 2.228 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.33 -48.58 4.14 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.039 -1.271 . . . . 0.0 110.559 -178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 76' ' ' VAL . 18.8 p -132.04 154.35 49.48 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.281 -0.887 . . . . 0.0 109.647 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.806 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t -140.26 89.28 10.94 Favored Pre-proline 0 C--N 1.303 -1.418 0 O-C-N 121.222 -0.924 . . . . 0.0 109.315 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.593 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 72.1 Cg_endo -85.2 161.15 11.43 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.877 2.385 . . . . 0.0 112.482 179.87 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -59.64 148.9 85.68 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.676 2.251 . . . . 0.0 111.778 179.637 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.568 HG23 HG23 ' A' ' 6' ' ' VAL . 14.6 p -130.44 141.26 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.382 -0.824 . . . . 0.0 109.926 -179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -112.77 160.17 18.24 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.454 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.13 135.63 43.36 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 120.976 -1.077 . . . . 0.0 109.179 -179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.626 ' HZ1' ' C ' ' A' ' 21' ' ' PRO . 16.1 tttm -60.13 -34.94 74.22 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.287 -0.883 . . . . 0.0 109.444 -179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.566 ' CD2' ' HB1' ' A' ' 22' ' ' ALA . 53.4 mt -84.88 142.95 29.35 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.159 -0.963 . . . . 0.0 109.521 -179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 26.0 mt-30 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 117.938 -1.03 . . . . 0.0 109.488 -179.914 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.1 mtp . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.379 -0.601 . . . . 0.0 109.379 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.748 ' OE1' HG21 ' A' ' 81' ' ' THR . 91.9 mt-30 -59.86 -37.28 78.84 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.31 -0.869 . . . . 0.0 109.598 -179.875 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -144.36 34.87 1.19 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.241 -0.912 . . . . 0.0 109.542 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.847 ' HB2' ' OD1' ' A' ' 73' ' ' ASP . . . -59.57 -32.48 70.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.241 -0.912 . . . . 0.0 109.676 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.5 m -58.46 -37.42 75.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.125 -0.984 . . . . 0.0 109.971 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.433 ' O ' ' N ' ' A' ' 10' ' ' PHE . 54.8 t -63.97 -40.85 90.55 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.064 -1.022 . . . . 0.0 109.131 179.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.538 HG22 HG23 ' A' ' 69' ' ' ILE . 76.7 mt -60.02 -47.92 89.89 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.443 -0.786 . . . . 0.0 109.27 179.956 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.01 99.11 Favored 'General case' 0 N--CA 1.489 1.489 0 N-CA-C 108.24 -1.022 . . . . 0.0 108.24 179.14 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.62 -37.38 86.42 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 178.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.464 ' O ' ' CE ' ' A' ' 87' ' ' LYS . 33.5 t80 -60.67 -52.89 63.22 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.513 -0.742 . . . . 0.0 109.886 -179.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.496 HG23 ' CD1' ' A' ' 36' ' ' ILE . 4.0 p -73.48 -42.01 56.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.106 -0.996 . . . . 0.0 109.89 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.2 t -65.02 -35.59 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.769 0 O-C-N 121.36 -0.837 . . . . 0.0 110.911 -179.16 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.4 tt0 -56.17 -36.17 68.04 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.023 -1.048 . . . . 0.0 110.353 -178.435 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.434 ' HB2' ' CE2' ' A' ' 15' ' ' PHE . 75.6 mm-40 -66.06 -31.5 72.42 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.043 -1.036 . . . . 0.0 109.884 -179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.434 ' CE2' ' HB2' ' A' ' 14' ' ' GLU . 0.2 OUTLIER -135.02 43.84 2.66 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.126 -0.984 . . . . 0.0 109.907 -179.968 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.855 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.5 135.89 52.85 Favored Pre-proline 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.119 . . . . 0.0 110.116 -179.733 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 71.6 Cg_endo -77.4 -149.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.319 0 C-N-CA 122.143 1.895 . . . . 0.0 110.184 178.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.591 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.1 p30 -79.52 11.25 3.16 Favored 'General case' 0 C--N 1.3 -1.585 0 O-C-N 120.794 -1.191 . . . . 0.0 108.637 179.08 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.591 HG23 ' OD1' ' A' ' 18' ' ' ASP . 26.8 t -113.75 136.16 51.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.519 -0.738 . . . . 0.0 109.841 -179.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.57 140.92 75.65 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.126 -0.983 . . . . 0.0 108.916 179.311 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -48.41 -29.33 13.29 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 121.875 1.717 . . . . 0.0 111.998 179.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.21 -21.16 66.3 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.384 -0.823 . . . . 0.0 109.283 179.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -103.27 3.25 35.25 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.44 -0.787 . . . . 0.0 108.886 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 49.1 t -104.93 138.94 27.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 N-CA-C 108.448 -0.945 . . . . 0.0 108.448 179.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.579 ' C ' ' H ' ' A' ' 27' ' ' ASP . 59.5 t0 -68.78 102.59 1.57 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.105 -0.997 . . . . 0.0 109.354 -179.255 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.465 HG12 ' CB ' ' A' ' 8' ' ' ALA . 26.0 m -59.62 6.41 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.433 -0.792 . . . . 0.0 109.933 -179.946 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.579 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.4 m-20 -89.92 10.11 25.16 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.03 -1.044 . . . . 0.0 108.632 179.248 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.2 tp -86.88 133.67 33.6 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.533 -0.729 . . . . 0.0 109.499 -179.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -67.45 121.27 15.43 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 179.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -73.31 9.79 1.19 Allowed 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.123 -0.986 . . . . 0.0 109.349 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.464 ' CG1' ' N ' ' A' ' 32' ' ' ASP . 5.4 p -52.51 -39.45 29.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.275 -0.891 . . . . 0.0 108.825 179.877 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.464 ' N ' ' CG1' ' A' ' 31' ' ' VAL . 91.4 m-20 -57.71 -36.18 71.65 Favored 'General case' 0 N--CA 1.488 1.445 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 178.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.617 ' O ' ' N ' ' A' ' 35' ' ' VAL . 60.9 m-80 -84.43 14.81 4.11 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 108.299 -1.0 . . . . 0.0 108.299 178.89 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.53 -15.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.617 ' N ' ' O ' ' A' ' 33' ' ' ASN . 53.3 t -51.58 -37.75 20.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 120.852 -1.381 . . . . 0.0 108.223 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.624 ' O ' ' N ' ' A' ' 41' ' ' LEU . 4.6 tt -71.04 -24.56 24.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.547 -0.721 . . . . 0.0 110.104 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.427 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 86.4 m-20 -60.57 -32.15 71.24 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.153 -0.967 . . . . 0.0 111.358 -178.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.551 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.4 OUTLIER -105.84 -65.11 1.09 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.864 -1.148 . . . . 0.0 111.393 -178.657 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.3 tt -72.33 -52.36 16.49 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.177 -0.952 . . . . 0.0 110.916 -178.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.732 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.69 92.28 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 -179.616 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.624 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.4 tp -58.88 -41.12 86.34 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.379 -1.071 . . . . 0.0 109.301 -179.625 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 8.9 tp -62.8 -44.33 96.45 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.213 -0.93 . . . . 0.0 108.762 179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 83.7 mttt -71.87 -38.26 70.07 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.421 -0.8 . . . . 0.0 109.948 179.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.732 HG23 ' O ' ' A' ' 40' ' ' GLY . 86.5 t -64.79 -45.12 96.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.6 0 O-C-N 121.328 -0.858 . . . . 0.0 110.249 -179.259 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -61.9 -42.47 94.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.171 -0.956 . . . . 0.0 109.607 -179.81 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.77 -43.09 97.42 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.181 -0.949 . . . . 0.0 109.971 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 0.7 OUTLIER -76.38 -43.68 39.62 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 109.842 -179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 31.4 tp -60.0 -42.5 94.41 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.275 -0.891 . . . . 0.0 109.842 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.609 ' O ' ' N ' ' A' ' 53' ' ' GLY . 4.1 tt0 -66.46 -41.69 88.7 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.12 -0.988 . . . . 0.0 108.996 179.531 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.8 t0 -66.61 -37.15 84.27 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.419 -0.8 . . . . 0.0 109.828 179.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 72.3 ttt-85 -59.04 -41.72 88.53 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.498 -0.751 . . . . 0.0 110.818 -178.527 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.563 ' CE1' HG21 ' A' ' 80' ' ' THR . 1.1 m-85 -118.93 -4.02 10.67 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.101 -0.999 . . . . 0.0 110.437 -179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.609 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 74.74 43.19 29.4 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.811 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 67.9 mt -101.08 140.7 19.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.138 -1.213 . . . . 0.0 109.323 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.59 ' HB3' ' HB2' ' A' ' 58' ' ' ASP . . . -62.26 136.61 58.01 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.884 -1.135 . . . . 0.0 109.374 -179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -64.23 -33.63 76.25 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.363 -0.836 . . . . 0.0 109.458 -179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -94.48 8.24 42.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.265 -0.897 . . . . 0.0 109.809 -179.769 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.59 ' HB2' ' HB3' ' A' ' 55' ' ' ALA . 21.3 t70 -53.05 -37.31 61.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.093 -1.004 . . . . 0.0 109.293 -179.929 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.465 HG21 ' CZ ' ' A' ' 75' ' ' PHE . 12.6 p -133.27 144.78 35.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.451 -0.781 . . . . 0.0 109.169 179.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 86.1 tt0 -77.75 137.38 38.43 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.159 -0.963 . . . . 0.0 109.429 -179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 25.3 mt -104.04 138.82 40.02 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.344 -0.848 . . . . 0.0 109.711 -179.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -135.58 154.85 78.53 Favored Pre-proline 0 N--CA 1.488 1.47 0 O-C-N 121.321 -0.862 . . . . 0.0 109.06 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.34 -30.66 81.13 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 C-N-CA 122.608 2.205 . . . . 0.0 112.339 -179.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.79 -32.1 73.44 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.376 -0.828 . . . . 0.0 110.013 -179.706 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -68.8 -26.48 65.21 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.288 -0.882 . . . . 0.0 110.897 -179.086 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -94.38 5.59 51.32 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.846 -1.159 . . . . 0.0 110.932 -178.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.7 mmm180 -59.65 -40.87 89.14 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.034 -179.887 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 49.0 m -129.45 145.26 51.45 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.25 -0.906 . . . . 0.0 110.184 -179.641 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.636 HD13 ' HA ' ' A' ' 8' ' ' ALA . 82.1 mt -63.7 -36.28 75.96 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 O-C-N 121.467 -0.771 . . . . 0.0 109.759 179.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 37.9 ttp180 -60.33 -37.66 81.31 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.339 -0.851 . . . . 0.0 110.402 -179.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.4 m -57.66 -43.46 84.96 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.999 -1.063 . . . . 0.0 109.633 -179.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.0 mt -68.04 -38.74 80.33 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.261 -0.899 . . . . 0.0 109.634 179.702 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.847 ' OD1' ' HB2' ' A' ' 4' ' ' ALA . 50.4 t0 -57.72 -40.45 79.62 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.384 -0.823 . . . . 0.0 110.302 -179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.04 -45.68 80.56 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.029 -1.044 . . . . 0.0 109.624 -179.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.465 ' CZ ' HG21 ' A' ' 59' ' ' VAL . 71.7 t80 -63.54 -45.84 88.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.373 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.496 ' O ' ' O ' ' A' ' 80' ' ' THR . 59.1 t -65.22 -44.74 95.13 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 O-C-N 121.362 -0.836 . . . . 0.0 109.976 -179.855 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.467 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.6 t -63.65 -39.39 85.2 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 O-C-N 121.11 -0.994 . . . . 0.0 109.838 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.74 -33.65 68.34 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.242 -1.143 . . . . 0.0 110.242 -179.49 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.5 -48.7 3.74 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.195 -1.179 . . . . 0.0 110.601 -179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.563 HG21 ' CE1' ' A' ' 52' ' ' PHE . 53.3 m -163.17 139.71 7.23 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.12 -0.987 . . . . 0.0 109.827 -179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.771 HG23 ' O ' ' A' ' 81' ' ' THR . 10.1 t -119.58 89.95 42.0 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.366 -0.834 . . . . 0.0 109.307 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -88.81 109.75 0.52 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 C-N-CA 123.062 2.508 . . . . 0.0 112.741 -179.647 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -78.51 130.27 9.8 Favored 'Trans proline' 0 C--N 1.314 -1.269 0 C-N-CA 122.012 1.808 . . . . 0.0 112.004 179.604 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 44.1 t -130.48 129.73 64.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.356 -0.84 . . . . 0.0 109.485 179.756 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 48.4 tp10 -65.7 -39.06 90.86 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 109.454 179.723 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -161.06 159.06 28.78 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.317 -0.864 . . . . 0.0 109.376 -179.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.464 ' CE ' ' O ' ' A' ' 10' ' ' PHE . 32.7 mttt -57.4 -33.31 67.73 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.103 -0.998 . . . . 0.0 109.455 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 68.5 mt -57.79 -35.6 71.04 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.216 -0.928 . . . . 0.0 109.403 -179.915 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 117.986 -1.006 . . . . 0.0 109.524 179.935 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.564 ' S12' ' C8 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.75 ' N ' ' H ' ' A' ' 85' ' ' GLU . 4.2 ptt? . . . . . 0 N--CA 1.49 1.566 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.51 ' N ' ' O ' ' A' ' 83' ' ' PRO . 91.8 mt-30 55.6 44.15 27.09 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.27 -0.894 . . . . 0.0 109.107 -179.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.402 ' C ' ' O ' ' A' ' 2' ' ' GLN . 67.0 m170 46.45 37.69 4.58 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.181 -0.95 . . . . 0.0 109.048 -179.543 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.541 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.75 -36.74 79.68 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.331 -0.856 . . . . 0.0 109.485 -179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . 0.44 ' OG ' ' CE ' ' A' ' 1' ' ' MET . 22.9 m -59.23 -39.58 83.2 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.19 -0.944 . . . . 0.0 109.285 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 68.8 t -66.83 -37.66 79.9 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.203 -0.936 . . . . 0.0 109.0 179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.577 ' O ' HG23 ' A' ' 11' ' ' VAL . 85.5 mt -60.48 -51.01 78.01 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.251 -0.906 . . . . 0.0 109.177 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.761 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.81 -48.14 75.48 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.374 -0.828 . . . . 0.0 109.301 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -62.85 -44.28 96.54 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.523 -0.736 . . . . 0.0 109.344 179.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.477 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 68.2 t80 -65.7 -48.7 71.14 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.57 -0.706 . . . . 0.0 109.486 -179.861 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.577 HG23 ' O ' ' A' ' 7' ' ' ILE . 90.9 t -67.33 -44.89 86.94 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.383 -0.823 . . . . 0.0 109.521 179.921 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 8' ' ' ALA . 94.3 t -64.25 -35.28 73.53 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.488 -0.757 . . . . 0.0 109.527 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.7 tt0 -55.8 -30.38 61.26 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.299 -0.876 . . . . 0.0 109.969 -179.568 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -65.66 -31.09 71.91 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.114 -0.992 . . . . 0.0 109.702 -179.635 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.563 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 33.5 p90 -143.29 45.79 1.53 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.101 -0.999 . . . . 0.0 109.671 -179.896 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.851 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.63 135.9 52.37 Favored Pre-proline 0 N--CA 1.489 1.508 0 O-C-N 121.036 -1.04 . . . . 0.0 110.177 -179.813 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -77.58 -151.29 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.366 0 C-N-CA 122.218 1.946 . . . . 0.0 110.364 178.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -78.72 12.18 2.22 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 120.826 -1.171 . . . . 0.0 108.748 179.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 22.0 t -113.4 137.0 48.01 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.579 -0.701 . . . . 0.0 109.881 -179.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.72 84.34 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.151 -0.968 . . . . 0.0 108.911 179.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.408 ' HD3' HD12 ' A' ' 16' ' ' LEU . 51.2 Cg_exo -48.2 -30.93 15.68 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 121.864 1.709 . . . . 0.0 112.179 179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.8 -22.92 66.0 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.419 -0.8 . . . . 0.0 109.434 179.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.1 m-20 -102.51 8.64 39.9 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.365 -0.834 . . . . 0.0 109.434 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 56.1 t -101.3 136.73 31.67 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.318 -0.864 . . . . 0.0 108.862 179.806 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.567 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.0 m-20 -68.71 89.34 0.38 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.134 -0.979 . . . . 0.0 109.275 -179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -61.57 6.39 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.272 -0.893 . . . . 0.0 109.563 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.567 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -93.34 8.55 39.98 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.111 -0.993 . . . . 0.0 108.918 179.444 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 6.0 tp -91.41 136.81 32.85 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.487 -0.758 . . . . 0.0 109.575 -179.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -62.43 121.79 14.12 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.031 -1.1 . . . . 0.0 108.031 179.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.61 10.53 1.68 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.257 -0.902 . . . . 0.0 110.101 -178.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 55.5 t -55.42 -42.08 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.907 -1.12 . . . . 0.0 108.932 179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.4 t0 -55.81 -35.53 66.44 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.924 -1.139 . . . . 0.0 107.924 178.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.638 ' O ' ' N ' ' A' ' 35' ' ' VAL . 78.6 m-20 -85.28 14.77 4.88 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.041 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.56 -15.19 0.02 OUTLIER Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 -179.648 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.638 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.5 t -53.24 -36.81 26.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.514 0 O-C-N 121.151 -1.205 . . . . 0.0 108.611 179.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.605 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.2 tt -70.46 -24.73 25.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.462 -0.774 . . . . 0.0 110.087 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.425 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 83.8 m-20 -61.11 -32.31 71.99 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.215 -0.928 . . . . 0.0 110.969 -178.588 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 46.1 m -105.77 -64.57 1.14 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.047 -1.033 . . . . 0.0 111.475 -178.557 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 4.1 mp -72.56 -52.4 15.75 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.072 -1.018 . . . . 0.0 110.969 -178.198 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.563 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -65.91 -37.4 93.25 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 -179.677 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.605 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.7 tp -59.39 -41.03 88.48 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.461 -1.023 . . . . 0.0 109.141 -179.739 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 10.9 tp -62.03 -43.96 97.72 Favored 'General case' 0 C--N 1.303 -1.441 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -65.48 -35.45 80.94 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.48 -0.763 . . . . 0.0 109.281 179.197 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.2 t -60.11 -43.86 93.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.427 -0.796 . . . . 0.0 110.102 -179.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -60.5 -44.88 97.42 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.688 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.9 -43.3 96.37 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.286 -0.884 . . . . 0.0 110.203 -179.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.477 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 0.7 OUTLIER -75.3 -38.84 60.13 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.875 . . . . 0.0 109.936 -179.694 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.7 tp -57.92 -44.16 86.67 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.285 -0.884 . . . . 0.0 110.014 -179.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.587 ' O ' ' N ' ' A' ' 53' ' ' GLY . 30.1 tt0 -66.34 -40.36 89.78 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 120.999 -1.063 . . . . 0.0 109.41 179.624 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -64.7 -44.04 91.54 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.319 -0.863 . . . . 0.0 110.574 -179.733 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 66.5 ttt180 -65.15 -43.23 92.53 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.333 -0.854 . . . . 0.0 111.596 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -106.57 -7.07 17.61 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 120.952 -1.093 . . . . 0.0 110.782 -178.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.587 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 67.38 33.51 82.29 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 -179.866 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.0 pt -108.78 153.12 10.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.363 -1.081 . . . . 0.0 109.961 -179.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.84 151.37 30.08 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.243 -0.91 . . . . 0.0 109.714 -179.365 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -57.27 -36.01 70.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.434 -0.791 . . . . 0.0 109.987 -179.366 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.6 m-20 52.91 49.53 20.02 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.162 -0.961 . . . . 0.0 108.864 -179.801 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 59.9 t0 -74.85 118.17 17.51 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.334 -0.854 . . . . 0.0 110.214 -179.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 21.8 m -129.59 163.78 33.95 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 179.477 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 88.1 tt0 -59.4 127.69 33.33 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.909 -1.119 . . . . 0.0 109.467 -179.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.54 HD12 HD21 ' A' ' 41' ' ' LEU . 28.6 mt -114.93 146.03 41.59 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.592 -0.693 . . . . 0.0 109.779 -179.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -107.35 155.7 39.01 Favored Pre-proline 0 N--CA 1.488 1.429 0 O-C-N 121.33 -0.856 . . . . 0.0 109.096 179.495 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.11 -25.57 77.42 Favored 'Trans proline' 0 C--N 1.307 -1.655 0 C-N-CA 122.644 2.229 . . . . 0.0 112.014 -179.89 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -62.54 -29.74 70.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.362 -0.836 . . . . 0.0 109.534 179.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.67 -26.66 66.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.268 -0.895 . . . . 0.0 109.795 -179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -99.39 8.49 44.58 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.148 -0.97 . . . . 0.0 109.69 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 26.4 tpt180 -55.93 -38.15 69.91 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.206 -0.934 . . . . 0.0 109.726 -179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 86.8 p -141.36 156.63 45.81 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.1 -1.0 . . . . 0.0 110.16 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 89.3 mt -61.79 -35.74 69.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.299 0 O-C-N 121.431 -0.793 . . . . 0.0 109.847 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 71.2 ttp85 -59.74 -39.03 83.4 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.188 -0.945 . . . . 0.0 109.848 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 29.2 t -58.48 -39.89 81.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.066 -1.021 . . . . 0.0 108.924 179.74 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 85.2 mt -60.84 -38.72 79.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.299 -0.876 . . . . 0.0 108.874 179.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.561 ' O ' HG23 ' A' ' 77' ' ' VAL . 56.0 t0 -56.21 -36.92 68.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.448 -0.783 . . . . 0.0 109.02 179.593 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -60.67 -40.64 92.83 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.257 -0.902 . . . . 0.0 108.768 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 68.3 t80 -60.64 -46.41 90.41 Favored 'General case' 0 N--CA 1.489 1.516 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 179.195 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.0 t -63.97 -40.62 89.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.411 -0.805 . . . . 0.0 108.934 179.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -57.97 -40.75 78.05 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.302 0 O-C-N 121.482 -0.761 . . . . 0.0 109.186 179.615 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.77 -34.31 86.36 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -99.88 -48.85 4.54 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 120.893 -1.357 . . . . 0.0 110.553 -179.082 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 17.6 p -128.7 152.74 48.06 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.32 -0.862 . . . . 0.0 108.721 179.659 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.79 HG23 ' O ' ' A' ' 81' ' ' THR . 9.0 t -137.81 89.58 15.03 Favored Pre-proline 0 N--CA 1.489 1.491 0 O-C-N 121.213 -0.929 . . . . 0.0 110.237 -179.728 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.429 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 15.7 Cg_exo -64.28 -176.65 0.41 Allowed 'Trans proline' 0 C--N 1.31 -1.488 0 C-N-CA 122.507 2.138 . . . . 0.0 111.476 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.51 ' O ' ' N ' ' A' ' 2' ' ' GLN . 25.9 Cg_exo -58.67 148.88 80.19 Favored 'Trans proline' 0 C--N 1.308 -1.578 0 C-N-CA 122.406 2.071 . . . . 0.0 111.937 -179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.416 ' HA ' ' H2 ' ' A' ' 1' ' ' MET . 45.7 t -112.42 136.06 49.82 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.397 -0.815 . . . . 0.0 109.889 -179.435 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.75 ' H ' ' N ' ' A' ' 1' ' ' MET . 84.7 tt0 -145.4 -90.75 0.1 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.354 -0.841 . . . . 0.0 109.345 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -162.33 122.04 2.38 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.081 -1.012 . . . . 0.0 109.427 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 48.2 tttp -59.1 -36.15 74.64 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.212 -0.93 . . . . 0.0 109.457 179.989 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 35.7 tp -97.48 130.88 44.53 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.196 -0.94 . . . . 0.0 109.469 -179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.552 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.412 -179.941 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.438 ' O3 ' ' O3P' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.657 ' SD ' ' NH2' ' A' ' 70' ' ' ARG . 59.8 mtt . . . . . 0 N--CA 1.488 1.427 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.477 ' HA ' HG22 ' A' ' 84' ' ' VAL . 99.8 mm-40 -59.49 -34.4 72.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.199 -0.938 . . . . 0.0 108.84 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.508 ' CE1' HG22 ' A' ' 77' ' ' VAL . 4.2 p-80 -171.94 26.79 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.563 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -61.28 -35.04 76.22 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.295 -0.878 . . . . 0.0 109.584 -179.834 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 t -59.11 -41.65 88.67 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.157 -0.965 . . . . 0.0 109.489 -179.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 67.5 t -65.24 -39.82 86.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.224 -0.922 . . . . 0.0 108.907 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.633 ' O ' HG12 ' A' ' 11' ' ' VAL . 88.9 mt -59.55 -50.71 78.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.456 -0.778 . . . . 0.0 109.351 -179.948 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.11 -42.3 96.94 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 108.865 179.389 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -65.82 -39.57 91.0 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.509 -0.745 . . . . 0.0 109.492 179.566 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.434 ' HE2' HG22 ' A' ' 44' ' ' VAL . 38.0 t80 -61.5 -52.22 65.39 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.356 -0.84 . . . . 0.0 109.847 -179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.633 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.3 p -72.51 -42.44 63.87 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.275 -0.891 . . . . 0.0 109.929 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 84.4 t -64.38 -38.39 82.43 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.356 -0.84 . . . . 0.0 110.294 -179.64 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -56.55 -28.0 59.06 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.216 -0.927 . . . . 0.0 110.143 -179.46 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -64.77 -30.05 71.04 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.054 -1.029 . . . . 0.0 109.028 -179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.516 ' CE2' ' O ' ' A' ' 11' ' ' VAL . 0.1 OUTLIER -154.47 55.47 0.69 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.352 -0.842 . . . . 0.0 109.208 179.686 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.518 HD23 ' H ' ' A' ' 16' ' ' LEU . 1.8 pt? -80.82 137.05 50.64 Favored Pre-proline 0 N--CA 1.486 1.331 0 O-C-N 121.079 -1.013 . . . . 0.0 110.106 -179.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -72.15 -153.55 0.04 OUTLIER 'Trans proline' 0 C--N 1.31 -1.474 0 C-N-CA 121.925 1.75 . . . . 0.0 110.837 179.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.483 ' OD1' HG23 ' A' ' 19' ' ' VAL . 54.0 p30 -82.16 15.31 2.42 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 108.838 179.484 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.483 HG23 ' OD1' ' A' ' 18' ' ' ASP . 44.7 t -112.96 137.15 46.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.623 -0.673 . . . . 0.0 109.912 -179.384 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.69 137.76 88.13 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.243 -0.911 . . . . 0.0 109.06 179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -48.94 -31.01 19.03 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.87 1.713 . . . . 0.0 112.152 179.663 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.27 -16.61 64.38 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.275 -0.89 . . . . 0.0 109.427 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 91.2 m-20 -102.2 8.81 40.46 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.403 -0.811 . . . . 0.0 109.172 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 46.4 t -99.86 136.47 31.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.589 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -69.4 90.12 0.51 Allowed 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.22 -0.925 . . . . 0.0 109.513 -179.386 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.595 HG23 ' HB2' ' A' ' 8' ' ' ALA . 7.1 p -59.17 6.22 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.45 0 O-C-N 121.327 -0.858 . . . . 0.0 109.845 179.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.589 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.0 m-20 -90.12 5.79 45.31 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.068 -1.02 . . . . 0.0 108.852 179.393 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.5 tp -94.39 136.25 34.89 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.468 -0.77 . . . . 0.0 109.449 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.498 ' C ' ' H ' ' A' ' 31' ' ' VAL . 88.2 m-20 -62.53 121.65 13.82 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.077 -1.082 . . . . 0.0 108.077 179.097 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -68.59 13.91 0.09 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.282 -0.886 . . . . 0.0 110.03 -178.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.498 ' H ' ' C ' ' A' ' 29' ' ' ASP . 79.6 t -55.15 -42.38 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.041 -1.037 . . . . 0.0 108.702 179.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.61 -35.36 65.77 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 178.909 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.625 ' O ' ' N ' ' A' ' 35' ' ' VAL . 77.9 m-20 -84.29 14.39 4.41 Favored 'General case' 0 C--N 1.305 -1.361 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.413 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.91 -14.53 0.01 OUTLIER Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.415 -1.474 . . . . 0.0 109.415 -179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.625 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.1 t -51.43 -34.42 15.33 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.19 -1.183 . . . . 0.0 108.817 179.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 1.6 tt -69.84 -24.34 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.463 -0.773 . . . . 0.0 110.11 -179.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.578 ' OD1' ' CG ' ' A' ' 66' ' ' PHE . 82.9 m-20 -57.11 -34.76 68.68 Favored 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.293 -0.879 . . . . 0.0 111.33 -178.3 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.577 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -105.65 -64.79 1.11 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.851 -1.156 . . . . 0.0 111.381 -178.226 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.415 HD21 ' NZ ' ' A' ' 43' ' ' LYS . 7.3 tt -70.88 -52.36 20.64 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.071 -1.018 . . . . 0.0 110.93 -178.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.605 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.39 -36.83 92.15 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.706 HD23 ' C ' ' A' ' 41' ' ' LEU . 7.2 tt -58.76 -42.09 88.08 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.451 -1.029 . . . . 0.0 109.484 -179.627 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 9.4 tp -61.88 -44.09 97.53 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.175 -0.953 . . . . 0.0 108.54 179.501 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . 0.415 ' NZ ' HD21 ' A' ' 39' ' ' LEU . 54.3 mttp -70.09 -38.33 75.64 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.426 -0.796 . . . . 0.0 109.897 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.605 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.8 t -64.09 -45.14 97.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.277 -0.889 . . . . 0.0 110.372 -179.221 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.2 mp -60.8 -44.68 98.03 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.2 -0.938 . . . . 0.0 109.727 -179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.37 -41.78 96.52 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.275 -0.89 . . . . 0.0 110.106 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . . . . . . . . . 1.0 OUTLIER -76.44 -43.47 39.98 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.213 -0.929 . . . . 0.0 110.097 -179.598 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 11.0 tp -58.04 -44.43 87.4 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.184 -0.947 . . . . 0.0 109.668 -179.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.412 ' O ' ' N ' ' A' ' 53' ' ' GLY . 15.3 tt0 -64.69 -38.17 90.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.17 -0.956 . . . . 0.0 109.088 179.589 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -71.42 -48.94 46.46 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.378 -0.826 . . . . 0.0 110.623 -179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 51.0 ttt180 -62.41 -42.47 99.46 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.362 -0.836 . . . . 0.0 111.279 -178.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.765 ' CE1' HG21 ' A' ' 80' ' ' THR . 98.6 m-85 -101.2 -6.52 24.14 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 120.866 -1.146 . . . . 0.0 110.353 -178.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 66.98 28.25 73.73 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 109.165 -1.574 . . . . 0.0 109.165 -179.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 63.0 mt -101.55 137.01 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.281 -1.129 . . . . 0.0 109.192 -179.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.51 141.95 57.38 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.076 -1.015 . . . . 0.0 109.291 -179.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -60.71 -36.82 79.78 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.27 -0.894 . . . . 0.0 109.441 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -61.39 -33.26 73.39 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -50.72 -34.59 27.51 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.226 -0.921 . . . . 0.0 109.836 -179.495 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 44.8 t -101.4 135.87 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.187 -0.945 . . . . 0.0 109.511 -179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -89.51 141.81 28.24 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.212 -0.93 . . . . 0.0 109.471 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.407 HD13 HD21 ' A' ' 41' ' ' LEU . 36.5 mt -97.31 134.26 40.83 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.278 -0.889 . . . . 0.0 109.74 -179.608 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.48 153.19 8.46 Favored Pre-proline 0 N--CA 1.49 1.544 0 O-C-N 121.216 -0.928 . . . . 0.0 109.226 179.631 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -62.07 -28.58 80.31 Favored 'Trans proline' 0 C--N 1.309 -1.503 0 C-N-CA 122.487 2.125 . . . . 0.0 111.964 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -65.05 -29.56 70.46 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.368 -0.833 . . . . 0.0 109.572 179.884 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -67.65 -26.97 66.48 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.347 -0.846 . . . . 0.0 109.75 -179.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.578 ' CG ' ' OD1' ' A' ' 37' ' ' ASP . 96.1 m-85 -103.49 6.82 37.75 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.281 -0.887 . . . . 0.0 110.161 -179.448 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 21.7 tpt180 -58.35 -41.69 85.22 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.029 -1.044 . . . . 0.0 109.904 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -153.74 158.86 41.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.902 -1.124 . . . . 0.0 110.116 -179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.441 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -62.74 -36.98 77.83 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.304 0 O-C-N 121.34 -0.85 . . . . 0.0 109.871 179.641 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.657 ' NH2' ' SD ' ' A' ' 1' ' ' MET . 4.6 tpm_? -60.7 -40.86 93.78 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.252 -0.905 . . . . 0.0 110.25 -179.382 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.9 m -60.25 -44.07 95.58 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.102 -0.999 . . . . 0.0 109.695 -179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 83.5 mt -66.11 -39.76 85.28 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 O-C-N 121.225 -0.922 . . . . 0.0 109.79 179.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.667 ' O ' HG23 ' A' ' 77' ' ' VAL . 55.5 t0 -58.02 -38.41 76.15 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.396 -0.815 . . . . 0.0 109.857 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -65.5 -46.2 80.61 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.207 -0.933 . . . . 0.0 109.847 -179.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -66.6 -41.63 88.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.091 -1.006 . . . . 0.0 109.225 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.49 ' O ' ' O ' ' A' ' 80' ' ' THR . 71.8 t -64.9 -42.48 94.94 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.334 0 O-C-N 121.349 -0.845 . . . . 0.0 109.706 179.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.667 HG23 ' O ' ' A' ' 73' ' ' ASP . 72.6 t -63.1 -41.46 92.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.312 0 O-C-N 121.253 -0.904 . . . . 0.0 109.79 -179.887 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -59.0 -30.33 66.51 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -100.44 -48.08 4.68 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -1.22 . . . . 0.0 110.21 -179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.765 HG21 ' CE1' ' A' ' 52' ' ' PHE . 7.2 t -143.3 155.53 44.49 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.184 -0.947 . . . . 0.0 109.737 -179.825 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.792 HG23 ' O ' ' A' ' 81' ' ' THR . 9.2 t -139.33 90.2 11.77 Favored Pre-proline 0 C--N 1.303 -1.434 0 O-C-N 121.29 -0.881 . . . . 0.0 109.281 179.916 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 16.8 Cg_exo -62.16 -178.11 0.32 Allowed 'Trans proline' 0 N--CA 1.493 1.497 0 C-N-CA 122.479 2.119 . . . . 0.0 112.221 -179.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.418 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 26.4 Cg_exo -59.08 150.58 72.36 Favored 'Trans proline' 0 N--CA 1.494 1.528 0 C-N-CA 122.602 2.202 . . . . 0.0 111.913 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 1' ' ' MET . 26.8 t -101.6 129.37 52.89 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.173 -0.954 . . . . 0.0 109.58 -179.697 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -136.49 153.03 51.14 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.391 -0.818 . . . . 0.0 109.377 179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -66.05 142.45 57.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.168 -0.958 . . . . 0.0 109.379 179.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 66.4 tttm -58.43 -37.5 75.5 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.225 -0.922 . . . . 0.0 109.451 179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 67.3 mt -59.39 -35.07 73.27 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.212 -0.93 . . . . 0.0 109.437 179.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 117.98 -1.01 . . . . 0.0 109.451 -179.976 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.577 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.9 mtt . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.241 0.543 . . . . 0.0 109.648 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.872 ' OE1' HG21 ' A' ' 81' ' ' THR . 90.6 mt-30 -82.08 135.05 35.37 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.32 -0.862 . . . . 0.0 108.745 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 56.4 m80 55.62 38.37 30.09 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.182 -0.949 . . . . 0.0 108.959 -179.563 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.459 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -58.93 -34.0 71.22 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.41 -0.806 . . . . 0.0 109.548 -179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -59.02 -38.64 79.74 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.21 -0.931 . . . . 0.0 109.679 -179.856 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.571 HG11 ' H ' ' A' ' 84' ' ' VAL . 53.2 t -64.4 -37.61 80.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.157 -0.964 . . . . 0.0 109.595 179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.49 ' CD1' ' CG ' ' A' ' 73' ' ' ASP . 84.4 mt -59.3 -50.42 79.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.37 -0.831 . . . . 0.0 109.618 -179.574 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.741 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.91 -42.66 97.34 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.154 -0.966 . . . . 0.0 108.787 179.28 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -67.36 -34.77 77.99 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.645 -0.659 . . . . 0.0 109.613 179.444 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.457 ' N ' ' O ' ' A' ' 6' ' ' VAL . 58.3 t80 -59.57 -53.11 61.83 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.397 -0.814 . . . . 0.0 110.352 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.446 HG23 ' N ' ' A' ' 12' ' ' VAL . 34.2 m -74.4 -40.88 49.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.101 -0.999 . . . . 0.0 109.948 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.741 HG23 ' O ' ' A' ' 8' ' ' ALA . 60.0 t -64.91 -37.6 80.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.669 0 O-C-N 121.309 -0.87 . . . . 0.0 110.451 -179.457 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 85.9 tt0 -56.64 -30.65 63.55 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.072 -1.018 . . . . 0.0 109.853 -179.285 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.529 ' OE2' ' CD1' ' A' ' 36' ' ' ILE . 84.4 tt0 -65.27 -31.27 72.33 Favored 'General case' 0 C--N 1.301 -1.516 0 O-C-N 121.233 -0.917 . . . . 0.0 109.719 -179.85 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.599 ' O ' ' CD2' ' A' ' 15' ' ' PHE . 32.3 p90 -143.06 46.17 1.55 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -0.932 . . . . 0.0 109.774 -179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.859 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.58 136.07 52.4 Favored Pre-proline 0 N--CA 1.489 1.516 0 O-C-N 121.061 -1.024 . . . . 0.0 110.157 -179.837 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_endo -77.62 -149.89 0.04 OUTLIER 'Trans proline' 0 C--N 1.313 -1.32 0 C-N-CA 122.143 1.895 . . . . 0.0 110.308 178.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.565 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.63 12.08 2.76 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.803 -1.185 . . . . 0.0 108.782 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.565 HG23 ' OD1' ' A' ' 18' ' ' ASP . 38.5 t -113.35 136.2 50.48 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.579 -0.701 . . . . 0.0 109.805 -179.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.42 139.43 84.15 Favored Pre-proline 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.971 . . . . 0.0 108.85 179.414 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.415 ' HD3' HD12 ' A' ' 16' ' ' LEU . 50.1 Cg_exo -48.23 -30.71 15.36 Favored 'Trans proline' 0 N--CA 1.493 1.453 0 C-N-CA 121.775 1.65 . . . . 0.0 112.129 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.06 -23.81 66.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.289 -0.882 . . . . 0.0 109.348 179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.5 m-20 -98.94 3.44 47.09 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.329 -0.857 . . . . 0.0 109.105 -179.952 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 53.0 t -104.88 137.03 35.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 N-CA-C 108.72 -0.845 . . . . 0.0 108.72 179.654 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 90.1 m-20 -63.65 99.28 0.22 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.198 -0.939 . . . . 0.0 109.514 -179.443 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.434 HG12 ' HB1' ' A' ' 8' ' ' ALA . 15.1 m -60.91 6.72 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.345 -0.847 . . . . 0.0 109.557 179.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 89.3 m-20 -88.77 11.29 18.13 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.171 -0.956 . . . . 0.0 108.905 179.455 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 37.5 tp -82.59 131.72 35.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.462 -0.774 . . . . 0.0 109.432 -179.877 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.4 m-20 -67.98 122.22 17.75 Favored 'General case' 0 C--N 1.303 -1.446 0 O-C-N 121.349 -0.845 . . . . 0.0 109.063 -179.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.692 HD11 HG12 ' A' ' 69' ' ' ILE . 66.2 mt -62.97 -10.12 12.5 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.341 -0.849 . . . . 0.0 109.491 -179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.461 HG13 ' N ' ' A' ' 32' ' ' ASP . 5.9 p -50.19 -39.44 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.099 -1.001 . . . . 0.0 109.245 -179.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.461 ' N ' HG13 ' A' ' 31' ' ' VAL . 91.7 m-20 -58.08 -37.66 74.92 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 108.018 -1.104 . . . . 0.0 108.018 178.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.603 ' O ' ' N ' ' A' ' 35' ' ' VAL . 58.2 m-80 -87.6 15.5 6.69 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.56 -0.904 . . . . 0.0 108.56 178.951 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.4 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.4 -18.37 0.02 OUTLIER Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.003 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.603 ' N ' ' O ' ' A' ' 33' ' ' ASN . 4.3 p -52.48 -35.37 20.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 120.797 -1.414 . . . . 0.0 108.185 179.163 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.617 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.8 tt -71.19 -25.06 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.589 -0.694 . . . . 0.0 109.869 179.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 82.8 m-20 -62.82 -30.19 71.29 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.302 -0.874 . . . . 0.0 110.999 -178.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.6 m -104.95 -65.14 1.06 Allowed 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.006 -1.059 . . . . 0.0 111.178 -178.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.452 ' H ' HD12 ' A' ' 39' ' ' LEU . 5.9 mp -74.17 -52.14 13.4 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.162 -0.961 . . . . 0.0 111.069 -178.262 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.528 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -64.86 -38.93 96.15 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.747 -1.341 . . . . 0.0 109.747 -179.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.617 ' N ' ' O ' ' A' ' 36' ' ' ILE . 7.6 tt -61.7 -42.12 98.52 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -1.084 . . . . 0.0 109.593 -179.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.568 HD13 ' O ' ' A' ' 42' ' ' LEU . 0.2 OUTLIER -58.73 -44.17 90.39 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.097 -1.002 . . . . 0.0 108.541 -179.562 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -66.82 -37.84 85.29 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.188 -0.945 . . . . 0.0 109.331 179.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.0 t -67.44 -47.85 79.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.398 -0.813 . . . . 0.0 111.102 -179.115 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -60.84 -43.49 95.66 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 120.727 -1.233 . . . . 0.0 109.922 -179.462 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -45.29 76.94 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 120.999 -1.063 . . . . 0.0 110.191 -179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.448 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.5 t90 -77.22 -46.84 21.89 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.238 -0.914 . . . . 0.0 110.09 -179.79 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.469 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 11.6 tp -56.97 -41.01 77.59 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.377 -0.827 . . . . 0.0 109.818 -179.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.605 ' O ' ' N ' ' A' ' 53' ' ' GLY . 10.5 tt0 -61.4 -42.52 98.86 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 120.982 -1.074 . . . . 0.0 108.955 179.551 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 54.3 t0 -66.9 -36.98 83.51 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.245 -0.909 . . . . 0.0 109.55 179.419 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.565 HH22 ' CD ' ' A' ' 89' ' ' GLN . 60.7 ttt85 -59.98 -46.31 89.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.389 -0.819 . . . . 0.0 111.137 -178.876 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.413 ' CZ ' ' HB3' ' A' ' 82' ' ' PRO . 47.3 m-85 -117.21 0.17 12.22 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.14 -0.975 . . . . 0.0 110.94 -179.066 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.605 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.68 40.37 65.91 Favored Glycine 0 N--CA 1.491 2.31 0 N-CA-C 109.494 -1.442 . . . . 0.0 109.494 179.818 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 69.9 mt -96.0 141.43 15.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.499 0 O-C-N 121.214 -1.168 . . . . 0.0 109.225 -179.84 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.86 140.67 58.25 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.004 -1.06 . . . . 0.0 109.427 -179.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.09 -32.22 72.75 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.338 -0.851 . . . . 0.0 109.381 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -91.03 9.82 29.2 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.335 -0.853 . . . . 0.0 109.56 179.979 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 55.5 t0 -52.9 -34.11 53.36 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.235 -0.916 . . . . 0.0 109.626 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.6 m -126.06 158.9 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.463 -0.773 . . . . 0.0 109.604 -179.7 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.492 ' C ' HD12 ' A' ' 61' ' ' LEU . 95.5 mt-10 -93.16 150.59 20.4 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.285 -0.885 . . . . 0.0 109.303 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.86 ' N ' HD12 ' A' ' 61' ' ' LEU . 4.4 mp -98.12 132.24 43.81 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.183 -0.948 . . . . 0.0 109.801 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -166.77 143.51 3.94 Favored Pre-proline 0 N--CA 1.488 1.465 0 O-C-N 121.21 -0.931 . . . . 0.0 109.058 179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -62.81 -24.92 74.54 Favored 'Trans proline' 0 N--CA 1.492 1.44 0 C-N-CA 122.146 1.898 . . . . 0.0 112.104 -179.926 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -65.27 -32.52 74.22 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.378 -0.826 . . . . 0.0 110.236 -179.644 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 85.7 t60 -72.89 -26.67 61.52 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.322 -0.861 . . . . 0.0 111.318 -178.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 99.1 m-85 -97.85 11.04 38.66 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.77 -1.206 . . . . 0.0 110.953 -178.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 32.2 mmt180 -58.56 -34.29 70.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 120.936 -1.102 . . . . 0.0 109.952 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.6 p -145.78 151.0 37.26 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.031 -1.043 . . . . 0.0 110.018 -179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.692 HG12 HD11 ' A' ' 30' ' ' LEU . 82.4 mt -66.27 -36.74 78.11 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.377 0 O-C-N 121.405 -0.809 . . . . 0.0 109.846 179.725 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.0 ttp180 -60.69 -39.09 87.2 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.346 -0.846 . . . . 0.0 110.574 -179.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 19.6 m -58.28 -42.41 86.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 120.984 -1.073 . . . . 0.0 109.927 -179.434 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 79.4 mt -68.03 -39.24 81.16 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.49 ' CG ' ' CD1' ' A' ' 7' ' ' ILE . 56.3 t0 -59.13 -41.21 87.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.347 -0.846 . . . . 0.0 110.474 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.09 -43.11 88.24 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.123 -0.986 . . . . 0.0 110.212 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 59.9 t80 -62.7 -48.67 78.26 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.179 -0.951 . . . . 0.0 109.596 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.608 HG12 ' O ' ' A' ' 80' ' ' THR . 71.8 t -65.37 -46.33 90.58 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.235 -0.916 . . . . 0.0 109.773 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.451 HG23 ' OD2' ' A' ' 73' ' ' ASP . 41.4 t -59.62 -39.55 79.8 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.332 0 O-C-N 121.068 -1.02 . . . . 0.0 109.534 179.832 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.82 -32.63 66.24 Favored Glycine 0 N--CA 1.487 2.069 0 N-CA-C 110.19 -1.164 . . . . 0.0 110.19 -179.65 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.8 -49.61 3.47 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.103 -1.234 . . . . 0.0 110.479 -179.354 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.608 ' O ' HG12 ' A' ' 76' ' ' VAL . 7.1 t -158.52 149.92 20.91 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.209 -0.932 . . . . 0.0 109.547 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.872 HG21 ' OE1' ' A' ' 2' ' ' GLN . 10.1 t -125.97 89.83 51.55 Favored Pre-proline 0 N--CA 1.489 1.488 0 O-C-N 121.292 -0.88 . . . . 0.0 109.182 179.83 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.413 ' HB3' ' CZ ' ' A' ' 52' ' ' PHE . 88.8 Cg_endo -92.14 109.52 0.26 Allowed 'Trans proline' 0 C--N 1.311 -1.425 0 C-N-CA 123.232 2.621 . . . . 0.0 112.955 -179.361 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -78.43 133.71 12.03 Favored 'Trans proline' 0 C--N 1.314 -1.276 0 C-N-CA 121.994 1.796 . . . . 0.0 111.715 179.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.571 ' H ' HG11 ' A' ' 6' ' ' VAL . 38.9 t -124.88 132.37 71.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 121.335 -0.853 . . . . 0.0 109.601 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -62.75 -37.13 85.41 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.278 -0.889 . . . . 0.0 109.377 179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.417 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -152.33 152.69 32.41 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.272 -0.892 . . . . 0.0 109.526 179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 57.3 tttm -58.67 -37.75 76.71 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.226 -0.921 . . . . 0.0 109.483 179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.6 mt -94.79 142.18 27.76 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.254 -0.904 . . . . 0.0 109.54 -179.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.565 ' CD ' HH22 ' A' ' 51' ' ' ARG . 94.2 mm-40 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 118.037 -0.982 . . . . 0.0 109.494 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.407 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 86.9 mmm . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.315 -0.624 . . . . 0.0 109.315 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.424 HE21 ' CD2' ' A' ' 3' ' ' HIS . 60.2 tp60 -98.99 119.57 38.0 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.361 -0.837 . . . . 0.0 109.229 179.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.424 ' CD2' HE21 ' A' ' 2' ' ' GLN . 37.4 m170 46.85 30.25 1.17 Allowed 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.241 -0.912 . . . . 0.0 109.195 -179.876 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.407 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.93 -35.8 79.47 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.299 -0.876 . . . . 0.0 109.697 -179.712 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.8 m -59.9 -38.55 82.61 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.228 -0.92 . . . . 0.0 109.859 -179.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.576 HG11 ' H ' ' A' ' 84' ' ' VAL . 72.7 t -64.28 -41.06 91.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.193 -0.942 . . . . 0.0 109.169 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.415 ' CD1' ' OD2' ' A' ' 73' ' ' ASP . 90.6 mt -59.53 -43.52 91.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.338 -0.851 . . . . 0.0 109.739 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.738 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.38 -47.74 80.77 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.21 -0.931 . . . . 0.0 109.158 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.432 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 0.9 OUTLIER -69.69 -33.14 72.13 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.357 -0.839 . . . . 0.0 109.591 179.611 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 52.7 t80 -59.86 -53.12 61.57 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.167 -0.958 . . . . 0.0 110.19 -179.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.586 ' O ' ' CE1' ' A' ' 15' ' ' PHE . 34.6 m -74.41 -40.67 49.54 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.147 -0.97 . . . . 0.0 110.193 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.738 HG23 ' O ' ' A' ' 8' ' ' ALA . 64.2 t -64.91 -36.35 77.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.354 -0.841 . . . . 0.0 110.588 -179.228 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -56.46 -33.94 66.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 109.931 -179.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.3 tt0 -65.68 -32.18 73.59 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.269 -0.894 . . . . 0.0 109.871 -179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.588 ' CE2' ' OD1' ' A' ' 33' ' ' ASN . 7.8 p90 -138.27 45.82 2.07 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.145 -0.972 . . . . 0.0 109.931 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.869 HD23 ' O ' ' A' ' 16' ' ' LEU . 0.6 OUTLIER -80.36 135.74 53.53 Favored Pre-proline 0 N--CA 1.488 1.459 0 O-C-N 120.951 -1.093 . . . . 0.0 109.946 -179.823 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -77.58 -150.38 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.37 0 C-N-CA 122.105 1.87 . . . . 0.0 110.264 178.431 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.558 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.8 p30 -79.52 12.09 2.69 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 120.8 -1.187 . . . . 0.0 108.708 179.138 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.558 HG23 ' OD2' ' A' ' 18' ' ' ASP . 25.6 t -113.64 136.64 49.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.549 -0.719 . . . . 0.0 109.818 -179.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.89 139.58 82.95 Favored Pre-proline 0 N--CA 1.488 1.444 0 O-C-N 121.152 -0.967 . . . . 0.0 108.751 179.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -48.52 -31.74 19.07 Favored 'Trans proline' 0 N--CA 1.493 1.489 0 C-N-CA 121.699 1.599 . . . . 0.0 111.966 179.647 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.17 -26.6 67.49 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.301 -0.874 . . . . 0.0 109.395 179.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -103.34 4.8 36.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.404 -0.81 . . . . 0.0 109.241 -179.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -99.22 144.01 12.57 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.326 -0.859 . . . . 0.0 108.695 179.745 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.559 ' C ' ' H ' ' A' ' 27' ' ' ASP . 57.3 t0 -71.82 95.06 1.47 Allowed 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.034 -1.041 . . . . 0.0 109.357 -179.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.48 ' O ' HD12 ' A' ' 69' ' ' ILE . 18.9 m -62.25 6.66 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.342 -0.849 . . . . 0.0 109.588 179.92 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.559 ' H ' ' C ' ' A' ' 25' ' ' ASP . 87.6 m-20 -90.77 12.08 20.34 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.184 -0.948 . . . . 0.0 109.017 179.605 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 34.6 tp -84.53 133.87 34.44 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.433 -0.792 . . . . 0.0 109.484 -179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.8 m-20 -65.21 122.34 16.87 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.271 -0.893 . . . . 0.0 108.824 179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.74 HD11 HG12 ' A' ' 69' ' ' ILE . 67.3 mt -64.92 -6.28 8.04 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.249 -0.907 . . . . 0.0 109.618 -179.4 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 73.0 t -50.91 -45.06 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.067 -1.021 . . . . 0.0 108.904 -179.525 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -56.7 -35.99 69.14 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.511 -1.292 . . . . 0.0 107.511 178.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.611 ' O ' ' N ' ' A' ' 35' ' ' VAL . 2.3 m120 -86.02 15.24 5.19 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.412 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -41.94 -16.88 0.02 OUTLIER Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 -179.22 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.611 ' N ' ' O ' ' A' ' 33' ' ' ASN . 51.3 t -51.76 -38.05 21.6 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 120.867 -1.372 . . . . 0.0 108.267 179.126 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.616 ' O ' ' N ' ' A' ' 41' ' ' LEU . 6.3 tt -71.09 -25.3 25.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.538 -0.726 . . . . 0.0 110.324 -179.904 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.423 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 85.7 m-20 -59.68 -35.65 74.89 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.258 -0.901 . . . . 0.0 111.105 -178.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.557 ' N ' ' O1P' ' A' ' 101' ' ' PN7 . 0.5 OUTLIER -106.31 -64.22 1.19 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.13 -0.981 . . . . 0.0 111.556 -178.419 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.55 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 3.0 mm? -69.99 -52.09 27.12 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.057 -1.027 . . . . 0.0 111.301 -178.056 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -69.3 -36.75 79.41 Favored Glycine 0 N--CA 1.49 2.259 0 C-N-CA 119.806 -1.188 . . . . 0.0 110.249 -179.295 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.616 ' N ' ' O ' ' A' ' 36' ' ' ILE . 6.8 tp -58.43 -47.83 82.67 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.335 -1.097 . . . . 0.0 109.582 -179.28 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 93.5 mt -61.38 -42.62 99.01 Favored 'General case' 0 C--N 1.297 -1.693 0 O-C-N 121.109 -0.995 . . . . 0.0 109.77 -179.887 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -63.63 -39.66 94.92 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.134 -0.979 . . . . 0.0 109.402 179.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.478 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 69.2 t -70.22 -49.7 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.268 -0.895 . . . . 0.0 110.554 -179.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 35.4 mm -62.17 -40.48 87.75 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 120.959 -1.088 . . . . 0.0 109.948 -179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.18 -45.99 75.32 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.081 -1.012 . . . . 0.0 110.039 -179.67 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.6 OUTLIER -77.61 -47.05 20.31 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.145 -0.972 . . . . 0.0 109.635 179.768 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.478 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 31.4 tp -56.75 -39.2 73.57 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.433 -0.792 . . . . 0.0 109.466 -179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.611 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.0 tm-20 -61.53 -42.74 99.28 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.176 -0.953 . . . . 0.0 109.466 179.667 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' OE2' ' A' ' 49' ' ' GLU . 20.9 t70 -64.33 -39.45 93.93 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.071 -1.018 . . . . 0.0 109.71 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.0 ttt180 -66.19 -45.53 80.48 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.375 -0.828 . . . . 0.0 111.549 -178.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.418 ' CZ ' ' HB3' ' A' ' 82' ' ' PRO . 53.5 m-85 -111.17 -1.49 16.15 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.98 -1.075 . . . . 0.0 111.151 -178.76 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.611 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.67 38.48 67.42 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.804 -1.319 . . . . 0.0 109.804 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.54 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 72.5 mt -88.44 145.38 7.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.103 -1.233 . . . . 0.0 109.37 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.96 122.9 16.61 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.978 -1.076 . . . . 0.0 109.703 -179.109 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -77.08 -19.72 56.69 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.468 -0.77 . . . . 0.0 109.741 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 89.9 m-20 -82.03 11.06 5.51 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.352 -0.842 . . . . 0.0 110.165 -179.261 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.3 t0 -78.94 112.37 16.05 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.03 -1.044 . . . . 0.0 109.527 -179.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 17.1 m -116.58 18.13 7.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.56 -0.713 . . . . 0.0 109.313 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -55.7 -28.27 54.76 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.201 -0.937 . . . . 0.0 109.827 -179.688 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.676 HD21 ' CZ ' ' A' ' 75' ' ' PHE . 64.0 mt -77.21 142.09 39.74 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.092 -1.005 . . . . 0.0 109.905 -179.492 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -120.92 164.78 21.46 Favored Pre-proline 0 N--CA 1.487 1.407 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -51.98 -33.13 51.0 Favored 'Trans proline' 0 C--N 1.309 -1.551 0 C-N-CA 122.349 2.033 . . . . 0.0 111.54 179.819 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -66.72 -27.42 67.61 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.512 -0.742 . . . . 0.0 109.251 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 19.6 t-80 -67.63 -26.62 66.33 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.377 -0.827 . . . . 0.0 109.768 -179.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -90.24 11.91 19.72 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.208 -0.933 . . . . 0.0 109.282 179.871 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 14.5 tpt180 -53.82 -37.64 63.76 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.381 -0.825 . . . . 0.0 109.792 -179.718 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 84.4 p -146.14 157.17 43.83 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.044 -1.035 . . . . 0.0 110.036 -179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.74 HG12 HD11 ' A' ' 30' ' ' LEU . 84.8 mt -64.36 -36.82 78.3 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.336 -0.853 . . . . 0.0 110.076 179.948 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 43.8 ttp180 -60.57 -40.55 92.11 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.314 -0.866 . . . . 0.0 110.381 -179.018 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.1 p -62.55 -38.64 90.83 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.012 -1.055 . . . . 0.0 109.71 -179.596 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 78.6 mt -68.23 -39.35 80.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.827 179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.444 ' OD2' HG23 ' A' ' 77' ' ' VAL . 59.4 t0 -59.43 -41.14 88.88 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.363 -0.836 . . . . 0.0 110.334 -179.363 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -43.29 86.55 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.098 -1.001 . . . . 0.0 110.512 -179.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.676 ' CZ ' HD21 ' A' ' 61' ' ' LEU . 67.3 t80 -61.96 -49.3 76.65 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.081 -1.012 . . . . 0.0 109.775 -179.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.528 HG12 ' O ' ' A' ' 80' ' ' THR . 68.4 t -66.52 -44.74 90.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.268 -0.895 . . . . 0.0 109.825 -179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.444 HG23 ' OD2' ' A' ' 73' ' ' ASP . 47.3 t -63.03 -39.53 85.57 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.337 0 O-C-N 121.011 -1.056 . . . . 0.0 109.894 179.965 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.7 -33.97 69.05 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 110.186 -1.166 . . . . 0.0 110.186 -179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -104.39 -48.79 3.73 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.122 -1.222 . . . . 0.0 110.644 -179.283 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.528 ' O ' HG12 ' A' ' 76' ' ' VAL . 60.2 m -158.36 137.86 11.84 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.125 -0.985 . . . . 0.0 109.839 -179.534 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.795 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -119.26 89.39 39.75 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.325 -0.859 . . . . 0.0 109.1 179.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.418 ' HB3' ' CZ ' ' A' ' 52' ' ' PHE . 64.2 Cg_endo -94.85 111.71 0.16 Allowed 'Trans proline' 0 C--N 1.31 -1.453 0 C-N-CA 123.304 2.669 . . . . 0.0 112.634 -179.79 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -78.07 134.35 13.0 Favored 'Trans proline' 0 C--N 1.314 -1.284 0 C-N-CA 121.987 1.792 . . . . 0.0 111.8 179.599 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.576 ' H ' HG11 ' A' ' 6' ' ' VAL . 41.9 t -124.92 133.09 70.37 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.297 -0.877 . . . . 0.0 109.595 -179.998 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -61.78 -37.73 85.42 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.219 -0.926 . . . . 0.0 109.435 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.423 ' H ' HG12 ' A' ' 84' ' ' VAL . . . -152.42 150.69 29.93 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.258 -0.901 . . . . 0.0 109.37 179.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 23.1 tttm -59.82 -37.07 78.15 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.255 -0.903 . . . . 0.0 109.496 179.982 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.0 mt -91.81 142.15 27.89 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.285 -0.884 . . . . 0.0 109.424 -179.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 118.016 -0.992 . . . . 0.0 109.488 179.892 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.557 ' O1P' ' N ' ' A' ' 38' ' ' SER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.5 mtm . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 121.391 0.615 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.492 ' OE1' ' OG1' ' A' ' 81' ' ' THR . 93.9 mt-30 -58.9 -36.61 74.98 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.317 -0.864 . . . . 0.0 109.062 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.564 ' CE1' HG21 ' A' ' 6' ' ' VAL . 0.0 OUTLIER -147.59 29.86 0.92 Allowed 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 179.734 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.486 ' HA ' HD12 ' A' ' 7' ' ' ILE . . . -60.38 -32.5 71.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.427 -0.796 . . . . 0.0 110.008 -179.638 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.0 p -58.97 -39.94 83.25 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.03 -1.044 . . . . 0.0 109.563 -179.492 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.564 HG21 ' CE1' ' A' ' 3' ' ' HIS . 70.0 t -68.07 -39.07 80.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.16 -0.963 . . . . 0.0 108.44 178.982 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.593 ' O ' HG23 ' A' ' 11' ' ' VAL . 82.2 mt -61.26 -50.48 80.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 O-C-N 121.502 -0.749 . . . . 0.0 109.151 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.739 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -64.36 -47.36 79.61 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.346 -0.846 . . . . 0.0 109.183 179.388 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -44.25 96.12 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.483 -0.76 . . . . 0.0 109.227 179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.592 ' CZ ' ' CE2' ' A' ' 47' ' ' TRP . 62.5 t80 -68.34 -48.85 63.73 Favored 'General case' 0 C--N 1.299 -1.606 0 CA-C-O 121.626 0.727 . . . . 0.0 109.452 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.701 HG13 ' CD1' ' A' ' 36' ' ' ILE . 93.7 t -67.02 -45.41 87.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.601 -0.687 . . . . 0.0 109.901 -179.576 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.739 HG23 ' O ' ' A' ' 8' ' ' ALA . 98.4 t -63.7 -37.74 80.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.309 -0.869 . . . . 0.0 109.272 -179.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -56.5 -30.59 63.17 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.462 -0.774 . . . . 0.0 109.789 179.941 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.93 -32.21 73.82 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.201 -0.937 . . . . 0.0 109.357 -179.843 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.453 ' HE1' HD12 ' A' ' 36' ' ' ILE . 6.9 p90 -147.01 52.86 1.08 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.322 -0.861 . . . . 0.0 109.112 179.203 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.7 pt? -80.3 136.58 52.94 Favored Pre-proline 0 N--CA 1.486 1.374 0 O-C-N 121.207 -0.933 . . . . 0.0 110.187 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_endo -72.67 -152.96 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.433 0 C-N-CA 121.815 1.676 . . . . 0.0 110.388 178.741 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -78.26 9.75 3.58 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 120.908 -1.12 . . . . 0.0 108.709 179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 41.7 t -113.85 136.16 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.498 -0.751 . . . . 0.0 109.883 -179.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -69.92 142.48 90.76 Favored Pre-proline 0 N--CA 1.489 1.481 0 O-C-N 121.19 -0.944 . . . . 0.0 108.574 179.174 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -48.67 -32.4 21.53 Favored 'Trans proline' 0 N--CA 1.491 1.346 0 C-N-CA 121.593 1.529 . . . . 0.0 111.638 179.805 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.81 -25.27 65.49 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.372 -0.83 . . . . 0.0 109.395 179.513 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 89.0 m-20 -105.01 6.42 33.4 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 109.26 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -96.6 143.4 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.282 -0.886 . . . . 0.0 108.762 179.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.553 ' C ' ' H ' ' A' ' 27' ' ' ASP . 51.6 t0 -72.39 92.33 1.42 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.126 -0.984 . . . . 0.0 109.365 -179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.688 HG21 ' HE3' ' A' ' 87' ' ' LYS . 18.3 m -62.79 6.23 0.11 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.893 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.553 ' H ' ' C ' ' A' ' 25' ' ' ASP . 86.9 m-20 -95.9 9.7 39.74 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.218 -0.926 . . . . 0.0 108.723 179.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 11.1 tp -90.22 135.6 33.57 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.487 -0.758 . . . . 0.0 109.561 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.585 ' OD2' ' NH2' ' A' ' 67' ' ' ARG . 90.0 m-20 -63.98 121.89 15.19 Favored 'General case' 0 C--N 1.302 -1.498 0 N-CA-C 108.266 -1.013 . . . . 0.0 108.266 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.41 ' HA ' HD22 ' A' ' 33' ' ' ASN . 0.6 OUTLIER -75.81 7.89 3.52 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.286 -0.884 . . . . 0.0 110.046 -178.954 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.0 t -53.43 -42.79 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.063 -1.023 . . . . 0.0 108.636 179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -55.74 -35.5 66.24 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 178.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.627 ' O ' ' N ' ' A' ' 35' ' ' VAL . 64.4 m-80 -85.19 15.12 4.44 Favored 'General case' 0 N--CA 1.487 1.391 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 178.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 33' ' ' ASN . . . -42.39 -15.45 0.02 OUTLIER Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 -179.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.627 ' N ' ' O ' ' A' ' 33' ' ' ASN . 49.7 t -51.73 -37.33 20.16 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.014 -1.286 . . . . 0.0 108.547 179.365 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.701 ' CD1' HG13 ' A' ' 11' ' ' VAL . 2.5 tt -70.81 -25.24 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.454 -0.779 . . . . 0.0 110.426 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 -58.1 -34.33 70.07 Favored 'General case' 0 C--N 1.296 -1.72 0 O-C-N 121.295 -0.878 . . . . 0.0 111.009 -178.322 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.92 -64.29 1.17 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.984 -1.073 . . . . 0.0 111.575 -178.479 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.531 ' N ' HD22 ' A' ' 39' ' ' LEU . 4.2 mm? -72.37 -52.5 15.8 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.976 -1.078 . . . . 0.0 111.211 -178.091 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.522 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -66.07 -36.02 91.37 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 110.033 -1.227 . . . . 0.0 110.033 -179.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.601 ' N ' ' O ' ' A' ' 36' ' ' ILE . 9.3 tp -57.71 -43.95 85.59 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.365 -1.079 . . . . 0.0 109.208 -179.171 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.411 HD23 ' HA ' ' A' ' 42' ' ' LEU . 94.2 mt -63.64 -41.82 98.21 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.242 -0.911 . . . . 0.0 108.98 179.259 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 95.5 mttt -64.26 -36.95 85.78 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.413 -0.804 . . . . 0.0 109.53 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 40' ' ' GLY . 74.8 t -62.66 -45.57 98.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.379 -0.825 . . . . 0.0 110.22 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 36.8 mm -61.35 -44.24 98.12 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.418 0 O-C-N 121.146 -0.971 . . . . 0.0 109.829 -179.81 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.0 -43.78 91.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.242 -0.911 . . . . 0.0 109.766 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.592 ' CE2' ' CZ ' ' A' ' 10' ' ' PHE . 1.7 t90 -73.39 -38.92 65.46 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.381 -0.825 . . . . 0.0 109.796 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 28.5 tp -59.69 -43.34 94.07 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.2 -0.938 . . . . 0.0 109.917 -179.607 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.577 ' O ' ' N ' ' A' ' 53' ' ' GLY . 59.3 tt0 -65.16 -36.09 83.12 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.26 -0.9 . . . . 0.0 109.951 179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -60.59 -38.99 86.47 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.984 -1.072 . . . . 0.0 110.125 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 32.7 mtp180 -74.67 -44.65 49.22 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.143 -0.973 . . . . 0.0 112.079 -178.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 96.5 m-85 -108.11 -7.17 16.14 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.765 -1.209 . . . . 0.0 111.354 -178.088 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.577 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 68.78 32.18 73.8 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 -179.921 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 89.1 mt -91.22 152.42 3.36 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.257 -1.143 . . . . 0.0 109.835 -179.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -60.1 150.48 29.44 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.075 -1.016 . . . . 0.0 109.008 -179.677 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -55.85 -40.27 72.61 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.251 -0.906 . . . . 0.0 109.969 -178.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 85.7 m-20 50.79 49.76 20.36 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.11 -0.994 . . . . 0.0 109.205 179.639 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 60.8 t0 -74.62 116.03 14.85 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.198 -0.939 . . . . 0.0 109.909 -179.319 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.466 HG12 ' H ' ' A' ' 61' ' ' LEU . 27.3 t -124.91 141.68 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 179.758 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.486 ' O ' ' O ' ' A' ' 61' ' ' LEU . 19.8 pt-20 -60.5 -31.95 70.98 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.085 -1.009 . . . . 0.0 110.466 -179.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.486 ' O ' ' O ' ' A' ' 60' ' ' GLU . 60.7 mt 44.04 -170.5 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.055 -1.028 . . . . 0.0 109.642 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -134.23 162.25 58.81 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.344 -0.848 . . . . 0.0 109.409 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_endo -60.83 -26.81 83.76 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 C-N-CA 122.756 2.304 . . . . 0.0 112.17 179.942 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -61.04 -31.53 71.17 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.39 -0.818 . . . . 0.0 109.909 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . . . . . . . . . 81.8 t60 -68.07 -26.46 65.85 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.184 -0.948 . . . . 0.0 110.205 -179.512 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.432 ' CZ ' HD13 ' A' ' 41' ' ' LEU . 94.1 m-85 -97.41 10.17 40.41 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.109 -0.994 . . . . 0.0 109.763 -179.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.585 ' NH2' ' OD2' ' A' ' 29' ' ' ASP . 34.2 tpt85 -55.61 -38.32 69.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.076 -1.015 . . . . 0.0 109.879 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 96.8 p -137.75 153.99 49.66 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.095 -1.003 . . . . 0.0 110.145 -179.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 85.4 mt -62.68 -36.58 75.92 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.307 0 O-C-N 121.264 -0.898 . . . . 0.0 110.006 179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 81.7 mtm180 -60.76 -36.78 79.8 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.235 -0.916 . . . . 0.0 110.251 -179.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 90.5 p -61.37 -36.16 79.45 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.022 -1.049 . . . . 0.0 109.449 -179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.6 mt -63.97 -38.96 83.75 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.238 -0.914 . . . . 0.0 109.097 179.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.712 ' O ' HG23 ' A' ' 77' ' ' VAL . 52.3 t0 -57.51 -36.98 72.26 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.46 -0.775 . . . . 0.0 109.352 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -61.38 -43.53 98.71 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.224 -0.923 . . . . 0.0 109.222 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.4 t80 -65.04 -46.95 79.14 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.259 -0.9 . . . . 0.0 109.207 179.514 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 53.2 t -65.24 -40.58 89.11 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.319 0 O-C-N 121.45 -0.781 . . . . 0.0 109.712 179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.712 HG23 ' O ' ' A' ' 73' ' ' ASP . 54.0 t -58.99 -42.46 86.25 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.243 -0.91 . . . . 0.0 109.684 -179.784 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -62.83 -35.02 91.4 Favored Glycine 0 N--CA 1.492 2.396 0 C-N-CA 120.222 -0.989 . . . . 0.0 110.645 -179.629 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -86.29 -48.02 8.89 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.899 -1.353 . . . . 0.0 109.853 -179.279 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 7.2 t -138.54 151.03 46.97 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 179.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.759 HG23 ' O ' ' A' ' 81' ' ' THR . 10.0 t -134.81 89.74 24.37 Favored Pre-proline 0 N--CA 1.487 1.414 0 O-C-N 121.253 -0.904 . . . . 0.0 110.139 -179.314 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.452 ' CB ' ' CD ' ' A' ' 83' ' ' PRO . 17.1 Cg_exo -63.63 -175.2 0.25 Allowed 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.715 2.276 . . . . 0.0 111.6 179.222 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.452 ' CD ' ' CB ' ' A' ' 82' ' ' PRO . 35.6 Cg_exo -58.4 150.59 66.77 Favored 'Trans proline' 0 C--N 1.309 -1.531 0 C-N-CA 122.423 2.082 . . . . 0.0 111.505 179.748 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.519 HG23 ' O ' ' A' ' 84' ' ' VAL . 5.6 m -89.35 127.61 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.042 -1.036 . . . . 0.0 110.044 -179.139 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -139.08 142.82 38.14 Favored 'General case' 0 N--CA 1.487 1.386 0 O-C-N 121.49 -0.756 . . . . 0.0 109.151 179.666 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -62.75 142.07 58.32 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.107 -0.995 . . . . 0.0 109.432 179.957 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.688 ' HE3' HG21 ' A' ' 26' ' ' VAL . 49.3 tttp -81.49 138.45 35.49 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.186 -0.946 . . . . 0.0 109.265 179.946 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 71.6 mt -57.06 -36.47 70.57 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.249 -0.907 . . . . 0.0 109.602 -179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 95.2 mt-30 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 118.034 -0.984 . . . . 0.0 109.535 179.89 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.455 ' O2P' ' O3 ' ' A' ' 101' ' ' PN7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 91.6 mtp . . . . . 0 N--CA 1.491 1.575 0 CA-C-O 121.302 0.573 . . . . 0.0 109.931 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.484 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 98.5 mm-40 -87.07 123.76 32.49 Favored 'General case' 0 N--CA 1.489 1.493 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.596 ' CE1' ' O ' ' A' ' 82' ' ' PRO . 22.3 m-70 54.54 15.78 1.14 Allowed 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.107 -0.996 . . . . 0.0 108.654 -179.386 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.401 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -64.19 -39.81 94.76 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.459 -0.776 . . . . 0.0 110.196 -179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.1 m -60.72 -39.24 87.89 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.177 -0.952 . . . . 0.0 110.157 -179.343 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.6 t -64.77 -37.69 80.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.158 -0.964 . . . . 0.0 109.307 179.955 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.402 ' O ' HG12 ' A' ' 11' ' ' VAL . 90.4 mt -63.98 -36.73 77.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.355 -0.841 . . . . 0.0 110.54 -179.645 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.734 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.47 -51.09 67.08 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.959 -1.088 . . . . 0.0 110.049 -179.422 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.41 ' CD ' ' C ' ' A' ' 9' ' ' GLN . 3.5 pp0? -70.92 -36.72 72.8 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.101 -0.999 . . . . 0.0 109.473 179.508 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.423 ' CZ ' ' NH2' ' A' ' 51' ' ' ARG . 59.6 t80 -65.74 -51.32 60.17 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.345 -0.847 . . . . 0.0 109.97 -179.611 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.484 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.5 p -68.33 -41.87 83.92 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.221 -0.925 . . . . 0.0 109.589 -179.847 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.734 HG23 ' O ' ' A' ' 8' ' ' ALA . 87.0 t -64.61 -39.32 85.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.215 -0.928 . . . . 0.0 109.521 179.855 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 84.6 tt0 -55.95 -28.16 55.75 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.392 -0.817 . . . . 0.0 109.731 -179.763 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -65.09 -29.16 70.01 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.263 -0.898 . . . . 0.0 108.833 179.911 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.617 ' CD1' ' O ' ' A' ' 15' ' ' PHE . 22.8 p90 -151.0 48.99 0.85 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.376 -0.827 . . . . 0.0 109.076 179.563 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.485 ' N ' ' O ' ' A' ' 12' ' ' VAL . 1.8 pt? -79.76 137.12 54.52 Favored Pre-proline 0 N--CA 1.487 1.4 0 O-C-N 120.975 -1.078 . . . . 0.0 110.343 -179.217 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -72.83 -152.93 0.04 OUTLIER 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 121.974 1.782 . . . . 0.0 110.51 178.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.544 ' OD2' HG23 ' A' ' 19' ' ' VAL . 53.9 p30 -81.05 13.29 2.82 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 120.923 -1.111 . . . . 0.0 108.803 179.242 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.544 HG23 ' OD2' ' A' ' 18' ' ' ASP . 38.6 t -113.43 136.65 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.609 -0.682 . . . . 0.0 109.91 -179.35 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.03 140.61 73.86 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.26 -0.9 . . . . 0.0 109.039 179.354 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.584 ' O ' ' NZ ' ' A' ' 87' ' ' LYS . 52.3 Cg_exo -48.41 -31.75 18.6 Favored 'Trans proline' 0 N--CA 1.492 1.396 0 C-N-CA 121.795 1.664 . . . . 0.0 111.575 179.307 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.37 -21.87 65.6 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.519 -0.738 . . . . 0.0 109.412 179.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -97.6 1.61 48.99 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.421 -0.8 . . . . 0.0 109.119 -179.923 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 43.2 t -107.09 137.54 37.51 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.65 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.577 ' C ' ' H ' ' A' ' 27' ' ' ASP . 60.0 t0 -70.56 99.87 1.72 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.129 -0.982 . . . . 0.0 109.319 -179.505 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.69 ' CG1' ' HZ2' ' A' ' 87' ' ' LYS . 12.6 m -60.07 5.84 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.379 -0.826 . . . . 0.0 109.682 -179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.577 ' H ' ' C ' ' A' ' 25' ' ' ASP . 88.7 m-20 -96.4 9.19 42.03 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.166 -0.959 . . . . 0.0 108.748 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 10.3 tp -90.66 137.94 31.96 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.561 -0.712 . . . . 0.0 109.52 -179.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . 0.411 ' C ' ' H ' ' A' ' 31' ' ' VAL . 92.0 m-20 -65.14 121.51 14.92 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 179.162 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.519 ' H ' HD23 ' A' ' 30' ' ' LEU . 0.4 OUTLIER -71.07 8.51 0.93 Allowed 'General case' 0 C--N 1.301 -1.541 0 O-C-N 121.195 -0.94 . . . . 0.0 109.493 -179.231 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.459 ' O ' ' N ' ' A' ' 34' ' ' GLY . 57.0 t -56.39 -41.81 72.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.164 -0.96 . . . . 0.0 108.8 179.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.2 t0 -55.51 -34.09 64.33 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.312 -1.366 . . . . 0.0 107.312 178.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.724 ' N ' HD22 ' A' ' 33' ' ' ASN . 0.8 OUTLIER -84.02 14.45 4.14 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 178.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 31' ' ' VAL . . . -42.46 -15.91 0.02 OUTLIER Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.134 -1.187 . . . . 0.0 110.134 -179.116 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.598 ' N ' ' O ' ' A' ' 33' ' ' ASN . 55.8 t -52.09 -39.29 26.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 O-C-N 120.921 -1.341 . . . . 0.0 108.324 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.636 ' O ' ' N ' ' A' ' 41' ' ' LEU . 5.7 tt -71.14 -25.2 25.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.605 -0.685 . . . . 0.0 110.118 179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.42 ' O ' ' CB ' ' A' ' 41' ' ' LEU . 84.6 m-20 -62.12 -32.1 72.64 Favored 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 110.797 -178.465 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 4.5 m -105.44 -64.93 1.09 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.004 -1.06 . . . . 0.0 111.306 -178.682 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 7.0 tt -71.71 -52.15 19.25 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.097 -1.002 . . . . 0.0 111.19 -178.22 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.643 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -68.1 -36.69 86.12 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -179.246 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.636 ' N ' ' O ' ' A' ' 36' ' ' ILE . 5.5 tp -58.53 -43.36 89.19 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.348 -1.089 . . . . 0.0 109.881 -179.051 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.416 HD23 ' HA ' ' A' ' 42' ' ' LEU . 93.9 mt -67.53 -44.11 79.15 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 110.111 -179.639 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 69.4 mttm -65.08 -35.03 79.83 Favored 'General case' 0 C--N 1.303 -1.443 0 O-C-N 121.177 -0.952 . . . . 0.0 110.227 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.643 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.7 t -63.21 -44.99 99.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.293 -0.879 . . . . 0.0 110.979 -178.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.06 -43.85 93.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 120.655 -1.278 . . . . 0.0 110.062 -179.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.29 -45.32 76.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.109 -0.994 . . . . 0.0 110.396 -179.453 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.485 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 1.0 OUTLIER -76.6 -44.63 33.53 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.167 -0.958 . . . . 0.0 109.957 -179.709 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 10.5 tp -57.02 -39.0 73.94 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.337 -0.852 . . . . 0.0 109.207 -179.947 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.602 ' O ' ' N ' ' A' ' 53' ' ' GLY . 12.0 tt0 -60.87 -43.27 98.63 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.204 -0.935 . . . . 0.0 109.25 179.58 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -66.09 -40.04 90.5 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.199 -0.938 . . . . 0.0 110.025 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.423 ' NH2' ' CZ ' ' A' ' 10' ' ' PHE . 73.8 ttt180 -63.48 -45.94 88.44 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.252 -0.905 . . . . 0.0 111.177 -178.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -106.86 -5.3 18.42 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.002 -1.062 . . . . 0.0 110.63 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.602 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 69.63 34.04 72.44 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 -179.747 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 71.9 mt -98.88 144.32 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.301 -1.117 . . . . 0.0 109.633 -179.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -61.45 148.57 41.37 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.136 -0.978 . . . . 0.0 109.586 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.48 -29.8 68.08 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.442 -0.786 . . . . 0.0 109.693 -179.563 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.96 ' O ' HG13 ' A' ' 59' ' ' VAL . 85.3 m-20 54.62 49.03 19.01 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.297 -0.877 . . . . 0.0 109.283 -179.878 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.497 ' OD2' ' O ' ' A' ' 58' ' ' ASP . 45.1 p30 -39.25 91.8 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.498 -0.751 . . . . 0.0 110.254 -179.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.96 HG13 ' O ' ' A' ' 57' ' ' ASP . 29.4 m -128.43 158.05 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.439 -0.788 . . . . 0.0 108.981 179.564 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.482 ' OE1' ' O8 ' ' A' ' 101' ' ' PN7 . 84.3 tt0 -100.35 129.96 46.39 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.126 -0.984 . . . . 0.0 109.729 -179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 4.9 mp -109.3 140.92 42.35 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.448 -0.782 . . . . 0.0 109.421 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -86.83 156.13 55.57 Favored Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.23 -0.919 . . . . 0.0 109.517 -179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -60.98 -26.59 83.44 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 C-N-CA 122.666 2.244 . . . . 0.0 112.031 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -63.35 -30.87 71.93 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.328 -0.857 . . . . 0.0 109.715 179.953 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.408 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 85.0 t60 -67.74 -26.79 66.31 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.304 -0.872 . . . . 0.0 109.662 -179.757 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 85.0 m-85 -93.65 9.22 37.83 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.179 -0.951 . . . . 0.0 109.358 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.402 ' O ' ' CB ' ' A' ' 29' ' ' ASP . 15.2 tpt180 -54.91 -39.59 68.96 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.237 -0.915 . . . . 0.0 109.807 -179.677 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -141.96 153.98 44.72 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.017 -1.052 . . . . 0.0 110.098 -179.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 82.2 mt -59.09 -36.66 63.73 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.34 0 O-C-N 121.365 -0.834 . . . . 0.0 109.838 179.855 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 51.9 ttp180 -60.28 -39.13 85.77 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.268 -0.895 . . . . 0.0 110.234 -179.211 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 23.7 t -58.3 -44.08 88.37 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.016 -1.053 . . . . 0.0 109.619 -179.657 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.494 HD11 HD11 ' A' ' 30' ' ' LEU . 80.0 mt -62.96 -38.74 82.77 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.177 -0.952 . . . . 0.0 109.427 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.606 ' O ' HG23 ' A' ' 77' ' ' VAL . 53.6 t0 -56.8 -37.88 71.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.396 -0.815 . . . . 0.0 109.702 -179.771 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -63.78 -42.57 97.74 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.2 -0.938 . . . . 0.0 109.672 -179.764 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.408 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 70.8 t80 -64.07 -48.34 76.59 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.148 -0.97 . . . . 0.0 109.459 179.835 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 80' ' ' THR . 53.3 t -65.75 -42.4 92.37 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.388 0 O-C-N 121.355 -0.841 . . . . 0.0 109.982 -179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 73' ' ' ASP . 62.9 t -63.14 -40.89 90.76 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 O-C-N 121.167 -0.958 . . . . 0.0 109.903 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.7 -33.78 74.13 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -179.509 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -102.16 -47.99 4.35 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.046 -1.267 . . . . 0.0 110.506 -179.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.497 ' O ' ' O ' ' A' ' 76' ' ' VAL . 48.8 m -128.68 138.16 52.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.341 -0.849 . . . . 0.0 109.943 -179.62 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.793 HG23 ' O ' ' A' ' 81' ' ' THR . 8.8 t -127.85 89.57 50.25 Favored Pre-proline 0 N--CA 1.488 1.438 0 O-C-N 121.308 -0.87 . . . . 0.0 109.185 179.549 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . 0.596 ' O ' ' CE1' ' A' ' 3' ' ' HIS . 63.8 Cg_endo -82.62 161.53 16.72 Favored 'Trans proline' 0 C--N 1.31 -1.451 0 C-N-CA 122.724 2.283 . . . . 0.0 112.556 -179.801 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.24 150.83 71.69 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 C-N-CA 122.91 2.407 . . . . 0.0 111.943 179.716 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.403 HG13 ' O ' ' A' ' 84' ' ' VAL . 12.0 p -101.22 134.13 42.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.158 -0.964 . . . . 0.0 109.867 -179.602 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . . . . . . . . . 78.1 mm-40 -124.43 163.37 21.93 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 108.887 -0.782 . . . . 0.0 108.887 179.708 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -54.12 138.45 37.92 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.038 -1.039 . . . . 0.0 109.192 179.958 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.69 ' HZ2' ' CG1' ' A' ' 26' ' ' VAL . 32.4 tttt -59.63 -34.57 72.97 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.187 -0.946 . . . . 0.0 109.436 -179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 58.8 mt -57.55 -35.63 70.57 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.286 -0.884 . . . . 0.0 109.428 -179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.9 mt-30 . . . . . 0 N--CA 1.49 1.534 0 CA-C-O 118.072 -0.966 . . . . 0.0 109.464 -179.955 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' PN7 . . . . . 0.482 ' O8 ' ' OE1' ' A' ' 60' ' ' GLU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 1 . 1 stop_ save_